<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40146162</PMID><DateRevised><Year>2025</Year><Month>05</Month><Day>15</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6173</ISSN><JournalIssue CitedMedium="Internet"><Volume>143</Volume><Issue>5</Issue><PubDate><Year>2025</Year><Month>May</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA ophthalmology</Title><ISOAbbreviation>JAMA Ophthalmol</ISOAbbreviation></Journal><ArticleTitle>The OHDSI Network in Ophthalmology-The Promise of Observational Health Data.</ArticleTitle><Pagination><StartPage>369</StartPage><EndPage>370</EndPage><MedlinePgn>369-370</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaophthalmol.2025.0399</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hribar</LastName><ForeName>Michelle R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Casey Eye Institute, Oregon Health &amp; Science University, Portland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Cindy X</ForeName><Initials>CX</Initials><AffiliationInfo><Affiliation>Wilmer Eye Institute, Johns Hopkins School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Informatics and Data Science, Division of General Internal Medicine, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goetz</LastName><ForeName>Kerry E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>Office of Data Science and Health Informatics, National Eye Institute, National Institutes of Health, Bethesda, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, New York.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Ophthalmol</MedlineTA><NlmUniqueID>101589539</NlmUniqueID><ISSNLinking>2168-6165</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><OtherAbstract Type="plain-language-summary" Language="eng"><AbstractText>This Viewpoint discusses how the Observational Health Data Sciences and Informatics community&#x2019;s health data network supports biomedical research in ophthalmology by providing access to a large, standardized dataset.</AbstractText></OtherAbstract></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>27</Day><Hour>13</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>27</Day><Hour>13</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>27</Day><Hour>11</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40146162</ArticleId><ArticleId IdType="doi">10.1001/jamaophthalmol.2025.0399</ArticleId><ArticleId IdType="pii">2831922</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40146872</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1438-8871</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><PubDate><Year>2025</Year><Month>May</Month><Day>15</Day></PubDate></JournalIssue><Title>Journal of medical Internet research</Title><ISOAbbreviation>J Med Internet Res</ISOAbbreviation></Journal><ArticleTitle>Breaking Digital Health Barriers Through a Large Language Model-Based Tool for Automated Observational Medical Outcomes Partnership Mapping: Development and Validation Study.</ArticleTitle><Pagination><StartPage>e69004</StartPage><MedlinePgn>e69004</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e69004</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.2196/69004</ELocationID><Abstract><AbstractText Label="BACKGROUND">The integration of diverse clinical data sources requires standardization through models such as Observational Medical Outcomes Partnership (OMOP). However, mapping data elements to OMOP concepts demands significant technical expertise and time. While large health care systems often have resources for OMOP conversion, smaller clinical trials and studies frequently lack such support, leaving valuable research data siloed.</AbstractText><AbstractText Label="OBJECTIVE">This study aims to develop and validate a user-friendly tool that leverages large language models to automate the OMOP conversion process for clinical trials, electronic health records, and registry data.</AbstractText><AbstractText Label="METHODS">We developed a 3-tiered semantic matching system using GPT-3 embeddings to transform heterogeneous clinical data to the OMOP Common Data Model. The system processes input terms by generating vector embeddings, computing cosine similarity against precomputed Observational Health Data Sciences and Informatics vocabulary embeddings, and ranking potential matches. We validated the system using two independent datasets: (1) a development set of 76 National Institutes of Health Helping to End Addiction Long-term Initiative clinical trial common data elements for chronic pain and opioid use disorders and (2) a separate validation set of electronic health record concepts from the National Institutes of Health National COVID Cohort Collaborative COVID-19 enclave. The architecture combines Unified Medical Language System semantic frameworks with asynchronous processing for efficient concept mapping, made available through an open-source implementation.</AbstractText><AbstractText Label="RESULTS">The system achieved an area under the receiver operating characteristic curve of 0.9975 for mapping clinical trial common data element terms. Precision ranged from 0.92 to 0.99 and recall ranged from 0.88 to 0.97 across similarity thresholds from 0.85 to 1.0. In practical application, the tool successfully automated mappings that previously required manual informatics expertise, reducing the technical barriers for research teams to participate in large-scale, data-sharing initiatives. Representative mappings demonstrated high accuracy, such as demographic terms achieving 100% similarity with corresponding Logical Observation Identifiers Names and Codes concepts. The implementation successfully processes diverse data types through both individual term mapping and batch processing capabilities.</AbstractText><AbstractText Label="CONCLUSIONS">Our validated large language model-based tool effectively automates the transformation of clinical data into the OMOP format while maintaining high accuracy. The combination of semantic matching capabilities and a researcher-friendly interface makes data harmonization accessible to smaller research teams without requiring extensive informatics support. This has direct implications for accelerating clinical research data standardization and enabling broader participation in initiatives such as the National Institutes of Health Helping to End Addiction Long-term Initiative Data Ecosystem.</AbstractText><CopyrightInformation>&#xa9;Meredith CB Adams, Matthew L Perkins, Cody Hudson, Vithal Madhira, Oguz Akbilgic, Da Ma, Robert W Hurley, Umit Topaloglu. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 15.05.2025.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Adams</LastName><ForeName>Meredith C B</ForeName><Initials>MCB</Initials><Identifier Source="ORCID">0000-0002-3969-4279</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology, Artificial Intelligence, Translational Neuroscience, and Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Perkins</LastName><ForeName>Matthew L</ForeName><Initials>ML</Initials><Identifier Source="ORCID">0009-0003-4127-2213</Identifier><AffiliationInfo><Affiliation>Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hudson</LastName><ForeName>Cody</ForeName><Initials>C</Initials><Identifier Source="ORCID">0009-0001-3374-3754</Identifier><AffiliationInfo><Affiliation>Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madhira</LastName><ForeName>Vithal</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0001-5359-1703</Identifier><AffiliationInfo><Affiliation>Palila Software LLC, Reno, NV, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akbilgic</LastName><ForeName>Oguz</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0003-0313-9254</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Da</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-3542-7798</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hurley</LastName><ForeName>Robert W</ForeName><Initials>RW</Initials><Identifier Source="ORCID">0000-0001-6591-9390</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology, Translational Neuroscience, and Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, NC, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Topaloglu</LastName><ForeName>Umit</ForeName><Initials>U</Initials><Identifier Source="ORCID">0000-0002-3241-8773</Identifier><AffiliationInfo><Affiliation>Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Translational Research Informatics Branch, National Cancer Institute, Bethesda, MD, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R24 DA058606</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RM1 DA055311</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 DA057016</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R24 DA055306</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 DA057612</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RM1 DA055301</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UH3 AR077360</GrantID><Acronym>AR</Acronym><Agency>NIAMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R25 DA061740</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RM1 DA055310</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RM1 DA055437</GrantID><Acronym>DA</Acronym><Agency>NIDA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D023361">Validation Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>J Med Internet Res</MedlineTA><NlmUniqueID>100959882</NlmUniqueID><ISSNLinking>1438-8871</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012660" MajorTopicYN="N">Semantics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="Y">Outcome Assessment, Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000098342" MajorTopicYN="N">Large Language Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000097103" MajorTopicYN="N">Digital Health</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">artificial intelligence</Keyword><Keyword MajorTopicYN="N">clinical trials</Keyword><Keyword MajorTopicYN="N">common data model</Keyword><Keyword MajorTopicYN="N">data harmonization</Keyword><Keyword MajorTopicYN="N">electronic health record</Keyword><Keyword MajorTopicYN="N">large language model</Keyword><Keyword MajorTopicYN="N">registry data</Keyword></KeywordList><CoiStatement>Conflicts of Interest: MCBA has received National Institutes of Health (NIH) grants as listed (NIH grant not related to this work: U01DA057016). RWH has received NIH grants as listed (NIH grants not related to this work: UH3AR077360); grants from Nevro, Inc (research funds to the institution on the topic of painful diabetic neuropathy and not related to this work); and grants from State Farm (expert/consulting not related to this work).</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>3</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>2</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>16</Day><Hour>11</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>27</Day><Hour>18</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>27</Day><Hour>14</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>5</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40146872</ArticleId><ArticleId IdType="pmc">PMC12123247</ArticleId><ArticleId IdType="doi">10.2196/69004</ArticleId><ArticleId IdType="pii">v27i1e69004</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Susukida R, Amin-Esmaeili M, Mayo-Wilson E, Mojtabai R. Data management in substance use disorder treatment research: implications from data harmonization of national institute on drug abuse-funded randomized controlled trials. Clin Trials. 2021;18(2):215&#x2013;225. doi: 10.1177/1740774520972687.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1740774520972687</ArticleId><ArticleId IdType="pubmed">33258697</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, Schuemie MJ, Krumholz HM, You SC, Chen R, Pratt N, Reich CG, Duke J, Madigan D, Hripcsak G, Ryan PB. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet. 2019;394(10211):1816&#x2013;1826. doi: 10.1016/S0140-6736(19)32317-7. 
 
S0140-6736(19)32317-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)32317-7</ArticleId><ArticleId IdType="pmc">PMC6924620</ArticleId><ArticleId IdType="pubmed">31668726</ArticleId></ArticleIdList></Reference><Reference><Citation>Papez V, Moinat M, Voss EA, Bazakou S, van Winzum A, Peviani A, Payralbe S, Kallfelz M, Asselbergs FW, Prieto-Alhambra D, Dobson RJB, Denaxas S. Transforming and evaluating the UK biobank to the OMOP common data model for COVID-19 research and beyond. J Am Med Inform Assoc. 2022;30(1):103&#x2013;111. doi: 10.1093/jamia/ocac203. 
 
6760234</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocac203</ArticleId><ArticleId IdType="pmc">PMC9619789</ArticleId><ArticleId IdType="pubmed">36227072</ArticleId></ArticleIdList></Reference><Reference><Citation>Burn E, You SC, Sena AG, Kostka K, Abedtash H, Abrah&#xe3;o MTF, Alberga A, Alghoul H, Alser O, Alshammari TM, Aragon M, Areia C, Banda JM, Cho J, Culhane AC. Deep phenotyping of 34,128 adult patients hospitalised with COVID-19 in an international network study. Nat Commun. 2020;11(1):5009. doi: 10.1038/s41467-020-18849-z. 
 
10.1038/s41467-020-18849-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-18849-z</ArticleId><ArticleId IdType="doi">10.1038/s41467-020-18849-z</ArticleId><ArticleId IdType="pmc">PMC7538555</ArticleId><ArticleId IdType="pubmed">33024121</ArticleId></ArticleIdList></Reference><Reference><Citation>Levinson MA, Niestroy J, Al Manir S, Fairchild K, Lake DE, Moorman JR, Clark T. FAIRSCAPE: a framework for FAIR and reproducible biomedical analytics. Neuroinformatics. 2022;20(1):187&#x2013;202. doi: 10.1007/s12021-021-09529-4. 
 
10.1007/s12021-021-09529-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12021-021-09529-4</ArticleId><ArticleId IdType="pmc">PMC8760356</ArticleId><ArticleId IdType="pubmed">34264488</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinecke I, Zoch M, Reich C, Sedlmayr M, Bathelt F. The usage of OHDSI OMOP - a scoping review. Stud Health Technol Inform. 2021;283:95&#x2013;103. doi: 10.3233/SHTI210546.SHTI210546</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/SHTI210546</ArticleId><ArticleId IdType="pubmed">34545824</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Schuemie MJ, Madigan D, Ryan PB, Suchard MA. Drawing reproducible conclusions from observational clinical data with OHDSI. Yearb Med Inform. 2021;30(1):283&#x2013;289. doi: 10.1055/s-0041-1726481. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0041-1726481</ArticleId><ArticleId IdType="pmc">PMC8416226</ArticleId><ArticleId IdType="pubmed">33882595</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang B, Yoon J, Kim HY, Jo SJ, Lee Y, Kam HJ. Deep-learning-based automated terminology mapping in OMOP-CDM. J Am Med Inform Assoc. 2021;28(7):1489&#x2013;1496. doi: 10.1093/jamia/ocab030. 
 
6275415</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocab030</ArticleId><ArticleId IdType="pmc">PMC8279781</ArticleId><ArticleId IdType="pubmed">33987667</ArticleId></ArticleIdList></Reference><Reference><Citation>Zoch M, Gierschner C, Peng Y, Gruhl M, Leutner LA, Sedlmayr M, Bathelt F. Adaption of the OMOP CDM for Rare Diseases. Stud Health Technol Inform. 2021;281:138&#x2013;142. doi: 10.3233/SHTI210136.SHTI210136</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/SHTI210136</ArticleId><ArticleId IdType="pubmed">34042721</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, Butler A, Stewart LA, Liu H, Yuan C, Southard CT, Kim JH, Weng C. Building an OMOP common data model-compliant annotated corpus for COVID-19 clinical trials. J Biomed Inform. 2021;118:103790. doi: 10.1016/j.jbi.2021.103790. 
 
S1532-0464(21)00119-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2021.103790</ArticleId><ArticleId IdType="pmc">PMC8079156</ArticleId><ArticleId IdType="pubmed">33887457</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier C, Kapsner LA, Mate S, Prokosch HU, Kraus S. Patient cohort identification on time series data using the OMOP common data model. Appl Clin Inform. 2021;12(1):57&#x2013;64. doi: 10.1055/s-0040-1721481. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0040-1721481</ArticleId><ArticleId IdType="pmc">PMC7840432</ArticleId><ArticleId IdType="pubmed">33506478</ArticleId></ArticleIdList></Reference><Reference><Citation>Majeed RW, Fischer P, G&#xfc;nther A. Accessing OMOP common data model repositories with the i2b2 webclient - algorithm for automatic query translation. Stud Health Technol Inform. 2021;278:251&#x2013;259. doi: 10.3233/SHTI210077.SHTI210077</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/SHTI210077</ArticleId><ArticleId IdType="pubmed">34042902</ArticleId></ArticleIdList></Reference><Reference><Citation>Rinner C, Gezgin D, Wendl C, Gall W. A clinical data warehouse based on OMOP and i2b2 for Austrian health claims data. Stud Health Technol Inform. 2018;248:94&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">29726424</ArticleId></ArticleIdList></Reference><Reference><Citation>Klann JG, Joss MAH, Embree K, Murphy SN. Data model harmonization for the All Of Us research program: transforming i2b2 data into the OMOP common data model. PLoS One. 2019;14(2):e0212463. doi: 10.1371/journal.pone.0212463. 
 
PONE-D-18-34751</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0212463</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0212463</ArticleId><ArticleId IdType="pmc">PMC6380544</ArticleId><ArticleId IdType="pubmed">30779778</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmadi N, Zoch M, Guengoeze O, Facchinello C, Mondorf A, Stratmann K, Musleh K, Erasmus HP, Tchertov J, Gebler R, Schaaf J, Frischen LS, Nasirian A, Dai J, Henke E, Tremblay D, Srisuwananukorn A, Bornh&#xe4;user M, R&#xf6;llig C, Eckardt JN, Middeke JM, Wolfien M, Sedlmayr M. How to customize common data models for rare diseases: an OMOP-based implementation and lessons learned. Orphanet J Rare Dis. 2024;19(1):298. doi: 10.1186/s13023-024-03312-9. 
 
10.1186/s13023-024-03312-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13023-024-03312-9</ArticleId><ArticleId IdType="doi">10.1186/s13023-024-03312-9</ArticleId><ArticleId IdType="pmc">PMC11325822</ArticleId><ArticleId IdType="pubmed">39143600</ArticleId></ArticleIdList></Reference><Reference><Citation>Hudson CL, Topaloglu U, Bian J, Hogan W, Kieber-Emmons T. Automated tools for clinical research data quality control using NCI common data elements. AMIA Jt Summits Transl Sci Proc. 2014;2014:60&#x2013;69. 
 
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4333694</ArticleId><ArticleId IdType="pubmed">25717402</ArticleId></ArticleIdList></Reference><Reference><Citation>Pesquita C, Faria D, Falc&#xe3;o AO, Lord P, Couto FM. Semantic similarity in biomedical ontologies. PLoS Comput Biol. 2009;5(7):e1000443. doi: 10.1371/journal.pcbi.1000443. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1000443</ArticleId><ArticleId IdType="doi">10.1371/journal.pcbi.1000443</ArticleId><ArticleId IdType="pmc">PMC2712090</ArticleId><ArticleId IdType="pubmed">19649320</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodenreider O. The Unified Medical Language System (UMLS): integrating biomedical terminology. Nucleic Acids Res. 2004;32(Database issue):D267&#x2013;D270. doi: 10.1093/nar/gkh061. 
 
32/suppl_1/D267</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkh061</ArticleId><ArticleId IdType="pmc">PMC308795</ArticleId><ArticleId IdType="pubmed">14681409</ArticleId></ArticleIdList></Reference><Reference><Citation>Yip V, Mete M, Topaloglu U, Kockara S. Concept discovery for pathology reports using an N-gram model. Summit Transl Bioinform. 2010;2010:43&#x2013;47. 
 
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3041542</ArticleId><ArticleId IdType="pubmed">21347147</ArticleId></ArticleIdList></Reference><Reference><Citation>Garla VN, Brandt C. Semantic similarity in the biomedical domain: an evaluation across knowledge sources. BMC Bioinformatics. 2012;13:261. doi: 10.1186/1471-2105-13-261. 
 
1471-2105-13-261</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-13-261</ArticleId><ArticleId IdType="doi">10.1186/1471-2105-13-261</ArticleId><ArticleId IdType="pmc">PMC3533586</ArticleId><ArticleId IdType="pubmed">23046094</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson CC, Zhu W, Davis CT, Bowman-Kirigin JA, Chan AC, Ling J, Walker AE, Goitre L, Delle Monache S, Retta SF, Shiu YE, Grossmann AH, Thomas KR, Donato AJ, Lesniewski LA, Whitehead KJ, Li DY. Strategy for identifying repurposed drugs for the treatment of cerebral cavernous malformation. Circulation. 2015;131(3):289&#x2013;299. doi: 10.1161/CIRCULATIONAHA.114.010403. 
 
CIRCULATIONAHA.114.010403</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.114.010403</ArticleId><ArticleId IdType="pmc">PMC4356181</ArticleId><ArticleId IdType="pubmed">25486933</ArticleId></ArticleIdList></Reference><Reference><Citation>Kelly M, Ghafurian M, West RL, Reitter D. Indirect associations in learning semantic and syntactic lexical relationships. J Mem Lang. 2020;115:104153. doi: 10.1016/j.jml.2020.104153. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jml.2020.104153</ArticleId><ArticleId IdType="doi">10.1016/j.jml.2020.104153</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho S, Sin M, Tsapepas D, Dale LA, Husain SA, Mohan S, Natarajan K. Content coverage evaluation of the OMOP vocabulary on the transplant domain focusing on concepts relevant for kidney transplant outcomes analysis. Appl Clin Inform. 2020;11(4):650&#x2013;658. doi: 10.1055/s-0040-1716528. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0040-1716528</ArticleId><ArticleId IdType="pmc">PMC7557323</ArticleId><ArticleId IdType="pubmed">33027834</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji H, Kim S, Yi S, Hwang H, Kim JW, Yoo S. Converting clinical document architecture documents to the common data model for incorporating health information exchange data in observational health studies: CDA to CDM. J Biomed Inform. 2020;107:103459. doi: 10.1016/j.jbi.2020.103459. 
 
S1532-0464(20)30087-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2020.103459</ArticleId><ArticleId IdType="pubmed">32470694</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyzy M, Bond R, Mulvenna M, Bai L, Dix A, Leigh S, Hunt S. System usability scale benchmarking for digital health apps: meta-analysis. JMIR Mhealth Uhealth. 2022;10(8):e37290. doi: 10.2196/37290. 
 
v10i8e37290</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/37290</ArticleId><ArticleId IdType="pmc">PMC9437782</ArticleId><ArticleId IdType="pubmed">35980732</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams MCB, Hurley RW, Siddons A, Topaloglu U, Wandner LD. NIH HEAL clinical data elements (CDE) implementation: NIH HEAL Initiative IMPOWR network IDEA-CC. Pain Med. 2023;24(7):743&#x2013;749. doi: 10.1093/pm/pnad018. 
 
7043983</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/pm/pnad018</ArticleId><ArticleId IdType="pmc">PMC10321760</ArticleId><ArticleId IdType="pubmed">36799548</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams MCB, Hurley RW, Topaloglu U. Connecting chronic pain and opioid use disorder clinical trials through data harmonization: Wake Forest IMPOWR Dissemination, Education, and Coordination center (IDEA-CC) Subst Use Addctn J. 2025;46(1):141&#x2013;145. doi: 10.1177/29767342241236287. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/29767342241236287?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub0pubmed</ArticleId><ArticleId IdType="doi">10.1177/29767342241236287</ArticleId><ArticleId IdType="pmc">PMC11884317</ArticleId><ArticleId IdType="pubmed">38516882</ArticleId></ArticleIdList></Reference><Reference><Citation>Burn E, You SC, Sena AG, Kostka K, Abedtash H, Abrah&#xe3;o MTF, Alberga A, Alghoul H, Alser O, Alshammari TM, Aragon M, Areia C, Banda JM, Cho J, Culhane AC. Deep phenotyping of 34,128 adult patients hospitalised with COVID-19 in an international network study. Nat Commun. 2020;11(1):5009. doi: 10.1038/s41467-020-18849-z. 
 
10.1038/s41467-020-18849-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-18849-z</ArticleId><ArticleId IdType="doi">10.1038/s41467-020-18849-z</ArticleId><ArticleId IdType="pmc">PMC7538555</ArticleId><ArticleId IdType="pubmed">33024121</ArticleId></ArticleIdList></Reference><Reference><Citation>El Aboudi N, Benhlima L. Big data management for healthcare systems: architecture, requirements, and implementation. Adv Bioinformatics. 2018;2018:4059018. doi: 10.1155/2018/4059018. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/4059018</ArticleId><ArticleId IdType="doi">10.1155/2018/4059018</ArticleId><ArticleId IdType="pmc">PMC6032968</ArticleId><ArticleId IdType="pubmed">30034468</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams MCB, Bann CM, Bayman EO, Chao M, Hergenroeder GW, Knott C, Lindquist MA, Luo ZD, Martin R, Martone ME, McCarthy J, McCumber M, Meropol SB, Ridenour TA, Saavedra LM, Sarker A, Anstrom KJ, Thompson WK. Building community through data: the value of a researcher driven open science ecosystem. Pain Med. 2025:pnaf003. doi: 10.1093/pm/pnaf003.7965903</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/pm/pnaf003</ArticleId><ArticleId IdType="pubmed">39836639</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams MCB, Brummett CM, Wandner LD, Topaloglu U, Hurley RW. Michigan body map: connecting the NIH HEAL IMPOWR network to the HEAL ecosystem. Pain Med. 2023;24(7):907&#x2013;909. doi: 10.1093/pm/pnad028. 
 
7058937</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/pm/pnad028</ArticleId><ArticleId IdType="pmc">PMC10321764</ArticleId><ArticleId IdType="pubmed">36847455</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams MCB, Hassett AL, Clauw DJ, Hurley RW. The NIH HEAL pain common data elements (CDE): a great start but a long way to the finish line. Pain Med. 2025;26(3):146&#x2013;155. doi: 10.1093/pm/pnae110.7874968</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/pm/pnae110</ArticleId><ArticleId IdType="pmc">PMC11879210</ArticleId><ArticleId IdType="pubmed">39495148</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams MCB, Sward KA, Perkins ML, Hurley RW. Standardizing research methods for opioid dose comparison: the NIH HEAL morphine milligram equivalent calculator. Pain. 2025 doi: 10.1097/j.pain.0000000000003529.00006396-990000000-00813</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/j.pain.0000000000003529</ArticleId><ArticleId IdType="pubmed">39907478</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams MCB, Hassett AL, Clauw DJ, Hurley RW. The NIH HEAL pain common data elements (CDE): a great start but a long way to the finish line. Pain Med. 2025;26(3):146&#x2013;155. doi: 10.1093/pm/pnae110.7874968</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/pm/pnae110</ArticleId><ArticleId IdType="pmc">PMC11879210</ArticleId><ArticleId IdType="pubmed">39495148</ArticleId></ArticleIdList></Reference><Reference><Citation>The Helping to End Addiction Long-term&#xae; Initiative. National Institutes of Health.  [2025-04-25].  
 https://heal.nih.gov/
</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40151318</PMID><DateRevised><Year>2025</Year><Month>03</Month><Day>29</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2574-2531</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>2</Issue><PubDate><Year>2025</Year><Month>Apr</Month></PubDate></JournalIssue><Title>JAMIA open</Title><ISOAbbreviation>JAMIA Open</ISOAbbreviation></Journal><ArticleTitle>Converting Health Level 7 Clinical Document Architecture (CDA) documents to Observational Medical Outcomes Partnership Common Data Model (OMOP CDM) by leveraging CDA Template definitions.</ArticleTitle><Pagination><StartPage>ooaf022</StartPage><MedlinePgn>ooaf022</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">ooaf022</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/jamiaopen/ooaf022</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">This work aims to develop a methodology for transforming Health Level 7 (HL7) Clinical Document Architecture (CDA) documents into the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM). The described method seeks to improve the Extract, Transform, Load (ETL) design process by using HL7 CDA Template definitions and the CDA Refined Message Information Model (CDA R-MIM).</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="UNASSIGNED">Our approach utilizes HL7 CDA Templates to define structural and semantic mappings. Supported by the CDA R-MIM for semantic alignment with the OMOP CDM, we developed a tool named CDA Rabbit that enables the generation of Rabbit-In-a-Hat project files from HL7 CDA Template definitions and could be successfully integrated into the existing toolchain around OMOP.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">We tested our approach using 13 CDA Templates from the Austrian national EHR System (ELGA) and 430 anonymized CDA test documents that were mapped to 10 OMOP CDM tables. The data quality assessment, using OMOP's DataQualityDashboard, showed a 99% pass rate, indicating a robust and accurate data transformation.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">This study presents a novel framework for transforming HL7 CDA documents into OMOP CDM using template definitions and CDA R-MIM. The methodology improves semantic interoperability, mapping reusability, and ETL design efficiency. Future work should focus on automating code generation, improving data profiling, and addressing cyclic dependencies within CDA templates. The presented approach supports improved secondary use of health data and research while adhering to standardized data models and semantics.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="UNASSIGNED">Using CDA Templates for ETL design addresses common ETL challenges, such as data accessibility during ETL design, by decoupling the process from the actual CDA instances. Future work could focus on extending this approach to automatically generate boilerplate code, address cyclic dependencies within CDA Templates, and adapt the method for the use with FHIR profiles.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2025. Published by Oxford University Press on behalf of the American Medical Informatics Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Katsch</LastName><ForeName>Florian</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-7952-9326</Identifier><AffiliationInfo><Affiliation>Center for Medical Data Science, Medical University of Vienna, 1090 Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ludwig Boltzmann Institute for Digital Health and Prevention, 5020 Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hussein</LastName><ForeName>Rada</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-1257-4848</Identifier><AffiliationInfo><Affiliation>Ludwig Boltzmann Institute for Digital Health and Prevention, 5020 Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stamm</LastName><ForeName>Tanja</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0003-3073-7284</Identifier><AffiliationInfo><Affiliation>Center for Medical Data Science, Medical University of Vienna, 1090 Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duftschmid</LastName><ForeName>Georg</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0001-8007-0735</Identifier><AffiliationInfo><Affiliation>Center for Medical Data Science, Medical University of Vienna, 1090 Vienna, Austria.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>03</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMIA Open</MedlineTA><NlmUniqueID>101730643</NlmUniqueID><ISSNLinking>2574-2531</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HL7 CDA</Keyword><Keyword MajorTopicYN="N">HL7 Templates</Keyword><Keyword MajorTopicYN="N">Health Information Interoperability</Keyword><Keyword MajorTopicYN="N">OMOP</Keyword></KeywordList><CoiStatement>All authors declare no competing interests relevant to this study.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>10</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>12</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>3</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>28</Day><Hour>6</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>28</Day><Hour>4</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>3</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40151318</ArticleId><ArticleId IdType="pmc">PMC11945294</ArticleId><ArticleId IdType="doi">10.1093/jamiaopen/ooaf022</ArticleId><ArticleId IdType="pii">ooaf022</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wang Y, Kung L, Byrd TA. &#xa0;Big data analytics: understanding its capabilities and potential benefits for healthcare organizations. Technol Forecast Soc Change. 2018;126:3-13. 10.1016/j.techfore.2015.12.019</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.techfore.2015.12.019</ArticleId></ArticleIdList></Reference><Reference><Citation>
European Commission. European Health Union: a European Health Data Space for people and science. 2022. Accessed March 20, 2025. https://ec.europa.eu/commission/presscorner/detail/e%20n/ip_22_2711</Citation></Reference><Reference><Citation>Dolin RH, Alschuler L, Boyer S, et al. &#xa0;HL7 clinical document architecture, release 2. J Am Med Inform Assoc. 2006;13:30-39. 10.1197/jamia.M1888</Citation><ArticleIdList><ArticleId IdType="doi">10.1197/jamia.M1888</ArticleId><ArticleId IdType="pmc">PMC1380194</ArticleId><ArticleId IdType="pubmed">16221939</ArticleId></ArticleIdList></Reference><Reference><Citation>Torab-Miandoab A, Samad-Soltani T, Jodati A, et al. &#xa0;Interoperability of heterogeneous health information systems: a systematic literature review. BMC Med Inform Decis Mak. 2023;23:18. 10.1186/s12911-023-02115-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12911-023-02115-5</ArticleId><ArticleId IdType="pmc">PMC9875417</ArticleId><ArticleId IdType="pubmed">36694161</ArticleId></ArticleIdList></Reference><Reference><Citation>Ait Abdelouahid R, Debauche O, Mahmoudi S, et al. &#xa0;Literature review: clinical data interoperability models. Information. 2023;14:364. 10.3390/info14070364</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/info14070364</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, et al. &#xa0;Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012;19:54-60. 10.1136/amiajnl-2011-000376</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000376</ArticleId><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>
European Health Data Evidence Network (EHDEN). Accessed March 20, 2025. https://www.ehden.eu/</Citation></Reference><Reference><Citation>Reich C, Ostropolets A, Ryan P, et al. &#xa0;OHDSI standardized vocabularies-a large-scale centralized reference ontology for international data harmonization. J Am Med Inform Assoc. 2024;31:583-590. 10.1093/jamia/ocad247</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocad247</ArticleId><ArticleId IdType="pmc">PMC10873827</ArticleId><ArticleId IdType="pubmed">38175665</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakrabarti S, Sen A, Huser V, et al. &#xa0;An interoperable similarity-based cohort identification method using the OMOP common data model version 5.0. J Healthc Inform Res. 2017;1:1-18. 10.1007/s41666-017-0005-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s41666-017-0005-6</ArticleId><ArticleId IdType="pmc">PMC5536903</ArticleId><ArticleId IdType="pubmed">28776047</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinecke I, Gulden C, K&#xfc;mmel M, et al. &#xa0;Design for a modular clinical trial recruitment support system based on FHIR and OMOP. Stud Health Technol Inform. 2020;270:158-162. 10.3233/SHTI200142</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/SHTI200142</ArticleId><ArticleId IdType="pubmed">32570366</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee GH, Park J, Kim J, et al. &#xa0;Feasibility study of federated learning on the distributed research network of OMOP common data model. Healthc Inform Res. 2023;29:168-173. 10.4258/hir.2023.29.2.168</Citation><ArticleIdList><ArticleId IdType="doi">10.4258/hir.2023.29.2.168</ArticleId><ArticleId IdType="pmc">PMC10209729</ArticleId><ArticleId IdType="pubmed">37190741</ArticleId></ArticleIdList></Reference><Reference><Citation>Talvik H-A, Oja M, Tamm S, et al. &#xa0;Repeatable process for extracting health data from Hl7 CDA documents. J Biomed Inform. 2025;161:104765. 10.1016/j.jbi.2024.104765</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2024.104765</ArticleId><ArticleId IdType="pubmed">39732354</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarwar T, Seifollahi S, Chan J, et al. &#xa0;The secondary use of electronic health records for data mining: data characteristics and challenges. ACM Comput Surv. 2023;55:1-40. 10.1145/3490234</Citation><ArticleIdList><ArticleId IdType="doi">10.1145/3490234</ArticleId></ArticleIdList></Reference><Reference><Citation>
Observational Health Data Sciences and Informatics (OHDSI). White Rabbit&#x2014;documentation. Accessed March 20, 2025. https://ohdsi.github.io/WhiteRabbit/WhiteRabbit.html</Citation></Reference><Reference><Citation>Ji H, Kim S, Yi S, et al. &#xa0;Converting clinical document architecture documents to the common data model for incorporating health information exchange data in observational health studies: CDA to CDM. J Biomed Inform. 2020;107:103459. 10.1016/j.jbi.2020.103459</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2020.103459</ArticleId><ArticleId IdType="pubmed">32470694</ArticleId></ArticleIdList></Reference><Reference><Citation>Oja M, Tamm S, Mooses K, et al. &#xa0;Transforming Estonian health data to the observational medical outcomes partnership (OMOP) common data model: lessons learned. JAMIA Open, 2023;6:ooad100. 10.1093/jamiaopen/ooad100</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamiaopen/ooad100</ArticleId><ArticleId IdType="pmc">PMC10697784</ArticleId><ArticleId IdType="pubmed">38058679</ArticleId></ArticleIdList></Reference><Reference><Citation>Korntheuer RL, Katsch F, Duftschmid G. &#xa0;Transforming documents of the Austrian nationwide EHR system into the OMOP CDM. Stud Health Technol Inform. 2023;301:54-59. 10.3233/SHTI230011</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/SHTI230011</ArticleId><ArticleId IdType="pubmed">37172152</ArticleId></ArticleIdList></Reference><Reference><Citation>Krastev E, Markov E, Abanos S, et al. &#xa0;Mapping the Bulgarian diabetes register to OMOP CDM: application results. Stud Health Technol Inform. 2024;313:28-33. 10.3233/SHTI240007</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/SHTI240007</ArticleId><ArticleId IdType="pubmed">38682500</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciampi M, Sicuranza M, Silvestri S. &#xa0;A privacy-preserving and standard-based architecture for secondary use of clinical data. Information. 2022;13:87. 10.3390/info13020087</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/info13020087</ArticleId></ArticleIdList></Reference><Reference><Citation>Pecoraro F, Luzi D, Ricci FL. &#xa0;The use of HL7 clinical document architecture schema to define a data warehouse dimensional model for secondary purposes. Eur J Biomed Inform (Praha). 2017;13:85-95. 10.24105/ejbi.2017.13.1.12</Citation><ArticleIdList><ArticleId IdType="doi">10.24105/ejbi.2017.13.1.12</ArticleId></ArticleIdList></Reference><Reference><Citation>Heitmann KU, Curry J, Nelson L. &#xa0;HL7 templates standard: specification and use of reusable information constraint templates, Release 1. 2018:1-102.</Citation></Reference><Reference><Citation>Voss EA, Blacketer C, van Sandijk S, et al. &#xa0;European health data &amp; evidence network-learnings from building out a standardized international health data network. J Am Med Inform Assoc. 2023;31:209-219. 10.1093/jamia/ocad214</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocad214</ArticleId><ArticleId IdType="pmc">PMC10746315</ArticleId><ArticleId IdType="pubmed">37952118</ArticleId></ArticleIdList></Reference><Reference><Citation>OMOP CDM v5.4. Accessed March 20, 2025. https://ohdsi.github.io/CommonDataModel/cdm54.html</Citation></Reference><Reference><Citation>Herbek S, Eisl HA, Hurch M, et al. &#xa0;The electronic health record in Austria: a strong network between health care and patients. Eur Surg. 2012;44:155-163. 10.1007/s10353-012-0092-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10353-012-0092-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabutsch S, Frohner M, Kleinoscheg G, et al. &#xa0;ELGA outpatient clinic report and ELGA telehealth note: two HL7-CDA&#xae;-based modular electronic documents. Stud Health Technol Inform. 2022;293:73-78. 10.3233/SHTI220350</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/SHTI220350</ArticleId><ArticleId IdType="pubmed">35592963</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanjga N, Krauss O. &#xa0;Dual implementation guides in FHIR and CDA. Stud Health Technol Inform. 2024;313:49-54. 10.3233/SHTI240011</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/SHTI240011</ArticleId><ArticleId IdType="pubmed">38682504</ArticleId></ArticleIdList></Reference><Reference><Citation>
DECOR Information f&#xfc;r Projekt: ELGA (Governance-Gruppe). Accessed March 20, 2025. https://elga.art-decor.org/</Citation></Reference><Reference><Citation>Katsch F, Hussein R, Korntheuer R, et al. &#xa0;Converting HL7 CDA based nationwide Austrian medication data to OMOP CDM. Stud Health Technol Inform. 2023;302:899-900. 10.3233/SHTI230300</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/SHTI230300</ArticleId><ArticleId IdType="pubmed">37203528</ArticleId></ArticleIdList></Reference><Reference><Citation>Ong T, Pradhananga R, Holve E, et al. &#xa0;A framework for classification of electronic health data extraction-transformation-loading challenges in data network participation. EGEMS (Wash DC). 2017;5:10. 10.5334/egems.222</Citation><ArticleIdList><ArticleId IdType="doi">10.5334/egems.222</ArticleId><ArticleId IdType="pmc">PMC5994935</ArticleId><ArticleId IdType="pubmed">29930958</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng Y, Henke E, Reinecke I, et al. &#xa0;An ETL-process design for data harmonization to participate in international research with German real-world data based on FHIR and OMOP CDM. Int J Med Inform. 2023;169:104925. 10.1016/j.ijmedinf.2022.104925</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijmedinf.2022.104925</ArticleId><ArticleId IdType="pubmed">36395615</ArticleId></ArticleIdList></Reference><Reference><Citation>Leese P, Anand A, Girvin A, et al. &#xa0;Clinical encounter heterogeneity and methods for resolving in networked EHR data: a study from N3C and RECOVER programs. J Am Med Inform Assoc. 2023;30:1125-1136. 10.1093/jamia/ocad057</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocad057</ArticleId><ArticleId IdType="pmc">PMC10198518</ArticleId><ArticleId IdType="pubmed">37087110</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40158304</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>55</Volume><PubDate><Year>2025</Year><Month>May</Month><Day>10</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>A rapid cycle analytics framework for vaccine safety surveillance within a real-world data network: Experience with enhanced surveillance of the Janssen COVID-19 vaccine.</ArticleTitle><Pagination><StartPage>127044</StartPage><MedlinePgn>127044</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2025.127044</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(25)00341-X</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To complement and support routine pharmacovigilance, Janssen conducted rapid real-world data analyses for near real-time safety monitoring of the Janssen COVID-19 vaccine and to contextualize potential safety signals.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Analyses were performed in four U.S. healthcare claims databases (February 2022-May 2023) using standardized algorithms for three vaccine exposures, 56 outcomes, and 93 negative controls. Three self-controlled case series and two comparative cohort variants were conducted, each with consideration of multiple at-risk periods following vaccination. Only results that passed pre-determined, standardized diagnostics were unblinded. Two evidence interpretation strategies were employed: 1) Discovery: aimed to support discovering potentially unknown associations for further investigation, correcting for multiple testing and sequential looks over time. 2) Estimation: aimed to quantify the strength of association for specific exposure-outcome pairs and assess statistical uncertainty.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 13 outcomes of interest showed results exceeding the prespecified Discovery threshold. Guillain-Barr&#xe9; Syndrome (GBS) and Bell's palsy had the most consistent signaling over time, analytic methods, and data sources. GBS, an adverse drug reaction that was added to the product information in August 2021, is used as the example to demonstrate the aspects of this rapid analytic framework. Estimation results for GBS were consistent, with effect estimates in the 1-28&#xa0;day risk window ranging from an incidence rate ratio of 4.0 (95&#xa0;% confidence interval: 2.1-7.7) in a self-controlled design to a hazard ratio of 6.3 (3.0-13.0) in a cohort design.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This work demonstrates the value and feasibility of conducting rapid cycle analysis across numerous outcomes in multiple databases employing complementary methodologies over successive time points while maintaining scientific integrity. The scalability of the approach is facilitated by the a priori specification of analytic diagnostics and corresponding thresholds, which excludes analyses likely to yield unreliable results, thereby minimizing subjective interpretation and post-hoc rationalization of failed diagnostic tests.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Newbern</LastName><ForeName>E Claire</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, 1125 Trenton Harbourton Rd, Titusville, NJ 08560, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shoaibi</LastName><ForeName>Azza</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, 1125 Trenton Harbourton Rd, Titusville, NJ 08560, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haynes</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, 1125 Trenton Harbourton Rd, Titusville, NJ 08560, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blacketer</LastName><ForeName>Clair</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, 1125 Trenton Harbourton Rd, Titusville, NJ 08560, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Willame</LastName><ForeName>Corinne</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, Turnhoutseweg 30, Beerse 2340, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeFalco</LastName><ForeName>Frank</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, 1125 Trenton Harbourton Rd, Titusville, NJ 08560, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Gowtham A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, 1125 Trenton Harbourton Rd, Titusville, NJ 08560, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davis</LastName><ForeName>Kourtney</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, 1125 Trenton Harbourton Rd, Titusville, NJ 08560, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Velarde</LastName><ForeName>Luis Anaya</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, 1125 Trenton Harbourton Rd, Titusville, NJ 08560, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Praet</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, Turnhoutseweg 30, Beerse 2340, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Makadia</LastName><ForeName>Rupa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, 1125 Trenton Harbourton Rd, Titusville, NJ 08560, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Yimei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, 1125 Trenton Harbourton Rd, Titusville, NJ 08560, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, 1125 Trenton Harbourton Rd, Titusville, NJ 08560, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, LLC, 1125 Trenton Harbourton Rd, Titusville, NJ 08560, United States. Electronic address: mschuemi@its.jnj.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>03</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="Y">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060735" MajorTopicYN="N">Pharmacovigilance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016907" MajorTopicYN="N">Adverse Drug Reaction Reporting Systems</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011358" MajorTopicYN="Y">Product Surveillance, Postmarketing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Algorithms</Keyword><Keyword MajorTopicYN="N">Coronavirus (COVID-19)</Keyword><Keyword MajorTopicYN="N">Pharmacoepidemiology</Keyword><Keyword MajorTopicYN="N">Phenotype</Keyword><Keyword MajorTopicYN="N">Vaccination</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Within the last 3&#xa0;years, all authors have any personal financial interests or professional relationships with Janssen Pharmaceuticals. All authors were employees of Janssen at this work. The following authors owned stock in Janssen: ECN, NP, KH, KJD, LA, RM, YX, CW. This research received NO additional support from an organization beyond the authors' academic institutions. There are NO patents or copyrights licensed to the author(s) that are relevant to the work submitted for publication to disclose. There are NO other relationship or activity for authors that may be interpreted as a conflict of interest by the reader.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>2</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>3</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>15</Day><Hour>6</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>3</Month><Day>31</Day><Hour>20</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>3</Month><Day>30</Day><Hour>19</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40158304</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2025.127044</ArticleId><ArticleId IdType="pii">S0264-410X(25)00341-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40167184</PMID><DateRevised><Year>2025</Year><Month>04</Month><Day>01</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1572-0241</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Apr</Month><Day>01</Day></PubDate></JournalIssue><Title>The American journal of gastroenterology</Title><ISOAbbreviation>Am J Gastroenterol</ISOAbbreviation></Journal><ArticleTitle>Incidence and survival of colorectal cancer in the United Kingdom from 2000-2021: a population-based cohort study.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.14309/ajg.0000000000003460</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The management of colorectal cancer (CRC) is evolving, with advances in screening and treatment.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To leverage population-based data to generate up-to-date UK estimates of age and sex-specific incidence and overall survival for the period 2000-2021.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">We analysed nationally representative primary care records from Clinical Practice Research Datalink (CPRD) GOLD and replicated in CPRD Aurum. We calculated incidence rates, and short- and long-term survival stratified by age, sex, and diagnosis year.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Overall incidence was 67.4/100,000 person years, increasing in 2000-2011 to drop slightly in 2011-2014, and then plateauing. In contrast, early-onset CRC raised uninterruptedly throughout the study period, from 8.33 to 19.07/100,000 person-years.Overall survival was 78.3%, 51.4% and 38.5% at 1-, 5-, and 10-years respectively, lower in men compared to women. Modest improvements in survival were observed over the study period, particularly for 60-69-year-old patients.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Although the overall incidence in the population has plateaued, a worrying increasing trend of early-onset CRC was observed. Moreover, the slight improvement in overall survival suggests that significant progress is still needed. These findings highlight the urgent need for continued research and resource allocation to improve the diagnosis and management of colorectal cancer.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of The American College of Gastroenterology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pedregal-Pascual</LastName><ForeName>Patricia</ForeName><Initials>P</Initials><Identifier Source="ORCID">0009-0003-4443-1865</Identifier><AffiliationInfo><Affiliation>Gastroenterology Department, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medicine Department, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guarner-Argente</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-8180-1488</Identifier><AffiliationInfo><Affiliation>Gastroenterology Department, Hospital de la Santa Creu i Sant Pau, Universitat Aut&#xf2;noma de Barcelona, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tan</LastName><ForeName>Eng Hooi</ForeName><Initials>EH</Initials><Identifier Source="ORCID">0000-0003-4470-2736</Identifier><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Golozar</LastName><ForeName>Asieh</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4243-155</Identifier><AffiliationInfo><Affiliation>Odysseus Data Service, Cambridge, MA USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>OHDSI Center at the Roux Institute, Northeastern University, Boston, MA USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duarte-Salles</LastName><ForeName>Talita</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-8274-0357</Identifier><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Centre, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rosen</LastName><ForeName>Andreas Weinberger</ForeName><Initials>AW</Initials><Identifier Source="ORCID">0000-0001-9990-8155</Identifier><AffiliationInfo><Affiliation>Center for Surgical Science, Zealand University Hospital, Lykkeb&#xe6;kvej 1, 4600, K&#xf8;ge, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delmestri</LastName><ForeName>Antonella</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-0388-3403</Identifier><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Man</LastName><ForeName>Wai Yi</ForeName><Initials>WY</Initials><Identifier Source="ORCID">0009-0001-7862-4628</Identifier><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burn</LastName><ForeName>Edward</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-9286-1128</Identifier><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-3950-6346</Identifier><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Centre, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Newby</LastName><ForeName>Danielle</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-3001-1478</Identifier><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>04</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Gastroenterol</MedlineTA><NlmUniqueID>0421030</NlmUniqueID><ISSNLinking>0002-9270</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>3</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>4</Month><Day>1</Day><Hour>11</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>4</Month><Day>1</Day><Hour>11</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>4</Month><Day>1</Day><Hour>8</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40167184</ArticleId><ArticleId IdType="doi">10.14309/ajg.0000000000003460</ArticleId><ArticleId IdType="pii">00000434-990000000-01672</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40169005</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2574-3414</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Annual review of biomedical data science</Title><ISOAbbreviation>Annu Rev Biomed Data Sci</ISOAbbreviation></Journal><ArticleTitle>Integrative Data Science in Drug Safety Research: Experiences, Challenges, and Perspectives.</ArticleTitle><Pagination><StartPage>275</StartPage><EndPage>285</EndPage><MedlinePgn>275-285</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1146/annurev-biodatasci-103123-095506</ELocationID><Abstract><AbstractText>Pharmaceutical research and development largely depend on the quantity and quality of data that are available to support projects. The secondary use of data by means of collaborative and integrative approaches is yielding promising results in drug safety research. However, there are challenges that must be overcome in these integrative approaches, such as interoperability issues, intellectual property protection, and, in the case of clinical information, personal data safeguards. The OMOP common data model and the EHDEN and DARWIN EU platforms constitute successful examples of data sharing initiatives in the clinical domain, while the eTOX, eTRANSAFE, and VICT3R international projects are examples of corporate data sharing in toxicology research. The VICT3R project is using these shared data for generating virtual control groups to be applied in nonclinical drug safety assessment. Drug-related knowledge bases that integrate information from different sources also constitute useful tools in the drug safety domain.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sanz</LastName><ForeName>Ferran</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Medicine and Life Sciences (MELIS), Universitat Pompeu Fabra, Barcelona, Spain; email: ferran.sanz@upf.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Program on Biomedical Informatics (GRIB), Hospital del Mar Research Institute (IMIM), Barcelona, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>04</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Annu Rev Biomed Data Sci</MedlineTA><NlmUniqueID>101714020</NlmUniqueID><ISSNLinking>2574-3414</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077488" MajorTopicYN="Y">Data Science</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="Y">Drug-Related Side Effects and Adverse Reactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D033181" MajorTopicYN="N">Information Dissemination</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">data sharing</Keyword><Keyword MajorTopicYN="N">drug safety</Keyword><Keyword MajorTopicYN="N">drug-related knowledge bases</Keyword><Keyword MajorTopicYN="N">integrative data science</Keyword><Keyword MajorTopicYN="N">virtual control groups</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>12</Day><Hour>0</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>4</Month><Day>2</Day><Hour>0</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>4</Month><Day>1</Day><Hour>18</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40169005</ArticleId><ArticleId IdType="doi">10.1146/annurev-biodatasci-103123-095506</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40169354</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>17</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1468-330X</ISSN><JournalIssue CitedMedium="Internet"><Volume>96</Volume><Issue>10</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>12</Day></PubDate></JournalIssue><Title>Journal of neurology, neurosurgery, and psychiatry</Title><ISOAbbreviation>J Neurol Neurosurg Psychiatry</ISOAbbreviation></Journal><ArticleTitle>Low-density lipoprotein cholesterol levels and risk of incident dementia: a distributed network analysis using common data models.</ArticleTitle><Pagination><StartPage>981</StartPage><EndPage>989</EndPage><MedlinePgn>981-989</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/jnnp-2024-334708</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The link between low-density lipoprotein cholesterol (LDL-C) levels and dementia risk is poorly understood, with conflicting evidence on the role of LDL-C and the impact of statin therapy on cognitive outcomes. Thus, we aimed to examine the association between low-density LDL-C levels and the risk of dementia and assess the influence of statin therapy.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We retrospectively analysed data from 11 university hospitals participating in the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM). Participants with a prior diagnosis of dementia or those with &lt;180&#x2009;days of observation before cohort inclusion, and those included in both cohorts were excluded. The primary outcome was all-cause dementia, with the secondary outcome being Alzheimer's disease-related dementia (ADRD). The study utilised 1:1 propensity score matching to compare individuals with LDL-C levels below 70&#x2009;mg/dL (1.8 mmol/L) against those with levels above 130&#x2009;mg/dL (3.4 mmol/L), resulting in a primary analysis cohort of 108&#x2009;980 matched patients. Secondary analyses further examined LDL-C thresholds below 55&#x2009;mg/dL (1.4 mmol/L) and the influence of statin use.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The LDL-C levels below 70&#x2009;mg/dL (1.8 mmol/L) were associated with a 26% reduction in the risk of all-cause dementia and a 28% reduction in the risk of ADRD, compared with levels above 130&#x2009;mg/dL (3.4 mmol/L). For LDL-C levels below 55&#x2009;mg/dL (1.4 mmol/L), there was an 18% risk reduction for both outcomes. Among those with LDL-C &lt;70&#x2009;mg/dL (&lt;1.8 mmol/L), statin use was associated with a 13% reduction in all-cause dementia risk and a 12% decrease in ADRD risk compared with non-users.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Low LDL-C levels (&lt;70 mg/dL (&lt;1.8 mmol/L)) are significantly associated with a reduced risk of dementia, including ADRD, with statin therapy providing additional protective effects. These findings support the necessity of targeted lipid management as a preventive strategy against dementia, indicating the importance of personalised treatment approaches.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2025. No commercial re-use. See rights and permissions. Published by BMJ Group.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Minwoo</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-8474-5744</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea (the Republic of).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Kyung Joo</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics &amp; Statistics, Kangdong Sacred Heart Hospital, Seoul, Korea (the Republic of).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jinseob</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Zarathu Co Ltd, Seoul, Korea (the Republic of).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Dong Yun</ForeName><Initials>DY</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Korea (the Republic of).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bongdam forest mental health clinic, Hwaseong, Korea (the Republic of).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Rae Woong</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Korea (the Republic of).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rhee</LastName><ForeName>Sang Youl</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Department of Digital Health and Department of Endocrinology and Metabolism, Kyung Hee University College of Medicine, Seoul, Korea (the Republic of).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cha</LastName><ForeName>Jae Myung</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, Kyung Hee University School of Medicine, Seoul, Korea (the Republic of).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Hyeon-Jong</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Soonchunhyang University Seoul Hospital, Soonchunhyang University College of Medicine, Seoul, Korea (the Republic of).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jang</LastName><ForeName>Jae-Won</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kangwon National University Hospital, Kangwon National University College of Medicine, Chuncheon, Korea (the Republic of).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jung</LastName><ForeName>Seunguk</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Gyeongsang National University Changwon Hospital, Changwon, Korea (the Republic of).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Jeeun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Myongji Hospital, Hanyang University College of Medicine, Goyang, Korea (the Republic of).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Sang-Hwa</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon, Korea (the Republic of).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Chulho</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-8762-8340</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon, Korea (the Republic of).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bae</LastName><ForeName>Jong-Seok</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea (the Republic of).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Yeo Jin</ForeName><Initials>YJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea (the Republic of).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Ju-Hun</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea (the Republic of).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bae</LastName><ForeName>Hyoeun</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Neurology, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea (the Republic of).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Yerim</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-7108-6302</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Kangdong Sacred Heart Hospital, Hallym University College of Medicine, Seoul, Korea (the Republic of) brainyrk@hallym.ac.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Neurol Neurosurg Psychiatry</MedlineTA><NlmUniqueID>2985191R</NlmUniqueID><ISSNLinking>0022-3050</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008078">Cholesterol, LDL</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019161">Hydroxymethylglutaryl-CoA Reductase Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008078" MajorTopicYN="Y">Cholesterol, LDL</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003704" MajorTopicYN="Y">Dementia</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019161" MajorTopicYN="N">Hydroxymethylglutaryl-CoA Reductase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="N">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057216" MajorTopicYN="N">Propensity Score</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CHOLESTEROL</Keyword><Keyword MajorTopicYN="N">DEMENTIA</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>2</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>16</Day><Hour>6</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>4</Month><Day>2</Day><Hour>0</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>4</Month><Day>1</Day><Hour>22</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40169354</ArticleId><ArticleId IdType="doi">10.1136/jnnp-2024-334708</ArticleId><ArticleId IdType="pii">jnnp-2024-334708</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40173432</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>15</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1929-0748</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><PubDate><Year>2025</Year><Month>Apr</Month><Day>02</Day></PubDate></JournalIssue><Title>JMIR research protocols</Title><ISOAbbreviation>JMIR Res Protoc</ISOAbbreviation></Journal><ArticleTitle>Conversion of Sensitive Data to the Observational Medical Outcomes Partnership Common Data Model: Protocol for the Development and Use of Carrot.</ArticleTitle><Pagination><StartPage>e60917</StartPage><MedlinePgn>e60917</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e60917</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.2196/60917</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The use of data standards is low across the health care system, and converting data to a common data model (CDM) is usually required to undertake international research. One such model is the Observational Medical Outcomes Partnership (OMOP) CDM. It has gained substantial traction across researchers and those who have developed data platforms. The Observational Health Care Data Sciences and Informatics (OHDSI) partnership manages OMOP and provides many open-source tools to assist in converting data to the OMOP CDM. The challenge, however, is in the skills, knowledge, know-how, and capacity within teams to convert their data to OMOP. The European Health Care Data Evidence Network provided funds to allow data owners to bring in external resources to do the required conversions. The Carrot software (University of Nottingham) is a new set of open-source tools designed to help address these challenges while not requiring data access by external resources.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The use of data protection rules is increasing, and privacy by design is a core principle under the European and UK legislations related to data protection. Our aims for the Carrot software were to have a standardized mechanism for managing the data curation process, capturing the rules used to convert the data, and creating a platform that can reuse rules across projects to drive standardization of process and improve the speed without compromising on quality. Most importantly, we aimed to deliver this design-by-privacy approach without requiring data access to those creating the rules.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The software was developed using Agile approaches by both software engineers and data engineers, who would ultimately use the system. Experts in OMOP were used to ensure the approaches were correct. An incremental release program was initiated to ensure we delivered continuous progress.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Carrot has been delivered and used on a project called COVID-Curated and Open Analysis and Research Platform (CO-CONNECT) to assist in the process of allowing datasets to be discovered via a federated platform. It has been used to create over 45,000 rules, and over 5 million patient records have been converted. This has been achieved while maintaining our principle of not allowing access to the underlying data by the team creating the rules. It has also facilitated the reuse of existing rules, with most rules being reused rather than manually curated.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Carrot has demonstrated how it can be used alongside existing OHDSI tools with a focus on the mapping stage. The COVID-Curated and Open Analysis and Research Platform project successfully managed to reuse rules across datasets. The approach is valid and brings the benefits expected, with future work continuing to optimize the generation of rules.</AbstractText><AbstractText Label="INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID)" NlmCategory="UNASSIGNED">RR1-10.2196/60917.</AbstractText><CopyrightInformation>&#xa9;Samuel Cox, Erum Masood, Vasiliki Panagi, Calum Macdonald, Gordon Milligan, Scott Horban, Roberto Santos, Chris Hall, Daniel Lea, Simon Tarr, Shahzad Mumtaz, Emeka Akashili, Andy Rae, Esmond Urwin, Christian Cole, Aziz Sheikh, Emily Jefferson, Philip Roy Quinlan. Originally published in JMIR Research Protocols (https://www.researchprotocols.org), 02.04.2025.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cox</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-9841-9816</Identifier><AffiliationInfo><Affiliation>Digital Research Service, University of Nottingham, Nottingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Masood</LastName><ForeName>Erum</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0001-8790-5352</Identifier><AffiliationInfo><Affiliation>Health Informatics Centre, University of Dundee, Dundee, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Panagi</LastName><ForeName>Vasiliki</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-4206-4024</Identifier><AffiliationInfo><Affiliation>Digital Research Service, University of Nottingham, Nottingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Macdonald</LastName><ForeName>Calum</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-7857-9188</Identifier><AffiliationInfo><Affiliation>University of Edinburgh, Edinburgh, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Milligan</LastName><ForeName>Gordon</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-1171-5234</Identifier><AffiliationInfo><Affiliation>Health Informatics Centre, University of Dundee, Dundee, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horban</LastName><ForeName>Scott</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-6431-8243</Identifier><AffiliationInfo><Affiliation>Health Informatics Centre, University of Dundee, Dundee, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Santos</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-1333-2605</Identifier><AffiliationInfo><Affiliation>Digital Research Service, University of Nottingham, Nottingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hall</LastName><ForeName>Chris</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-1368-4619</Identifier><AffiliationInfo><Affiliation>Health Informatics Centre, University of Dundee, Dundee, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lea</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-8152-0398</Identifier><AffiliationInfo><Affiliation>Digital Research Service, University of Nottingham, Nottingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tarr</LastName><ForeName>Simon</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-8464-1240</Identifier><AffiliationInfo><Affiliation>Digital Research Service, University of Nottingham, Nottingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mumtaz</LastName><ForeName>Shahzad</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-2606-2405</Identifier><AffiliationInfo><Affiliation>Health Informatics Centre, University of Dundee, Dundee, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akashili</LastName><ForeName>Emeka</ForeName><Initials>E</Initials><Identifier Source="ORCID">0009-0001-5739-9812</Identifier><AffiliationInfo><Affiliation>Digital Research Service, University of Nottingham, Nottingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rae</LastName><ForeName>Andy</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0004-8544-2576</Identifier><AffiliationInfo><Affiliation>NIHR Nottingham Biomedical Research Centre, School of Medicine, University of Nottingham, Nottingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Urwin</LastName><ForeName>Esmond</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-4626-2172</Identifier><AffiliationInfo><Affiliation>NIHR Nottingham Biomedical Research Centre, School of Medicine, University of Nottingham, Nottingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cole</LastName><ForeName>Christian</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-2560-2484</Identifier><AffiliationInfo><Affiliation>Health Informatics Centre, University of Dundee, Dundee, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheikh</LastName><ForeName>Aziz</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-7022-3056</Identifier><AffiliationInfo><Affiliation>University of Edinburgh, Edinburgh, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jefferson</LastName><ForeName>Emily</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-2992-7582</Identifier><AffiliationInfo><Affiliation>Health Informatics Centre, University of Dundee, Dundee, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quinlan</LastName><ForeName>Philip Roy</ForeName><Initials>PR</Initials><Identifier Source="ORCID">0000-0002-3012-6646</Identifier><AffiliationInfo><Affiliation>NIHR Nottingham Biomedical Research Centre, School of Medicine, University of Nottingham, Nottingham, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>04</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>JMIR Res Protoc</MedlineTA><NlmUniqueID>101599504</NlmUniqueID><ISSNLinking>1929-0748</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012984" MajorTopicYN="Y">Software</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016494" MajorTopicYN="Y">Computer Security</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064887" MajorTopicYN="N">Observational Studies as Topic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Carrot tool</Keyword><Keyword MajorTopicYN="N">ETL</Keyword><Keyword MajorTopicYN="N">OMOP</Keyword><Keyword MajorTopicYN="N">Observational Medical Outcomes Partnership</Keyword><Keyword MajorTopicYN="N">common data model</Keyword><Keyword MajorTopicYN="N">data discovery</Keyword><Keyword MajorTopicYN="N">data model</Keyword><Keyword MajorTopicYN="N">data privacy</Keyword><Keyword MajorTopicYN="N">data protection</Keyword><Keyword MajorTopicYN="N">data standard</Keyword><Keyword MajorTopicYN="N">data standardization</Keyword><Keyword MajorTopicYN="N">extract, transform, and load</Keyword><Keyword MajorTopicYN="N">health care</Keyword><Keyword MajorTopicYN="N">open-source</Keyword><Keyword MajorTopicYN="N">transparency</Keyword></KeywordList><CoiStatement>Conflicts of Interest: AS, PRQ, and EJ were a part of the CO-CONNECT project. CC is director of the Alleviate pain data hub.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>12</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>4</Month><Day>3</Day><Hour>18</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>4</Month><Day>2</Day><Hour>18</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>4</Month><Day>2</Day><Hour>16</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>4</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40173432</ArticleId><ArticleId IdType="pmc">PMC12004012</ArticleId><ArticleId IdType="doi">10.2196/60917</ArticleId><ArticleId IdType="pii">v14i1e60917</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>OMOP CDM v5.3. OHDSI GitHub.  [2022-05-13].  
 https://ohdsi.github.io/CommonDataModel/cdm53.html#Clinical_Data_Tables
.</Citation></Reference><Reference><Citation>OMOP Common Data Model. OHDSI GitHub.  [2022-10-05].  
 https://ohdsi.github.io/CommonDataModel/index.html
.</Citation></Reference><Reference><Citation>Kent S, Burn E, Dawoud D, Jonsson P, &#xd8;stby JT, Hughes N, Rijnbeek P, Bouvy JC. Common problems, common data model solutions: evidence generation for health technology assessment. Pharmacoeconomics. 2021;39(3):275&#x2013;285. doi: 10.1007/s40273-020-00981-9. 
 
10.1007/s40273-020-00981-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40273-020-00981-9</ArticleId><ArticleId IdType="pmc">PMC7746423</ArticleId><ArticleId IdType="pubmed">33336320</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Health Data Sciences and Informatics.  [2025-03-11].  
 https://www.ohdsi.org/
</Citation></Reference><Reference><Citation>Rabbit-in-a-Hat. OHDSI GitHub.  [2022-05-28].  
 http://ohdsi.github.io/WhiteRabbit/RabbitInAHat.html
.</Citation></Reference><Reference><Citation>WhiteRabbit. OHDSI GitHub.  [2021-07-23].  
 http://ohdsi.github.io/WhiteRabbit/WhiteRabbit.html
.</Citation></Reference><Reference><Citation>Usagi. OHDSI GitHub.  [2025-03-11].  
 http://ohdsi.github.io/Usagi/
</Citation></Reference><Reference><Citation>European Health Data and Evidence Network.  [2021-08-11].  
 https://www.ehden.eu/
</Citation></Reference><Reference><Citation>Harmonisation fund. European Health Data and Evidence Network.  [2024-09-12].  
 https://www.ehden.eu/open-calls/harmonisation-fund/
</Citation></Reference><Reference><Citation>Athena. OHDSI.  [2025-03-11].  
 https://athena.ohdsi.org/search-terms/start
.</Citation></Reference><Reference><Citation>Wilkinson MD, Dumontier M, Aalbersberg IJ, Appleton G, Axton M, Baak A, Blomberg N, Boiten J, da Silva Santos LB, Bourne PE, Bouwman J, Brookes AJ, Clark T, Crosas M, Dillo I, Dumon O, Edmunds S, Evelo CT, Finkers R, Gonzalez-Beltran A, Gray AJ, Groth P, Goble C, Grethe JS, Heringa J, 't Hoen PAC, Hooft R, Kuhn T, Kok R, Kok J, Lusher SJ, Martone ME, Mons A, Packer AL, Persson B, Rocca-Serra P, Roos M, van Schaik R, Sansone S, Schultes E, Sengstag T, Slater T, Strawn G, Swertz MA, Thompson M, van der Lei J, van Mulligen E, Velterop J, Waagmeester A, Wittenburg P, Wolstencroft K, Zhao J, Mons B. The FAIR Guiding Principles for scientific data management and stewardship. Sci Data. 2016 Mar 15;3:160018. doi: 10.1038/sdata.2016.18.sdata201618</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/sdata.2016.18</ArticleId><ArticleId IdType="pmc">PMC4792175</ArticleId><ArticleId IdType="pubmed">26978244</ArticleId></ArticleIdList></Reference><Reference><Citation>Biedermann P, Ong R, Davydov A, Orlova A, Solovyev P, Sun H, Wetherill G, Brand M, Didden E. Standardizing registry data to the OMOP Common Data Model: experience from three pulmonary hypertension databases. BMC Med Res Methodol. 2021;21(1):238. doi: 10.1186/s12874-021-01434-3. 
 
10.1186/s12874-021-01434-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12874-021-01434-3</ArticleId><ArticleId IdType="doi">10.1186/s12874-021-01434-3</ArticleId><ArticleId IdType="pmc">PMC8565035</ArticleId><ArticleId IdType="pubmed">34727871</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalid S, Yang C, Blacketer C, Duarte-Salles T, Fern&#xe1;ndez-Bertol&#xed;n S, Kim C, Park RW, Park J, Schuemie MJ, Sena AG, Suchard MA, You SC, Rijnbeek PR, Reps JM. A standardized analytics pipeline for reliable and rapid development and validation of prediction models using observational health data. Comput Methods Programs Biomed. 2021;211:106394. doi: 10.1016/j.cmpb.2021.106394. 
 
S0169-2607(21)00468-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmpb.2021.106394</ArticleId><ArticleId IdType="pmc">PMC8420135</ArticleId><ArticleId IdType="pubmed">34560604</ArticleId></ArticleIdList></Reference><Reference><Citation>Oja M, Tamm S, Mooses K, Pajusalu M, Talvik HA, Ott A, Laht M, Malk M, L&#xf5;o Marcus, Holm J, Haug M, &#x160;uvalov Hendrik, S&#xe4;rg Dage, Vilo J, Laur S, Kolde R, Reisberg S. Transforming Estonian health data to the Observational Medical Outcomes Partnership (OMOP) Common Data Model: lessons learned. JAMIA Open. 2023 Dec;6(4):ooad100. doi: 10.1093/jamiaopen/ooad100. 
 
ooad100</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamiaopen/ooad100</ArticleId><ArticleId IdType="pmc">PMC10697784</ArticleId><ArticleId IdType="pubmed">38058679</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoda R, Salleh N, Grundy J. The rise and evolution of agile software development. IEEE Softw. 2018;35(5):58&#x2013;63. doi: 10.1109/ms.2018.290111318.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/ms.2018.290111318</ArticleId></ArticleIdList></Reference><Reference><Citation>The MIT license. Open Source Initiative.  [2025-03-11].  
 https://opensource.org/license/mit/
</Citation></Reference><Reference><Citation>Cox S. Carrot-Mapper. Carrot Docs.  [2025-03-11].  
 https://carrot4omop.ac.uk/Carrot-Mapper/
</Citation></Reference><Reference><Citation>Macdonald C, Panagi V, Tarr R, Santos R, Schlessinger D, Mumtaz S. HDRUK/CaRROT-CDM: CaRROT CDM Builder Version 0.6.0. Zenodo.  [2022-01-10].  
 https://zenodo.org/records/6593954
.</Citation></Reference><Reference><Citation>Data Protection Act 2018. Legislation.gov.  [2023-07-20].  
 https://www.legislation.gov.uk/ukpga/2018/12/contents/enacted
.</Citation></Reference><Reference><Citation>Carrot Mapper.  [2025-09-11].  
 https://carrot.ac.uk/
</Citation></Reference><Reference><Citation>The Wellcome Covid-19 Questionnaire. University of Bristol.  [2025-01-11].  
 https://www.bristol.ac.uk/alspac/covid-19/wellcome-covid-19/
</Citation></Reference><Reference><Citation>Data standards. Carrot Docs.  [2025-03-11].  
 https://carrot4omop.ac.uk/standards/
</Citation></Reference><Reference><Citation>What is SNOMED CT? SNOMED International.  [2023-07-21].  
 https://www.snomed.org/five-step-briefing
.</Citation></Reference><Reference><Citation>International Classification of Diseases, Ninth Revision (ICD-9) Centers for Disease Control and Prevention.  [2023-07-21].  
 https://www.cdc.gov/nchs/icd/icd9.htm
.</Citation></Reference><Reference><Citation>Healthcare Common Procedure Coding System (HCPCS) Centers for Medicare &amp; Medicaid Services.  [2023-12-19].  
 https://www.cms.gov/medicare/coding-billing/healthcare-common-procedure-system
.</Citation></Reference><Reference><Citation>Health Data Research Gateway.  [2021-07-28].  
 https://www.healthdatagateway.org/
</Citation></Reference><Reference><Citation>Alleviate &#x2013; the Advanced Pain Discovery Platform (APDP) Data Hub. Health Data Research UK.  [2024-04-10].  
 https://www.hdruk.ac.uk/helping-with-health-data/our-hubs-across-the-uk/alleviate/
</Citation></Reference><Reference><Citation>Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, Curtis HJ, Mehrkar A, Evans D, Inglesby P, Cockburn J, McDonald HI, MacKenna B, Tomlinson L, Douglas IJ, Rentsch CT, Mathur R, Wong AYS, Grieve R, Harrison D, Forbes H, Schultze A, Croker R, Parry J, Hester F, Harper S, Perera R, Evans SJW, Smeeth L, Goldacre B. Factors associated with COVID-19-related death using OpenSAFELY. Nature. 2020;584(7821):430&#x2013;436. doi: 10.1038/s41586-020-2521-4. 
 
10.1038/s41586-020-2521-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2521-4</ArticleId><ArticleId IdType="pmc">PMC7611074</ArticleId><ArticleId IdType="pubmed">32640463</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleurence RL, Curtis LH, Califf RM, Platt R, Selby JV, Brown JS. Launching PCORnet, a national patient-centered clinical research network. J Am Med Inform Assoc. 2014;21(4):578&#x2013;582. doi: 10.1136/amiajnl-2014-002747. 
 
amiajnl-2014-002747</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2014-002747</ArticleId><ArticleId IdType="pmc">PMC4078292</ArticleId><ArticleId IdType="pubmed">24821743</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40185784</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Apr</Month><Day>04</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Secular trends in heat related illness and excess sun exposure rates across climatic zones in the United States from 2017 to 2022.</ArticleTitle><Pagination><StartPage>11629</StartPage><MedlinePgn>11629</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">11629</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-025-93441-3</ELocationID><Abstract><AbstractText>Heat waves are a major public health challenge, yet the link between heat-related illness (HRI) and regional climate and geography is underexplored. We examined HRI and excess sun exposure incidence rates (IR) [95% confidence interval (CI) per 100,000 person-years], and their correlation with regional maximum temperatures across 9 US climatic zones 33,603,572 individuals were followed from 2017 to 2022. We observed 10,652 individuals with HRI diagnosis (median age: 49&#xa0;years, 62.3% male). Seasonal peaks occurred during summer: highest overall IR (130.97 [119.93-142.75]) was recorded in July 2019, highest regional IR was reported in the South (186.04 [117.93-279.15]) during 2020. Strongest correlations between monthly maximum temperature and incidence of HRI were observed in the West (Pearson Correlation Coefficient (cor)&#x2009;=&#x2009;0.854) and Southwest (cor&#x2009;=&#x2009;0.832). In contrast, we observed 131,204 individuals with excess sun exposure (predominantly older adults [median age: 67&#xa0;years], 52.3% female, 30% with history of cancer). Overall IR for sun exposure peaked in March 2021 (664.31 [644.84-684.21]) and lacked a consistent seasonal pattern. Sun exposure exhibited weaker correlations with regional temperatures, even in high-temperature regions like the West (cor&#x2009;=&#x2009;0.305). These data indicate regional variations in HRI.&#xa0;With distinct at-risk groups for HRI and sun exposure, targeted regional interventions may be beneficial, such as heat safety protocols to reduce HRI risk and sun protection campaigns for older adults to mitigate sun exposure risk.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pineda-Moncus&#xed;</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine (CSM), Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Botnar Research Centre, Windmill Road, Oxford, OX3 7LD, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Rabia Ali</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine (CSM), Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Botnar Research Centre, Windmill Road, Oxford, OX3 7LD, UK. rabia.khan@ndorms.ox.ac.uk.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Epidemiological Insight Team, Advanced Analytics, Analysis and Intelligence Assessment Directorate, Chief Data Officer Group, UK Health Security Agency, London, UK. rabia.khan@ndorms.ox.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prats-Uribe</LastName><ForeName>Albert</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine (CSM), Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Botnar Research Centre, Windmill Road, Oxford, OX3 7LD, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine (CSM), Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Botnar Research Centre, Windmill Road, Oxford, OX3 7LD, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khalid</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine (CSM), Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Botnar Research Centre, Windmill Road, Oxford, OX3 7LD, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>04</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013472" MajorTopicYN="Y">Sunlight</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012621" MajorTopicYN="N">Seasons</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018882" MajorTopicYN="Y">Heat Stress Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006358" MajorTopicYN="Y">Hot Temperature</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002980" MajorTopicYN="N">Climate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Climate change</Keyword><Keyword MajorTopicYN="N">Electronic health records</Keyword><Keyword MajorTopicYN="N">Excess sun exposure</Keyword><Keyword MajorTopicYN="N">GIS</Keyword><Keyword MajorTopicYN="N">Health inequalities</Keyword><Keyword MajorTopicYN="N">Heat related illness</Keyword><Keyword MajorTopicYN="N">Heat stress</Keyword><Keyword MajorTopicYN="N">Heatwaves</Keyword><Keyword MajorTopicYN="N">Observational study</Keyword></KeywordList><CoiStatement>Declarations. Competing interests: MPM, RAK and APU declare that there are no conflicts of interest. DPA&#x2019;s department has received grant/s from Amgen, Chiesi-Taylor, Lilly, Janssen, Novartis, and UCB Biopharma. His research group has received consultancy fees from Astra Zeneca and UCB Biopharma. Amgen, Astellas, Janssen, Synapse Management Partners and UCB Biopharma have funded or supported training programmes organised by DPA&#x2019;s department. SK is supported by the Innovative Medicines Initiative, Bill &amp; Melinda Gates Foundation, Health Data Research UK, British Heart Foundation, Medical Research Council and Natural Environment Research Council outside of this work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>3</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>4</Month><Day>5</Day><Hour>15</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>4</Month><Day>5</Day><Hour>15</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>4</Month><Day>4</Day><Hour>23</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>4</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40185784</ArticleId><ArticleId IdType="pmc">PMC11971287</ArticleId><ArticleId IdType="doi">10.1038/s41598-025-93441-3</ArticleId><ArticleId IdType="pii">10.1038/s41598-025-93441-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gamboa, L. et al. Analysis of heat stroke and heat exhaustion cases in EudraVigilance pharmacovigilance database. Eur. J. Clin. Pharmacol.79(5), 679&#x2013;685. 10.1007/s00228-023-03487-3 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10068193</ArticleId><ArticleId IdType="pubmed">37009927</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson, R. et al. Heatwave mortality in Summer 2020 in England: An observational study. Int. J. Environ. Res. Public Health19(10), 6123 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9141696</ArticleId><ArticleId IdType="pubmed">35627660</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu, S. H., Gasparrini, A., Rodriguez, P. S. &amp; Jha, P. Mortality attributable to hot and cold ambient temperatures in India: A nationally representative case-crossover study. PLoS Med.15(7), e1002619. 10.1371/journal.pmed.1002619 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6057641</ArticleId><ArticleId IdType="pubmed">30040816</ArticleId></ArticleIdList></Reference><Reference><Citation>Climate Change Indicators: Heat Waves. United States Environmental Protection Agency. https://www.epa.gov/climate-indicators/climate-change-indicators-heat-waves#ref11 (Accessed 19 May 2024).</Citation></Reference><Reference><Citation>Watts, N. et al. Health and climate change: Policy responses to protect public health. Lancet386(10006), 1861&#x2013;1914. 10.1016/s0140-6736(15)60854-6 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26111439</ArticleId></ArticleIdList></Reference><Reference><Citation>N. C. Assessment, The Fifth National Climate Assessment. USA, 2023. https://nca2023.globalchange.gov/ (Accessed on 22 December 2023).</Citation></Reference><Reference><Citation>Kingsley, S. L., Eliot, M. N., Gold, J., Vanderslice, R. R. &amp; Wellenius, G. A. Current and projected heat-related morbidity and mortality in Rhode Island. Environ. Health Perspect.124(4), 460&#x2013;467. 10.1289/ehp.1408826 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4829994</ArticleId><ArticleId IdType="pubmed">26251954</ArticleId></ArticleIdList></Reference><Reference><Citation>Schramm, P. J. et al. Heat-related emergency department visits during the northwestern heat wave - United States, June 2021. MMWR Morb. Mortal. Wkly. Rep.70(29), 1020&#x2013;1021. 10.15585/mmwr.mm7029e1 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8297695</ArticleId><ArticleId IdType="pubmed">34292925</ArticleId></ArticleIdList></Reference><Reference><Citation>Alho, A. M., Oliveira, A. P., Viegas, S. &amp; Nogueira, P. Effect of heatwaves on daily hospital admissions in Portugal, 2000&#x2013;18: an observational study. Lancet Planet. Health8(5), e318&#x2013;e326. 10.1016/s2542-5196(24)00046-9 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38729671</ArticleId></ArticleIdList></Reference><Reference><Citation>Sousa, P. M. et al. Heat-related mortality amplified during the COVID-19 pandemic. Int. J. Biometeorol.66(3), 457&#x2013;468. 10.1007/s00484-021-02192-z (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8780052</ArticleId><ArticleId IdType="pubmed">35061075</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauer, R. &amp; Meyers, B. K. Heat-related illnesses. Am. Fam. Phys.99(8), 482&#x2013;489 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30990296</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, T., Horton, R. M. &amp; Kinney, P. L. Projections of seasonal patterns in temperature-related deaths for Manhattan, New York. Nat. Clim. Change3(8), 717&#x2013;721 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4045618</ArticleId><ArticleId IdType="pubmed">24910717</ArticleId></ArticleIdList></Reference><Reference><Citation>Sorensen, C. &amp; Hess, J. Treatment and prevention of heat-related illness. N. Engl. J. Med.387(15), 1404&#x2013;1413. 10.1056/NEJMcp2210623 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36170473</ArticleId></ArticleIdList></Reference><Reference><Citation>Khatana, S. A. M., Werner, R. M. &amp; Groeneveld, P. W. Association of extreme heat with all-cause mortality in the contiguous US, 2008&#x2013;2017. JAMA Netw. Open5(5), e2212957&#x2013;e2212957. 10.1001/jamanetworkopen.2022.12957 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9121188</ArticleId><ArticleId IdType="pubmed">35587347</ArticleId></ArticleIdList></Reference><Reference><Citation>Stearns, R. L. et al. Incidence of recurrent exertional heat stroke in a warm-weather road race. Medicina (Kaunas)56(12), 720. 10.3390/medicina56120720 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7766530</ArticleId><ArticleId IdType="pubmed">33371206</ArticleId></ArticleIdList></Reference><Reference><Citation>Romero, J. J., Clement, P. F. &amp; Beiden, C. Neuropsychological sequelae of heat stroke: Report of three cases and discussion. Milit. Med.165(6), 500&#x2013;503. 10.1093/milmed/165.6.500 (2000).</Citation><ArticleIdList><ArticleId IdType="pubmed">10870374</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor, E. V. et al. Differences in heat-related mortality by citizenship status: United States, 2005&#x2013;2014. Am. J. Public Health108(S2), S131&#x2013;S136. 10.2105/ajph.2017.304006 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5920731</ArticleId><ArticleId IdType="pubmed">29072944</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaidyanathan, A., Malilay, J., Schramm, P. &amp; Saha, S. Heat-related deaths - United States, 2004&#x2013;2018. MMWR Morb. Mortal. Wkly. Rep.69(24), 729&#x2013;734. 10.15585/mmwr.mm6924a1 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7302478</ArticleId><ArticleId IdType="pubmed">32555133</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Neill, M. S., Zanobetti, A. &amp; Schwartz, J. Disparities by race in heat-related mortality in four US cities: The role of air conditioning prevalence. J. Urban Health82, 191&#x2013;197 (2005).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3456567</ArticleId><ArticleId IdType="pubmed">15888640</ArticleId></ArticleIdList></Reference><Reference><Citation>Sera, F. et al. Air conditioning and heat-related mortality: A multi-country longitudinal study. Epidemiology31(6), 779&#x2013;787 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33003149</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmeltz, M. T., Petkova, E. P. &amp; Gamble, J. L. Economic burden of hospitalizations for heat-related illnesses in the United States, 2001&#x2013;2010. Int. J. Environ. Res. Public Health13(9), 894 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5036727</ArticleId><ArticleId IdType="pubmed">27618079</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeargin, S., Hirschhorn, R. &amp; Grundstein, A. Heat-related illnesses transported by United States emergency medical services. Medicina56(10), 543 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7602997</ArticleId><ArticleId IdType="pubmed">33080867</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, S., Kim, D. H., Lee, H. H. &amp; Lee, J. Y. Frequency of firefighters&#x2019; heat-related illness and its association with removing personal protective equipment and working hours. Ind. Health57(3), 370&#x2013;380. 10.2486/indhealth.2018-0063 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6546580</ArticleId><ArticleId IdType="pubmed">30210098</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinzerling, A. et al. Risk factors for occupational heat-related illness among California workers, 2000&#x2013;2017. Am. J. Ind. Med.63(12), 1145&#x2013;1154. 10.1002/ajim.23191 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33075156</ArticleId></ArticleIdList></Reference><Reference><Citation>Layton, J. B. et al. Heatwaves, medications, and heat-related hospitalization in older Medicare beneficiaries with chronic conditions. PLoS One15(12), e0243665. 10.1371/journal.pone.0243665 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7728169</ArticleId><ArticleId IdType="pubmed">33301532</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalisch Ellett, L. M., Pratt, N. L., Le Blanc, V. T., Westaway, K. &amp; Roughead, E. E. Increased risk of hospital admission for dehydration or heat-related illness after initiation of medicines: A sequence symmetry analysis. J. Clin. Pharm. Ther.41(5), 503&#x2013;507. 10.1111/jcpt.12418 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27378245</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin-Latry, K. et al. Psychotropic drugs use and risk of heat-related hospitalisation. Eur. Psychiatry22(6), 335&#x2013;338. 10.1016/j.eurpsy.2007.03.007 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17513091</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilhelmi, O. V., Howe, P. D., Hayden, M. H. &amp; O&#x2019;Lenick, C. R. Compounding hazards and intersecting vulnerabilities: Experiences and responses to extreme heat during COVID-19. Environ. Res. Lett.16(8), 084060. 10.1088/1748-9326/ac1760 (2021).</Citation></Reference><Reference><Citation>Faurie, C., Varghese, B. M., Liu, J. &amp; Bi, P. Association between high temperature and heatwaves with heat-related illnesses: A systematic review and meta-analysis. Sci. Total Environ.852, 158332. 10.1016/j.scitotenv.2022.158332 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36041616</ArticleId></ArticleIdList></Reference><Reference><Citation>Radgoudarzi, N. et al. Medical, environmental, and social determinants associated with periocular cutaneous malignancies in the united states using the all of us national database. Cureus16(7), e65831. 10.7759/cureus.65831 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11363474</ArticleId><ArticleId IdType="pubmed">39219888</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivry, G. B., Ogle, C. A. &amp; Shim, E. K. Role of sun exposure in melanoma. Dermatol. Surg.32(4), 481&#x2013;492 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16681655</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveria, S. A., Saraiya, M., Geller, A. C., Heneghan, M. K. &amp; Jorgensen, C. Sun exposure and risk of melanoma. Arch. Dis. Childhood91(2), 131&#x2013;138. 10.1136/adc.2005.086918 (2006).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2082713</ArticleId><ArticleId IdType="pubmed">16326797</ArticleId></ArticleIdList></Reference><Reference><Citation>IQVIA. IQVIA PharMetrics&#xae; Plus for Academics Enhanced with Mortality Data. https://www.iqvia.com/locations/united-states/library/fact-sheets/iqvia-pharmetrics-plus-for-academics-enhanced-with-mortality-data (Accessed 01 November, 2024).</Citation></Reference><Reference><Citation>Ma, Q. et al. Patterns of use of systemic therapies among patients with metastatic melanoma: A retrospective claims database analysis in the United States. J. Dermatol. Treat.28(6), 549&#x2013;553. 10.1080/09546634.2016.1277176 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28100090</ArticleId></ArticleIdList></Reference><Reference><Citation>Hallinan, C. M. et al. Seamless EMR data access: Integrated governance, digital health and the OMOP-CDM. BMJ Health Care Inform.10.1136/bmjhci-2023-100953 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10882353</ArticleId><ArticleId IdType="pubmed">38387992</ArticleId></ArticleIdList></Reference><Reference><Citation>Biedermann, P. et al. Standardizing registry data to the OMOP Common Data Model: Experience from three pulmonary hypertension databases. BMC Med. Res. Methodol.21, 1&#x2013;16 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8565035</ArticleId><ArticleId IdType="pubmed">34727871</ArticleId></ArticleIdList></Reference><Reference><Citation>N. C. f. E. Information. Climate at a Glance Regional Time Series. NOAA&#x2019;s National Centers for Environmental Information (NCEI). https://www.ncei.noaa.gov/access/monitoring/climate-at-a-glance/regional/time-series/105/tavg/12/0/2017-2022?base_prd=true&amp;begbaseyear=2015&amp;endbaseyear=2024 (Accessed 3, November 2024).</Citation></Reference><Reference><Citation>US Climate Regions. National Centers for Environmental Information. https://www.ncei.noaa.gov/access/monitoring/reference-maps/us-climate-regions (Accessed 30 October, 2024).</Citation></Reference><Reference><Citation>T. Karl and W. J. Koss, Regional and national monthly, seasonal, and annual temperature weighted by area. 1895&#x2013;1983 (1984).</Citation></Reference><Reference><Citation>A. f. H. R. a. Quality. NIS Overview. Agency for Healthcare Research and Quality. https://hcup-us.ahrq.gov/nisoverview.jsp (Accessed 29 November, 2024).</Citation></Reference><Reference><Citation>N. O. a. A. Administration. Summer 2020 ranked as one of the hottest on record for U.S. August was remarkably hot and destructive. https://www.noaa.gov/news/summer-2020-ranked-as-one-of-hottest-on-record-for-us#:~:text=August%202020%20will%20be%20remembered,derecho%20and%20raging%20wildfires%20out (Accessed November 21, 2024).</Citation></Reference><Reference><Citation>Narayanan, D. L., Saladi, R. N. &amp; Fox, J. L. Ultraviolet radiation and skin cancer. Int. J. Dermatol.49(9), 978&#x2013;986. 10.1111/j.1365-4632.2010.04474.x (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">20883261</ArticleId></ArticleIdList></Reference><Reference><Citation>Raimondi, S., Suppa, M. &amp; Gandini, S. Melanoma epidemiology and sun exposure. Acta Derm. Venereol.100(11), adv00136. 10.2340/00015555-3491 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9189754</ArticleId><ArticleId IdType="pubmed">32346751</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40189628</PMID><DateRevised><Year>2025</Year><Month>04</Month><Day>24</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2398-6352</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Apr</Month><Day>07</Day></PubDate></JournalIssue><Title>NPJ digital medicine</Title><ISOAbbreviation>NPJ Digit Med</ISOAbbreviation></Journal><ArticleTitle>A scoping review of OMOP CDM adoption for cancer research using real world data.</ArticleTitle><Pagination><StartPage>189</StartPage><MedlinePgn>189</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">189</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41746-025-01581-7</ELocationID><Abstract><AbstractText>The Observational Medical Outcomes Partnership (OMOP) common data model (CDM) supports large-scale research by enabling distributed network analyses. However, the breadth of its adoption in cancer research is not well understood. We conducted a scoping review to describe the adoption of the OMOP CDM in cancer research. A total of 49 unique articles were included in the review, with 30 on the data analysis theme, and 20 on the infrastructure theme. This review highlighted that while the OMOP CDM ecosystem has enabled successful data support for cancer research, particularly for collaborative studies, ongoing model development and iterative improvement remain needed to fulfill additional research data needs. Expanding disease sites, specifically for rare cancers, integrating more diverse types of data sources, improving data quality, adopting advanced analytics methodology, and increasing multisite evaluations serve as important opportunities to facilitate secondary usage of observational data in future cancer research.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Wang</LastName><ForeName>Liwei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>McWilliams School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Wen</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>McWilliams School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fu</LastName><ForeName>Sunyang</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>McWilliams School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruan</LastName><ForeName>Xiaoyang</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>McWilliams School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Ming</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>McWilliams School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Rui</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>McWilliams School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Qiuhao</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>McWilliams School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lyu</LastName><ForeName>Heather</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Surgical Oncology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Andrew E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Clinical and Translational Science Institute, Tufts Medical Center, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Hongfang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>McWilliams School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX, USA. hongfang.liu@uth.tmc.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>RF1AG072799</GrantID><Agency>National Institute of Aging grant</Agency><Country/></Grant><Grant><GrantID>R01LM11934</GrantID><Agency>U.S. National Library of Medicine</Agency><Country/></Grant><Grant><GrantID>RF1 AG072799</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RR230020</GrantID><Agency>Cancer Prevention and Research Institute of Texas</Agency><Country/></Grant><Grant><GrantID>R01HG12748</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HG012748</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM011934</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>04</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>NPJ Digit Med</MedlineTA><NlmUniqueID>101731738</NlmUniqueID><ISSNLinking>2398-6352</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>medRxiv. 2024 Aug 23:2024.08.23.24311950. doi: 10.1101/2024.08.23.24311950.</RefSource><PMID Version="1">39228725</PMID></CommentsCorrections></CommentsCorrectionsList><CoiStatement>Competing interests: Heather Lyu is an associate editor, and Hongfang Liu is an Editorial Board Member of NPJ Digital Medicine.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>3</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>4</Month><Day>7</Day><Hour>2</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>4</Month><Day>7</Day><Hour>2</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>4</Month><Day>6</Day><Hour>23</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>4</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40189628</ArticleId><ArticleId IdType="pmc">PMC11973147</ArticleId><ArticleId IdType="doi">10.1038/s41746-025-01581-7</ArticleId><ArticleId IdType="pii">10.1038/s41746-025-01581-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bray, F., Laversanne, M., Weiderpass, E. &amp; Soerjomataram, I. The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer127, 3029&#x2013;3030 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34086348</ArticleId></ArticleIdList></Reference><Reference><Citation>Booth, C. M., Karim, S. &amp; Mackillop, W. J. Real-world data: towards achieving the achievable in cancer care. Nat. Rev. Clin. Oncol.16, 312&#x2013;325 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30700859</ArticleId></ArticleIdList></Reference><Reference><Citation>Baxter, N. N., Tepper, J. E., Durham, S. B., Rothenberger, D. A. &amp; Virnig, B. A. Increased risk of rectal cancer after prostate radiation: a population-based study. Gastroenterology128, 819&#x2013;824 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15825064</ArticleId></ArticleIdList></Reference><Reference><Citation>Callahan, A., Shah, N. H. &amp; Chen, J. H. Research and reporting considerations for observational studies using electronic health record data. Ann. Intern. Med.172, S79&#x2013;S84 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7413106</ArticleId><ArticleId IdType="pubmed">32479175</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss, E. A. et al. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. J. Am. Med. Inform. Assoc.22, 553&#x2013;564 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4457111</ArticleId><ArticleId IdType="pubmed">25670757</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak, G. et al. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud. Health Technol. Inform.216, 574 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Randhawa, G. S. &amp; Slutsky, J. R. Building sustainable multi-functional prospective electronic clinical data systems. Med. Care50, S3&#x2013;S6 (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">22692255</ArticleId></ArticleIdList></Reference><Reference><Citation>Toh, S. et al. The National Patient-Centered Clinical Research Network (PCORnet) bariatric study cohort: rationale, methods, and baseline characteristics. JMIR Res. Protoc.6, e8323 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5736875</ArticleId><ArticleId IdType="pubmed">29208590</ArticleId></ArticleIdList></Reference><Reference><Citation>Gottesman, O. et al. The electronic medical records and genomics (eMERGE) network: past, present, and future. Genet. Med.15, 761&#x2013;771 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3795928</ArticleId><ArticleId IdType="pubmed">23743551</ArticleId></ArticleIdList></Reference><Reference><Citation>Roel, E. et al. Characteristics and outcomes of over 300,000 patients with COVID-19 and history of cancer in the United States and Spain. Cancer Epidemiol. Biomark. Prev.30, 1884&#x2013;1894 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8974356</ArticleId><ArticleId IdType="pubmed">34272262</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, S. M. et al. Association between use of hydrochlorothiazide and nonmelanoma skin cancer: common data model cohort study in Asian population. J. Clin. Med.9, 2910 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7563303</ArticleId><ArticleId IdType="pubmed">32916988</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinecke, I., Zoch, M., Reich, C., Sedlmayr, M. &amp; Bathelt, F. The usage of OHDSI OMOP&#x2013;a scoping review. Ger. Med. Data Sci. 2021 Digital Med. Recognize&#x2013;Understand&#x2013;Heal21, 95&#x2013;103 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34545824</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmadi, N., Peng, Y., Wolfien, M., Zoch, M. &amp; Sedlmayr, M. OMOP CDM can facilitate Data-driven studies for cancer prediction: a systematic review. Int. J. Mol. Sci.23, 11834 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9569469</ArticleId><ArticleId IdType="pubmed">36233137</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong, N. et al. Preliminary exploration of survival analysis using the OHDSI common data model: a case study of intrahepatic cholangiocarcinoma. BMC Med. Inform. Decis. Mak.18, 81&#x2013;88 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6284277</ArticleId><ArticleId IdType="pubmed">30526572</ArticleId></ArticleIdList></Reference><Reference><Citation>Bardenheuer, K., Van Speybroeck, M., Hague, C., Nikai, E. &amp; Price, M. Haematology Outcomes Network in Europe (HONEUR)&#x2014;A collaborative, interdisciplinary platform to harness the potential of real-world data in hematology. Eur. J. Haematol.109, 138&#x2013;145 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35460296</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho, J. et al. Application of epidemiological geographic information system: an open-source spatial analysis tool based on the OMOP Common Data Model. Int. J. Environ. Res. Public Health17, 7824 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7663469</ArticleId><ArticleId IdType="pubmed">33114631</ArticleId></ArticleIdList></Reference><Reference><Citation>Glicksberg, B. S. et al. Blockchain-authenticated sharing of genomic and clinical outcomes data of patients with cancer: a prospective cohort study. J. Med. Internet Res.22, e16810 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7125440</ArticleId><ArticleId IdType="pubmed">32196460</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin, S. J. et al. Genomic common data model for seamless interoperation of biomedical data in clinical practice: retrospective study. J. Med. Internet Res.21, e13249 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6454347</ArticleId><ArticleId IdType="pubmed">30912749</ArticleId></ArticleIdList></Reference><Reference><Citation>Unberath, P. et al. EHR-independent predictive decision support architecture based on OMOP. Appl. Clin. Inform.11, 399&#x2013;404 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7269719</ArticleId><ArticleId IdType="pubmed">32492716</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu, Y. et al. Integrating electronic health record data into the ADEpedia-on-OHDSI platform for improved signal detection: a case study of immune-related adverse events. AMIA Summits Transl. Sci. Proc.2020, 710 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7233056</ArticleId><ArticleId IdType="pubmed">32477694</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, Y. et al. Comparative safety and effectiveness of alendronate versus raloxifene in women with osteoporosis. Sci. Rep.10, 11115 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7338498</ArticleId><ArticleId IdType="pubmed">32632237</ArticleId></ArticleIdList></Reference><Reference><Citation>Spotnitz, M. E., Natarajan, K., Ryan, P. B. &amp; Westhoff, C. L. Relative risk of cervical neoplasms among copper and levonorgestrel-releasing intrauterine system users. Obstet. Gynecol.135, 319&#x2013;327 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7012337</ArticleId><ArticleId IdType="pubmed">31923062</ArticleId></ArticleIdList></Reference><Reference><Citation>You, S. C. et al. Ranitidine use and incident cancer in a multinational cohort. JAMA Netw. open6, e2333495 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10509724</ArticleId><ArticleId IdType="pubmed">37725377</ArticleId></ArticleIdList></Reference><Reference><Citation>Na, J. et al. Characterizing phenotypic abnormalities associated with high-risk individuals developing lung cancer using electronic health records from the All of Us researcher workbench. J. Am. Med. Inform. Assoc.28, 2313&#x2013;2324 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8510381</ArticleId><ArticleId IdType="pubmed">34505903</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeon, H. et al. Characterizing the anticancer treatment trajectory and pattern in patients receiving chemotherapy for cancer using harmonized observational databases: retrospective study. JMIR Med. Inform.9, e25035 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8058693</ArticleId><ArticleId IdType="pubmed">33720842</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, R. et al. Treatment patterns for chronic comorbid conditions in patients with cancer using a large-scale observational data network. JCO Clin. Cancer Inform.4, 171&#x2013;183 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7113074</ArticleId><ArticleId IdType="pubmed">32134687</ArticleId></ArticleIdList></Reference><Reference><Citation>Belenkaya, R. et al. Extending the OMOP common data model and standardized vocabularies to support observational cancer research. JCO Clin. Cancer Inform.5, 12&#x2013;20 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8140810</ArticleId><ArticleId IdType="pubmed">33411620</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang, X., Beaton, M. A., Gillberg, J., Williams, A. &amp; Natarajan, K. Feasibility of linking areadeprivation index data to the OMOP common data model. In AMIA AnnualSymposium Proceedings. 2022, 587 (American Medical Informatics Association, 2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10148322</ArticleId><ArticleId IdType="pubmed">37128466</ArticleId></ArticleIdList></Reference><Reference><Citation>Michael, C. L., Sholle, E. T., Wulff, R. T., Roboz, G. J. &amp; Campion, T. R. Jr Mapping local biospecimen records to the OMOP common data model. AMIA Summits Transl. Sci. Proc.2020, 422 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7233045</ArticleId><ArticleId IdType="pubmed">32477663</ArticleId></ArticleIdList></Reference><Reference><Citation>Warner, J. L. et al. HemOnc: a new standard vocabulary for chemotherapy regimen representation in the OMOP common data model. J. Biomed. Inform.96, 103239 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6697579</ArticleId><ArticleId IdType="pubmed">31238109</ArticleId></ArticleIdList></Reference><Reference><Citation>Carus, J., N&#xfc;rnberg, S., &#xdc;ckert, F., Schl&#xfc;ter, C. &amp; Bartels, S. Mapping cancer registry data to the episode domain of the Observational Medical Outcomes Partnership Model (OMOP). Appl. Sci.12, 4010 (2022).</Citation></Reference><Reference><Citation>Carus, J. et al. Mapping the oncological basis dataset to the standardized vocabularies of a common data model: a feasibility study. Cancers15, 4059 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10452256</ArticleId><ArticleId IdType="pubmed">37627087</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruendner, J. et al. KETOS: clinical decision support and machine learning as a service&#x2013;A training and deployment platform based on Docker, OMOP-CDM, and FHIR Web Services. PloS one14, e0223010 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6776354</ArticleId><ArticleId IdType="pubmed">31581246</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalokyri, V. et al. MI-Common Data Model: extending Observational Medical Outcomes Partnership-Common Data Model (OMOP-CDM) for registering medical imaging metadata and subsequent curation processes. JCO Clin. Cancer Inform.7, e2300101 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10715775</ArticleId><ArticleId IdType="pubmed">38061012</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier, C. et al. Towards implementation of OMOP in a German university hospital consortium. Appl. Clin. Inform.9, 054&#x2013;061 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5801887</ArticleId><ArticleId IdType="pubmed">29365340</ArticleId></ArticleIdList></Reference><Reference><Citation>Park, J., Lee, J. Y., Moon, M. H., Park, Y. H. &amp; Rho, M. J. Cancer research line (CAREL): development of expanded distributed research networks for prostate cancer and lung cancer. Technol. Cancer Res. Treat.22, 15330338221149262 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10061631</ArticleId><ArticleId IdType="pubmed">36977531</ArticleId></ArticleIdList></Reference><Reference><Citation>Park, J. et al. A framework (SOCRATex) for hierarchical annotation of unstructured electronic health records and integration into a standardized medical database: development and usability study. JMIR Med. Inform.9, e23983 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8044740</ArticleId><ArticleId IdType="pubmed">33783361</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryu, B. et al. Transformation of pathology reports into the common data model with oncology module: use case for colon cancer. J. Med. Internet Res.22, e18526 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7758167</ArticleId><ArticleId IdType="pubmed">33295294</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoo, S. et al. Transforming thyroid cancer diagnosis and staging information from unstructured reports to the observational medical outcome partnership common data model. Appl. Clin. Inform.13, 521&#x2013;531 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9200482</ArticleId><ArticleId IdType="pubmed">35705182</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin, V. et al. Training prediction models for individual risk assessment of postoperative complications after surgery for colorectal cancer. Tech. Coloproctol.26, 665&#x2013;675 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35593971</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian, Y. et al. Establishment and evaluation of a multicenter collaborative prediction model construction framework supporting model generalization and continuous improvement: a pilot study. Int. J. Med. Inform.141, 104173 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32531725</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, S. -H., et al. Angiotensin converting enzyme inhibitors and incidence of lung cancer in a population based cohort of common data model in Korea. Sci. Rep.11, 18576 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8448874</ArticleId><ArticleId IdType="pubmed">34535723</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, J. -H. et al. Assessment of inter-institutional post-operative hypoparathyroidism status using a common data model. J. Clin. Med.10, 4454 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8509408</ArticleId><ArticleId IdType="pubmed">34640472</ArticleId></ArticleIdList></Reference><Reference><Citation>Seol, S. et al. Effect of statin use on head and neck cancer prognosis in a multicenter study using a Common Data Model. Sci. Rep.13, 19770 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10643676</ArticleId><ArticleId IdType="pubmed">37957229</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, S. -H. et al. Renin-angiotensin-aldosterone system inhibitors and risk of Cancer: a population-based cohort study using a common data model. Diagnostics12, 263 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8871518</ArticleId><ArticleId IdType="pubmed">35204354</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, S. et al. Second primary malignancy risk in thyroid cancer and matched patients with and without radioiodine therapy analysis from the observational health data sciences and informatics. Eur. J. Nucl. Med. Mol. Imaging49, 3547&#x2013;3556 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35362796</ArticleId></ArticleIdList></Reference><Reference><Citation>Felmeister, A. S. et al. Preliminary exploratory data analysis of simulated national clinical data research network for future use in annotation of a rare tumor biobanking initiative. in 2017 IEEE International Conference on Bioinformatics and Biomedicine (BIBM). 2098&#x2013;2104 (IEEE, 2017).</Citation></Reference><Reference><Citation>Hartwig, M., Br&#xe4;uner, K. B., Vogelsang, R. &amp; G&#xf6;genur, I. Preoperative prediction of lymph node status in patients with colorectal cancer. Developing a predictive model using machine learning. Int. J. Colorectal Dis.37, 2517&#x2013;2524 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36435940</ArticleId></ArticleIdList></Reference><Reference><Citation>Seneviratne, M. G., Banda, J. M., Brooks, J. D., Shah, N. H. &amp; Hernandez-Boussard, T. M. Hernandez-Boussard."Identifying cases of metastatic prostate cancer using machine learning on electronic health records. in AMIA Annual Symposium Proceedings2018, 1498 (American Medical Informatics Association, 2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6371284</ArticleId><ArticleId IdType="pubmed">30815195</ArticleId></ArticleIdList></Reference><Reference><Citation>Seo, S. I. et al. Association between proton pump inhibitor use and gastric cancer: a population-based cohort study using two different types of nationwide databases in Korea. Gut70, 2066&#x2013;2075 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33975868</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon, J. Y., Kwak, M. S., Kim, H. I. &amp; Cha, J. M. Seasonal variations in the diagnosis of the top 10 cancers in Korea: a nationwide population-based study using a common data model. J. Gastroenterol. Hepatol.36, 3371&#x2013;3380 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34293206</ArticleId></ArticleIdList></Reference><Reference><Citation>Seo, S. I. et al. Aspirin, metformin, and statin use on the risk of gastric cancer: a nationwide population-based cohort study in Korea with systematic review and meta-analysis. Cancer Med.11, 1217&#x2013;1231 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8855895</ArticleId><ArticleId IdType="pubmed">34970858</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim, T. et al. Decreasing incidence of gastric cancer with increasing time after helicobacter pylori treatment: a nationwide population-based cohort study. Antibiotics11, 1052 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9405442</ArticleId><ArticleId IdType="pubmed">36009921</ArticleId></ArticleIdList></Reference><Reference><Citation>Seo, S. I. et al. Incidence and survival outcomes of colorectal cancer in long-term metformin users with diabetes: a population-based cohort study using a common data model. J. Personalized Med.12, 584 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9031185</ArticleId><ArticleId IdType="pubmed">35455700</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, Y. H., Kim, D. -H., Kim, J. &amp; Lee, J. Risk assessment of postoperative pneumonia in cancer patients using a common data model. Cancers14, 5988 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9740852</ArticleId><ArticleId IdType="pubmed">36497470</ArticleId></ArticleIdList></Reference><Reference><Citation>Ha, H. et al. Application of the Khorana score for cancer-associated thrombosis prediction in patients of East Asian ethnicity undergoing ambulatory chemotherapy. Thrombosis J.21, 63 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10240689</ArticleId><ArticleId IdType="pubmed">37271814</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, A. R. et al. Risk prediction of emergency department visits in patients with lung cancer using machine learning: retrospective observational study. JMIR Med. Inform.11, e53058 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10733827</ArticleId><ArticleId IdType="pubmed">38055320</ArticleId></ArticleIdList></Reference><Reference><Citation>Song, Q. et al. Risk and outcome of breakthrough COVID-19 infections in vaccinated patients with cancer: real-world evidence from the National COVID Cohort Collaborative. J. Clin. Oncol.40, 1414 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9061155</ArticleId><ArticleId IdType="pubmed">35286152</ArticleId></ArticleIdList></Reference><Reference><Citation>Meystre, S. M., Heider, P. M., Kim, Y., Aruch, D. B. &amp; Britten, C. D. Automatic trial eligibility surveillance based on unstructured clinical data. Int. J. Med. Inform.129, 13&#x2013;19 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6717538</ArticleId><ArticleId IdType="pubmed">31445247</ArticleId></ArticleIdList></Reference><Reference><Citation>Br&#xe4;uner, K. B. et al. Developing prediction models for short-term mortality after surgery for colorectal cancer using a Danish national quality assurance database. Int. J. Colorectal Dis.37, 1835&#x2013;1843 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35849195</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI. Observational Health Data Sciences and Informatics OHDSI Publications, https://www.ohdsi.org/publications/.</Citation></Reference><Reference><Citation>Bathelt, F. The usage of OHDSI OMOP&#x2013;a scoping review. Proce. German Med. Data Sci. (GMDS), 95&#x2013;103 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34545824</ArticleId></ArticleIdList></Reference><Reference><Citation>Kondylakis, H. et al. Data infrastructures for AI in medical imaging: a report on the experiences of five EU projects. Eur. Radiol. Exp.7, 20 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10164664</ArticleId><ArticleId IdType="pubmed">37150779</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, L. et al. Assessment of electronic health record for cancer research and patient care through a scoping review of cancer natural language processing. JCO Clin. Cancer Inform.6, e2200006 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9470142</ArticleId><ArticleId IdType="pubmed">35917480</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, S. et al. An open natural language processing (NLP) framework for EHR-based clinical research: a case demonstration using the National COVID Cohort Collaborative (N3C). J. Am. Med. Inform. Assoc.30, 2036&#x2013;2040 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10654844</ArticleId><ArticleId IdType="pubmed">37555837</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen A. et al. The RECOVER Initiative. An NLP System for COVID/PASC: A Case Demonstration of the OHNLP Toolkit from the National COVID Cohort Collaborative and the RECOVER programs. JMIR Med. Inform.12, e49997 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11420592</ArticleId><ArticleId IdType="pubmed">39250782</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, Y. W., Strong, D. M., Kahn, B. K. &amp; Wang, R. Y. AIMQ: a methodology for information quality assessment. Inf. Manag.40, 133&#x2013;146 (2002).</Citation></Reference><Reference><Citation>Fu, S. et al. The implication of latent information quality to the reproducibility of secondary use of electronic health records. Stud. health Technol. Inform.290, 173 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9754076</ArticleId><ArticleId IdType="pubmed">35672994</ArticleId></ArticleIdList></Reference><Reference><Citation>National Library of Medicine Value Set Authority Center. https://vsac.nlm.nih.gov/.</Citation></Reference><Reference><Citation>Peterson, K. J., Jiang, G., Brue, S. M., Shen, F. &amp; Liu, H. Mining hierarchies and similarity clusters from value set repositories. in AMIAAnnual Symposium Proceedings. 2017, 1372 (American Medical Informatics Association, 2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5977603</ArticleId><ArticleId IdType="pubmed">29854206</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen, A. et al. Desiderata for delivering NLP to accelerate healthcare AI advancement and a Mayo Clinic NLP-as-a-service implementation. NPJ Digital Med.2, 130 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6917754</ArticleId><ArticleId IdType="pubmed">31872069</ArticleId></ArticleIdList></Reference><Reference><Citation>Munn, Z. et al. Systematic review or scoping review? Guidance for authors when choosing between a systematic or scoping review approach. BMC Med. Res. Methodol.18, 1&#x2013;7 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6245623</ArticleId><ArticleId IdType="pubmed">30453902</ArticleId></ArticleIdList></Reference><Reference><Citation>Arksey, H. &amp; O&#x2019;Malley, L. Scoping studies: towards a methodological framework. Int. J. Soc. Res. Methodol.8, 19&#x2013;32 (2005).</Citation></Reference><Reference><Citation>Tricco, A. C. et al. PRISMA extension for scoping reviews (PRISMA-ScR): checklist and explanation. Ann. Intern. Med.169, 467&#x2013;473 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30178033</ArticleId></ArticleIdList></Reference><Reference><Citation>Von Elm, E. et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet370, 1453&#x2013;1457 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">18064739</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40193233</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>04</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1536-481X</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>8</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of glaucoma</Title><ISOAbbreviation>J Glaucoma</ISOAbbreviation></Journal><ArticleTitle>Gap Analysis of Standard Automated Perimetry Concept Representation in Medical Terminologies.</ArticleTitle><Pagination><StartPage>644</StartPage><EndPage>649</EndPage><MedlinePgn>644-649</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/IJG.0000000000002575</ELocationID><Abstract><AbstractText Label="PRCIS" NlmCategory="CONCLUSIONS">In this multi-institutional effort, we identified gaps in SAP data elements within medical terminologies. We proposed new concepts to LOINC to enhance SAP data standards and big data representation and improve interoperability across health care systems.</AbstractText><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To identify gaps in the representation of Standard Automated Perimetry (SAP) data elements in Logical Observation Identifiers Names and Codes (LOINC) and the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) and propose solutions for those gaps.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">SAP source data elements and Digital Imaging and Communications in Medicine (DICOM) standard from 2 commonly used perimeter devices were extracted and compared against existing concepts in standardized terminologies using the OMOP CDM Athena browser and LOINC using the LOINC browser. Gap areas were identified and classified following conventions used by Health Level 7 Fast Healthcare Interoperability Resources and discussed within the OHDSI Eye Care and Vision Research Workgroup in iterative rounds aiming to address gaps. New codes were developed upon reaching a consensus and proposed for inclusion in LOINC.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 107 data elements extracted from the perimeters, 82% (n=88) of SAP data elements lacked representation. Of the 19 remaining elements, 2.8% (n=3) were wider, 1.9% (n=2) were narrower, and 13% (n=14) had equivalent representation. In addition, only 2.6% (n=3) of the 116 DICOM attributes related to SAP had representation in standardized terminologies. Several existing relevant codes were defined ambiguously or erroneously (eg, visual field index, pupil diameter, perimeter format Kowa).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">There is a lack of representation of some SAP data elements in standardized medical terminologies, hampering interoperability and data sharing. We identified gaps and proposed new concepts for addition to LOINC, aiming to improve SAP data standards and interoperability.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Wolters Kluwer Health, Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hallaj</LastName><ForeName>Shahin</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-9541-1915</Identifier><AffiliationInfo><Affiliation>Division of Ophthalmology Informatics and Data Science, Hamilton Glaucoma Center, Viterbi Family Department of Ophthalmology and Shiley Eye Institute.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Biomedical Informatics, Department of Medicine, University of California San Diego, La Jolla, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Halfpenny</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Division of Ophthalmology Informatics and Data Science, Hamilton Glaucoma Center, Viterbi Family Department of Ophthalmology and Shiley Eye Institute.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Biomedical Informatics, Department of Medicine, University of California San Diego, La Jolla, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Radgoudarzi</LastName><ForeName>Niloofar</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Division of Ophthalmology Informatics and Data Science, Hamilton Glaucoma Center, Viterbi Family Department of Ophthalmology and Shiley Eye Institute.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Biomedical Informatics, Department of Medicine, University of California San Diego, La Jolla, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boland</LastName><ForeName>Michael V</ForeName><Initials>MV</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Mass Eye and Ear, Harvard Medical School, Cambridge, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swaminathan</LastName><ForeName>Swarup S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Sophia Y</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Byers Eye Institute, Stanford University, Palo Alto, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Benjamin Y</ForeName><Initials>BY</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Roski Eye Institute, Keck School of Medicine at the University of Southern California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amarasekera</LastName><ForeName>Dilru C</ForeName><Initials>DC</Initials><AffiliationInfo><Affiliation>Glaucoma Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stagg</LastName><ForeName>Brian</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology and Visual Sciences, John Moran Eye Center, Salt Lake City.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Population Health Sciences, University of Utah, UT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Aiyin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Casey Eye Institute, Portland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hribar</LastName><ForeName>Michelle</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, Casey Eye Institute, Portland.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Office of Data Science and Health Informatics, National Eye Institute, National Institutes of Health, Baltimore, MD.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics and Clinical Epidemiology, Oregon Health &amp; Science University, Portland, OR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thakoor</LastName><ForeName>Kaveri A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Department of Biomedical Engineering, Columbia University.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Columbia University Irving Medical Center, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goetz</LastName><ForeName>Kerry E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>Office of Data Science and Health Informatics, National Eye Institute, National Institutes of Health, Baltimore, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Myers</LastName><ForeName>Jonathan S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Glaucoma Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Aaron Y</ForeName><Initials>AY</Initials><AffiliationInfo><Affiliation>Department of Ophthalmology, School of Medicine, University of Washington, Seattle, WA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Christopher</LastName><ForeName>Mark A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Division of Ophthalmology Informatics and Data Science, Hamilton Glaucoma Center, Viterbi Family Department of Ophthalmology and Shiley Eye Institute.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zangwill</LastName><ForeName>Linda M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>Division of Ophthalmology Informatics and Data Science, Hamilton Glaucoma Center, Viterbi Family Department of Ophthalmology and Shiley Eye Institute.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weinreb</LastName><ForeName>Robert N</ForeName><Initials>RN</Initials><AffiliationInfo><Affiliation>Division of Ophthalmology Informatics and Data Science, Hamilton Glaucoma Center, Viterbi Family Department of Ophthalmology and Shiley Eye Institute.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baxter</LastName><ForeName>Sally L</ForeName><Initials>SL</Initials><Identifier Source="ORCID">0000-0002-5271-7690</Identifier><AffiliationInfo><Affiliation>Division of Ophthalmology Informatics and Data Science, Hamilton Glaucoma Center, Viterbi Family Department of Ophthalmology and Shiley Eye Institute.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Biomedical Informatics, Department of Medicine, University of California San Diego, La Jolla, CA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>04</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Glaucoma</MedlineTA><NlmUniqueID>9300903</NlmUniqueID><ISSNLinking>1057-0829</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058609" MajorTopicYN="Y">Visual Field Tests</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014794" MajorTopicYN="Y">Visual Fields</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009626" MajorTopicYN="Y">Terminology as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005901" MajorTopicYN="Y">Glaucoma</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D039703" MajorTopicYN="Y">Logical Observation Identifiers Names and Codes</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">LOINC</Keyword><Keyword MajorTopicYN="N">OMOP</Keyword><Keyword MajorTopicYN="N">glaucoma</Keyword><Keyword MajorTopicYN="N">perimetry</Keyword><Keyword MajorTopicYN="N">standards</Keyword><Keyword MajorTopicYN="N">terminology</Keyword><Keyword MajorTopicYN="N">visual field</Keyword></KeywordList><CoiStatement>Disclosure: S.L.B. reports consulting fees from Topcon and equipment support from Topcon and Optomed outside the submitted work. R.N.W. reports consulting fees from Abbvie, Alcon, Balance, Editas, Eyenovia, iSTAR Medical, Nicox, and Topcon outside the submitted work. He also has stock options from Amydis, Balance, Eyenovia, Iantrek, Implandata,and Toku outside the submitted work and intellectual property licensed from UCSD to Toromedes outside the submitted work. L.M.Z. has received consulting fees from Topcon and Abbvie and received financial support from Heidelberg Engineering and nonfinancial support (equipment) from Heidelberg Engineering, Carl Zeiss Meditec, Optovue, Topcon, ICare Inc., Optomed Inc., outside the submitted work. M.V.B. reports consulting fees from Carl Zeiss Meditec and Topcon Healthcare and speaking fees from Carl Zeiss Meditec. S.S.S. reports consulting fees from Lumata Health, AbbVie, and Topcon Healthcare outside the submitted work. The reamaining authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>3</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>4</Day><Hour>18</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>4</Month><Day>7</Day><Hour>13</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>4</Month><Day>7</Day><Hour>12</Hour><Minute>16</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40193233</ArticleId><ArticleId IdType="doi">10.1097/IJG.0000000000002575</ArticleId><ArticleId IdType="pii">00061198-202508000-00012</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sauer CM, Chen LC, Hyland SL, et al. Leveraging electronic health records for data science: common pitfalls and how to avoid them. Lancet Digit Health. 2022;4:e893&#x2013;e898.</Citation></Reference><Reference><Citation>Baxter SL, Apathy NC, Cross DA, et al. Measures of electronic health record use in outpatient settings across vendors. J Am Med Inform Assoc. 2021;28:955&#x2013;959.</Citation></Reference><Reference><Citation>Tavakoli K, Kalaw FGP, Bhanvadia S, et al. Concept coverage analysis of ophthalmic infections and trauma among the standardized medical terminologies SNOMED-CT, ICD-10-CM, and ICD-11. Ophthalmol Sci. 2023;3:100337.</Citation></Reference><Reference><Citation>Quon JC, Halfpenny WD, Cai CX, et al. Implementing a common data model in ophthalmology: Comparison of general eye examination mapping to standard OMOP concepts across two major EHR systems OphthalmolSci Volume 5:(Issue 2)100666&#x2013;100666.</Citation></Reference><Reference><Citation>Shweikh Y, Sekimitsu S, Boland MV, et al. The growing need for ophthalmic data standardization. Ophthalmol Sci. 2023;3:100262.</Citation></Reference><Reference><Citation>Halfpenny W, Baxter SL. Towards effective data sharing in ophthalmology: data standardization and data privacy. Curr Opin Ophthalmol. 2022;33:418&#x2013;424.</Citation></Reference><Reference><Citation>Baxter SL, Marks C, Kuo TT, et al. Machine learning-based predictive modeling of surgical intervention in glaucoma using systemic data from electronic health records. Am J Ophthalmol. 2019;208:30&#x2013;40.</Citation></Reference><Reference><Citation>Kent S, Burn E, Dawoud D, et al. Common problems, common data model solutions: evidence generation for health technology assessment. Pharmacoeconomics. 2021;39:275&#x2013;285.</Citation></Reference><Reference><Citation>Quiroz JC, Chard T, Sa Z, Ritchie A, Jorm L, Gallego B, et al. Extract, transform, load framework for the conversion of health databases to OMOP. PLoS One. 2022;17:e0266911.</Citation></Reference><Reference><Citation>Cai CX, Halfpenny W, Boland MV, et al. Advancing Toward a common data model in ophthalmology: gap analysis of general eye examination concepts to standard observational medical outcomes partnership (OMOP) concepts. Ophthalmol Sci. 2023;3:100391.</Citation></Reference><Reference><Citation>Nouri-Mahdavi K. Selecting visual field tests and assessing visual field deterioration in glaucoma. Can J Ophthalmol. 2014;49:497&#x2013;505.</Citation></Reference><Reference><Citation>Jampel HD, Singh K, Lin SC, et al. Assessment of visual function in glaucoma: a report by the American Academy of. Ophthalmology. 2011;118:986&#x2013;1002.</Citation></Reference><Reference><Citation>Delgado MF, Nguyen NT, Cox TA, et al. Automated perimetry: a report by the American Academy of. Ophthalmology. 2002;109:2362&#x2013;2374.</Citation></Reference><Reference><Citation>Goetz KE, Reed AA, Chiang MF, et al. Accelerating care: a roadmap to interoperable ophthalmic imaging standards in the United States. Ophthalmology. 2024;131:12&#x2013;15.</Citation></Reference><Reference><Citation>Wang SY, Pershing S, Lee AY&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;&#x200b;,&#x200b; AAO Taskforce on AI and AAO Medical Information Technology Committee. Big data requirements for artificial intelligence. Curr Opin Ophthalmol. 2020;31:318&#x2013;323.</Citation></Reference><Reference><Citation>Park WY, Jeon K, Schmidt TS, et al. Development of medical imaging data standardization for imaging-based observational research: OMOP common data model extension. J Imaging Inform Med. 2024;37:899&#x2013;908.</Citation></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, et al. Observational Health Data Sciences and Informatics (OHDSI): Opportunities for Observational Researchers. Stud Health Technol Inform. 2015;216:574&#x2013;578.</Citation></Reference><Reference><Citation>Regenstrief, L. f. Accessed June 2, 2024. https://loinc.org</Citation></Reference><Reference><Citation>MITA. M. I. a. T. A. Accessed June 2, 2024. http://dicom.nema.org</Citation></Reference><Reference><Citation>MITA. M. I. T. A. DICOM Supplement Overview. Accessed May 29, 2024. https://www.dicomstandard.org/supplements</Citation></Reference><Reference><Citation>Athena. 2024. Accessed May 26, 2024. https://athena.ohdsi.org/search-terms/start</Citation></Reference><Reference><Citation>Rao A, Padhy D, Mudunuri H, et al. Central field index versus visual field index for central visual function in stable glaucoma. J Glaucoma. 2017;26:1&#x2013;7.</Citation></Reference><Reference><Citation>Forrey AW, McDonald CJ, DeMoor G, et al. Logical observation identifier names and codes (LOINC) database: a public use set of codes and names for electronic reporting of clinical laboratory test results. Clin Chem. 1996;42:81&#x2013;90.</Citation></Reference><Reference><Citation>Schweitzer M, Steger B, Hoerbst A, et al. Data exchange standards in teleophthalmology: current and future developments. Stud Health Technol Inform. 2022;293:270&#x2013;277.</Citation></Reference><Reference><Citation>Ayaz M, Pasha MF, Alzahrani MY, et al. The Fast Health Interoperability Resources (FHIR) Standard: systematic literature review of implementations, applications, challenges and opportunities. JMIR Med Inform. 2021;9:e21929.</Citation></Reference><Reference><Citation>Peng Y, Nassirian A, Ahmadi N, et al. Towards the representation of genomic data in HL7 FHIR and OMOP CDM. Stud Health Technol Inform. 2021;283:86&#x2013;94.</Citation></Reference><Reference><Citation>Fischer P, St&#xf6;hr MR, Gall H, et al. Data integration into OMOP CDM for heterogeneous clinical data collections via HL7 FHIR bundles and XSLT. Stud Health Technol Inform. 2020;270:138&#x2013;142.</Citation></Reference><Reference><Citation>Tang S-T, Tjia V, Noga T, et al. Creating a medical imaging workflow based on FHIR, DICOMweb, and SVG. J Digit Imaging. 2023;36:794&#x2013;803.</Citation></Reference><Reference><Citation>Monsalve B, Ferreras A, Calvo P, et al. Diagnostic ability of Humphrey perimetry, Octopus perimetry, and optical coherence tomography for glaucomatous optic neuropathy. Eye (Lond). 2017;31:443&#x2013;451.</Citation></Reference><Reference><Citation>Monsalve B, Ferreras A, Khawaja AP, et al. The relationship between structure and function as measured by OCT and Octopus perimetry. Br J Ophthalmol. 2015;99:1230&#x2013;1235.</Citation></Reference><Reference><Citation>Rajalakshmi AR, Suma E, Prabhu DR. Comparative analysis of visual field plotting by Octopus Interzeag 1-2-3, Humphrey Field Analyser II and frequency doubling perimetry in glaucoma patients in South Indian population. J Clin Diagn Res. 2015;9:NC01&#x2013;NC03.</Citation></Reference><Reference><Citation>Bhaskaran K, Phuljhele S, Kumar P, et al. Comparative evaluation of Octopus semi-automated kinetic perimeter with Humphrey and Goldmann perimeters in neuro-ophthalmic disorders. Indian J Ophthalmol. 2021;69:918&#x2013;922.</Citation></Reference><Reference><Citation>Roberti G, Manni G, Riva I, et al. Detection of central visual field defects in early glaucomatous eyes: Comparison of Humphrey and Octopus perimetry. PLoS One. 2017;12:e0186793.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40200494</PMID><DateCompleted><Year>2025</Year><Month>04</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>323</Volume><PubDate><Year>2025</Year><Month>Apr</Month><Day>08</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>From Heterogeneity to Uniformity: A Metadata-Driven ETL Process for Transforming FHIR Data into OMOP CDM.</ArticleTitle><Pagination><StartPage>290</StartPage><EndPage>291</EndPage><MedlinePgn>290-291</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI250097</ELocationID><Abstract><AbstractText>Heterogeneous data formats complicate unified analysis in multisite clinical studies. Standardizing data in the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) requires Extract-Transform-Load (ETL) processes, which are complex and time-consuming to develop, especially with different source data specifications. The aim of our work is to develop a generalized, metadata-driven ETL process to transform Fast Healthcare Interoperability Resources (FHIR) into OMOP CDM. In this paper, we present first results of the developed metadata-driven ETL process on the example of two different Patient FHIR specifications.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henke</LastName><ForeName>Elisa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sedlmayr</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000071253" MajorTopicYN="Y">Metadata</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073892" MajorTopicYN="Y">Health Information Interoperability</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName><QualifierName UI="Q000458" MajorTopicYN="N">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="Y">Outcome Assessment, Health Care</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ETL</Keyword><Keyword MajorTopicYN="N">FHIR</Keyword><Keyword MajorTopicYN="N">OMOP CDM</Keyword><Keyword MajorTopicYN="N">metadata</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>4</Month><Day>9</Day><Hour>10</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>4</Month><Day>9</Day><Hour>10</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>4</Month><Day>9</Day><Hour>1</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40200494</ArticleId><ArticleId IdType="doi">10.3233/SHTI250097</ArticleId><ArticleId IdType="pii">SHTI250097</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40200507</PMID><DateCompleted><Year>2025</Year><Month>04</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>323</Volume><PubDate><Year>2025</Year><Month>Apr</Month><Day>08</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Mapping National Vocabularies to International Standards Using OHDSI Standardized Vocabularies.</ArticleTitle><Pagination><StartPage>349</StartPage><EndPage>353</EndPage><MedlinePgn>349-353</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI250110</ELocationID><Abstract><AbstractText>Ensuring semantic interoperability in international studies is crucial. In this context, the mapping of national to international vocabularies is necessary. The Standardized Vocabularies of OHDSI provide such a mapping, which forms the basis for semantic interoperability in the standardized data model OMOP CDM. The aim of this paper is to provide a guideline for vocabulary mapping that supports developers in efficiently implementing the technical application of mappings into the ETL process for transforming data to OMOP CDM. By implementing materialized views and creating a decision tree, we provide a solid foundation for efficient semantic mapping in OMOP CDM. With our work, we mark an important step in realizing international observational studies based on OMOP CDM.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Henke</LastName><ForeName>Elisa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lorenz</LastName><ForeName>Stephan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zoch</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sedlmayr</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D018875" MajorTopicYN="Y">Vocabulary, Controlled</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012660" MajorTopicYN="N">Semantics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D038622" MajorTopicYN="N">Internationality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008498" MajorTopicYN="Y">Medical Record Linkage</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">OHDSI</Keyword><Keyword MajorTopicYN="N">OMOP CDM</Keyword><Keyword MajorTopicYN="N">semantic interoperability</Keyword><Keyword MajorTopicYN="N">vocabularies</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>4</Month><Day>9</Day><Hour>10</Hour><Minute>14</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>4</Month><Day>9</Day><Hour>10</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>4</Month><Day>9</Day><Hour>1</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40200507</ArticleId><ArticleId IdType="doi">10.3233/SHTI250110</ArticleId><ArticleId IdType="pii">SHTI250110</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40216777</PMID><DateCompleted><Year>2025</Year><Month>04</Month><Day>11</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Apr</Month><Day>11</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Cardiovascular post-acute sequelae of SARS-CoV-2 in children and adolescents: cohort study using electronic health records.</ArticleTitle><Pagination><StartPage>3445</StartPage><MedlinePgn>3445</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">3445</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-025-56284-0</ELocationID><Abstract><AbstractText>The risk of cardiovascular outcomes following SARS-CoV-2 infection has been reported in adults, but evidence in children and adolescents is limited. This paper assessed the risk of a multitude of cardiac signs, symptoms, and conditions 28-179 days after infection, with outcomes stratified by the presence of congenital heart defects (CHDs), using electronic health records (EHR) data from 19 children's hospitals and health institutions from the United States within the RECOVER consortium between March 2020 and September 2023. The cohort included 297,920 SARS-CoV-2-positive individuals and 915,402 SARS-CoV-2-negative controls. Every individual had at least a six-month follow-up after cohort entry. Here we show that children and adolescents with prior SARS-CoV-2 infection are at a statistically significant increased risk of various cardiovascular outcomes, including hypertension, ventricular arrhythmias, myocarditis, heart failure, cardiomyopathy, cardiac arrest, thromboembolism, chest pain, and palpitations, compared to uninfected controls. These findings were consistent among patients with and without CHDs. Awareness of the heightened risk of cardiovascular disorders after SARS-CoV-2 infection can lead to timely referrals, diagnostic evaluations, and management to mitigate long-term cardiovascular complications in children and adolescents.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Bingyu</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Graduate Group in Applied Mathematics and Computational Science, School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thacker</LastName><ForeName>Deepika</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Nemours Cardiac Center, Nemours Children's Health System, Wilmington, DE, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Ting</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Dazheng</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-1431-0785</Identifier><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lei</LastName><ForeName>Yuqing</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jiajie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chrischilles</LastName><ForeName>Elizabeth A</ForeName><Initials>EA</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, College of Public Health, The University of Iowa, Iowa City, IA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Christakis</LastName><ForeName>Dimitri A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Center for Child Health, Behavior and Development, Seattle Children's Research Institute, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandez</LastName><ForeName>Soledad</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics and Center for Biostatistics, Ohio State University, Columbus, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garg</LastName><ForeName>Vidu</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-3778-5927</Identifier><AffiliationInfo><Affiliation>Heart Center and Center for Cardiovascular Research, Nationwide Children's Hospital, Columbus, OH, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, The Ohio State University, Columbus, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Division of Pediatric Rheumatology, Benioff Children's Hospital, University of California San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mosa</LastName><ForeName>Abu S M</ForeName><Initials>ASM</Initials><Identifier Source="ORCID">0000-0002-8956-1466</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Biostatistics and Medical Epidemiology, University of Missouri School of Medicine, Columbia, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sills</LastName><ForeName>Marion R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Research, OCHIN, Inc, Portland, OR, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>Bradley W</ForeName><Initials>BW</Initials><Identifier Source="ORCID">0000-0002-6414-4172</Identifier><AffiliationInfo><Affiliation>Clinical and Translational Science Institute, Medical College of Wisconsin, Milwaukee, WI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Qiong</ForeName><Initials>Q</Initials><Identifier Source="ORCID">0000-0001-5747-1899</Identifier><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics and Health Data Science, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Forrest</LastName><ForeName>Christopher B</ForeName><Initials>CB</Initials><Identifier Source="ORCID">0000-0003-1252-068X</Identifier><AffiliationInfo><Affiliation>Applied Clinical Research Center, Department of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, USA. forrestc@chop.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Chen</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-0835-0788</Identifier><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, PA, USA. ychen123@pennmedicine.upenn.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Graduate Group in Applied Mathematics and Computational Science, School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA, USA. ychen123@pennmedicine.upenn.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. ychen123@pennmedicine.upenn.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leonard Davis Institute of Health Economics, Philadelphia, PA, USA. ychen123@pennmedicine.upenn.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Penn Medicine Center for Evidence-based Practice (CEP), Philadelphia, PA, USA. ychen123@pennmedicine.upenn.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Penn Institute for Biomedical Informatics (IBI), Philadelphia, PA, USA. ychen123@pennmedicine.upenn.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R56 AG069880</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>OT2 HL161847</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM014344</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG077820</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM013519</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM012607</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>OT2HL161847-01</GrantID><Agency>U.S. Department of Health &amp; Human Services | NIH | National Heart, Lung, and Blood Institute (NHLBI)</Agency><Country/></Grant><Grant><GrantID>R21 AI167418</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 TR003709</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG074604</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG073435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI130460</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 EY034179</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>04</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>medRxiv. 2024 May 15:2024.05.14.24307380. doi: 10.1101/2024.05.14.24307380.</RefSource><PMID Version="1">38798448</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="Y">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006330" MajorTopicYN="N">Heart Defects, Congenital</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>1</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>4</Month><Day>12</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>4</Month><Day>12</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>4</Month><Day>11</Day><Hour>23</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>4</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40216777</ArticleId><ArticleId IdType="pmc">PMC11992182</ArticleId><ArticleId IdType="doi">10.1038/s41467-025-56284-0</ArticleId><ArticleId IdType="pii">10.1038/s41467-025-56284-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization. A Clinical Case Definition of Post COVID-19 Condition by a Delphi Consensus (WHO, 2021).</Citation></Reference><Reference><Citation>World Health Organization. A clinical case definition for post COVID-19 condition in children and adolescents by expert consensus (WHO, 2023).</Citation></Reference><Reference><Citation>Shah, W., Hillman, T., Playford, E. D. &amp; Hishmeh, L. Managing the long term effects of covid-19: summary of NICE, SIGN, and RCGP rapid guideline. BMJ372, n136 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33483331</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institutes of Health (NIH). What isLong COVID? Building Our Understanding AboutRecovery. https://recovercovid.org/long-covid (NIH, 2024).</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention (CDC). Long COVID or Post-COVID Conditions. https://www.cdc.gov/covid/long-term-effects/?CDC_AAref_Val=https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html (Centers for Disease Control and Prevention (CDC), 2023).</Citation></Reference><Reference><Citation>EpiCore. Obtaining Long COVID Definition Through EpiCore. https://endingpandemics.org/wp-content/uploads/2023/03/EPICORE-Long-Covid-Definitions-NASEM-2023-4.pdf (EpiCore, 2023).</Citation></Reference><Reference><Citation>Al-Aly, Z, Xie, Y &amp; Bowe, B High-dimensional characterization of post-acute sequelae of COVID-19. Nature594, 259&#x2013;264 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33887749</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao, S. et al. Clinical features and burden of postacute sequelae of SARS-CoV-2 infection in children and adolescents. JAMA Pediatr.176, 1000&#x2013;1009 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9396470</ArticleId><ArticleId IdType="pubmed">35994282</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie, Y., Xu, E., Bowe, B. &amp; Al-Aly, Z. Long-term cardiovascular outcomes of COVID-19. Nat. Med.28, 583&#x2013;590 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8938267</ArticleId><ArticleId IdType="pubmed">35132265</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani, D. et al. Post-covid syndrome in individuals admitted to hospital with covid-19: retrospective cohort study. BMJ372, n693 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8010267</ArticleId><ArticleId IdType="pubmed">33789877</ArticleId></ArticleIdList></Reference><Reference><Citation>Daugherty, S. E. et al. Risk of clinical sequelae after the acute phase of SARS-CoV-2 infection: retrospective cohort study. BMJ373, n1098 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8132065</ArticleId><ArticleId IdType="pubmed">34011492</ArticleId></ArticleIdList></Reference><Reference><Citation>Carf&#xec;, A., Bernabei, R. &amp; Landi, F. Persistent symptoms in patients after acute COVID-19. JAMA324, 603&#x2013;605 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7349096</ArticleId><ArticleId IdType="pubmed">32644129</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang, C. et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet397, 220&#x2013;232 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Raman, B., Bluemke, D. A., L&#xfc;scher, T. F. &amp; Neubauer, S. Long COVID: post-acute sequelae of COVID-19 with a cardiovascular focus. Eur. Heart J.43, 1157&#x2013;1172 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8903393</ArticleId><ArticleId IdType="pubmed">35176758</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, W., Wang, C.-Y., Wang, S.-I. &amp; Wei, J. C.-C. Long-term cardiovascular outcomes in COVID-19 survivors among non-vaccinated population: a retrospective cohort study from the TriNetX US collaborative networks. eClinicalMedicine53, 101619 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9366236</ArticleId><ArticleId IdType="pubmed">35971425</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim, J. T. et al. Long-term cardiovascular, cerebrovascular, and other thrombotic complications in COVID-19 survivors: a retrospective cohort study. Clin. Infect. Dis.78, 70&#x2013;79 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10810710</ArticleId><ArticleId IdType="pubmed">37746872</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao, S. et al. Postacute Sequelae of SARS-CoV-2 in Children. Pediatrics153, e2023062570 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10904902</ArticleId><ArticleId IdType="pubmed">38321938</ArticleId></ArticleIdList></Reference><Reference><Citation>Block, J. P. et al. Cardiac complications after SARS-CoV-2 infection and mRNA COVID-19 vaccination&#x2014;PCORnet, United States, january 2021&#x2013;January 2022. Morb. Mortal. Wkly. Rep.71, 517 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8989373</ArticleId><ArticleId IdType="pubmed">35389977</ArticleId></ArticleIdList></Reference><Reference><Citation>Abi Nassif, T. et al. Cardiac manifestations in COVID-19 patients: a focus on the pediatric population. Can. J. Infect. Dis. Med. Microbiol.2021, 5518979 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8287458</ArticleId><ArticleId IdType="pubmed">34326911</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakraborty, A. et al. Long-term cardiovascular outcomes of multisystem inflammatory syndrome in children associated with COVID-19 using an institution based algorithm. Pediatr. Cardiol.44, 367&#x2013;380 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9549828</ArticleId><ArticleId IdType="pubmed">36214896</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu, Q. et al. Real-world effectiveness of BNT162b2 against infection and severe diseases in children and adolescents. Ann. Intern. Med.177, 165&#x2013;176 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11956830</ArticleId><ArticleId IdType="pubmed">38190711</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu, P. P., Blet, A., Smyth, D. &amp; Li, H. The science underlying COVID-19: implications for the cardiovascular system. Circulation142, 68&#x2013;78 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32293910</ArticleId></ArticleIdList></Reference><Reference><Citation>Bozkurt, B. et al. 2022 AHA/ACC key data elements and definitions for cardiovascular and noncardiovascular complications of COVID-19: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Data Standards. Circ. Cardiovasc. Qual. Outcomes15, e000111 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9297692</ArticleId><ArticleId IdType="pubmed">35737748</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Der Bom, T. et al. The changing epidemiology of congenital heart disease. Nat. Rev. Cardiol.8, 50&#x2013;60 (2011).</Citation><ArticleIdList><ArticleId IdType="pubmed">21045784</ArticleId></ArticleIdList></Reference><Reference><Citation>Razzaghi, H. et al. Vaccine effectiveness against long COVID in children. Pediatrics153, e2023064446 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10979300</ArticleId><ArticleId IdType="pubmed">38225804</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, T. et al. Body Mass Index and Postacute Sequelae of SARS-CoV-2 Infection in Children and Young Adults. JAMA Netw. Open7, e2441970&#x2013;e2441970 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11581483</ArticleId><ArticleId IdType="pubmed">39466241</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu, Q. et al. Real-world effectiveness and causal mediation study of BNT162b2 on long COVID risks in children and adolescents. EClinicalMedicine79, 102962 (2025).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11667630</ArticleId><ArticleId IdType="pubmed">39720603</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon, T. D., Haaland, W., Hawley, K., Lambka, K. &amp; Mangione-Smith, R. Development and validation of the Pediatric Medical Complexity Algorithm (PMCA) version 3.0. Acad. Pediatr.18, 577&#x2013;580 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6035108</ArticleId><ArticleId IdType="pubmed">29496546</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard, M. A. et al. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet394, 1816&#x2013;1826 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6924620</ArticleId><ArticleId IdType="pubmed">31668726</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin, P. C. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivar. Behav. Res.46, 399&#x2013;424 (2011).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3144483</ArticleId><ArticleId IdType="pubmed">21818162</ArticleId></ArticleIdList></Reference><Reference><Citation>Amoah, J. et al. Comparing propensity score methods versus traditional regression analysis for the evaluation of observational data: a case study evaluating the treatment of gram-negative bloodstream infections. Clin. Infect. Dis.71, e497&#x2013;e505 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7713675</ArticleId><ArticleId IdType="pubmed">32069360</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker, A. M. et al. A tool for assessing the feasibility of comparative effectiveness research. Comp. Eff. Res.3, 11&#x2013;20 (2013).</Citation></Reference><Reference><Citation>Schuemie, M., Madigan, D., Suchard M. &amp; Ryan P. Population-level estimation. in The Book of OHDSI, CH. 12. https://ohdsi.github.io/TheBookOfOhdsi/PopulationLevelEstimation.html (GitHub, 2021).</Citation></Reference><Reference><Citation>Murk, W. et al. Diagnosis-wide analysis of COVID-19 complications: an exposure-crossover study. CMAJ193, E10&#x2013;E18 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7774475</ArticleId><ArticleId IdType="pubmed">33293424</ArticleId></ArticleIdList></Reference><Reference><Citation>Boehmer, T. K. et al. Association between COVID-19 and myocarditis using hospital-based administrative data&#x2014;United States, March 2020&#x2013;January 2021. Morb. Mortal. Wkly. Rep.70, 1228 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8422872</ArticleId><ArticleId IdType="pubmed">34473684</ArticleId></ArticleIdList></Reference><Reference><Citation>Barda, N. et al. Safety of the BNT162b2 mRNA Covid-19 vaccine in a nationwide setting. N. Engl. J. Med.385, 1078&#x2013;1090 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8427535</ArticleId><ArticleId IdType="pubmed">34432976</ArticleId></ArticleIdList></Reference><Reference><Citation>Rathore, S. S. et al. Myocarditis associated with Covid-19 disease: a systematic review of published case reports and case series. Int J. Clin. Pr.75, e14470 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34235815</ArticleId></ArticleIdList></Reference><Reference><Citation>Alsaied, T. et al. Review of cardiac involvement in multisystem inflammatory syndrome in children. Circulation143, 78&#x2013;88 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33166178</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanni, S. E., Tonon, C. R., Gatto, M., Mota, G. A. F. &amp; Okoshi, M. P. Post-COVID-19 syndrome: Cardiovascular manifestations. Int J. Cardiol.369, 80 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9434909</ArticleId><ArticleId IdType="pubmed">36058345</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee, C. C. E. et al. COVID-19-associated cardiovascular complications. Diseases9, 47 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8293160</ArticleId><ArticleId IdType="pubmed">34209705</ArticleId></ArticleIdList></Reference><Reference><Citation>Bisaccia, G. et al. Post-acute sequelae of COVID-19 and cardiovascular autonomic dysfunction: what do we know? J. Cardiovasc Dev. Dis.8, 156 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8621226</ArticleId><ArticleId IdType="pubmed">34821709</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie, Y., Choi, T. &amp; Al-Aly, Z. Postacute sequelae of SARS-CoV-2 infection in the pre-delta, delta, and omicron eras. N. Engl. J. Med.391, 515&#x2013;525 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11687648</ArticleId><ArticleId IdType="pubmed">39018527</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballouz, T. et al. Post COVID-19 condition after Wildtype, Delta, and Omicron SARS-CoV-2 infection and prior vaccination: pooled analysis of two population-based cohorts. PLoS ONE18, e0281429 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9946205</ArticleId><ArticleId IdType="pubmed">36812215</ArticleId></ArticleIdList></Reference><Reference><Citation>Hyams, C. et al. Severity of Omicron (B. 1.1. 529) and Delta (B. 1.617. 2) SARS-CoV-2 infection among hospitalised adults: a prospective cohort study in Bristol, United Kingdom. Lancet Reg. Health&#x2013;Eur.25, 100556 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9742675</ArticleId><ArticleId IdType="pubmed">36530491</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenland, S., Pearl, J. &amp; Robins, J. M. Confounding and collapsibility in causal inference. Stat. Sci.14, 29&#x2013;46 (1999).</Citation></Reference><Reference><Citation>Whitcomb, B. W. &amp; Naimi, A. I. Defining, quantifying, and interpreting &#x201c;noncollapsibility&#x201d; in epidemiologic studies of measures of &#x201c;effect&#x201d;. Am. J. Epidemiol.190, 697&#x2013;700 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8530151</ArticleId><ArticleId IdType="pubmed">33305812</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie, M. J., Hripcsak, G., Ryan, P. B., Madigan, D. &amp; Suchard, M. A. Empirical confidence interval calibration for population-level effect estimation studies in observational healthcare data. Proc. Natl. Acad. Sci.115, 2571&#x2013;2577 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5856503</ArticleId><ArticleId IdType="pubmed">29531023</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie, M. J., Ryan, P. B., DuMouchel, W., Suchard, M. A. &amp; Madigan, D. Interpreting observational studies: why empirical calibration is needed to correct p-values. Stat. Med33, 209&#x2013;218 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4285234</ArticleId><ArticleId IdType="pubmed">23900808</ArticleId></ArticleIdList></Reference><Reference><Citation>Chowdhury, D. et al. Return to activity after SARS-CoV-2 infection: cardiac clearance for children and adolescents. Sports Health14, 460&#x2013;465 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9214892</ArticleId><ArticleId IdType="pubmed">34427496</ArticleId></ArticleIdList></Reference><Reference><Citation>Daniels, C. J. et al. Prevalence of clinical and subclinical myocarditis in competitive athletes with recent SARS-CoV-2 infection: results from the big ten COVID-19 cardiac registry. JAMA Cardiol.6, 1078&#x2013;1087 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8160916</ArticleId><ArticleId IdType="pubmed">34042947</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis, H. E., McCorkell, L., Vogel, J. M. &amp; Topol, E. J. Long COVID: major findings, mechanisms and recommendations. Nat. Rev. Microbiol21, 133&#x2013;146 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, Y., Wang, J., Chubak, J. &amp; Hubbard, R. A. Inflation of type I error rates due to differential misclassification in EHR-derived outcomes: empirical illustration using breast cancer recurrence. Pharmacoepidemiol Drug Saf.28, 264&#x2013;268 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6716793</ArticleId><ArticleId IdType="pubmed">30375122</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan, R. et al. An empirical study for impacts of measurement errors on EHR based association studies. in AMIA Annual Symposium Proceedings, Vol. 2016, 1764&#x2013;1773 (American Medical Informatics Association, 2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5333313</ArticleId><ArticleId IdType="pubmed">28269935</ArticleId></ArticleIdList></Reference><Reference><Citation>Asch, D. A. et al. Variation in US Hospital Mortality Rates for Patients Admitted With COVID-19 During the First 6 Months of the Pandemic. JAMA Intern. Med. 181, 471&#x2013;478 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7756246</ArticleId><ArticleId IdType="pubmed">33351068</ArticleId></ArticleIdList></Reference><Reference><Citation>Truong, D. T. et al. Clinically suspected myocarditis temporally related to COVID-19 vaccination in adolescents and young adults: suspected myocarditis after COVID-19 vaccination. Circulation145, 345&#x2013;356 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">34865500</ArticleId></ArticleIdList></Reference><Reference><Citation>Kohli, U. et al. mRNA coronavirus disease 2019 vaccine-associated myopericarditis in adolescents: a survey study. J. Pediatr.243, 208&#x2013;213 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691954</ArticleId><ArticleId IdType="pubmed">34952008</ArticleId></ArticleIdList></Reference><Reference><Citation>Stowe, J., Miller, E., Andrews, N. &amp; Whitaker, H. J. Risk of myocarditis and pericarditis after a COVID-19 mRNA vaccine booster and after COVID-19 in those with and without prior SARS-CoV-2 infection: a self-controlled case series analysis in England. PLoS Med20, e1004245 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10286992</ArticleId><ArticleId IdType="pubmed">37285378</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabatino, J. et al. Mid-and long-term atrio-ventricular functional changes in children after recovery from COVID-19. J. Clin. Med12, 186 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9820895</ArticleId><ArticleId IdType="pubmed">36614987</ArticleId></ArticleIdList></Reference><Reference><Citation>Ortega-Paz, L. et al. One-year cardiovascular outcomes after coronavirus disease 2019: The cardiovascular COVID-19 registry. PLoS ONE17, e0279333 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9803130</ArticleId><ArticleId IdType="pubmed">36583998</ArticleId></ArticleIdList></Reference><Reference><Citation>Radtke, T., Ulyte, A., Puhan, M. A. &amp; Kriemler, S. Long-term symptoms after SARS-CoV-2 infection in children and adolescents. JAMA326, 869&#x2013;871 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8283661</ArticleId><ArticleId IdType="pubmed">34264266</ArticleId></ArticleIdList></Reference><Reference><Citation>Chavers, B. M., Li, S., Collins, A. J. &amp; Herzog, C. A. Cardiovascular disease in pediatric chronic dialysis patients. Kidney Int.62, 648&#x2013;653 (2002).</Citation><ArticleIdList><ArticleId IdType="pubmed">12110030</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma, C. et al. Multisystem inflammatory syndrome in children and Kawasaki disease: a critical comparison. Nat. Rev. Rheumatol.17, 731&#x2013;748 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8554518</ArticleId><ArticleId IdType="pubmed">34716418</ArticleId></ArticleIdList></Reference><Reference><Citation>Harahsheh, A. S. et al. Kawasaki Disease in the time of COVID-19 and MIS-C: the International Kawasaki Disease Registry. Can. J. Cardiol.40, 58&#x2013;72 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10245460</ArticleId><ArticleId IdType="pubmed">37290536</ArticleId></ArticleIdList></Reference><Reference><Citation>Peco-Anti&#x107;, A. &amp; Paripovi&#x107;, D. Renal hypertension and cardiovascular disorder in children with chronic kidney disease. Srp. Arh. Celok. Lek.142, 113&#x2013;117 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24684043</ArticleId></ArticleIdList></Reference><Reference><Citation>Weaver, D. J. &amp; Mitsnefes, M. Cardiovascular disease in children and adolescents with chronic kidney disease. in Seminars in Nephrology, Vol. 38, 559&#x2013;569 (Elsevier, 2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30413251</ArticleId></ArticleIdList></Reference><Reference><Citation>Pawar, S. M. Multi system inflammatory syndrome in children and adolescents temporally related to COVID-19. GFNPSS-Int J. Multidiscip. Res1, 97&#x2013;102 (2020).</Citation></Reference><Reference><Citation>Matsubara, D. et al. Echocardiographic findings in pediatric multisystem inflammatory syndrome associated with COVID-19 in the United States. J. Am. Coll. Cardiol.76, 1947&#x2013;1961 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7467656</ArticleId><ArticleId IdType="pubmed">32890666</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention. COVID Data Tracker. Atlanta, GA: US Department of Health and Human Services, CDC. https://covid.cdc.gov/covid-data-tracker (2023).</Citation></Reference><Reference><Citation>Forrest, C. B. et al. PEDSnet: a national pediatric learning health system. J. Am. Med. Inform. Assoc.21, 602&#x2013;606 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4078288</ArticleId><ArticleId IdType="pubmed">24821737</ArticleId></ArticleIdList></Reference><Reference><Citation>PCORnet Common Data Model. https://pcornet.org/data/common-data-model/.</Citation></Reference><Reference><Citation>PEDSnet Common Data Model. https://pedsnet.org/data/pedsnet-common-data-model/.</Citation></Reference><Reference><Citation>Woodruff, R. C. et al. Risk factors for severe COVID-19 in children. Pediatrics149, e2021053418 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9213563</ArticleId><ArticleId IdType="pubmed">34935038</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin, P. C. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat. Med.28, 3083&#x2013;3107 (2009).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3472075</ArticleId><ArticleId IdType="pubmed">19757444</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou, G. A modified poisson regression approach to prospective studies with binary data. Am. J. Epidemiol.159, 702&#x2013;706 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15033648</ArticleId></ArticleIdList></Reference><Reference><Citation>Forrest, C. B. et al. Severity of acute COVID-19 in children&lt;18 years old March 2020 to December 2021. Pediatrics149, e2021055765 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35322270</ArticleId></ArticleIdList></Reference><Reference><Citation>GISAID, via CoVariants.org&#x2014;processed by Our World in Data. https://ourworldindata.org/grapher/covid-variants-area?time=earliest..2023-03-06&amp;country=~USA (2024).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40232773</PMID><DateCompleted><Year>2025</Year><Month>04</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>02</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1438-8871</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><PubDate><Year>2025</Year><Month>Apr</Month><Day>15</Day></PubDate></JournalIssue><Title>Journal of medical Internet research</Title><ISOAbbreviation>J Med Internet Res</ISOAbbreviation></Journal><ArticleTitle>Data Interoperability in Context: The Importance of Open-Source Implementations When Choosing Open Standards.</ArticleTitle><Pagination><StartPage>e66616</StartPage><MedlinePgn>e66616</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e66616</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.2196/66616</ELocationID><Abstract><AbstractText>Following the proposal by Tsafnat et al (2024) to converge on three open health data standards, this viewpoint offers a critical reflection on their proposed alignment of openEHR, Fast Health Interoperability Resources (FHIR), and Observational Medical Outcomes Partnership (OMOP) as default data standards for clinical care and administration, data exchange, and longitudinal analysis, respectively. We argue that open standards are a necessary but not sufficient condition to achieve health data interoperability. The ecosystem of open-source software needs to be considered when choosing an appropriate standard for a given context. We discuss two specific contexts, namely standardization of (1) health data for federated learning, and (2) health data sharing in low- and middle-income countries. Specific design principles, practical considerations, and implementation choices for these two contexts are described, based on ongoing work in both areas. In the case of federated learning, we observe convergence toward OMOP and FHIR, where the two standards can effectively be used side-by-side given the availability of mediators between the two. In the case of health information exchanges in low and middle-income countries, we see a strong convergence toward FHIR as the primary standard. We propose practical guidelines for context-specific adaptation of open health data standards.</AbstractText><CopyrightInformation>&#xa9;Daniel Kapitan, Femke Heddema, Andr&#xe9; Dekker, Melle Sieswerda, Bart-Jan Verhoeff, Matt Berg. Originally published in the Journal of Medical Internet Research (https://www.jmir.org), 15.04.2025.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kapitan</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-8979-9194</Identifier><AffiliationInfo><Affiliation>Eindhoven AI Systems Institute (EAISI), Eindhoven University of Technology, Eindhoven, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>PharmAccess Foundation, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Dutch Hospital Data, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heddema</LastName><ForeName>Femke</ForeName><Initials>F</Initials><Identifier Source="ORCID">0009-0007-4240-9786</Identifier><AffiliationInfo><Affiliation>PharmAccess Foundation, Amsterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dekker</LastName><ForeName>Andr&#xe9;</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-0422-7996</Identifier><AffiliationInfo><Affiliation>MAASTRO Clinic, Maastricht University Medical Centre, Maastricht University, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sieswerda</LastName><ForeName>Melle</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2025-0771</Identifier><AffiliationInfo><Affiliation>Netherlands Comprehensive Cancer Organisation, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verhoeff</LastName><ForeName>Bart-Jan</ForeName><Initials>BJ</Initials><Identifier Source="ORCID">0009-0002-3292-2424</Identifier><AffiliationInfo><Affiliation>Expertisecentrum Zorgalgoritmen, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berg</LastName><ForeName>Matt</ForeName><Initials>M</Initials><Identifier Source="ORCID">0009-0003-3041-5709</Identifier><AffiliationInfo><Affiliation>Ona, Burlington, VT, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>04</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>J Med Internet Res</MedlineTA><NlmUniqueID>100959882</NlmUniqueID><ISSNLinking>1438-8871</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000073892" MajorTopicYN="Y">Health Information Interoperability</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012984" MajorTopicYN="N">Software</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">FHIR</Keyword><Keyword MajorTopicYN="N">Fast Health Interoperability Resources</Keyword><Keyword MajorTopicYN="N">LMIC</Keyword><Keyword MajorTopicYN="N">OMOP</Keyword><Keyword MajorTopicYN="N">Observational Medical Outcomes Partnership</Keyword><Keyword MajorTopicYN="N">clinical care</Keyword><Keyword MajorTopicYN="N">data exchange</Keyword><Keyword MajorTopicYN="N">data interoperability</Keyword><Keyword MajorTopicYN="N">data sharing</Keyword><Keyword MajorTopicYN="N">developing countries</Keyword><Keyword MajorTopicYN="N">developing nations</Keyword><Keyword MajorTopicYN="N">digital platform</Keyword><Keyword MajorTopicYN="N">health care informatics</Keyword><Keyword MajorTopicYN="N">health information exchange</Keyword><Keyword MajorTopicYN="N">information standards</Keyword><Keyword MajorTopicYN="N">longitudinal analysis</Keyword><Keyword MajorTopicYN="N">low and middle-income countries</Keyword><Keyword MajorTopicYN="N">low income</Keyword><Keyword MajorTopicYN="N">middle-income</Keyword><Keyword MajorTopicYN="N">open source implementations</Keyword><Keyword MajorTopicYN="N">open standards</Keyword><Keyword MajorTopicYN="N">openEHR</Keyword><Keyword MajorTopicYN="N">secondary use</Keyword></KeywordList><CoiStatement>Conflicts of Interest: AD is the founder, an employee, and a stockholder of Medical Data Works B.V., which provides commercial services for federated data infrastructures. BJV is the co-founder, a stockholder and director of Expertisecentrum Zorgalgoritmen, an AI software company. MB is a co-founder, a stockholder and CEO of Ona, which provides commercial services for health information exchange infrastructures.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>3</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>2</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>4</Month><Day>15</Day><Hour>18</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>4</Month><Day>15</Day><Hour>12</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>4</Month><Day>15</Day><Hour>11</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>4</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40232773</ArticleId><ArticleId IdType="pmc">PMC12041819</ArticleId><ArticleId IdType="doi">10.2196/66616</ArticleId><ArticleId IdType="pii">v27i1e66616</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tsafnat G, Dunscombe R, Gabriel D, Grieve G, Reich C. Converge or collide? Making sense of a plethora of open data standards in health care. J Med Internet Res. 2024;26:e55779. doi: 10.2196/55779. 
 
v26i1e55779</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/55779</ArticleId><ArticleId IdType="pmc">PMC11040436</ArticleId><ArticleId IdType="pubmed">38593431</ArticleId></ArticleIdList></Reference><Reference><Citation>de Reuver M, S&#xf8;rensen C, Basole RC. The digital platform: a research agenda. J Inf Technol. 2018;33(2):124&#x2013;135. doi: 10.1057/s41265-016-0033-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1057/s41265-016-0033-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Keller P, Tarkowski A. The paradox of open. Open Future. 2021.  [2024-03-25].  
 https://openfuture.pubpub.org/pub/paradox-of-open/release/1
.</Citation></Reference><Reference><Citation>Estrin D, Sim I. Health care delivery. Open mHealth architecture: an engine for health care innovation. Science. 2010;330(6005):759&#x2013;760. doi: 10.1126/science.1196187.330/6005/759</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1196187</ArticleId><ArticleId IdType="pubmed">21051617</ArticleId></ArticleIdList></Reference><Reference><Citation>Beck M. On the hourglass model. Commun ACM. 2019;62(7):48&#x2013;57. doi: 10.1145/3274770.</Citation><ArticleIdList><ArticleId IdType="doi">10.1145/3274770</ArticleId></ArticleIdList></Reference><Reference><Citation>de RM, Ofe H, Agahari W, Abbas A, Zuiderwijk A. The openness of data platforms: a research agenda. CoNEXT '22: The 18th International Conference on emerging Networking EXperiments and Technologies; December 9, 2022; Rome Italy. ACM; 2022. pp. 34&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="doi">10.1145/3565011.3569056</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds CJ, Wyatt JC. Open source, open standards, and health care information systems. J Med Internet Res. 2011;13(1):e24. doi: 10.2196/jmir.1521. 
 
v13i1e24</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/jmir.1521</ArticleId><ArticleId IdType="pmc">PMC3221346</ArticleId><ArticleId IdType="pubmed">21447469</ArticleId></ArticleIdList></Reference><Reference><Citation>GSM. Wikipedia. 2024.  [2024-09-20].  
 https://en.wikipedia.org/w/index.php?title=GSM&amp;oldid=1245675274
.</Citation></Reference><Reference><Citation>The state of FHIR 2024 survey results. HL7.  [2024-04-04].  
 https://www.hl7.org/documentcenter/public/white-papers/2024%20StateofFHIRSurveyResults_final.pdf
.</Citation></Reference><Reference><Citation>Carmo A, Martins H. D2.2&#x2014;EHRxF in a Nutshell-WP2-ISCTE. 2024.  [2025-03-28].  
 https://ehr-exchange-format.eu/wp-content/uploads/2024/10/D2.2-v20240704-EHRxF-in-a-Nutshell-WP2-ISCTE.pdf
.</Citation></Reference><Reference><Citation>FHIR in US healthcare regulations. Firely. 2023.  [2024-05-30].  
 https://simplifier.net/organization/firely/news/153
.</Citation></Reference><Reference><Citation>National digital health mission. India National Health Authority. 2020.  [2025-03-28].  
 https://www.niti.gov.in/sites/default/files/2023-02/ndhm_strategy_overview.pdf
.</Citation></Reference><Reference><Citation>HCX Protocol V0.9. 2023.  [2024-09-18].  
 http://hcxprotocol.io/
</Citation></Reference><Reference><Citation>Tilahun B, Mamuye A, Yilma T, Shehata Y. African Union health information exchange guidelines and standards. 2023.  [2025-03-28].  
 https://africacdc.org/download/african-union-health-information-exchange-guidelines-and-standards/
</Citation></Reference><Reference><Citation>Mehl GL, Seneviratne MG, Berg ML. A full-STAC remedy for global digital health transformation: open standards, technologies, architectures and content. Oxford Open Digital Health. 2023;1:oqae048. doi: 10.1093/oodh/oqae048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/oodh/oqae048</ArticleId><ArticleId IdType="pmc">PMC11932414</ArticleId><ArticleId IdType="pubmed">40231272</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandl KD, Gottlieb D, Mandel JC, Ignatov V, Sayeed R, Grieve G, Jones J, Ellis A, Culbertson A. Push button population health: the SMART/HL7 FHIR bulk data access application programming interface. NPJ Digital Med. 2020;3(1):151. doi: 10.1038/s41746-020-00358-4. 
 
10.1038/s41746-020-00358-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41746-020-00358-4</ArticleId><ArticleId IdType="doi">10.1038/s41746-020-00358-4</ArticleId><ArticleId IdType="pmc">PMC7678833</ArticleId><ArticleId IdType="pubmed">33299056</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones J, Gottlieb D, Mandel J, Ignatov V, Ellis A, Kubick W, Mandl KD. A landscape survey of planned SMART/HL7 bulk FHIR data access API implementations and tools. J Am Med Inform Assoc. 2021;28(6):1284&#x2013;1287. doi: 10.1093/jamia/ocab028. 
 
6155897</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocab028</ArticleId><ArticleId IdType="pmc">PMC8661398</ArticleId><ArticleId IdType="pubmed">33675659</ArticleId></ArticleIdList></Reference><Reference><Citation>SQL on FHIR V2.0.0-Pre.  [2024-09-20].  
 https://build.fhir.org/ig/FHIR/sql-on-fhir-v2/
</Citation></Reference><Reference><Citation>FHIR Open Source Implementations.  [2024-09-20].  
 https://confluence.hl7.org/display/FHIR/Open+Source+Implementations
.</Citation></Reference><Reference><Citation>Software tools. OHDSI.  [2024-09-20].  
 https://www.ohdsi.org/software-tools/
</Citation></Reference><Reference><Citation>Beale SHT. OpenEHR platform.  [2024-09-20].  
 https://openehr.org/products_tools/platform/
</Citation></Reference><Reference><Citation>EHRbase 2.0 Website. 2024.  [2024-09-20].  
 https://www.ehrbase.org/
</Citation></Reference><Reference><Citation>Rieke N, Hancox J, Li W, Milletar&#xec; F, Roth HR, Albarqouni S, Bakas S, Galtier MN, Landman BA, Maier-Hein K, Ourselin S, Sheller M, Summers RM, Trask A, Xu D, Baust M, Cardoso MJ. The future of digital health with federated learning. NPJ Digital Med. 2020;3:119. doi: 10.1038/s41746-020-00323-1. 
 
10.1038/s41746-020-00323-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41746-020-00323-1</ArticleId><ArticleId IdType="doi">10.1038/s41746-020-00323-1</ArticleId><ArticleId IdType="pmc">PMC7490367</ArticleId><ArticleId IdType="pubmed">33015372</ArticleId></ArticleIdList></Reference><Reference><Citation>Teo ZL, Jin L, Li S, Miao D, Zhang X, Ng WY, Tan TF, Lee DM, Chua KJ, Heng J, Liu Y, Goh RSM, Ting DSW. Federated machine learning in healthcare: a systematic review on clinical applications and technical architecture. Cell Rep Med. 2024;5(2):101419. doi: 10.1016/j.xcrm.2024.101419. 
 
S2666-3791(24)00042-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2024.101419</ArticleId><ArticleId IdType="pmc">PMC10897620</ArticleId><ArticleId IdType="pubmed">38340728</ArticleId></ArticleIdList></Reference><Reference><Citation>Platform voor uitwisseling en hergebruik van klinische data nederland. PLUGIN.  [2024-03-14].  
 https://plugin.healthcare/
</Citation></Reference><Reference><Citation>Agreements on the national health data infrastructure for research, policy and innovation - health-RI nationale gezondheidsdata-infrastructuur - confluence. Health-RI. 2024.  [2024-06-03].  
 https://health-ri.atlassian.net/wiki/spaces/HNG/pages/997466565/Health+data+infrastructure+for+research+policy+and+innovation
.</Citation></Reference><Reference><Citation>Khalid S, Yang C, Blacketer C, Duarte-Salles T, Fern&#xe1;ndez-Bertol&#xed;n S, Kim C, Park RW, Park J, Schuemie MJ, Sena AG, Suchard MA, You SC, Rijnbeek PR, Reps JM. A standardized analytics pipeline for reliable and rapid development and validation of prediction models using observational health data. Comput Methods Programs Biomed. 2021;211:106394. doi: 10.1016/j.cmpb.2021.106394. 
 
S0169-2607(21)00468-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmpb.2021.106394</ArticleId><ArticleId IdType="pmc">PMC8420135</ArticleId><ArticleId IdType="pubmed">34560604</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee S, Kim C, Chang J, Park RW. FeederNet (Federated E-Health Big Data for Evidence Renovation Network) platform in Korea. OHSDI.  [2024-06-04].  
 https://www.ohdsi.org/2022showcase-33/
</Citation></Reference><Reference><Citation>Mateus P, Moonen J, Beran M, Jaarsma E, van der Landen SM, Heuvelink J, Birhanu M, Harms AG, Bron E, Wolters FJ, Cats D, Mei H, Oomens J, Jansen W, Schram MT, Dekker A, Bermejo I. Data harmonization and federated learning for multi-cohort dementia research using the OMOP common data model: a Netherlands consortium of dementia cohorts case study. J Biomed Inform. 2024;155:104661. doi: 10.1016/j.jbi.2024.104661. 
 
S1532-0464(24)00079-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2024.104661</ArticleId><ArticleId IdType="pubmed">38806105</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroes JA, Bansal AT, Berret E, Christian N, Kremer A, Alloni A, Gabetta M, Marshall C, Wagers S, Djukanovic R, Porsbjerg C, Hamerlijnck D, Fulton O, Ten Brinke A, Bel EH, Sont JK. Blueprint for harmonising unstandardised disease registries to allow federated data analysis: prepare for the future. ERJ Open Res. 2022;8(4):00168&#x2013;2022. doi: 10.1183/23120541.00168-2022. 
 
00168-2022</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/23120541.00168-2022</ArticleId><ArticleId IdType="pmc">PMC9530887</ArticleId><ArticleId IdType="pubmed">36199590</ArticleId></ArticleIdList></Reference><Reference><Citation>Deltomme C, Denturck K, De JP. Federated Health Innovation Network (FHIN)  [2024-09-20].  
 https://www.ohdsi-europe.org/images/symposium-2024/Posters/poster%20OHDSI%20FHIN%20Camille%20Deltomme%20-%20Camille%20Deltomme.pdf
.</Citation></Reference><Reference><Citation>Moncada-Torres A, Martin F, Sieswerda M, Van Soest J, Geleijnse G. VANTAGE6: an open source priVAcy preserviNg federaTed leArninG infrastructurE for secure insight eXchange. AMIA Annu Symp Proc. 2020;2020:870&#x2013;877. 
 
122_3404526</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8075508</ArticleId><ArticleId IdType="pubmed">33936462</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhury A, van SJ, Nayak S, Dekker A. Personal health train on FHIR: a privacy preserving federated approach for analyzing FAIR data in healthcare. Machine Learning, Image Processing, Network Security and Data Sciences; July 30-31, 2020; Silchar, India. Springer; 2020. pp. 85&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-981-15-6315-7_7</ArticleId></ArticleIdList></Reference><Reference><Citation>Smits D, Van Beusekom B, Martin F, Veen L, Geleijnse G, Moncada-Torres A. An improved infrastructure for privacy-preserving analysis of patient data. Stud Health Technol Inform. 2022;295:144&#x2013;147. doi: 10.3233/SHTI220682.SHTI220682</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/SHTI220682</ArticleId><ArticleId IdType="pubmed">35773828</ArticleId></ArticleIdList></Reference><Reference><Citation>Duda SN, Kennedy N, Conway D, Cheng AC, Nguyen V, Zayas-Cab&#xe1;n T, Harris PA. HL7 FHIR-based tools and initiatives to support clinical research: a scoping review. J Am Med Inform Assoc. 2022;29(9):1642&#x2013;1653. doi: 10.1093/jamia/ocac105. 
 
6639865</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocac105</ArticleId><ArticleId IdType="pmc">PMC9382376</ArticleId><ArticleId IdType="pubmed">35818340</ArticleId></ArticleIdList></Reference><Reference><Citation>Mullie L, Afilalo J, Archambault P, Bouchakri R, Brown K, Buckeridge DL, Cavayas YA, Turgeon AF, Martineau D, Lamontagne F, Lebrasseur M, Lemieux R, Li J, Sauthier M, St-Onge P, Tang A, Witteman W, Chass&#xe9; M. CODA: an open-source platform for federated analysis and machine learning on distributed healthcare data. J Am Med Inform Assoc. 2024;31(3):651&#x2013;665. doi: 10.1093/jamia/ocad235. 
 
7486840</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocad235</ArticleId><ArticleId IdType="pmc">PMC10873779</ArticleId><ArticleId IdType="pubmed">38128123</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinaci AA, Gencturk M, Alvarez-Romero C, Laleci Erturkmen GB, Martinez-Garcia A, Escalona-Cuaresma MJ, Parra-Calderon CL. Privacy-preserving federated machine learning on FAIR health data: a real-world application. Comput Struct Biotechnol J. 2024;24:136&#x2013;145. doi: 10.1016/j.csbj.2024.02.014. 
 
S2001-0370(24)00038-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.csbj.2024.02.014</ArticleId><ArticleId IdType="pmc">PMC10904920</ArticleId><ArticleId IdType="pubmed">38434250</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruendner J, Schwachhofer T, Sippl P, Wolf N, Erpenbeck M, Gulden C, Kapsner LA, Zierk J, Mate S, St&#xfc;rzl M, Croner R, Prokosch H, Toddenroth D. KETOS: Clinical decision support and machine learning as a service&#x2014;a training and deployment platform based on docker, OMOP-CDM, and FHIR web services. PLoS One. 2019;14(10):e0223010. doi: 10.1371/journal.pone.0223010. 
 
PONE-D-19-12555</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0223010</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0223010</ArticleId><ArticleId IdType="pmc">PMC6776354</ArticleId><ArticleId IdType="pubmed">31581246</ArticleId></ArticleIdList></Reference><Reference><Citation>Cremonesi F, Planat V, Kalokyri V, Kondylakis H, Sanavia T, Resinas VMM, Singh B, Uribe S. The need for multimodal health data modeling: a practical approach for a federated-learning healthcare platform. J Biomed Inform. 2023;141:104338. doi: 10.1016/j.jbi.2023.104338. 
 
S1532-0464(23)00059-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2023.104338</ArticleId><ArticleId IdType="pubmed">37023843</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng Y, Henke E, Reinecke I, Zoch M, Sedlmayr M, Bathelt F. An ETL-process design for data harmonization to participate in international research with German real-world data based on FHIR and OMOP CDM. Int J Med Inform. 2023;169:104925. doi: 10.1016/j.ijmedinf.2022.104925. 
 
S1386-5056(22)00239-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijmedinf.2022.104925</ArticleId><ArticleId IdType="pubmed">36395615</ArticleId></ArticleIdList></Reference><Reference><Citation>OMOPonFHIR.  [2024-09-20].  
 https://omoponfhir.org/
</Citation></Reference><Reference><Citation>Hai R, Koutras C, Quix C, Jarke M. Data Lakes: a survey of functions and systems. IEEE Trans Knowl Data Eng. 2023;35(12):12571&#x2013;12590. doi: 10.1109/tkde.2023.3270101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/tkde.2023.3270101</ArticleId></ArticleIdList></Reference><Reference><Citation>Harby AA, Zulkernine F. From data warehouse to lakehouse: a comparative review. IEEE International Conference on Big Data (Big Data); December 17-20, 2022; Osaka, Japan. IEEE; 2022. pp. 389&#x2013;395.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/bigdata55660.2022.10020719</ArticleId></ArticleIdList></Reference><Reference><Citation>Harby A, Zulkernine F. Data lakehouse: a survey and experimental study. Inf Syst. 2025;127:102460. doi: 10.2139/ssrn.4765588.</Citation><ArticleIdList><ArticleId IdType="doi">10.2139/ssrn.4765588</ArticleId></ArticleIdList></Reference><Reference><Citation>Armbrust M, Ghodsi A, Xin R, Zaharia M. Lakehouse: a new generation of open platforms that unify data warehousing and advanced analytics. 2021.  [2025-03-28].  
 https://www.cidrdb.org/cidr2021/papers/cidr2021_paper17.pdf
.</Citation></Reference><Reference><Citation>Pedreira P, Erling O, Karanasos K, Schneider S, McKinney W, Valluri SR, Zait M, Nadeau J. The composable data management system manifesto. Proc VLDB Endow. 2023;16(10):2679&#x2013;2685. doi: 10.14778/3603581.3603604.</Citation><ArticleIdList><ArticleId IdType="doi">10.14778/3603581.3603604</ArticleId></ArticleIdList></Reference><Reference><Citation>Apache Arrow.  [2024-09-20].  
 https://arrow.apache.org/
</Citation></Reference><Reference><Citation>Apache Parquet. 2024.  [2024-09-20].  
 https://parquet.apache.org/
</Citation></Reference><Reference><Citation>Jain P, Kraft P, Power C, Das T, Stoica I, Zaharia M. Analyzing and comparing lakehouse storage systems. 2023.  [2025-03-28].  
 https://www.cidrdb.org/cidr2023/papers/p92-jain.pdf
.</Citation></Reference><Reference><Citation>Apache Iceberg.  [2024-09-20].  
 https://iceberg.apache.org/
</Citation></Reference><Reference><Citation>An in-process SQL OLAP database management system.  [2024-10-10].  
 https://duckdb.org/
</Citation></Reference><Reference><Citation>Karamagi HC, Muneene D, Droti B, Jepchumba V, Okeibunor JC, Nabyonga J, Asamani JA, Traore M, Kipruto H. eHealth or e-Chaos: the use of digital health interventions for health systems strengthening in Sub-Saharan Africa over the last 10 years: A scoping review. J Global Health. 2022;12:04090. doi: 10.7189/jogh.12.04090. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.7189/jogh.12.04090</ArticleId><ArticleId IdType="pmc">PMC9718445</ArticleId><ArticleId IdType="pubmed">36462201</ArticleId></ArticleIdList></Reference><Reference><Citation>OpenHIE framework V5.2-En.  [2024-08-27].  
 https://ohie.org/
</Citation></Reference><Reference><Citation>Mamuye AL, Yilma TM, Abdulwahab A, Broomhead S, Zondo P, Kyeng M, Maeda J, Abdulaziz M, Wuhib T, Tilahun BC. Health information exchange policy and standards for digital health systems in Africa: a systematic review. PLOS Digital Health. 2022;1(10):e0000118. doi: 10.1371/journal.pdig.0000118. 
 
PDIG-D-22-00058</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pdig.0000118</ArticleId><ArticleId IdType="pmc">PMC9931258</ArticleId><ArticleId IdType="pubmed">36812615</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalhatu I, Aniekwe C, Bashorun A, Abdulkadir A, Dirlikov E, Ohakanu S, Adedokun O, Oladipo A, Jahun I, Murie L, Yoon S, Abdu-Aguye MG, Sylvanus A, Indyer S, Abbas I, Bello M, Nalda N, Alagi M, Odafe S, Adebajo S, Ogorry O, Akpu M, Okoye I, Kakanfo K, Onovo AA, Ashefor G, Nzelu C, Ikpeazu A, Aliyu G, Ellerbrock T, Boyd M, Stafford KA, Swaminathan M. From paper files to web-based application for data-driven monitoring of HIV programs: Nigeria's journey to a national data repository for decision-making and patient care. Methods Inf Med. 2023;62(3-04):130&#x2013;139. doi: 10.1055/s-0043-1768711. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0043-1768711</ArticleId><ArticleId IdType="pmc">PMC10462428</ArticleId><ArticleId IdType="pubmed">37247622</ArticleId></ArticleIdList></Reference><Reference><Citation>Thaiya M, Julia K, Joram M, Benard M, Nambiro D. Adoption of ICT to enhance access to healthcare in Kenya. IOSR-JCE. 2021;23(2):45&#x2013;50. 
 
</Citation></Reference><Reference><Citation>Nsaghurwe A, Dwivedi V, Ndesanjo W, Bamsi H, Busiga M, Nyella E, Massawe JV, Smith D, Onyejekwe K, Metzger J, Taylor P. One country's journey to interoperability: Tanzania's experience developing and implementing a national health information exchange. BMC Med Inform Decis Mak. 2021;21(1):139. doi: 10.1186/s12911-021-01499-6. 
 
10.1186/s12911-021-01499-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12911-021-01499-6</ArticleId><ArticleId IdType="doi">10.1186/s12911-021-01499-6</ArticleId><ArticleId IdType="pmc">PMC8086308</ArticleId><ArticleId IdType="pubmed">33926428</ArticleId></ArticleIdList></Reference><Reference><Citation>HAPI FHIR&#x2014;the open source FHIR API for Java.  [2024-09-20].  
 https://hapifhir.io/
</Citation></Reference><Reference><Citation>Syzdykova A, Malta A, Zolfo M, Diro E, Oliveira JL. Open-source electronic health record systems for low-resource settings: systematic review. JMIR Med Inform. 2017;5(4):e44. doi: 10.2196/medinform.8131. 
 
v5i4e44</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/medinform.8131</ArticleId><ArticleId IdType="pmc">PMC5703976</ArticleId><ArticleId IdType="pubmed">29133283</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehl G. Open smart register platform (OpenSRP) OpenSRP. 2020.  [2023-01-21].  
 https://lib.digitalsquare.io/handle/123456789/77592
.</Citation></Reference><Reference><Citation>Open Health Stack.  [2024-09-20].  
 https://developers.google.com/open-health-stack
.</Citation></Reference><Reference><Citation>Development SI for BUNDA app. SUMMIT Institute for Development. 2023.  [2024-01-18].  
 https://www.sid-indonesia.org/post/bunda-app
.</Citation></Reference><Reference><Citation>Kurniawan K, FitriaSyah I, Jayakusuma A, Armis RA, Lubis Y, Haryono MA, Harefa B, Shankar A. Midwife service coverage, quality of work, and client health improved after deployment of an openSRP-driven client management application in Indonesia. Proceedings of the 5th International Conference on Health Sciences (ICHS 2018); November 04, 2018; Yogyakarta, Indonesia. Atlantis Press; 2019. pp. 155&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="doi">10.2991/ichs-18.2019.21</ArticleId></ArticleIdList></Reference><Reference><Citation>Beda EMR.  [2024-12-30].  
 https://beda.software/emr
.</Citation></Reference><Reference><Citation>Clickhouse: fast open-source OLAP DBMS. ClickHouse.  [2024-09-20].  
 https://clickhouse.com
.</Citation></Reference><Reference><Citation>Dbt.  [2024-09-20].  
 https://www.getdbt.com/index
.</Citation></Reference><Reference><Citation>Balch JA, Ruppert MM, Loftus TJ, Guan Z, Ren Y, Upchurch GR, Ozrazgat-Baslanti T, Rashidi P, Bihorac A. Machine learning-enabled clinical information systems using fast healthcare interoperability resources data standards: scoping review. JMIR Med Inform. 2023;11:e48297. doi: 10.2196/48297. 
 
v11i1e48297</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/48297</ArticleId><ArticleId IdType="pmc">PMC10468818</ArticleId><ArticleId IdType="pubmed">37646309</ArticleId></ArticleIdList></Reference><Reference><Citation>Digital public goods alliance. 2024.  [2024-02-05].  
 https://digitalpublicgoods.net/
</Citation></Reference><Reference><Citation>Instant OpenHIE V2. 2024.  [2024-09-20].  
 https://jembi.gitbook.io/instant-v2/
</Citation></Reference><Reference><Citation>Delussu G, Frexia F, Mascia C, Sulis A, Meloni V, Del Rio M, Lianas L. A survey of openEHR clinical data repositories. Int J Med Inform. 2024;191:105591. doi: 10.1016/j.ijmedinf.2024.105591.S1386-5056(24)00254-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijmedinf.2024.105591</ArticleId><ArticleId IdType="pubmed">39191089</ArticleId></ArticleIdList></Reference><Reference><Citation>FHIR Connect specfication. 2024.  [2025-02-04].  
 https://github.com/better-care/fhir-connect-mapping-spec
.</Citation></Reference><Reference><Citation>Welcome to openFHIR&#x2019;s documentation! openFHIR 0.9.3 documentation.  [2025-02-04].  
 https://open-fhir.com/documentation/index.html
.</Citation></Reference><Reference><Citation>Pedrera-Jim&#xe9;nez M, Garc&#xed;a-Barrio N, Frid S, Moner D, Bosc&#xe1;-Tom&#xe1;s D, Lozano-Rub&#xed; R, Kalra D, Beale T, Mu&#xf1;oz-Carrero A, Serrano-Balazote P. Can openEHR, ISO 13606, and HL7 FHIR work together? An agnostic approach for the selection and application of electronic health record standards to the next-generation health data spaces. J Med Internet Res. 2023;25:e48702. doi: 10.2196/48702. 
 
v25i1e48702</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/48702</ArticleId><ArticleId IdType="pmc">PMC10784985</ArticleId><ArticleId IdType="pubmed">38153779</ArticleId></ArticleIdList></Reference><Reference><Citation>Pohjonen H. Roadmap to Successful Digital Health Ecosystems. United States: Academic Press; 2022. Norway, Sweden, and Finland as forerunners in open ecosystems and openEHR; pp. 457&#x2013;471.</Citation></Reference><Reference><Citation>Bajri&#x107; S. Building a sustainable ecosystem for eHealth in Slovenia: opportunities, challenges, and strategies. Digital Health. 2023;9:20552076231205743. doi: 10.1177/20552076231205743. 
 
10.1177_20552076231205743</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/20552076231205743?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub0pubmed</ArticleId><ArticleId IdType="doi">10.1177/20552076231205743</ArticleId><ArticleId IdType="pmc">PMC10557408</ArticleId><ArticleId IdType="pubmed">37808243</ArticleId></ArticleIdList></Reference><Reference><Citation>Demonstratie proof of concept regionaal data-ecosysteem Zuid-Limburg. YouTube. 2025.  [2025-02-26].  
 https://www.youtube.com/watch?v=jT5UTLRX5VQ
.</Citation></Reference><Reference><Citation>Wright SA, Druta D. Open source and standards: the role of open source in the dialogue between research and standardization. IEEE Globecom Workshops (GC Wkshps); December 08-12, 2014; Austin, TX, USA. IEEE; 2014. pp. 650&#x2013;655.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/glocomw.2014.7063506</ArticleId></ArticleIdList></Reference><Reference><Citation>Blind K, B&#xf6;hm M.  Publications Office of the European Union. Publications Office of the European Union; 2019.  [2025-04-04]. The relationship between open source software and standard setting. 
 https://op.europa.eu/en/publication-detail/-/publication/6521f427-01df-11ea-8c1f-01aa75ed71a1/language-en
.</Citation></Reference><Reference><Citation>Erickson BJ, Langer S, Nagy P. The role of open-source software in innovation and standardization in radiology. J Am Coll Radiol. 2005;2(11):927&#x2013;931. doi: 10.1016/j.jacr.2005.05.004.S1546-1440(05)00144-4</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacr.2005.05.004</ArticleId><ArticleId IdType="pubmed">17411967</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy P. Open source in imaging informatics. J Digital Imaging. 2007;20 Suppl 1(Suppl 1):1&#x2013;10. doi: 10.1007/s10278-007-9056-1. 
 
</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10278-007-9056-1</ArticleId><ArticleId IdType="pmc">PMC2039818</ArticleId><ArticleId IdType="pubmed">17674101</ArticleId></ArticleIdList></Reference><Reference><Citation>Simcoe T, Watson J. Forking, fragmentation, and splintering. Strategy Sci. 2019;4(4):283&#x2013;297. doi: 10.1287/stsc.2019.0094.</Citation><ArticleIdList><ArticleId IdType="doi">10.1287/stsc.2019.0094</ArticleId></ArticleIdList></Reference><Reference><Citation>Sovereign Tech Agency. 2025.  [2025-02-28].  
 https://www.sovereign.tech/
</Citation></Reference><Reference><Citation>Chang V, Mills H, Newhouse S. From open source to long-term sustainability: review of business models and case studies. University of Southampton. 2007.  [2025-02-08].  
 https://eprints.soton.ac.uk/263925/
</Citation></Reference><Reference><Citation>Nyman L, Lindman J. Code forking, governance, and sustainability in open source software. Technology Innovation Management Review. 2013.  [2025-03-28].  
 http://timreview.ca/article/644
.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40247385</PMID><DateRevised><Year>2025</Year><Month>04</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2397-7523</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Apr</Month><Day>17</Day></PubDate></JournalIssue><Title>Diagnostic and prognostic research</Title><ISOAbbreviation>Diagn Progn Res</ISOAbbreviation></Journal><ArticleTitle>Can we develop real-world prognostic models using observational healthcare data? Large-scale experiment to investigate model sensitivity to database and phenotypes.</ArticleTitle><Pagination><StartPage>10</StartPage><MedlinePgn>10</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">10</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s41512-025-00191-x</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Large observational healthcare databases are frequently used to develop models to be implemented in real-world clinical practice populations. For example, these databases were used to develop COVID severity models that guided interventions such as who to prioritize vaccinating during the pandemic. However, the clinical setting and observational databases often differ in the types of patients (case mix), and it is a nontrivial process to identify patients with medical conditions (phenotyping) in these databases. In this study, we investigate how sensitive a model's performance is to the choice of development database, population, and outcome phenotype.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We developed&#x2009;&gt;&#x2009;450 different logistic regression models for nine prediction tasks across seven databases with a range of suitable population and outcome phenotypes. Performance stability within tasks was calculated by applying each model to data created by permuting the database, population, or outcome phenotype. We investigate performance (AUROC, scaled Brier, and calibration-in-the-large) stability and individual risk estimate stability.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In general, changing the outcome definitions or population phenotype made little impact on the model validation discrimination. However, validation discrimination was unstable when the database changed. Calibration and Brier performance were unstable when the population, outcome definition, or database changed. This may be problematic if a model developed using observational data is implemented in a real-world setting.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">These results highlight the importance of validating a model developed using observational data in the clinical setting prior to using it for decision-making. Calibration and Brier score should be evaluated to prevent miscalibrated risk estimates being used to aid clinical decisions.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Reps</LastName><ForeName>Jenna M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>, Johnson &amp; Johnson, Raritan, NJ, USA. jreps@its.jnj.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands. jreps@its.jnj.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rijnbeek</LastName><ForeName>Peter R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>, Johnson &amp; Johnson, Raritan, NJ, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>04</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Diagn Progn Res</MedlineTA><NlmUniqueID>101718985</NlmUniqueID><ISSNLinking>2397-7523</ISSNLinking></MedlineJournalInfo><CoiStatement>Declarations. Ethics approval and consent to participate: The use of the anonymized data in this study was reviewed by the New England Institutional Review Board and was determined to be exempt from broad Institutional Review Board approval. Consent for publication: Not applicable. Competing interests: JMR and PBR are employees and shareholders of Johnson &amp; Johnson. PRR works for a research group that received/receives unconditional research grants from Yamanouchi, Pfizer-Boehringer Ingelheim, Novartis, GSK, Chiesi, Astra-Zeneca, Amgen, Janssen Research &amp; Development.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>4</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>4</Month><Day>18</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>4</Month><Day>18</Day><Hour>0</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>4</Month><Day>17</Day><Hour>23</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>4</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40247385</ArticleId><ArticleId IdType="pmc">PMC12004590</ArticleId><ArticleId IdType="doi">10.1186/s41512-025-00191-x</ArticleId><ArticleId IdType="pii">10.1186/s41512-025-00191-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Clift AK, Coupland CA, Keogh RH, Diaz-Ordaz K, Williamson E, Harrison EM, Hayward A, Hemingway H, Horby P, Mehta N, Benger J. Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. Bmj. 2020;371:m3731.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7574532</ArticleId><ArticleId IdType="pubmed">33082154</ArticleId></ArticleIdList></Reference><Reference><Citation>Hippisley-Cox J, Coupland C, Vinogradova Y, Robson J, May M, Brindle P. Derivation and validation of QRISK, a new cardiovascular disease risk score for the United Kingdom: prospective open cohort study. BMJ. 2007;335(7611):136.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1925200</ArticleId><ArticleId IdType="pubmed">17615182</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee TH, Marcantonio ER, Mangione CM, Thomas EJ, Polanczyk CA, Cook EF, Sugarbaker DJ, Donaldson MC, Poss R, Ho KK, Ludwig LE. Derivation and prospective validation of a simple index for prediction of cardiac risk of major noncardiac surgery. Circulation. 1999;100(10):1043&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10477528</ArticleId></ArticleIdList></Reference><Reference><Citation>Wynants L, Van Calster B, Collins GS, Riley RD, Heinze G, Schuit E, Albu E, Arshi B, Bellou V, Bonten MM, Dahly DL. Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal. bmj. 2020;7:369.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7222643</ArticleId><ArticleId IdType="pubmed">32265220</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams RD, Markus AF, Yang C, Duarte-Salles T, DuVall SL, Falconer T, Jonnagaddala J, Kim C, Rho Y, Williams AE, Machado AA. Seek COVER: using a disease proxy to rapidly develop and validate a personalized risk calculator for COVID-19 outcomes in an international network. BMC Med Res Methodol. 2022;22(1):1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8801189</ArticleId><ArticleId IdType="pubmed">35094685</ArticleId></ArticleIdList></Reference><Reference><Citation>Reps JM, Kim C, Williams RD, Markus AF, Yang C, Duarte-Salles T, Falconer T, Jonnagaddala J, Williams A, Fern&#xe1;ndez-Bertol&#xed;n S, DuVall SL. Implementation of the COVID-19 vulnerability index across an international network of health care data sets: collaborative external validation study. JMIR Med Inform. 2021;9(4):e21547.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8023380</ArticleId><ArticleId IdType="pubmed">33661754</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel J, Scott F, Mohan R. It&#x2019;s a risky business: use of the QCovid risk calculator in a psychiatric rehabilitation population to enhance prevention. BJPsych open. 2021;7(S1):S46&#x2013;S46.</Citation></Reference><Reference><Citation>Sperrin M, Riley RD, Collins GS, Martin GP. Targeted validation: validating clinical prediction models in their intended population and setting. Diagnostic and prognostic research. 2022;6(1):24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9773429</ArticleId><ArticleId IdType="pubmed">36550534</ArticleId></ArticleIdList></Reference><Reference><Citation>Wessler BS, Nelson J, Park JG, McGinnes H, Gulati G, Brazil R, Van Calster B, van Klaveren D, Venema E, Steyerberg E, Paulus JK. External validations of cardiovascular clinical prediction models: a large-scale review of the literature. Circulation: Cardiovascular Quality and Outcomes. 2021;14(8): e007858.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8366535</ArticleId><ArticleId IdType="pubmed">34340529</ArticleId></ArticleIdList></Reference><Reference><Citation>Shivade C, et al. A review of approaches to identifying patient phenotype cohorts using electronic health records. Journal of the American Medical Informatics Association. 2014;21(2):221&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3932460</ArticleId><ArticleId IdType="pubmed">24201027</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai X, Li Y. Are AMI patients with comorbid mental illness more likely to be admitted to hospitals with lower quality of AMI care? PLoS ONE. 2013;8(4): e60258.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3614995</ArticleId><ArticleId IdType="pubmed">23565212</ArticleId></ArticleIdList></Reference><Reference><Citation>Mentz RJ, et al. Assessment of administrative data to identify acute myocardial infarction in electronic health records. Journal of the American College of Cardiology. 2016;67(20):2441&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6292432</ArticleId><ArticleId IdType="pubmed">27199066</ArticleId></ArticleIdList></Reference><Reference><Citation>Riley RD, Collins GS. Stability of clinical prediction models developed using statistical or machine learning methods. Biom J. 2023;65(8): 2200302.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10952221</ArticleId><ArticleId IdType="pubmed">37466257</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss EA, et al. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. Journal of the American Medical Informatics Association. 2015;22(3):553&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4457111</ArticleId><ArticleId IdType="pubmed">25670757</ArticleId></ArticleIdList></Reference><Reference><Citation>Reps JM, et al. Design and implementation of a standardized framework to generate and evaluate patient-level prediction models using observational healthcare data. Journal of the American Medical Informatics Association. 2018;25(8):969&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6077830</ArticleId><ArticleId IdType="pubmed">29718407</ArticleId></ArticleIdList></Reference><Reference><Citation>Reps JM, Rijnbeek P, Cuthbert A, Ryan PB, Pratt N, Schuemie M. An empirical analysis of dealing with patients who are lost to follow-up when developing prognostic models using a cohort design. BMC Med Inform Decis Mak. 2021;21:1&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7866757</ArticleId><ArticleId IdType="pubmed">33549087</ArticleId></ArticleIdList></Reference><Reference><Citation>Reps JM, Wong J, Fridgeirsson EA, Kim C, John LH, Williams RD, Fisher RR, Ryan PB. Finding a constrained number of predictor phenotypes for multiple outcome prediction. BMJ Health &amp; Care Informatics. 2025;32(1):e101227.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11751890</ArticleId><ArticleId IdType="pubmed">39824520</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, Simpson SE, Zorych I, et al. Massive parallelization of serial inference algorithms for complex generalized linear models. ACM Transact Model Comput Simulation. 2013;231:10&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4201181</ArticleId><ArticleId IdType="pubmed">25328363</ArticleId></ArticleIdList></Reference><Reference><Citation>Reps JM, Ryan P, Rijnbeek PR. Investigating the impact of development and internal validation design when training prognostic models using a retrospective cohort in big US observational healthcare data. BMJ Open. 2021;11(12): e050146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8710861</ArticleId><ArticleId IdType="pubmed">34952871</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">7063747</ArticleId></ArticleIdList></Reference><Reference><Citation>John LH, Kors JA, Reps JM, Ryan PB, Rijnbeek PR. Logistic regression models for patient-level prediction based on massive observational data: do we need all data? Int J Med Informatics. 2022;163: 104762.</Citation><ArticleIdList><ArticleId IdType="pubmed">35429722</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40252169</PMID><DateRevised><Year>2025</Year><Month>06</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2193-8229</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>6</Issue><PubDate><Year>2025</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Infectious diseases and therapy</Title><ISOAbbreviation>Infect Dis Ther</ISOAbbreviation></Journal><ArticleTitle>Predicting ICU Admission Risk in Children with Respiratory Syncytial Virus.</ArticleTitle><Pagination><StartPage>1277</StartPage><EndPage>1286</EndPage><MedlinePgn>1277-1286</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40121-025-01155-w</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Respiratory syncytial virus (RSV) is a common infection in young children and a frequent cause of hospitalization. In some cases, RSV can lead to severe lower respiratory tract illness requiring admission to the intensive care unit (ICU). Here, we explore risk factors for RSV-related ICU admission in children.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a retrospective study using Electronic Medical Record (EMR) data transformed into the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) from three tertiary care centers in Korea between 2008 and 2022. We identified 1529 children hospitalized with RSV according to the CDM and examined risk factors for ICU admission in this population.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of 33,674 children aged 0-9 years who tested for RSV, 1529 (4.5%) were positive. The highest proportion of RSV-positive children were less than 10 months old. The ICU admission rate among RSV-positive children was 1.8% (29/1529), and the highest ICU admission rate occurred in children aged 0-5 months (4.4%). In a multivariable logistic regression model, we found that the odds of ICU admission were higher in younger age groups, with the highest odds of ICU admission occurring in children aged 0-5 months (aOR 10.39, 95% CI 2.33-46.29). We also found that gestational age less than 27 weeks was associated with a 71-fold increased odds of ICU admission (aOR 71.64, 95% CI 4.64-1106.50) and that extremely low birth weight was associated with a 31-fold increase in odds of ICU admission (aOR 31.16, 95% CI 2.35-414.00).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We used the OMOP-CDM to identify risk factors for severe RSV infection requiring ICU admission in children. We found that young age, low gestational age, and low birth weight were associated with increased odds of ICU admission. Further research is needed to validate our findings and to examine other potential risk factors for severe RSV infection.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Young Hwa</ForeName><Initials>YH</Initials><AffiliationInfo><Affiliation>Allergy Immunology Center, Korea University, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choe</LastName><ForeName>Young June</ForeName><Initials>YJ</Initials><Identifier Source="ORCID">0000-0003-2733-0715</Identifier><AffiliationInfo><Affiliation>Allergy Immunology Center, Korea University, Seoul, Republic of Korea. choey@korea.ac.kr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Korea University Anam Hospital, 73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea. choey@korea.ac.kr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Korea University College of Medicine, Seoul, Republic of Korea. choey@korea.ac.kr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoon</LastName><ForeName>Yoon Sun</ForeName><Initials>YS</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Korea University College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Korea University Guro Hospital, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Ji Young</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Korea University College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Korea University Ansan Hospital, Ansan, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Yun-Kyung</ForeName><Initials>YK</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Korea University College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Korea University Ansan Hospital, Ansan, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joo</LastName><ForeName>Hyung Joon</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Cardiovascular Center, Korea University College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Korea University College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Institute for Medical Bigdata Science, Korea University College of Medicine, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Sujin</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Medical Affairs, Sanofi Pasteur, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hyun Jung</ForeName><Initials>HJ</Initials><AffiliationInfo><Affiliation>Medical Affairs, Sanofi Pasteur, Seoul, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bertizzolo</LastName><ForeName>Lorenzo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Medical Evidence Generation, Sanofi, Lyon, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>04</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Infect Dis Ther</MedlineTA><NlmUniqueID>101634499</NlmUniqueID><ISSNLinking>2193-6382</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Children</Keyword><Keyword MajorTopicYN="N">ICU</Keyword><Keyword MajorTopicYN="N">RSV</Keyword><Keyword MajorTopicYN="N">Respiratory syncytial virus</Keyword><Keyword MajorTopicYN="N">Severe</Keyword></KeywordList><CoiStatement>Declarations. Conflict of Interest: Young Hwa Lee, Yoon Sun Yoon, Yun-Kyung Kim, Ji Young Park and Hyung Joon Joo have nothing to disclose. Young June Choe received a Research Grant from Sanofi. Hyunjung Kim, Sujin Choi, and Lorenzo Bertizzolo are Sanofi employees who may hold shares and/or stock options in a company. The funders provided financial support only and had no role in the study design, data collection, analysis, interpretation, or manuscript preparation. Ethical Approval: Korea University Anam Hospital IRB Committee (IRB No. 2022AN0400) approved the study protocol and waived the requirements for informed consent.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>4</Month><Day>19</Day><Hour>22</Hour><Minute>12</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>4</Month><Day>19</Day><Hour>22</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>4</Month><Day>19</Day><Hour>11</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>4</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40252169</ArticleId><ArticleId IdType="pmc">PMC12151929</ArticleId><ArticleId IdType="doi">10.1007/s40121-025-01155-w</ArticleId><ArticleId IdType="pii">10.1007/s40121-025-01155-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Li Y, Wang X, Blau DM, Caballero MT, Feikin DR, Gill CJ, et al. Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis. Lancet. 2022;399(10340):2047&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7613574</ArticleId><ArticleId IdType="pubmed">35598608</ArticleId></ArticleIdList></Reference><Reference><Citation>Tahamtan A, Samadizadeh S, Rastegar M, Nakstad B, Salimi V. Respiratory syncytial virus infection: why does disease severity vary among individuals? Expert Rev Respir Med. 2020;14(4):415&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">31995408</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi T, Balsells E, Wastnedge E, Singleton R, Rasmussen ZA, Zar HJ, et al. Risk factors for respiratory syncytial virus associated with acute lower respiratory infection in children under five years: systematic review and meta-analysis. J Glob Health. 2015;5(2): 020416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4676580</ArticleId><ArticleId IdType="pubmed">26682048</ArticleId></ArticleIdList></Reference><Reference><Citation>Havdal LB, B&#xf8;&#xe5;s H, Bekkevold T, Bakken Kran AM, Rojahn AE, St&#xf8;rdal K, et al. Risk factors associated with severe disease in respiratory syncytial virus infected children under 5 years of age. Front Pediatr. 2022;10:1004739.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9468371</ArticleId><ArticleId IdType="pubmed">36110112</ArticleId></ArticleIdList></Reference><Reference><Citation>Andeweg SP, Schepp RM, van de Kassteele J, Mollema L, Berbers GAM, van Boven M. Population-based serology reveals risk factors for RSV infection in children younger than 5 years. Sci Rep. 2021;11(1):8953.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8076290</ArticleId><ArticleId IdType="pubmed">33903695</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtis JR, Foster PJ, Saag KG. Tools and methods for real-world evidence generation: pragmatic trials, electronic consent, and data linkages. Rheum Dis Clin North Am. 2019;45(2):275&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6499376</ArticleId><ArticleId IdType="pubmed">30952398</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamal A, Barakat S, Rezk A. Standardized electronic health record data modeling and persistence: a comparative review. J Biomed Inform. 2021;114: 103670.</Citation><ArticleIdList><ArticleId IdType="pubmed">33359548</ArticleId></ArticleIdList></Reference><Reference><Citation>Motheral BR, Fairman KA. The use of claims databases for outcomes research: rationale, challenges, and strategies. Clin Ther. 1997;19(2):346&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pubmed">9152572</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, et al. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Ryan PB, Hripcsak G, Madigan D, Suchard MA. Improving reproducibility by using high-throughput observational studies with empirical calibration. Philos Trans A Math Phys Eng Sci. 2018;376(2128):20170356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6107542</ArticleId><ArticleId IdType="pubmed">30082302</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai EC, Ryan P, Zhang Y, Schuemie M, Hardy NC, Kamijima Y, et al. Applying a common data model to Asian databases for multinational pharmacoepidemiologic studies: opportunities and challenges. Clin Epidemiol. 2018;10:875&#x2013;85.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6067778</ArticleId><ArticleId IdType="pubmed">30100761</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneeweiss S, Brown JS, Bate A, Trifir&#xf2; G, Bartels DB. Choosing among common data models for real-world data analyses fit for making decisions about the effectiveness of medical products. Clin Pharmacol Ther. 2020;107(4):827&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">31330042</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HY, Yun KW, Cheong HJ, Choi EH, Lee HJ. Respiratory syncytial virus infection and the need for immunization in Korea. Expert Rev Vaccines. 2023;22(1):327&#x2013;40.</Citation><ArticleIdList><ArticleId IdType="pubmed">36960592</ArticleId></ArticleIdList></Reference><Reference><Citation>Cai W, Buda S, Schuler E, Hirve S, Zhang W, Haas W. Risk factors for hospitalized respiratory syncytial virus disease and its severe outcomes. Influenza Other Respir Viruses. 2020;14(6):658&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7578333</ArticleId><ArticleId IdType="pubmed">32064773</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraha HY, Lanct&#xf4;t KL, Paes B. Risk of respiratory syncytial virus infection in preterm infants: reviewing the need for prevention. Expert Rev Respir Med. 2015;9(6):779&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pubmed">26457970</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonseca W, Lukacs NW, Ptaschinski C. Factors affecting the immunity to respiratory syncytial virus: from epigenetics to microbiome. Front Immunol. 2018;9:226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5825926</ArticleId><ArticleId IdType="pubmed">29515570</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang EE, Law BJ, Robinson JL, Dobson S, al Jumaah S, Stephens D, et al. study of the role of age and respiratory syncytial virus neutralizing antibody on respiratory syncytial virus illness in patients with underlying heart or lung disease. Pediatrics. 1997;99(3):E9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9099774</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40261065</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1941-7705</ISSN><JournalIssue CitedMedium="Internet"><Volume>18</Volume><Issue>5</Issue><PubDate><Year>2025</Year><Month>May</Month></PubDate></JournalIssue><Title>Circulation. Cardiovascular quality and outcomes</Title><ISOAbbreviation>Circ Cardiovasc Qual Outcomes</ISOAbbreviation></Journal><ArticleTitle>Computational Phenomapping of Randomized Clinical Trial Participants to Enable Assessment of Their Real-World Representativeness and Personalized Inference.</ArticleTitle><Pagination><StartPage>e011306</StartPage><MedlinePgn>e011306</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1161/CIRCOUTCOMES.124.011306</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Assessing the generalizability of randomized clinical trials (RCTs) to real-world patients remains challenging. We propose a multidimensional metric to quantify the representativeness of an RCT cohort in an electronic health record (EHR) population and estimate real-world effects based on individualized treatment effects observed in the RCT.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We identified 65 clinical prerandomization characteristics of patients with heart failure with preserved ejection fraction within the TOPCAT (Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist Trial) and extracted those features in similar patients in EHR data from 4 hospitals in the Yale New Haven Health System. We then assessed the real-world generalizability of TOPCAT by developing a novel statistic, the phenotypic distance metric, to quantify the representation of TOPCAT participants within EHR patients. Finally, applying a machine learning method to learn individualized treatment effect in TOPCAT participants stratified by region, the United States (US) and Eastern Europe (EE), we predicted spironolactone benefit within the EHR cohorts.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">There were 3445 patients in TOPCAT (median age 69, interquartile range [IQR], 61-76 years, 52% women) and 8121 patients with heart failure with preserved ejection fraction across 4 hospitals (median age range 77, IQR, 68-86; years to 85; IQR, 77-91 years, 54% to 62% women). Across covariates, the EHR patients were more similar to each other than the TOPCAT-US participants (median standardized mean difference 0.065, IQR, 0.011-0.144 versus median standardized mean difference 0.186, IQR, 0.040-0.479). The phenotypic distance metric found a higher generalizability of the TOPCAT-US participants to the EHR patients than the TOPCAT-EE participants. Using a TOPCAT-US-derived model of individualized treatment effect, all EHR patients were predicted to derive benefit from spironolactone treatment, while a TOPCAT-EE-derived model predicted 13% of EHR patients to derive benefit.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">This novel multidimensional metric evaluates the real-world representativeness of RCT participants against corresponding patients in the EHR, enabling the evaluation of an RCT's implication for real-world patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thangaraj</LastName><ForeName>Phyllis M</ForeName><Initials>PM</Initials><Identifier Source="ORCID">0000-0003-3968-1563</Identifier><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT (P.M.T., E.K.O., L.S.D., A.A., R.J., R.K.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oikonomou</LastName><ForeName>Evangelos K</ForeName><Initials>EK</Initials><Identifier Source="ORCID">0000-0003-4362-0720</Identifier><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT (P.M.T., E.K.O., L.S.D., A.A., R.J., R.K.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dhingra</LastName><ForeName>Lovedeep S</ForeName><Initials>LS</Initials><Identifier Source="ORCID">0000-0002-5664-4126</Identifier><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT (P.M.T., E.K.O., L.S.D., A.A., R.J., R.K.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aminorroaya</LastName><ForeName>Arya</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-3197-2657</Identifier><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT (P.M.T., E.K.O., L.S.D., A.A., R.J., R.K.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jayaram</LastName><ForeName>Rahul H</ForeName><Initials>RH</Initials><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT (P.M.T., E.K.O., L.S.D., A.A., R.J., R.K.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0001-9818-479X</Identifier><AffiliationInfo><Affiliation>Department of Biostatistics, Fielding School of Public Health, University of California, Los Angeles (M.A.S.).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Departments of Computational Medicine and Human Genetics, David Geffen School of Medicine at UCLA, University of California, Los Angeles (M.A.S.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khera</LastName><ForeName>Rohan</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-9467-6199</Identifier><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, CT (P.M.T., E.K.O., L.S.D., A.A., R.J., R.K.).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Section of Health Informatics, Department of Biostatistics, Yale School of Public Health, New Haven, CT (R.K.).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Section of Biomedical Informatics and Data Science, Yale School of Medicine, New Haven, CT (R.K.).</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT (R.K.).</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T35 HL007649</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG089981</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>F32 HL170592</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 HL153775</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 HL155000</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL167858</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>04</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Circ Cardiovasc Qual Outcomes</MedlineTA><NlmUniqueID>101489148</NlmUniqueID><ISSNLinking>1941-7713</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000451">Mineralocorticoid Receptor Antagonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>27O7W4T232</RegistryNumber><NameOfSubstance UI="D013148">Spironolactone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>medRxiv. 2025 Jan 24:2024.05.15.24306285. doi: 10.1101/2024.05.15.24306285.</RefSource><PMID Version="1">38798457</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003237" MajorTopicYN="N" Type="Geographic">Connecticut</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057225" MajorTopicYN="Y">Data Mining</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="Y">Heart Failure</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069550" MajorTopicYN="N">Machine Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000451" MajorTopicYN="Y">Mineralocorticoid Receptor Antagonists</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018579" MajorTopicYN="Y">Patient Selection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057285" MajorTopicYN="Y">Precision Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="Y">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013148" MajorTopicYN="Y">Spironolactone</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013318" MajorTopicYN="N">Stroke Volume</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">electronic health record</Keyword><Keyword MajorTopicYN="N">heart failure</Keyword><Keyword MajorTopicYN="N">randomized controlled trials</Keyword><Keyword MajorTopicYN="N">spironolactone</Keyword></KeywordList><CoiStatement>Drs Thangaraj, Oikonomou, and Khera are coinventors of a provisional patent not related to the current work (63/606&#x2005;203). Dr Khera is an Associate Editor of JAMA and receives research support, through Yale, from the Blavatnik Foundation, Bristol-Myers Squibb, Novo Nordisk, and BridgeBio. He is a coinventor of US Provisional Patent Applications 63/177117, 63/428569, 63/346610, 63/484426, 63/508315, 63/580137, 63/562335, and a cofounder of Ensight-AI, Inc, and Evidence2Health, LLC. Dr Oikonomou is an academic co-founder of Evidence2Health LLC, and has been a consultant for Caristo Diagnostics, Ltd, and Ensight-AI, Inc. He is a coinventor in patent applications (US17/720068, 63/619241, 63/177117, 63/580137, 63/606203, 63/562335, WO2018078395A1, WO2020058713A1) and has received royalty fees from technology licensed through the University of Oxford. Dr Suchard receives grants and contracts from the US Food &amp; Drug Administration, the US Department of Veterans Affairs and Johnson &amp; Johnson. The other authors report no conflicts.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2026</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>21</Day><Hour>18</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>4</Month><Day>22</Day><Hour>16</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>4</Month><Day>22</Day><Hour>9</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40261065</ArticleId><ArticleId IdType="mid">NIHMS2072871</ArticleId><ArticleId IdType="pmc">PMC12203226</ArticleId><ArticleId IdType="doi">10.1161/CIRCOUTCOMES.124.011306</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lim YMF, Molnar M, Vaartjes I, Savarese G, Eijkemans MJC, Uijl A, Vradi E, Suzart-Woischnik K, Brugts JJ, Brunner-La Rocca H- P, et al. Generalizability of randomized controlled trials in heart failure with reduced ejection fraction. Eur Heart J Qual Care Clin Outcomes 2022;8:761&#x2013;769.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9603541</ArticleId><ArticleId IdType="pubmed">34596659</ArticleId></ArticleIdList></Reference><Reference><Citation>Spieth PM, Kubasch AS, Penzlin AI, Illigens BM- W, Barlinn K, Siepmann T. Randomized controlled trials - a matter of design. Neuropsychiatr Dis Treat 2016;12:1341&#x2013;1349.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4910682</ArticleId><ArticleId IdType="pubmed">27354804</ArticleId></ArticleIdList></Reference><Reference><Citation>Averitt AJ, Ryan PB, Weng C, Perotte A. A conceptual framework for external validity. J Biomed Inform 2021;121:103870.</Citation><ArticleIdList><ArticleId IdType="pubmed">34302957</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothwell PM. External validity of randomised controlled trials: &#x201c;to whom do the results of this trial apply?&#x201d; Lancet 2005;365:82&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">15639683</ArticleId></ArticleIdList></Reference><Reference><Citation>DeFilippis EM, Echols M, Adamson PB, Batchelor WB, Cooper LB, Cooper LS, Desvigne-Nickens P, George RT, Ibrahim NE, Jessup M, et al. Improving Enrollment of Underrepresented Racial and Ethnic Populations in Heart Failure Trials: A Call to Action From the Heart Failure Collaboratory. JAMA Cardiol 2022;7:540&#x2013;548.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9098689</ArticleId><ArticleId IdType="pubmed">35319725</ArticleId></ArticleIdList></Reference><Reference><Citation>Reza N, Gruen J, Bozkurt B. Representation of women in heart failure clinical trials: Barriers to enrollment and strategies to close the gap. Am Heart J Plus 2022;13. doi: 10.1016/j.ahjo.2022.100093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ahjo.2022.100093</ArticleId><ArticleId IdType="pmc">PMC8890694</ArticleId><ArticleId IdType="pubmed">35243454</ArticleId></ArticleIdList></Reference><Reference><Citation>Filbey L, Zhu JW, D&#x2019;Angelo F, Thabane L, Khan MS, Lewis E, Patel MR, Powell-Wiley T, Miranda JJ, Zuhlke L, et al. Improving representativeness in trials: a call to action from the Global Cardiovascular Clinical Trialists Forum. Eur Heart J 2023;44:921&#x2013;930.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10226751</ArticleId><ArticleId IdType="pubmed">36702610</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy-Martin T, Curtis S, Faries D, Robinson S, Johnston J. A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results. Trials 2015;16:495.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4632358</ArticleId><ArticleId IdType="pubmed">26530985</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranganathan M, Bhopal R. Exclusion and inclusion of nonwhite ethnic minority groups in 72 North American and European cardiovascular cohort studies. PLoS Med 2006;3:e44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1324792</ArticleId><ArticleId IdType="pubmed">16379500</ArticleId></ArticleIdList></Reference><Reference><Citation>Sardar MR, Badri M, Prince CT, Seltzer J, Kowey PR. Underrepresentation of women, elderly patients, and racial minorities in the randomized trials used for cardiovascular guidelines. JAMA Intern Med 2014;174:1868&#x2013;1870.</Citation><ArticleIdList><ArticleId IdType="pubmed">25264856</ArticleId></ArticleIdList></Reference><Reference><Citation>Joosten LPT, van Doorn S, van de Ven PM, K&#xf6;hlen BTG, Nierman MC, Koek HL, Hemels MEW, Huisman MV, Kruip M, Faber LM, et al. Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial. Circulation 2023. doi: 10.1161/CIRCULATIONAHA.123.066485.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.123.066485</ArticleId><ArticleId IdType="pubmed">37634130</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers JR, Hripcsak G, Cheung YK, Weng C. Clinical comparison between trial participants and potentially eligible patients using electronic health record data: A generalizability assessment method. J Biomed Inform 2021;119:103822.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8260457</ArticleId><ArticleId IdType="pubmed">34044156</ArticleId></ArticleIdList></Reference><Reference><Citation>Laffin LJ, Besser SA, Alenghat FJ. A data-zone scoring system to assess the generalizability of clinical trial results to individual patients. Eur J Prev Cardiol 2019;26:569&#x2013;575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6459598</ArticleId><ArticleId IdType="pubmed">30477321</ArticleId></ArticleIdList></Reference><Reference><Citation>Sen A, Chakrabarti S, Goldstein A, Wang S, Ryan PB, Weng C. GIST 2.0: A scalable multi-trait metric for quantifying population representativeness of individual clinical studies. J Biomed Inform 2016;63:325&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5077682</ArticleId><ArticleId IdType="pubmed">27600407</ArticleId></ArticleIdList></Reference><Reference><Citation>Weng C, Li Y, Ryan P, Zhang Y, Liu F, Gao J, Bigger JT, Hripcsak G. A distribution-based method for assessing the differences between clinical trial target populations and patient populations in electronic health records. Appl Clin Inform 2014;5:463&#x2013;479.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4081748</ArticleId><ArticleId IdType="pubmed">25024761</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunlay SM, Roger VL, Redfield MM. Epidemiology of heart failure with preserved ejection fraction. Nat Rev Cardiol 2017;14:591&#x2013;602.</Citation><ArticleIdList><ArticleId IdType="pubmed">28492288</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah SJ. Innovative Clinical Trial Designs for Precision Medicine in Heart Failure with Preserved Ejection Fraction. J Cardiovasc Transl Res 2017;10:322&#x2013;336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5571647</ArticleId><ArticleId IdType="pubmed">28681133</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah SJ, Katz DH, Selvaraj S, Burke MA, Yancy CW, Gheorghiade M, Bonow RO, Huang C-C, Deo RC. Phenomapping for Novel Classification of Heart Failure With Preserved Ejection Fraction. Circulation 2015;131:269&#x2013;279.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4302027</ArticleId><ArticleId IdType="pubmed">25398313</ArticleId></ArticleIdList></Reference><Reference><Citation>Oikonomou EK, Spatz ES, Suchard MA, Khera R. Individualising intensive systolic blood pressure reduction in hypertension using computational trial phenomaps and machine learning: a post-hoc analysis of randomised clinical trials. Lancet Digit Health 2022;4:e796&#x2013;e805.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9768739</ArticleId><ArticleId IdType="pubmed">36307193</ArticleId></ArticleIdList></Reference><Reference><Citation>Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, et al. Spironolactone for Heart Failure with Preserved Ejection Fraction. N Engl J Med 2014;370:1383&#x2013;1392.</Citation><ArticleIdList><ArticleId IdType="pubmed">24716680</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, et al. Regional Variation in Patients and Outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) Trial. Circulation 2015;131:34&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pubmed">25406305</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen JB, Schrauben SJ, Zhao L, Basso MD, Cvijic ME, Li Z, Yarde M, Wang Z, Bhattacharya PT, Chirinos DA, et al. Clinical Phenogroups in Heart Failure With Preserved Ejection Fraction: Detailed Phenotypes, Prognosis, and Response to Spironolactone. JACC Heart Fail 2020;8:172&#x2013;184.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7058514</ArticleId><ArticleId IdType="pubmed">31926856</ArticleId></ArticleIdList></Reference><Reference><Citation>Stekhoven DJ, B&#xfc;hlmann P. MissForest--non-parametric missing value imputation for mixed-type data. Bioinformatics 2012;28:112&#x2013;118.</Citation><ArticleIdList><ArticleId IdType="pubmed">22039212</ArticleId></ArticleIdList></Reference><Reference><Citation>MissForest. PyPI n.d. https://pypi.org/project/MissForest/ (accessed April 2, 2023).</Citation></Reference><Reference><Citation>Li J, Yan XS, Chaudhary D, Avula V, Mudiganti S, Husby H, Shahjouei S, Afshar A, Stewart WF, Yeasin M, et al. Imputation of missing values for electronic health record laboratory data. NPJ Digit Med 2021;4:147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8505441</ArticleId><ArticleId IdType="pubmed">34635760</ArticleId></ArticleIdList></Reference><Reference><Citation>van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate Imputation by Chained Equations inR. J Stat Softw 2011;45:1&#x2013;67.</Citation></Reference><Reference><Citation>Gower JC. A General Coefficient of Similarity and Some of Its Properties. Biometrics 1971;27:857&#x2013;871.</Citation></Reference><Reference><Citation>Oikonomou EK, Suchard MA, McGuire DK, Khera R. Phenomapping-Derived Tool to Individualize the Effect of Canagliflozin on Cardiovascular Risk in Type 2 Diabetes. Diabetes Care 2022;45:965&#x2013;974.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9016734</ArticleId><ArticleId IdType="pubmed">35120199</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollard TJ, Johnson AEW, Raffa JD, Mark RG. tableone: An open source Python package for producing summary statistics for research papers. JAMIA Open 2018;1:26&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6951995</ArticleId><ArticleId IdType="pubmed">31984317</ArticleId></ArticleIdList></Reference><Reference><Citation>McInnes L, Healy J, Melville J. UMAP: Uniform Manifold Approximation and Projection for Dimension Reduction. ArXiv [StatML] 2018. ePrint 1802.03426.</Citation></Reference><Reference><Citation>Oikonomou EK, Van Dijk D, Parise H, Suchard MA, de Lemos J, Antoniades C, Velazquez EJ, Miller EJ, Khera R. A phenomapping-derived tool to personalize the selection of anatomical vs. functional testing in evaluating chest pain (ASSIST). Eur Heart J 2021;42:2536&#x2013;2548.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8488385</ArticleId><ArticleId IdType="pubmed">33881513</ArticleId></ArticleIdList></Reference><Reference><Citation>Averitt AJ, Weng C, Ryan P, Perotte A. Translating evidence into practice: eligibility criteria fail to eliminate clinically significant differences between real-world and study populations. NPJ Digit Med 2020;3:67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7214444</ArticleId><ArticleId IdType="pubmed">32411828</ArticleId></ArticleIdList></Reference><Reference><Citation>Belkin MN, Blair JE, Shah SJ, Alenghat FJ. A composite metric for predicting benefit from spironolactone in heart failure with preserved ejection fraction. ESC Heart Fail 2021;8:3495&#x2013;3503.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8497352</ArticleId><ArticleId IdType="pubmed">34369088</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SV, Schneeweiss S, RCT-DUPLICATE Initiative, Franklin JM, Desai RJ, Feldman W, Garry EM, Glynn RJ, Lin KJ, Paik J, et al. Emulation of Randomized Clinical Trials With Nonrandomized Database Analyses: Results of 32 Clinical Trials. JAMA 2023;329:1376&#x2013;1385.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10130954</ArticleId><ArticleId IdType="pubmed">37097356</ArticleId></ArticleIdList></Reference><Reference><Citation>Oikonomou EK, Thangaraj PM, Bhatt DL, Ross JS, Young LH, Krumholz HM, Suchard MA, Khera R. An explainable machine learning-based phenomapping strategy for adaptive predictive enrichment in randomized clinical trials. NPJ Digit Med 2023;6:217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10673945</ArticleId><ArticleId IdType="pubmed">38001154</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Ryan PB, Duke JD, Shah NH, Park RW, Huser V, Suchard MA, Schuemie MJ, DeFalco FJ, Perotte A, et al. Characterizing treatment pathways at scale using the OHDSI network. Proc Natl Acad Sci U S A 2016;113:7329&#x2013;7336.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4941483</ArticleId><ArticleId IdType="pubmed">27274072</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore JH, Li X, Chang J-H, Tatonetti NP, Theodorescu D, Chen Y, Asselbergs FW, Venkatesan M, Wang ZP. SynTwin: A graph-based approach for predicting clinical outcomes using digital twins derived from synthetic patients. Pac Symp Biocomput 2024;29:96&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10827004</ArticleId><ArticleId IdType="pubmed">38160272</ArticleId></ArticleIdList></Reference><Reference><Citation>Keany E. BorutaShap : A wrapper feature selection method which combines the Boruta feature selection algorithm with Shapley values. (1.1). Zenodo 2020; 10.5281/zenodo.4247618.</Citation><ArticleIdList><ArticleId IdType="doi">10.5281/zenodo.4247618</ArticleId></ArticleIdList></Reference><Reference><Citation>Kursa MB, Rudnicki WR. Feature Selection with theBorutaPackage. J Stat Softw. 2010;36:1&#x2013;13.</Citation></Reference><Reference><Citation>Lundberg S, Lee S-I. A unified approach to interpreting model predictions. arXiv [cs.AI] 2017. ePrint 1705.07874.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40270380</PMID><DateCompleted><Year>2025</Year><Month>04</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>324</Volume><PubDate><Year>2025</Year><Month>Apr</Month><Day>24</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Standardizing Heat-Related Diagnoses for Predictive Modeling in Healthcare.</ArticleTitle><Pagination><StartPage>43</StartPage><EndPage>44</EndPage><MedlinePgn>43-44</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI250156</ELocationID><Abstract><AbstractText>Climate change is increasing acute heat events, intensifying health risks and straining healthcare systems. This study aims to support heat-related diagnoses prediction models for Germany by assigning ICD-10-GM codes to relevant conditions identified from the literature. Using the OHDSI mapping tool and clinical validation, 64 heat-related conditions were coded, enhancing data standardization. This approach facilitates reliable inclusion of diagnoses in association analyses and paves the way for improved resource allocation during heat events.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Thiel</LastName><ForeName>Jakob</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry, Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden University of Technology, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sedlmayr</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry, Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden University of Technology, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Henke</LastName><ForeName>Elisa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry, Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden University of Technology, Dresden, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018882" MajorTopicYN="Y">Heat Stress Disorders</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D038801" MajorTopicYN="N">International Classification of Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006358" MajorTopicYN="Y">Hot Temperature</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">heat events</Keyword><Keyword MajorTopicYN="N">heat forecast</Keyword><Keyword MajorTopicYN="N">interoperability</Keyword><Keyword MajorTopicYN="N">resource utilization</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>4</Month><Day>24</Day><Hour>12</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>4</Month><Day>24</Day><Hour>5</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40270380</ArticleId><ArticleId IdType="doi">10.3233/SHTI250156</ArticleId><ArticleId IdType="pii">SHTI250156</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40270411</PMID><DateCompleted><Year>2025</Year><Month>04</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>04</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>324</Volume><PubDate><Year>2025</Year><Month>Apr</Month><Day>24</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>FOX BOXes as Fundamental Enablers for EHR-Standardised Data Sharing - Building the Austrian Health Data Donation Space.</ArticleTitle><Pagination><StartPage>198</StartPage><EndPage>204</EndPage><MedlinePgn>198-204</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI250187</ELocationID><Abstract><AbstractText>Efficient secondary use of real-world data (RWD) is a cornerstone for advancing data-driven medical research and personalised healthcare. However, significant challenges persist, including data fragmentation in silos, the lack of record linkage, and legal constraints that often hinder data utilisation. Especially Electronic Health Records (EHRs) represent a valuable data source, yet their potential remains largely untapped due to these barriers. Especially modern data space solutions promise to address these challenges, focusing on standardisation and harmonisation efforts, data governance aspects, as well as federated data-sharing approaches. A significant push in this area represents the European Health Data Space (EHDS) Act, focusing on an opt-out based approach for secondary use of health data. An additional consent-based approach (opt-in) represents data donation, which empowers individuals to contribute their data to research while maintaining trust and privacy under the current legal situation. The flagship project Smart FOX lays the foundations for making citizen-based data donations of EHR-standardised information usable in clinical research in Austria. As part of the architecture of the Austrian Health Data Donation Space (AHDDS), data donation boxes - Federated Open data eXchange Boxes (FOX BOXes) - present the fundamental decentralised building blocks for sharing EHR-standardised data. This paper outlines the architecture, functionality, and governance of FOX BOXes, highlighting its role in overcoming key barriers to health data sharing and its potential to accelerate data-driven research.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Donsa</LastName><ForeName>Klaus</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>AIT Austrian Institute of Technology, Graz &amp; Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mangesius</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Siemens Healthcare Diagnostics GmbH, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lauschensky</LastName><ForeName>Aaron</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>AIT Austrian Institute of Technology, Graz &amp; Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baumgartner</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>AIT Austrian Institute of Technology, Graz &amp; Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tanjga</LastName><ForeName>Nikola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>AIT Austrian Institute of Technology, Graz &amp; Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>ELGA GmbH, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beyer</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>AIT Austrian Institute of Technology, Graz &amp; Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schreier</LastName><ForeName>G&#xfc;nter</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>AIT Austrian Institute of Technology, Graz &amp; Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kreiner</LastName><ForeName>Karl</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>AIT Austrian Institute of Technology, Graz &amp; Vienna, Austria.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName><QualifierName UI="Q000458" MajorTopicYN="N">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001317" MajorTopicYN="N" Type="Geographic">Austria</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D033181" MajorTopicYN="Y">Information Dissemination</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003219" MajorTopicYN="N">Confidentiality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008498" MajorTopicYN="N">Medical Record Linkage</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Data Donation</Keyword><Keyword MajorTopicYN="N">Electronic Health Records</Keyword><Keyword MajorTopicYN="N">FHIR</Keyword><Keyword MajorTopicYN="N">Health Data Spaces</Keyword><Keyword MajorTopicYN="N">OMOP CDM</Keyword><Keyword MajorTopicYN="N">Privacy Preservation</Keyword><Keyword MajorTopicYN="N">Secondary Use</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>4</Month><Day>24</Day><Hour>12</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>4</Month><Day>24</Day><Hour>6</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>4</Month><Day>24</Day><Hour>5</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40270411</ArticleId><ArticleId IdType="doi">10.3233/SHTI250187</ArticleId><ArticleId IdType="pii">SHTI250187</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40277433</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1527-6473</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Apr</Month><Day>26</Day></PubDate></JournalIssue><Title>Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society</Title><ISOAbbreviation>Liver Transpl</ISOAbbreviation></Journal><ArticleTitle>Characterizing practice variations in the care of hospitalized patients with cirrhosis across the University of California Health.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1097/LVT.0000000000000630</ELocationID><Abstract><AbstractText>Despite publicly available practice guidelines, in-hospital cirrhosis care remains highly variable. Prior studies of cirrhosis guideline adherence have been limited by administrative claims data. We aimed to overcome these limitations by using a novel multicenter electronic health record (EHR) database, the University of California Health Data Warehouse (UCHDW), to compare guideline adherence in the 5 medical centers of the University of California Health (UCH). We identified adult patients with cirrhosis hospitalized from 2013 to 2022. We evaluated adherence to 5 care quality measures applicable to inpatients. We used t tests to compare pairwise differences between individual UCH sites. We assessed the impact of patient-level and center-level factors (transplant services) through multivariate logistic regressions. We identified 17,249 patients with cirrhosis with 31,512 admissions: 39% women, 43% White, 31% Hispanic/Latino, 11% Asian, 7% Black/African-American, and 8% Unknown/Other. In pairwise comparisons, we found differences in adherence rates across all measures except for antibiotics for gastrointestinal bleeding. In multivariate modeling, we found positive associations between care at transplant centers and receiving paracenteses for those admitted for ascites or HE, albumin/antibiotics for those admitted for spontaneous bacterial peritonitis, endoscopy for those admitted for gastrointestinal bleeding, and lactulose for those admitted for HE. In addition, we observed negative associations between Black/African-American race and guideline adherence for receiving paracenteses for ascites or HE. Through our analyses of high-dimensional EHR data, we found significant differences in care associated with admissions at the transplant center and race/ethnicity. Our use of high-dimensional EHR data indicates that there is still significant room for improvement in the provision of high-quality cirrhosis care.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 American Association for the Study of Liver Diseases.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ge</LastName><ForeName>Jin</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-1574-1525</Identifier><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, Department of Medicine, University of California-San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Albert</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-3821-4376</Identifier><AffiliationInfo><Affiliation>Academic Research Services, University of California-San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bakar Computational Health Sciences Institute, University of California-San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gologorskaya</LastName><ForeName>Oksana</ForeName><Initials>O</Initials><Identifier Source="ORCID">0009-0005-3505-7300</Identifier><AffiliationInfo><Affiliation>Academic Research Services, University of California-San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bakar Computational Health Sciences Institute, University of California-San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Far</LastName><ForeName>Aryana T</ForeName><Initials>AT</Initials><Identifier Source="ORCID">0009-0004-9664-902</Identifier><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, Department of Medicine, University of California-San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bastani</LastName><ForeName>Asal</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-2433-1504</Identifier><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, Department of Medicine, University of California-San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Chiung-Yu</ForeName><Initials>CY</Initials><Identifier Source="ORCID">0000-0003-2313-3562</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California-San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pletcher</LastName><ForeName>Mark J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0002-6966-1312</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, University of California-San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lai</LastName><ForeName>Jennifer C</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0003-2092-6380</Identifier><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, Department of Medicine, University of California-San Francisco, San Francisco, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>KL2 TR001870</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K24 AG080021</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001872</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P30 DK026743</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG059183</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 DK139455</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>04</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Liver Transpl</MedlineTA><NlmUniqueID>100909185</NlmUniqueID><ISSNLinking>1527-6465</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">OMOP</Keyword><Keyword MajorTopicYN="N">cirrhosis</Keyword><Keyword MajorTopicYN="N">guidelines</Keyword><Keyword MajorTopicYN="N">quality metrics</Keyword></KeywordList><CoiStatement>Disclosures: The authors of this manuscript have the following potential conflicts of interest to disclose as described by <i>Liver Transplantation</i>:   Dr. Jin Ge receives research support from Merck and Co and consults for Astellas Pharmaceuticals/Iota Biosciences. He previously served on an advisory board for Gilead Sciences and consulted for Madrigal Pharmaceuticals.   Dr. Jennifer C. Lai receives research support from Lipocene and Vir Biotechnologies; receives an education grant from Nestle Nutrition Sciences; serves on an advisory board for Novo Nordisk; and consults for Genfit, Third Rock Ventures, and Boehringer Ingelheim. </CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>4</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2026</Year><Month>4</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>4</Month><Day>25</Day><Hour>13</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>4</Month><Day>25</Day><Hour>13</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>4</Month><Day>25</Day><Hour>9</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40277433</ArticleId><ArticleId IdType="mid">NIHMS2076440</ArticleId><ArticleId IdType="pmc">PMC12353353</ArticleId><ArticleId IdType="doi">10.1097/LVT.0000000000000630</ArticleId><ArticleId IdType="pii">01445473-990000000-00609</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ma C, Qian AS, Nguyen NH, et al. Trends in the Economic Burden of Chronic Liver Diseases and Cirrhosis in the United States: 1996-2016. Am J Gastroenterol. 2021;116(10):2060&#x2013;2067.</Citation><ArticleIdList><ArticleId IdType="pubmed">33998785</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirode G, Saab S, Wong RJ. Trends in the burden of chronic liver disease among hospitalized US adults. JAMA Netw Open. 2020;3(4):e201997.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7118516</ArticleId><ArticleId IdType="pubmed">32239220</ArticleId></ArticleIdList></Reference><Reference><Citation>Vergara M, Cl&#xe8;ries M, Vela E, Bustins M, Miquel M, Campo R. Hospital mortality over time in patients with specific complications of cirrhosis. Liver Int. 2013;33(6):828&#x2013;833.</Citation><ArticleIdList><ArticleId IdType="pubmed">23496284</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathur AK, Chakrabarti AK, Mellinger JL, et al. Hospital resource intensity and cirrhosis mortality in United States. World J Gastroenterol. 2017;23(10):1857&#x2013;1865.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5352927</ArticleId><ArticleId IdType="pubmed">28348492</ArticleId></ArticleIdList></Reference><Reference><Citation>Mellinger JL, Richardson CR, Mathur AK, Volk ML. Variation among United States hospitals in inpatient mortality for cirrhosis. Clin Gastroenterol Hepatol. 2015;13(3):577&#x2013;584; quiz e30.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4333025</ArticleId><ArticleId IdType="pubmed">25264271</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanwal F, Kramer J, Asch SM, et al. An explicit quality indicator set for measurement of quality of care in patients with cirrhosis. Clin Gastroenterol Hepatol. 2010;8(8):709&#x2013;717.</Citation><ArticleIdList><ArticleId IdType="pubmed">20385251</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanwal F, Tapper EB, Ho C, et al. Development of quality measures in cirrhosis by the practice metrics committee of the american association for the study of liver diseases. Hepatology. 2019;69(4):1787&#x2013;1797.</Citation><ArticleIdList><ArticleId IdType="pubmed">30586188</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghaoui R, Friderici J, Visintainer P, Lindenauer PK, Lagu T, Desilets D. Measurement of the quality of care of patients admitted with decompensated cirrhosis. Liver Int. 2014;34(2):204&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">23763303</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanwal F, Kramer JR, Buchanan P, et al. The quality of care provided to patients with cirrhosis and ascites in the Department of Veterans Affairs. Gastroenterology. 2012;143(1):70&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">22465432</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel N, Silvey S, O&#x2019;Leary JG, et al. Early paracentesis is associated with better prognosis compared with late or no-paracentesis in hospitalized veterans with cirrhosis and ascites. Liver Transpl. 2023;29(9):919&#x2013;927.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10523869</ArticleId><ArticleId IdType="pubmed">36971257</ArticleId></ArticleIdList></Reference><Reference><Citation>Tapper EB, Aberasturi D, Zhao Z, Hsu C-Y, Parikh ND. Outcomes after hepatic encephalopathy in population-based cohorts of patients with cirrhosis. Aliment Pharmacol Ther. 2020;51(12):1397&#x2013;1405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7266029</ArticleId><ArticleId IdType="pubmed">32363684</ArticleId></ArticleIdList></Reference><Reference><Citation>Bajaj JS, O&#x2019;Leary JG, Tandon P, et al. Targets to improve quality of care for patients with hepatic encephalopathy: data from a multi-centre cohort. Aliment Pharmacol Ther. 2019;49(12):1518&#x2013;1527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6538445</ArticleId><ArticleId IdType="pubmed">31032966</ArticleId></ArticleIdList></Reference><Reference><Citation>OMOP Common Data Model &#x2013; OHDSI. Accessed February 17, 2021. https://www.ohdsi.org/data-standardization/the-common-data-model/</Citation></Reference><Reference><Citation>Nguyen GC, Segev DL, Thuluvath PJ. Racial disparities in the management of hospitalized patients with cirrhosis and complications of portal hypertension: a national study. Hepatology. 2007;45(5):1282&#x2013;1289.</Citation><ArticleIdList><ArticleId IdType="pubmed">17464970</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge J, Pletcher MJ, Lai JC, N3C Consortium. Outcomes of SARS-CoV-2 Infection in Patients With Chronic Liver Disease and Cirrhosis: A National COVID Cohort Collaborative Study. Gastroenterology. 2021;161(5):1487&#x2013;1501.e5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8286237</ArticleId><ArticleId IdType="pubmed">34284037</ArticleId></ArticleIdList></Reference><Reference><Citation>Philip G, Djerboua M, Carlone D, Flemming JA. Validation of a hierarchical algorithm to define chronic liver disease and cirrhosis etiology in administrative healthcare data. PLoS ONE. 2020;15(2):e0229218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7028265</ArticleId><ArticleId IdType="pubmed">32069337</ArticleId></ArticleIdList></Reference><Reference><Citation>Pintus R, Yang Y, Rushmeier H. ATHENA. J Comput Cult Herit. 2015;8(1):1&#x2013;25.</Citation></Reference><Reference><Citation>Kim WR, Mannalithara A, Heimbach JK, et al. MELD 3.0: The Model for End-Stage Liver Disease Updated for the Modern Era. Gastroenterology. 2021;161(6):1887&#x2013;1895.e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8608337</ArticleId><ArticleId IdType="pubmed">34481845</ArticleId></ArticleIdList></Reference><Reference><Citation>ATLAS. Accessed June 30, 2024. https://atlas-demo.ohdsi.org/</Citation></Reference><Reference><Citation>Carpenter J, Bithell J. Bootstrap confidence intervals: when, which, what? A practical guide for medical statisticians. Statistics in Medicine. May 15, 2000.</Citation><ArticleIdList><ArticleId IdType="pubmed">10797513</ArticleId></ArticleIdList></Reference><Reference><Citation>Sedgwick P Multiple significance tests: the Bonferroni correction. BMJ. 2012;344(jan25 4):e509&#x2013;e509.</Citation></Reference><Reference><Citation>Burkholder DA, Moran IJ, DiBattista JV, Lok AS, Parikh ND, Chen VL. Accuracy of International Classification of Diseases-10 Codes for Cirrhosis and Portal Hypertensive Complications. Dig Dis Sci. 2022;67(8):3623&#x2013;3631.</Citation><ArticleIdList><ArticleId IdType="pubmed">34674069</ArticleId></ArticleIdList></Reference><Reference><Citation>Shearer JE, Gonzalez JJ, Min T, et al. Systematic review: development of a consensus code set to identify cirrhosis in electronic health records. Aliment Pharmacol Ther. 2022;55(6):645&#x2013;657.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9302659</ArticleId><ArticleId IdType="pubmed">35166399</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge J, Fontil V, Ackerman S, Pletcher MJ, Lai JC. Clinical decision support and electronic interventions to improve care quality in chronic liver diseases and cirrhosis. Hepatology. August 23, 2023.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10998693</ArticleId><ArticleId IdType="pubmed">37611253</ArticleId></ArticleIdList></Reference><Reference><Citation>Ge J, Sun S, Owens J, et al. Development of a liver disease-specific large language model chat interface using retrieval-augmented generation. Hepatology. 2024;80(5):1158&#x2013;1168.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11706764</ArticleId><ArticleId IdType="pubmed">38451962</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40327502</PMID><DateCompleted><Year>2025</Year><Month>06</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1367-4811</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>6</Issue><PubDate><Year>2025</Year><Month>Jun</Month><Day>02</Day></PubDate></JournalIssue><Title>Bioinformatics (Oxford, England)</Title><ISOAbbreviation>Bioinformatics</ISOAbbreviation></Journal><ArticleTitle>dsOMOP: bridging OMOP CDM and DataSHIELD for secure federated analysis of standardized clinical data.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">btaf286</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/bioinformatics/btaf286</ELocationID><Abstract><AbstractText Label="MOTIVATION" NlmCategory="BACKGROUND">Collaborative clinical research projects face several challenges related to data sharing. The disparity between data standards and strict privacy regulations become more relevant as the number of involved institutions increases. To address these challenges, the scientific community has progressively adopted common data models like the Observational Medical Outcomes Partnership Common Data Model (OMOP CDM) for multicenter data standardization and implemented federated data analysis platforms like DataSHIELD to perform remote analyses without transferring individual-level data between centers, thus mitigating disclosure risks. However, there is no native implementation that automatically combines both solutions, revealing the need for a tool that enables interoperability between these systems.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We present dsOMOP, a collection of DataSHIELD packages that facilitates automated extraction and transformation of OMOP CDM data into DataSHIELD-compatible datasets, enabling disclosure-controlled federated analyses of standardized clinical data. dsOMOP allows research institutions to provide access to their data for collaborative projects in a format that is interoperable with the project's available data, thus facilitating the analysis of large-scale, multicenter clinical data. It incorporates OMOP data directly into the DataSHIELD workflow, where all analyses occur entirely in a federated environment subject to rigorous disclosure controls, ensuring that only aggregated, non-disclosive results are ever returned to analysts.</AbstractText><AbstractText Label="AVAILABILITY AND IMPLEMENTATION" NlmCategory="METHODS">The general information page for the dsOMOP environment is available at https://isglobal-brge.github.io/dsOMOP, where the most recent installation instructions and usage guides for all dsOMOP packages and their extensions can be found in the "Packages" section.The dsOMOP package and its complementary tools are fully available under the MIT license on GitHub: dsOMOP (https://github.com/isglobal-brge/dsOMOP), dsOMOPClient (https://github.com/isglobal-brge/dsOMOPClient), dsOMOPHelper (https://github.com/isglobal-brge/dsOMOPHelper), and dsOMOP.oracle (https://github.com/isglobal-brge/dsOMOP.oracle).Usage vignettes for the client-side packages are available at the websites of dsOMOPClient (https://isglobal-brge.github.io/dsOMOPClient) and dsOMOPHelper (https://isglobal-brge.github.io/dsOMOPHelper). A permanent archival snapshot of the exact code used in this manuscript is deposited at Figshare: https://doi.org/10.6084/m9.figshare.28607186.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2025. Published by Oxford University Press.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sarrat-Gonz&#xe1;lez</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-9064-3303</Identifier><AffiliationInfo><Affiliation>Bioinformatic Research Group in Epidemiology (BRGE), Barcelona Institute for Global Health (ISGlobal), 08003 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Escrib&#xe0;-Montagut</LastName><ForeName>Xavier</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0003-2888-8948</Identifier><AffiliationInfo><Affiliation>Bioinformatic Research Group in Epidemiology (BRGE), Barcelona Institute for Global Health (ISGlobal), 08003 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Houghtaling</LastName><ForeName>Jared</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute for Clinical Research and Health Policy Studies (ICRHPS), Tufts University School of Medicine, Boston, MA 02111, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonz&#xe1;lez</LastName><ForeName>Juan R</ForeName><Initials>JR</Initials><Identifier Source="ORCID">0000-0003-3267-2146</Identifier><AffiliationInfo><Affiliation>Bioinformatic Research Group in Epidemiology (BRGE), Barcelona Institute for Global Health (ISGlobal), 08003 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER in Epidemiology and Public Health (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>PID2021-122855OB-I00</GrantID><Agency>National Agency for Research, and the Fund for Regional Development</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Bioinformatics</MedlineTA><NlmUniqueID>9808944</NlmUniqueID><ISSNLinking>1367-4803</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D012984" MajorTopicYN="Y">Software</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D033181" MajorTopicYN="Y">Information Dissemination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016494" MajorTopicYN="Y">Computer Security</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>4</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>25</Day><Hour>0</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>6</Day><Hour>18</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>6</Day><Hour>12</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>5</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40327502</ArticleId><ArticleId IdType="pmc">PMC12187060</ArticleId><ArticleId IdType="doi">10.1093/bioinformatics/btaf286</ArticleId><ArticleId IdType="pii">8125806</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ahmadi E, Nielsen HC, Roostaei F &#xa0;et al. &#xa0;OMOP CDM can facilitate data-driven studies for cancer prediction: a systematic review. JCO Clin Cancer Inform &#xa0;2022;7:e2300101.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9569469</ArticleId><ArticleId IdType="pubmed">36233137</ArticleId></ArticleIdList></Reference><Reference><Citation>Avraam D, Wilson RC, Aguirre Chan N &#xa0;et al. &#xa0;DataSHIELD: mitigating disclosure risk in a multi-site federated analysis platform. Bioinform Adv &#xa0;2025;5:vbaf046.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11968321</ArticleId><ArticleId IdType="pubmed">40191546</ArticleId></ArticleIdList></Reference><Reference><Citation>Budin-Lj&#xf8;sne I, Burton P, Isaeva J &#xa0;et al. &#xa0;DataSHIELD: an ethically robust solution to multiple-site individual-level data analysis. Public Health Genomics &#xa0;2015;18:87&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">25532061</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaye A, Marcon Y, Isaeva J &#xa0;et al. &#xa0;DataSHIELD: taking the analysis to the data, not the data to the analysis. Int J Epidemiol &#xa0;2014;43:1929&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4276062</ArticleId><ArticleId IdType="pubmed">25261970</ArticleId></ArticleIdList></Reference><Reference><Citation>Holtjer JCS, Bloemsma LD, Beijers RJHCG &#xa0;et al. &#xa0;Identifying risk factors for COPD and adult-onset asthma: an umbrella review. Eur Respir Rev &#xa0;2023;32:230009.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10155046</ArticleId><ArticleId IdType="pubmed">37137510</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson AEW, Bulgarelli L, Shen L &#xa0;et al. &#xa0;MIMIC-IV, a freely accessible electronic health record dataset. Sci Data &#xa0;2023;10:219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9810617</ArticleId><ArticleId IdType="pubmed">36596836</ArticleId></ArticleIdList></Reference><Reference><Citation>
Kallfelz M, Tsvetkova A, Pollard T &#xa0;et al.  MIMIC-IV demo data in the OMOP Common Data Model (version 0.9). PhysioNet, 2021. Published 21 June 2021. Available at: https://physionet.org/content/mimic-iv-demo-omop/0.9/ (29 November 2024, date last accessed).</Citation></Reference><Reference><Citation>Marcon Y, Bishop TE, Avraam D &#xa0;et al. &#xa0;Orchestrating privacy-protected big data analyses of data from different resources with R and DataSHIELD. PLoS Comput Biol &#xa0;2021;17:e1008880.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8034722</ArticleId><ArticleId IdType="pubmed">33784300</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss E, Makadia R, Matcho A &#xa0;et al. &#xa0;Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. J Am Med Inform Assoc &#xa0;2015;22:553&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4457111</ArticleId><ArticleId IdType="pubmed">25670757</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilson RC, Butters OW, Avraam D &#xa0;et al. &#xa0;DataSHIELD&#x2014;New directions and dimensions. Data Sci J &#xa0;2017;16:21.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40340493</PMID><DateRevised><Year>2025</Year><Month>05</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2043-6289</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>May</Month><Day>08</Day></PubDate></JournalIssue><Title>The Journal of hand surgery, European volume</Title><ISOAbbreviation>J Hand Surg Eur Vol</ISOAbbreviation></Journal><ArticleTitle>The burden of hand trauma surgery on primary care in the United Kingdom: a nation-wide analysis of antibiotic and opioid prescriptions.</ArticleTitle><Pagination><StartPage>17531934251338120</StartPage><MedlinePgn>17531934251338120</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/17531934251338120</ELocationID><Abstract><AbstractText>Although surgical site infection (SSI) risk after hand trauma surgery is around 5%, the severity of these infections is not known. The risk of superficial SSI in a cohort study was evaluated using NHS UK-wide primary care records (<i>n</i>&#x2009;=&#x2009;641,223), using the Clinical Practice Research Datalink GOLD database. Within this cohort, a subcohort of those who had undergone a hand surgery operation for trauma were identified (<i>n</i>&#x2009;=&#x2009;3,088). Antibiotic and analgesic prescriptions were analysed at 30 and 90 days postoperatively. By 30 days, 6.2% had been prescribed antibiotics appropriate for SSI, rising to 14.4% (CI [13.2 to 15.8]) by 90 days. By 30 days, 10% had been prescribed opioid analgaesia and by 90 days this had increased to 13.8%. Antibiotics prescriptions for SSI in primary care are substantially higher than the NICE estimate for SSI overall and the expected risk in hand trauma. The implications of this study are that many patients are receiving treatment for SSI in primary care and may be in more pain, for longer, than we expect. Further exploration of this is warranted and future research in hand trauma surgery should capture adverse events occurring outside of the hospital environment.<b>Level of evidence:</b> II.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wormald</LastName><ForeName>Justin Cr</ForeName><Initials>JC</Initials><Identifier Source="ORCID">0000-0001-6197-4093</Identifier><AffiliationInfo><Affiliation>Kadoorie Centre for Critical Care Research and Education, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lane</LastName><ForeName>Jennifer Ce</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Barts Bone and Joint Health, Faculty of Medicine and Dentistry, Queen Mary University of London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Catal&#xe0;</LastName><ForeName>Marti</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Botnar Institute for Musculoskeletal Sciences, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delmestri</LastName><ForeName>Antonella</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Botnar Institute for Musculoskeletal Sciences, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cook</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Botnar Institute for Musculoskeletal Sciences, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodrigues</LastName><ForeName>Jeremy N</ForeName><Initials>JN</Initials><AffiliationInfo><Affiliation>Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Plastic Surgery, Stoke Mandeville Hospital, Buckinghamshire Healthcare NHS Trust, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costa</LastName><ForeName>Matthew L</ForeName><Initials>ML</Initials><AffiliationInfo><Affiliation>Oxford Trauma and Emergency Care, Kadoorie Centre, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Botnar Institute for Musculoskeletal Sciences, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Hand Surg Eur Vol</MedlineTA><NlmUniqueID>101315820</NlmUniqueID><ISSNLinking>0266-7681</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antibiotics</Keyword><Keyword MajorTopicYN="N">hand surgery</Keyword><Keyword MajorTopicYN="N">infection</Keyword><Keyword MajorTopicYN="N">trauma</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>9</Day><Hour>12</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>9</Day><Hour>12</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>9</Day><Hour>11</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40340493</ArticleId><ArticleId IdType="doi">10.1177/17531934251338120</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40380420</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>327</Volume><PubDate><Year>2025</Year><Month>May</Month><Day>15</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Machine Learning-Based Clinical Decision Support System for Suicide Risk Management: The PERMANENS Project.</ArticleTitle><Pagination><StartPage>221</StartPage><EndPage>222</EndPage><MedlinePgn>221-222</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI250308</ELocationID><Abstract><AbstractText>The PERMANENS European project addresses the global public health challenge of self-harm and suicide by developing a machine learning-based Clinical Decision Support System (CDSS) to assist emergency departments (EDs) in providing personalized care. With over 700,000 suicides annually, suicide prevention is critical, especially in Europe where consistent surveillance is lacking. The project harmonizes national suicide attempt registries from regions in Spain, Ireland, Norway, and Sweden using the OMOP Common Data Model (CDM) to create a comprehensive database for real-time analysis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Leis</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Hospital del Mar Research Institute, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mortier</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Hospital del Mar Research Institute, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER of Epidemiology and Public Health, Carlos III Health Institute Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amigo</LastName><ForeName>Franco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Hospital del Mar Research Institute, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER of Epidemiology and Public Health, Carlos III Health Institute Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhargav</LastName><ForeName>Madhav</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>School of Public Health &amp; National Suicide Research Foundation, University College Cork, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conde</LastName><ForeName>Susana</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Hospital del Mar Research Institute, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrer</LastName><ForeName>Montserrat</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hospital del Mar Research Institute, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER of Epidemiology and Public Health, Carlos III Health Institute Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flygare</LastName><ForeName>Oskar</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Karolinska Institutet, &amp; Stockholm Health Care Services, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kizilaslan</LastName><ForeName>Busenur</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>National Centre for Suicide Research and Prevention, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Latorre Moreno</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Hospital del Mar Research Institute, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayer</LastName><ForeName>Miguel-Angel</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Hospital del Mar Research Institute, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xe9;rez Sola</LastName><ForeName>V&#xed;ctor</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Neuropsychiatry and Drug Addiction Institute, Barcelona MAR Health Park Consortium PSMAR, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER of Mental Health and Carlos III Health Institute, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Portillo van Diest</LastName><ForeName>Ana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Hospital del Mar Research Institute, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER of Epidemiology and Public Health, Carlos III Health Institute Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ram&#xed;rez-Anguita</LastName><ForeName>Juan Manuel</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Hospital del Mar Research Institute, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanz</LastName><ForeName>Ferran</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vilagut</LastName><ForeName>Gemma</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Hospital del Mar Research Institute, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER of Epidemiology and Public Health, Carlos III Health Institute Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alonso</LastName><ForeName>Jordi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hospital del Mar Research Institute, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBER of Epidemiology and Public Health, Carlos III Health Institute Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehlum</LastName><ForeName>Lars</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>National Centre for Suicide Research and Prevention, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arensman</LastName><ForeName>Ella</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>School of Public Health &amp; National Suicide Research Foundation, University College Cork, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bjureberg</LastName><ForeName>Johan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Clinical Neuroscience, Karolinska Institutet, &amp; Stockholm Health Care Services, Stockholm, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pastor</LastName><ForeName>Manuel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine and Life Sciences, Universitat Pompeu Fabra, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Ping</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>National Centre for Suicide Research and Prevention, Institute of Clinical Medicine, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000069550" MajorTopicYN="Y">Machine Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020000" MajorTopicYN="Y">Decision Support Systems, Clinical</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="N">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000092864" MajorTopicYN="Y">Suicide Prevention</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012308" MajorTopicYN="Y">Risk Management</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004636" MajorTopicYN="Y">Emergency Service, Hospital</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="N">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N" Type="Geographic">Europe</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Suicide</Keyword><Keyword MajorTopicYN="N">clinical support system</Keyword><Keyword MajorTopicYN="N">machine learning</Keyword><Keyword MajorTopicYN="N">self-harm</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>17</Day><Hour>17</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>17</Day><Hour>17</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>17</Day><Hour>1</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40380420</ArticleId><ArticleId IdType="doi">10.3233/SHTI250308</ArticleId><ArticleId IdType="pii">SHTI250308</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40380423</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>327</Volume><PubDate><Year>2025</Year><Month>May</Month><Day>15</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>A Federated Learning Model for the Prediction of Blood Transfusion in Intensive Care Units.</ArticleTitle><Pagination><StartPage>227</StartPage><EndPage>228</EndPage><MedlinePgn>227-228</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI250311</ELocationID><Abstract><AbstractText>Accurate prediction of blood transfusion requirements is crucial for patient outcomes and resource management in clinical settings. We developed a machine learning model using XGBoost to predict the need for a blood transfusion 2 hours in advance based on up to 7 hours of prior data from two large databases, MIMIC-IV and eICU-CRD. Our federated model showed promising results, with F1 scores of 0.72 and 0.66, respectively.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schwinn</LastName><ForeName>Johanna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Digital Medicine, University Hospital of Augsburg, Augsburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sheikhalishahi</LastName><ForeName>Seyedmostafa</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Digital Medicine, University Hospital of Augsburg, Augsburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morhart</LastName><ForeName>Matthaeus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Digital Medicine, University Hospital of Augsburg, Augsburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaspar</LastName><ForeName>Mathias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Digital Medicine, University Hospital of Augsburg, Augsburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hinske</LastName><ForeName>Ludwig Christian</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Digital Medicine, University Hospital of Augsburg, Augsburg, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001803" MajorTopicYN="Y">Blood Transfusion</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="Y">Intensive Care Units</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000069550" MajorTopicYN="Y">Machine Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000098407" MajorTopicYN="N">Federated Learning</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Federated Learning</Keyword><Keyword MajorTopicYN="N">Flower framework</Keyword><Keyword MajorTopicYN="N">ICU</Keyword><Keyword MajorTopicYN="N">OMOP CDM</Keyword><Keyword MajorTopicYN="N">blood transfusion</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>17</Day><Hour>17</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>17</Day><Hour>17</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>17</Day><Hour>1</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40380423</ArticleId><ArticleId IdType="doi">10.3233/SHTI250311</ArticleId><ArticleId IdType="pii">SHTI250311</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40380527</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>327</Volume><PubDate><Year>2025</Year><Month>May</Month><Day>15</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Conversion of Nursing Statements into the OMOP Common Data Model.</ArticleTitle><Pagination><StartPage>611</StartPage><EndPage>612</EndPage><MedlinePgn>611-612</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI250417</ELocationID><Abstract><AbstractText>The aim of this study is to convert nursing statements into the OMOP CDM for use in observational studies. We mapped nursing statements to SNOMED CT concepts and converted them into the OMOP CDM format through an ETL process. As a result, approximately 200 million nursing statements were loaded into the CDM's OBSERVATION, PROCEDURE_OCCURRENCE, and MEASUREMENT tables.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jung</LastName><ForeName>Hyesil</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>School of Nursing, Inha University, Incheon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Seok</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Office of eHealth Research and Business, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoo</LastName><ForeName>Sooyoung</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Office of eHealth Research and Business, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D039061" MajorTopicYN="Y">Systematized Nomenclature of Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000072917" MajorTopicYN="Y">Standardized Nursing Terminology</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009737" MajorTopicYN="Y">Nursing Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009323" MajorTopicYN="Y">Natural Language Processing</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Common Data Model</Keyword><Keyword MajorTopicYN="N">Nursing Statements</Keyword><Keyword MajorTopicYN="N">Systematized Nomenclature of Medicine Clinical Terms</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>17</Day><Hour>17</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>17</Day><Hour>17</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>17</Day><Hour>1</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40380527</ArticleId><ArticleId IdType="doi">10.3233/SHTI250417</ArticleId><ArticleId IdType="pii">SHTI250417</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40380528</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>327</Volume><PubDate><Year>2025</Year><Month>May</Month><Day>15</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Federated Learning for Predictive Analytics in Weaning from Mechanical Ventilation.</ArticleTitle><Pagination><StartPage>613</StartPage><EndPage>614</EndPage><MedlinePgn>613-614</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI250418</ELocationID><Abstract><AbstractText>Mechanical ventilation is crucial for critically ill patients in ICUs, requiring accurate weaning and extubations timing for optimal outcomes. Current prediction models struggle with generalizability across datasets like MIMIC-IV and eICU-CRD. We propose a federated learning approach using XGBoost with bagging aggregation to improve weaning predictions while ensuring patient data privacy, compliant with GDPR and HIPAA. Using the OMOP Common Data Model, our method integrates machine learning techniques across three ICU databases, encompassing over 33,000 patients. Our model achieved robust performance with 77% AUC and 73% AUPRC. Planned pilot studies in Germany will further refine and validate our approach. This study demonstrates the potential of federated learning to enhance critical care by providing personalized, data-driven insights for ventilation management.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sheikhalishahi</LastName><ForeName>Seyedmostafa</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Digital Medicine, University Hospital of Augsburg, Augsburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwinn</LastName><ForeName>Johanna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Digital Medicine, University Hospital of Augsburg, Augsburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morhart</LastName><ForeName>Matthaeus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Digital Medicine, University Hospital of Augsburg, Augsburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaspar</LastName><ForeName>Mathias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Digital Medicine, University Hospital of Augsburg, Augsburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hinske</LastName><ForeName>Ludwig Christian</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Digital Medicine, University Hospital of Augsburg, Augsburg, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015300" MajorTopicYN="Y">Ventilator Weaning</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069550" MajorTopicYN="Y">Machine Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012121" MajorTopicYN="Y">Respiration, Artificial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000098407" MajorTopicYN="N">Federated Learning</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Federated Learning</Keyword><Keyword MajorTopicYN="N">Intensive Care Unit</Keyword><Keyword MajorTopicYN="N">Mechanical Ventilation</Keyword><Keyword MajorTopicYN="N">Weaning</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>17</Day><Hour>17</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>17</Day><Hour>17</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>17</Day><Hour>1</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40380528</ArticleId><ArticleId IdType="doi">10.3233/SHTI250418</ArticleId><ArticleId IdType="pii">SHTI250418</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40380541</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>327</Volume><PubDate><Year>2025</Year><Month>May</Month><Day>15</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>OMOP-on-FHIR: Integrating the Clinical Data Through FHIR Bundle to OMOP CDM.</ArticleTitle><Pagination><StartPage>667</StartPage><EndPage>671</EndPage><MedlinePgn>667-671</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI250432</ELocationID><Abstract><AbstractText>The harmonization of the OMOP Common Data Model (CDM) with HL7 FHIR aims to enhance interoperability in clinical research by harmonizing diverse healthcare datasets. This process, referred to as OMOP-on-FHIR, leverages FHIR Bundles for real-time clinical data exchange and transforms these resources into OMOP CDM format using an ETL process. The ETL pipeline, facilitated by tools like XSLT, enables the extraction, transformation, and loading of data while maintaining semantic consistency. By bridging these two standards, OMOP-on-FHIR promotes the seamless exchange of data across clinical systems and research-oriented databases, supporting global health studies, advanced analytics, and personalized medicine. This methodology advances cross-border research by providing a standardized approach to data management and analysis, thereby improving healthcare outcomes.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jayathissa</LastName><ForeName>Prabath</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Ludwig Boltzmann Institute for Digital Health and Prevention, Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rohatsch</LastName><ForeName>Lukas</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>University of Applied Sciences/FH-Technikum Wien, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sauermann</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of Applied Sciences/FH-Technikum Wien, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hussein</LastName><ForeName>Rada</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Ludwig Boltzmann Institute for Digital Health and Prevention, Salzburg, Austria.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName><QualifierName UI="Q000458" MajorTopicYN="N">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057208" MajorTopicYN="Y">Health Level Seven</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008498" MajorTopicYN="Y">Medical Record Linkage</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073892" MajorTopicYN="Y">Health Information Interoperability</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clinical Research</Keyword><Keyword MajorTopicYN="N">ETL Pipeline</Keyword><Keyword MajorTopicYN="N">FHIR</Keyword><Keyword MajorTopicYN="N">Healthcare Interoperability</Keyword><Keyword MajorTopicYN="N">OMOP</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>17</Day><Hour>17</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>17</Day><Hour>17</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>17</Day><Hour>1</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40380541</ArticleId><ArticleId IdType="doi">10.3233/SHTI250432</ArticleId><ArticleId IdType="pii">SHTI250432</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40380566</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>327</Volume><PubDate><Year>2025</Year><Month>May</Month><Day>15</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Building a Research Infrastructure with REDCap and FHIR.</ArticleTitle><Pagination><StartPage>763</StartPage><EndPage>764</EndPage><MedlinePgn>763-764</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI250457</ELocationID><Abstract><AbstractText>At the university hospital of Giessen since 2018 a research infrastructure has been implemented as part of the German Medical Informatics Initiative. A central FHIR repository acts as the core part of this architecture where clinical data from various subsystems is consolidated. In the past, research projects were connected via FHIR or research databases like i2b2 or OMOP to this core dataset. REDCap was added as an electronic data capture platform especially for local research projects that need to combine data entry together with the available dataset on the central FHIR repository. Meanwhile this infrastructure has been successfully used within 3 research projects in internal medicine and psychosomatic medicine.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Michel-Backofen</LastName><ForeName>Achim</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Data Integration Center, Institute of Medical Informatics, Justus Liebig University, Giessen, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University Hospital of Giessen, Giessen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blasini</LastName><ForeName>Romina</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Data Integration Center, Institute of Medical Informatics, Justus Liebig University, Giessen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beck</LastName><ForeName>J&#xf6;rdis</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Data Integration Center, Institute of Medical Informatics, Justus Liebig University, Giessen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marquardt</LastName><ForeName>Kurt</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>University Hospital of Giessen, Giessen, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="N">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035843" MajorTopicYN="Y">Biomedical Research</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="N">organization &amp; administration</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ETL</Keyword><Keyword MajorTopicYN="N">FHIR</Keyword><Keyword MajorTopicYN="N">REDCap</Keyword><Keyword MajorTopicYN="N">electronic data capture</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>17</Day><Hour>17</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>17</Day><Hour>17</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>17</Day><Hour>1</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40380566</ArticleId><ArticleId IdType="doi">10.3233/SHTI250457</ArticleId><ArticleId IdType="pii">SHTI250457</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40380695</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>327</Volume><PubDate><Year>2025</Year><Month>May</Month><Day>15</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Comparative Study of ETL Tools for Transforming Healthcare Data to the OMOP Common Data Model (CDM).</ArticleTitle><Pagination><StartPage>1238</StartPage><EndPage>1239</EndPage><MedlinePgn>1238-1239</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI250590</ELocationID><Abstract><AbstractText>Healthcare data is often complex, sparse, and frequently updated, which makes standardization essential. The OMOP Common Data Model (CDM) is gaining increasing attention because of its ability to standardize healthcare data and enable consistent and reproducible research outputs. This paper evaluates three ETL (Extract, Transform, Load) tools: Pentaho, Apache NiFi, and a custom-built tool to transform healthcare data into the OMOP CDM. The evaluation criteria, based on a literature review, include connectivity and interoperability, user interface and ease of use, performance, and technical flexibility. Results indicate that while minor differences in the tools' features exist, all tools are adequate for basic transformation tasks. Pentaho is noted for its ease of use, particularly helpful for non-expert users, while Apache NiFi is better suited for more advanced users. A custom-built tool, though often offering user-friendly interfaces and more flexibility, comes at the cost of additional development efforts.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jouned</LastName><ForeName>Adnan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Medical Information Management, Center for Medical Data Science, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>D&#xfc;sseldorf</LastName><ForeName>Heike</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Medical Information Management, Center for Medical Data Science, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Katsch</LastName><ForeName>Florian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institute of Medical Information Management, Center for Medical Data Science, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ludwig Boltzmann Institute for Digital Health and Prevention, Salzburg, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jafarpour</LastName><ForeName>Maryam</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Medical Information Management, Center for Medical Data Science, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duftschmid</LastName><ForeName>Georg</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Institute of Medical Information Management, Center for Medical Data Science, Medical University of Vienna, Vienna, Austria.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName><QualifierName UI="Q000458" MajorTopicYN="N">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012984" MajorTopicYN="Y">Software</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014584" MajorTopicYN="N">User-Computer Interface</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016247" MajorTopicYN="Y">Information Storage and Retrieval</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Data Transformation</Keyword><Keyword MajorTopicYN="N">ETL</Keyword><Keyword MajorTopicYN="N">Healthcare Data Integration</Keyword><Keyword MajorTopicYN="N">OMOP CDM</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>17</Day><Hour>17</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>17</Day><Hour>17</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>17</Day><Hour>1</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40380695</ArticleId><ArticleId IdType="doi">10.3233/SHTI250590</ArticleId><ArticleId IdType="pii">SHTI250590</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40380701</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>327</Volume><PubDate><Year>2025</Year><Month>May</Month><Day>15</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Preliminary Results of an OMOP-CDM Based Characterization Study for Rhabdomyolysis in Greece.</ArticleTitle><Pagination><StartPage>1250</StartPage><EndPage>1251</EndPage><MedlinePgn>1250-1251</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI250596</ELocationID><Abstract><AbstractText>This study presents preliminary results from a rhabdomyolysis cohort characterization using data from Papageorgiou General Hospital (PGH), a big hospital in Northern Greece, mapped to the OMOP-CDM. Most patients in the cohort were male and generally younger than the female patients, leading to gender differences in related diseases and medications.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rekkas</LastName><ForeName>Alexandros</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farmaki</LastName><ForeName>Anastasia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chytas</LastName><ForeName>Achilleas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lazaridis</LastName><ForeName>Antonios</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>1st Department of Internal Medicine, Papageorgiou General Hospital, Aristotle University of Thessaloniki, PC:56403, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gkaliagkousi</LastName><ForeName>Eugenia</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>3rd Department of Internal Medicine, Papageorgiou General Hospital, Aristotle University of Thessaloniki, PC:56403, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Natsiavas</LastName><ForeName>Pantelis</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006115" MajorTopicYN="N" Type="Geographic">Greece</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012206" MajorTopicYN="Y">Rhabdomyolysis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">OMOP-CDM</Keyword><Keyword MajorTopicYN="N">Real World Data</Keyword><Keyword MajorTopicYN="N">Rhabdomyolysis</Keyword><Keyword MajorTopicYN="N">characterization</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>17</Day><Hour>17</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>17</Day><Hour>17</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>17</Day><Hour>1</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40380701</ArticleId><ArticleId IdType="doi">10.3233/SHTI250596</ArticleId><ArticleId IdType="pii">SHTI250596</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40380722</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>327</Volume><PubDate><Year>2025</Year><Month>May</Month><Day>15</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>From Fragmentation to Integration: Challenges and Solutions for Record Linkage in OMOP CDM.</ArticleTitle><Pagination><StartPage>1333</StartPage><EndPage>1337</EndPage><MedlinePgn>1333-1337</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI250619</ELocationID><Abstract><AbstractText>Secondary use of data for research purposes is becoming increasingly important to improve medical research and thus patient care. In this context, linking different data sources provides a unique opportunity to gain a comprehensive overview of a patient's medical history. The interoperability of different data sets can be ensured by using the standardized data model OMOP. However, the record linkage of separate OMOP databases is an open problem. In this paper, we present an approach to link disparate datasets in OMOP using German clinical data and claims data as an example. We highlight three challenges and propose solutions for them to ensure accurate and efficient data integration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Henke</LastName><ForeName>Elisa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zoch</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gruhl</LastName><ForeName>Mirko</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sedlmayr</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, Dresden, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D008498" MajorTopicYN="Y">Medical Record Linkage</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="N">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ETL</Keyword><Keyword MajorTopicYN="N">OHDSI</Keyword><Keyword MajorTopicYN="N">OMOP CDM</Keyword><Keyword MajorTopicYN="N">record linkage</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>17</Day><Hour>17</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>17</Day><Hour>17</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>17</Day><Hour>1</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40380722</ArticleId><ArticleId IdType="doi">10.3233/SHTI250619</ArticleId><ArticleId IdType="pii">SHTI250619</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40380743</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>17</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>327</Volume><PubDate><Year>2025</Year><Month>May</Month><Day>15</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Metadata-Driven Approach to Generalisation of Transformations in ETL Processes.</ArticleTitle><Pagination><StartPage>1438</StartPage><EndPage>1442</EndPage><MedlinePgn>1438-1442</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI250640</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The secondary use of clinical data becomes more important, whereby a large number of ETL routes for data integration are implemented for specific purposes. The metadata driven approach allows a generalization of ETL processes to reuse existing implementations.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The metadata stored in the MDR, which describes different attributes of data, is used for this purpose, based on the ISO 21526 and governance and provenance data were taken into account to record the history of the data throughout its lifecycle, based on the W3C PROV model.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">To achieve a metadata-driven approach the data structure of the source and target system are represented in a MDR. Afterwards, relations between elements have to be defined with respective transformation rules. These information are used by an generic ETL implementation, so that use case specific content is outsourced within the MDR.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">A rule-based approach of the MDD ETL implementation allows a generalization of the extract and load phase, however the transformation process has to be standardized further. Moreover, a user-friendly interface is essential for integrating expertise without technical skills.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bachir</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Goethe University Frankfurt, University Medicine, Institute of Medical Informatics (IMI), Frankfurt am Main, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vengadeswaran</LastName><ForeName>Abishaa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Goethe University Frankfurt, University Medicine, Institute of Medical Informatics (IMI), Frankfurt am Main, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Storf</LastName><ForeName>Holger</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Goethe University Frankfurt, University Medicine, Institute of Medical Informatics (IMI), Frankfurt am Main, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kadioglu</LastName><ForeName>Dennis</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Goethe University Frankfurt, University Medicine, Institute of Medical Informatics (IMI), Frankfurt am Main, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000071253" MajorTopicYN="Y">Metadata</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016247" MajorTopicYN="Y">Information Storage and Retrieval</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="N">organization &amp; administration</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Data Integration</Keyword><Keyword MajorTopicYN="N">ETL process</Keyword><Keyword MajorTopicYN="N">MDR</Keyword><Keyword MajorTopicYN="N">Metadata-driven approach</Keyword><Keyword MajorTopicYN="N">OMOP CDM</Keyword><Keyword MajorTopicYN="N">metadata</Keyword><Keyword MajorTopicYN="N">rule-based approach</Keyword><Keyword MajorTopicYN="N">secondary use</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>17</Day><Hour>17</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>17</Day><Hour>17</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>17</Day><Hour>1</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40380743</ArticleId><ArticleId IdType="doi">10.3233/SHTI250640</ArticleId><ArticleId IdType="pii">SHTI250640</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40385382</PMID><DateRevised><Year>2025</Year><Month>05</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>May</Month><Day>09</Day></PubDate></JournalIssue><Title>medRxiv : the preprint server for health sciences</Title><ISOAbbreviation>medRxiv</ISOAbbreviation></Journal><ArticleTitle>Comparative Safety of Second-Line Antihyperglycemic Agents in Older Adults with Type 2 Diabetes: A Multinational Real-World Evidence From LEGEND-T2DM.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2025.05.08.25327248</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1101/2025.05.08.25327248</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">As prescribing of newer antihyperglycemic agents expands, there remains limited comparative safety data for older adults-a population particularly vulnerable to adverse drug events and underrepresented in clinical trials. We aimed to evaluate the real-world safety of second-line antihyperglycemic agents among older adults with type 2 diabetes.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We conducted a multinational cohort study using nine harmonized electronic health record and claims databases from the U.S. and Europe, applying a consistent analytical framework based on the LEGEND-T2DM initiative. Among adults aged &#x2265;65 years who initiated a second-line agent after metformin monotherapy, we compared safety outcomes across four drug classes: GLP-1 receptor agonists (GLP1RAs), SGLT2 inhibitors (SGLT2Is), DPP-4 inhibitors (DPP4Is), and sulfonylureas (SUs). We used propensity score adjustment, empirical calibration, and prespecified diagnostics to estimate hazard ratios (HRs) for 18 safety outcomes.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">In a cohort of 1.8 million older adults, both GLP1RAs and SGLT2Is were linked to significantly lower risks of hypoglycemia (HR 0.21 [95% CI, 0.16-0.27] for GLP1RA vs SU; HR 0.21 [0.13-0.33] for SGLT2I vs SU) and hyperkalemia (HR 0.63 [0.50-0.81] for GLP1RA vs SU; HR 0.75 [0.63-0.90] for SGLT2I vs SU) and peripheral edema (HR 0.81 [0.71-0.92] for GLP1RAs vs. DPP4Is; HR 0.62 [0.46-0.84] for SGLT2Is vs. SU). However, SGLT2Is were associated with a higher risk of diabetic ketoacidosis compared to both GLP1RAs (HR 2.03 [1.38-2.99]) and SUs (HR 1.64 [1.27-2.11]). GLP1RAs had significantly higher risks of nausea (HR 0.63 [0.55-0.72]) and vomiting (HR 0.63 [0.57-0.69]) relative to SGLT2Is. Results were consistent across both on-treatment and intent-to-treat sensitivity analyses.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">In older adults with type 2 diabetes, GLP1RAs and SGLT2Is demonstrated more favorable safety profiles than SUs and DPP4Is across multiple clinically relevant outcomes. These results support more informed, safety-conscious prescribing in a population underrepresented in clinical trials yet highly susceptible to adverse effects.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Chungsoo</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-1802-1777</Identifier><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Yale New Haven Hospital Center for Outcomes Research and Evaluation.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bu</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, University of Michigan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blacketer</LastName><ForeName>Clair</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-2570-2124</Identifier><AffiliationInfo><Affiliation>Johnson and Johnson.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ostropolets</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Johnson and Johnson.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duarte-Salles</LastName><ForeName>Talita</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-8274-0357</Identifier><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Viernes</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>VA Informatics and Computing Infrastructure, United States Department of Veterans Affairs.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falconer</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pistillo</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Data Transformation, Analytics, and Artificial Intelligence, Real World Solutions, IQVIA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Can</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Data Transformation, Analytics, and Artificial Intelligence, Real World Solutions, IQVIA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Zandt</LastName><ForeName>Mui</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Data Transformation, Analytics, and Artificial Intelligence, Real World Solutions, IQVIA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagy</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Radiology, Johns Hopkins University School of Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishimura</LastName><ForeName>Akihiko</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minty</LastName><ForeName>Evan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>O'Brien Institute for Public Health, University of Calgary.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>You</LastName><ForeName>Seng Chan</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Biomedicine Systems Informatics, Yonsei University College of Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sawano</LastName><ForeName>Mitsuaki</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2789-1758</Identifier><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Yale New Haven Hospital Center for Outcomes Research and Evaluation.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sawano</LastName><ForeName>Shoko</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Yale New Haven Hospital Center for Outcomes Research and Evaluation.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeon</LastName><ForeName>Ja Young</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Department of Endocrinology and Metabolism, Ajou University School of Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aminorroaya</LastName><ForeName>Arya</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-3197-2657</Identifier><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dhingra</LastName><ForeName>Lovedeep S</ForeName><Initials>LS</Initials><Identifier Source="ORCID">0000-0002-5664-4126</Identifier><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pedroso</LastName><ForeName>Aline F</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thangraraj</LastName><ForeName>Phyllis</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dorr</LastName><ForeName>David A</ForeName><Initials>DA</Initials><Identifier Source="ORCID">0000-0003-2318-7261</Identifier><AffiliationInfo><Affiliation>Department of Medical Informatics &amp; Clinical Epidemiology, Oregon Health &amp; Science University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pratt</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Quality Use of Medicines and Pharmacy Research Centre, Clinical and Health Sciences, University of South Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Man</LastName><ForeName>Kenneth K C</ForeName><Initials>KKC</Initials><Identifier Source="ORCID">0000-0001-8645-1942</Identifier><AffiliationInfo><Affiliation>Research Department of Practice and Policy, UCL School of Pharmacy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lau</LastName><ForeName>Wallis C Y</ForeName><Initials>WCY</Initials><AffiliationInfo><Affiliation>Research Department of Practice and Policy, UCL School of Pharmacy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morales</LastName><ForeName>Daniel R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Division of Population Health and Genomics, University of Dundee.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khera</LastName><ForeName>Rohan</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-9467-6199</Identifier><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Yale New Haven Hospital Center for Outcomes Research and Evaluation.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Johnson and Johnson.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Johnson and Johnson.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krumholz</LastName><ForeName>Harlan M</ForeName><Initials>HM</Initials><Identifier Source="ORCID">0000-0003-2046-127X</Identifier><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Yale New Haven Hospital Center for Outcomes Research and Evaluation.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0001-9818-479X</Identifier><AffiliationInfo><Affiliation>VA Informatics and Computing Infrastructure, United States Department of Veterans Affairs.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Fielding School of Public Health, University of California, Los Angeles.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-5264-2169</Identifier><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Yale New Haven Hospital Center for Outcomes Research and Evaluation.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HG006139</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL169171</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL169954</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U58 DP002022</GrantID><Acronym>DP</Acronym><Agency>NCCDPHP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG089981</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>K23 HL153775</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 HL155000</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL167858</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000076942">Preprint</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>medRxiv</MedlineTA><NlmUniqueID>101767986</NlmUniqueID></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>19</Day><Hour>12</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>19</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>19</Day><Hour>6</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>5</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40385382</ArticleId><ArticleId IdType="pmc">PMC12083636</ArticleId><ArticleId IdType="doi">10.1101/2025.05.08.25327248</ArticleId><ArticleId IdType="pii">2025.05.08.25327248</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>American Diabetes Association Professional Practice Committee; 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes&#x2014;2024. Diabetes Care 47, S158&#x2013;S178 (2023). 10.2337/dc24-S009</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc24-S009</ArticleId><ArticleId IdType="pmc">PMC10725810</ArticleId><ArticleId IdType="pubmed">38078590</ArticleId></ArticleIdList></Reference><Reference><Citation>Qaseem A. et al. Newer Pharmacologic Treatments in Adults With Type 2 Diabetes: A Clinical Guideline From the American College of Physicians. Annals of Internal Medicine (2024). 10.7326/M23-2788</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M23-2788</ArticleId><ArticleId IdType="pmc">PMC11614146</ArticleId><ArticleId IdType="pubmed">38639546</ArticleId></ArticleIdList></Reference><Reference><Citation>American Diabetes Association Professional Practice Committee; 13. Older Adults: Standards of Care in Diabetes&#x2014;2024. Diabetes Care 47, S244&#x2013;S257 (2023). 10.2337/dc24-S013</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc24-S013</ArticleId><ArticleId IdType="pmc">PMC10725804</ArticleId><ArticleId IdType="pubmed">38078580</ArticleId></ArticleIdList></Reference><Reference><Citation>Engler C. et al. Long-term trends in the prescription of antidiabetic drugs: real-world evidence from the Diabetes Registry Tyrol 2012&#x2013;2018. BMJ Open Diabetes Research &amp; Care 8, e001279 (2020). 10.1136/bmjdrc-2020-001279</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjdrc-2020-001279</ArticleId><ArticleId IdType="pmc">PMC7467522</ArticleId><ArticleId IdType="pubmed">32873600</ArticleId></ArticleIdList></Reference><Reference><Citation>Schernthaner G. et al. Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes. Cardiovascular Diabetology 19, 185 (2020). 10.1186/s12933-020-01154-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-020-01154-w</ArticleId><ArticleId IdType="pmc">PMC7585305</ArticleId><ArticleId IdType="pubmed">33097060</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellary S. &amp; Barnett A. H. SGLT2 inhibitors in older adults: overcoming the age barrier. The Lancet Healthy Longevity 4, e127&#x2013;e128 (2023). 10.1016/S2666-7568(23)00039-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-7568(23)00039-9</ArticleId><ArticleId IdType="pubmed">37003269</ArticleId></ArticleIdList></Reference><Reference><Citation>Khera R. et al. Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DM. BMJ Medicine 2, e000651 (2023). 10.1136/bmjmed-2023-000651</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjmed-2023-000651</ArticleId><ArticleId IdType="pmc">PMC10565313</ArticleId><ArticleId IdType="pubmed">37829182</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard M. A. et al. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. The Lancet 394, 1816&#x2013;1826 (2019). 10.1016/S0140-6736(19)32317-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)32317-7</ArticleId><ArticleId IdType="pmc">PMC6924620</ArticleId><ArticleId IdType="pubmed">31668726</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie M. J. et al. Principles of Large-scale Evidence Generation and Evaluation across a Network of Databases (LEGEND). Journal of the American Medical Informatics Association 27, 1331&#x2013;1337 (2020). 10.1093/jamia/ocaa103</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocaa103</ArticleId><ArticleId IdType="pmc">PMC7481029</ArticleId><ArticleId IdType="pubmed">32909033</ArticleId></ArticleIdList></Reference><Reference><Citation>Khera R. et al. Comparative Effectiveness of Second-Line Antihyperglycemic Agents for Cardiovascular Outcomes: A Multinational, Federated Analysis of LEGEND-T2DM. Journal of the American College of Cardiology 84, 904&#x2013;917 (2024). 10.1016/j.jacc.2024.05.069</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2024.05.069</ArticleId><ArticleId IdType="pmc">PMC12045554</ArticleId><ArticleId IdType="pubmed">39197980</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G. et al. in MEDINFO 2015: eHealth-enabled Health 574&#x2013;578 (IOS Press, 2015).</Citation></Reference><Reference><Citation>Hripcsak G.
et al.
RESEARCH PROTOCOL Large-scale evidence generation and evaluation across a network of databases for type 2
diabetes mellitus, &lt;https://ohdsi-studies.github.io/LegendT2dm/Protocol.html&gt; (2021).</Citation></Reference><Reference><Citation>Khera R. et al. Large-scale evidence generation and evaluation across a network of databases for type 2 diabetes mellitus (LEGEND-T2DM): a protocol for a series of multinational, real-world comparative cardiovascular effectiveness and safety studies. BMJ Open 12, e057977 (2022). 10.1136/bmjopen-2021-057977</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2021-057977</ArticleId><ArticleId IdType="pmc">PMC9185490</ArticleId><ArticleId IdType="pubmed">35680274</ArticleId></ArticleIdList></Reference><Reference><Citation>von Elm E. et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. The Lancet 370, 1453&#x2013;1457 (2007). 10.1016/S0140-6736(07)61602-X</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(07)61602-X</ArticleId><ArticleId IdType="pubmed">18064739</ArticleId></ArticleIdList></Reference><Reference><Citation>Diabetes A. A. Updates to the Standards of Medical Care in Diabetes&#x2014;2018. Diabetes Care 41, 2045&#x2013;2047 (2018). 10.2337/dc18-su09</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc18-su09</ArticleId><ArticleId IdType="pubmed">30135199</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao G. (2024).</Citation></Reference><Reference><Citation>Tian Y., Schuemie M. J. &amp; Suchard M. A. Evaluating large-scale propensity score performance through real-world and synthetic data experiments. International Journal of Epidemiology 47, 2005&#x2013;2014 (2018). 10.1093/ije/dyy120</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyy120</ArticleId><ArticleId IdType="pmc">PMC6280944</ArticleId><ArticleId IdType="pubmed">29939268</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie M. J., Ryan P. B., DuMouchel W., Suchard M. A. &amp; Madigan D. Interpreting observational studies: why empirical calibration is needed to correct p-values. Statistics in Medicine 33, 209&#x2013;218 (2014). 10.1002/sim.5925</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.5925</ArticleId><ArticleId IdType="pmc">PMC4285234</ArticleId><ArticleId IdType="pubmed">23900808</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker A. M. et al. A tool for assessing the feasibility of comparative effectiveness research. Comparative Effectiveness Research 3, 11&#x2013;20 (2013). 10.2147/CER.S40357</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CER.S40357</ArticleId></ArticleIdList></Reference><Reference><Citation>ARMSTRONG B. A SIMPLE ESTIMATOR OF MINIMUM DETECTABLE RELATIVE RISK, SAMPLE SIZE, OR POWER IN COHORT STUDIES. American Journal of Epidemiology 126, 356&#x2013;358 (1987). 10.1093/aje/126.2.356</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/126.2.356</ArticleId><ArticleId IdType="pubmed">3605062</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie M. et al. Health-Analytics Data to Evidence Suite (HADES): Open-Source Software for Observational Research. Stud Health Technol Inform 310, 966&#x2013;970 (2024). 10.3233/shti231108</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/shti231108</ArticleId><ArticleId IdType="pmc">PMC10868467</ArticleId><ArticleId IdType="pubmed">38269952</ArticleId></ArticleIdList></Reference><Reference><Citation>The GRADE Study Research Group, Glycemia Reduction in Type 2 Diabetes &#x2014; Glycemic Outcomes. New England Journal of Medicine 387, 1063&#x2013;1074 (2022). 10.1056/NEJMoa2200433</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2200433</ArticleId><ArticleId IdType="pmc">PMC9829320</ArticleId><ArticleId IdType="pubmed">36129996</ArticleId></ArticleIdList></Reference><Reference><Citation>Zinman B. et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. New England Journal of Medicine 373, 2117&#x2013;2128 (2015). 10.1056/NEJMoa1504720</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1504720</ArticleId><ArticleId IdType="pubmed">26378978</ArticleId></ArticleIdList></Reference><Reference><Citation>Neal B. et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. New England Journal of Medicine 377, 644&#x2013;657 (2017). 10.1056/NEJMoa1611925</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1611925</ArticleId><ArticleId IdType="pubmed">28605608</ArticleId></ArticleIdList></Reference><Reference><Citation>Neuen B. L. et al. Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People With Type 2 Diabetes: A Meta-Analysis of Individual Participant Data From Randomized, Controlled Trials. Circulation 145, 1460&#x2013;1470 (2022). 10.1161/CIRCULATIONAHA.121.057736</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.121.057736</ArticleId><ArticleId IdType="pubmed">35394821</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu E. L. et al. SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors and risk of hyperkalemia among people with type 2 diabetes in clinical practice: population based cohort study. BMJ 385, e078483 (2024). 10.1136/bmj-2023-078483</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2023-078483</ArticleId><ArticleId IdType="pmc">PMC11200155</ArticleId><ArticleId IdType="pubmed">38925801</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang T. et al. GLP-1RA vs DPP-4i Use and Rates of Hyperkalemia and RAS Blockade Discontinuation in Type 2 Diabetes. JAMA Internal Medicine 184, 1195&#x2013;1203 (2024). 10.1001/jamainternmed.2024.3806</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2024.3806</ArticleId><ArticleId IdType="pmc">PMC11320332</ArticleId><ArticleId IdType="pubmed">39133509</ArticleId></ArticleIdList></Reference><Reference><Citation>Fralick M., Schneeweiss S. &amp; Patorno E. Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor. New England Journal of Medicine 376, 2300&#x2013;2302 (2017). 10.1056/NEJMc1701990</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc1701990</ArticleId><ArticleId IdType="pubmed">28591538</ArticleId></ArticleIdList></Reference><Reference><Citation>Douros A. et al. Sodium&#x2013;Glucose Cotransporter-2 Inhibitors and the Risk for Diabetic Ketoacidosis. Annals of Internal Medicine 173, 417&#x2013;425 (2020). 10.7326/M20-0289</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M20-0289</ArticleId><ArticleId IdType="pubmed">32716707</ArticleId></ArticleIdList></Reference><Reference><Citation>Fralick M., Colacci M., Thiruchelvam D., Gomes T. &amp; Redelmeier D. A. Sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors and the risk of heart failure: A nationwide cohort study of older adults with diabetes mellitus. Diabetes, Obesity and Metabolism 23, 950&#x2013;960 (2021). 10.1111/dom.14300</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.14300</ArticleId><ArticleId IdType="pubmed">33336894</ArticleId></ArticleIdList></Reference><Reference><Citation>Patorno E. et al. Comparative Effectiveness and Safety of Sodium&#x2013;Glucose Cotransporter 2 Inhibitors Versus Glucagon-Like Peptide 1 Receptor Agonists in Older Adults. Diabetes Care 44, 826&#x2013;835 (2021). 10.2337/dc20-1464</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/dc20-1464</ArticleId><ArticleId IdType="pmc">PMC7896266</ArticleId><ArticleId IdType="pubmed">33495295</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldman A. et al. The real-world safety profile of sodium-glucose co-transporter-2 inhibitors among older adults (&#x2265; 75 years): a retrospective, pharmacovigilance study. Cardiovascular Diabetology 22, 16 (2023). 10.1186/s12933-023-01743-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-023-01743-5</ArticleId><ArticleId IdType="pmc">PMC9875397</ArticleId><ArticleId IdType="pubmed">36694178</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhuo M. et al. Association of Sodium-Glucose Cotransporter&#x2013;2 Inhibitors With Fracture Risk in Older Adults With Type 2 Diabetes. JAMA Network Open 4, e2130762&#x2013;e2130762 (2021). 10.1001/jamanetworkopen.2021.30762</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.30762</ArticleId><ArticleId IdType="pmc">PMC8552056</ArticleId><ArticleId IdType="pubmed">34705014</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L., Chen J., Wang L., Chen C. &amp; Chen L. Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: A real-world disproportionality study based on FDA adverse event reporting system database. Frontiers in Endocrinology 13 (2022). 10.3389/fendo.2022.1043789</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2022.1043789</ArticleId><ArticleId IdType="pmc">PMC9770009</ArticleId><ArticleId IdType="pubmed">36568085</ArticleId></ArticleIdList></Reference><Reference><Citation>Alenzi K. A., Alsuhaibani D., Batarfi B. &amp; Alshammari T. M. Pancreatitis with use of new diabetic medications: a real-world data study using the post-marketing FDA adverse event reporting system (FAERS) database. Frontiers in Pharmacology 15 (2024). 10.3389/fphar.2024.1364110</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2024.1364110</ArticleId><ArticleId IdType="pmc">PMC11163090</ArticleId><ArticleId IdType="pubmed">38860168</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh A. K., Gangopadhyay K. K. &amp; Singh R. Risk of acute pancreatitis with incretin-based therapy: a systematic review and updated meta-analysis of cardiovascular outcomes trials. Expert Review of Clinical Pharmacology 13, 461&#x2013;468 (2020). 10.1080/17512433.2020.1736041</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17512433.2020.1736041</ArticleId><ArticleId IdType="pubmed">32129106</ArticleId></ArticleIdList></Reference><Reference><Citation>Marso S. P. et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine 375, 1834&#x2013;1844 (2016). 10.1056/NEJMoa1607141</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1607141</ArticleId><ArticleId IdType="pubmed">27633186</ArticleId></ArticleIdList></Reference><Reference><Citation>Gerstein H. C. et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. The Lancet 394, 121&#x2013;130 (2019). 10.1016/S0140-6736(19)31149-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)31149-3</ArticleId><ArticleId IdType="pubmed">31189511</ArticleId></ArticleIdList></Reference><Reference><Citation>Holman R. R. et al. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. New England Journal of Medicine 377, 1228&#x2013;1239 (2017). 10.1056/NEJMoa1612917</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1612917</ArticleId><ArticleId IdType="pmc">PMC9792409</ArticleId><ArticleId IdType="pubmed">28910237</ArticleId></ArticleIdList></Reference><Reference><Citation>Abd El Aziz M., Cahyadi O., Meier J. J., Schmidt W. E. &amp; Nauck M. A. Incretin-based glucose-lowering medications and the risk of acute pancreatitis and malignancies: a meta-analysis based on cardiovascular outcomes trials. Diabetes, Obesity and Metabolism 22, 699&#x2013;704 (2020). 10.1111/dom.13924</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/dom.13924</ArticleId><ArticleId IdType="pubmed">31750601</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40414829</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1976-2437</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>6</Issue><PubDate><Year>2025</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Yonsei medical journal</Title><ISOAbbreviation>Yonsei Med J</ISOAbbreviation></Journal><ArticleTitle>Association of COX-2 Selectivity in Pain Medication Use with Endometriosis Incidence: Retrospective Cohort Study.</ArticleTitle><Pagination><StartPage>374</StartPage><EndPage>382</EndPage><MedlinePgn>374-382</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3349/ymj.2024.0255</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">This retrospective cohort study aimed to investigate the association between the use of pain medications with varying cyclooxygenase-2 (COX-2) selectivity and the incidence of endometriosis (EMS) in women.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Medical records from January 1, 1994, to December 31, 2022, were retrospectively analyzed. The cohort included 33406 patients diagnosed with any pain-related condition who were prescribed either selective COX-2 inhibitors or nonsteroidal anti-inflammatory drugs (NSAIDs). Patients were followed for up to 5 years from the cohort entry date. The incidence of EMS was compared between the two medication groups using Cox proportional hazards models, adjusting for confounding factors such as age, past drug use, and prior diagnosis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The incidence rates of EMS were 3.00 per 1000 person-years in the COX-2 inhibitor group and 3.97 per 1000 person-years in the NSAIDs group. After adjustment for confounders, the hazard ratio for EMS incidence in the COX-2 inhibitor group compared to the NSAIDs group was 0.77 [95% confidence interval (CI), 0.63 to 0.93; <i>p</i>&lt;0.01], indicating a significantly lower risk in the COX-2 inhibitor group. Subgroup analysis revealed that this association was particularly significant in younger women aged 20-44 years, with a hazard ratio of 0.71 (95% CI, 0.54 to 0.95; <i>p</i>&lt;0.05) in this age group.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The findings suggest that COX-2 inhibitors may reduce the incidence of EMS compared to traditional NSAIDs, highlighting their potential as a strategic option for managing EMS, particularly among younger women. Further prospective studies are needed to confirm these findings.</AbstractText><CopyrightInformation>&#xa9; Copyright: Yonsei University College of Medicine 2025.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Park</LastName><ForeName>Jongchan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-3485-4616</Identifier><AffiliationInfo><Affiliation>Department of Convergence Healthcare Medicine, Graduate School of Ajou University, Suwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Chang</LastName><ForeName>Hye Jin</ForeName><Initials>HJ</Initials><Identifier Source="ORCID">0000-0002-1122-1269</Identifier><AffiliationInfo><Affiliation>Department of Obstetrics &amp; Gynecology, Ajou University School of Medicine, Suwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hwang</LastName><ForeName>Kyung Joo</ForeName><Initials>KJ</Initials><Identifier Source="ORCID">0000-0001-7073-9124</Identifier><AffiliationInfo><Affiliation>Department of Obstetrics &amp; Gynecology, Ajou University School of Medicine, Suwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yum</LastName><ForeName>Sun Hyung</ForeName><Initials>SH</Initials><Identifier Source="ORCID">0000-0003-0033-9170</Identifier><AffiliationInfo><Affiliation>Department of Obstetrics &amp; Gynecology, Ajou University School of Medicine, Suwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Chang Eun</ForeName><Initials>CE</Initials><Identifier Source="ORCID">0009-0008-7291-4334</Identifier><AffiliationInfo><Affiliation>Department of Convergence Healthcare Medicine, Graduate School of Ajou University, Suwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Joo Hee</ForeName><Initials>JH</Initials><Identifier Source="ORCID">0000-0003-3458-0528</Identifier><AffiliationInfo><Affiliation>Regulatory Strategy Center for Combination Products, Ajou University, Suwon, Korea. elisekim@ajou.ac.kr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Miran</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-5553-5334</Identifier><AffiliationInfo><Affiliation>Department of Convergence Healthcare Medicine, Graduate School of Ajou University, Suwon, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Obstetrics &amp; Gynecology, Ajou University School of Medicine, Suwon, Korea. kmr5300@ajou.ac.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>21153MFDS431</GrantID><Acronym>MFDS</Acronym><Agency>Ministry of Food and Drug Safety</Agency><Country>Korea</Country></Grant><Grant><GrantID>P0017805</GrantID><Acronym>KIAT</Acronym><Agency>Korea Institute for Advancement of Technology (KIAI)</Agency><Country>Korea</Country></Grant><Grant><GrantID>RS-2023-00266038</GrantID><Acronym>KHIDI</Acronym><Agency>Korea Health Industry Development Institute (KHIDI)</Agency><Country>Korea</Country></Grant><Grant><GrantID>RS-2024-00398522</GrantID><Acronym>MOTIE</Acronym><Agency>Ministry of Trade, Industry and Energy</Agency><Country>Korea</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>Yonsei Med J</MedlineTA><NlmUniqueID>0414003</NlmUniqueID><ISSNLinking>0513-5796</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D052246">Cyclooxygenase 2 Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000894">Anti-Inflammatory Agents, Non-Steroidal</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.99.1</RegistryNumber><NameOfSubstance UI="D051546">Cyclooxygenase 2</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004715" MajorTopicYN="Y">Endometriosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D052246" MajorTopicYN="Y">Cyclooxygenase 2 Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000894" MajorTopicYN="Y">Anti-Inflammatory Agents, Non-Steroidal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051546" MajorTopicYN="Y">Cyclooxygenase 2</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010146" MajorTopicYN="Y">Pain</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COX-2</Keyword><Keyword MajorTopicYN="N">Celecoxib</Keyword><Keyword MajorTopicYN="N">Cohort Study</Keyword><Keyword MajorTopicYN="N">Endometriosis</Keyword><Keyword MajorTopicYN="N">Ibuprofen</Keyword><Keyword MajorTopicYN="N">OMOP-CDM</Keyword></KeywordList><CoiStatement>The authors have no potential conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>12</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>1</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>26</Day><Hour>0</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>26</Day><Hour>0</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>25</Day><Hour>23</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40414829</ArticleId><ArticleId IdType="pmc">PMC12116869</ArticleId><ArticleId IdType="doi">10.3349/ymj.2024.0255</ArticleId><ArticleId IdType="pii">66.374</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Malutan AM, Drugan T, Costin N, Ciortea R, Bucuri C, Rada MP, et al. Pro-inflammatory cytokines for evaluation of inflammatory status in endometriosis. Cent Eur J Immunol. 2015;40:96&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4472546</ArticleId><ArticleId IdType="pubmed">26155190</ArticleId></ArticleIdList></Reference><Reference><Citation>Defr&#xe8;re S, Lousse JC, Gonz&#xe1;lez-Ramos R, Colette S, Donnez J, Van Langendonckt A. Potential involvement of iron in the pathogenesis of peritoneal endometriosis. Mol Hum Reprod. 2008;14:377&#x2013;385.</Citation><ArticleIdList><ArticleId IdType="pubmed">18508952</ArticleId></ArticleIdList></Reference><Reference><Citation>Asghari S, Valizadeh A, Aghebati-Maleki L, Nouri M, Yousefi M. Endometriosis: perspective, lights, and shadows of etiology. Biomed Pharmacother. 2018;106:163&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pubmed">29958140</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu QB, Sun GP. Expression of COX-2 and HER-2 in colorectal cancer and their correlation. World J Gastroenterol. 2015;21:6206&#x2013;6214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4445097</ArticleId><ArticleId IdType="pubmed">26034355</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnez J, Cacciottola L. Endometriosis: an inflammatory disease that requires new therapeutic options. Int J Mol Sci. 2022;23:1518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8836207</ArticleId><ArticleId IdType="pubmed">35163463</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Y, Gong H, Gou J, Liu X, Li Z. Dienogest as a maintenance treatment for endometriosis following surgery: a systematic review and meta-analysis. Front Med (Lausanne) 2021;8:652505.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8058209</ArticleId><ArticleId IdType="pubmed">33898487</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown J, Crawford TJ, Allen C, Hopewell S, Prentice A. Nonsteroidal anti-inflammatory drugs for pain in women with endometriosis. Cochrane Database Syst Rev. 2017;1:CD004753.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6464974</ArticleId><ArticleId IdType="pubmed">28114727</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferrero S, Barra F, Leone Roberti Maggiore U. Current and emerging therapeutics for the management of endometriosis. Drugs. 2018;78:995&#x2013;1012.</Citation><ArticleIdList><ArticleId IdType="pubmed">29946962</ArticleId></ArticleIdList></Reference><Reference><Citation>Miku&#x161; M, &#x160;prem Gold&#x161;tajn M, Lagan&#xe0; AS, Vukorepa F, &#x106;ori&#x107; M. Clinical efficacy, pharmacokinetics, and safety of the available medical options in the treatment of endometriosis-related pelvic pain: a scoping review. Pharmaceuticals (Basel) 2023;16:1315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10537015</ArticleId><ArticleId IdType="pubmed">37765123</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricciotti E, FitzGerald GA. Prostaglandins and inflammation. Arterioscler Thromb Vasc Biol. 2011;31:986&#x2013;1000.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3081099</ArticleId><ArticleId IdType="pubmed">21508345</ArticleId></ArticleIdList></Reference><Reference><Citation>Yarla NS, Bishayee A, Sethi G, Reddanna P, Kalle AM, Dhananjaya BL, et al. Targeting arachidonic acid pathway by natural products for cancer prevention and therapy. Semin Cancer Biol. 2016;40-41:48&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="pubmed">26853158</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarghi A, Arfaei S. Selective COX-2 inhibitors: a review of their structure-activity relationships. Iran J Pharm Res. 2011;10:655&#x2013;683.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3813081</ArticleId><ArticleId IdType="pubmed">24250402</ArticleId></ArticleIdList></Reference><Reference><Citation>Goumenou AG, Matalliotakis IM, Tzardi M, Fragouli YG, Mahutte NG, Arici A. Apoptosis and differential expression of apoptosis-related proteins in endometriotic glandular and stromal cells. J Soc Gynecol Investig. 2004;11:318&#x2013;322.</Citation><ArticleIdList><ArticleId IdType="pubmed">15219886</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho S, Park SH, Choi YS, Seo SK, Kim HY, Park KH, et al. Expression of cyclooxygenase-2 in eutopic endometrium and ovarian endometriotic tissue in women with severe endometriosis. Gynecol Obstet Invest. 2010;69:93&#x2013;100.</Citation><ArticleIdList><ArticleId IdType="pubmed">20068324</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai ZZ, Yang HL, Ha SY, Chang KK, Mei J, Zhou WJ, et al. Cyclooxygenase-2 in endometriosis. Int J Biol Sci. 2019;15:2783&#x2013;2797.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6909960</ArticleId><ArticleId IdType="pubmed">31853218</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebert AD, Bartley J, David M. Aromatase inhibitors and cyclooxygenase-2 (COX-2) inhibitors in endometriosis: new questions--old answers? Eur J Obstet Gynecol Reprod Biol. 2005;122:144&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">16157442</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, Reich CG, Huser V, Schuemie MJ, et al. Observational health data sciences and informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>You SC, Lee S, Cho SY, Park H, Jung S, Cho J, et al. Conversion of national health insurance service-national sample cohort (NHIS-NSC) database into observational medical outcomes partnership-common data model (OMOP-CDM) Stud Health Technol Inform. 2017;245:467&#x2013;470.</Citation><ArticleIdList><ArticleId IdType="pubmed">29295138</ArticleId></ArticleIdList></Reference><Reference><Citation>Aminoshariae A, Kulild JC, Donaldson M. Short-term use of nonsteroidal anti-inflammatory drugs and adverse effects: an updated systematic review. J Am Dent Assoc. 2016;147:98&#x2013;110.</Citation><ArticleIdList><ArticleId IdType="pubmed">26562732</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonnesen K, Schmidt M. Recategorization of non-aspirin nonsteroidal anti-inflammatory drugs according to clinical relevance: abandoning the traditional NSAID terminology. Can J Cardiol. 2021;37:1705&#x2013;1707.</Citation><ArticleIdList><ArticleId IdType="pubmed">34182020</ArticleId></ArticleIdList></Reference><Reference><Citation>Nnoaham KE, Hummelshoj L, Webster P, d'Hooghe T, de Cicco Nardone F, de Cicco Nardone C, et al. Impact of endometriosis on quality of life and work productivity: a multicenter study across ten countries. Fertil Steril. 2011;96:366&#x2013;373.e8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3679489</ArticleId><ArticleId IdType="pubmed">21718982</ArticleId></ArticleIdList></Reference><Reference><Citation>Attar E, Bulun SE. Aromatase and other steroidogenic genes in endometriosis: translational aspects. Hum Reprod Update. 2006;12:49&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">16123052</ArticleId></ArticleIdList></Reference><Reference><Citation>Banu SK, Lee J, Speights VO, Jr, Starzinski-Powitz A, Arosh JA. Cyclooxygenase-2 regulates survival, migration, and invasion of human endometriotic cells through multiple mechanisms. Endocrinology. 2008;149:1180&#x2013;1189.</Citation><ArticleIdList><ArticleId IdType="pubmed">18039779</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40417462</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>26</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>12</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1942-597X</ISSN><JournalIssue CitedMedium="Internet"><Volume>2024</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>AMIA ... Annual Symposium proceedings. AMIA Symposium</Title><ISOAbbreviation>AMIA Annu Symp Proc</ISOAbbreviation></Journal><ArticleTitle>Variation in Phenotype Definitions in Observational Clinical Research: A Review of Three Conditions.</ArticleTitle><Pagination><StartPage>1021</StartPage><EndPage>1029</EndPage><MedlinePgn>1021-1029</MedlinePgn></Pagination><Abstract><AbstractText>Our study examined the heterogeneity of phenotype algorithms (PA) in literature on Alzheimer's disease (AD), major depressive disorder (MDD), and pulmonary arterial hypertension (PAI), focusing on the impact of PA differences on patient overlap and incidence rate variability across conditions in six observational databases. We reviewed 49 replicated PAs (13 for AD, 23 for MDD, and 13 for PAI) and found significant heterogeneity. These varied PAs identified distinct patient cohorts, resulting in significant incidence rate heterogeneity. Despite some papers reporting primary condition codes and inclusion. comprehensive documentation ensuring reproducibility was often lacking, underscoring the need for more transparent and robust research practices.</AbstractText><CopyrightInformation>&#xa9;2024 AMIA - All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Shoaibi</LastName><ForeName>Azza</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ostropolets</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weaver</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Gowtham A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Golozar</LastName><ForeName>Asieh</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Odysseus Data Services, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swerdel</LastName><ForeName>Joel</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huser</LastName><ForeName>Vojtech</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Odysseus Data Services, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adam</LastName><ForeName>Atif</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>IQVIA Ltd., Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alshammari</LastName><ForeName>Thamir</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>King Saud University, Riyad, Saudi Arabia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anikpezie</LastName><ForeName>Nnabuchi</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Population Health, University of Mississippi Medical Center, Jackson, MS, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baumgartner</LastName><ForeName>William A</ForeName><Initials>WA</Initials><Suffix>Jr</Suffix><AffiliationInfo><Affiliation>University of Colorado School of Medicine, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brand</LastName><ForeName>Milou</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Real World Solutions, IQVIA, Cambridge, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fan</LastName><ForeName>Ruochong</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kanter</LastName><ForeName>Andrew S</ForeName><Initials>AS</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kern</LastName><ForeName>Dave</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Melisa</LastName><ForeName>Septi</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>International PhD Program in Biotech and Healthcare M-anagement, Taipei Medical University, Taipei, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minty</LastName><ForeName>Evan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>O'Brien Institute for Public Health, University of Calgary, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mo</LastName><ForeName>Jessica</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Johns Hopkins University School of Medicine, Baltimore, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oluwalade</LastName><ForeName>Bolu</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>The Children's Hospital of Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schilling</LastName><ForeName>Lisa M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>University of Colorado School of Medicine, Aurora, CO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spence</LastName><ForeName>Hayden</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Aptive Resources LLC, Alexandria, VA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stocking</LastName><ForeName>Jacqueline C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Davis School of Medicine, University of California, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Linying</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Janssen Research &amp; Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>AMIA Annu Symp Proc</MedlineTA><NlmUniqueID>101209213</NlmUniqueID><ISSNLinking>1559-4076</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="Y">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000465" MajorTopicYN="Y">Algorithms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003865" MajorTopicYN="Y">Depressive Disorder, Major</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006976" MajorTopicYN="Y">Hypertension, Pulmonary</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064887" MajorTopicYN="Y">Observational Studies as Topic</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>26</Day><Hour>17</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>26</Day><Hour>17</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>5</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40417462</ArticleId><ArticleId IdType="pmc">PMC12099327</ArticleId><ArticleId IdType="pii">5749</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>George Hripcsak, Albers David J. High-fidelity phenotyping: richness and freedom from bias. Journal of the American Medical Informatics Association. 2017;25(3):289&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7282504</ArticleId><ArticleId IdType="pubmed">29040596</ArticleId></ArticleIdList></Reference><Reference><Citation>Jie Xu, Rasmussen Luke V, Shaw Pamela L, et al. Review and evaluation of electronic health records-driven phenotype algorithm authoring tools for clinical and translational research. Journal of the American Medical Informatics Association. 2015;22(6):1251&#x2013;1260.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5009915</ArticleId><ArticleId IdType="pubmed">26224336</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei-Qi Wei, Robb Rowley, Angela Wood, et al. Improving reporting standards for phenotyping algorithm in biomedical research: 5 fundamental dimensions. [ocae005] Journal of the American Medical Informatics Association. 2024.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10990558</ArticleId><ArticleId IdType="pubmed">38269642</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G., Shang N., Peissig P. L., et al. Facilitating phenotype transfer using a common data model [in eng] J Biomed Inform. Aug 2019;96(suppl 31325501):103253. PMC6697565.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6697565</ArticleId><ArticleId IdType="pubmed">31325501</ArticleId></ArticleIdList></Reference><Reference><Citation> 
 https://ohdsi.github.io/TheBookOfOhdsi/OhdsiAnalyticsTools.html#atlas
.</Citation></Reference><Reference><Citation>  https://ohdsi.github.io/CohortDiagnostics/ Available at. Accessed.</Citation></Reference><Reference><Citation>Rao Gowtham A., Azza Shoaibi, Rupa Makadia, et al. CohortDiagnostics: phenotype evaluation across a network of observational data sources using population-level characterization. medRxiv. 2023:2023.2006.2028.23291982.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11737733</ArticleId><ArticleId IdType="pubmed">39820599</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss Erica A, Rupa Makadia, Amy Matcho, et al. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. Journal of the American Medical Informatics Association. 2015;22(3):553&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4457111</ArticleId><ArticleId IdType="pubmed">25670757</ArticleId></ArticleIdList></Reference><Reference><Citation>Manderscheid R. W., Ryff C. D., Freeman E. J., et al. Evolving definitions of mental illness and wellness [in eng] Prev Chronic Dis. 2010;7(1) (suppl 20040234) Jan:A19 PMC2811514.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2811514</ArticleId><ArticleId IdType="pubmed">20040234</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S. V., Verpillat P, Rassen J. A., et al. Transparency and Reproducibility of Observational Cohort Studies Using Large Healthcare Databases [in eng] Clin Pharmacol Ther. 2016;99(3) (suppl 26690726) Mar:325-332 PMC7833029.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833029</ArticleId><ArticleId IdType="pubmed">26690726</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostropolets A., Albogami Y., Conover M., et al. Reproducible variability: assessing investigator discordance across 9 research teams attempting to reproduce the same observational study [in eng] J Am Med Inform Assoc. 2023;30(5) (suppl 36826399) Apr 19:859-868 PMC10114120.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10114120</ArticleId><ArticleId IdType="pubmed">36826399</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40417523</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>26</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>21</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1942-597X</ISSN><JournalIssue CitedMedium="Internet"><Volume>2024</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>AMIA ... Annual Symposium proceedings. AMIA Symposium</Title><ISOAbbreviation>AMIA Annu Symp Proc</ISOAbbreviation></Journal><ArticleTitle>Optimizing Medication Querying Using Ontology-Driven Approach with OMOP: with an application to a large-scale COVID-19 EHR dataset.</ArticleTitle><Pagination><StartPage>693</StartPage><EndPage>702</EndPage><MedlinePgn>693-702</MedlinePgn></Pagination><Abstract><AbstractText>Efficient querying for medication information in Electronic Health Record (EHR) datasets is crucial for effective patient care and clinical research. To address the complexity and data volume challenges involved in efficient medication information retrieval, we propose an ontology-driven medication query (ODMQ) optimization approach, leveraging the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM). Integrating semantic ontology structures from the OMOP CDM can help enhance query accuracy and efficiency by broadening the scope of relevant medication terms like drug names, National Drug Codes, and generics, resulting in more comprehensive query outcomes than traditional methods. ODMQ significantly reduces manual search time and enhances query capabilities. We validate ODMQ's efficacy using real-world COVID-19 EHR data, demonstrating improved query performance. Through a comprehensive manual review, ODMQ ensures that expanded search terms are relevant to user inputs. It also includes an intuitive query interface and visualizes patient history for result validation and exploration.</AbstractText><CopyrightInformation>&#xa9;2024 AMIA - All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiaojin</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas 77030, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Texas Institute for Restorative Neurotechnologies, The University of Texas Health Science Center at Houston, Houston, Texas 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas 77030, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Texas Institute for Restorative Neurotechnologies, The University of Texas Health Science Center at Houston, Houston, Texas 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Licong</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>McWilliams School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, Texas 77030, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Texas Institute for Restorative Neurotechnologies, The University of Texas Health Science Center at Houston, Houston, Texas 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tao</LastName><ForeName>Shiqiang</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas 77030, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Texas Institute for Restorative Neurotechnologies, The University of Texas Health Science Center at Houston, Houston, Texas 77030, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Guo-Qiang</ForeName><Initials>GQ</Initials><AffiliationInfo><Affiliation>McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, Texas 77030, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>McWilliams School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, Texas 77030, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Texas Institute for Restorative Neurotechnologies, The University of Texas Health Science Center at Houston, Houston, Texas 77030, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 LM013335</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS126690</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>AMIA Annu Symp Proc</MedlineTA><NlmUniqueID>101209213</NlmUniqueID><ISSNLinking>1559-4076</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016247" MajorTopicYN="Y">Information Storage and Retrieval</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064229" MajorTopicYN="Y">Biological Ontologies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012660" MajorTopicYN="N">Semantics</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>26</Day><Hour>12</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>26</Day><Hour>12</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>5</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40417523</ArticleId><ArticleId IdType="pmc">PMC12099415</ArticleId><ArticleId IdType="pii">4928</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tao S, Lhatoo S, Hampson J, Cui L, Zhang G.-Q. A bespoke electronic health record for epilepsy care (epitome): Development and qualitative evaluation. Journal of Medical Internet Research. 2021;23(2):e22939.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7910122</ArticleId><ArticleId IdType="pubmed">33576745</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakkar M, Davis D. C. Risks, barriers, and benefits of ehr systems: a comparative study based on size of hospital. Perspectives in Health Information Management/AHIMA, American Health Information Management Association. 2006;3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2047303</ArticleId><ArticleId IdType="pubmed">18066363</ArticleId></ArticleIdList></Reference><Reference><Citation>Meystre S. M, Lovis C, B&#xa8;urkle T, Tognola G, Budrionis A, Lehmann C. U. Clinical data reuse or secondary use: current status and potential future progress. Yearbook of medical informatics. 2017;26(01):38&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6239225</ArticleId><ArticleId IdType="pubmed">28480475</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker J, Pan E, Johnston D, Adler-Milstein J, Bates D. W, Middleton B. The value of health care information exchange and interoperability: There is a business case to be made for spending money on a fully standardized nationwide system. Health affairs. 2005;24(Suppl1):W5&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">15659453</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Hernandez G, Krallinger M, Mu&#xf1;oz M, Rodriguez-Esteban R, Uzuner &#xd6;, Hirschman L. Challenges and opportunities for mining adverse drug reactions: perspectives from pharma, regulatory agencies, healthcare providers and consumers. Database. 2022;2022:baac071.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9436770</ArticleId><ArticleId IdType="pubmed">36050787</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellazzi R, Diomidous M, Sarkar I N, Takabayashi K, Ziegler A, McCray A. T. Data analysis and data mining: current issues in biomedical informatics. Methods of information in medicine. 2011;50(06):536&#x2013;544.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3233983</ArticleId><ArticleId IdType="pubmed">22146916</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodenreider O. The unified medical language system (umls): integrating biomedical terminology. Nucleic acids research. 2004;32(suppl1):D267&#x2013;D270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC308795</ArticleId><ArticleId IdType="pubmed">14681409</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly K, et al. Snomed-ct: The advanced terminology and coding system for ehealth. Studies in health technology and informatics. 2006;121:279.</Citation><ArticleIdList><ArticleId IdType="pubmed">17095826</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahmadi N, Peng Y, Wolfien M, Zoch M, Sedlmayr M. Omop cdm can facilitate data-driven studies for cancer prediction: a systematic review. International Journal of Molecular Sciences. 2022;23(19):11834.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9569469</ArticleId><ArticleId IdType="pubmed">36233137</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu D, Carterette B. In 2012 IEEE International Conference on Bioinformatics and Biomedicine. IEEE; 2012. Improving health records search using multiple query expansion collections; pp. p. 1&#x2013;7.</Citation></Reference><Reference><Citation>Martinez D, Otegi A, Soroa A, Agirre E. Improving search over electronic health records using umls-based query expansion through random walks. Journal of biomedical informatics. 2014;51:100&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">24768598</ArticleId></ArticleIdList></Reference><Reference><Citation>Jain H, Thao C, Zhao H. Enhancing electronic medical record retrieval through semantic query expansion. Information systems and e-business management. 2012;10:165&#x2013;181.</Citation></Reference><Reference><Citation>Xu B, Lin H, Lin Y. Learning to refine expansion terms for biomedical information retrieval using semantic resources. IEEE/ACM transactions on computational biology and bioinformatics. 2018;16(3):954&#x2013;966.</Citation><ArticleIdList><ArticleId IdType="pubmed">29994423</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes J. H, Beinlich J, Boland M. R, Bowles K. H, Chen Y, Cook T. S, Demiris G, Draugelis M, Fluharty L, Gabriel P. E, et al. Why is the electronic health record so challenging for research and clinical care? Methods of information in medicine. 2021;60(01/02):032&#x2013;048.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9295893</ArticleId><ArticleId IdType="pubmed">34282602</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarwar T, Seifollahi S, Chan J, Zhang X, Aksakalli V, Hudson I, Verspoor K, Cavedon L. The secondary use of electronic health records for data mining: Data characteristics and challenges. ACM Computing Surveys (CSUR) 2022;55(2):1&#x2013;40.</Citation></Reference><Reference><Citation>Bennett C. C. Utilizing rxnorm to support practical computing applications: capturing medication history in live electronic health records. Journal of biomedical informatics. 2012;45(4):634&#x2013;641.</Citation><ArticleIdList><ArticleId IdType="pubmed">22426081</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong Y, Zeng M. L. International classification of diseases (icd) KO Knowledge Organization. 2023;49(7):496&#x2013;528.</Citation></Reference><Reference><Citation>ICD.  Available online.  https://www.who.int/standards/classifications/classification-of-diseases (accessed on 15 March 2024)</Citation></Reference><Reference><Citation>SNOMED-CT.  Available online.  https://www.snomed.org/ (accessed on 15 March 2024)</Citation></Reference><Reference><Citation>Nelson S. J, Zeng K, Kilbourne J, Powell T, Moore R. Normalized names for clinical drugs: Rxnorm at 6 years. Journal of the American Medical Informatics Association. 2011;18(4):441&#x2013;448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3128404</ArticleId><ArticleId IdType="pubmed">21515544</ArticleId></ArticleIdList></Reference><Reference><Citation>RxNorm.  Available online.  https://www.nlm.nih.gov/research/umls/rxnorm/index.html (accessed on 15 March 2024)</Citation></Reference><Reference><Citation>ATHENA.  Available online.  https://athena.ohdsi.org/search-terms/start (accessed on 15 March 2024)</Citation></Reference><Reference><Citation>Reps J. M, Schuemie M. J, Suchard M. A, Ryan P. B, Rijnbeek P. R. Design and implementation of a standardized framework to generate and evaluate patient-level prediction models using observational healthcare data. Journal of the American Medical Informatics Association. 2018;25(8):969&#x2013;975.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6077830</ArticleId><ArticleId IdType="pubmed">29718407</ArticleId></ArticleIdList></Reference><Reference><Citation>Rijnbeek P, Reps J. Chapter 13 patient-level prediction. The Book of OHDSI. 2021</Citation></Reference><Reference><Citation>Danese M. D, Halperin M, Duryea J, Duryea R. The generalized data model for clinical research. BMC medical informatics and decision making. 2019;19:1&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6591926</ArticleId><ArticleId IdType="pubmed">31234921</ArticleId></ArticleIdList></Reference><Reference><Citation>Kent S, Burn E, Dawoud D, Jonsson P, &#xd8;stby J. T, Hughes N, Rijnbeek P, Bouvy J. C. Common problems, common data model solutions: evidence generation for health technology assessment. Pharmacoeconomics. 2021;39(3):275&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7746423</ArticleId><ArticleId IdType="pubmed">33336320</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu B. Health query expansion using wordnet and umls. 2015</Citation></Reference><Reference><Citation>Yunzhi C, Huijuan L, Shapiro L, Travillian R. S, Lanjuan L. An approach to semantic query expansion system based on hepatitis ontology. Journal of Biological Research-Thessaloniki. 2016;23:11&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4943513</ArticleId><ArticleId IdType="pubmed">27437196</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar K. S, Deepa K. Medical query expansion using umls. Indian Journal of Science and Technology. 2016</Citation></Reference><Reference><Citation>Malik S, Shoaib U, El-Sayed H, Khan M. A. 2020 14th International Conference on Innovations in Information Technology (IIT) IEEE; 2020. Query expansion framework leveraging clinical diagnosis information ontology; pp. p. 18&#x2013;23.</Citation></Reference><Reference><Citation>Steinman M. A, Chren M.-M, Landefeld C. S. What&#x2019;s in a name? use of brand versus generic drug names in united states outpatient practice. Journal of general internal medicine. 2007;22:645&#x2013;648.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1852907</ArticleId><ArticleId IdType="pubmed">17443372</ArticleId></ArticleIdList></Reference><Reference><Citation>Ross J. S, Rohde S, Sangaralingham L, Brito J. P, Choi L, Dutcher S. K, Graham D. J, Jenkins M. R, Lipska K. J, Mendoza M, et al. Generic and brand-name thyroid hormone drug use among commercially insured and medicare beneficiaries, 2007 through 2016. The Journal of Clinical Endocrinology &amp; Metabolism. 2019;104(6):2305&#x2013;2314.</Citation><ArticleIdList><ArticleId IdType="pubmed">30690529</ArticleId></ArticleIdList></Reference><Reference><Citation>Schellekens H. National drug codes. the national drug. Nature. 201:4.</Citation></Reference><Reference><Citation>Huang Y, Li X, Zhang G.-Q. Elii: A novel inverted index for fast temporal query, with application to a large covid-19 ehr dataset. Journal of Biomedical Informatics. 2021;117:103744.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9759789</ArticleId><ArticleId IdType="pubmed">33775815</ArticleId></ArticleIdList></Reference><Reference><Citation>Mongodb.   https://www.mongodb.com/ (Online; accessed March, 2024)</Citation></Reference><Reference><Citation>P&#xb4;erez C. A, Zhang G.-Q, Li X, Huang Y, Lincoln J. A, Samudralwar R. D, Gupta R. K, Lindsey J. W. Covid-19 severity and outcome in multiple sclerosis: Results of a national, registry-based, matched cohort study. Multiple Sclerosis and Related Disorders. 2021;55:103217.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8366056</ArticleId><ArticleId IdType="pubmed">34418735</ArticleId></ArticleIdList></Reference><Reference><Citation>Betaseron.  Available online.  https://www.betaseron.com/resources/frequently-asked-questions (accessed on 15 March 2024)</Citation></Reference><Reference><Citation>OHDSI ATLAS.  Available online.  https://atlas-demo.ohdsi.org/#/home/ (accessed on 15 March 2024)</Citation></Reference><Reference><Citation>Bhattacharjee T, Kiwuwa-Muyingo S, Kanjala C, Maoyi M. L, Amadi D, Ochola M, Kadengye D, Gregory A, Kiragga A, Taylor A, et al. Inspire datahub: a pan-african integrated suite of services for harmonising longitudinal population health data using ohdsi tools. Frontiers in Digital Health. 2024;6:1329630.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10859396</ArticleId><ArticleId IdType="pubmed">38347885</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40417561</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>26</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>27</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1942-597X</ISSN><JournalIssue CitedMedium="Internet"><Volume>2024</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>AMIA ... Annual Symposium proceedings. AMIA Symposium</Title><ISOAbbreviation>AMIA Annu Symp Proc</ISOAbbreviation></Journal><ArticleTitle>Leveraging Cluster Causal Diagrams for Determining Causal Effects in Medicine.</ArticleTitle><Pagination><StartPage>134</StartPage><EndPage>141</EndPage><MedlinePgn>134-141</MedlinePgn></Pagination><Abstract><AbstractText>Causal inference, or the task of estimating the causal effect of an exposure or interventional variable on an outcome from an observational dataset, requires precise and rigorous methods, based on assumptions about the system under study. Such assumptions can be articulated as a causal diagram, however use of this technique in medicine is uncommon due to challenges in causal diagram construction in high-dimensional settings. Recent introduction of cluster causal diagrams or C-DAGs promise to ease the task of diagram construction by allowing for the representation of some unknown or partially defined relationships. We evaluate the practical application of C-DAGs in simulated medical contexts. We estimate causal effects under varying sets of assumptions, determined by both causal diagrams and C-DAGs and compare our results. Our findings show empirically similar results, with little discrepancy between causal effect sizes or variance across experimental runs, although estimation and efficiency challenges remain to be explored.</AbstractText><CopyrightInformation>&#xa9;2024 AMIA - All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Anand</LastName><ForeName>Tara V</ForeName><Initials>TV</Initials><AffiliationInfo><Affiliation>Columbia University Medical Center, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Columbia University Medical Center, New York, NY.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>AMIA Annu Symp Proc</MedlineTA><NlmUniqueID>101209213</NlmUniqueID><ISSNLinking>1559-4076</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D015984" MajorTopicYN="Y">Causality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016000" MajorTopicYN="N">Cluster Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>26</Day><Hour>12</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>26</Day><Hour>12</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>5</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40417561</ArticleId><ArticleId IdType="pmc">PMC12099438</ArticleId><ArticleId IdType="pii">4520</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pearl J. xvi. New York, NY, US: Cambridge University Press; 2000. Causality: Models, reasoning, and inference; p. 384 p.. (Causality: Models, reasoning, and inference)</Citation></Reference><Reference><Citation>Spirtes. MIT Press. 2000.  [cited 2023 Jun 2] Causation, Prediction, and Search Available from:  https://mitpress.mit.edu/9780262527927/causation-prediction-and-search/</Citation></Reference><Reference><Citation>Bareinboim E, Pearl J. Causal inference and the data-fusion problem. Proceedings of the National Academy of Sciences. 2016 Jul 5;113(27):7345&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4941504</ArticleId><ArticleId IdType="pubmed">27382148</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters J, Janzing D, Sch&#xf6;lkopf B.  Cambridge, MA, USA: The MIT Press; 2017. Elements of Causal Inference- Foundations and Learning Algorithms [Internet] [cited 2024 Mar 16]. (Adaptive Computation and Machine Learning Series). Available from:  https://mitpress.mit.edu/9780262037310/elements-of-causal-inference/</Citation></Reference><Reference><Citation>Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika. 1983 Apr;70(1):41&#x2013;55.</Citation></Reference><Reference><Citation>Rubin DB. Causal Inference Using Potential Outcomes: Design, Modeling, Decisions. Journal of the American Statistical Association. 2005;100(469):322&#x2013;31.</Citation></Reference><Reference><Citation>Pearl J. Causal diagrams for empirical research. Biometrika. 1995 Dec 1;82(4):669&#x2013;88.</Citation></Reference><Reference><Citation>Tian J, Pearl J. A General Identification Condition for Causal Effects. Proceedings of the National Conference on Artificial Intelligence. 2003 Aug 24.</Citation></Reference><Reference><Citation>Shpitser I, Pearl J. Identification of Joint Interventional Distributions in Recursive Semi-Markovian Causal Models. Proceedings of the Twenty-First AAAI Conference on Artificial Intelligence. pp. 1219&#x2013;26.</Citation></Reference><Reference><Citation>Huang Y, Valtorta M. Pearl&#x2019;s Calculus of Intervention Is Complete. Proceedings of the 22nd Conference on Uncertainty in Artificial Intelligence. 2006:217&#x2013;24.</Citation></Reference><Reference><Citation>Lee S, Correa J, Bareinboim E. Adams R, Gogate V, editors. General Identifiability with Arbitrary Surrogate Experiments. 35TH UNCERTAINTY IN ARTIFICIAL INTELLIGENCE CONFERENCE (UAI 2019) 2020. pp. p. 389&#x2013;98.</Citation></Reference><Reference><Citation>Anand TV, Ribeiro AH, Tian J, Bareinboim E. Causal Effect Identification in Cluster DAGs. Proceedings of the AAAI Conference on Artificial Intelligence. 2023 Jun 26;37(10):12172&#x2013;9.</Citation></Reference><Reference><Citation>Beinlich IA, Suermondt HJ, Chavez RM, Cooper GF. The ALARM Monitoring System: A Case Study with two Probabilistic Inference Techniques for Belief Networks. In: Hunter J, Cookson J, Wyatt J, editors. AIME 89. Berlin, Heidelberg: Springer; 1989. pp. p. 247&#x2013;56.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40417568</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>26</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>27</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1942-597X</ISSN><JournalIssue CitedMedium="Internet"><Volume>2024</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>AMIA ... Annual Symposium proceedings. AMIA Symposium</Title><ISOAbbreviation>AMIA Annu Symp Proc</ISOAbbreviation></Journal><ArticleTitle>EHR Phenotyping Methods for Measuring Treatment Adherence Among People Living With HIV in All of Us: Towards Disparities and Inequalities in HIV Care Continuum.</ArticleTitle><Pagination><StartPage>1294</StartPage><EndPage>1302</EndPage><MedlinePgn>1294-1302</MedlinePgn></Pagination><Abstract><AbstractText>HIV treatment adherence is among the most important determinants of HIV outcomes. However, only 50% of people living with HIV in the US were retained in care. Measuring HIV treatment adherence in the clinical settings is feasible but when it comes to the growing number of multi-site Electronic Health Records (EHR), there has been a dearth of research for adequate informatics methods to handle EHR. We sought to address this gap by developing a cluster of metrics for measuring HIV treatment adherence via EHR phenotyping methods. Our methods were developed and tested in the All of Us research program. We also performed preliminary analyses to explore disparities in HIV treatment adherence and demographic factors contributing to poor adherence. This study paves the way for systematic data mining and analyses for the HIV care continuum, disparities, and inequality research on All of Us and other EHR normalized with the OMOP Common Data Model.</AbstractText><CopyrightInformation>&#xa9;2024 AMIA - All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yue</LastName><ForeName>Yuanzhen</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>University of South Carolina Arnold School of Public Health, Columbia, South Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khanal</LastName><ForeName>Ashok</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>University of South Carolina Arnold School of Public Health, Columbia, South Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lyu</LastName><ForeName>Tianchu</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>University of South Carolina Arnold School of Public Health, Columbia, South Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weissman</LastName><ForeName>Sharon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of South Carolina School of Medicine, Columbia, South Carolina, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Prisma Health, Columbia, South Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Chen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University of South Carolina Arnold School of Public Health, Columbia, South Carolina, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of Washington, School of Medicine, Department of Biomedical Informatics and Medical Education, Seattle, Washington.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Institutes of Health, Bethesda, Washington DC.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>AMIA Annu Symp Proc</MedlineTA><NlmUniqueID>101209213</NlmUniqueID><ISSNLinking>1559-4076</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="Y">HIV Infections</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003266" MajorTopicYN="Y">Continuity of Patient Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054625" MajorTopicYN="Y">Healthcare Disparities</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>26</Day><Hour>12</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>26</Day><Hour>12</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>5</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40417568</ArticleId><ArticleId IdType="pmc">PMC12099386</ArticleId><ArticleId IdType="pii">5949</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Teeraananchai S, Kerr SJ, Amin J, Ruxrungtham K, Law MG. Life expectancy of HIV-positive people after starting combination antiretroviral therapy: a meta-analysis. HIV Med. 2017;18(4):256&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">27578404</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention. Monitoring Selected National HIV Prevention and Care Objectives By Using HIV Surveillance Data United States and 6 Dependent Areas. 2019. p. 2019.</Citation></Reference><Reference><Citation>Rebeiro PF, Abraham AG, Horberg MA, et al. Sex, race, and HIV risk disparities in discontinuity of HIV care after antiretroviral therapy initiation in the United States and Canada. AIDS Patient Care STDS. 2017;31(3):129&#x2013;144.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5359655</ArticleId><ArticleId IdType="pubmed">28282246</ArticleId></ArticleIdList></Reference><Reference><Citation>Panahi S, Rathi N, Hurley J, Sundrud J, Lucero M, Kamimura A. Patient adherence to health care provider recommendations and medication among free clinic patients. J Patient Exp. 2022;9:23743735221077524.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8832560</ArticleId><ArticleId IdType="pubmed">35155751</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinicalinfo.HIV.gov. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV.  Published 2023. Accessed March 15, 2024.  https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/adherence-continuum-care.</Citation></Reference><Reference><Citation>Castillo-Mancilla JR, Haberer JE. Adherence measurements in HIV: new advancements in pharmacologic methods and real-time monitoring. Curr HIV/AIDS Rep. 2018;15:49&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5876155</ArticleId><ArticleId IdType="pubmed">29380227</ArticleId></ArticleIdList></Reference><Reference><Citation>McMahon JH, Jordan MR, Kelley K, et al. Pharmacy adherence measures to assess adherence to antiretroviral therapy: review of the literature and implications for treatment monitoring. Clinical Infectious Diseases. 2011;52(4):493&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3060901</ArticleId><ArticleId IdType="pubmed">21245156</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinelli MA, Haberer JE, Chai PR, Castillo-Mancilla J, Anderson PL, Gandhi M. Approaches to objectively measure antiretroviral medication adherence and drive adherence interventions. Curr HIV/AIDS Rep. 2020;17:301&#x2013;314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7363551</ArticleId><ArticleId IdType="pubmed">32424549</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg KM, Arnsten JH. Practical and conceptual challenges in measuring antiretroviral adherence. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2006;43:S79&#x2013;S87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2866146</ArticleId><ArticleId IdType="pubmed">17133207</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith R, Villanueva G, Probyn K, et al. Accuracy of measures for antiretroviral adherence in people living with HIV. Cochrane Database of Systematic Reviews. 2022;(7)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9309033</ArticleId><ArticleId IdType="pubmed">35871531</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinelli MA, Haberer JE, Chai PR, Castillo-Mancilla J, Anderson PL, Gandhi M. Approaches to objectively measure antiretroviral medication adherence and drive adherence interventions. Curr HIV/AIDS Rep. 2020;17:301&#x2013;314.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7363551</ArticleId><ArticleId IdType="pubmed">32424549</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg KM, Arnsten JH. Practical and conceptual challenges in measuring antiretroviral adherence. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2006;43:S79&#x2013;S87.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2866146</ArticleId><ArticleId IdType="pubmed">17133207</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmann A, Aslani P, Ahmed R, et al. Assessing medication adherence: options to consider. Int J Clin Pharm. 2014;36:55&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">24166659</ArticleId></ArticleIdList></Reference><Reference><Citation>Stirratt MJ, Dunbar-Jacob J, Crane HM, et al. Self-report measures of medication adherence behavior: recommendations on optimal use. Transl Behav Med. 2015;5(4):470&#x2013;482.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4656225</ArticleId><ArticleId IdType="pubmed">26622919</ArticleId></ArticleIdList></Reference><Reference><Citation>Costa E, Giardini A, Prados-Torres A, Cahir C, Marengoni A. Interventional tools to improve prescription and adherence to medical plans. Biomed Res Int. 2015. p. 2015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4672111</ArticleId><ArticleId IdType="pubmed">26688812</ArticleId></ArticleIdList></Reference><Reference><Citation>Staroselsky M, Volk LA, Tsurikova R, et al. Improving electronic health record (EHR) accuracy and increasing compliance with health maintenance clinical guidelines through patient access and input. Int J Med Inform. 2006;75(10-11):693&#x2013;700.</Citation><ArticleIdList><ArticleId IdType="pubmed">16338169</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailey SC, Wallia A, Wright S, et al. Electronic Health Record&#x2013;Based Strategy to Promote Medication Adherence Among Patients With Diabetes: Longitudinal Observational Study. J Med Internet Res. 2019;21(10):e13499.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6829279</ArticleId><ArticleId IdType="pubmed">31638592</ArticleId></ArticleIdList></Reference><Reference><Citation>Franklin JM, Gopalakrishnan C, Krumme AA, et al. The relative benefits of claims and electronic health record data for predicting medication adherence trajectory. Am Heart J. 2018;197:153&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pubmed">29447776</ArticleId></ArticleIdList></Reference><Reference><Citation>McInnes DK, Shimada SL, Midboe AM, et al. Patient use of electronic prescription refill and secure messaging and its association with undetectable HIV viral load: a retrospective cohort study. J Med Internet Res. 2017;19(2):e34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5332835</ArticleId><ArticleId IdType="pubmed">28202428</ArticleId></ArticleIdList></Reference><Reference><Citation>Galozy A, Nowaczyk S, Sant&#x2019;Anna A, Ohlsson M, Lingman M. Pitfalls of medication adherence approximation through EHR and pharmacy records: definitions, data and computation. Int J Med Inform. 2020;136:104092.</Citation><ArticleIdList><ArticleId IdType="pubmed">32062562</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang C. Patient Safety Narratives as a Key to Promoting Quality Measurement. J Health Med Informat. 2017;8(290):2.</Citation></Reference><Reference><Citation>Mills AM, Schulman KL, Fusco JS, et al. Virologic outcomes among people living with human immunodeficiency virus with high pretherapy viral load burden initiating on common core agents. Open Forum Infectious Diseases. 2021;Vol 8:ofab363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8351805</ArticleId><ArticleId IdType="pubmed">34381843</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyu T, Qiao S, Hair N, Liang C, Li X. Federal funding allocation on HIV/AIDS research in the United States (2008&#x2013;2018): an exploratory study using Big Data. AIDS Care. 2023;35(8):1069&#x2013;1075.</Citation><ArticleIdList><ArticleId IdType="pubmed">33682543</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyu T, Liang C. AMIA Annual Symposium Proceedings 2023. Vol. 2023. American Medical Informatics Association; Computational Phenotyping of OMOP CDM Normalized EHR for Prenatal and Postpartum Episodes: An Informatics Framework and Clinical Implementation on All of Us; p. p. 1096.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10785883</ArticleId><ArticleId IdType="pubmed">38222375</ArticleId></ArticleIdList></Reference><Reference><Citation>MacCarthy S, Hoffmann M, Ferguson L, Nunn A, Irvin R, Bangsberg D, Gruskin S, Dourado I. The HIV care cascade: models, measures and moving forward. African Journal of Reproduction and Gynaecological Endoscopy. 2015 Jan 1;18(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4348400</ArticleId><ArticleId IdType="pubmed">25735869</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40417570</PMID><DateCompleted><Year>2025</Year><Month>05</Month><Day>26</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>27</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1942-597X</ISSN><JournalIssue CitedMedium="Internet"><Volume>2024</Volume><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>AMIA ... Annual Symposium proceedings. AMIA Symposium</Title><ISOAbbreviation>AMIA Annu Symp Proc</ISOAbbreviation></Journal><ArticleTitle>A Novel Sentence Transformer-based Natural Language Processing Approach for Schema Mapping of Electronic Health Records to the OMOP Common Data Model.</ArticleTitle><Pagination><StartPage>1332</StartPage><EndPage>1339</EndPage><MedlinePgn>1332-1339</MedlinePgn></Pagination><Abstract><AbstractText>Mapping electronic health records (EHR) data to common data models (CDMs) enables the standardization of clinical records, enhancing interoperability and enabling large-scale, multi-centered clinical investigations. Using 2 large publicly available datasets, we developed transformer-based natural language processing models to map medication-related concepts from the EHR at a large and diverse healthcare system to standard concepts in OMOP CDM. We validated the model outputs against standard concepts manually mapped by clinicians. Our best model reached out-of-box accuracies of 96.5% in mapping the 200 most common drugs and 83.0% in mapping 200 random drugs in the EHR. For these tasks, this model outperformed a state-of-the-art large language model (SFR-Embedding-Mistral, 89.5% and 66.5% in accuracy for the two tasks), a widely used software for schema mapping (Usagi, 90.0% and 70.0% in accuracy), and direct string match (7.5% and 7.5% accuracy). Transformer-based deep learning models outperform existing approaches in the standardized mapping of EHR elements and can facilitate an end-to-end automated EHR transformation pipeline.</AbstractText><CopyrightInformation>&#xa9;2024 AMIA - All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Xinyu</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Yale School of Public Health, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dhingra</LastName><ForeName>Lovedeep Singh</ForeName><Initials>LS</Initials><AffiliationInfo><Affiliation>Yale School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aminorroaya</LastName><ForeName>Arya</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Yale School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adejumo</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Yale School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khera</LastName><ForeName>Rohan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Yale School of Public Health, New Haven, CT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Yale School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biomedical Informatics and Data Science, Yale School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>AMIA Annu Symp Proc</MedlineTA><NlmUniqueID>101209213</NlmUniqueID><ISSNLinking>1559-4076</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D009323" MajorTopicYN="Y">Natural Language Processing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>26</Day><Hour>12</Hour><Minute>38</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>26</Day><Hour>12</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>5</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40417570</ArticleId><ArticleId IdType="pmc">PMC12099400</ArticleId><ArticleId IdType="pii">5274</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Biedermann P, Ong R, Davydov A, Orlova A, Solovyev P, Sun H, et al. Standardizing registry data to the OMOP Common Data Model: experience from three pulmonary hypertension databases. BMC medical research methodology. 2021;21(1):1&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8565035</ArticleId><ArticleId IdType="pubmed">34727871</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Shang N, Peissig PL, Rasmussen LV, Liu C, Benoit B, et al. Facilitating phenotype transfer using a common data model. Journal of biomedical informatics. 2019;96:103253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6697565</ArticleId><ArticleId IdType="pubmed">31325501</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang B, Yoon J, Kim HY, Jo SJ, Lee Y, Kam HJ. Deep-learning-based automated terminology mapping in OMOP-CDM. Journal of the American Medical Informatics Association. 2021;28(7):1489&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8279781</ArticleId><ArticleId IdType="pubmed">33987667</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao G, Pfaff E, Prud&#x2019;hommeaux E, Booth D, Sharma DK, Huo N, et al. FHIR-Ontop-OMOP: Building clinical knowledge graphs in FHIR RDF with the OMOP Common data Model. Journal of Biomedical Informatics. 2022;134:104201.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9561043</ArticleId><ArticleId IdType="pubmed">36089199</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss EA, Makadia R, Matcho A, Ma Q, Knoll C, Schuemie M, et al. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. Journal of the American Medical Informatics Association. 2015;22(3):553&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4457111</ArticleId><ArticleId IdType="pubmed">25670757</ArticleId></ArticleIdList></Reference><Reference><Citation>USAGI for vocabulary mapping.  [Available from:  https://www.ohdsi.org/analytic-tools/usagi/</Citation></Reference><Reference><Citation>Reimers N, Gurevych I. Sentence-bert: Sentence embeddings using siamese bert-networks. arXiv preprint arXiv:190810084. 2019.</Citation></Reference><Reference><Citation>OHDSI Athena. 2023.  [Available from:  https://athena.ohdsi.org/search-terms/start.</Citation></Reference><Reference><Citation>Grossman Liu L, Grossman RH, Mitchell EG, Weng C, Natarajan K, Hripcsak G, et al. A deep database of medical abbreviations and acronyms for natural language processing. Scientific Data. 2021;8(1):149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8172575</ArticleId><ArticleId IdType="pubmed">34078918</ArticleId></ArticleIdList></Reference><Reference><Citation>Remy F, Demuynck K, Demeester T. BioLORD: Learning Ontological Representations from Definitions (for Biomedical Concepts and their Textual Descriptions) arXiv preprint arXiv:221011892. 2022.</Citation></Reference><Reference><Citation>Sentence-transformers pretrained models. 2023.  [Available from:  https://www.sbert.net/docs/pretrained models.html.</Citation></Reference><Reference><Citation>Song K, Tan X, Qin T, Lu J, Liu T-Y. Mpnet: Masked and permuted pre-training for language understanding. Advances in neural information processing systems. 2020;33:16857&#x2013;67.</Citation></Reference><Reference><Citation>Yang X, Chen A, PourNejatian N, Shin HC, Smith KE, Parisien C, et al. A large language model for electronic health records. NPJ Digital Medicine. 2022;5(1):194.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9792464</ArticleId><ArticleId IdType="pubmed">36572766</ArticleId></ArticleIdList></Reference><Reference><Citation>Devlin J, Chang M-W, Lee K, Toutanova K. Bert: Pre-training of deep bidirectional transformers for language understanding. arXiv preprint arXiv:181004805. 2018.</Citation></Reference><Reference><Citation>Vaswani A, Shazeer N, Parmar N, Uszkoreit J, Jones L, Gomez AN, et al. Attention is all you need. arXiv preprint arXiv:170603762. 2017.</Citation></Reference><Reference><Citation>USAGI - Observational Health Data Sciences and Informatics (OHDSI) team.  [Available from:  https://ohdsi.github.io/Usagi/</Citation></Reference><Reference><Citation>Wang L, Yang N, Huang X, Yang L, Majumder R, Wei F. Improving text embeddings with large language models. arXiv preprint arXiv:240100368. 2023.</Citation></Reference><Reference><Citation>Muennighoff N, Tazi N, Magne L, Reimers N. MTEB: Massive text embedding benchmark. arXiv preprint arXiv:221007316. 2022.</Citation></Reference><Reference><Citation>Meng R, Liu Y, Joty SR, Xiong C, Zhou Y, Yavuz S. Sfrembedding-mistral: enhance text retrieval with transfer learning. Salesforce AI Research Blog. 2024. p. 3.</Citation></Reference><Reference><Citation>RapidFuzz 3.9.6 documentation.  [Available from:  https://rapidfuzz.github.io/RapidFuzz/</Citation></Reference><Reference><Citation>Jiang AQ, Sablayrolles A, Mensch A, Bamford C, Chaplot DS, Casas Ddl, et al. Mistral 7B. arXiv preprint arXiv:231006825. 2023.</Citation></Reference><Reference><Citation>Erickson BJ, Kitamura F. Magician&#x2019;s corner: 9. Performance metrics for machine learning models. Radiological Society of North America. 2021. p. p. e200126.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8204137</ArticleId><ArticleId IdType="pubmed">34136815</ArticleId></ArticleIdList></Reference><Reference><Citation>Gunawardana A, Shani G. A survey of accuracy evaluation metrics of recommendation tasks. Journal of Machine Learning Research. 2009;10(12)</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40426310</PMID><DateRevised><Year>2025</Year><Month>05</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2093-5978</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>May</Month><Day>28</Day></PubDate></JournalIssue><Title>Endocrinology and metabolism (Seoul, Korea)</Title><ISOAbbreviation>Endocrinol Metab (Seoul)</ISOAbbreviation></Journal><ArticleTitle>Comprehensive Evaluation of Treatment Patterns in Postmenopausal Patients with Osteoporosis without Fractures: Insights from Tertiary Care Institutions and Nationwide OMOP-CDM Data.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.3803/EnM.2024.2252</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Osteoporosis is a global health concern. Despite emerging treatment options for this condition, limited data are available on hospital practices in South Korea. This study addresses the need for a hospital network database that reflects changes in routine clinical practice for osteoporosis in a timely manner.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We analyzed prescription patterns for anti-osteoporosis medications (AOMs) in postmenopausal women aged &#x2265;50 years diagnosed with osteoporosis between 2012 and 2021 using data from Osteoporosis Analysis and Surveillance Initiative using Standardized data (OASIS) (four tertiary hospitals in South Korea) and a nationwide database from the Health Insurance Review and Assessment (HIRA) Service. AOMs were categorized into antiresorptive and anabolic agents, with a focus on secular changes in the use of oral bisphosphonates, denosumab, selective estrogen receptor modulators (SERMs), and anabolic agents.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">In the OASIS cohort, oral bisphosphonates were the most prescribed first-line AOM (49.0%), followed by denosumab (15.7%) and SERMs (18.0%). Denosumab use increased from 2% in 2016 to 40% in 2020, while oral bisphosphonate use declined from 69% in 2012 to 22% in 2021. The use of anabolic agents, including romosozumab and teriparatide, doubled to 6% after 2019. In the HIRA cohort, parenteral bisphosphonates were most common (54.3%), with significant denosumab use (17.3%).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Pronounced shifts in AOM prescription patterns were observed in South Korea, marked by a notable increase in denosumab prescriptions and a decline in bisphosphonate use. These trends highlight the impact of policy changes and clinical guidelines on osteoporosis treatment and may inform future management strategies.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Kyoung Jin</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boo</LastName><ForeName>Dachung</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Innovation in Digital Healthcare, Yonsei University, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Jimi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoon</LastName><ForeName>Hyemin</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Big Data Research Center, Asan Institute of Life Science, Asan Medical Center, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jung</LastName><ForeName>Chai Young</ForeName><Initials>CY</Initials><AffiliationInfo><Affiliation>Biomedical Research Institute, Inha University Hospital, Incheon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahn</LastName><ForeName>Seong Hee</ForeName><Initials>SH</Initials><AffiliationInfo><Affiliation>Division of Endocrinology and Metabolism, Department of Internal Medicine, Inha University Hospital, Inha University College of Medicine, Incheon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Namki</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Institute for Innovation in Digital Healthcare, Yonsei University, Seoul, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Endocrine Research Institute, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Beom-Jun</ForeName><Initials>BJ</Initials><AffiliationInfo><Affiliation>Division of Endocrinology &amp; Metabolism, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oh</LastName><ForeName>Ji Seon</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Big Data Research Center, Asan Institute of Life Science, Asan Medical Center, Seoul, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Information Medicine, Asan Medical Center, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>You</LastName><ForeName>Seng Chan</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Innovation in Digital Healthcare, Yonsei University, Seoul, Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>Endocrinol Metab (Seoul)</MedlineTA><NlmUniqueID>101554139</NlmUniqueID><ISSNLinking>2093-596X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Drug prescriptions</Keyword><Keyword MajorTopicYN="N">Osteoporosis, postmenopausal</Keyword><Keyword MajorTopicYN="N">Practice patterns, physicians&#x2019;</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>11</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>2</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>5</Month><Day>28</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>5</Month><Day>28</Day><Hour>0</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40426310</ArticleId><ArticleId IdType="doi">10.3803/EnM.2024.2252</ArticleId><ArticleId IdType="pii">EnM.2024.2252</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40457713</PMID><DateCompleted><Year>2025</Year><Month>06</Month><Day>03</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1099-1557</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>6</Issue><PubDate><Year>2025</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Pharmacoepidemiology and drug safety</Title><ISOAbbreviation>Pharmacoepidemiol Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Use of Machine Learning to Compare Disease Risk Scores and Propensity Scores Across Complex Confounding Scenarios: A Simulation Study.</ArticleTitle><Pagination><StartPage>e70165</StartPage><MedlinePgn>e70165</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e70165</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/pds.70165</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">The surge of treatments for COVID-19 in the second quarter of 2020 had a low prevalence of treatment and high outcome risk. Motivated by that, we conducted a simulation study comparing disease risk scores (DRS) and propensity scores (PS) using a range of scenarios with different treatment prevalences and outcome risks.</AbstractText><AbstractText Label="METHOD" NlmCategory="METHODS">Four methods were used to estimate PS and DRS: logistic regression (reference method), least absolute shrinkage and selection operator (LASSO), multilayer perceptron (MLP), and XgBoost. Monte Carlo simulations generated data across 25 scenarios varying in treatment prevalence, outcome risk, data complexity, and sample size. Average treatment effects were calculated after matching. Relative bias and average absolute standardized mean difference (ASMD) were reported.</AbstractText><AbstractText Label="RESULT" NlmCategory="RESULTS">Estimation bias increased as treatment prevalence decreased. DRS showed lower bias than PS when treatment prevalence was below 0.1, especially in nonlinear data. However, DRS did not outperform PS in linear or small sample data. PS had comparable or lower bias than DRS when treatment prevalence was 0.1-0.5. Three machine learning (ML) methods performed similarly, with LASSO and XgBoost outperforming the reference method in some nonlinear scenarios. ASMD results indicated that DRS was less impacted by decreasing treatment prevalence compared to PS.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Under nonlinear data, DRS reduced bias compared to PS in scenarios with low treatment prevalence, while PS was preferable for data with treatment prevalence greater than 0.1, regardless of the outcome risk. ML methods can outperform the logistic regression method for PS and DRS estimation. Both decreasing sample size and adding nonlinearity and nonadditivity in data increased bias for all methods tested.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). Pharmacoepidemiology and Drug Safety published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Yuchen</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-0847-4855</Identifier><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strauss</LastName><ForeName>Victoria Y</ForeName><Initials>VY</Initials><AffiliationInfo><Affiliation>Boehringer-Ingelheim Pharma GmbH &amp; co., KG, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khalid</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-3950-6346</Identifier><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Pharmacoepidemiol Drug Saf</MedlineTA><NlmUniqueID>9208369</NlmUniqueID><ISSNLinking>1053-8569</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057216" MajorTopicYN="Y">Propensity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069550" MajorTopicYN="Y">Machine Learning</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003198" MajorTopicYN="N">Computer Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015982" MajorTopicYN="N">Bias</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009010" MajorTopicYN="N">Monte Carlo Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015986" MajorTopicYN="N">Confounding Factors, Epidemiologic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">causal inference</Keyword><Keyword MajorTopicYN="N">disease risk scores</Keyword><Keyword MajorTopicYN="N">machine learning</Keyword><Keyword MajorTopicYN="N">propensity scores</Keyword><Keyword MajorTopicYN="N">treatment effect</Keyword></KeywordList><CoiStatement>Prof. Daniel Prieto&#x2010;Alhambra's research group has received grant support from Amgen, Chesi&#x2010;Taylor, Novartis and UCB Biopharma. His department has received advisory or consultancy fees from Amgen, Astellas, AstraZeneca, Johnson and Johnson, and UCB Biopharma and fees for speaker services from Amgen and UCB Biopharma. Janssen, on behalf of IMI&#x2010;funded EHDEN and EMIF consortiums and Synapse Management Partners, has supported training programmes organised by DPA's department and open for external participants organised by his department, all unrelated to the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>2</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>3</Day><Hour>2</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>6</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40457713</ArticleId><ArticleId IdType="pmc">PMC12130674</ArticleId><ArticleId IdType="doi">10.1002/pds.70165</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Austin P. C., &#x201c;The Relative Ability of Different Propensity Score Methods to Balance Measured Covariates Between Treated and Untreated Subjects in Observational Studies,&#x201d; Medical Decision Making 29, no. 6 (2009): 661&#x2013;677.</Citation><ArticleIdList><ArticleId IdType="pubmed">19684288</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin P. C., &#x201c;An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies,&#x201d; Multivariate Behavioral Research 46, no. 3 (2011): 399&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3144483</ArticleId><ArticleId IdType="pubmed">21818162</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali M. S., Groenwold R. H., and Klungel O. H., &#x201c;Best (But Oft&#x2010;Forgotten) Practices: Propensity Score Methods in Clinical Nutrition Research,&#x201d; American Journal of Clinical Nutrition 104, no. 2 (2016): 247&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pubmed">27413128</ArticleId></ArticleIdList></Reference><Reference><Citation>Hajage D., Tubach F., Steg P. G., Bhatt D. L., and De Rycke Y., &#x201c;On the Use of Propensity Scores in Case of Rare Exposure,&#x201d; BMC Medical Research Methodology 16, no. 1 (2016): 38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815252</ArticleId><ArticleId IdType="pubmed">27036963</ArticleId></ArticleIdList></Reference><Reference><Citation>Arbogast P. G. and Ray W. A., &#x201c;Performance of Disease Risk Scores, Propensity Scores, and Traditional Multivariable Outcome Regression in the Presence of Multiple Confounders,&#x201d; American Journal of Epidemiology 174, no. 5 (2011): 613&#x2013;620, 10.1093/aje/kwr143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwr143</ArticleId><ArticleId IdType="pubmed">21749976</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu S., Shetterly S., Cook A. J., et&#xa0;al., &#x201c;Evaluation of Propensity Scores, Disease Risk Scores, and Regression in Confounder Adjustment for the Safety of Emerging Treatment With Group Sequential Monitoring,&#x201d; Pharmacoepidemiology and Drug Safety 25, no. 4 (2016): 453&#x2013;461.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4930363</ArticleId><ArticleId IdType="pubmed">26875591</ArticleId></ArticleIdList></Reference><Reference><Citation>Glynn R. J., Gagne J. J., and Schneeweiss S., &#x201c;Role of Disease Risk Scores in Comparative Effectiveness Research With Emerging Therapies,&#x201d; Pharmacoepidemiology and Drug Safety 21, no. S2 (2012): 138&#x2013;147.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3454457</ArticleId><ArticleId IdType="pubmed">22552989</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyss R., Ellis A. R., Brookhart M. A., et&#xa0;al., &#x201c;Matching on the Disease Risk Score in Comparative Effectiveness Research of New Treatments,&#x201d; Pharmacoepidemiology and Drug Safety 24, no. 9 (2015): 951&#x2013;961.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4833391</ArticleId><ArticleId IdType="pubmed">26112690</ArticleId></ArticleIdList></Reference><Reference><Citation>Cannas M. and Arpino B., &#x201c;A Comparison of Machine Learning Algorithms and Covariate Balance Measures for Propensity Score Matching and Weighting,&#x201d; Biometrical Journal 61, no. 4 (2019): 1049&#x2013;1072.</Citation><ArticleIdList><ArticleId IdType="pubmed">31090108</ArticleId></ArticleIdList></Reference><Reference><Citation>Westreich D., Lessler J., and Funk M. J., &#x201c;Propensity Score Estimation: Neural Networks, Support Vector Machines, Decision Trees (CART), and Meta&#x2010;Classifiers as Alternatives to Logistic Regression,&#x201d; Journal of Clinical Epidemiology 63, no. 8 (2010): 826&#x2013;833.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2907172</ArticleId><ArticleId IdType="pubmed">20630332</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee B. K., Lessler J., and Stuart E. A., &#x201c;Improving Propensity Score Weighting Using Machine Learning,&#x201d; Statistics in Medicine 29, no. 3 (2010): 337&#x2013;346.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2807890</ArticleId><ArticleId IdType="pubmed">19960510</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenland S., &#x201c;Invited Commentary: Variable Selection Versus Shrinkage in the Control of Multiple Confounders,&#x201d; American Journal of Epidemiology 167, no. 5 (2008): 523.</Citation><ArticleIdList><ArticleId IdType="pubmed">18227100</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneeweiss S., Rassen J. A., Glynn R. J., Avorn J., Mogun H., and Brookhart M. A., &#x201c;High&#x2010;Dimensional Propensity Score Adjustment in Studies of Treatment Effects Using Health Care Claims Data,&#x201d; Epidemiology (Cambridge, Mass.) 20, no. 4 (2009): 512&#x2013;522.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3077219</ArticleId><ArticleId IdType="pubmed">19487948</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C., Wang S., Shi F., and Wang Z., &#x201c;Robust Propensity Score Computation Method Based on Machine Learning With Label&#x2010;Corrupted Data,&#x201d; arXivorg (2018).</Citation></Reference><Reference><Citation>Setoguchi S., Schneeweiss S., Brookhart M. A., Glynn R. J., and Cook E. F., &#x201c;Evaluating Uses of Data Mining Techniques in Propensity Score Estimation: A Simulation Study,&#x201d; Pharmacoepidemiology and Drug Safety 17, no. 6 (2008): 546&#x2013;555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2905676</ArticleId><ArticleId IdType="pubmed">18311848</ArticleId></ArticleIdList></Reference><Reference><Citation>Pirracchio R., Resche&#x2010;Rigon M., and Chevret S., &#x201c;Evaluation of the Propensity Score Methods for Estimating Marginal Odds Ratios in Case of Small Sample Size,&#x201d; BMC Medical Research Methodology 12, no. 1 (2012): 70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3511219</ArticleId><ArticleId IdType="pubmed">22646911</ArticleId></ArticleIdList></Reference><Reference><Citation>Adelson J. L., McCoach D. B., Rogers H. J., Adelson J. A., and Sauer T. M., &#x201c;Developing and Applying the Propensity Score to Make Causal Inferences: Variable Selection and Stratification,&#x201d; Frontiers in Psychology 8 (2017): 1413.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5562725</ArticleId><ArticleId IdType="pubmed">28861028</ArticleId></ArticleIdList></Reference><Reference><Citation>Miettinen O. S., &#x201c;Stratification by a Multivariate Confounder Score,&#x201d; American Journal of Epidemiology 104, no. 6 (1976): 609&#x2013;620.</Citation><ArticleIdList><ArticleId IdType="pubmed">998608</ArticleId></ArticleIdList></Reference><Reference><Citation>Brier G. W., &#x201c;Verification of Forecasts Expressed in Terms of Probability,&#x201d; Monthly Weather Review 78, no. 1 (1950): 1&#x2013;3.</Citation></Reference><Reference><Citation>Guo Y., Strauss V., Prieto&#x2010;Alhambra D., and Khalid S., &#x201c;Evaluation Metrics for Data&#x2010;Driven Propensity Score Estimation: A Simulation Study,&#x201d; In: ICPE all Access Conference Abstracts, Pharmacoepidemiol Drug Saf 31, no. S2 (2022): 116, 10.1002/pds.5518.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.5518</ArticleId></ArticleIdList></Reference><Reference><Citation>van Smeden M., de Groot J., Moons K., et&#xa0;al., &#x201c;No Rationale for 1 Variable per 10 Events Criterion for Binary Logistic Regression Analysis,&#x201d; BMC Medical Research Methodology 16, no. 163 (2016), 10.1186/s12874-016-0267-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12874-016-0267-3</ArticleId><ArticleId IdType="pmc">PMC5122171</ArticleId><ArticleId IdType="pubmed">27881078</ArticleId></ArticleIdList></Reference><Reference><Citation>Shortreed S. M. and Ertefaie A., &#x201c;Outcome&#x2010;Adaptive Lasso: Variable Selection for Causal Inference,&#x201d; Biometrics 73, no. 4 (2017): 1111&#x2013;1122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5591052</ArticleId><ArticleId IdType="pubmed">28273693</ArticleId></ArticleIdList></Reference><Reference><Citation>Benkeser D. and Van Der Laan M., &#x201c;The Highly Adaptive Lasso Estimator,&#x201d; 2016 IEEE International Conference on Data Science and Advanced Analytics (DSAA) 2016 (2016): 689&#x2013;696.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5662030</ArticleId><ArticleId IdType="pubmed">29094111</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin P. C. and Stuart E. A., &#x201c;Moving Towards Best Practice When Using Inverse Probability of Treatment Weighting (IPTW) Using the Propensity Score to Estimate Causal Treatment Effects in Observational Studies,&#x201d; Statistics in Medicine 34, no. 28 (2015): 3661&#x2013;3679.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4626409</ArticleId><ArticleId IdType="pubmed">26238958</ArticleId></ArticleIdList></Reference><Reference><Citation>Franklin J. M., Schneeweiss S., Polinski J. M., and Rassen J. A., &#x201c;Plasmode Simulation for the Evaluation of Pharmacoepidemiologic Methods in Complex Healthcare Databases,&#x201d; Computational Statistics and Data Analysis 72 (2014): 219&#x2013;226.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3935334</ArticleId><ArticleId IdType="pubmed">24587587</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40465422</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>21</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1935-5548</ISSN><JournalIssue CitedMedium="Internet"><Volume>48</Volume><Issue>8</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>Diabetes care</Title><ISOAbbreviation>Diabetes Care</ISOAbbreviation></Journal><ArticleTitle>Risk of Thyroid Tumors With GLP-1 Receptor Agonists: A Retrospective Cohort Study.</ArticleTitle><Pagination><StartPage>1386</StartPage><EndPage>1394</EndPage><MedlinePgn>1386-1394</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2337/dc25-0154</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess the association between glucagon-like peptide 1 receptor agonist (GLP-1RA) use and risk of incident thyroid tumors.</AbstractText><AbstractText Label="RESEARCH DESIGN AND METHODS" NlmCategory="METHODS">The retrospective, active-comparator new-user cohort study used international administrative claims and electronic health record databases. Participants included patients with type 2 diabetes mellitus (T2DM) with prior metformin therapy initiating a GLP-1RA versus new users of sodium-glucose cotransporter 2 inhibitors (SGLT2is), dipeptidyl peptidase 4 inhibitors (DPP-4is), and sulfonylureas (SUs). The outcome was incident thyroid tumor and thyroid malignancy. Propensity score matching and stratification were used to adjust for confounders with an intention-to-treat and on-treatment strategy. Cox regression was used to estimate hazard ratios (HRs) pooled using a random-effects meta-analysis. Unmeasured confounding was evaluated using negative outcomes, with calibration of the HR.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 460,032 users of GLP-1RAs, 717,792 users of SGLT2is, 2,055,583 users of DPP-4is, and 1,119,868 users of SUs were included. Only U.S. cohorts passed study diagnostics. Thyroid tumor incidence ranged from 0.88 to 1.03 per 1,000 person-years in GLP-1RA cohorts. GLP-1RA exposure was not associated with an increased risk of thyroid tumors compared with SGLT2is, DPP-4is, or SUs (meta-analysis: GLP-1RA vs. SGLT2i HR range from 0.83 [95% CI 0.57-1.27] to 0.95 [0.85-1.06]; GLP-1RA vs. SU HR range from 0.95 [0.75-1.20] to 1.03 [0.87-1.23]; GLP-1RA vs. DPP-4i HR range from 0.78 [0.60-1.01] to 0.93 [0.83-1.04]). Analysis using thyroid malignancy and including a 1-year lag period produced similar conclusions.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In patients with T2DM initiating second-line treatments, we observed no increased risk of thyroid tumors with GLP-1RA exposure.</AbstractText><CopyrightInformation>&#xa9; 2025 by the American Diabetes Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Morales</LastName><ForeName>Daniel R</ForeName><Initials>DR</Initials><Identifier Source="ORCID">0000-0002-0063-8069</Identifier><AffiliationInfo><Affiliation>Division of Population Health and Genomics, School of Medicine, University of Dundee, Dundee, U.K.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bu</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, University of Michigan at Ann Arbor, Ann Arbor, MI.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Viernes</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Veterans Affairs Informatics and Computing Infrastructure Department of Veterans Affairs, Salt Lake City, UT.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Utah School of Medicine, Salt Lake City, UT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DuVall</LastName><ForeName>Scott L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Veterans Affairs Informatics and Computing Infrastructure Department of Veterans Affairs, Salt Lake City, UT.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Utah School of Medicine, Salt Lake City, UT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matheny</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Tennessee Valley Healthcare System, Veterans Affairs Medical Center, Nashville, TN.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simon</LastName><ForeName>Katherine R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>Tennessee Valley Healthcare System, Veterans Affairs Medical Center, Nashville, TN.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falconer</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richter</LastName><ForeName>Lauren R</ForeName><Initials>LR</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Pediatric Endocrinology, Diabetes, and Metabolism, Department of Pediatrics, Columbia University Irving Medical Center, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ostropolets</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lau</LastName><ForeName>Wallis C Y</ForeName><Initials>WCY</Initials><AffiliationInfo><Affiliation>Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Data Discovery for Health (D24H), Hong Kong Science Park, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Department of Practice and Policy, School of Pharmacy, University College London, London, U.K.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Medicines Optimisation Research and Education, University College London Hospitals NHS Foundation Trust, London, U.K.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Man</LastName><ForeName>Kenneth K C</ForeName><Initials>KKC</Initials><AffiliationInfo><Affiliation>Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Data Discovery for Health (D24H), Hong Kong Science Park, Hong Kong, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Research Department of Practice and Policy, School of Pharmacy, University College London, London, U.K.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Medicines Optimisation Research and Education, University College London Hospitals NHS Foundation Trust, London, U.K.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chattopadhyay</LastName><ForeName>Shounak</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Fielding School of Public Health, University of California, Los Angeles, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mathioudakis</LastName><ForeName>Nestoras</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-0210-655X</Identifier><AffiliationInfo><Affiliation>Division of Endocrinology, Diabetes, and Metabolism, Johns Hopkins University School of Medicine, Baltimore, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Minty</LastName><ForeName>Evan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, O'Brien Institute for Public Health, University of Calgary, Calgary, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishimura</LastName><ForeName>Akihiko</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Feng</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-4334-6805</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, Peking University, Beijing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yin</LastName><ForeName>Can</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>DTA&amp;AI, Real World Solutions, IQVIA, Durham, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seager</LastName><ForeName>Sarah L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>DTA&amp;AI, Real World Solutions, IQVIA, Durham, NC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chai</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Jin J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Fielding School of Public Health, University of California, Los Angeles, CA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University, New Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reyes</LastName><ForeName>Carlen</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0001-8486-3265</Identifier><AffiliationInfo><Affiliation>Real-World Epidemiology Research Group, Fundaci Institut Universitari per a la recerca a l'Atenci Primria de Salut Jordi Gol i Gurina, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pistillo</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Real-World Epidemiology Research Group, Fundaci Institut Universitari per a la recerca a l'Atenci Primria de Salut Jordi Gol i Gurina, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duarte-Salles</LastName><ForeName>Talita</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Real-World Epidemiology Research Group, Fundaci Institut Universitari per a la recerca a l'Atenci Primria de Salut Jordi Gol i Gurina, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blacketer</LastName><ForeName>Clair</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Observational Health Data Analytics, Janssen Research and Development, LLC, Titusville, NJ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Fielding School of Public Health, University of California, Los Angeles, CA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Epidemiology, Office of the Chief Medical Officer, Johnson &amp; Johnson, Titusville, NJ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Epidemiology, Office of the Chief Medical Officer, Johnson &amp; Johnson, Titusville, NJ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krumholz</LastName><ForeName>Harlan M</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University, New Haven, CT.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Policy and Management, Yale School of Public Health, New Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khera</LastName><ForeName>Rohan</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-9467-6199</Identifier><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Internal Medicine, Yale University, New Haven, CT.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Outcomes Research and Evaluation, Yale New Haven Hospital, New Haven, CT.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Section of Health Informatics, Department of Biostatistics, Yale School of Public Health, New Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Veterans Affairs Informatics and Computing Infrastructure Department of Veterans Affairs, Salt Lake City, UT.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Fielding School of Public Health, University of California, Los Angeles, CA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomathematics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Human Genetics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 HL169954</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HG006139</GrantID><Acronym>HG</Acronym><Agency>NHGRI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL169954</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 HL153775</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM006910</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>K23 HL153775</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HG006139</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>ORD 22-D4V</GrantID><Agency>US Department of Veterans Affairs</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Diabetes Care</MedlineTA><NlmUniqueID>7805975</NlmUniqueID><ISSNLinking>0149-5992</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000097789">Glucagon-Like Peptide-1 Receptor Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054873">Dipeptidyl-Peptidase IV Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077203">Sodium-Glucose Transporter 2 Inhibitors</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013964" MajorTopicYN="Y">Thyroid Neoplasms</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000097789" MajorTopicYN="Y">Glucagon-Like Peptide-1 Receptor Agonists</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="Y">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D054873" MajorTopicYN="N">Dipeptidyl-Peptidase IV Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077203" MajorTopicYN="N">Sodium-Glucose Transporter 2 Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Duality of Interest.</b> R.K. is an associate editor of the <i>Journal of the American Medical Association</i> and reported receiving support from the Doris Duke Charitable Foundation. He also receives research support through Yale from Bristol-Myers Squibb, Novo Nordisk, and BridgeBio. He is a coinventor of U.S. Provisional Patent Applications 63/619,241; 63/606,203; 63/177,117; 63/346,610; 63/428,569; and 63/484,426 unrelated to the current work. He is also a cofounder of Evidence2Health and Ensight-AI, both representing precision health platforms to improve evidence-based cardiovascular care. S.L.D. reports receiving grants from Alnylam Pharmaceuticals, Inc.; AstraZeneca Pharmaceuticals LP; Biodesix, Inc.; Celgene Corporation; Cerner Enviza; GSK PLC; Janssen Pharmaceuticals, Inc.; Novartis International AG; and Parexel International Corporation through the University of Utah or Western Institute for Veteran Research outside the submitted work. K.K.C.M. reported receiving support through a Maplethorpe Fellowship and the National Institute of Health Research, U.K.; European Commission Framework Horizon 2020; Hong Kong Research Grant Council; and Innovation and Technology Commission of the Hong Kong Special Administration Region Government outside the submitted work. In the past 3 years, H.M.K. received expenses and/or personal fees from UnitedHealth, Element Science, Aetna, Reality Labs, Tesseract/4Catalyst, F-Prime, the Siegfried and Jensen Law Firm, Arnold and Porter Law Firm, and Martin/Baughman Law Firm. He is a cofounder of Refactor Health and HugoHealth and is associated with contracts, through Yale New Haven Hospital, from the Centers for Medicare &amp; Medicaid Services and through Yale University from Johnson &amp; Johnson. No other potential conflicts of interest relevant to this article were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>21</Day><Hour>18</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>4</Day><Hour>18</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>4</Day><Hour>12</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>6</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40465422</ArticleId><ArticleId IdType="pmc">PMC12281980</ArticleId><ArticleId IdType="doi">10.2337/dc25-0154</ArticleId><ArticleId IdType="pii">160553</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Drucker DJ. Mechanisms of action and therapeutic application of glucagon-like peptide-1. Cell Metab 2018;27:740&#x2013;756</Citation><ArticleIdList><ArticleId IdType="pubmed">29617641</ArticleId></ArticleIdList></Reference><Reference><Citation>Zinman B, Wanner C, Lachin JM, et al.; EMPA-REG OUTCOME Investigators . Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015;373:2117&#x2013;2128</Citation><ArticleIdList><ArticleId IdType="pubmed">26378978</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiviott SD, Raz I, Sabatine MS, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. Reply. N Engl J Med 2019;380:1881&#x2013;1882</Citation><ArticleIdList><ArticleId IdType="pubmed">31067395</ArticleId></ArticleIdList></Reference><Reference><Citation>Neal B, Perkovic V, Matthews DR, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:2099.</Citation><ArticleIdList><ArticleId IdType="pubmed">29166232</ArticleId></ArticleIdList></Reference><Reference><Citation>Marso SP, Bain SC, Consoli A, et al.; SUSTAIN-6 Investigators . Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834&#x2013;1844</Citation><ArticleIdList><ArticleId IdType="pubmed">27633186</ArticleId></ArticleIdList></Reference><Reference><Citation>Marso SP, Daniels GH, Brown-Frandsen K, et al.; LEADER Trial Investigators . Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 2016;375:311&#x2013;322</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4985288</ArticleId><ArticleId IdType="pubmed">27295427</ArticleId></ArticleIdList></Reference><Reference><Citation>Khera R, Dhingra LS, Aminorroaya A, et al. Multinational patterns of second line antihyperglycaemic drug initiation across cardiovascular risk groups: federated pharmacoepidemiological evaluation in LEGEND-T2DM. BMJ Med 2023;2:e000651</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10565313</ArticleId><ArticleId IdType="pubmed">37829182</ArticleId></ArticleIdList></Reference><Reference><Citation>
American Diabetes Association . 9. Pharmacologic approaches to glycemic treatment: <i>Standards of Care in Diabetes&#x2014;2023</i>. Diabetes Care
2023;46(Suppl. 1):S140&#x2013;S157
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9810476</ArticleId><ArticleId IdType="pubmed">36507650</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjerre Knudsen L, Madsen LW, Andersen S, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010;151:1473&#x2013;1486</Citation><ArticleIdList><ArticleId IdType="pubmed">20203154</ArticleId></ArticleIdList></Reference><Reference><Citation>Byrd RA, Sorden SD, Ryan T, et al. Chronic toxicity and carcinogenicity studies of the long-acting GLP-1 receptor agonist dulaglutide in rodents. Endocrinology 2015;156:2417&#x2013;2428</Citation><ArticleIdList><ArticleId IdType="pubmed">25860029</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulchandani D, Nachnani JS, Herndon B, et al. Effect of exendin (exenatide)&#x2013;GLP 1 receptor agonist on the thyroid and parathyroid gland in a rat model. Eur J Pharmacol 2012;691:292&#x2013;296</Citation><ArticleIdList><ArticleId IdType="pubmed">22819704</ArticleId></ArticleIdList></Reference><Reference><Citation>
Highlights of prescribing information VICTOZA. Accessed 21 October 2023. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/022341s031lbl.pdf</Citation></Reference><Reference><Citation>
Highlights of prescribing information TRULICITY. Accessed 21 October 2023. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/125469s036lbl.pdf</Citation></Reference><Reference><Citation>
Highlights of prescribing information BYDUREON. Accessed 21 October 2023. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022200s026lbl.pdf</Citation></Reference><Reference><Citation>
Highlights of prescribing information OZEMPIC. Accessed 21 October 2023. Available from https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf</Citation></Reference><Reference><Citation>Bezin J, Gouverneur A, P&#xe9;nichon M, et al. GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care 2023;46:384&#x2013;390</Citation><ArticleIdList><ArticleId IdType="pubmed">36356111</ArticleId></ArticleIdList></Reference><Reference><Citation>Endo M, Roth MY, Tylee TS, DeSantis A, Hirsch IB.. Comment on Bezin et&#xa0;al. GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care 2023;46:384-390. Diabetes Care 2023;46:e118.</Citation><ArticleIdList><ArticleId IdType="pubmed">37185687</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldenberg RM, Jain AB.. Comment on Bezin et&#xa0;al. GLP-1 Receptor agonists and the risk of thyroid cancer. Diabetes Care 2023;46:384-390. Diabetes Care 2023;46:e117.</Citation><ArticleIdList><ArticleId IdType="pubmed">37185678</ArticleId></ArticleIdList></Reference><Reference><Citation>Smits MM, van Raalte DH.. Comment on Bezin et&#xa0;al. GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care 2023;46:384-390. Diabetes Care 2023;46:e120.</Citation><ArticleIdList><ArticleId IdType="pubmed">37185688</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma&#xf1;as-Martinez AB, Gimeno-Orna JA.. Comment on Bezin et&#xa0;al. GLP-1 receptor agonists and the risk of thyroid cancer. Diabetes Care 2023;46:384-390. Diabetes Care 2023;46:e119.</Citation><ArticleIdList><ArticleId IdType="pubmed">37185691</ArticleId></ArticleIdList></Reference><Reference><Citation>Khera R, Schuemie MJ, Lu Y, et al. Large-Scale Evidence Generation and Evaluation Across a Network of Databases for Type 2 Diabetes Mellitus (LEGEND-T2DM): a protocol for a series of multinational, real-world comparative cardiovascular effectiveness and safety studies. BMJ Open 2022;12:e057977</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9185490</ArticleId><ArticleId IdType="pubmed">35680274</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshida K, Solomon DH, Kim SC.. Active-comparator design and new-user design in observational studies. Nat Rev Rheumatol 2015;11:437&#x2013;441</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4486631</ArticleId><ArticleId IdType="pubmed">25800216</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson ES, Bartman BA, Briesacher BA, et al. The incident user design in comparative effectiveness research. Pharmacoepidemiol Drug Saf 2013;22:1&#x2013;6</Citation><ArticleIdList><ArticleId IdType="pubmed">23023988</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie M, Reps J, Black A, et al. Health-Analytics Data to Evidence Suite (HADES): open-source software for observational research. Stud Health Technol Inform 2024;310:966&#x2013;970</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10868467</ArticleId><ArticleId IdType="pubmed">38269952</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbaum PR, Rubin DB.. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41&#x2013;55</Citation></Reference><Reference><Citation>Tian Y, Schuemie MJ, Suchard MA.. Evaluating large-scale propensity score performance through real-world and synthetic data experiments. Int J Epidemiol 2018;47:2005&#x2013;2014</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6280944</ArticleId><ArticleId IdType="pubmed">29939268</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneeweiss S, Rassen JA, Glynn RJ, et al. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology 2009;20:512&#x2013;522</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3077219</ArticleId><ArticleId IdType="pubmed">19487948</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, Simpson SE, Zorych I, Ryan P, Madigan D.. Massive parallelization of serial inference algorithms for a complex generalized linear model. ACM Trans Model Comput Simul 2013;23:10.1145/2414416.2414791</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4201181</ArticleId><ArticleId IdType="pubmed">25328363</ArticleId></ArticleIdList></Reference><Reference><Citation>DerSimonian R, Laird N.. Meta-analysis in clinical trials. Controlled Clinical Trials 1986;7:177&#x2013;188</Citation><ArticleIdList><ArticleId IdType="pubmed">3802833</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss EA, Boyce RD, Ryan PB, et al. Accuracy of an automated knowledge base for identifying drug adverse reactions. J Biomed Inform 2017;66:72&#x2013;81</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5316295</ArticleId><ArticleId IdType="pubmed">27993747</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Hripcsak G, Ryan PB, et al. Empirical confidence interval calibration for population-level effect estimation studies in observational healthcare data. Proc Nat Acad Sci U S A 2018;115:2571&#x2013;2577</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5856503</ArticleId><ArticleId IdType="pubmed">29531023</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Ryan PB, DuMouchel W, Suchard MA, Madigan D.. Interpreting observational studies: why empirical calibration is needed to correct p-values. Stat Med 2014;33:209&#x2013;218</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4285234</ArticleId><ArticleId IdType="pubmed">23900808</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med 2009;28:3083&#x2013;3107</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3472075</ArticleId><ArticleId IdType="pubmed">19757444</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker AM, Patrick AR, Lauer MS, et al. A tool for assessing the feasibility of comparative effectiveness research. Comp Eff Res 2013;3:11&#x2013;20</Citation></Reference><Reference><Citation>Hern&#xe1;n MA, Hern&#xe1;ndez-D&#xed;az S.. Beyond the intention-to-treat in comparative effectiveness research. Clin Trials 2012;9:48&#x2013;55</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3731071</ArticleId><ArticleId IdType="pubmed">21948059</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu W, Song R, Cheng R, et al. Use of GLP-1 receptor agonists and occurrence of thyroid disorders: a meta-analysis of randomized controlled trials. Front Endocrinol (Lausanne) 2022;13:927859.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9309474</ArticleId><ArticleId IdType="pubmed">35898463</ArticleId></ArticleIdList></Reference><Reference><Citation>Bea S, Son H, Bae JH, Cho SW, Shin J-Y, Cho YM.. Risk of thyroid cancer associated with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes: a population-based cohort study. Diabetes Obes Metab 2024;26:108&#x2013;117</Citation><ArticleIdList><ArticleId IdType="pubmed">37735822</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasternak B, Wintzell V, Hviid A, et al. Glucagon-like peptide 1 receptor agonist use and risk of thyroid cancer: Scandinavian cohort study. BMJ 2024;385:e078225.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11004669</ArticleId><ArticleId IdType="pubmed">38683947</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert MP, Pratley RE.. GLP-1 analogs and DPP-4 inhibitors in type 2 diabetes therapy: review of head-to-head clinical trials. Front Endocrinol (Lausanne) 2020;11:178.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7145895</ArticleId><ArticleId IdType="pubmed">32308645</ArticleId></ArticleIdList></Reference><Reference><Citation>Orlandi AM, Alcaraz G, Bielski L, et al.; Thyroid Department of Sociedad Argentina de Endocrinolog&#xed;a y Metabolismo . Thyroid gland: a rare site of metastasis. Endocrine 2024;84:607&#x2013;614</Citation><ArticleIdList><ArticleId IdType="pubmed">38224445</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40467833</PMID><DateRevised><Year>2025</Year><Month>06</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1179-1942</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jun</Month><Day>04</Day></PubDate></JournalIssue><Title>Drug safety</Title><ISOAbbreviation>Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Large-scale Empirical Identification of Candidate Comparators for Pharmacoepidemiological Studies.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40264-025-01569-y</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVE" NlmCategory="OBJECTIVE">The new user cohort design has emerged as a best practice for the estimation of drug effects from observational data. However, despite its advantages, this design requires the selection and evaluation of comparators for appropriateness, a process that can be challenging. The objective of this work was to introduce an empirical approach to rank candidate comparators in terms of their similarity to a target drug in high-dimensional covariate space.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We generated new user cohorts for each RxNorm ingredient and Anatomic Therapeutic Chemical level 4 class in five administrative claims databases then extracted aggregated pre-treatment covariate data for each cohort across five clinically oriented domains. We formed all pairs of cohorts with &#x2265;&#xa0;1000 patients and computed a scalar similarity score, defined as the average of cosine similarities computed within each domain, for each pair. We then generated ranked lists of candidate comparators for each cohort.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Across up to 1350 cohorts forming 922,761 comparisons, drugs that were more similar in the Anatomic Therapeutic Chemical hierarchy had higher cohort similarity scores. The most similar candidate comparators for each of six example drugs corresponded to alternative treatments used in the target drug's indication(s), and choosing the top-ranked comparator for randomly selected drugs tended to produce balance on most covariates. This approach also ranked highly those comparators chosen in high-quality published new user cohort design studies.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Empirical comparator recommendations may serve as a useful aid to investigators and could ultimately enable the automated generation of new user cohort design-derived evidence, a process that has previously been limited to self-controlled designs.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bohn</LastName><ForeName>Justin</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-4430-798X</Identifier><AffiliationInfo><Affiliation>Global Epidemiology Organization, Johnson &amp; Johnson, 1125 Trenton-Harbourton Road, Titusville, NJ, 08560, USA. jbohn2@its.jnj.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gilbert</LastName><ForeName>James P</ForeName><Initials>JP</Initials><Identifier Source="ORCID">0000-0003-2294-3459</Identifier><AffiliationInfo><Affiliation>Global Epidemiology Organization, Johnson &amp; Johnson, 1125 Trenton-Harbourton Road, Titusville, NJ, 08560, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Knoll</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-4046-2683</Identifier><AffiliationInfo><Affiliation>Global Epidemiology Organization, Johnson &amp; Johnson, 1125 Trenton-Harbourton Road, Titusville, NJ, 08560, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kern</LastName><ForeName>David M</ForeName><Initials>DM</Initials><Identifier Source="ORCID">0000-0001-5417-3925</Identifier><AffiliationInfo><Affiliation>Global Epidemiology Organization, Johnson &amp; Johnson, 1125 Trenton-Harbourton Road, Titusville, NJ, 08560, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Global Epidemiology Organization, Johnson &amp; Johnson, 1125 Trenton-Harbourton Road, Titusville, NJ, 08560, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Drug Saf</MedlineTA><NlmUniqueID>9002928</NlmUniqueID><ISSNLinking>0114-5916</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CoiStatement>Declarations. Funding: This work was funded by Janssen Research and Development, a subsidiary of Johnson &amp; Johnson. All authors are employees of Janssen Research and Development. Conflicts of interest: All authors are employees of Johnson &amp; Johnson. Consent for publication: Not applicable. Consent to participate: Not applicable. Ethics approval: Not applicable. Data availability: The full suite of results described here is available as an interactive web application ( https://data.ohdsi.org/ComparatorSelectionExplorer ), which can be used to identify and diagnose potential comparators for a given target cohort. Note that this application undergoes periodic updates, including the updating of existing data sources to newer versions, the addition of new data sources, and the modification of existing functionality. As such, some results derived from the application may differ from those presented here. Code availability: All code necessary to run the analytic pipeline described here and to generate the web application is available via GitHub ( https://github.com/OHDSI/ComparatorSelectionExplorer ). Author contributions: Justin Bohn designed and performed the analysis, conducted the literature review, drafted the manuscript, and led the manuscript revision process. James P. Gilbert designed and performed the analysis and reviewed and contributed to the manuscript. Christopher Knoll designed the analysis and reviewed and contributed to the manuscript. David M. Kern designed the analysis and reviewed and contributed to the manuscript. Patrick B. Ryan designed the analysis, conducted the literature review, and reviewed and contributed to the manuscript. All authors read and approved the final version.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>5</Day><Hour>0</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>5</Day><Hour>0</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>4</Day><Hour>23</Hour><Minute>28</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40467833</ArticleId><ArticleId IdType="doi">10.1007/s40264-025-01569-y</ArticleId><ArticleId IdType="pii">10.1007/s40264-025-01569-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ray WA. Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol. 2003;158:915&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwg231</ArticleId><ArticleId IdType="pubmed">14585769</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson ES, Bartman BA, Briesacher BA, et al. The incident user design in comparative effectiveness research. Pharmacoepidemiol Drug Saf. 2013;22(1):1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.3334</ArticleId><ArticleId IdType="pubmed">23023988</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Arcy M, St&#xfc;rmer T, Lund JL. The importance and implications of comparator selection in pharmacoepidemiologic research. Curr Epidemiol Rep. 2018;5:272&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40471-018-0155-y</ArticleId><ArticleId IdType="pubmed">30666285</ArticleId><ArticleId IdType="pmc">6338470</ArticleId></ArticleIdList></Reference><Reference><Citation>Lund JL, Richardson DB, St&#xfc;rmer T. The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application. Curr Epidemiol Rep. 2015;2:221&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40471-015-0053-5</ArticleId><ArticleId IdType="pubmed">26954351</ArticleId><ArticleId IdType="pmc">4778958</ArticleId></ArticleIdList></Reference><Reference><Citation>Sendor R, St&#xfc;rmer T. Core concepts in pharmacoepidemiology: confounding by indication and the role of active comparators. Pharmacoepidemiol Drug Saf. 2022;31:261&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.5407</ArticleId><ArticleId IdType="pubmed">35019190</ArticleId><ArticleId IdType="pmc">9121653</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipsitch M, Tchetgen Tchetgen E, Cohen T. Negative controls: a tool for detecting confounding and bias in observational studies. Epidemiology. 2010;21:383&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0b013e3181d61eeb</ArticleId><ArticleId IdType="pubmed">20335814</ArticleId><ArticleId IdType="pmc">3053408</ArticleId></ArticleIdList></Reference><Reference><Citation>Dusetzina SB, Brookhart MA, Maciejewski ML. Control outcomes and exposures for improving internal validity of nonrandomized studies. Health Serv Res. 2015;50:1432&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1475-6773.12279</ArticleId><ArticleId IdType="pubmed">25598384</ArticleId><ArticleId IdType="pmc">4600355</ArticleId></ArticleIdList></Reference><Reference><Citation>Setoguchi S, Glynn RJ, Avorn J, Mogun H, Schneeweiss S. Statins and the risk of lung, breast, and colorectal cancer in the elderly. Circulation. 2007;115:27&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.106.650176</ArticleId><ArticleId IdType="pubmed">17179016</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon DH, Avorn J, St&#xfc;rmer T, Glynn RJ, Mogun H, Schneeweiss S. Cardiovascular outcomes in new users of coxibs and nonsteroidal antiinflammatory drugs: high-risk subgroups and time course of risk. Arthritis Rheum. 2006;54:1378&#x2013;89.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.21887</ArticleId><ArticleId IdType="pubmed">16645966</ArticleId></ArticleIdList></Reference><Reference><Citation>Huitfeldt A, Hernan MA, Kalager M, Robins JM. Comparative effectiveness research using observational data: active comparators to emulate target trials with inactive comparators. EGEMs Gener Evid Methods Improve Patient Outcomes. 2016;4:20.</Citation><ArticleIdList><ArticleId IdType="doi">10.13063/2327-9214.1234</ArticleId></ArticleIdList></Reference><Reference><Citation>Setoguchi S, Gerhard T, et al. Chapter 5: comparator selection. In: Velentgas P, Dreyer NA, Nourjah P, et al., editors. Developing a protocol for observational comparative effectiveness research: a user&#x2019;s guide. Rockville: Agency for Healthcare Research and Quality; 2013.</Citation></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012;19:54&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000376</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>OMOP CDM v5.4. http://ohdsi.github.io/CommonDataModel/cdm54.html#Standardized_Derived_Elements . Accessed 28 Nov 2022.</Citation></Reference><Reference><Citation>Tan P-N, Steinbach M, Kumar V. Chapter 8. Introduction to data mining. 1st ed. Boston: Pearson Addison Wesley; 2006. p. 500.</Citation></Reference><Reference><Citation>WHOCC&#x2014;structure and principles. https://www.whocc.no/atc/structure_and_principles/ . Accessed 24 Nov 2022.</Citation></Reference><Reference><Citation>Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28:3083&#x2013;107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.3697</ArticleId><ArticleId IdType="pubmed">19757444</ArticleId><ArticleId IdType="pmc">3472075</ArticleId></ArticleIdList></Reference><Reference><Citation>Normand S-LT, Landrum MB, Guadagnoli E, et al. Validating recommendations for coronary angiography following acute myocardial infarction in the elderly: a matched analysis using propensity scores. J Clin Epidemiol. 2001;54(4):387&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0895-4356(00)00321-8</ArticleId><ArticleId IdType="pubmed">11297888</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale: L. Erlbaum Associates; 1988.</Citation></Reference><Reference><Citation>Hauser SL, Cree BAC. Treatment of multiple sclerosis: a review. Am J Med. 2020;133:1380-1390.e2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2020.05.049</ArticleId><ArticleId IdType="pubmed">32682869</ArticleId><ArticleId IdType="pmc">7704606</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulldorff M, Dashevsky I, Avery TR, Chan AK, Davis RL, Graham D, et al. Drug safety data mining with a tree-based scan statistic: tree-based scan statistic data mining method. Pharmacoepidemiol Drug Saf. 2013;22:517&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.3423</ArticleId><ArticleId IdType="pubmed">23512870</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang SV, Maro JC, Baro E, Izem R, Dashevsky I, Rogers JR, et al. Data mining for adverse drug events with a propensity score-matched tree-based scan statistic. Epidemiology. 2018;29:895&#x2013;903.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0000000000000907</ArticleId><ArticleId IdType="pubmed">30074538</ArticleId><ArticleId IdType="pmc">6167151</ArticleId></ArticleIdList></Reference><Reference><Citation>Nor&#xe9;n GN, Hopstadius J, Bate A, Star K, Edwards IR. Temporal pattern discovery in longitudinal electronic patient records. Data Min Knowl Discov. 2010;20:361&#x2013;87.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10618-009-0152-3</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavallee M, Yu T, Evans L, Van Hemelrijck M, Bosco C, Golozar A, et al. Evaluating the performance of temporal pattern discovery: new application using statins and rhabdomyolysis in OMOP databases. BMC Med Inform Decis Mak. 2022;22:31.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12911-022-01765-1</ArticleId><ArticleId IdType="pubmed">35115001</ArticleId><ArticleId IdType="pmc">8812213</ArticleId></ArticleIdList></Reference><Reference><Citation>Boehringer Ingelheim. Safety and effectiveness study comparing dabigatran, rivaroxaban and apixaban in non-valvular atrial fibrillation patients enrolled in the US Department of Defense Military Health System. 2019 Feb. Report No.: NCT03026556. https://clinicaltrials.gov/ct2/show/NCT03026556 . Accessed 21 Nov 2024.</Citation></Reference><Reference><Citation>Lip GYH, Keshishian A, Kamble S, et al. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin: a propensity score matched analysis. Thromb Haemost. 2016;116:975&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="doi">10.1160/TH16-05-0403</ArticleId><ArticleId IdType="pubmed">27538358</ArticleId></ArticleIdList></Reference><Reference><Citation>Smolen JS, Burmester G-R, Combe B, et al. Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE study. Lancet. 2016;388:2763&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(16)31651-8</ArticleId><ArticleId IdType="pubmed">27863807</ArticleId></ArticleIdList></Reference><Reference><Citation>UCB Pharma SA. A multicenter, single-blind, randomized parallel-group study to assess the short- and long-term efficacy of certolizumab pegol plus methotrexate compared to adalimumab plus methotrexate in subjects with moderate to severe rheumatoid arthritis responding inadequately to methotrexate. 2018 Jul. Report No.: NCT01500278. https://clinicaltrials.gov/ct2/show/NCT01500278 .</Citation></Reference><Reference><Citation>Dirks P, Zingler V, Leemhuis J, Berthold H, Hieke-Schulz S, Wormser D, et al. Design of a non-interventional post-marketing study to assess the long-term safety and effectiveness of ocrelizumab in German real world multiple sclerosis cohorts&#x2014;the CONFIDENCE study protocol. BMC Neurol. 2020;20:95.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12883-020-01667-7</ArticleId><ArticleId IdType="pubmed">32171264</ArticleId><ArticleId IdType="pmc">7071560</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown AS, Kong SW, Kohane IS, Patel CJ. ksRepo: a generalized platform for computational drug repositioning. BMC Bioinform. 2016;17:78.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12859-016-0931-y</ArticleId></ArticleIdList></Reference><Reference><Citation>Grover MP, Ballouz S, Mohanasundaram KA, et al. Identification of novel therapeutics for complex diseases from genome-wide association data. BMC Med Genom. 2014;7:S8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1755-8794-7-S1-S8</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown AS, Patel CJ. MeSHDD: literature-based drug-drug similarity for drug repositioning. J Am Med Inform Assoc. 2017;24:614&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocw142</ArticleId><ArticleId IdType="pubmed">27678460</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng X, Jia Z, He Z, Chen W, Lu X, Duan H, et al. Measure clinical drug&#x2013;drug similarity using electronic medical records. Int J Med Inf. 2019;124:97&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijmedinf.2019.02.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenland S, Neutra R. Control of confounding in the assessment of medical technology. Int J Epidemiol. 1980;9:361&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/9.4.361</ArticleId><ArticleId IdType="pubmed">7203778</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker A, Patrick, Lauer, Hornbrook, Marin, Platt, et al. A tool for assessing the feasibility of comparative effectiveness research. Comp Eff Res. 2013;3:11&#x2013;20. https://doi.org/10.2147/CER.S40357 .</Citation></Reference><Reference><Citation>Schneeweiss S, Rassen JA, Glynn RJ, Avorn J, Mogun H, Brookhart MA. High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009;20:512&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0b013e3181a663cc</ArticleId><ArticleId IdType="pubmed">19487948</ArticleId><ArticleId IdType="pmc">3077219</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Wang Y, Schuemie MJ, Blei DM, Hripcsak G. Adjusting for indirectly measured confounding using large-scale propensity score. J Biomed Inform. 2022;134: 104204.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2022.104204</ArticleId><ArticleId IdType="pubmed">36108816</ArticleId><ArticleId IdType="pmc">9692203</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss EA, Boyce RD, Ryan PB, van der Lei J, Rijnbeek PR, Schuemie MJ. Accuracy of an automated knowledge base for identifying drug adverse reactions. J Biomed Inform. 2017;66:72&#x2013;81.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2016.12.005</ArticleId><ArticleId IdType="pubmed">27993747</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI/CommonEvidenceModel Wiki. GitHub. https://github.com/OHDSI/CommonEvidenceModel . Accessed 25 Nov 2022.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40494801</PMID><DateCompleted><Year>2025</Year><Month>06</Month><Day>10</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0254-6450</ISSN><JournalIssue CitedMedium="Print"><Volume>46</Volume><Issue>5</Issue><PubDate><Year>2025</Year><Month>May</Month><Day>10</Day></PubDate></JournalIssue><Title>Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi</Title><ISOAbbreviation>Zhonghua Liu Xing Bing Xue Za Zhi</ISOAbbreviation></Journal><ArticleTitle>[Study of application of Common Data Model of Observational Medical Outcomes Partnership in China].</ArticleTitle><Pagination><StartPage>907</StartPage><EndPage>913</EndPage><MedlinePgn>907-913</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3760/cma.j.cn112338-20240924-00595</ELocationID><Abstract><AbstractText><b>Objective:</b> To comprehensively evaluate the application of Common Data Model (CDM) of Observational Medical Outcomes Partnership (OMOP) in China, and provide reference for the implementation of data standardization and evidence sharing in China. <b>Methods:</b> PubMed, Embase, Web of Science, CNKI, VIP, WanFang and SinoMed databases were used for literature retrieval to collect the research papers of OMOP CDM application for data standardization in China until March 15, 2023. The information about institutions, types and numbers of patients were extracted. <b>Results:</b> A total of 14 research papers, including 9 in English and 5 in Chinese, were selected. The research papers published since 2018 were collected, which focused on patients with hypertension, diabetes, and depression. A total of 12 institutions or platforms transformed data into OMOP CDM. Jiangsu Provincial People's Hospital was the first one to apply the CDM and demonstrated its feasibility in China. Additionally, the regional information system in Yinzhou District of Ningbo, Zhejiang Province, standardized the multi-dimensional data of patients with diabetes and hypertension. Based on this platform, a series of prediction models for complications in patients with diabetes were constructed. Another major database in Beijing Anding Hospital applied OMOP CDM to analyze the characteristics of patients with late-life depression and dementia. <b>Conclusions:</b> This study analyzed the application of OMOP CDM in China. Through in-depth analysis of specific cases, the study provided guidance for the future cross-regional evidence sharing and collaboration.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China Key Laboratory of Epidemiology of Major Diseases (Peking University), Ministry of Education, Beijing 100191, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shen</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Yinzhou District Center for Disease Control and Prevention of Ningbo, Ningbo 315100, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Z K</ForeName><Initials>ZK</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China Key Laboratory of Epidemiology of Major Diseases (Peking University), Ministry of Education, Beijing 100191, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Zandt</LastName><ForeName>Mui</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>IQVIA, North Carolina 27703, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>IQVIA, North Carolina 27703, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Wonders Information Company Limited, Shanghai 201112, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Y X</ForeName><Initials>YX</Initials><AffiliationInfo><Affiliation>Yinzhou District Center for Disease Control and Prevention of Ningbo, Ningbo 315100, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>J Q</ForeName><Initials>JQ</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, The Botnar Research Centre, University of Oxford, Oxford OX1 3QR, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wan</LastName><ForeName>Y U K F A I</ForeName><Initials>YUKFAI</Initials><AffiliationInfo><Affiliation>Department of Family Medicine and Primary Care, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong 999077, China Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong 999077, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>George</LastName><ForeName>Hripcsak</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York 10027, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Y</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia 19019, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>H B</ForeName><Initials>HB</Initials><AffiliationInfo><Affiliation>Yinzhou District Center for Disease Control and Prevention of Ningbo, Ningbo 315100, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhan</LastName><ForeName>S Y</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China Key Laboratory of Epidemiology of Major Diseases (Peking University), Ministry of Education, Beijing 100191, China Clinical Epidemiology Research Center, Peking University Third Hospital, Beijing 100191, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing 100191, China Key Laboratory of Epidemiology of Major Diseases (Peking University), Ministry of Education, Beijing 100191, China Xinjiang Medical University, Urumqi 830017, China Department of Ophthalmology, Peking University Third Hospital, Beijing 100191, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>chi</Language><GrantList CompleteYN="Y"><Grant><GrantID>72361127500</GrantID><Agency>Projects of International Cooperation and Exchanges, National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>72474008, 72074011</GrantID><Agency>National Natural Science Foundation of China</Agency><Country/></Grant><Grant><GrantID>RS2024X006, RS2024Z008</GrantID><Agency>The Third Batch of Key Projects of Scientific Act for Drug Regulation of China</Agency><Country/></Grant><Grant><GrantID>ZDYF2024LCLH002</GrantID><Agency>Hainan Provincial Science Technology Department Key Research and Development Project</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Zhonghua Liu Xing Bing Xue Za Zhi</MedlineTA><NlmUniqueID>8208604</NlmUniqueID><ISSNLinking>0254-6450</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006973" MajorTopicYN="N">Hypertension</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003920" MajorTopicYN="N">Diabetes Mellitus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="Y">Outcome Assessment, Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="chi"><AbstractText><b>&#x76ee;&#x7684;&#xff1a;</b> &#x603b;&#x7ed3;&#x89c2;&#x6d4b;&#x6027;&#x533b;&#x7597;&#x7ed3;&#x679c;&#x5408;&#x4f5c;&#x7ec4;&#x7ec7;&#xff08;OMOP&#xff09;&#x901a;&#x7528;&#x6570;&#x636e;&#x6a21;&#x578b;&#xff08;CDM&#xff09;&#x5728;&#x4e2d;&#x56fd;&#x7684;&#x5e94;&#x7528;&#x7814;&#x7a76;&#x73b0;&#x72b6;&#xff0c;&#x4e3a;&#x6211;&#x56fd;&#x6570;&#x636e;&#x6807;&#x51c6;&#x5316;&#x548c;&#x8bc1;&#x636e;&#x5171;&#x4eab;&#x7684;&#x5b9e;&#x65bd;&#x7b56;&#x7565;&#x63d0;&#x4f9b;&#x53c2;&#x8003;&#x3002; <b>&#x65b9;&#x6cd5;&#xff1a;</b> &#x68c0;&#x7d22;PubMed&#x3001;Embase&#x3001;Web of Science&#x3001;&#x4e2d;&#x56fd;&#x77e5;&#x7f51;&#x3001;&#x7ef4;&#x666e;&#x6570;&#x636e;&#x5e93;&#x3001;&#x4e07;&#x65b9;&#x6570;&#x636e;&#x77e5;&#x8bc6;&#x670d;&#x52a1;&#x5e73;&#x53f0;&#x3001;&#x4e2d;&#x56fd;&#x751f;&#x7269;&#x533b;&#x5b66;&#x6587;&#x732e;&#x7cfb;&#x7edf;&#x7b49;&#x6570;&#x636e;&#x5e93;&#x81ea;&#x5efa;&#x5e93;&#x4ee5;&#x6765;&#x81f3;2023&#x5e74;3&#x6708;15&#x65e5;&#x4e2d;&#x56fd;&#x533b;&#x7597;&#x673a;&#x6784;/&#x5e73;&#x53f0;&#x4f7f;&#x7528;OMOP CDM&#x5bf9;&#x6570;&#x636e;&#x8fdb;&#x884c;&#x6807;&#x51c6;&#x5316;&#x7684;&#x76f8;&#x5173;&#x7814;&#x7a76;&#x3002;&#x63d0;&#x53d6;&#x673a;&#x6784;&#x3001;&#x60a3;&#x8005;&#x7c7b;&#x578b;&#x548c;&#x6570;&#x91cf;&#x7b49;&#x4fe1;&#x606f;&#x3002; <b>&#x7ed3;&#x679c;&#xff1a;</b> &#x5171;&#x7eb3;&#x5165;14&#x7bc7;&#x6587;&#x732e;&#xff0c;&#x5176;&#x4e2d;&#x82f1;&#x6587;9&#x7bc7;&#xff0c;&#x4e2d;&#x6587;5&#x7bc7;&#x3002;&#x81ea;2018&#x5e74;&#x4ee5;&#x6765;&#xff0c;&#x76f8;&#x5173;&#x7814;&#x7a76;&#x9646;&#x7eed;&#x53d1;&#x8868;&#xff0c;&#x91cd;&#x70b9;&#x5173;&#x6ce8;&#x9ad8;&#x8840;&#x538b;&#x3001;&#x7cd6;&#x5c3f;&#x75c5;&#x548c;&#x6291;&#x90c1;&#x60a3;&#x8005;&#x3002;&#x5171;&#x6709;12&#x5bb6;&#x673a;&#x6784;/&#x5e73;&#x53f0;&#x5c06;&#x6570;&#x636e;&#x8f6c;&#x5316;&#x4e3a;OMOP CDM&#x3002;&#x6c5f;&#x82cf;&#x7701;&#x4eba;&#x6c11;&#x533b;&#x9662;&#x5728;&#x56fd;&#x5185;&#x7387;&#x5148;&#x5e94;&#x7528;OMOP&#xff0c;&#x8bba;&#x8bc1;&#x4e86;&#x5176;&#x53ef;&#x884c;&#x6027;&#x3002;&#x5b81;&#x6ce2;&#x5e02;&#x911e;&#x5dde;&#x533a;&#x533a;&#x57df;&#x4fe1;&#x606f;&#x5e73;&#x53f0;&#x5bf9;&#x7cd6;&#x5c3f;&#x75c5;&#x548c;&#x9ad8;&#x8840;&#x538b;&#x60a3;&#x8005;&#x7684;&#x591a;&#x7ef4;&#x6570;&#x636e;&#x8fdb;&#x884c;&#x4e86;&#x6807;&#x51c6;&#x5316;&#x3002;&#x57fa;&#x4e8e;&#x6b64;&#x5e73;&#x53f0;&#x5df2;&#x6784;&#x5efa;&#x4e86;&#x7cd6;&#x5c3f;&#x75c5;&#x60a3;&#x8005;&#x5e76;&#x53d1;&#x75c7;&#x7cfb;&#x5217;&#x9884;&#x6d4b;&#x6a21;&#x578b;&#x3002;&#x6765;&#x81ea;&#x5317;&#x4eac;&#x5b89;&#x5b9a;&#x533b;&#x9662;&#x7684;&#x53e6;&#x4e00;&#x5927;&#x578b;&#x6570;&#x636e;&#x5e93;&#x4f7f;&#x7528;OMOP CDM&#x63a2;&#x8ba8;&#x8001;&#x5e74;&#x6291;&#x90c1;&#x75c7;&#x548c;&#x75f4;&#x5446;&#x60a3;&#x8005;&#x7684;&#x7279;&#x5f81;&#x3002; <b>&#x7ed3;&#x8bba;&#xff1a;</b> &#x672c;&#x7814;&#x7a76;&#x603b;&#x7ed3;&#x4e86;OMOP CDM&#x5728;&#x4e2d;&#x56fd;&#x7684;&#x5e94;&#x7528;&#x7814;&#x7a76;&#x73b0;&#x72b6;&#x3002;&#x901a;&#x8fc7;&#x5bf9;&#x5177;&#x4f53;&#x6848;&#x4f8b;&#x7684;&#x6df1;&#x5165;&#x5206;&#x6790;&#xff0c;&#x672c;&#x7814;&#x7a76;&#x4e3a;&#x8de8;&#x533a;&#x57df;&#x7684;&#x8bc1;&#x636e;&#x5171;&#x4eab;&#x548c;&#x5408;&#x4f5c;&#x63d0;&#x4f9b;&#x4e86;&#x6f5c;&#x5728;&#x7684;&#x65b9;&#x5411;&#x3002;.</AbstractText></OtherAbstract></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>11</Day><Hour>0</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>11</Day><Hour>0</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>10</Day><Hour>22</Hour><Minute>14</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40494801</ArticleId><ArticleId IdType="doi">10.3760/cma.j.cn112338-20240924-00595</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40496104</PMID><DateRevised><Year>2025</Year><Month>06</Month><Day>13</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2769-2450</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Public health challenges</Title><ISOAbbreviation>Public Health Chall</ISOAbbreviation></Journal><ArticleTitle>Reductions in Blood Lead Level Screening During Peak COVID-19 Restrictions and Beyond.</ArticleTitle><Pagination><StartPage>e70021</StartPage><MedlinePgn>e70021</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e70021</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/puh2.70021</ELocationID><Abstract><AbstractText Label="BACKGROUND AND OBJECTIVES" NlmCategory="UNASSIGNED">Among the multitude of health effects on children associated with the COVID-19 pandemic, there have been significant interruptions in the provision of routine pediatric primary care, including blood lead level (BLL) screening. We aimed to investigate trends in BLL screening before and during the pandemic era using patient-level electronic health record data extracted from CurrentCare, Rhode Island's statewide health information exchange (HIE).</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">De-identified data were analyzed from CurrentCare for the study period January 2018 to December 2021. We utilized ATLAS, a web-based analytics platform from the Observational Health Data Sciences and Informatics (OHDSI) community, to extract and stratify BLL by variables of interest from the CurrentCare data, standardized to OHDSI's Observational Medical Outcomes Partnership common data model.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A decrease in BLL screening occurred in the spring of 2020, aligning with initial periods of shelter-in-place in response to the novel coronavirus outbreak; there was a 48% decrease comparing quarter 2 (April to June) of 2019 and 2020. BLL screening rebounded in the summer of 2020, however, it remained 16% lower overall in 2020 than in 2019. In 2021, BLL screening fell again to 23% lower than in 2019. Although overall numbers of BLL screenings were reduced, the proportion of abnormal BLLs was higher, particularly in the range of 3.5-5.0&#xa0;&#xb5;g/dL.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">Leveraging statewide HIE data, we found that significant deficiencies in BLL screening remain unresolved since the beginning of the COVID-19 pandemic. The disruption of children's lives by the COVID-19 pandemic appears to have greatly affected lead screening and exposure in Rhode Island.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). Public Health Challenges published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McCarthy</LastName><ForeName>Meghan L</ForeName><Initials>ML</Initials><Identifier Source="ORCID">0000-0002-0384-030X</Identifier><AffiliationInfo><Affiliation>Warren Alpert Medical School of Brown University Providence Rhode Island USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bradenday</LastName><ForeName>Jonah</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Brown Center for Biomedical Informatics Providence Rhode Island USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Warren Alpert Medical School of Brown University Providence Rhode Island USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brown Center for Biomedical Informatics Providence Rhode Island USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zonfrillo</LastName><ForeName>Mark R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine Warren Alpert Medical School of Brown University Providence Rhode Island USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics Warren Alpert Medical School of Brown University Providence Rhode Island USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarkar</LastName><ForeName>Indra Neil</ForeName><Initials>IN</Initials><AffiliationInfo><Affiliation>Warren Alpert Medical School of Brown University Providence Rhode Island USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Brown Center for Biomedical Informatics Providence Rhode Island USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Rhode Island Quality Institute Providence Rhode Island USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U54 GM104942</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 GM115677</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>02</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><MedlineTA>Public Health Chall</MedlineTA><NlmUniqueID>9918574282106676</NlmUniqueID><ISSNLinking>2769-2450</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">health information exchange</Keyword><Keyword MajorTopicYN="N">lead exposure</Keyword><Keyword MajorTopicYN="N">lead screening</Keyword><Keyword MajorTopicYN="N">pediatric primary care</Keyword><Keyword MajorTopicYN="N">screening</Keyword><Keyword MajorTopicYN="N">well child care</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>5</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>10</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>12</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>11</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>11</Day><Hour>5</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>2</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40496104</ArticleId><ArticleId IdType="pmc">PMC12039357</ArticleId><ArticleId IdType="doi">10.1002/puh2.70021</ArticleId><ArticleId IdType="pii">PUH270021</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Naranjo V. I., Hendricks M., and Jones K. S., &#x201c;Lead Toxicity in Children: An Unremitting Public Health Problem,&#x201d; Pediatric Neurology 113 (2020): 51&#x2013;55, 10.1016/j.pediatrneurol.2020.08.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pediatrneurol.2020.08.005</ArticleId><ArticleId IdType="pubmed">33011642</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayans L., &#x201c;Lead Poisoning in Children,&#x201d; American Family Physician 100 (2019): 24&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">31259498</ArticleId></ArticleIdList></Reference><Reference><Citation>Needleman H. L., Schell A., Bellinger D., et&#xa0;al., &#x201c;The Long&#x2010;Term Effects of Exposure to Low Doses of Lead in Childhood,&#x201d; New England Journal of Medicine 322 (1990): 83&#x2013;88, 10.1056/nejm199001113220203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/nejm199001113220203</ArticleId><ArticleId IdType="pubmed">2294437</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x201c;Blood Lead Reference Value,&#x201d; Centers for Disease Control and Prevention
. accessed November 30, 2023, 2022, https://www.cdc.gov/nceh/lead/data/blood&#x2010;lead&#x2010;reference&#x2010;value.htm.</Citation></Reference><Reference><Citation>&#x201c;Healthy Homes and Lead Poisoning Information for Healthcare Providers,&#x201d; Rhode Island Department of Health
. accessed November 30, 2023, https://health.ri.gov/healthrisks/poisoning/lead/for/providers/.</Citation></Reference><Reference><Citation>Courtney J. G., Chuke S. O., Dyke K., et&#xa0;al., &#x201c;Decreases in Young Children Who Received Blood Lead Level Testing During COVID&#x2010;19&#x2014;34 Jurisdictions, January&#x2013;May 2020,&#x201d; Morbidity and Mortality Weekly Report 70 (2021): 155&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7861485</ArticleId><ArticleId IdType="pubmed">33539334</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x201c;Lead Poisoning: Populations at Higher Risk,&#x201d; CDC
, 2022, https://www.cdc.gov/nceh/lead/prevention/children.htm.</Citation></Reference><Reference><Citation>Sarkar I. N., &#x201c;Transforming Health Data to Actionable Information: Recent Progress and Future Opportunities in Health Information Exchange,&#x201d; Yearbook of Medical Informatics 31 (2022): 203&#x2013;214.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9719753</ArticleId><ArticleId IdType="pubmed">36463879</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarkar I. N., &#x201c;Health Information Exchange as a Global Utility,&#x201d; Chest 163 (2023): 1023&#x2013;1025.</Citation><ArticleIdList><ArticleId IdType="pubmed">37164575</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker C., Loresto Jr F., Pickett K., et&#xa0;al., &#x201c;Facilitating Health Information Exchange to Improve Health Outcomes for School&#x2010;Aged Children: School Nurse Electronic Health Record Access,&#x201d; Applied Clinical Informatics 13 (2022): 803&#x2013;810.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9451949</ArticleId><ArticleId IdType="pubmed">35858639</ArticleId></ArticleIdList></Reference><Reference><Citation>Vest J. R., Jasperson J., Zhao H., et&#xa0;al., &#x201c;Use of a Health Information Exchange System in the Emergency Care of Children,&#x201d; BMC Medical Informatics and Decision Making 11 (2011): 78, 10.1186/1472-6947-11-78.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1472-6947-11-78</ArticleId><ArticleId IdType="pmc">PMC3295672</ArticleId><ArticleId IdType="pubmed">22208182</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahous M. C. and Shadmi E., &#x201c;Health Information Exchange and Information Gaps in Referrals to a Pediatric Emergency Department,&#x201d; International Journal of Medical Informatics 87 (2016): 68&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">26806713</ArticleId></ArticleIdList></Reference><Reference><Citation>Bedgood M., Kuelbs C. L., Jones V. G., et&#xa0;al., &#x201c;Organizational Perspectives on Technical Capabilities and Barriers Related to Pediatric Data Sharing and Confidentiality,&#x201d; JAMA Network Open 5 (2022): e2219692, 10.1001/jamanetworkopen.2022.19692.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2022.19692</ArticleId><ArticleId IdType="pmc">PMC9250046</ArticleId><ArticleId IdType="pubmed">35796214</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x201c;Childhood Lead Poisoning Prevention,&#x201d; Centers for Disease Control and Prevention
. accessed November 30, 2023, https://www.cdc.gov/nceh/lead/programs/ri.htm.</Citation></Reference><Reference><Citation>&#x201c;Childhood Lead Poisoning,&#x201d; Rhode Island Department of Health
, accessed November 30, 2023, https://health.ri.gov/data/childhoodleadpoisoning/.</Citation></Reference><Reference><Citation>Haendel M. A., Chute C. G., Bennett T. D., et&#xa0;al., &#x201c;The National COVID Cohort Collaborative (N3C): Rationale, Design, Infrastructure, and Deployment,&#x201d; Journal of the American Medical Informatics Association 28 (2021): 427&#x2013;443.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7454687</ArticleId><ArticleId IdType="pubmed">32805036</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G., Schuemie M. J., Madigan D., et&#xa0;al., &#x201c;Drawing Reproducible Conclusions From Observational Clinical Data With OHDSI,&#x201d; Yearbook of Medical Informatics 30 (2021): 283&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8416226</ArticleId><ArticleId IdType="pubmed">33882595</ArticleId></ArticleIdList></Reference><Reference><Citation>&#x201c;United States Census: Rhode Island QuickFacts,&#x201d; United States Census Bureau
. accessed November 30, 2023, https://www.census.gov/quickfacts/fact/table/RI/PST045222.</Citation></Reference><Reference><Citation>Loza A. J. and Doolittle B. R., &#x201c;The Effect of COVID&#x2010;19 Pandemic Restrictions on Lead Screening in a Primary Care Clinic,&#x201d; Journal of Pediatric Health Care 36 (2022): 64&#x2013;70, 10.1016/j.pedhc.2021.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pedhc.2021.03.004</ArticleId><ArticleId IdType="pmc">PMC8139238</ArticleId><ArticleId IdType="pubmed">34120794</ArticleId></ArticleIdList></Reference><Reference><Citation>Seither R., Calhoun K., Yusuf O. B., et&#xa0;al., &#x201c;Vaccination Coverage With Selected Vaccines and Exemption Rates Among Children in Kindergarten &#x2013; United States, 2021&#x2013;22 School Year,&#x201d; MMWR Morbidity and Mortality Weekly Report 72 (2023): 26&#x2013;32, 10.15585/mmwr.mm7202a2.</Citation><ArticleIdList><ArticleId IdType="doi">10.15585/mmwr.mm7202a2</ArticleId><ArticleId IdType="pmc">PMC9869733</ArticleId><ArticleId IdType="pubmed">36634005</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackerson B. K., Sy L. S., Glenn S. C., et&#xa0;al., &#x201c;Pediatric Vaccination During the COVID&#x2010;19 Pandemic,&#x201d; Pediatrics 148 (2021): e2020047092, 10.1542/peds.2020-047092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2020-047092</ArticleId><ArticleId IdType="pubmed">33858983</ArticleId></ArticleIdList></Reference><Reference><Citation>Vivier P. M., Hauptman M., Weitzen S. H., et&#xa0;al., &#x201c;The Important Health Impact of Where a Child Lives: Neighborhood Characteristics and the Burden of Lead Poisoning,&#x201d; Maternal and Child Health Journal 15 (2011): 1195&#x2013;1202, 10.1007/s10995-010-0692-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10995-010-0692-6</ArticleId><ArticleId IdType="pmc">PMC3734857</ArticleId><ArticleId IdType="pubmed">20972613</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephen A. H., Andrea S. B., Banerjee D., et&#xa0;al., &#x201c;The Association Between Household and Neighborhood Characteristics and COVID&#x2010;19 Related ICU Admissions,&#x201d; SSM&#x2010;Population Health 19 (2022): 101133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9212995</ArticleId><ArticleId IdType="pubmed">35756546</ArticleId></ArticleIdList></Reference><Reference><Citation>RI Department of Health, Rhode Island COVID&#x2010;19 Issue Brief COVID&#x2010;19 Hospitalizations: Trends, Demographics, and Risk Factors for Critical Illness (Providence, RI: RI Department of Health, 2020).</Citation></Reference><Reference><Citation>Ho Z. V., Arias S. A., Kunicki Z. J., et&#xa0;al., &#x201c;Characterizing Suicidal Ideation, Suicidal Behaviors, and Service Utilization Among Unhoused Individuals Using a Health Information Exchange,&#x201d; Journal of Clinical Psychology 79 (2023): 2542&#x2013;2555.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10592413</ArticleId><ArticleId IdType="pubmed">37433045</ArticleId></ArticleIdList></Reference><Reference><Citation>Abhyankar S., Goodwin R. M., Sontag M., et&#xa0;al., &#x201c;An Update on the Use of Health Information Technology in Newborn Screening,&#x201d; Seminars in Perinatology 39 (2015): 188&#x2013;193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4433800</ArticleId><ArticleId IdType="pubmed">25935354</ArticleId></ArticleIdList></Reference><Reference><Citation>Abhyankar S., Lloyd&#x2010;Puryear M. A., Goodwin R., et&#xa0;al., &#x201c;Standardizing Newborn Screening Results for Health Information Exchange,&#x201d; in AMIA Annual Symposium Proceedings (Bethesda, MD: American Medical Informatics Association, 2010), 1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3041276</ArticleId><ArticleId IdType="pubmed">21346929</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40502243</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>09</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2153-4063</ISSN><JournalIssue CitedMedium="Internet"><Volume>2025</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science</Title><ISOAbbreviation>AMIA Jt Summits Transl Sci Proc</ISOAbbreviation></Journal><ArticleTitle>A Generalized Tool to Assess Algorithmic Fairness in Disease Phenotype Definitions.</ArticleTitle><Pagination><StartPage>624</StartPage><EndPage>633</EndPage><MedlinePgn>624-633</MedlinePgn></Pagination><Abstract><AbstractText>For evidence from observational studies to be reliable, researchers must ensure that the patient populations of interest are accurately defined. However, disease definitions can be extremely difficult to standardize and implement accurately across different datasets and study requirements. Furthermore, in this context, they must also ensure that populations are represented fairly to accurately reflect populations' various demographic dynamics and to not overgeneralize across non-applicable populations. In this work, we present a generalized tool to assess the fairness of disease definitions by evaluating their implementation across common fairness metrics. Our approach calculates fairness metrics and provides a robust method to examine coarse and strongly intersecting populations across many characteristics. We highlight workflows when working with disease definitions, provide an example analysis using an OMOP CDM patient database, and discuss potential directions for future improvement and research.</AbstractText><CopyrightInformation>&#xa9;2025 AMIA - All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zelko</LastName><ForeName>Jacob S</ForeName><Initials>JS</Initials><AffiliationInfo><Affiliation>Department of Mathematics, Northeastern University, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manjourides</LastName><ForeName>Justin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Public Health and Health Sciences, Northeastern University, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Public Health and Health Sciences, Northeastern University, Boston, MA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>10</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>AMIA Jt Summits Transl Sci Proc</MedlineTA><NlmUniqueID>101539486</NlmUniqueID></MedlineJournalInfo><CoiStatement>The authors have no conflicts of interest to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>12</Day><Hour>11</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>12</Day><Hour>11</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>12</Day><Hour>6</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>6</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40502243</ArticleId><ArticleId IdType="pmc">PMC12150753</ArticleId><ArticleId IdType="pii">6756</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Walonoski J, et al. Journal of the American Medical Informatics Association. Vol. 25. Publisher: Oxford University Press; 2018. Synthea: An approach, method, and software mechanism for generating synthetic patients and the synthetic electronic health care record; pp. 230&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7651916</ArticleId><ArticleId IdType="pubmed">29025144</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, PE Stang. Journal of the American Medical Informatics Association. Vol. 19. Publisher: BMJ Group BMA House, Tavistock Square, London, WC1H 9JR; 2012. Validation of a common data model for active safety surveillance research; pp. 54&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Food and Drug Administration  Real-world evidence. 2021 Sep Available from: https://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence .</Citation></Reference><Reference><Citation>Ergina PL, Barkun JS, McCulloch P, Cook JA, DG Altman. BMJ (Clinical research ed.) Vol. 346. Publisher: British Medical Journal Publishing Group; 2013. IDEAL framework for surgical innovation 2: observational studies in the exploration and assessment stages.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3685514</ArticleId><ArticleId IdType="pubmed">23778426</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandel JC, Kreda DA, Mandl KD, Kohane IS, RB Ramoni. SMART on FHIR: a standards-based, interoperable apps platform for electronic health records. Journal of the American Medical Informatics Association. 2016 Sep;23:899&#x2013;908. Doi: 10.1093/jamia/ocv189. Available from: https://doi.org/10.1093/jamia/ocv189.  [Accessed on: 2024 Jan 6]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4997036</ArticleId><ArticleId IdType="pubmed">26911829</ArticleId></ArticleIdList></Reference><Reference><Citation>Bender D, Sartipi K. HL7 FHIR: An Agile and RESTful approach to healthcare information exchange. Proceedings of the 26th IEEE International Symposium on Computer-Based Medical Systems. ISSN: 1063-7125. 2013 Jun:326&#x2013;31. Doi: 10.1109/CBMS.2013.6627810. Available from: https://ieeexplore.ieee.org/document/6627810 [Accessed on: 2024 Jan 6]</Citation></Reference><Reference><Citation>Hripcsak G, et al. MEDINFO 2015: eHealth-enabled health. IOS Press; 2015. Observational health data sciences and informatics (OHDSI): opportunities for observational researchers; pp. 574&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Zelko JS, et al.  Developing a Robust Computable Phenotype Definition Workflow to Describe Health and Disease in Observational Health Research. arXiv:2304.06504 [cs] 2023 Mar Doi: 10.48550/arXiv.2304.06504. Available from: http://arxiv.org/abs/2304.06504.  [Accessed on: 2023 Apr 16]</Citation></Reference><Reference><Citation>Milner KA, Funk M, Richards S, Wilmes RM, Vaccarino V, HM Krumholz. The American journal of cardiology. Vol. 84. Publisher: Elsevier; 1999. Gender differences in symptom presentation associated with coronary heart disease; pp. 396&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10468075</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun TY, Bhave S, Altosaar J, N Elhadad. Assessing Phenotype Definitions for Algorithmic Fairness. en. arXiv:2203.05174 [cs, q-bio] 2022 Mar arXiv: 2203.05174. Available from: http://arxiv.org/ abs/2203.05174 [Accessed on: 2022 Apr 29]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10148336</ArticleId><ArticleId IdType="pubmed">37128361</ArticleId></ArticleIdList></Reference><Reference><Citation>Khera R, et al. BMJ open. Vol. 12. Publisher: British Medical Journal Publishing Group; 2022. Large-scale evidence generation and evaluation across a network of databases for type 2 diabetes mellitus (LEGEND-T2DM): a protocol for a series of multinational, real-world comparative cardiovascular effectiveness and safety studies; p. e057977.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9185490</ArticleId><ArticleId IdType="pubmed">35680274</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller DR, Safford MM, LM Pogach. Diabetes care. Vol. 27. Publisher: Am Diabetes Assoc; 2004. Who has diabetes? Best estimates of diabetes prevalence in the Department of Veterans Affairs based on computerized patient data; pp. b10&#x2013;b21.</Citation><ArticleIdList><ArticleId IdType="pubmed">15113777</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao G. PhenotypeLibrary: The OHDSI phenotype library. manual. 2024</Citation></Reference><Reference><Citation>Kirby JC, et al. Journal of the American Medical Informatics Association. Vol. 23. Publisher: Oxford University Press; 2016. PheKB: a catalog and workflow for creating electronic phenotype algorithms for transportability; pp. 1046&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5070514</ArticleId><ArticleId IdType="pubmed">27026615</ArticleId></ArticleIdList></Reference><Reference><Citation>Choo HY, Ferree MM. Sociological theory. Vol. 28. CA: Los Angeles, CA: Publisher: SAGE Publications Sage; 2010. Practicing intersectionality in sociological research: A critical analysis of inclusions, interactions, and institutions in the study of inequalities; pp. 129&#x2013;49.</Citation></Reference><Reference><Citation>Simonov K, Evans CC, JS Zelko. FunSQL : Julia library for compositional construction of SQL queries. 2023 Mar Doi: 10.5281/zenodo.7705325. Available from: https://doi.org/10.5281/zenodo.7705325 .</Citation></Reference><Reference><Citation>Homan P, Brown TH, B King. Structural Intersectionality as a New Direction for Health Disparities Research. en. Journal of Health and Social Behavior. 2021 Sep;62:350&#x2013;70. Doi: 10.1177/ 00221465211032947. Available from: http://journals.sagepub.com/doi/10.1177/00221465211032947 [Accessed on: 2022 Oct 21]</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8628816</ArticleId><ArticleId IdType="pubmed">34355603</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40506029</PMID><DateRevised><Year>2025</Year><Month>06</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2005-9256</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jun</Month><Day>05</Day></PubDate></JournalIssue><Title>Cancer research and treatment</Title><ISOAbbreviation>Cancer Res Treat</ISOAbbreviation></Journal><ArticleTitle>Secondary Cancer Risk in Breast Cancer with and without Radiotherapy: The Observational Health Data Sciences and Informatics (OHDSI) Cohort Study.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.4143/crt.2024.968</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="UNASSIGNED">Radiotherapy is used to reduce the risk of breast cancer recurrence after surgery, but it is a potential cause of secondary cancer. We validated the risk of secondary cancer in primary breast cancer who received radiotherapy compared with those who did not from a matched cohort using a large-scale observational study of the Observational Health Data Sciences and Informatics (OHDSI) data network.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="UNASSIGNED">A retrospective comparative cohort study using propensity score-matched cohorts was performed using two Observational Medical Outcome Partnership common data model databases, from tertiary general hospitals in South Korea. Among female patients who underwent surgery after the diagnosis of breast cancer, the risk of secondary primary malignant occurrence after 1:1 matching was analyzed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Among 27,078 patients with breast cancer, there was no significant difference in the risk of secondary cancer following radiotherapy in 4,268 patients after 1:1 propensity-score matching. Further, there were no significant differences in the sensitivity analysis according to age, latency period, and number of radiation treatments.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">There was no difference in the risk of secondary cancer in the patients diagnosed with breast cancer depending on whether or not radiotherapy was performed after surgery. In the future, it is necessary to analyze including data generated during cancer treatment.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Seok</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Office of eHealth Research and Business, Seoul National University Bundang Hospital, Seongnam, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Boo</LastName><ForeName>Dachung</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Biomedical Systems Informatics, Yonsei University College of Medicine Institute for Innovation in Digital Healthcare, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoo</LastName><ForeName>Sooyoung</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Office of eHealth Research and Business, Seoul National University Bundang Hospital, Seongnam, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Borham</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Office of eHealth Research and Business, Seoul National University Bundang Hospital, Seongnam, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Kyubo</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Radiation Oncology, Seoul National University Bundang Hospital, Seongnam, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Kwangsoo</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Transdisciplinary Medicine, Institute of Convergence Medicine with Innovation Technology, Seoul National University Hospital, Seoul, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Innovative Medical Technology Research Institute, Seoul National University Hospital, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Eunhye</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Data Science Research, Innovative Medical Technology Research Institute, Seoul National University Hospital, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Junmo</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Interdisciplinary Program in Bioengineering, Seoul National University, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryoo</LastName><ForeName>Hyun Gee</ForeName><Initials>HG</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Seoul National University Hospital, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paeng</LastName><ForeName>Jin Chul</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Seoul National University Hospital, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>In Young</ForeName><Initials>IY</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, College of Medicine, The Catholic University of Korea, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ko</LastName><ForeName>SooJeong</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, College of Medicine, The Catholic University of Korea, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yoo</LastName><ForeName>Ie Ryung</ForeName><Initials>IR</Initials><AffiliationInfo><Affiliation>Division of Nuclear Medicine, Department of Radiology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Rae Woong</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, School of Medicine, Ajou University, Suwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Ho-Young</ForeName><Initials>HY</Initials><AffiliationInfo><Affiliation>Office of eHealth Research and Business, Seoul National University Bundang Hospital, Seongnam, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Nuclear Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>Cancer Res Treat</MedlineTA><NlmUniqueID>101155137</NlmUniqueID><ISSNLinking>1598-2998</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Breast neoplasms</Keyword><Keyword MajorTopicYN="N">Common data model</Keyword><Keyword MajorTopicYN="N">Propensity-score matching</Keyword><Keyword MajorTopicYN="N">Radiotherapy</Keyword><Keyword MajorTopicYN="N">Secondary primary malignant</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>10</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>13</Day><Hour>0</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>13</Day><Hour>0</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>12</Day><Hour>19</Hour><Minute>44</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40506029</ArticleId><ArticleId IdType="doi">10.4143/crt.2024.968</ArticleId><ArticleId IdType="pii">crt.2024.968</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40517846</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>16</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-5921</ISSN><JournalIssue CitedMedium="Internet"><Volume>185</Volume><PubDate><Year>2025</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of clinical epidemiology</Title><ISOAbbreviation>J Clin Epidemiol</ISOAbbreviation></Journal><ArticleTitle>Clusters of post-acute COVID-19 symptoms: a latent class analysis across 9 databases and 7 countries.</ArticleTitle><Pagination><StartPage>111867</StartPage><MedlinePgn>111867</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jclinepi.2025.111867</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0895-4356(25)00200-8</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Prior evidence has suggested the multisystem symptomatic manifestations of post-acute COVID-19 condition (PCC). Here we conducted a network cluster analysis of 24 World Health Organization-proposed symptoms to identify potential latent subclasses of PCC.</AbstractText><AbstractText Label="STUDY DESIGN AND SETTING" NlmCategory="METHODS">Individuals with a positive test of or diagnosed with SARS-CoV-2 after September 2020 and with at least 1 symptom within &#x2265;90 to 365 days following infection were included. Subanalyses were conducted among people with &#x2265;3 different symptoms. Summary characteristics were provided for each cluster. All analyses were conducted separately in 9 databases from 7 countries, including data from primary care, hospitals, national health claims and national health registries, allowing to compare clusters across the different healthcare settings.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">This study included 787,078 persons with PCC. Single-symptom clusters were common across all databases, particularly for joint pain, anxiety, depression and allergy. Complex clusters included anxiety-depression and abdominal-gastrointestinal symptoms.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Substantial heterogeneity within and between PCC clusters was seen across health-care settings. Current definitions of PCC should be critically reviewed to reflect this variety in clinical presentation.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>L&#xf3;pez-G&#xfc;ell</LastName><ForeName>Kim</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Catal&#xe0;</LastName><ForeName>Mart&#xed;</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dedman</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>CPRD, Medicines and Healthcare products Regulatory Agency, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duarte-Salles</LastName><ForeName>Talita</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain; Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kolde</LastName><ForeName>Raivo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Computer Science, University of Tartu, Tartu, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf3;pez-Blasco</LastName><ForeName>Ra&#xfa;l</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Biocomputing Unit, Aragon Health Sciences Institute (IACS), Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mart&#xed;nez</LastName><ForeName>&#xc1;lvaro</ForeName><Initials>&#xc1;</Initials><AffiliationInfo><Affiliation>The Health Research Institute Hospital La Fe, Avenida Fernando Abril Martorell, 106 Torre A 7a planta, Valencia 46026, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mercier</LastName><ForeName>Gregoire</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Public Health Department, University Hospital of Montpellier, Montpellier 34295, France; IDESP, Universit&#xe9; de Montpellier, INSERM, Montpellier 34000, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abellan</LastName><ForeName>Alicia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arinze</LastName><ForeName>Johnmary T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burkard</LastName><ForeName>Theresa</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burn</LastName><ForeName>Edward</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cuccu</LastName><ForeName>Zara</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>CPRD, Medicines and Healthcare products Regulatory Agency, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delmestri</LastName><ForeName>Antonella</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delseny</LastName><ForeName>Dominique</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Public Health Department, University Hospital of Montpellier, Montpellier 34295, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khalid</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Chungsoo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Ji-Woo</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Big Data Department, Health Insurance Review and Assessment Service, Wonju, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kostka</LastName><ForeName>Kristin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; The OHDSI Center at the Roux Institute, Northeastern University, Portland, ME, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loste</LastName><ForeName>Cora</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases &amp; irsiCaixa AIDS Research Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain; University of Vic- Central University of Catalonia (UVic-UCC), Vic, Spain; REICOP (Red de Investigaci&#xf3;n Covid Persistente), Madrid, Spain; Fundaci&#xf3; Lluita Contra les Infeccions, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayer</LastName><ForeName>Miguel A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Parc de Salut Mar, Hospital del Mar Medical Research Institute, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mel&#xe9;ndez-Cardiel</LastName><ForeName>Jaime</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Biocomputing Unit, Aragon Health Sciences Institute (IACS), Zaragoza, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mercad&#xe9;-Besora</LastName><ForeName>N&#xfa;ria</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mosseveld</LastName><ForeName>Mees</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nishimura</LastName><ForeName>Akihito</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nordeng</LastName><ForeName>Hedvig Me</ForeName><Initials>HM</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Pharmacoepidemiology and Drug Safety Research Group, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway; Department of Child Health and Development, Norwegian Institute of Public Health, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oyinlola</LastName><ForeName>Jessie O</ForeName><Initials>JO</Initials><AffiliationInfo><Affiliation>CPRD, Medicines and Healthcare products Regulatory Agency, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paredes</LastName><ForeName>Roger</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases &amp; irsiCaixa AIDS Research Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain; University of Vic- Central University of Catalonia (UVic-UCC), Vic, Spain; Fundaci&#xf3; Lluita Contra les Infeccions, Badalona, Catalonia, Spain; Department of Pathology, Center for Global Health and Diseases, Case Western Reserve University School of Medicine, Cleveland, OH; Universitat Aut&#xf2;noma de Barcelona, Catalonia, Spain; CIBER Infectious Diseases (CIBERINFEC), Institute of Health Carlos III (ISCIII), Madrid, Spain; IrsiCaixa AIDS Research Institute, Germans Trias i Pujol Research Institute (IGTP), Can Ruti Campus, Badalona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xe9;rez-Crespo</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pineda-Moncus&#xed;</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ram&#xed;rez-Anguita</LastName><ForeName>Juan Manuel</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Parc de Salut Mar, Hospital del Mar Medical Research Institute, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trinh</LastName><ForeName>Nhung T H</ForeName><Initials>NTH</Initials><AffiliationInfo><Affiliation>Department of Pharmacy, Pharmacoepidemiology and Drug Safety Research Group, Faculty of Mathematics and Natural Sciences, University of Oslo, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Uusk&#xfc;la</LastName><ForeName>Anneli</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute of Family Medicine and Public Health, University of Tartu, Tartu, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valdivieso</LastName><ForeName>Bernardo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>The Health Research Institute Hospital La Fe, Avenida Fernando Abril Martorell, 106 Torre A 7a planta, Valencia 46026, Spain; The University and Polytechnic La Fe Hospital of Valencia, Avenida Fernando Abril Martorell, 106 Torre H 1a planta, Valencia 46026, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK; Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands. Electronic address: daniel.prietoalhambra@ndorms.ox.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Junqing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mateu</LastName><ForeName>Lourdes</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Infectious Diseases &amp; irsiCaixa AIDS Research Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Catalonia, Spain; University of Vic- Central University of Catalonia (UVic-UCC), Vic, Spain; REICOP (Red de Investigaci&#xf3;n Covid Persistente), Madrid, Spain; Fundaci&#xf3; Lluita Contra les Infeccions, Badalona, Catalonia, Spain; Universitat Aut&#xf2;noma de Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>J&#xf6;dicke</LastName><ForeName>Annika M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Epidemiol</MedlineTA><NlmUniqueID>8801383</NlmUniqueID><ISSNLinking>0895-4356</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016000" MajorTopicYN="N">Cluster Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000094024" MajorTopicYN="N">Post-Acute COVID-19 Syndrome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077272" MajorTopicYN="N">Latent Class Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clustering</Keyword><Keyword MajorTopicYN="N">Latent class analysis</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Post-acute COVID-19 condition</Keyword><Keyword MajorTopicYN="N">Real-world data</Keyword></KeywordList><CoiStatement>Declaration of competing interest D.P.A.&#x2019;s department has received grant/s from Amgen, Chiesi&#x2013;Taylor, Lilly, Janssen, Novartis, and UCB Biopharma. His research group has received consultancy fees from Astra Zeneca and UCB Biopharma. Amgen, Astellas, Janssen, Synapse Management Partners and UCB Biopharma have funded or supported training programs organized by D.P.A.'s department. R.P. reports serving on advisory boards for Gilead Sciences, Inc, Pfizer, Inc, Roche Therapeutics, MSD, GSK, ViiV Healthcare, Eli Lilly and Company, PharmaMar, and Atea Pharmaceuticals, Inc; and receiving research grants paid to his institution from MSD, ViiV Healthcare, Gilead Sciences, and PharmaMar. L.M. reports receiving grants from Grifols; receiving honoraria as a speaker from AstraZeneca, Gilead Sciences, GSK, and Pfizer; and participation in advisory boards for Gilead Sciences and Merck. M.M. works for a research group that in the past 3 years received unconditional research grants from Chiesi, UCB, Amgen, Johnson &amp; Johnson, Innovative Medicines Initiative and the European Medicines Agency. D.Ded., Z.C. and J.O. are employees of the Medicines and Healthcare Products Regulatory Agency, which provides the CPRD research service. K.K. is a consortial author in the US National Institutes of Health National COVID Cohort Collaborative (funding expired in 2022 with no renewal or active impact on any current work). There are no competing interests for any other author.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>5</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>16</Day><Hour>13</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>16</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>15</Day><Hour>19</Hour><Minute>12</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40517846</ArticleId><ArticleId IdType="doi">10.1016/j.jclinepi.2025.111867</ArticleId><ArticleId IdType="pii">S0895-4356(25)00200-8</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40574694</PMID><DateRevised><Year>2025</Year><Month>06</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1527-974X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jun</Month><Day>17</Day></PubDate></JournalIssue><Title>Journal of the American Medical Informatics Association : JAMIA</Title><ISOAbbreviation>J Am Med Inform Assoc</ISOAbbreviation></Journal><ArticleTitle>Enhancing diagnostic precision for rare diseases using case-based reasoning.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">ocaf092</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/jamia/ocaf092</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study aims to enhance the diagnostic process for rare diseases using case-based reasoning (CBR). CBR compares new cases with historical data, utilizing both structured and unstructured clinical data.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">The study uses a dataset of 4295 patient cases from the University Hospital Frankfurt. Data were standardized using the OMOP Common Data Model. Three methods-TF, TF-IDF, and TF-IDF with semantic vector embeddings-were employed to represent patient records. Similarity search effectiveness was evaluated using cross-validation to assess diagnostic precision. High-weighted concepts were rated by medical experts for relevance. Additionally, the impact of different levels of ICD-10 code granularity on prediction outcomes was analyzed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The TF-IDF method showed a high degree of precision, with an average positive predictive value of 91% in the 10 most similar cases. The differences between the methods were not statistically significant. The expert evaluation rated the medical relevance of high-weighted concepts as moderate. The granularity of ICD-10 coding significantly influences the precision of predictions, with more granular codes showing decreased precision.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">The methods effectively handle data from multiple medical specialties, suggesting broad applicability. The use of broader ICD-10 codes with high precision in prediction could improve initial diagnostic guidance. The use of Explainable AI could enhance diagnostic transparency, leading to better patient outcomes. Limitations include standardization issues and the need for more comprehensive lab value integration.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">While CBR shows promise for rare disease diagnostics, its utility depends on the specific needs of the decision support system and its intended clinical application.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2025. Published by Oxford University Press on behalf of the American Medical Informatics Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Noll</LastName><ForeName>Richard</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-5240-8484</Identifier><AffiliationInfo><Affiliation>Institute of Medical Informatics, Goethe University Frankfurt, University Medicine, 60590 Frankfurt am Main, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berger</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Frankfurt Reference Centre for Rare Diseases, University Medicine, Goethe University Frankfurt, 60596 Frankfurt am Main, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Facchinello</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Academic Teaching Practice of the Heinrich-Heine-University D&#xfc;sseldorf, 40885 Ratingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stratmann</LastName><ForeName>Katharina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Medical Clinic 1, Goethe University Frankfurt, University Medicine, 60596 Frankfurt am Main, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schaaf</LastName><ForeName>Jannik</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Medical Informatics, Goethe University Frankfurt, University Medicine, 60590 Frankfurt am Main, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Storf</LastName><ForeName>Holger</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Institute of Medical Informatics, Goethe University Frankfurt, University Medicine, 60590 Frankfurt am Main, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>2520DAT02B</GrantID><Agency>Federal Ministry of Health in Germany</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Am Med Inform Assoc</MedlineTA><NlmUniqueID>9430800</NlmUniqueID><ISSNLinking>1067-5027</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">case-based reasoning</Keyword><Keyword MajorTopicYN="N">diagnostic techniques and procedures</Keyword><Keyword MajorTopicYN="N">interdisciplinary research</Keyword><Keyword MajorTopicYN="N">medical informatics</Keyword><Keyword MajorTopicYN="N">rare diseases</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>4</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>27</Day><Hour>6</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>27</Day><Hour>4</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40574694</ArticleId><ArticleId IdType="doi">10.1093/jamia/ocaf092</ArticleId><ArticleId IdType="pii">8165644</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40582069</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>09</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-460X</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>9</Issue><PubDate><Year>2025</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of diabetes and its complications</Title><ISOAbbreviation>J Diabetes Complications</ISOAbbreviation></Journal><ArticleTitle>Heterogeneity of treatment effects of glucose-lowering drug classes for type 2 diabetes: LEGEND-T2DM network real-world evidence.</ArticleTitle><Pagination><StartPage>109114</StartPage><MedlinePgn>109114</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jdiacomp.2025.109114</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1056-8727(25)00167-9</ELocationID><Abstract><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">To assess heterogeneity of treatment effects (HTE) of glucose-lowering drug classes by clinical (cardiovascular [CV] risk, renal impairment) and demographic (age, sex) subgroups in adults with type 2 diabetes mellitus (T2D).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The LEGEND-T2DM network identified 4,746,939 adults with T2D on metformin monotherapy who initiated one of four glucose-lowering drug classes: glucagon-like peptide-1 receptor agonists (GLP-1 RA), sodium-glucose cotransporter 2 inhibitors (SGLT2i), dipeptidyl peptidase-4 inhibitor (DPP-4i) or sulfonylureas. HTE was assessed between glucose-lowering drug classes by clinical (low CV risk vs. higher CV risk; without renal impairment vs. renal impairment) and demographic (lower vs. middle vs. older age; male vs. female) subgroups. Outcomes included MACE (primary), acute myocardial infarction, stroke, sudden cardiac death and safety endpoints.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Pairwise differences (n&#xa0;=&#xa0;1115 tests) between adjusted hazard ratios (HRs) showed 49 nominally significant associations (p&#xa0;&lt;&#xa0;0.05) and one statistically significant difference after Bonferroni correction (p&#xa0;&lt;&#xa0;4.5&#xa0;&#xd7;&#xa0;10<sup>-5</sup>). Among older subjects (vs. younger), those taking GLP-1 RA (vs. sulfonylureas) had statistically significant difference in risk of hypoglycemia (HRs: lower age, 0.53&#xa0;&#xb1;&#xa0;0.14 vs. older age, 0.20&#xa0;&#xb1;&#xa0;0.05, p&#xa0;&lt;&#xa0;0.001).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">HTE among glucose-lowering drug classes by clinical and demographic subgroups may provide guidance to generate hypothesis-testing studies to inform T2D treatment decisions.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>D&#xe1;vila-Garc&#xed;a</LastName><ForeName>David M</ForeName><Initials>DM</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY, United States; Institute for Informatics, Data Science &amp; Biostatistics, Washington University School of Medicine in Saint Louis, Saint Louis, MO, United States. Electronic address: davila-garcia@wustl.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falconer</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY, United States. Electronic address: tf2428@cumc.columbia.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pratt</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Quality Use of Medicines and Pharmacy Research Centre, University of South Australia, Adelaide, Australia. Electronic address: Nicole.Pratt@unisa.edu.au.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Natarajan</LastName><ForeName>Karthik</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY, United States. Electronic address: kn2174@cumc.columbia.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY, United States. Electronic address: hripcsak@columbia.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>06</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Diabetes Complications</MedlineTA><NlmUniqueID>9204583</NlmUniqueID><ISSNLinking>1056-8727</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077203">Sodium-Glucose Transporter 2 Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054873">Dipeptidyl-Peptidase IV Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013453">Sulfonylurea Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000097789">Glucagon-Like Peptide-1 Receptor Agonists</NameOfSubstance></Chemical><Chemical><RegistryNumber>9100L32L2N</RegistryNumber><NameOfSubstance UI="D008687">Metformin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="Y">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077203" MajorTopicYN="N">Sodium-Glucose Transporter 2 Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054873" MajorTopicYN="N">Dipeptidyl-Peptidase IV Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013453" MajorTopicYN="N">Sulfonylurea Compounds</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000097789" MajorTopicYN="N">Glucagon-Like Peptide-1 Receptor Agonists</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008687" MajorTopicYN="N">Metformin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="N">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001786" MajorTopicYN="N">Blood Glucose</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000096962" MajorTopicYN="N">Treatment Effect Heterogeneity</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clinical epidemiology</Keyword><Keyword MajorTopicYN="N">Glucose-lowering drug classes</Keyword><Keyword MajorTopicYN="N">Heterogeneity of treatment effect</Keyword><Keyword MajorTopicYN="N">LEGEND-T2DM</Keyword><Keyword MajorTopicYN="N">Real-world evidence</Keyword><Keyword MajorTopicYN="N">Type 2 diabetes</Keyword></KeywordList><CoiStatement>Declaration of competing interest David M. D&#xe1;vila-Garc&#xed;a: none; Thomas Falconer: none; Nicole Pratt: none; Karthik Natarajan: none; George Hripcsak: research grants from the US National Institutes of Health; contracts from Janssen Research and Development.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>10</Day><Hour>0</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>1</Day><Hour>4</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>29</Day><Hour>18</Hour><Minute>2</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40582069</ArticleId><ArticleId IdType="doi">10.1016/j.jdiacomp.2025.109114</ArticleId><ArticleId IdType="pii">S1056-8727(25)00167-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40588922</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>01</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>328</Volume><PubDate><Year>2025</Year><Month>Jun</Month><Day>26</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Harmonizing Electronic Health Records to the OMOP Common Data Model: A Case Study on Surgical Complications.</ArticleTitle><Pagination><StartPage>261</StartPage><EndPage>265</EndPage><MedlinePgn>261-265</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI250715</ELocationID><Abstract><AbstractText>This study details the transformation of Asunci&#xf3;n Klinika's EHR data, including surgical records, into the OMOP Common Data Model 5.4 standard. The harmonized dataset, which includes patient demographics, diagnoses, procedures, prescribed drugs and laboratory tests, facilitates large-scale studies and comparative analysis. Extensive structural and conceptual mapping ensures high compatibility with key OMOP tables, making the data compatible with global research networks. By using standardized vocabularies, this transformation lays the foundation for powerful predictive models and decision support systems, with applications in surgical complications and broader clinical outcomes, paving the way for more informed, data-driven healthcare solutions.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mendez</LastName><ForeName>Naroa</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Vicomtech Foundation, Basque Research and Technology Alliance, Donostia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alonso</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Vicomtech Foundation, Basque Research and Technology Alliance, Donostia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Computer Architecture and Technology, University of the Basque Country (UPV/EHU), Donostia - San Sebasti&#xe1;n, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Espejo</LastName><ForeName>Mois&#xe9;s David</ForeName><Initials>MD</Initials><AffiliationInfo><Affiliation>Asuncion Klinika, Tolosa, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Universidad de Alcal&#xe1;, Facultad de Medicina y Ciencias de la Salud, Departamento de Biolog&#xed;a de Sistemas, Alcal&#xe1; de Henares, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf3;pez</LastName><ForeName>Maite</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Asuncion Klinika, Tolosa, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alonso-Arce</LastName><ForeName>Maykel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>STT Ingenier&#xed;a y Sistemas SL (STT Systems), Donostia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rojo</LastName><ForeName>E&#xf1;aut</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>STT Ingenier&#xed;a y Sistemas SL (STT Systems), Donostia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garin-Muga</LastName><ForeName>Alba</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Vicomtech Foundation, Basque Research and Technology Alliance, Donostia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Biogipuzkoa Health Research Institute, E-Health Group, 20014 San Sebasti&#xe1;n (Spain).</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName><QualifierName UI="Q000458" MajorTopicYN="N">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="Y">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008498" MajorTopicYN="Y">Medical Record Linkage</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Electronic Health Records</Keyword><Keyword MajorTopicYN="N">OMOP</Keyword><Keyword MajorTopicYN="N">data harmonization</Keyword><Keyword MajorTopicYN="N">surgical complications</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>1</Day><Hour>9</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>1</Day><Hour>9</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>1</Day><Hour>1</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40588922</ArticleId><ArticleId IdType="doi">10.3233/SHTI250715</ArticleId><ArticleId IdType="pii">SHTI250715</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40595474</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>02</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>04</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>02</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Ethnic disparities in COVID-19 mortality and cardiovascular disease in England and Wales between 2020-2022.</ArticleTitle><Pagination><StartPage>6059</StartPage><MedlinePgn>6059</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">6059</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-025-59951-4</ELocationID><Abstract><AbstractText>An increased risk of&#xa0;COVID-19 mortality risk among certain ethnic groups&#xa0;is well-reported, however data on ethnic disparities in COVID-19-related cardiovascular disease (CVD) &#xa0;are lacking. We estimated age-standardised incidence rates and adjusted hazard ratios for 28-day mortality and 30-day CVD by sex&#xa0;for individual ethnicity groups from England and Wales, using linked health and administrative data. We studied 6-level census-based ethnicity group classification, 10-level classification (only for Wales), and 19-level classification as well as any ethnicity sub-groups comprising &gt;1000 individuals each (only for England). COVID-19 28-day mortality and 30-day CVD risk was increased in most non-White ethnic groups in England, and Asian population in Wales, between 23rd January 2020 and 1st April 2022. English data show mortality decreased during the Omicron variant's dominance, whilst CVD risk [95% confidence interval] remained elevated for certain ethnic groups when compared to White populations (January-April 2022): by 120% [28-280%] in White and Asian men and 58% [32-90%] in Pakistan men, as compared to White British men; and by 75% [13-172%] in Bangladeshi women, 55% [19-102%] in Caribbean women, and 82% [31-153%] in Any Other Ethnic Group women, as compared to White British women. Ethnically diverse populations in the UK&#xa0;remained disproportionately affected by CVD throughout and beyond the COVID-19 pandemic.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pineda-Moncus&#xed;</LastName><ForeName>Marta</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-0567-0137</Identifier><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allery</LastName><ForeName>Freya</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0002-5580-7237</Identifier><AffiliationInfo><Affiliation>Institute of Health Informatics, 222 Euston Road, London, NW1 2DA. University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UK Research and Innovation Centre for Doctoral Training in AI-enabled Healthcare Systems, University College London Hospitals Biomedical Research Centre, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abbasizanjani</LastName><ForeName>Hoda</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-9575-4758</Identifier><AffiliationInfo><Affiliation>Population Data Science, Swansea University Medical School, Faculty of Medicine, Health &amp; Life Science, Swansea University, Swansea, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Powell</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Population Data Science, Swansea University Medical School, Faculty of Medicine, Health &amp; Life Science, Swansea University, Swansea, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prats-Uribe</LastName><ForeName>Albert</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-1202-9153</Identifier><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Thygesen</LastName><ForeName>Johan H</ForeName><Initials>JH</Initials><Identifier Source="ORCID">0000-0002-7479-3459</Identifier><AffiliationInfo><Affiliation>Institute of Health Informatics, 222 Euston Road, London, NW1 2DA. University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wood</LastName><ForeName>Angela</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-7937-304X</Identifier><AffiliationInfo><Affiliation>British Heart Foundation Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care, and Cambridge Centre for AI in Medicine, University of Cambridge, Cambridge, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>British Heart Foundation Data Science Centre, Health Data Research UK, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tomlinson</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-0903-5395</Identifier><AffiliationInfo><Affiliation>Institute of Health Informatics, 222 Euston Road, London, NW1 2DA. University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Banerjee</LastName><ForeName>Amitava</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-8741-3411</Identifier><AffiliationInfo><Affiliation>Institute of Health Informatics, 222 Euston Road, London, NW1 2DA. University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akbari</LastName><ForeName>Ashley</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-0814-0801</Identifier><AffiliationInfo><Affiliation>Population Data Science, Swansea University Medical School, Faculty of Medicine, Health &amp; Life Science, Swansea University, Swansea, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delmestri</LastName><ForeName>Antonella</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0003-0388-3403</Identifier><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coates</LastName><ForeName>Laura C</ForeName><Initials>LC</Initials><Identifier Source="ORCID">0000-0002-4756-663X</Identifier><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Denaxas</LastName><ForeName>Spiros</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Health Informatics, 222 Euston Road, London, NW1 2DA. University College London, London, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>British Heart Foundation Data Science Centre, Health Data Research UK, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khunti</LastName><ForeName>Kamlesh</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Diabetes Research Centre, Leicester Diabetes Research Centre, University of Leicester, Leicester, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Collins</LastName><ForeName>Gary</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-2772-2316</Identifier><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-3950-6346</Identifier><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery &amp; Sports Medicine, Erasmus MC University Medical Centre Rotterdam, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khalid</LastName><ForeName>Sara</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-2845-5731</Identifier><AffiliationInfo><Affiliation>Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), University of Oxford, Oxford, UK. sara.khalid@ndorms.ox.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>CVD-COVID-UK/COVID-IMPACT Consortium</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="Y">Cardiovascular Diseases</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004739" MajorTopicYN="N" Type="Geographic">England</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005006" MajorTopicYN="Y">Ethnicity</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054624" MajorTopicYN="Y">Health Status Disparities</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014852" MajorTopicYN="N" Type="Geographic">Wales</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D044465" MajorTopicYN="N">White People</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests: K.K. is a chair of the Ethnicity Subgroup of the UK Scientific Advisory Group for Emergences (SAGE), and a member of SAGE. This work was also supported by The Alan Turing Institute via &#x2018;Towards Turing 2.0&#x2019; EPSRC Grant Funding. DPA&#x2019;s research group has received grant/s from Amgen, Chiesi-Taylor, Lilly, Janssen, Novartis, and UCB Biopharma, and consultancy fees from AstraZeneca and UCB Biopharma. Amgen, Astellas, Janssen, Synapse Management Partners and UCB Biopharma have funded or supported training programmes organised by S.K. and DPA&#x2019;s department. S.K. receives funding support from Amgen BioPharma outside of this work. This research is part of the Data and Connectivity National Core Study, led by Health Data Research UK in partnership with the Office for National Statistics and funded by UK Research and Innovation (grant ref MC_PC_20058). The remaining authors have nothing to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>2</Day><Hour>2</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40595474</ArticleId><ArticleId IdType="pmc">PMC12217090</ArticleId><ArticleId IdType="doi">10.1038/s41467-025-59951-4</ArticleId><ArticleId IdType="pii">10.1038/s41467-025-59951-4</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Baloch, S., Baloch, M. A., Zheng, T. &amp; Pei, X. The Coronavirus Disease 2019 (COVID-19) Pandemic. <i>Tohoku J. Exp. Med.</i><b>250</b>, 271&#x2013;278 (2020).
</Citation><ArticleIdList><ArticleId IdType="pubmed">32321874</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang, X. et al. Epidemiological, comorbidity factors with severity and prognosis of COVID-19: a systematic review and meta-analysis. <i>Aging</i><b>12</b>, 12493&#x2013;12503 (2020).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7377860</ArticleId><ArticleId IdType="pubmed">32658868</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramirez-Soto, M. C., Ortega-Caceres, G. &amp; Arroyo-Hernandez, H. Sex differences in COVID-19 fatality rate and risk of death: An analysis in 73 countries, 2020-2021. <i>Infez. Med.</i><b>29</b>, 402&#x2013;407 (2021).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8805484</ArticleId><ArticleId IdType="pubmed">35146345</ArticleId></ArticleIdList></Reference><Reference><Citation>Doerre, A. &amp; Doblhammer, G. The influence of gender on COVID-19 infections and mortality in Germany: Insights from age- and gender-specific modeling of contact rates, infections, and deaths in the early phase of the pandemic. <i>PLoS ONE</i><b>17</b>, e0268119 (2022).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9075634</ArticleId><ArticleId IdType="pubmed">35522614</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabiao, J. et al. Why do men have worse COVID-19-related outcomes? A systematic review and meta-analysis with sex adjusted for age. <i>Braz. J. Med. Biol. Res.</i><b>55</b>, e11711 (2022).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8856598</ArticleId><ArticleId IdType="pubmed">35195196</ArticleId></ArticleIdList></Reference><Reference><Citation>Danielsen, A. C. et al. Sex disparities in COVID-19 outcomes in the United States: Quantifying and contextualizing variation. <i>Soc. Sci. Med.</i><b>294</b>, 114716 (2022).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8743486</ArticleId><ArticleId IdType="pubmed">35042136</ArticleId></ArticleIdList></Reference><Reference><Citation>Office for National Statistics. <i>Updating ethnic contrasts in deaths involving the coronavirus (COVID-19)</i>, <i>England</i>: <i>24 January 2020 to 31 March 2021</i>https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/articles/updatingethniccontrastsindeathsinvolvingthecoronaviruscovid19englandandwales/24january2020to31march2021 (2021).</Citation></Reference><Reference><Citation>Commission on Race and Ethnic Disparities. <i>The report of the Commission on Race and Ethnic Disparities</i>, https://www.gov.uk/government/publications/the-report-of-the-commission-on-race-and-ethnic-disparities/health#covid-19 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33836999</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayoubkhani, D. et al. Ethnic-minority groups in England and Wales-factors associated with the size and timing of elevated COVID-19 mortality: a retrospective cohort study linking census and death records. <i>Int. J. Epidemiol.</i><b>49</b>, 1951&#x2013;1962 (2021).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7799112</ArticleId><ArticleId IdType="pubmed">33349855</ArticleId></ArticleIdList></Reference><Reference><Citation>Nafilyan, V. et al. Ethnic differences in COVID-19 mortality during the first two waves of the Coronavirus Pandemic: a nationwide cohort study of 29 million adults in England. <i>Eur. J. Epidemiol.</i><b>36</b>, 605&#x2013;617 (2021).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8206182</ArticleId><ArticleId IdType="pubmed">34132940</ArticleId></ArticleIdList></Reference><Reference><Citation>Basu-Ray, I., Almaddah, N. K., Adeboye, A. &amp; Soos, M. P. in <i>StatPearls</i> (StatPearls Publishing Copyright &#xa9; 2022, StatPearls Publishing LLC., 2022).</Citation></Reference><Reference><Citation>Singh, A. K. et al. Prevalence of co-morbidities and their association with mortality in patients with COVID-19: A systematic review and meta-analysis. <i>Diabetes Obes. Metab.</i><b>22</b>, 1915&#x2013;1924 (2020).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7361304</ArticleId><ArticleId IdType="pubmed">32573903</ArticleId></ArticleIdList></Reference><Reference><Citation>Ali, R., Raleigh, V., Majeed, A. &amp; Khunti, K. Life expectancy by ethnic group in England. <i>BMJ</i><b>375</b>, e068537 (2021).
</Citation><ArticleIdList><ArticleId IdType="pubmed">34753743</ArticleId></ArticleIdList></Reference><Reference><Citation>Islam, S. J. et al. County-Level Social Vulnerability is Associated With In-Hospital Death and Major Adverse Cardiovascular Events in Patients Hospitalized With COVID-19: An Analysis of the American Heart Association COVID-19 Cardiovascular Disease Registry. <i>Circ. Cardiovasc. Qual. Outcomes</i><b>15</b>, e008612 (2022).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9387665</ArticleId><ArticleId IdType="pubmed">35862003</ArticleId></ArticleIdList></Reference><Reference><Citation>Pineda-Moncusi, M. et al. Ethnicity data resource in population-wide health records: completeness, coverage and granularity of diversity. <i>Sci. Data</i><b>11</b>, 221 (2024).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10883937</ArticleId><ArticleId IdType="pubmed">38388690</ArticleId></ArticleIdList></Reference><Reference><Citation>Katikireddi, S. V. et al. Unequal impact of the COVID-19 crisis on minority ethnic groups: a framework for understanding and addressing inequalities. <i>J. Epidemiol. Community Health</i><b>75</b>, 970&#x2013;974 (2021).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8458062</ArticleId><ArticleId IdType="pubmed">33883198</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, S. &amp; Mak, H. W. Generational health improvement or decline? Exploring generational differences of British ethnic minorities in six physical health outcomes. <i>Ethn. Health</i><b>25</b>, 1041&#x2013;1054 (2020).
</Citation><ArticleIdList><ArticleId IdType="pubmed">29699405</ArticleId></ArticleIdList></Reference><Reference><Citation>Eto, F. et al. Ethnic differences in early onset multimorbidity and associations with health service use, long-term prescribing, years of life lost, and mortality: A cross-sectional study using clustering in the UK Clinical Practice Research Datalink. <i>PLoS Med.</i><b>20</b>, e1004300 (2023).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10610074</ArticleId><ArticleId IdType="pubmed">37889900</ArticleId></ArticleIdList></Reference><Reference><Citation>B&#xe9;cares L. Which ethnic groups have the poorest health? In <i>Ethnic Identity and Inequalities in Britain: The Dynamics of Diversity</i>. (eds Jivraj, S. &amp; Simpson, L.) 123&#x2013;140 (Bristol University Press, 2015).</Citation></Reference><Reference><Citation>Matthews, D. The impact of ethnicity on health inequalities. <i>Nurs</i><b>111</b>, 18&#x2013;20 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">26665383</ArticleId></ArticleIdList></Reference><Reference><Citation>Asthana, S. et al. Inequity in cardiovascular care in the English National Health Service (NHS): a scoping review of the literature. <i>Health Soc. Care Community</i><b>26</b>, 259&#x2013;272 (2018).
</Citation><ArticleIdList><ArticleId IdType="pubmed">27747961</ArticleId></ArticleIdList></Reference><Reference><Citation>Watkinson, R. E., Sutton, M. &amp; Turner, A. J. Ethnic inequalities in health-related quality of life among older adults in England: secondary analysis of a national cross-sectional survey. <i>Lancet Public Health</i><b>6</b>, e145&#x2013;e154 (2021).
</Citation><ArticleIdList><ArticleId IdType="pubmed">33516278</ArticleId></ArticleIdList></Reference><Reference><Citation>Office for National Statistics. <i>Coronavirus (COVID-19) and the different effects on men and women in the UK, March 2020 to February 2021</i>https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19andthedifferenteffectsonmenandwomenintheukmarch2020tofebruary2021/2021-03-10 (2021).</Citation></Reference><Reference><Citation>Bots, S. H., Peters, S. A. E. &amp; Woodward, M. Sex differences in coronary heart disease and stroke mortality: a global assessment of the effect of ageing between 1980 and 2010. <i>BMJ Glob. Health</i><b>2</b>, e000298 (2017).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5435266</ArticleId><ArticleId IdType="pubmed">28589033</ArticleId></ArticleIdList></Reference><Reference><Citation>Wise, J. Covid-19: Death rate gap for ethnic minorities closes, ONS data show. <i>BMJ</i><b>380</b>, p448 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36822639</ArticleId></ArticleIdList></Reference><Reference><Citation>Carethers, J. M. Insights into disparities observed with COVID-19. <i>J. Intern. Med.</i><b>289</b>, 463&#x2013;473 (2021).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9325576</ArticleId><ArticleId IdType="pubmed">33164230</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison, S. L., Buckley, B. J. R., Rivera-Caravaca, J. M., Zhang, J. &amp; Lip, G. Y. H. Cardiovascular risk factors, cardiovascular disease, and COVID-19: an umbrella review of systematic reviews. <i>Eur. Heart J. Qual. Care Clin. Outcomes</i><b>7</b>, 330&#x2013;339 (2021).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8294691</ArticleId><ArticleId IdType="pubmed">34107535</ArticleId></ArticleIdList></Reference><Reference><Citation>Bunsawat, K., Grosicki, G. J., Jeong, S. &amp; Robinson, A. T. Racial and ethnic disparities in cardiometabolic disease and COVID-19 outcomes in White, Black/African American, and Latinx populations: Physiological underpinnings. <i>Prog. Cardiovasc. Dis.</i><b>71</b>, 11&#x2013;19 (2022).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9050188</ArticleId><ArticleId IdType="pubmed">35490869</ArticleId></ArticleIdList></Reference><Reference><Citation>Khunti, K., Routen, A., Banerjee, A. &amp; Pareek, M. The need for improved collection and coding of ethnicity in health research. <i>J. Public Health</i><b>43</b>, e270&#x2013;e272 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">33283239</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathur, R. et al. Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform. <i>Lancet</i><b>397</b>, 1711&#x2013;1724 (2021).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8087292</ArticleId><ArticleId IdType="pubmed">33939953</ArticleId></ArticleIdList></Reference><Reference><Citation>GOV.UK. <i>Timeline of testing in the UK</i>, https://www.gov.uk/government/publications/technical-report-on-the-covid-19-pandemic-in-the-uk/chapter-6-testing#timeline-of-testing (2023).</Citation></Reference><Reference><Citation>Wood, A. et al. Linked electronic health records for research on a nationwide cohort of more than 54 million people in England: data resource. <i>BMJ</i><b>373</b>, n826 (2021).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8413899</ArticleId><ArticleId IdType="pubmed">33827854</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones, K. H., Ford, D. V., Thompson, S. &amp; Lyons, R. A. A Profile of the SAIL Databank on the UK Secure Research Platform. <i>Int. J. Popul Data Sci.</i><b>4</b>, 1134 (2019).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8142954</ArticleId><ArticleId IdType="pubmed">34095541</ArticleId></ArticleIdList></Reference><Reference><Citation>Office for National Statistics. <i>Updating ethnic contrasts in deaths involving the coronavirus (COVID-19), England and Wales: deaths occurring 2 March to 28 July 2020</i>, https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/articles/updatingethniccontrastsindeathsinvolvingthecoronaviruscovid19englandandwales/deathsoccurring2marchto28july2020 (2021).</Citation></Reference><Reference><Citation>Scientific Advisory Group for Emergencies. <i>COVID-19 Ethnicity subgroup: Interpreting differential health outcomes among minority ethnic groups in wave 1 and 2, 24 March 2021</i>, https://www.gov.uk/government/publications/covid-19-ethnicity-subgroup-interpreting-differential-health-outcomes-among-minority-ethnic-groups-in-wave-1-and-2-24-march-2021/covid-19-ethnicity-subgroup-interpreting-differential-health-outcomes-among-minority-ethnic-groups-in-wave-1-and-2-24-march-2021#executive-summary (2022).</Citation></Reference><Reference><Citation>Rachel Woods, A. C. <i>User guide to mortality statistics</i>, https://www.ons.gov.uk/peoplepopulationandcommunity/birthsdeathsandmarriages/deaths/methodologies/userguidetomortalitystatisticsjuly2017#introduction (2022).</Citation></Reference><Reference><Citation>NHS-Digital. <i>Master Person Service (MPS)</i>, &lt;https://digital.nhs.uk/services/master-person-service (2025).</Citation></Reference><Reference><Citation>Lyons, J. et al. Understanding and responding to COVID-19 in Wales: protocol for a privacy-protecting data platform for enhanced epidemiology and evaluation of interventions. <i>BMJ Open</i><b>10</b>, e043010 (2020).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7580065</ArticleId><ArticleId IdType="pubmed">33087383</ArticleId></ArticleIdList></Reference><Reference><Citation>Akbari, A. et al. Exploring ethnicity dynamics in Wales: a longitudinal population-scale linked data study and development of a harmonised ethnicity spine. <i>BMJ Open</i><b>14</b>, e077675 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11733787</ArticleId><ArticleId IdType="pubmed">39097317</ArticleId></ArticleIdList></Reference><Reference><Citation>Lillie, P. J. et al. Novel coronavirus disease (Covid-19): The first two patients in the UK with person to person transmission. <i>J. Infect.</i><b>80</b>, 578&#x2013;606 (2020).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7127394</ArticleId><ArticleId IdType="pubmed">32119884</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavrentieva, A., Kaimakamis, E., Voutsas, V. &amp; Bitzani, M. An observational study on factors associated with ICU mortality in Covid-19 patients and critical review of the literature. <i>Sci. Rep.</i><b>13</b>, 7804 (2023).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10182846</ArticleId><ArticleId IdType="pubmed">37179397</ArticleId></ArticleIdList></Reference><Reference><Citation>Thygesen, J. H. et al. Prevalence and demographics of 331 rare diseases and associated COVID-19-related mortality among 58 million individuals: a nationwide retrospective observational study. <i>Lancet Digit Health</i><b>7</b>, e145&#x2013;e156 (2025).
</Citation><ArticleIdList><ArticleId IdType="pubmed">39890245</ArticleId></ArticleIdList></Reference><Reference><Citation>Office for National Statistics. <i>National identity, ethnic group, language and religion question development for Census 2021.</i>https://www.ons.gov.uk/census/censustransformationprogramme/questiondevelopment/nationalidentityethnicgrouplanguageandreligionquestiondevelopmentforcensus2021 (2022).</Citation></Reference><Reference><Citation>National-Health-Service. <i>NHS Data Model and Dictionary.</i>https://www.datadictionary.nhs.uk/ (2025).</Citation></Reference><Reference><Citation>NHS Digital. SNOMED CT https://digital.nhs.uk/services/terminology-and-classifications/snomed-ct (2025).</Citation></Reference><Reference><Citation>Khunti, K., Routen, A., Banerjee, A. &amp; Pareek, M. The need for improved collection and coding of ethnicity in health research. <i>J. Public Health</i><b>43</b>, e270&#x2013;e272 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">33283239</ArticleId></ArticleIdList></Reference><Reference><Citation>Kontopantelis, E. et al. Geographical epidemiology of health and overall deprivation in England, its changes and persistence from 2004 to 2015: a longitudinal spatial population study. <i>J. Epidemiol. Community Health</i><b>72</b>, 140&#x2013;147 (2018).
</Citation><ArticleIdList><ArticleId IdType="pubmed">29263178</ArticleId></ArticleIdList></Reference><Reference><Citation>Ministry of Housing, Communities &amp; Local. English indices of deprivation 2019: research report. (2019).</Citation></Reference><Reference><Citation>NHS England. <i>Equality, diversity and health inequalities: Deprivation - What is deprivation health?</i>https://www.england.nhs.uk/about/equality/equality-hub/national-healthcare-inequalities-improvement-programme/what-are-healthcare-inequalities/deprivation/ (2022).</Citation></Reference><Reference><Citation>The PHI Lab, U. o. O. <i>Project Patient and Public Involvement: &#x2018;Be proud of your ethnicity&#x2019;</i>, https://www.ndorms.ox.ac.uk/research/research-groups/planetary-health-informatics/projects/ethnicity-equity-and-ai-study/project-patient-and-public-involvement (2024).</Citation></Reference><Reference><Citation>Whitaker, M. et al. Variant-specific symptoms of COVID-19 in a study of 1,542,510 adults in England. <i>Nat. Commun.</i><b>13</b>, 6856 (2022).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9651890</ArticleId><ArticleId IdType="pubmed">36369151</ArticleId></ArticleIdList></Reference><Reference><Citation>Hippisley-Cox, J., Coupland, C. &amp; Brindle, P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. <i>BMJ</i><b>357</b>, j2099 (2017).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5441081</ArticleId><ArticleId IdType="pubmed">28536104</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40599890</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>03</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2949-7612</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>3</Issue><PubDate><Year>2025</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Mayo Clinic proceedings. Digital health</Title><ISOAbbreviation>Mayo Clin Proc Digit Health</ISOAbbreviation></Journal><ArticleTitle>Implementation and Updating of Clinical Prediction Models: A Systematic Review.</ArticleTitle><Pagination><StartPage>100228</StartPage><MedlinePgn>100228</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100228</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.mcpdig.2025.100228</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To summarize the implementation approaches and updating methods of clinically implemented models and consecutively advise researchers on the implementation and updating.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="UNASSIGNED">We included studies describing the implementation of prognostic binary prediction models in a clinical setting. We retrieved articles from Embase, Medline, and Web of Science from January 1, 2010, to January 1, 2024. We performed data extraction, based on Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis and Prediction Model Risk of Bias Assessment guidelines, and summarized.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The search yielded 1872 articles. Following screening, 37 articles, describing 56 prediction models, were eligible for inclusion. The overall risk of bias was high in 86% of publications. In model development and internal validation, 32% of the models was assessed for calibration. External validation was performed for 27% of the models. Most models were implemented into the hospital information system (63%), followed by a web application (32%) and a patient decision aid tool (5%). Moreover, 13% of models have been updated following implementation.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Impact assessments generally showed successful model implementation and the ability to improve patient care, despite not fully adhering to prediction modeling best practice. Both impact assessment and updating could play a key role in identifying and lowering bias in models.</AbstractText><CopyrightInformation>&#xa9; 2025 The Authors.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Saelmans</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seinen</LastName><ForeName>Tom</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pera</LastName><ForeName>Victor</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Markus</LastName><ForeName>Aniek F</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fridgeirsson</LastName><ForeName>Egill</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>John</LastName><ForeName>Luis H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schiphof-Godart</LastName><ForeName>Lieke</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rijnbeek</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reps</LastName><ForeName>Jenna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Janssen Research and Development, Titusville, NJ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Ross</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>05</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Mayo Clin Proc Digit Health</MedlineTA><NlmUniqueID>9918662584506676</NlmUniqueID><ISSNLinking>2949-7612</ISSNLinking></MedlineJournalInfo><CoiStatement>Dr Reps is an employee and shareholder of Johnson &amp; Johnson. All authors work for a research group at Erasmus University Medical Center that receives/received an unconditional grant for methodological research by Johnson &amp; Johnson. The grant is for the institute.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>2</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>2</Day><Hour>5</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>5</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40599890</ArticleId><ArticleId IdType="pmc">PMC12212251</ArticleId><ArticleId IdType="doi">10.1016/j.mcpdig.2025.100228</ArticleId><ArticleId IdType="pii">S2949-7612(25)00035-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Stiggelbout A.M., van der Weijden T., de Wit M.P., et al. Shared decision making: really putting patients at the centre of healthcare. BMJ. 2012;344 doi: 10.1136/bmj.e256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.e256</ArticleId><ArticleId IdType="pubmed">22286508</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrell F.J. Springer; 2001. Regression Modeling Strategies With Applications to Linear Models, Logistic Regression, and Survival Analysis.</Citation></Reference><Reference><Citation>Moons K.G.M., Royston P., Vergouwe Y., Grobbee D.E., Altman D.G. Prognosis and prognostic research: what, why and how? BMJ. 2009;338 doi: 10.1136/bmj.b375.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.b375</ArticleId><ArticleId IdType="pubmed">19237405</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyerberg E. Springer; 2009. Clinical Prediction Models: A Practical Approach to Development, Validation, and Updating.</Citation></Reference><Reference><Citation>Steyerberg E.W., Moons K.G., van der Windt D.A., et al. Prognosis Research Strategy (PROGRESS) 3: prognostic model research. PLoS Med. 2013;10(2) doi: 10.1371/journal.pmed.1001381.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1001381</ArticleId><ArticleId IdType="pmc">PMC3564751</ArticleId><ArticleId IdType="pubmed">23393430</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Sande D., van Genderen M.E., Huiskens J., Gommers D., van Bommel J. Moving from bytes to bedside: a systematic review on the use of artificial intelligence in the intensive care unit. Intensive Care Med. 2021;47(7):750&#x2013;760. doi: 10.1007/s00134-021-06446-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-021-06446-7</ArticleId><ArticleId IdType="pmc">PMC8178026</ArticleId><ArticleId IdType="pubmed">34089064</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaid A., Sawant A., Suarez-Farinas M., et al. Implications of the use of artificial intelligence predictive models in health care settings: a simulation study. Ann Intern Med. 2023;176(10):1358&#x2013;1369. doi: 10.7326/M23-0949.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M23-0949</ArticleId><ArticleId IdType="pubmed">37812781</ArticleId></ArticleIdList></Reference><Reference><Citation>Damen J.A., Hooft L., Schuit E., et al. Prediction models for cardiovascular disease risk in the general population: systematic review. BMJ. 2016;353 doi: 10.1136/bmj.i2416.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.i2416</ArticleId><ArticleId IdType="pmc">PMC4868251</ArticleId><ArticleId IdType="pubmed">27184143</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins G., Mallett S., Omar O., Yu L.M. Developing risk prediction models for type 2 diabetes: a systematic review of methodology and reporting. BMC Med. 2011;9:103. doi: 10.1186/1741-7015-9-103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1741-7015-9-103</ArticleId><ArticleId IdType="pmc">PMC3180398</ArticleId><ArticleId IdType="pubmed">21902820</ArticleId></ArticleIdList></Reference><Reference><Citation>Moorthie S. What is clinical utility? PHG Foundation. 2021. https://www.phgfoundation.org/explainer/clinical-utility</Citation></Reference><Reference><Citation>Vickers A.J., van Calster B., Steyerberg E.W. A simple, step-by-step guide to interpreting decision curve analysis. Diagn Progn Res. 2019;3:18. doi: 10.1186/s41512-019-0064-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41512-019-0064-7</ArticleId><ArticleId IdType="pmc">PMC6777022</ArticleId><ArticleId IdType="pubmed">31592444</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyerberg E.W., Vickers A.J., Cook N.R., et al. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology. 2010;21(1):128&#x2013;138. doi: 10.1097/EDE.0b013e3181c30fb2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0b013e3181c30fb2</ArticleId><ArticleId IdType="pmc">PMC3575184</ArticleId><ArticleId IdType="pubmed">20010215</ArticleId></ArticleIdList></Reference><Reference><Citation>Binuya M.A.E., Engelhardt E.G., Schats W., Schmidt M.K., Steyerberg E.W. Methodological guidance for the evaluation and updating of clinical prediction models: a systematic review. BMC Med Res Methodol. 2022;22(1):316. doi: 10.1186/s12874-022-01801-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12874-022-01801-8</ArticleId><ArticleId IdType="pmc">PMC9742671</ArticleId><ArticleId IdType="pubmed">36510134</ArticleId></ArticleIdList></Reference><Reference><Citation>Castillo D. What is covariate shift? Seldon. 2021 https://www.seldon.io/what-is-covariate-shift</Citation></Reference><Reference><Citation>Finlayson S.G., Subbaswamy A., Singh K., et al. The clinician and dataset shift in artificial intelligence. N Engl J Med. 2021;385(3):283&#x2013;286. doi: 10.1056/NEJMc2104626.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2104626</ArticleId><ArticleId IdType="pmc">PMC8665481</ArticleId><ArticleId IdType="pubmed">34260843</ArticleId></ArticleIdList></Reference><Reference><Citation>Implementation and updating of artificial intelligence clinical prediction models: a systematic review. PROSPERO identifier: CRD42024506783. Updated March 25, 2024. https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024506783</Citation></Reference><Reference><Citation>Page M., McKenzie J.E., Bossuyt P.M., et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372 doi: 10.1136/bmj.n71.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n71</ArticleId><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Snell K.I.E., Levis B., Damen J.A.A., et al. Transparent reporting of multivariable prediction models for individual prognosis or diagnosis: checklist for systematic reviews and meta-analyses (TRIPOD-SRMA) BMJ. 2023;381 doi: 10.1136/bmj-2022-073538.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj-2022-073538</ArticleId><ArticleId IdType="pmc">PMC10155050</ArticleId><ArticleId IdType="pubmed">37137496</ArticleId></ArticleIdList></Reference><Reference><Citation>Rethlefsen M., Kirtley S., Waffenschmidt S., et al. PRISMA-S: an extension to the PRISMA Statement for Reporting Literature Searches in Systematic Reviews. Syst Rev. 2021;10(1):39. doi: 10.1186/s13643-020-01542-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13643-020-01542-z</ArticleId><ArticleId IdType="pmc">PMC7839230</ArticleId><ArticleId IdType="pubmed">33499930</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Schoot R., de Bruin J., Schram R., et al. An open source machine learning framework for efficient and transparent systematic reviews. Nat Mach Intell. 2021;3:125&#x2013;133. doi: 10.1038/s42256-020-00287-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s42256-020-00287-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins G.S., Reitsma J.B., Altman D.G., Moons K.G. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. J Clin Epidemiol. 2015;68(2):134&#x2013;143. doi: 10.1016/j.jclinepi.2014.11.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2014.11.010</ArticleId><ArticleId IdType="pubmed">25579640</ArticleId></ArticleIdList></Reference><Reference><Citation>Moons K.G., de Groot J.A., Bouwmeester W., et al. Critical appraisal and data extraction for systematic reviews of prediction modelling studies: the CHARMS checklist. PLoS Med. 2014;11(10) doi: 10.1371/journal.pmed.1001744.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1001744</ArticleId><ArticleId IdType="pmc">PMC4196729</ArticleId><ArticleId IdType="pubmed">25314315</ArticleId></ArticleIdList></Reference><Reference><Citation>Moons K.G.M., Wolff R.F., Riley R.D., et al. PROBAST: a tool to assess risk of bias and applicability of prediction model studies: explanation and elaboration. Ann Intern Med. 2019;170(1):W1&#x2013;W33. doi: 10.7326/M18-1377.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/M18-1377</ArticleId><ArticleId IdType="pubmed">30596876</ArticleId></ArticleIdList></Reference><Reference><Citation>Agius R., Riis-Jensen A.C., Wimmer B., et al. Implementing the data-driven CLL-TIM algorithm into an EPIC-based EHR: proof of concept for automated decision support models. Leuk Lymphoma. 2023;64</Citation></Reference><Reference><Citation>Chang C.H., Chen C.J., Ma Y.S., et al. Real-time artificial intelligence predicts adverse outcomes in acute pancreatitis in the emergency department: comparison with clinical decision rule. Acad Emerg Med. 2023;31(2):149&#x2013;155. doi: 10.1111/acem.14824.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/acem.14824</ArticleId><ArticleId IdType="pubmed">37885118</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi D.H., Lim M.H., Kim K.H., Shin S.D., Hong K.J., Kim S. Development of an artificial intelligence bacteremia prediction model and evaluation of its impact on physician predictions focusing on uncertainty. Sci Rep. 2023;13(1) doi: 10.1038/s41598-023-40708-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-40708-2</ArticleId><ArticleId IdType="pmc">PMC10439897</ArticleId><ArticleId IdType="pubmed">37598221</ArticleId></ArticleIdList></Reference><Reference><Citation>Cronin P., Greenwald J., Crevensten G., Chueh H., Zai A. Development and implementation of a real-time 30-day readmission predictive model. AMIA Annu Symp Proc. 2014;2014:424&#x2013;431.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4419988</ArticleId><ArticleId IdType="pubmed">25954346</ArticleId></ArticleIdList></Reference><Reference><Citation>Dontchos B., Cavallo-Hom K., Lamb L.R., et al. Impact of a deep learning model for predicting mammographic breast density in routine clinical practice. J Am Coll Radiol. 2022;19(9):1021&#x2013;1030. doi: 10.1016/j.jacr.2022.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacr.2022.04.001</ArticleId><ArticleId IdType="pubmed">35618002</ArticleId></ArticleIdList></Reference><Reference><Citation>Esbenshade A.J., Zhao Z., Baird A., et al. Prospective implementation of a risk prediction model for bloodstream infection safely reduces antibiotic usage in febrile pediatric cancer patients without severe neutropenia. J Clin Oncol. 2020;38(27):3150&#x2013;3160. doi: 10.1200/JCO.20.00591.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.20.00591</ArticleId><ArticleId IdType="pmc">PMC7499608</ArticleId><ArticleId IdType="pubmed">32762614</ArticleId></ArticleIdList></Reference><Reference><Citation>Fenn A., Davis C., Buckland D.M., et al. Development of machine learning models to predict admission from emergency department to inpatient and intensive units. Acad Emerg Med. 2021;78(2):290&#x2013;302. doi: 10.1016/j.annemergmed.2021.02.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annemergmed.2021.02.029</ArticleId><ArticleId IdType="pubmed">33972128</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannini H.M., Ginestra J.C., Chivers C., et al. A machine learning algorithm to predict severe sepsis and septic shock: development, implementation, and impact on clinical practice. Crit Care Med. 2019;47(11):1485&#x2013;1492. doi: 10.1097/CCM.0000000000003891.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000003891</ArticleId><ArticleId IdType="pmc">PMC8635476</ArticleId><ArticleId IdType="pubmed">31389839</ArticleId></ArticleIdList></Reference><Reference><Citation>Grout R.W., Hui S.L., Imler T.D., et al. Development, validation, and proof-of-concept implementation of a two-year risk prediction model for undiagnosed atrial fibrillation using common electronic health data (UNAFIED) BMC Med Inf Decis Mak. 2021;21(1):112. doi: 10.1186/s12911-021-01482-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12911-021-01482-1</ArticleId><ArticleId IdType="pmc">PMC8019173</ArticleId><ArticleId IdType="pubmed">33812369</ArticleId></ArticleIdList></Reference><Reference><Citation>de Holanda W.D., Silva L.C., Sobrinho A.A.C. Machine learning models for predicting hospitalization and mortality risks of COVID-19 patients. Expert Syst Appl. 2024;240 doi: 10.1016/j.eswa.2023.122670.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eswa.2023.122670</ArticleId></ArticleIdList></Reference><Reference><Citation>Hsu C.C., Kao Y., Hsu C.C., et al. Using artificial intelligence to predict adverse outcomes in emergency department patients with hyperglycemic crises in real time. BMC Endocr Disord. 2023;23(1):234. doi: 10.1186/s12902-023-01437-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12902-023-01437-9</ArticleId><ArticleId IdType="pmc">PMC10594858</ArticleId><ArticleId IdType="pubmed">37872536</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulsbergen A.F.C., Lo Y.T., Awakimjan I., et al. Survival prediction after neurosurgical resection of brain metastases: a machine learning approach. Neurosurgery. 2022;91(3):381&#x2013;388. doi: 10.1227/neu.0000000000002037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1227/neu.0000000000002037</ArticleId><ArticleId IdType="pmc">PMC10553019</ArticleId><ArticleId IdType="pubmed">35608378</ArticleId></ArticleIdList></Reference><Reference><Citation>Jauk S., Kramer D., Grosauer B., et al. Risk prediction of delirium in hospitalized patients using machine learning: an implementation and prospective evaluation study. J Am Med Inform Assoc. 2020;27(9):1383&#x2013;1392. doi: 10.1093/jamia/ocaa113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocaa113</ArticleId><ArticleId IdType="pmc">PMC7647341</ArticleId><ArticleId IdType="pubmed">32968811</ArticleId></ArticleIdList></Reference><Reference><Citation>Jauk S., Kramer D., Stark G., et al. Development of a machine learning model predicting an ICU admission for patients with elective surgery and its prospective validation in clinical practice. Stud Health Technol Inform. 2019;264:173&#x2013;177. doi: 10.3233/SHTI190206.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/SHTI190206</ArticleId><ArticleId IdType="pubmed">31437908</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeon J., Yu J.Y., Song Y., et al. Prediction tool for renal adaptation after living kidney donation using interpretable machine learning. Front Med (Lausanne) 2023;10 doi: 10.3389/fmed.2023.1222973.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2023.1222973</ArticleId><ArticleId IdType="pmc">PMC10375292</ArticleId><ArticleId IdType="pubmed">37521345</ArticleId></ArticleIdList></Reference><Reference><Citation>Karabacak M., Margetis K. A machine learning-based online prediction tool for predicting short-term postoperative outcomes following spinal tumor resections. Cancers (Basel) 2023;15(3):812. doi: 10.3390/cancers15030812.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers15030812</ArticleId><ArticleId IdType="pmc">PMC9913622</ArticleId><ArticleId IdType="pubmed">36765771</ArticleId></ArticleIdList></Reference><Reference><Citation>Kilpatrick C.R., Elliott M.B., Pratt E., et al. Prevention of inpatient hypoglycemia with a real-time informatics alert. J Hosp Med. 2014;9(10):621&#x2013;626. doi: 10.1002/jhm.2221.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jhm.2221</ArticleId><ArticleId IdType="pubmed">24898687</ArticleId></ArticleIdList></Reference><Reference><Citation>Kiss S., Pinter J., Molontay R., et al. Early prediction of acute necrotizing pancreatitis by artificial intelligence: a prospective cohort-analysis of 2387 cases. Sci Rep. 2022;12(1):7827. doi: 10.1038/s41598-022-11517-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-11517-w</ArticleId><ArticleId IdType="pmc">PMC9098474</ArticleId><ArticleId IdType="pubmed">35552440</ArticleId></ArticleIdList></Reference><Reference><Citation>Koppes D.M., van Hees M.S.F., Koenders V.M., et al. Nationwide implementation of a decision aid on vaginal birth after cesarean: a before and after cohort study. J Perinat Med. 2021;49(7):783&#x2013;790. doi: 10.1515/jpm-2021-0007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/jpm-2021-0007</ArticleId><ArticleId IdType="pubmed">34049425</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar M., Ang L.T., Png H., et al. Automated machine learning (AutoML)-derived preconception predictive risk model to guide early intervention for gestational diabetes mellitus. Int J Environ Res Public Health. 2022;19(11):6792. doi: 10.3390/ijerph19116792.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph19116792</ArticleId><ArticleId IdType="pmc">PMC9180245</ArticleId><ArticleId IdType="pubmed">35682375</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazebnik T., Bahouth Z., Bunimovich-Mendrazitsky S., Halachmi S. Predicting acute kidney injury following open partial nephrectomy treatment using SAT-pruned explainable machine learning model. BMC Med Inf Decis Mak. 2022;22(1):133. doi: 10.1186/s12911-022-01877-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12911-022-01877-8</ArticleId><ArticleId IdType="pmc">PMC9112450</ArticleId><ArticleId IdType="pubmed">35578278</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin S., Barnes S., Toerper M., et al. Machine-learning-based hospital discharge predictions can support multidisciplinary rounds and decrease hospital length-of-stay. BMJ Innov. 2021;7(2):414&#x2013;421. doi: 10.1136/bmjinnov-2020-000420.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjinnov-2020-000420</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y.Y., Wang J.J., Huang S.H., et al. Implementation of a machine learning application in preoperative risk assessment for hip repair surgery. BMC Anesthesiol. 2022;22(1):116. doi: 10.1186/s12871-022-01648-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12871-022-01648-y</ArticleId><ArticleId IdType="pmc">PMC9034633</ArticleId><ArticleId IdType="pubmed">35459103</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu M.Y., Liu C.F., Lin T.C., Ma Y.S. Implementing a novel machine learning system for nutrition education in diabetes mellitus nutritional clinic: predicting 1-year blood glucose control. Bioengineering. 2023;10(10):1139. doi: 10.3390/bioengineering10101139.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/bioengineering10101139</ArticleId><ArticleId IdType="pmc">PMC10604578</ArticleId><ArticleId IdType="pubmed">37892869</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Li C., Xu J., Wu H. A patient-oriented clinical decision support system for CRC risk assessment and preventative care. BMC Med Inf Decis Mak. 2018;18(suppl 5):118. doi: 10.1186/s12911-018-0691-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12911-018-0691-x</ArticleId><ArticleId IdType="pmc">PMC6284274</ArticleId><ArticleId IdType="pubmed">30526596</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupei M.I., Li D., Ingraham N.E., et al. A 12-hospital prospective evaluation of a clinical decision support prognostic algorithm based on logistic regression as a form of machine learning to facilitate decision making for patients with suspected COVID-19. PLos One. 2022;17(1) doi: 10.1371/journal.pone.0262193.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0262193</ArticleId><ArticleId IdType="pmc">PMC8730444</ArticleId><ArticleId IdType="pubmed">34986168</ArticleId></ArticleIdList></Reference><Reference><Citation>Major V.J., Aphinyanaphongs Y. Development, implementation, and prospective validation of a model to predict 60-day end-of-life in hospitalized adults upon admission at three sites. BMC Med Inf Decis Mak. 2020;20(1):214. doi: 10.1186/s12911-020-01235-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12911-020-01235-6</ArticleId><ArticleId IdType="pmc">PMC7487547</ArticleId><ArticleId IdType="pubmed">32894128</ArticleId></ArticleIdList></Reference><Reference><Citation>Saglietto A., Gaita F., Blomstrom-Lundqvist C., et al. AFA-Recur: an ESC EORP AFA-LT registry machine-learning web calculator predicting atrial fibrillation recurrence after ablation. Europace. 2023;25(1):92&#x2013;100. doi: 10.1093/europace/euac145.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/europace/euac145</ArticleId><ArticleId IdType="pmc">PMC10103564</ArticleId><ArticleId IdType="pubmed">36006664</ArticleId></ArticleIdList></Reference><Reference><Citation>Schrempf M., Polat Erdeniz S., Kramer D., et al. Development of an architecture to implement machine learning based risk prediction in clinical routine: a service-oriented approach. Stud Health Technol Inform. 2022;293:262&#x2013;269. doi: 10.3233/SHTI220379.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/SHTI220379</ArticleId><ArticleId IdType="pubmed">35592992</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah N., Konchak C., Chertok D., et al. Clinical Analytics Prediction Engine (CAPE): development, electronic health record integration and prospective validation of hospital mortality, 180-day mortality and 30-day readmission risk prediction models. PLoS One. 2020;15(8) doi: 10.1371/journal.pone.0238065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0238065</ArticleId><ArticleId IdType="pmc">PMC7451512</ArticleId><ArticleId IdType="pubmed">32853223</ArticleId></ArticleIdList></Reference><Reference><Citation>Solomon M., Henao R., Economau-Zavlanos N., et al. Encounter appropriateness score for you model: development and pilot implementation of a predictive model to identify visits appropriate for telehealth in rheumatology. Arthritis Care Res (Hoboken) 2024;76(1):63&#x2013;71. doi: 10.1002/acr.25247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.25247</ArticleId><ArticleId IdType="pubmed">37781782</ArticleId></ArticleIdList></Reference><Reference><Citation>Starr A.J., Julka M., Nethi A., et al. Parkland trauma index of mortality: real-time predictive model for trauma patients. J Orthop Trauma. 2022;36(6):280&#x2013;286. doi: 10.1097/BOT.0000000000002290.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOT.0000000000002290</ArticleId><ArticleId IdType="pubmed">34653106</ArticleId></ArticleIdList></Reference><Reference><Citation>Syed A.H., Khan T. Machine learning-based application for predicting risk of type 2 diabetes mellitus (T2DM) in Saudi Arabia: a retrospective cross-sectional study. IEEE Access. 2020;8:199539&#x2013;199561. doi: 10.1109/ACCESS.2020.3035026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/ACCESS.2020.3035026</ArticleId></ArticleIdList></Reference><Reference><Citation>Tammem&#xe4;gi M.C., Darling G.E., Schmidt H., et al. Selection of individuals for lung cancer screening based on risk prediction model performance and economic factors - The Ontario experience. Lung Cancer. 2021;156:31&#x2013;40. doi: 10.1016/j.lungcan.2021.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lungcan.2021.04.005</ArticleId><ArticleId IdType="pubmed">33887677</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S., Han J., Jung S.Y., et al. Development and implementation of patient-level prediction models of end-stage renal disease for type 2 diabetes patients using fast healthcare interoperability resources. Sci Rep. 2022;12(1) doi: 10.1038/s41598-022-15036-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-15036-6</ArticleId><ArticleId IdType="pmc">PMC9253099</ArticleId><ArticleId IdType="pubmed">35789173</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang K., Shi Q., Sun C., et al. A machine learning model for visualization and dynamic clinical prediction of stroke recurrence in acute ischemic stroke patients: a real-world retrospective study. Front Neurosci. 2023;17 doi: 10.3389/fnins.2023.1130831.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnins.2023.1130831</ArticleId><ArticleId IdType="pmc">PMC10084928</ArticleId><ArticleId IdType="pubmed">37051146</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeh C.C., Lin Y.S., Chen C.C., Liu C.F. Implementing AI models for prognostic predictions in high-risk burn patients. Diagnostics (Basel) 2023;13(18):2984. doi: 10.3390/diagnostics13182984.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/diagnostics13182984</ArticleId><ArticleId IdType="pmc">PMC10528558</ArticleId><ArticleId IdType="pubmed">37761351</ArticleId></ArticleIdList></Reference><Reference><Citation>Andaur Navarro C., Damen J., Takada T., et al. Risk of bias in studies on prediction models developed using supervised machine learning techniques: systematic review. BMJ. 2021;375 doi: 10.1136/bmj.n2281.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n2281</ArticleId><ArticleId IdType="pmc">PMC8527348</ArticleId><ArticleId IdType="pubmed">34670780</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C., Kors J.A., Ioannou S., et al. Trends in the conduct and reporting of clinical prediction model development and validation: a systematic review. J Am Med Inform Assoc. 2022;29(5):983&#x2013;989. doi: 10.1093/jamia/ocac002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocac002</ArticleId><ArticleId IdType="pmc">PMC9006694</ArticleId><ArticleId IdType="pubmed">35045179</ArticleId></ArticleIdList></Reference><Reference><Citation>Andaur Navarro C., Damen J., van Smeden M., et al. Systematic review identifies the design and methodological conduct of studies on machine learning-based prediction models. J Clin Epidemiol. 2023;154:8&#x2013;22. doi: 10.1016/j.jclinepi.2022.11.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2022.11.015</ArticleId><ArticleId IdType="pubmed">36436815</ArticleId></ArticleIdList></Reference><Reference><Citation>Andaur Navarro C.L., Damen J.A.A., Takada T., et al. Completeness of reporting of clinical prediction models developed using supervised machine learning: a systematic review. BMC Med Res Methodol. 2022;22(1):12. doi: 10.1186/s12874-021-01469-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12874-021-01469-6</ArticleId><ArticleId IdType="pmc">PMC8759172</ArticleId><ArticleId IdType="pubmed">35026997</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins G.S., de Groot J.A., Dutton S., et al. External validation of multivariable prediction models: a systematic review of methodological conduct and reporting. BMC Med Res Methodol. 2014;14:40. doi: 10.1186/1471-2288-14-40.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2288-14-40</ArticleId><ArticleId IdType="pmc">PMC3999945</ArticleId><ArticleId IdType="pubmed">24645774</ArticleId></ArticleIdList></Reference><Reference><Citation>Whittle R., Ensor J., Archer L., et al. Extended sample size calculations for evaluation of prediction models using a threshold for classification. Preprint. Posted online June 28, 2024 doi: 10.48550/arXiv.2406.19673. Preprint. Posted online June 28, 2024. arXiv. 2024.</Citation><ArticleIdList><ArticleId IdType="doi">10.48550/arXiv.2406.19673</ArticleId></ArticleIdList></Reference><Reference><Citation>Reps J.M., Williams R.D., You S.C., et al. Feasibility and evaluation of a large-scale external validation approach for patient-level prediction in an international data network: validation of models predicting stroke in female patients newly diagnosed with atrial fibrillation. BMC Med Res Methodol. 2020;20:102. doi: 10.1186/s12874-020-00991-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12874-020-00991-3</ArticleId><ArticleId IdType="pmc">PMC7201646</ArticleId><ArticleId IdType="pubmed">32375693</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong A., Otles E., Donnelly J.P., et al. External validation of a widely implemented proprietary sepsis prediction model in hospitalized patients. JAMA Intern Med. 2021;181(8):1065&#x2013;1070. doi: 10.1001/jamainternmed.2021.2626.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2021.2626</ArticleId><ArticleId IdType="pmc">PMC8218233</ArticleId><ArticleId IdType="pubmed">34152373</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40603892</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>03</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>05</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>02</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Jackalope Plus tool for post-coordination, ontology development, and precise mapping in observational health studies.</ArticleTitle><Pagination><StartPage>23674</StartPage><MedlinePgn>23674</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">23674</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-025-04046-9</ELocationID><Abstract><AbstractText>Accurate mapping of complex health data to the OMOP CDM while preserving clinical nuance remains a challenge. We introduce Jackalope Plus, a novel tool leveraging SNOMED CT post-coordination and a GPT-4o mini LLM, to significantly enhance the precision and efficiency of this process. Our two-step approach combines semantic search with LLM-driven standardization, enabling accurate conversion of intricate medical concepts. Evaluation on benchmark and custom datasets demonstrates that Jackalope Plus identifies correct mappings for over 77.5% of complex terminologies, substantially outperforming Usagi (52.5%) and matching the accuracy of manual mapping while offering up to 50% time savings. Jackalope Plus offers a versatile solution for diverse healthcare data environments. Future work will focus on refining the tool through user feedback integration and addressing ambiguities in overlapping concepts. A free beta version is available for research and feedback. Ethical review confirms no storage of patient-identifiable information.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Trofymenko</LastName><ForeName>Maksym</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>IT company SciForce, Kharkiv, Ukraine. maksym.trofymenko@sciforce.tech.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Taras Shevchenko National University of Kyiv, Kyiv, Ukraine. maksym.trofymenko@sciforce.tech.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Korchmar</LastName><ForeName>Eduard</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>University of London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaduk</LastName><ForeName>Denys</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>IT company SciForce, Kharkiv, Ukraine.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>V. N. Karazin Kharkiv National University, Kharkiv, Ukraine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vikhrak</LastName><ForeName>Marta</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>IT company SciForce, Kharkiv, Ukraine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khilchevskyi</LastName><ForeName>Bohdan</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>IT company SciForce, Kharkiv, Ukraine.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Kharkiv National Medical University, Kharkiv, Ukraine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nesmiian</LastName><ForeName>Tetiana</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>IT company SciForce, Kharkiv, Ukraine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Talapova</LastName><ForeName>Polina</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>IT company SciForce, Kharkiv, Ukraine.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Kharkiv National Medical University, Kharkiv, Ukraine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ved</LastName><ForeName>Max</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>IT company SciForce, Kharkiv, Ukraine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ageeva</LastName><ForeName>Inna</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>IT company SciForce, Kharkiv, Ukraine.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039061" MajorTopicYN="N">Systematized Nomenclature of Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012984" MajorTopicYN="Y">Software</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064229" MajorTopicYN="Y">Biological Ontologies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064887" MajorTopicYN="N">Observational Studies as Topic</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Declarations. Competing interests: The authors are employees of SciForce, the company that developed Jackalope and Jackalope Plus. As such, they may have a financial interest in the success of these tools. This affiliation could potentially influence the study&#x2019;s outcomes. The authors declare that all efforts have been made to conduct and present the research objectively and without bias, adhering to academic integrity and transparency throughout the study. Ethical approval: Not applicable. This article does not contain any studies with human participants or animals performed by any of the authors. Informed consent: Not applicable. This research does not involve human participants or their data.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>12</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>3</Day><Hour>0</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>2</Day><Hour>23</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40603892</ArticleId><ArticleId IdType="pmc">PMC12223214</ArticleId><ArticleId IdType="doi">10.1038/s41598-025-04046-9</ArticleId><ArticleId IdType="pii">10.1038/s41598-025-04046-9</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Cheng, K. Y., Pazmino, S. &amp; Schreiweis, B. ETL Processes for Integrating Healthcare Data - Tools and Architecture Patterns. <i>Stud. Health Technol. Inf.</i> ;<b>299</b>:151&#x2013;156. doi: 10.3233/SHTI220974. (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36325856</ArticleId></ArticleIdList></Reference><Reference><Citation>Reinecke, I., Zoch, M., Reich, C., Sedlmayr, M. &amp; Bathelt, F. The usage of OHDSI OMOP - A scoping review. <i>Stud. Health Technol. Inf.</i><b>283</b>, 95&#x2013;103. 10.3233/SHTI210546 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">34545824</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang, E. &amp; Mostafa, J. The use of SNOMED CT, 2013&#x2013;2020: a literature review. <i>J. Am. Med. Inf. Assoc.</i><b>28</b> (9), 2017&#x2013;2026. 10.1093/jamia/ocab084 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8363812</ArticleId><ArticleId IdType="pubmed">34151978</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI &amp; Usagi Mapping Source Codes to Standard Terminologies [Internet]. Available from: https://ohdsi.github.io/Usagi/index.html. Accessed 01 November 2024.</Citation></Reference><Reference><Citation>Kaduk, D. et al. AI-Enhanced Solution for Mapping Unmappable Concepts [Abstract]. OHDSI Global Symposium. Available from: https://www.ohdsi.org/wp-content/uploads/2023/10/24-Kaduk-report-Denys-Kaduk.pdf. Accessed 01 November 2024 (2023).</Citation></Reference><Reference><Citation>Reich, C. et al. OHDSI standardized Vocabularies-a large-scale centralized reference ontology for international data harmonization. <i>J. Am. Med. Inf. Assoc.</i><b>31</b> (3), 583&#x2013;590. 10.1093/jamia/ocad247 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10873827</ArticleId><ArticleId IdType="pubmed">38175665</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackalope. Official page [Internet]. Available from: https://jackalope.sciforce.tech/. Accessed 01 November 2024.</Citation></Reference><Reference><Citation>Castell-D&#xed;az, J., Mi&#xf1;arro-Gim&#xe9;nez, J. A. &amp; Mart&#xed;nez-Costa, C. Supporting SNOMED CT postcoordination with knowledge graph embeddings. <i>J. Biomed. Inf.</i><b>139</b>, 104297. 10.1016/j.jbi.2023.104297 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36736448</ArticleId></ArticleIdList></Reference><Reference><Citation>Generating Necessary Normal Form Relationships from the OWL Refsets [Internet]. Available from: https://confluence.ihtsdotools.org/display/DOCOWL/2.5.+Generating+Necessary+Normal+Form+Relationships+from+the+OWL+Refsets. Accessed 01 November 2024.</Citation></Reference><Reference><Citation>OHDSI &amp; fact_relationship table. Available from: https://ohdsi.github.io/CommonDataModel/cdm54.html#fact_relationship. Accessed 01 November 2024.</Citation></Reference><Reference><Citation>Stram, M. et al. Logical observation identifiers names and codes for laboratorians. <i>Arch. Pathol. Lab. Med.</i><b>144</b> (2), 229&#x2013;239. 10.5858/arpa.2018-0477-RA (2020).
</Citation><ArticleIdList><ArticleId IdType="pubmed">31219342</ArticleId></ArticleIdList></Reference><Reference><Citation>Fritz, A. ICD-O-3 terminology approved for use with cases diagnosed January 1, 2014 and after. <i>J Registry Manag.</i> Fall <b>40</b>(3), PMID: 24818314 140-3 (2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24818314</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez-Ibarburu, G. et al. ICD-10-PCS extension with ICD-9 procedure codes to support integrated access to clinical legacy data. <i>Int. J. Med. Inf.</i><b>122</b>, 70&#x2013;79. 10.1016/j.ijmedinf.2018.11.002 (2019).</Citation><ArticleIdList><ArticleId IdType="pubmed">30623787</ArticleId></ArticleIdList></Reference><Reference><Citation>Blasini, R., Buchowicz, K. M., Schneider, H., Samans, B. &amp; Sohrabi, K. Implementation of inclusion and exclusion criteria in clinical studies in OHDSI ATLAS software. <i>Sci. Rep.</i><b>13</b> (1), 22457. 10.1038/s41598-023-49560-w (2023).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10725886</ArticleId><ArticleId IdType="pubmed">38105303</ArticleId></ArticleIdList></Reference><Reference><Citation>Korchmar, E., Talapova, P., Kolesnyk, M., Kaduk, D. &amp; Jackalope A software tool for meaningful post-coordination for ETL purposes [Abstract]. European OHDSI Symposium; Data Standardization. Available from: https://www.ohdsi.org/2022showcase-41/. Accessed 01 November 2024. (2022).</Citation></Reference><Reference><Citation>Sanderson, L. A., Caron, C. T., Tan, R. L. &amp; Bett, K. E. A PostgreSQL tripal solution for large-scale genotypic and phenotypic data. <i>Database (Oxford)</i>. <b>2021</b>, baab051. 10.1093/database/baab051 (2021).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8363843</ArticleId><ArticleId IdType="pubmed">34389844</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI. Standardized Vocabularies [Internet]. In: The Book of OHDSI. 1st ed. Available from: https://ohdsi.github.io/TheBookOfOhdsi/StandardizedVocabularies.html. Accessed 01 November 2024.</Citation></Reference><Reference><Citation>Rodr&#xed;guez-Garc&#xed;a, M. &#xc1;. &amp; Hoehndorf, R. Inferring ontology graph structures using OWL reasoning. <i>BMC Bioinform.</i><b>19</b> (1), 7. 10.1186/s12859-017-1999-8 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5756413</ArticleId><ArticleId IdType="pubmed">29304741</ArticleId></ArticleIdList></Reference><Reference><Citation>Python Software Foundation. Python Release Python 3.10.0 [Internet]. Available from: https://www.python.org/downloads/release/python-3100/. Accessed 01 November 2024.</Citation></Reference><Reference><Citation>Pandas Development Team. Pandas [Internet]. Available from: https://pandas.pydata.org/about/index.html. Accessed 01 November 2024.</Citation></Reference><Reference><Citation>SQLAlchemy Documentation. SQLAlchemy [Internet]. Available from: https://docs.sqlalchemy.org/en/20/intro.html. Accessed 01 November 2024.</Citation></Reference><Reference><Citation>ANTLR. ANTLR. ANother Tool for Language Recognition [Internet]. Available from: https://www.antlr.org/about.html. Accessed 01 November 2024.</Citation></Reference><Reference><Citation>NetworkX. NetworkX Documentation: Network Analysis in Python [Internet]. Available from: https://networkx.org/documentation/stable/. Accessed 01 November 2024.</Citation></Reference><Reference><Citation>BLAKE2. BLAKE2: Cryptographic Hash and MAC Function [Internet]. Available from: https://www.blake2.net/. Accessed 01 November 2024.</Citation></Reference><Reference><Citation>Flask Flask Documentation: Web Development Framework for Python [Internet]. Available from: https://flask.palletsprojects.com/en/3.0.x/#user-s-guide. Accessed 01 November 2024.</Citation></Reference><Reference><Citation>Pydantic, P. Data Validation and Settings Management Using Python Type Hints [Internet]. Available from: https://docs.pydantic.dev/latest/. Accessed 01 November 2024.</Citation></Reference><Reference><Citation>W3C. OWL 2 Web Ontology Language: Overview [Internet]. Available from: https://www.w3.org/TR/owl2-overview/. Accessed 01 November 2024.</Citation></Reference><Reference><Citation>OHDSI &amp; Concept_relationship Table OMOP Common Data Model Version 5.4 [Internet]. Available from: https://ohdsi.github.io/CommonDataModel/cdm54.html#concept_relationship. Accessed 01 November 2024.</Citation></Reference><Reference><Citation>OHDSI &amp; Concept_ancestor Table OMOP Common Data Model Version 5.4 [Internet]. Available from: https://ohdsi.github.io/CommonDataModel/cdm54.html#concept_ancestor. Accessed 01 November 2024.</Citation></Reference><Reference><Citation>OHDSI &amp; Concept Table OMOP Common Data Model Version 5.4 [Internet]. Available from: https://ohdsi.github.io/CommonDataModel/cdm54.html#concept. Accessed 01 November 2024.</Citation></Reference><Reference><Citation>OHDSI &amp; Concept_synonym Table OMOP Common Data Model Version 5.4 [Internet]. Available from: https://ohdsi.github.io/CommonDataModel/cdm54.html#concept_synonym. Accessed 01 November 2024.</Citation></Reference><Reference><Citation>OHDSI &amp; Athena Search Terms [Internet]. Available from: https://athena.ohdsi.org/search-terms/terms. Accessed 01 November 2024.</Citation></Reference><Reference><Citation>Kang, M. et al. An Embedding-Based Semantic Similarity Method for Clinical Concept Mapping. Appl Sci [Internet]. Available from: https://pubmed.ncbi.nlm.nih.gov/33987667/. Accessed 01 November 2024.</Citation></Reference><Reference><Citation>Zhou, Y. et al. Transformer-based Drug Concept Mapping with Contextualized Embeddings [Preprint]. medRxiv [Internet]. Available from: https://www.medrxiv.org/content/10.1101/2024.03.21.24304616v1. Accessed 01 November 2024.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40618784</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>25</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-2742</ISSN><JournalIssue CitedMedium="Internet"><Volume>91</Volume><Issue>2</Issue><PubDate><Year>2025</Year><Month>Aug</Month></PubDate></JournalIssue><Title>The Journal of infection</Title><ISOAbbreviation>J Infect</ISOAbbreviation></Journal><ArticleTitle>Impact of climate change and extreme temperature on the incidence of infectious disease among children and adolescents in China: A nationwide case-crossover study with over 8.7 million cases between 2008 and 2019.</ArticleTitle><Pagination><StartPage>106547</StartPage><MedlinePgn>106547</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jinf.2025.106547</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0163-4453(25)00141-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The relationship between ambient temperature and infectious disease incidence lacks comprehensive documentation. Our study, therefore, sought to systematically determine the national association between temperature and the incidence of infectious diseases, categorized into respiratory, gastrointestinal and enterovirus, and vector-borne categories. We aimed to study the association between extreme cold and heat extreme temperature on infectious disease occurrence among children and teenagers, and to evaluate the secular trends in these diseases in relation to temperature extremes.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We accessed the dataset encompassing 8,731,930 cases of 27 distinct infectious diseases, spanning respiratory, gastrointestinal and enterovirus infections, and vector-borne categories, across 507 Chinese cities from 2008 to 2019. Employing a time-stratified case-crossover design, we quantified the association between temperature exposure and the risk of infectious diseases specific to each city. The attributable fractions for temperature-related risks were determined by identifying extreme temperatures exceeding the 90th percentile and falling below the 10th percentile of the respective city-specific temperature distributions, indicative of heat and cold effects. A comparative analysis of these attributable fractions between the periods 2008-2010 and 2017-2019 was conducted to evaluate the secular changes of infectious diseases associated with cold and heat.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="RESULTS">Our analysis revealed significant non-linear associations between temperature and the incidence of specific infectious diseases. Cold temperatures were found to be responsible for 1.35% (95% CI: 1.18 to 1.51%) of respiratory infectious disease cases. In contrast, heat was attributed to a lower proportion, with 0.29% (95% CI: 0.25 to 0.33%) of such cases. Among gastrointestinal and enterovirus diseases, a more substantial 4.93% (95% CI: 4.82 to 5.04%) of cases were linked to heat exposure. Notably, vector-borne diseases demonstrated the highest attributable fraction to heat, with 22.12% (95% CI: 21.82 to 22.41%) of cases affected. Specifically, five diseases-scarlet fever, tuberculosis, mumps, leprosy, and typhus-exhibited an increased incidence associated with cold temperatures. Notably, for scarlet fever, leprosy, and typhus, the attributable fraction escalated from the period 2008-2010 to 2017-2019. However, findings for leprosy should be interpreted with caution due to its low incidence. As for heat-related diseases, thirteen were identified, with the attributable fraction for nine diseases-tuberculosis, pertussis, hand, foot, and mouth disease, infectious diarrhea, dysentery, hepatitis A, typhoid and paratyphoid, dengue, and Japanese encephalitis-showing a marked increase over the same comparative timeframes.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="CONCLUSIONS">The temperature increase observed from 2008-2010 to 2017-2019 has been accompanied by a rising trend in heat-related infections. Among all infectious diseases in Chinese children and adolescents, more than half (13 out of 24) are heat-related, compared to five infections linked to extreme cold. The risk of gastrointestinal and enterovirus infections was associated with extreme hot temperatures, with vector-borne diseases particularly responsive to extreme heat. These findings highlight an urgent requirement for proactive public health measures to address the potential impact of temperature variability on infectious disease outbreaks, safeguarding vulnerable demographics in the context of climate change.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Authors. Published by Elsevier Ltd.. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Li</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Institute of Child and Adolescent Health, School of Public Health, Peking University, National Health Commission Key Laboratory of Reproductive Health, Beijing 100191, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Duanke</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Beijing Institute of Ophthalmology, Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Key Laboratory of Ophthalmology and Visual Sciences, Beijing 100730, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Yuchen</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine and The NIHR Oxford Biomedical Research Centre, NDORMS, University of Oxford, Oxford, England.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wen</LastName><ForeName>Bo</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>School of Public Health and Preventive Medicine, Monash University, Melbourne 3004, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Yao</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>School of Public Health and Preventive Medicine, Monash University, Melbourne 3004, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xing</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute of Child and Adolescent Health, School of Public Health, Peking University, National Health Commission Key Laboratory of Reproductive Health, Beijing 100191, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute of Child and Adolescent Health, School of Public Health, Peking University, National Health Commission Key Laboratory of Reproductive Health, Beijing 100191, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Xinli</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Institute of Child and Adolescent Health, School of Public Health, Peking University, National Health Commission Key Laboratory of Reproductive Health, Beijing 100191, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>RuoLin</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Child and Adolescent Health, School of Public Health, Peking University, National Health Commission Key Laboratory of Reproductive Health, Beijing 100191, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Jianuo</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Child and Adolescent Health, School of Public Health, Peking University, National Health Commission Key Laboratory of Reproductive Health, Beijing 100191, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qin</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute of Child and Adolescent Health, School of Public Health, Peking University, National Health Commission Key Laboratory of Reproductive Health, Beijing 100191, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma</LastName><ForeName>Jun</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Child and Adolescent Health, School of Public Health, Peking University, National Health Commission Key Laboratory of Reproductive Health, Beijing 100191, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geng</LastName><ForeName>Mengjie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Infectious Disease Control and Prevention, Key Laboratory of Surveillance and Early Warning on Infectious Disease, Chinese Center for Disease Control and Prevention, Beijing 102206, China. Electronic address: gengmj@chinacdc.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dong</LastName><ForeName>Yanhui</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute of Child and Adolescent Health, School of Public Health, Peking University, National Health Commission Key Laboratory of Reproductive Health, Beijing 100191, China. Electronic address: dongyanhui@bjmu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Yi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Institute of Child and Adolescent Health, School of Public Health, Peking University, National Health Commission Key Laboratory of Reproductive Health, Beijing 100191, China. Electronic address: songyi@bjmu.edu.cn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine and The NIHR Oxford Biomedical Research Centre, NDORMS, University of Oxford, Oxford, England; Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Junqing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Centre for Statistics in Medicine and The NIHR Oxford Biomedical Research Centre, NDORMS, University of Oxford, Oxford, England.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Infect</MedlineTA><NlmUniqueID>7908424</NlmUniqueID><ISSNLinking>0163-4453</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018592" MajorTopicYN="N">Cross-Over Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003141" MajorTopicYN="Y">Communicable Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057231" MajorTopicYN="Y">Climate Change</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="N">Enterovirus Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006358" MajorTopicYN="N">Hot Temperature</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005767" MajorTopicYN="N">Gastrointestinal Diseases</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055874" MajorTopicYN="Y">Extreme Heat</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012141" MajorTopicYN="N">Respiratory Tract Infections</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Children and adolescents</Keyword><Keyword MajorTopicYN="N">Gastrointestinal and enterovirus diseases</Keyword><Keyword MajorTopicYN="N">Respiratory diseases</Keyword><Keyword MajorTopicYN="N">Temperature</Keyword><Keyword MajorTopicYN="N">Vector-borne diseases</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>31</Day><Hour>20</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>7</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>6</Day><Hour>19</Hour><Minute>35</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40618784</ArticleId><ArticleId IdType="doi">10.1016/j.jinf.2025.106547</ArticleId><ArticleId IdType="pii">S0163-4453(25)00141-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40619597</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1099-1557</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>7</Issue><PubDate><Year>2025</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Pharmacoepidemiology and drug safety</Title><ISOAbbreviation>Pharmacoepidemiol Drug Saf</ISOAbbreviation></Journal><ArticleTitle>Core Concepts in Pharmacoepidemiology: Multi-Database Distributed Data Networks.</ArticleTitle><Pagination><StartPage>e70177</StartPage><MedlinePgn>e70177</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e70177</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/pds.70177</ELocationID><Abstract><AbstractText>Multi-database distributed data networks for post-marketing surveillance of drug safety and effectiveness use two main approaches: common data models (CDMs) and common protocols. Networks such as the U.S. Sentinel System, the Observational Health Data Sciences and Informatics (OHDSI) network, and the Data Analysis and Real-World Interrogation Network in Europe (DARWIN-EU) use a CDM approach in which participating databases are translated into a standardized structure so that a single, common analytic program can be used. On the other hand, the common protocol approach involves applying a single common protocol to site-specific data maintained in their native format, with analytic programs tailored to each data source. Some networks, such as the Canadian Network for Observational Drug Effect Studies (CNODES) and the Asian Pharmacoepidemiology Network (AsPEN), use a variety of approaches for multi-database studies. Regardless of the approach, distributed networks support comprehensive pharmacoepidemiologic studies by leveraging large-scale health data. For example, utilization studies can uncover prescribing trends in different jurisdictions and the impact of policy changes on drug use, while safety and effectiveness studies benefit from large, diverse patient populations, leading to increased precision, representativeness, and potential early detection of safety threats. Challenges include varying coding practices and data heterogeneity, which complicate the standardization of evidence and the comparability and generalizability of findings. In this Core Concepts paper, we review the purpose and different types of distributed data networks in pharmacoepidemiology, discuss their advantages and disadvantages, and describe commonly faced challenges and opportunities in conducting research using multi-database networks.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). Pharmacoepidemiology and Drug Safety published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Haber</LastName><ForeName>Rachelle</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Center for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montr&#xe9;al, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montr&#xe9;al, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Webster-Clark</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Center for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montr&#xe9;al, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, McGill University, Montr&#xe9;al, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pratt</LastName><ForeName>Nicole</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-8730-8910</Identifier><AffiliationInfo><Affiliation>Quality Use of Medicines and Pharmacy Research Center, University of South Australia, Adelaide, South Australia, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barclay</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Nuffield Department of Clinical Neurosciences, University of Oxford, England, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pharmaco- and Device Epidemiology Group, Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xue</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Medicine, School of Clinical Medicine, LKS Faculty of Medicine, University of Hong Kong, Hong Kong, SAR, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pharmacology and Pharmacy, LKS Faculty of Medicine, University of Hong Kong, Hong Kong, SAR, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maro</LastName><ForeName>Judith C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Population Medicine, Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Platt</LastName><ForeName>Robert W</ForeName><Initials>RW</Initials><Identifier Source="ORCID">0000-0002-5981-8443</Identifier><AffiliationInfo><Affiliation>Center for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montr&#xe9;al, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montr&#xe9;al, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, McGill University, Montr&#xe9;al, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-3950-6346</Identifier><AffiliationInfo><Affiliation>Pharmaco- and Device Epidemiology Group, Centre for Statistics in Medicine, Nuffield Department of Orthopaedics, Rheumatology, and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus Medical Centre University, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Filion</LastName><ForeName>Kristian B</ForeName><Initials>KB</Initials><Identifier Source="ORCID">0000-0001-6055-0088</Identifier><AffiliationInfo><Affiliation>Center for Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital, Montr&#xe9;al, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montr&#xe9;al, Quebec, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, McGill University, Montr&#xe9;al, Quebec, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Pharmacoepidemiol Drug Saf</MedlineTA><NlmUniqueID>9208369</NlmUniqueID><ISSNLinking>1053-8569</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D017891" MajorTopicYN="Y">Pharmacoepidemiology</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="Y">Databases, Factual</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011358" MajorTopicYN="Y">Product Surveillance, Postmarketing</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064420" MajorTopicYN="N">Drug-Related Side Effects and Adverse Reactions</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D060735" MajorTopicYN="N">Pharmacovigilance</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">common data model</Keyword><Keyword MajorTopicYN="N">distributed data networks</Keyword><Keyword MajorTopicYN="N">drug effectiveness</Keyword><Keyword MajorTopicYN="N">drug safety</Keyword><Keyword MajorTopicYN="N">real&#x2010;world evidence</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>5</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>11</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>7</Day><Hour>6</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>7</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>6</Day><Hour>23</Hour><Minute>52</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40619597</ArticleId><ArticleId IdType="pmc">PMC12230205</ArticleId><ArticleId IdType="doi">10.1002/pds.70177</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sibbald B., &#x201c;Rofecoxib (Vioxx) Voluntarily Withdrawn From Market,&#x201d; CMAJ 171, no. 9 (2004): 1027&#x2013;1028.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC526313</ArticleId><ArticleId IdType="pubmed">15505253</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xfc;ni P., Nartey L., Reichenbach S., et&#xa0;al., &#x201c;Risk of Cardiovascular Events and Rofecoxib: Cumulative Meta&#x2010;Analysis,&#x201d; Lancet 364, no. 9450 (2004): 2021&#x2013;2029.</Citation><ArticleIdList><ArticleId IdType="pubmed">15582059</ArticleId></ArticleIdList></Reference><Reference><Citation>
FDA
, &#x201c;FDA's Sentinel Initiative,&#x201d; accessed January 20, 2024, https://www.fda.gov/safety/fdas&#x2010;sentinel&#x2010;initiative.</Citation></Reference><Reference><Citation>
Sentinel
, accessed January 15, 2024, https://www.sentinelinitiative.org/.</Citation></Reference><Reference><Citation>
CNODES
, accessed January 15, 2024, https://www.cnodes.ca/.</Citation></Reference><Reference><Citation>Suissa S., Henry D., Caetano P., et&#xa0;al., &#x201c;CNODES: The Canadian Network for Observational Drug Effect Studies,&#x201d; Open Medicine 6, no. 4 (2012): e134.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3654509</ArticleId><ArticleId IdType="pubmed">23687528</ArticleId></ArticleIdList></Reference><Reference><Citation>
Data Analysis and Real World Interrogation Network (DARWIN EU)
, accessed January 15, 2024, https://www.darwin&#x2010;eu.org/.</Citation><ArticleIdList><ArticleId IdType="pubmed">39532529</ArticleId></ArticleIdList></Reference><Reference><Citation>
Asian Pharmacoepidemiology Network (AsPEN)
, accessed January 15, 2024, https://www.aspensig.asia/category/about&#x2010;us/.</Citation></Reference><Reference><Citation>Huang C., Jalbert J., Kimura M., et&#xa0;al., &#x201c;The Asian Pharmacoepidemiology Network (AsPEN): Promoting Multi&#x2010;National Collaboration for Pharmacoepidemiologic Research in Asia,&#x201d; Pharmacoepidemiology and Drug Safety 22 (2013): 700&#x2013;704.</Citation><ArticleIdList><ArticleId IdType="pubmed">23653370</ArticleId></ArticleIdList></Reference><Reference><Citation>
Observational Health Data Sciences and Informatics
, accessed January 15, 2024, https://www.ohdsi.org/.</Citation></Reference><Reference><Citation>
VAC4EU
, &#x201c;Vaccine Monitoring Collaboration for Europe,&#x201d; accessed February, 2025, https://vac4eu.org/overview/.</Citation></Reference><Reference><Citation>
EMA
, &#x201c;Vaccine Monitoring Collaboration for Europe (VAC4EU),&#x201d; accessed February, 2025, https://catalogues.ema.europa.eu/network/37277.</Citation></Reference><Reference><Citation>
SIGMA
, &#x201c;SIGMA Consortium,&#x201d; accessed February, 2025, https://sigmaconsortium.eu/.</Citation></Reference><Reference><Citation>
EMA
, &#x201c;The SIGMA Consortium (SIGMA),&#x201d; accessed February, 2025, https://catalogues.ema.europa.eu/network/45592.</Citation></Reference><Reference><Citation>
University U
, &#x201c;EU PE&amp;PV Research Network,&#x201d; accessed February, 2025, https://www.uu.nl/en/research/eu&#x2010;pepv&#x2010;research&#x2010;network.</Citation></Reference><Reference><Citation>
EMA
, &#x201c;EU Pharmacoepidemiology and Pharmacovigilance (PE&amp;PV) Research Network,&#x201d; accessed February, 2025, https://catalogues.ema.europa.eu/network/2221162.</Citation></Reference><Reference><Citation>Yamaguchi M., Inomata S., Harada S., et&#xa0;al., &#x201c;Establishment of the MID&#x2010;NET Medical Information Database Network as a Reliable and Valuable Database for Drug Safety Assessments in Japan,&#x201d; Pharmacoepidemiology and Drug Safety 28, no. 10 (2019): 1395&#x2013;1404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6851601</ArticleId><ArticleId IdType="pubmed">31464008</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin J. Y., Jung S. Y., Ahn S. H., et&#xa0;al., &#x201c;New Initiatives for Pharmacovigilance in South Korea: Introducing the Korea Institute of Drug Safety and Risk Management (KIDS),&#x201d; Pharmacoepidemiology and Drug Safety 23, no. 11 (2014): 1115&#x2013;1122.</Citation><ArticleIdList><ArticleId IdType="pubmed">25251052</ArticleId></ArticleIdList></Reference><Reference><Citation>Gini R., Sturkenboom M. C., Sultana J., et&#xa0;al., &#x201c;Different Strategies to Execute Multi&#x2010;Database Studies for Medicines Surveillance in Real&#x2010;World Setting: A Reflection on the European Model,&#x201d; Clinical Pharmacology and Therapeutics 108, no. 2 (2020): 228&#x2013;235.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7484985</ArticleId><ArticleId IdType="pubmed">32243569</ArticleId></ArticleIdList></Reference><Reference><Citation>Halvorsen S., Johnsen S. P., Madsen M., et&#xa0;al., &#x201c;Effectiveness and Safety of Non&#x2010;Vitamin K Antagonist Oral Anticoagulants and Warfarin in Atrial Fibrillation: A Scandinavian Population&#x2010;Based Cohort Study,&#x201d; European Heart Journal &#x2010; Quality of Care and Clinical Outcomes 8, no. 5 (2022): 577&#x2013;587.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9382660</ArticleId><ArticleId IdType="pubmed">34244745</ArticleId></ArticleIdList></Reference><Reference><Citation>Kieler H., Artama M., Engeland A., et&#xa0;al., &#x201c;Selective Serotonin Reuptake Inhibitors During Pregnancy and Risk of Persistent Pulmonary Hypertension in the Newborn: Population Based Cohort Study From the Five Nordic Countries,&#x201d; BMJ (Clinical Research Ed.) 344 (2012): d8012.</Citation><ArticleIdList><ArticleId IdType="pubmed">22240235</ArticleId></ArticleIdList></Reference><Reference><Citation>Selmer R., Haglund B., Furu K., et&#xa0;al., &#x201c;Individual&#x2010;Based Versus Aggregate Meta&#x2010;Analysis in Multi&#x2010;Database Studies of Pregnancy Outcomes: The Nordic Example of Selective Serotonin Reuptake Inhibitors and Venlafaxine in Pregnancy,&#x201d; Pharmacoepidemiology and Drug Safety 25, no. 10 (2016): 1160&#x2013;1169.</Citation><ArticleIdList><ArticleId IdType="pubmed">27193296</ArticleId></ArticleIdList></Reference><Reference><Citation>McNeil M. M., Gee J., Weintraub E. S., et&#xa0;al., &#x201c;The Vaccine Safety Datalink: Successes and Challenges Monitoring Vaccine Safety,&#x201d; Vaccine 32, no. 42 (2014): 5390&#x2013;5398.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6727851</ArticleId><ArticleId IdType="pubmed">25108215</ArticleId></ArticleIdList></Reference><Reference><Citation>Weeks J. and Pardee R., &#x201c;Learning to Share Health Care Data: A Brief Timeline of Influential Common Data Models and Distributed Health Data Networks in US Health Care Research,&#x201d; EGEMs 7, no. 1 (2019): 4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6437693</ArticleId><ArticleId IdType="pubmed">30937326</ArticleId></ArticleIdList></Reference><Reference><Citation>Eworuke E., Cosgrove A., Her Q. L., Lyons J. G., Martin D., and Adimadhyam S., &#x201c;Spironolactone Utilization Among Patients With Reduced and Preserved Ejection Fraction Heart Failure,&#x201d; Pharmacoepidemiology 1, no. 3 (2022): 89&#x2013;100.</Citation></Reference><Reference><Citation>Khera R., Dhingra L. S., Aminorroaya A., et&#xa0;al., &#x201c;Multinational Patterns of Second Line Antihyperglycaemic Drug Initiation Across Cardiovascular Risk Groups: Federated Pharmacoepidemiological Evaluation in LEGEND&#x2010;T2DM,&#x201d; BMJ Medicine 2, no. 1 (2023): e000651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10565313</ArticleId><ArticleId IdType="pubmed">37829182</ArticleId></ArticleIdList></Reference><Reference><Citation>Moriello C., Paterson J. M., Reynier P., et&#xa0;al., &#x201c;Off&#x2010;Label Postpartum Use of Domperidone in Canada: A Multidatabase Cohort Study,&#x201d; CMAJ Open 9, no. 2 (2021): E500&#x2013;E509.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8157989</ArticleId><ArticleId IdType="pubmed">33990364</ArticleId></ArticleIdList></Reference><Reference><Citation>Du M., Dernie F., Catal&#xe0; M., et&#xa0;al., &#x201c;Treatment of Systemic Lupus Erythematosus: Analysis of Treatment Patterns in Adult and Paediatric Patients Across Four European Countries,&#x201d; European Journal of Internal Medicine 130 (2024): 106&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">39134452</ArticleId></ArticleIdList></Reference><Reference><Citation>
Roughead E. E., Chan E. W., Choi N.&#x2010;K., et&#xa0;al., &#x201c;Proton Pump Inhibitors and Risk of 
<i>Clostridium difficile</i>
 Infection: A Multi&#x2010;Country Study Using Sequence Symmetry Analysis,&#x201d; Expert Opinion on Drug Safety
15, no. 12 (2016): 1589&#x2013;1595.
</Citation><ArticleIdList><ArticleId IdType="pubmed">27645304</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Ham H. A., Souverein P. C., Klungel O. H., et&#xa0;al., &#x201c;Major Bleeding in Users of Direct Oral Anticoagulants in Atrial Fibrillation: A Pooled Analysis of Results From Multiple Population&#x2010;Based Cohort Studies,&#x201d; Pharmacoepidemiology and Drug Safety 30, no. 10 (2021): 1339&#x2013;1352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8456818</ArticleId><ArticleId IdType="pubmed">34173286</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandler R. E., &#x201c;Nintedanib and Ischemic Colitis: Signal Assessment With the Integrated Use of Two Types of Real&#x2010;World Evidence, Spontaneous Reports of Suspected Adverse Drug Reactions, and Observational Data From Large Health&#x2010;Care Databases,&#x201d; Pharmacoepidemiology and Drug Safety 29, no. 8 (2020): 951&#x2013;957.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7496543</ArticleId><ArticleId IdType="pubmed">32399991</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai E. C. C., Shin J. Y., Kubota K., et&#xa0;al., &#x201c;Comparative Safety of NSAIDs for Gastrointestinal Events in Asia&#x2010;Pacific Populations: A Multi&#x2010;Database, International Cohort Study,&#x201d; Pharmacoepidemiology and Drug Safety 27, no. 11 (2018): 1223&#x2013;1230.</Citation><ArticleIdList><ArticleId IdType="pubmed">30232832</ArticleId></ArticleIdList></Reference><Reference><Citation>Roughead E. E., Chan E. W., Choi N.&#x2010;K., et&#xa0;al., &#x201c;Variation in Association Between Thiazolidinediones and Heart Failure Across Ethnic Groups: Retrospective Analysis of Large Healthcare Claims Databases in Six Countries,&#x201d; Drug Safety 38 (2015): 823&#x2013;831.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4561996</ArticleId><ArticleId IdType="pubmed">26216600</ArticleId></ArticleIdList></Reference><Reference><Citation>Filion K. B., Lix L. M., Oriana H., et&#xa0;al., &#x201c;Sodium Glucose Cotransporter 2 Inhibitors and Risk of Major Adverse Cardiovascular Events: Multi&#x2010;Database Retrospective Cohort Study,&#x201d; BMJ (Clinical Research Ed.) 370 (2020): m3442.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8009082</ArticleId><ArticleId IdType="pubmed">32967856</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard M. A., Schuemie M. J., Krumholz H. M., et&#xa0;al., &#x201c;Comprehensive Comparative Effectiveness and Safety of First&#x2010;Line Antihypertensive Drug Classes: A Systematic, Multinational, Large&#x2010;Scale Analysis,&#x201d; Lancet 394, no. 10211 (2019): 1816&#x2013;1826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6924620</ArticleId><ArticleId IdType="pubmed">31668726</ArticleId></ArticleIdList></Reference><Reference><Citation>Catal&#xe0; M., Mercad&#xe9;&#x2010;Besora N., Kolde R., et&#xa0;al., &#x201c;The Effectiveness of COVID&#x2010;19 Vaccines to Prevent Long COVID Symptoms: Staggered Cohort Study of Data From the UK, Spain, and Estonia,&#x201d; Lancet Respiratory Medicine 12, no. 3 (2024): 225&#x2013;236.</Citation><ArticleIdList><ArticleId IdType="pubmed">38219763</ArticleId></ArticleIdList></Reference><Reference><Citation>Akehurst R., Murphy L. A., Sol&#xe0;&#x2010;Morales O., et&#xa0;al., Using Real&#x2010;World Data in the Health Technology Assessment of Pharmaceuticals: Strengths, Difficulties, and a Pragmatic Way Forward (Elsevier, 2023), 11&#x2013;19.</Citation><ArticleIdList><ArticleId IdType="pubmed">36706952</ArticleId></ArticleIdList></Reference><Reference><Citation>Claire R., Elvidge J., Hanif S., et&#xa0;al., &#x201c;Advancing the Use of Real World Evidence in Health Technology Assessment: Insights From a Multi&#x2010;Stakeholder Workshop,&#x201d; Frontiers in Pharmacology 14 (2024): 1289365.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10811058</ArticleId><ArticleId IdType="pubmed">38283835</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein P., Blommestein H., Al M., et&#xa0;al., &#x201c;Real&#x2010;World Evidence in Health Technology Assessment of High&#x2010;Risk Medical Devices: Fit for Purpose?,&#x201d; Health Economics 31 (2022): 10&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9541731</ArticleId><ArticleId IdType="pubmed">35989520</ArticleId></ArticleIdList></Reference><Reference><Citation>Raman S. R., Man K. K., Bahmanyar S., et&#xa0;al., &#x201c;Trends in Attention&#x2010;Deficit Hyperactivity Disorder Medication Use: A Retrospective Observational Study Using Population&#x2010;Based Databases,&#x201d; Lancet Psychiatry 5, no. 10 (2018): 824&#x2013;835.</Citation><ArticleIdList><ArticleId IdType="pubmed">30220514</ArticleId></ArticleIdList></Reference><Reference><Citation>
Sentinel F., &#x201c;Hydrochlorothiazide Use Following Labeling Update to Include the Risk of Non&#x2010;Melanoma Skin Cancer: An Interrupted Time Series Analysis,&#x201d; accessed September, 2024, https://www.sentinelinitiative.org/studies/drugs/individual&#x2010;drug&#x2010;analyses/hydrochlorothiazide&#x2010;use&#x2010;following&#x2010;labeling&#x2010;update&#x2010;include&#x2010;0.</Citation></Reference><Reference><Citation>Lee H.&#x2010;J., Roughead E. E., Han E., Lee J., and Kalisch Ellett L., &#x201c;Post&#x2010;Market Utilization Patterns of Alzheimer's Disease Treatments in South Korea: Comparison With Countries With Universal Health Coverage,&#x201d; European Journal of Clinical Pharmacology 77 (2021): 921&#x2013;929.</Citation><ArticleIdList><ArticleId IdType="pubmed">33409682</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang Y.&#x2010;L., Moon J., and Segal J. B., &#x201c;A Comparison of Active Adverse Event Surveillance Systems Worldwide,&#x201d; Drug Safety 37 (2014): 581&#x2013;596.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4134479</ArticleId><ArticleId IdType="pubmed">25022829</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai E. C.&#x2010;C., Stang P., Yang Y.&#x2010;H. K., Kubota K., Wong I. C. K., and Setoguchi S., &#x201c;International Multi&#x2010;Database Pharmacoepidemiology: Potentials and Pitfalls,&#x201d; Current Epidemiology Reports 2 (2015): 229&#x2013;238.</Citation></Reference><Reference><Citation>Tong X., Shen C. Y., Jeon H. L., et&#xa0;al., &#x201c;Cardiovascular Risk in Rheumatoid Arthritis Patients Treated With Targeted Synthetic and Biological Disease&#x2010;Modifying Antirheumatic Drugs: A Multi&#x2010;Centre Cohort Study,&#x201d; Journal of Internal Medicine 294, no. 3 (2023): 314&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pubmed">37282790</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong J., Prieto&#x2010;Alhambra D., Rijnbeek P. R., Desai R. J., Reps J. M., and Toh S., &#x201c;Applying Machine Learning in Distributed Data Networks for Pharmacoepidemiologic and Pharmacovigilance Studies: Opportunities, Challenges, and Considerations,&#x201d; Drug Safety 45, no. 5 (2022): 493&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9112258</ArticleId><ArticleId IdType="pubmed">35579813</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtis L. H., Weiner M. G., Boudreau D. M., et&#xa0;al., &#x201c;Design Considerations, Architecture, and Use of the Mini&#x2010;Sentinel Distributed Data System,&#x201d; Pharmacoepidemiology and Drug Safety 21 (2012): 23&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">22262590</ArticleId></ArticleIdList></Reference><Reference><Citation>Toh S., Pratt N., Klungel O., Gagne J. J., and Platt R. W., &#x201c;Distributed Networks of Databases Analyzed Using Common Protocols and/or Common Data Models,&#x201d; in Pharmacoepidemiology, 6th ed., ed. Strom B. L., Kimmel S. E., Hennessy S., and Dal Pan S. L. (Wiley, 2019), 617&#x2013;638.</Citation></Reference><Reference><Citation>Schneeweiss S., Brown J. S., Bate A., Trifir&#xf2; G., and Bartels D. B., &#x201c;Choosing Among Common Data Models for Real&#x2010;World Data Analyses Fit for Making Decisions About the Effectiveness of Medical Products,&#x201d; Clinical Pharmacology &amp; Therapeutics 107, no. 4 (2020): 827&#x2013;833.</Citation><ArticleIdList><ArticleId IdType="pubmed">31330042</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown J. S., Mendelsohn A. B., Nam Y. H., et&#xa0;al., &#x201c;The US Food and Drug Administration Sentinel System: A National Resource for a Learning Health System,&#x201d; Journal of the American Medical Informatics Association 29, no. 12 (2022): 2191&#x2013;2200.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9667154</ArticleId><ArticleId IdType="pubmed">36094070</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss E. A., Blacketer C., van Sandijk S., et&#xa0;al., &#x201c;European Health Data &amp; Evidence Network&#x2014;Learnings From Building out a Standardized International Health Data Network,&#x201d; Journal of the American Medical Informatics Association 31, no. 1 (2024): 209&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10746315</ArticleId><ArticleId IdType="pubmed">37952118</ArticleId></ArticleIdList></Reference><Reference><Citation>
DARWIN&#x2010;EU
, &#x201c;Studies,&#x201d; accessed January 19, 2024, https://www.darwin&#x2010;eu.org/index.php/studies.</Citation></Reference><Reference><Citation>
OHDSI
, &#x201c;Research Community &#x2013; Publications,&#x201d; accessed January 19, 2024, https://dash.ohdsi.org/research.</Citation></Reference><Reference><Citation>Cohen J. M., Cesta C. E., Kjerpeseth L., et&#xa0;al., &#x201c;A Common Data Model for Harmonization in the Nordic Pregnancy Drug Safety Studies (NorPreSS),&#x201d; Norsk Epidemiologi 29, no. 1&#x2010;2 (2021): 117&#x2013;123.</Citation></Reference><Reference><Citation>Thurin N. H., Pajouheshnia R., Roberto G., et&#xa0;al., &#x201c;From Inception to ConcePTION: Genesis of a Network to Support Better Monitoring and Communication of Medication Safety During Pregnancy and Breastfeeding,&#x201d; Clinical Pharmacology and Therapeutics 111, no. 1 (2022): 321&#x2013;331.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9299060</ArticleId><ArticleId IdType="pubmed">34826340</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunt N. B., Multi&#x2010;Database Methodologies to Enhance Real&#x2010;World Evidence Generation (Utrecht University, 2024).</Citation></Reference><Reference><Citation>
CNODES
, &#x201c;Organizational Structure,&#x201d; accessed January 20, 2024, https://www.cnodes.ca/about/organizational&#x2010;structure/.</Citation></Reference><Reference><Citation>Platt R. W., Dormuth C. R., Chateau D., and Filion K., &#x201c;Observational Studies of Drug Safety in Multi&#x2010;Database Studies: Methodological Challenges and Opportunities,&#x201d; EGEMs (Generating Evidence &amp; Methods to Improve Patient Outcomes) 4, no. 1 (2016): 1221.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4909373</ArticleId><ArticleId IdType="pubmed">27376096</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang T. Y., Welch E. C., Shinde M. U., et&#xa0;al., &#x201c;Reproducing Protocol&#x2010;Based Studies Using Parameterizable Tools&#x2014;Comparison of Analytic Approaches Used by Two Medical Product Surveillance Networks,&#x201d; Clinical Pharmacology &amp; Therapeutics 107, no. 4 (2020): 966&#x2013;977.</Citation><ArticleIdList><ArticleId IdType="pubmed">31630391</ArticleId></ArticleIdList></Reference><Reference><Citation>Pratt N., Andersen M., Bergman U., et&#xa0;al., &#x201c;Multi&#x2010;Country Rapid Adverse Drug Event Assessment: The Asian Pharmacoepidemiology Network (AsPEN) Antipsychotic and Acute Hyperglycaemia Study,&#x201d; Pharmacoepidemiology and Drug Safety 22, no. 9 (2013): 915&#x2013;924.</Citation><ArticleIdList><ArticleId IdType="pubmed">23696036</ArticleId></ArticleIdList></Reference><Reference><Citation>Filion K. B., Chateau D., Targownik L. E., et&#xa0;al., &#x201c;Proton Pump Inhibitors and the Risk of Hospitalisation for Community&#x2010;Acquired Pneumonia: Replicated Cohort Studies With Meta&#x2010;Analysis,&#x201d; Gut 63, no. 4 (2014): 552&#x2013;558.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3963530</ArticleId><ArticleId IdType="pubmed">23856153</ArticleId></ArticleIdList></Reference><Reference><Citation>Lawlor D. A., Tilling K., and Davey Smith G., &#x201c;Triangulation in Aetiological Epidemiology,&#x201d; International Journal of Epidemiology 45, no. 6 (2017): 1866&#x2013;1886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5841843</ArticleId><ArticleId IdType="pubmed">28108528</ArticleId></ArticleIdList></Reference><Reference><Citation>Gini R., Pajouheshnia R., Gardarsdottir H., et&#xa0;al., &#x201c;Describing Diversity of Real World Data Sources in Pharmacoepidemiologic Studies: The DIVERSE Scoping Review,&#x201d; Pharmacoepidemiology and Drug Safety 33, no. 5 (2024): e5787.</Citation><ArticleIdList><ArticleId IdType="pubmed">38724471</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40627823</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>08</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2473-4276</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><PubDate><Year>2025</Year><Month>Jul</Month></PubDate></JournalIssue><Title>JCO clinical cancer informatics</Title><ISOAbbreviation>JCO Clin Cancer Inform</ISOAbbreviation></Journal><ArticleTitle>Assessing the Data Quality Dimensions of Surgical Oncology Cohorts in the <i>All of Us</i> Research Program.</ArticleTitle><Pagination><StartPage>e2500078</StartPage><MedlinePgn>e2500078</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/CCI-25-00078</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Cancer is a leading cause of morbidity and mortality in the United States. Mapping electronic health record (EHR) data to the Observational Medical Outcomes Partnership Common Data Model (OMOP CDM) may standardize data structure and allow for multiple database oncology studies. However, the number of oncology studies produced with the OMOP CDM has been low. To investigate the discrepancy between the public health impact of cancer and the output of OMOP CDM clinical cancer studies, we evaluated (EHR) data quality of five surgical oncology cohorts in the <i>All of Us</i> Research Program: mastectomy, prostatectomy, colectomy, melanoma excision, and lung cancer resection.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We selected procedure codes that were the basis of each phenotype. We used a data quality checklist to evaluate five domains systematically: conformance, completeness, concordance, plausibility, and temporality.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Most phenotype-defining source codes were mapped to Current Procedural Terminology 4, which is an EHR standard. All cohorts had low concept prevalence. Most bivariate correlations between concepts were weak (&#x2374; &#x2264; 0.5). The small number of biomarkers available for use limited our plausibility analysis. The median time between biopsy and surgery varied across cohorts.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">We identified multiple data completeness issues, which limited the fitness for use evaluation. Also, using the OMOP CDM procedure concepts and mappings presented challenges for our study. Variable amounts of missingness in OMOP CDM surgical oncology data may affect the fitness for use of cancer data. Further research is warranted to improve the quality of that data.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Spotnitz</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2869-0237</Identifier><AffiliationInfo><Affiliation>All of Us Research Program, Office of the Director, National Institutes of Health, Bethesda, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giannini</LastName><ForeName>John</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-7626-6540</Identifier><AffiliationInfo><Affiliation>All of Us Research Program, Office of the Director, National Institutes of Health, Bethesda, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clark</LastName><ForeName>Emily</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-0039-0470</Identifier><AffiliationInfo><Affiliation>GAP Solutions, Inc, Herndon, VA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ostchega</LastName><ForeName>Yechiam</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0009-0001-8054-9727</Identifier><AffiliationInfo><Affiliation>All of Us Research Program, Office of the Director, National Institutes of Health, Bethesda, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Litwin</LastName><ForeName>Tamara R</ForeName><Initials>TR</Initials><AffiliationInfo><Affiliation>All of Us Research Program, Office of the Director, National Institutes of Health, Bethesda, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Goff</LastName><ForeName>Stephanie L</ForeName><Initials>SL</Initials><Identifier Source="ORCID">0000-0003-3317-9804</Identifier><AffiliationInfo><Affiliation>Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berman</LastName><ForeName>Lew</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>All of Us Research Program, Office of the Director, National Institutes of Health, Bethesda, MD.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Z99 OD999999</GrantID><Acronym>ImNIH</Acronym><Agency>Intramural NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JCO Clin Cancer Inform</MedlineTA><NlmUniqueID>101708809</NlmUniqueID><ISSNLinking>2473-4276</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071077" MajorTopicYN="Y">Surgical Oncology</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000068598" MajorTopicYN="Y">Data Accuracy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009369" MajorTopicYN="Y">Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008495" MajorTopicYN="N">Medical Oncology</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2026</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>8</Day><Hour>18</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>8</Day><Hour>18</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>8</Day><Hour>16</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40627823</ArticleId><ArticleId IdType="mid">NIHMS2083397</ArticleId><ArticleId IdType="pmc">PMC12240465</ArticleId><ArticleId IdType="doi">10.1200/CCI-25-00078</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>The Center for Disease Control, &#x201c;Leading Causes of Death&#x201d; https://www.cdc.gov/nchs/fastats/leading-causes-of-death.htm/. Accessed February 21, 2025.</Citation></Reference><Reference><Citation>Unger JM, Cook E, Tai E and Bleyer A. The Role of Clinical Trial Participation in Cancer Research: Barriers, Evidence, and Strategies 2016. American Society of Clinical Oncology Educational Book; 35:185&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5495113</ArticleId><ArticleId IdType="pubmed">27249699</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang M, Pearson S-A, Simes RJ, and Chua BH Harnessing Real-World Evidence to Advance Cancer Research. Curr. Oncol 2023, 30, 1844&#x2013;1859. 10.3390/curroncol30020143</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/curroncol30020143</ArticleId><ArticleId IdType="pmc">PMC9955401</ArticleId><ArticleId IdType="pubmed">36826104</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherman RE, Anderson SA, Dal Pan GJ et al. Real-world evidence - What is it and what can it tell us? N Engl J Med 2016;375: 2293&#x2013;2297. doi: 10.1007/s40290-022-00456-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40290-022-00456-6</ArticleId><ArticleId IdType="pubmed">27959688</ArticleId></ArticleIdList></Reference><Reference><Citation>National Cancer Institute Surveillance, Epidemiology, and End Results Program, &#x201c;Cancer Stat Facts&#x201d;, https://seer.cancer.gov/statfacts/html/common.html/. Accessed December 31, 2024.</Citation></Reference><Reference><Citation>Boyce-Fappiano D, Bedrosian I, Shen Y et al. Evaluation of overall survival and barriers to surgery for patients with breast cancer treated without surgery: a National Cancer Database analysis. npj Breast Cancer 2021; 7:87; 10.1038/s41523-021-00294-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41523-021-00294-w</ArticleId><ArticleId IdType="pmc">PMC8257645</ArticleId><ArticleId IdType="pubmed">34226566</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaps B, Leapman M, An Y. Trends in prostatectomy utilization: Increasing upfront prostatectomy and postprostatectomy radiotherapy for high-risk prostate cancer. Cancer Medicine. 2020; 9:8754&#x2013;8764. doi: 10.1002/cam4.3482.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cam4.3482</ArticleId><ArticleId IdType="pmc">PMC7724485</ArticleId><ArticleId IdType="pubmed">33128858</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopes J, Rodrigues CMP, Gaspar MM and Reis CP. Melanoma Management: From Epidemiology to Treatment and Latest Advances. Cancers 2022; 14: 4652. doi: 10.3390/cancers14194652.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cancers14194652</ArticleId><ArticleId IdType="pmc">PMC9562203</ArticleId><ArticleId IdType="pubmed">36230575</ArticleId></ArticleIdList></Reference><Reference><Citation>American Cancer Society. Colorectal Cancer Facts &amp; Figures 2020-2022. Atlanta: American Cancer Society; 2020.</Citation></Reference><Reference><Citation>Raman V, Yang CF, Deng JZ and D&#x2019;Amico TA. Surgical treatment for early stage non-small cell lung cancer. J Thorac Dis. 2018; 10(Suppl 7): S898&#x2013;S904. doi: 10.21037/jtd.2018.01.172</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/jtd.2018.01.172</ArticleId><ArticleId IdType="pmc">PMC5945689</ArticleId><ArticleId IdType="pubmed">29780636</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsimberidou AM, Sireci A, Dumanois R and Pritchard D. Strategies to Address the Clinical Practice Gaps Affecting the Implementation of Personalized Medicine in Cancer Care. JCO Oncol Pract 2024; 20:761&#x2013;766. doi: 10.1200/OP.23.00601</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/OP.23.00601</ArticleId><ArticleId IdType="pmc">PMC11638942</ArticleId><ArticleId IdType="pubmed">38442324</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu J, Groot G, Boden C et al. Review of Factors Influencing Women's Choice of Mastectomy Versus Breast Conserving Therapy in Early Stage Breast Cancer: A Systematic Review. Clinical Breast Cancer. 2017; 18(4): e539&#x2013;4. doi: 10.1016/j.clbc.2017.12.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clbc.2017.12.013</ArticleId><ArticleId IdType="pubmed">29396079</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel HD, Humphreys E, Trock BJ, Han M, and Carter HB. Practice Patterns and Individual Variability of Surgeons Performing Radical Prostatectomy at a High Volume Academic Center. J Urol. 2015;193(3):812&#x2013;9. doi: 10.1016/j.juro.2014.08.101</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.juro.2014.08.101</ArticleId><ArticleId IdType="pubmed">25196659</ArticleId></ArticleIdList></Reference><Reference><Citation>Aquina CT, Becerra AZ, Justiniano CF et al. Surgeon, Hospital, and Geographic Variation in Minimally Invasive Colectomy. Ann Surg 2019;269:1109&#x2013;1116. doi: 10.1097/SLA.0000000000002694</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0000000000002694</ArticleId><ArticleId IdType="pubmed">31082909</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelsattar ZM, Allen MS, Shen R et al. Video-Assisted Thoracoscopic Lobectomy for Lung Cancer and the Effect on Outcomes. Ann Thorac Surg 2017;103:454&#x2013;61. doi: 10.1016/j.athoracsur.2016.08.091</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2016.08.091</ArticleId><ArticleId IdType="pubmed">27825690</ArticleId></ArticleIdList></Reference><Reference><Citation><i>All of Us</i> Research Program Investigators. The "<i>All of Us</i>" research program. New England Journal of Medicine. 381.7
2019: 668&#x2013;676. doi: 10.1056/NEJMsr1809937</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMsr1809937</ArticleId><ArticleId IdType="pmc">PMC8291101</ArticleId><ArticleId IdType="pubmed">31412182</ArticleId></ArticleIdList></Reference><Reference><Citation>Berman L, Ostchega Y, Giannini J, et al. Application of a Data Quality Framework to Ductal Carcinoma in Situ Using Electronic Health Record Data from the All of Us Research Program. JCO Clinical Cancer Informatics. 2024;8:e2400052. doi: 10.1200/CCI.24.00052.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/CCI.24.00052</ArticleId><ArticleId IdType="pubmed">39178364</ArticleId></ArticleIdList></Reference><Reference><Citation>Spotnitz M, Giannini J, Ostchega Y, et al. Assessing the Data Quality Dimensions of Partial and Complete Mastectomy Cohorts in the All of Us Research Program: A Cross-Sectional Study. JMIR Cancer (forthcoming). doi: 10.2196/59298</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/59298</ArticleId><ArticleId IdType="pmc">PMC11918980</ArticleId><ArticleId IdType="pubmed">40068169</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH et al. Observational Health Data Sciences and Informatics (OHDSI): Opportunities for Observational Researchers. Stud Health Technol Inform. 2015; 216: 574&#x2013;578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG et al. Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012; 19(1): 54&#x2013;60. doi: 10.1136/amiajnl-2011-000376.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/amiajnl-2011-000376</ArticleId><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Reich C, Ostropolets A, Ryan P, Rijnbeek P, Schuemie M, Davydov A, Dymshyts D, &amp; Hripcsak G (2024). OHDSI Standardized Vocabularies-a large-scale centralized reference ontology for international data harmonization. Journal of the American Medical Informatics Association : JAMIA, 31(3), 583&#x2013;590. 10.1093/jamia/ocad247</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocad247</ArticleId><ArticleId IdType="pmc">PMC10873827</ArticleId><ArticleId IdType="pubmed">38175665</ArticleId></ArticleIdList></Reference><Reference><Citation>All of Us Research Program, &#x201c; Data Dictionaries&#x201d;, https://support.researchallofus.org/hc/en-us/articles/360033200232-Data-Dictionaries, Accessed February 21, 2025.</Citation></Reference><Reference><Citation>Waks AG and Winer EP. Breast Cancer Treatment: A Review. JAMA. 2019;321(3):288&#x2013;300. doi: 10.1001/jama.2018.19323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2018.19323</ArticleId><ArticleId IdType="pubmed">30667505</ArticleId></ArticleIdList></Reference><Reference><Citation>Association of Breast Surgery at BASO 2009. Surgical Guidelines for the Management of Breast Cancer. EJSO. 2009; 35:S1&#x2013;S22. doi: 10.1016/j.ejso.2009.01.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejso.2009.01.008</ArticleId></ArticleIdList></Reference><Reference><Citation>Litwin MS and Tan H-J. The Diagnosis and Treatment of Prostate Cancer: A Review. JAMA. (2017);317(24):2532&#x2013;2542. doi: 10.1001/jama.2017.7248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2017.7248</ArticleId><ArticleId IdType="pubmed">28655021</ArticleId></ArticleIdList></Reference><Reference><Citation>Dunn MW and Kazer MW. Prostate Cancer Overview. Seminars in Oncology Nursing, 2011; 27(4):241&#x2013;250. doi: 10.1016/j.soncn.2011.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.soncn.2011.07.002</ArticleId><ArticleId IdType="pubmed">22018403</ArticleId></ArticleIdList></Reference><Reference><Citation>Sebesta EM and Anderson CB. The Surgical Management of Prostate Cancer. Seminars in Oncology 2017; 44:347&#x2013;357. doi: 10.1053/j.seminoncol.2018.01.003</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.seminoncol.2018.01.003</ArticleId><ArticleId IdType="pubmed">29580436</ArticleId></ArticleIdList></Reference><Reference><Citation>Teo MY, Rathkopf DE and Kantoff P. Treatment of Advanced Prostate Cancer. Annu. Rev. Med (2019) 70:479&#x2013;99. doi: 10.1146/annurev-med-051517-011947.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-med-051517-011947</ArticleId><ArticleId IdType="pmc">PMC6441973</ArticleId><ArticleId IdType="pubmed">30691365</ArticleId></ArticleIdList></Reference><Reference><Citation>Biller LH and Schrag D. Diagnosis and Treatment of Metastatic Colorectal Cancer A Review. JAMA. 2021;325(7):669&#x2013;685. doi: 10.1001/jama.2021.0106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.0106</ArticleId><ArticleId IdType="pubmed">33591350</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie Y-H, Chen Y-X, and Fang J-F. Comprehensive review of targeted therapy for colorectal cancer. Signal Transduction and Targeted Therapy (2020) 5:22. doi: 10.1038/s41392-020-0116-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-020-0116-z</ArticleId><ArticleId IdType="pmc">PMC7082344</ArticleId><ArticleId IdType="pubmed">32296018</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolpin BM and Mayer RJ. Systemic Treatment of Colorectal Cancer. Gastroenterology 2008;134:1296&#x2013;1310. DOI: 10.1053/j.gastro.2008.02.098</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2008.02.098</ArticleId><ArticleId IdType="pmc">PMC2528832</ArticleId><ArticleId IdType="pubmed">18471507</ArticleId></ArticleIdList></Reference><Reference><Citation>Stintzing S. Management of colorectal cancer. F1000 Prime Reports 2014, 6:108. doi: 10.12703/P6-108</Citation><ArticleIdList><ArticleId IdType="doi">10.12703/P6-108</ArticleId><ArticleId IdType="pmc">PMC4229728</ArticleId><ArticleId IdType="pubmed">25580262</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis Lauren E., Shalin Sara C. and Tackett Alan J. (2019) Current state of melanoma diagnosis and treatment, Cancer Biology &amp; Therapy, 20:11, 1366&#x2013;1379. doi: 10.1080/15384047.2019.1640032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15384047.2019.1640032</ArticleId><ArticleId IdType="pmc">PMC6804807</ArticleId><ArticleId IdType="pubmed">31366280</ArticleId></ArticleIdList></Reference><Reference><Citation>Algazi Alain P, Soon Christopher W and Daud Adil I (2010) Treatment of cutaneous melanoma: current approaches and future prospects, Cancer Management and Research, 197&#x2013;211. doi: 10.2147/CMR.S6073.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CMR.S6073</ArticleId><ArticleId IdType="pmc">PMC3004577</ArticleId><ArticleId IdType="pubmed">21188111</ArticleId></ArticleIdList></Reference><Reference><Citation>Hartman RI and Lin JY. Cutaneous Melanoma&#x2014;A Review in Detection, Staging, and Management. Hematol Oncol Clin N Am 2019; 33(1):25&#x2013;38. doi: 10.1016/j.hoc.2018.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hoc.2018.09.005</ArticleId><ArticleId IdType="pubmed">30497675</ArticleId></ArticleIdList></Reference><Reference><Citation>Schadendorf D, Fisher DE, Garbe C, et al. Melanoma. Nat Rev Dis Primers 2015; 1:15003. doi: 10.1038/nrdp.2015.3</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2015.3</ArticleId><ArticleId IdType="pubmed">27188223</ArticleId></ArticleIdList></Reference><Reference><Citation>Domingues Beatriz, Lopes Jos&#xe9; Manuel, Soares Paula and P&#xf3;pulo Helena. Melanoma treatment in review. ImmunoTargets and Therapy 2018; 7: 35&#x2013;49. doi: 10.2147/ITT.S134842.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/ITT.S134842</ArticleId><ArticleId IdType="pmc">PMC5995433</ArticleId><ArticleId IdType="pubmed">29922629</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatia S, Tykodi SS and Thompson JA. Treatment of Metastatic Melanoma: An Overview. Oncology. 2009; 23(6): 488&#x2013;496.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2737459</ArticleId><ArticleId IdType="pubmed">19544689</ArticleId></ArticleIdList></Reference><Reference><Citation>https://www.cancer.gov/about-cancer/treatment/drugs/lung/. Accessed February 21, 2025.</Citation></Reference><Reference><Citation>Hirsch FR, Scagliotti GV, Mulshine JL et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017. Jan 21;389(10066):299&#x2013;311. doi: 10.1016/S0140-6736(16)30958-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(16)30958-8</ArticleId><ArticleId IdType="pubmed">27574741</ArticleId></ArticleIdList></Reference><Reference><Citation>Spiro SG and Porter JC. Lung Cancer&#x2014;Where Are We Today? Current Advances in Staging and Nonsurgical Treatment. Am J Respir Crit Care Med 2002; 166:1166&#x2013;1196. doi: 10.1164/rccm.200202-070SO</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.200202-070SO</ArticleId><ArticleId IdType="pubmed">12403687</ArticleId></ArticleIdList></Reference><Reference><Citation>Lemjabbar-Alaoui H, Hassan OU, Yang Y-W and Buchanan P. Lung cancer: Biology and treatment options. Biochimica et Biophysica Acta 2015;1856: 189&#x2013;210. 10.1016/j.bbcan.2015.08.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbcan.2015.08.002</ArticleId><ArticleId IdType="pmc">PMC4663145</ArticleId><ArticleId IdType="pubmed">26297204</ArticleId></ArticleIdList></Reference><Reference><Citation>Zappa C and Mousa SK. Non-small cell lung cancer: current treatment and future advances. Translational Lung Cancer Research 2016; 5(3). doi: 10.21037/tlcr.2016.06.07</Citation><ArticleIdList><ArticleId IdType="doi">10.21037/tlcr.2016.06.07</ArticleId><ArticleId IdType="pmc">PMC4931124</ArticleId><ArticleId IdType="pubmed">27413711</ArticleId></ArticleIdList></Reference><Reference><Citation>Molina JR, Yang P, Cassivi S, Schild SE, and Adjei AA. Non&#x2013;Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship. Mayo Clin Proc. 2008;83(5):584&#x2013;594. doi: 10.4065/83.5.584</Citation><ArticleIdList><ArticleId IdType="doi">10.4065/83.5.584</ArticleId><ArticleId IdType="pmc">PMC2718421</ArticleId><ArticleId IdType="pubmed">18452692</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarogoulidis K, Zarogoulidis P, Darwiche K et al. Treatment of non-small cell lung cancer (NSCLC). J Thorac Dis 2013;5(S4):S389&#x2013;S396. doi: 10.3978/j.issn.2072-1439.2013.07.10.</Citation><ArticleIdList><ArticleId IdType="doi">10.3978/j.issn.2072-1439.2013.07.10</ArticleId><ArticleId IdType="pmc">PMC3791496</ArticleId><ArticleId IdType="pubmed">24102012</ArticleId></ArticleIdList></Reference><Reference><Citation>Kankanala VL; Mukkamalla SKR. Carcinoembryonic Antigen. StatPearls [Internet], Treasure Island (FL): StatPearls Publishing, 2024. Jan.</Citation><ArticleIdList><ArticleId IdType="pubmed">35201700</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner MG, Livshits A, Carozzoni C et al. Derivation of Malignancy Status from ICD-9 Codes. AMIA Annu Symp Proc. 2003;2003:1050.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1480106</ArticleId><ArticleId IdType="pubmed">14728553</ArticleId></ArticleIdList></Reference><Reference><Citation>All of Us Research Program, &#x201c;All of Us Researcher Workbench&#x201d;, https://workbench.researchallofus.org, accessed February 21, 2025</Citation></Reference><Reference><Citation>The National Comprehensive Cancer Network, https://www.nccn.org/, accessed December 31, 2024.</Citation></Reference><Reference><Citation>Chan YH. Biostatistics 104: correlational analysis. Singap Med J. 2003;44(12):614&#x2013;619.</Citation><ArticleIdList><ArticleId IdType="pubmed">14770254</ArticleId></ArticleIdList></Reference><Reference><Citation>The American Cancer Society, &#x201c;Key Statistics for Melanoma Skin Cancer&#x201d; https://www.cancer.org/cancer/types/melanoma-skin-cancer/about/key-statistics.html#references. Accessed February 21, 2025.</Citation></Reference><Reference><Citation>Islami F, Bispo JB, Lee H et al. American Cancer Society&#x2019;s report on the status of cancer disparities in the United States, 2023.CA Cancer J Clin. 2024;74:136&#x2013;166. doi: 10.3322/caac.21812.</Citation><ArticleIdList><ArticleId IdType="doi">10.3322/caac.21812</ArticleId><ArticleId IdType="pubmed">37962495</ArticleId></ArticleIdList></Reference><Reference><Citation>Swaminathan A, Ren AL, Wu JY et al. Extraction of Unstructured Electronic Health Records to Evaluate Glioblastoma Treatment Patterns. JCO Clin Cancer Inform. 2024:8:e2300091. doi: 10.1200/CCI.23.00091</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/CCI.23.00091</ArticleId><ArticleId IdType="pmc">PMC11371099</ArticleId><ArticleId IdType="pubmed">38857465</ArticleId></ArticleIdList></Reference><Reference><Citation>All of Us Research Program, &#x201c;Center for Linkage and Acquisition of Data&#x201d;, https://allofus.nih.gov/funding-and-program-partners/center-for-linkage-and-aquisition-of-data, Accessed February 21, 2025.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40630514</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2693-5015</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jul</Month><Day>03</Day></PubDate></JournalIssue><Title>Research square</Title><ISOAbbreviation>Res Sq</ISOAbbreviation></Journal><ArticleTitle>Vaccine Effectiveness Among 5- to 17-year-old Individuals with Prior SARS-CoV-2 Infection: An EHR-Based Target Trial Emulation Study from the RECOVER Project.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">rs.3.rs-6945998</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.21203/rs.3.rs-6945998/v1</ELocationID><Abstract><AbstractText>The effectiveness of COVID-19 vaccination in children and adolescents with prior SARS-CoV-2 infection remains unclear, particularly for Omicron subvariants. We evaluated vaccine effectiveness against reinfection with Omicron BA.1/2, BA.4/5, XBB, and later subvariants among 5- to 17-year-olds using data from the RECOVER initiative, a national electronic health record database covering 37 U.S. pediatric institutions. We emulated target trials by age group and variant period, comparing previously infected participants between January 2022 and August 2023. During the BA.1/2 period, vaccination reduced the risk of reinfection, with effectiveness rates of 62% in children and 65% in adolescents. During the BA.4/5 period, protection effectiveness in children was 57%, whereas no statistically significant protection was observed in adolescents. During the XBB or later period, no significant protection was observed in either group. In summary, COVID-19 vaccination provided protection against reinfection during early and mid-Omicron periods in previously infected pediatric populations, but effectiveness declined for later variants.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-0835-0788</Identifier><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lei</LastName><ForeName>Yuqing</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>University of Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jiajie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University of Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Qiong</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>University of Pittsburgh.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Ting</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>University of Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Bingyu</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>University of Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Becich</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-5998-8074</Identifier><AffiliationInfo><Affiliation>University of Pittsburgh School of Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bisyuk</LastName><ForeName>Yuriy</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-2380-4776</Identifier><AffiliationInfo><Affiliation>University Medical Center New Orleans.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blecker</LastName><ForeName>Saul</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Population Health, New York University Grossman School of Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chrischilles</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, College of Public Health, The University of Iowa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Christakis</LastName><ForeName>Dimitri</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Center for Child Health, Behavior and Development, Seattle Children's Research Institute.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cowell</LastName><ForeName>Lindsay</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>UT Southwestern Medical Center.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cummins</LastName><ForeName>Mollie</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7078-8479</Identifier><AffiliationInfo><Affiliation>University of Utah.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fernandez</LastName><ForeName>Soledad</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Ohio State University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fort</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Ochsner Health.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonzalez</LastName><ForeName>Sandy</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Nicklaus Children's Hospital, Miami, FL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Herring</LastName><ForeName>Sharon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Program for Maternal Health Equity, Center for Urban Bioethics, Department of Population Health and Urban Bioethics, Center for Obesity Research and Education, College of Public Health, Lewis Katz S.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horne</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-2656-0263</Identifier><AffiliationInfo><Affiliation>Intermountain Medical Center Heart Institute.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horowitz</LastName><ForeName>Carol</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Icahn School of Medicine at Mount Sinai.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Mei</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-8036-2110</Identifier><AffiliationInfo><Affiliation>University of Florida.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of California, San Francisco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mirhaji</LastName><ForeName>Parsa</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Albert Einstein College of Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mosa</LastName><ForeName>Abu</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-8956-1466</Identifier><AffiliationInfo><Affiliation>University of Alabama at Birmingham.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muszynski</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Nationwide Children's Hospital.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paules</LastName><ForeName>Catharine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Medicine, Penn State Health Milton S. Hershey Medical Center, Hershey, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Alice</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-9827-201X</Identifier><AffiliationInfo><Affiliation>982162 Nebraska Medical Center, Omaha, NE 68198.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwenk</LastName><ForeName>Hayden</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Stanford School of Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sengupta</LastName><ForeName>Soumitra</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Columbia University.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suresh</LastName><ForeName>Srinivasan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of Pittsburgh School of Medicine.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>Bradley</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0002-6414-4172</Identifier><AffiliationInfo><Affiliation>Medical College of Wisconsin.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-5052-4895</Identifier><AffiliationInfo><Affiliation>University of Michigan Medical School.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Yongqun</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-9189-9661</Identifier><AffiliationInfo><Affiliation>University of Michigan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morris</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-8520-6088</Identifier><AffiliationInfo><Affiliation>University of Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jhaveri</LastName><ForeName>Ravi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Ann &amp; Robert H. Lurie Children's Hospital of Chicago.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forrest</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-1252-068X</Identifier><AffiliationInfo><Affiliation>Children's Hospital of Philadelphia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>OT2 HL161847</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG077820</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM013519</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 MH136069</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 EY034179</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AI167418</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 TR003709</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DK128237</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM014344</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG074604</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG073435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000076942">Preprint</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Res Sq</MedlineTA><NlmUniqueID>101768035</NlmUniqueID><ISSNLinking>2693-5015</ISSNLinking></MedlineJournalInfo></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>9</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>9</Day><Hour>4</Hour><Minute>59</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40630514</ArticleId><ArticleId IdType="pmc">PMC12236908</ArticleId><ArticleId IdType="doi">10.21203/rs.3.rs-6945998/v1</ArticleId><ArticleId IdType="pii">rs.3.rs-6945998</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wu Q. et al. Real-World Effectiveness of BNT162b2 Against Infection and Severe Diseases in Children and Adolescents. Ann Intern Med 177, 165&#x2013;176 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11956830</ArticleId><ArticleId IdType="pubmed">38190711</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Q. et al. Real-world effectiveness and causal mediation study of BNT162b2 on long COVID risks in children and adolescents. EClinicalMedicine 79, 102962 (2025).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11667630</ArticleId><ArticleId IdType="pubmed">39720603</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez Bernal J. et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. New England Journal of Medicine 385, 585&#x2013;594 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8314739</ArticleId><ArticleId IdType="pubmed">34289274</ArticleId></ArticleIdList></Reference><Reference><Citation>Feldstein L. R. et al. Effectiveness of Bivalent mRNA COVID-19 Vaccines in Preventing SARS-CoV-2 Infection in Children and Adolescents Aged 5 to 17 Years. JAMA 331, 408 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10848053</ArticleId><ArticleId IdType="pubmed">38319331</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrews N. et al. Covid-19 Vaccine Effectiveness against the Omicron (B.1.1.529) Variant. New England Journal of Medicine 386, 1532&#x2013;1546 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8908811</ArticleId><ArticleId IdType="pubmed">35249272</ArticleId></ArticleIdList></Reference><Reference><Citation>Hungerford D. &amp; Cunliffe N. A. Real world effectiveness of covid-19 vaccines. BMJ n2034 (2021) doi: 10.1136/bmj.n2034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n2034</ArticleId></ArticleIdList></Reference><Reference><Citation>Pilishvili T. et al. Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel. New England Journal of Medicine 385, (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8482809</ArticleId><ArticleId IdType="pubmed">34551224</ArticleId></ArticleIdList></Reference><Reference><Citation>Tartof S. Y. et al. Estimated Effectiveness of the BNT162b2 XBB Vaccine Against COVID-19. JAMA Intern Med 184, 932 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11197441</ArticleId><ArticleId IdType="pubmed">38913355</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen C. H. et al. Short-term effectiveness of the XBB.1.5 updated COVID-19 vaccine against hospitalisation in Denmark: a national cohort study. Lancet Infect Dis 24, e73&#x2013;e74 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38190834</ArticleId></ArticleIdList></Reference><Reference><Citation>Brannock M. D. et al. Long COVID risk and pre-COVID vaccination in an EHR-based cohort study from the RECOVER program. Nat Commun 14, 2914 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10201472</ArticleId><ArticleId IdType="pubmed">37217471</ArticleId></ArticleIdList></Reference><Reference><Citation>https://www.cdc.gov/covid/vaccines/faq.html.</Citation></Reference><Reference><Citation>Mongin D. et al. Effect of SARS-CoV-2 prior infection and mRNA vaccination on contagiousness and susceptibility to infection. Nat Commun 14, 5452 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10482859</ArticleId><ArticleId IdType="pubmed">37673865</ArticleId></ArticleIdList></Reference><Reference><Citation>Matuchansky C. Protection against SARS-CoV-2 after Vaccination and Previous Infection. N Engl J Med 386, 2534 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35704417</ArticleId></ArticleIdList></Reference><Reference><Citation>Painter M. M. et al. Prior vaccination promotes early activation of memory T cells and enhances immune responses during SARS-CoV-2 breakthrough infection. Nat Immunol 24, 1711&#x2013;1724 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37735592</ArticleId></ArticleIdList></Reference><Reference><Citation>Sokal A. et al. Maturation and persistence of the anti-SARS-CoV-2 memory B cell response. Cell 184, 1201&#x2013;1213.e14 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7994111</ArticleId><ArticleId IdType="pubmed">33571429</ArticleId></ArticleIdList></Reference><Reference><Citation>Gazit S. et al. The Incidence of SARS-CoV-2 Reinfection in Persons With Naturally Acquired Immunity With and Without Subsequent Receipt of a Single Dose of BNT162b2 Vaccine. Ann Intern Med 175, 674&#x2013;681 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8855786</ArticleId><ArticleId IdType="pubmed">35157493</ArticleId></ArticleIdList></Reference><Reference><Citation>Bobrovitz N. et al. Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression. Lancet Infect Dis 23, 556&#x2013;567 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10014083</ArticleId><ArticleId IdType="pubmed">36681084</ArticleId></ArticleIdList></Reference><Reference><Citation>Yung C. F. et al. BNT162b2 vaccine protection against omicron and effect of previous infection variant and vaccination sequence among children and adolescents in Singapore: a population-based cohort study. Lancet Child Adolesc Health 7, 463&#x2013;470 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10185330</ArticleId><ArticleId IdType="pubmed">37201540</ArticleId></ArticleIdList></Reference><Reference><Citation>Gazit S. et al. Hybrid immunity against reinfection with SARS-CoV-2 following a previous SARS-CoV-2 infection and single dose of the BNT162b2 vaccine in children and adolescents: a target trial emulation. Lancet Microbe 4, e495&#x2013;e505 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10101759</ArticleId><ArticleId IdType="pubmed">37062294</ArticleId></ArticleIdList></Reference><Reference><Citation>Singanayagam A. et al. Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study. Lancet Infect Dis 22, 183&#x2013;195 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8554486</ArticleId><ArticleId IdType="pubmed">34756186</ArticleId></ArticleIdList></Reference><Reference><Citation>Andeweg S. P. et al. Protection of COVID-19 vaccination and previous infection against Omicron BA.1, BA.2 and Delta SARS-CoV-2 infections. Nat Commun 13, 4738 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9373894</ArticleId><ArticleId IdType="pubmed">35961956</ArticleId></ArticleIdList></Reference><Reference><Citation>Altarawneh H. N. et al. Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta SARS-CoV-2 infections: an observational study. EBioMedicine 95, 104734 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10404859</ArticleId><ArticleId IdType="pubmed">37515986</ArticleId></ArticleIdList></Reference><Reference><Citation>Altarawneh H. N. et al. Effects of Previous Infection and Vaccination on Symptomatic Omicron Infections. New England Journal of Medicine 387, 21&#x2013;34 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9258753</ArticleId><ArticleId IdType="pubmed">35704396</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu S. et al. Protection of prior SARS-CoV-2 infection, COVID-19 boosters, and hybrid immunity against Omicron severe illness: A population-based cohort study of five million residents in Canada. PLoS One 19, e0299304 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10889649</ArticleId><ArticleId IdType="pubmed">38394091</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;ndez-D&#xed;az S. et al. Emulating a Target Trial of Interventions Initiated During Pregnancy with Healthcare Databases: The Example of COVID-19 Vaccination. Epidemiology 34, 238&#x2013;246 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9891154</ArticleId><ArticleId IdType="pubmed">36722806</ArticleId></ArticleIdList></Reference><Reference><Citation>Ioannou G. N. et al. Effectiveness of Nirmatrelvir&#x2013;Ritonavir Against the Development of Post&#x2013;COVID-19 Conditions Among U.S. Veterans. Ann Intern Med 176, 1486&#x2013;1497 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10620954</ArticleId><ArticleId IdType="pubmed">37903369</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;n M. A. &amp; Robins J. M. Using Big Data to Emulate a Target Trial When a Randomized Trial Is Not Available: Table 1. Am J Epidemiol 183, 758&#x2013;764 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4832051</ArticleId><ArticleId IdType="pubmed">26994063</ArticleId></ArticleIdList></Reference><Reference><Citation>Forrest C. B. et al. Severity of Acute COVID-19 in Children &lt;18 Years Old March 2020 to December 2021. Pediatrics 149, (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">35322270</ArticleId></ArticleIdList></Reference><Reference><Citation>Nziza N. et al. Humoral profiles of toddlers and young children following SARS-CoV-2 mRNA vaccination. Nat Commun 15, 905 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10827750</ArticleId><ArticleId IdType="pubmed">38291080</ArticleId></ArticleIdList></Reference><Reference><Citation>https://www.cdc.gov/acip/evidence-to-recommendations/covid-19-pfizer-biontech-etr-12-15-years.html.</Citation></Reference><Reference><Citation>https://www.fda.gov/news-events/press-announcements/fda-approves-first-covid-19-vaccine.</Citation></Reference><Reference><Citation>The Lancet Infectious Diseases. Why hybrid immunity is so triggering. Lancet Infect Dis 22, 1649 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9648977</ArticleId><ArticleId IdType="pubmed">36372089</ArticleId></ArticleIdList></Reference><Reference><Citation>Lasrado N. &amp; Barouch D. H. SARS-CoV-2 Hybrid Immunity: The Best of Both Worlds. J Infect Dis 228, 1311&#x2013;1313 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37592872</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikolajczyk R. et al. Likelihood of Post-COVID Condition in people with hybrid immunity; data from the German National Cohort (NAKO). Journal of Infection 89, 106206 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38897239</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss W. N. et al. Hybrid immunity to SARS-CoV-2 arises from serological recall of IgG antibodies distinctly imprinted by infection or vaccination. Cell Rep Med 5, 101668 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11384961</ArticleId><ArticleId IdType="pubmed">39094579</ArticleId></ArticleIdList></Reference><Reference><Citation>Aguilar-Bretones M. et al. SARS-CoV-2-specific immune responses converge in kidney disease patients and controls with hybrid immunity. NPJ Vaccines 9, 93 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11133345</ArticleId><ArticleId IdType="pubmed">38806532</ArticleId></ArticleIdList></Reference><Reference><Citation>https://www.ohdsi.org/data-standardization/.</Citation></Reference><Reference><Citation>Simon T. D., Cawthon M. L., Popalisky J. &amp; Mangione-Smith R. Development and Validation of the Pediatric Medical Complexity Algorithm (PMCA) Version 2.0. Hosp Pediatr 7, 373&#x2013;377 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5485351</ArticleId><ArticleId IdType="pubmed">28634166</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40664765</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>19</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2398-6352</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>15</Day></PubDate></JournalIssue><Title>NPJ digital medicine</Title><ISOAbbreviation>NPJ Digit Med</ISOAbbreviation></Journal><ArticleTitle>COLA-GLM: collaborative one-shot and lossless algorithms of generalized linear models for decentralized observational healthcare data.</ArticleTitle><Pagination><StartPage>442</StartPage><MedlinePgn>442</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">442</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41746-025-01781-1</ELocationID><Abstract><AbstractText>Clinical insights from real-world data often require aggregating information from institutions to ensure sufficient sample sizes and generalizability. However, patient privacy concerns only limit the sharing of patient-level data, and traditional federated learning algorithms, relying on extensive back-and-forth communications, can be inefficient to implement. We introduce the Collaborative One-shot Lossless Algorithm for Generalized Linear Models (COLA-GLM), a novel federated learning algorithm that supports diverse outcome types via generalized linear models and achieves results identical to a pooled patient-level data analysis (lossless) with only a single round of aggregated data exchange (one-shot). To further protect aggregated institutional data, we developed a secure extension, secure-COLA-GLM, utilizing homomorphic encryption. We demonstrated the effectiveness and lossless property of COLA-GLM through applications to an international influenza cohort and a decentralized U.S. COVID-19 mortality study. COLA-GLM and secure-COLA-GLM offer a scalable, efficient solution for decentralized collaborative learning involving multiple data partners and diverse security requirements.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Qiong</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Health Data Science, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reps</LastName><ForeName>Jenna M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Janssen Research &amp; Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Lu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Graduate Group in Applied Mathematics and Computational Science, School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Bingyu</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Graduate Group in Applied Mathematics and Computational Science, School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Yiwen</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Graduate Group in Applied Mathematics and Computational Science, School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tong</LastName><ForeName>Jiayi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Dazheng</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lumley</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Statistics, Faculty of Science, University of Auckland, Auckland, New Zealand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brand</LastName><ForeName>Milou T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Real World Solutions, IQVIA, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Zandt</LastName><ForeName>Mui</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Real World Solutions, IQVIA, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falconer</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Xing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Health Data Science, Indiana University, Indianapolis, IN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Health Data Science, Indiana University, Indianapolis, IN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Haoyang</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yan</LastName><ForeName>Chao</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Guojun</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Electrical and Software Engineering, University of Calgary, Calgary, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Andrew E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>Clinical and Translational Science Institute, Tufts Medical Center, Boston, MA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Fei</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bian</LastName><ForeName>Jiang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Health Data Science, Indiana University, Indianapolis, IN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Malin</LastName><ForeName>Bradley</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Computer Science, Vanderbilt University, Nashville, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Janssen Research &amp; Development, Titusville, NJ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, University of California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Yun</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Center for Biologics Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drew</LastName><ForeName>Steve</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Electrical and Software Engineering, University of Calgary, Calgary, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Jiayu</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Information, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asch</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of General Internal Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. ychen123@upenn.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, PA, USA. ychen123@upenn.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, PA, USA. ychen123@upenn.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Penn Medicine Center for Evidence-based Practice (CEP), Philadelphia, PA, USA. ychen123@upenn.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Penn Institute for Biomedical Informatics (IBI), Philadelphia, PA, USA. ychen123@upenn.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1R01LM012607</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG069880</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 TR003709</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG077820</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>ME-2019C3-18315</GrantID><Agency>Patient-Centered Outcomes Research Institute (PCORI) Project Program</Agency><Country/></Grant><Grant><GrantID>R01 LM013519</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM012607</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI130460</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG074604</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG073435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>NPJ Digit Med</MedlineTA><NlmUniqueID>101731738</NlmUniqueID><ISSNLinking>2398-6352</ISSNLinking></MedlineJournalInfo><CoiStatement>Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>1</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>16</Day><Hour>0</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>16</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>15</Day><Hour>23</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>15</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40664765</ArticleId><ArticleId IdType="pmc">PMC12263967</ArticleId><ArticleId IdType="doi">10.1038/s41746-025-01781-1</ArticleId><ArticleId IdType="pii">10.1038/s41746-025-01781-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Friedman, C. P., Wong, A. K. &amp; Blumenthal, D. Achieving a nationwide learning health system. <i>Sci. Transl. Med.</i><b>2</b>, 57cm29 (2010).
</Citation><ArticleIdList><ArticleId IdType="pubmed">21068440</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak, G. et al. Observational health data sciences and informatics (OHDSI): opportunities for observational researchers. <i>Stud. Health Technol. Inf.</i><b>216</b>, 574&#x2013;578 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleurence, R. L. et al. Launching PCORnet, a national patient-centered clinical research network. <i>J. Am. Med Inf. Assoc.</i><b>21</b>, 578&#x2013;582 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4078292</ArticleId><ArticleId IdType="pubmed">24821743</ArticleId></ArticleIdList></Reference><Reference><Citation>Horwitz, L. I. et al. Researching COVID to Enhance Recovery (RECOVER) adult study protocol: Rationale, objectives, and design. <i>PLoS One</i><b>18</b>, e0286297 (2023).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10289397</ArticleId><ArticleId IdType="pubmed">37352211</ArticleId></ArticleIdList></Reference><Reference><Citation>Haendel, M. A. et al. The National COVID Cohort Collaborative (N3C): Rationale, design, infrastructure, and deployment. <i>J. Am. Med. Inform. Assoc.</i><b>28</b>, 427&#x2013;443 (2021).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7454687</ArticleId><ArticleId IdType="pubmed">32805036</ArticleId></ArticleIdList></Reference><Reference><Citation>Brat, G. A. et al. International electronic health record-derived COVID-19 clinical course profiles: the 4CE consortium. <i>NPJ Digit Med</i><b>3</b>, 109 (2020).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7438496</ArticleId><ArticleId IdType="pubmed">32864472</ArticleId></ArticleIdList></Reference><Reference><Citation>The Biologics Effectiveness and Safety (BEST) Initiative. https://bestinitiative.org/.</Citation></Reference><Reference><Citation>U.S. Food &amp; Drug Administration. FDA&#x2019;s Sentinel Initiative. https://www.fda.gov/safety/fdas-sentinel-initiative.</Citation></Reference><Reference><Citation>U.S. Food &amp; Drug Administration. Considerations for the Use of Real-World Data and Real-World Evidence to Support Regulatory Decision-Making for Drug and Biological Products. https://www.fda.gov/media/171667/download.</Citation></Reference><Reference><Citation>Zuo, X., Chen, Y., Ohno-Machado, L. &amp; Xu, H. How do we share data in COVID-19 research? A systematic review of COVID-19 datasets in PubMed Central Articles. <i>Brief. Bioinform.</i><b>22</b>, 800&#x2013;811 (2021).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7799277</ArticleId><ArticleId IdType="pubmed">33757278</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno-Machado, L. To Share or Not To Share: That Is Not the Question. <i>Sci Transl Med</i><b>4</b>, (2012).</Citation><ArticleIdList><ArticleId IdType="pubmed">23253606</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohno-Machado, L. et al. pSCANNER: patient-centered Scalable National Network for Effectiveness Research. <i>J. Am. Med. Inform. Assoc.</i><b>21</b>, 621&#x2013;626 (2014).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4078293</ArticleId><ArticleId IdType="pubmed">24780722</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu, Y., Jiang, X., Kim, J. &amp; Ohno-Machado, L. Grid Binary LOgistic REgression (GLORE): building shared models without sharing data. <i>J. Am. Med. Inform. Assoc.</i><b>19</b>, 758&#x2013;764 (2012).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3422844</ArticleId><ArticleId IdType="pubmed">22511014</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu, C.-L. et al. WebDISCO: a web service for distributed cox model learning without patient-level data sharing. <i>J. Am. Med. Inform. Assoc.</i><b>22</b>, 1212&#x2013;1219 (2015).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5009917</ArticleId><ArticleId IdType="pubmed">26159465</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, J., Kolar, M., Srebro, N. &amp; Zhang, T. Efficient distributed learning with sparsity. In <i>International Conference on Machine Learning</i> 3636&#x2013;3645 (PMLR, 2017).</Citation></Reference><Reference><Citation>Jordan, M. I., Lee, J. D. &amp; Yang, Y. Communication-efficient distributed statistical inference. <i>J. Am. Stat. Assoc.</i><b>114</b>, 668&#x2013;681 (2019).</Citation></Reference><Reference><Citation>Duan, R. et al. Learning from electronic health records across multiple sites: A communication-efficient and privacy-preserving distributed algorithm. <i>J. Am. Med. Inform. Assoc.</i><b>27</b>, 376&#x2013;385 (2020).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7025371</ArticleId><ArticleId IdType="pubmed">31816040</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan, R., Boland, M. R., Moore, J. H. &amp; Chen, Y. ODAL: A one-shot distributed algorithm to perform logistic regressions on electronic health records data from multiple clinical sites. <i>Pac. Symp. Biocomput</i><b>24</b>, 30&#x2013;41 (2019).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6417819</ArticleId><ArticleId IdType="pubmed">30864308</ArticleId></ArticleIdList></Reference><Reference><Citation>Edmondson, M. J. et al. Distributed Quasi-Poisson regression algorithm for modeling multi-site count outcomes in distributed data networks. <i>J. Biomed. Inf.</i><b>131</b>, 104097 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11874216</ArticleId><ArticleId IdType="pubmed">35643272</ArticleId></ArticleIdList></Reference><Reference><Citation>Edmondson, M. J. et al. An efficient and accurate distributed learning algorithm for modeling multi-site zero-inflated count outcomes. <i>Sci. Rep.</i><b>11</b>, 19647 (2021).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8490431</ArticleId><ArticleId IdType="pubmed">34608222</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan, R. et al. Learning from local to global: An efficient distributed algorithm for modeling time-to-event data. <i>J. Am. Med Inf. Assoc.</i><b>27</b>, 1028&#x2013;1036 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7647322</ArticleId><ArticleId IdType="pubmed">32626900</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo, C. et al. ODACH: a one-shot distributed algorithm for Cox model with heterogeneous multi-center data. <i>Sci. Rep.</i><b>12</b>, 6627 (2022).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9033863</ArticleId><ArticleId IdType="pubmed">35459767</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, R., Romano, J. D., Chen, Y. &amp; Moore, J. H. Centralized and federated models for the analysis of clinical data. <i>Annu Rev. Biomed. Data Sci.</i><b>7</b>, 179&#x2013;199 (2024).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11571052</ArticleId><ArticleId IdType="pubmed">38723657</ArticleId></ArticleIdList></Reference><Reference><Citation>dGEM: Decentralized algorithm for Generalized mixed Effect Models with the Application in Hospital Profiling. https://www.ohdsi.org/2022showcase-72/.</Citation></Reference><Reference><Citation>Chen, Y. et al. Regression cubes with lossless compression and aggregation. <i>IEEE Trans. Knowl. Data Eng.</i><b>18</b>, 1585&#x2013;1599 (2006).</Citation></Reference><Reference><Citation>Luo, C. et al. DLMM as a lossless one-shot algorithm for collaborative multi-site distributed linear mixed models. <i>Nat. Commun.</i><b>13</b>, 1678 (2022).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8967932</ArticleId><ArticleId IdType="pubmed">35354802</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams, R. D. et al. Seek COVER: using a disease proxy to rapidly develop and validate a personalized risk calculator for COVID-19 outcomes in an international network. <i>BMC Med Res Methodol.</i><b>22</b>, 35 (2022).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8801189</ArticleId><ArticleId IdType="pubmed">35094685</ArticleId></ArticleIdList></Reference><Reference><Citation>Penn Computing Inference Learning (PennCIL) lab. Privacy-Preserving Distributed Algorithms. https://github.com/Penncil/pda.</Citation></Reference><Reference><Citation>OHDSI Community. OMOP Common Data Model. https://ohdsi.github.io/CommonDataModel/.</Citation></Reference><Reference><Citation>CMS Cell Size Suppression Policy. https://resdac.org/articles/cms-cell-size-suppression-policy.</Citation></Reference><Reference><Citation>California Department of Health Care Services. Data De-identification Guidelines (DDG). https://www.dhcs.ca.gov/dataandstats/Documents/DHCS-DDG-V2.0-120116.pdf.</Citation></Reference><Reference><Citation>Bonanad, C. et al. The Effect of Age on Mortality in Patients With COVID-19: A Meta-Analysis With 611,583 Subjects. <i>J. Am. Med Dir. Assoc.</i><b>21</b>, 915&#x2013;918 (2020).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7247470</ArticleId><ArticleId IdType="pubmed">32674819</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen, N. T. et al. Male gender is a predictor of higher mortality in hospitalized adults with COVID-19. <i>PLoS One</i><b>16</b>, e0254066 (2021).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8270145</ArticleId><ArticleId IdType="pubmed">34242273</ArticleId></ArticleIdList></Reference><Reference><Citation>Corona, G. et al. Diabetes is most important cause for mortality in COVID-19 hospitalized patients: Systematic review and meta-analysis. <i>Rev. Endocr. Metab. Disord.</i><b>22</b>, 275&#x2013;296 (2021).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7899074</ArticleId><ArticleId IdType="pubmed">33616801</ArticleId></ArticleIdList></Reference><Reference><Citation>Du, Y., Zhou, N., Zha, W. &amp; Lv, Y. Hypertension is a clinically important risk factor for critical illness and mortality in COVID-19: A meta-analysis. <i>Nutr., Metab. Cardiovascular Dis.</i><b>31</b>, 745&#x2013;755 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7831720</ArticleId><ArticleId IdType="pubmed">33549450</ArticleId></ArticleIdList></Reference><Reference><Citation>Wasserman, L. &amp; Zhou, S. A Statistical Framework for Differential Privacy. <i>J. Am. Stat. Assoc.</i><b>105</b>, 375&#x2013;389 (2010).</Citation></Reference><Reference><Citation>Jiang, W. et al. WebGLORE: a Web service for Grid LOgistic REgression. <i>Bioinformatics</i><b>29</b>, 3238&#x2013;3240 (2013).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3842761</ArticleId><ArticleId IdType="pubmed">24072732</ArticleId></ArticleIdList></Reference><Reference><Citation>Shu, D., Yoshida, K., Fireman, BH. &amp; Toh, S. Inverse probability weighted Cox model in multi-site studies without sharing individual-level data. <i>Stat. Methods Med. Res.</i><b>29</b>, 1668&#x2013;1681 (2019).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7042068</ArticleId><ArticleId IdType="pubmed">31448681</ArticleId></ArticleIdList></Reference><Reference><Citation>McCullagh, P. &amp; Nelder, J. A. <i>Generalized Linear Models</i>. (Routledge, 2019). 10.1201/9780203753736.</Citation></Reference><Reference><Citation>Hilbe, J. M. <i>Negative Binomial Regression</i>. (Cambridge University Press, 2011). 10.1017/CBO9780511973420.</Citation></Reference><Reference><Citation>Ver Hoef, J. M. &amp; Boveng, P. L. Quasi-Poisson vs. negative binomial regression: how should we model overdispersed count data? <i>Ecology</i><b>88</b>, 2766&#x2013;2772 (2007).
</Citation><ArticleIdList><ArticleId IdType="pubmed">18051645</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia, W. et al. Managing re-identification risks while providing access to the All of Us research program. <i>J. Am. Med Inf. Assoc.</i><b>30</b>, 907&#x2013;914 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10114067</ArticleId><ArticleId IdType="pubmed">36809550</ArticleId></ArticleIdList></Reference><Reference><Citation>Department of Health Agency Standards for Reporting Data with Small Numbers. https://doh.wa.gov/sites/default/files/legacy/Documents/1500//SmallNumbers.pdf (2018).</Citation></Reference><Reference><Citation>Utah Department of Health Data Suppression/Data Aggregation Guidelines Summary. https://ibis.health.utah.gov/ibisph-view/pdf/resource/DataSuppressionSummary.pdf (2022).</Citation></Reference><Reference><Citation>Shokri, R. &amp; Shmatikov, V. Privacy-preserving deep learning. In <i>2015 53rd Annual Allerton Conference on Communication, Control, and Computing (Allerton)</i> 909&#x2013;910 (IEEE, 2015). 10.1109/ALLERTON.2015.7447103.</Citation></Reference><Reference><Citation>Phong, L. T., Aono, Y., Hayashi, T., Wang, L. &amp; Moriai, S. Privacy-preserving deep learning via additively homomorphic encryption. <i>IEEE Trans. Inf. Forensics Security</i><b>13</b>, 1333&#x2013;1345 (2018).</Citation></Reference><Reference><Citation>Zhang, C. <i>et al</i>. BatchCrypt: efficient homomorphic encryption for cross-silo federated learning. In <i>Proc. 2020 USENIX Conference on Usenix Annual Technical Conference</i> (USENIX Association, USA, 2020).</Citation></Reference><Reference><Citation>Fang, H. &amp; Qian, Q. Privacy preserving machine learning with homomorphic encryption and federated learning. <i>Future Internet</i><b>13</b>, 94 (2021).</Citation></Reference><Reference><Citation>Xie, Q. et al. Efficiency optimization techniques in privacy-preserving federated learning with homomorphic encryption: a brief survey. <i>IEEE Int. Things J.</i><b>11</b>, 24569&#x2013;24580 (2024).</Citation></Reference><Reference><Citation>Aono, Y., Hayashi, T., Phong, L. T. &amp; Wang, L. Privacy-preserving logistic regression with distributed data sources via homomorphic encryption. <i>IEICE Trans. Inf. Syst.</i><b>E99.D</b>, 2079&#x2013;2089 (2016).</Citation></Reference><Reference><Citation>Park, J. &amp; Lim, H. Privacy-preserving federated learning using homomorphic encryption. <i>Appl. Sci.</i><b>12</b>, 734 (2022).</Citation></Reference><Reference><Citation>Han, K., Hong, S., Cheon, J. H. &amp; Park, D. Logistic regression on homomorphic encrypted data at scale. <i>Proc. AAAI Conf. Artif. Intell.</i><b>33</b>, 9466&#x2013;9471 (2019).</Citation></Reference><Reference><Citation>Cheon, J. H., Kim, A., Kim, M. &amp; Song, Y. Homomorphic encryption for arithmetic of approximate numbers. In <i>Advances in Cryptology&#x2013;ASIACRYPT 2017: 23rd International Conference on the Theory and Applications of Cryptology and Information Security</i>, Proceedings, part I 23, 409&#x2013;437 (Springer International Publishing, Hong kong, China, 2017).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40676203</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2398-6352</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>17</Day></PubDate></JournalIssue><Title>NPJ digital medicine</Title><ISOAbbreviation>NPJ Digit Med</ISOAbbreviation></Journal><ArticleTitle>Negative control-calibrated difference-in-difference analyses: addressing unmeasured confounding in RWD with application to racial/ethnic differences.</ArticleTitle><Pagination><StartPage>452</StartPage><MedlinePgn>452</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">452</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41746-025-01821-w</ELocationID><Abstract><AbstractText>Real-world data (RWD) from electronic health records and digital health databases present unique opportunities to study causal effects in healthcare. While Difference-in-Differences (DiD) analysis is widely used for such analyses, it can be biased when time-varying unmeasured confounding violates the parallel trends assumption. We propose a negative control-calibrated difference-in-difference (NC-DiD) approach that uses negative control outcomes (NCOs) both before and after the intervention to detect and adjust for such confounding. The method remains robust even with partially unreliable controls. In simulations, NC-DiD reduces bias, controls type-I error, and improves estimation accuracy. We applied NC-DiD to assess racial/ethnic disparities in post COVID-19 health outcomes using RWD emulated from pediatric 15,373 patients across eight children's hospitals. Results revealed worse long-term outcomes for minority groups compared to Non-Hispanic White patients. NC-DiD offers a robust framework for deriving reliable causal insights from digital health data, supporting evidence-based clinical decision-making and potentially improving patient outcomes.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhang</LastName><ForeName>Dazheng</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhang</LastName><ForeName>Bingyu</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Applied Mathematics and Computational Science, School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Wang</LastName><ForeName>Huiyuan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Yiwen</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Applied Mathematics and Computational Science, School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolock</LastName><ForeName>Charles J</ForeName><Initials>CJ</Initials><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Wenjie</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Linbo</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Statistical Sciences, University of Toronto, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Informatics Services, New York-Presbyterian Hospital, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, PA, USA. ychen123@upenn.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, University of Pennsylvania, Philadelphia, PA, USA. ychen123@upenn.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Applied Mathematics and Computational Science, School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA, USA. ychen123@upenn.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leonard Davis Institute of Health Economics, Philadelphia, PA, USA. ychen123@upenn.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Penn Medicine Center for Evidence-based Practice (CEP), Philadelphia, PA, USA. ychen123@upenn.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Penn Institute for Biomedical Informatics (IBI), Philadelphia, PA, USA. ychen123@upenn.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>1R01LM014344</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>ME-2019C3-18315</GrantID><Acronym>PCORI</Acronym><Agency>Patient-Centered Outcomes Research Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG077820</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM013519</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 MH136069</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 EY034179</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AI167418</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 TR003709</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DK128237</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM014344</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG074604</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG073435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>NPJ Digit Med</MedlineTA><NlmUniqueID>101731738</NlmUniqueID><ISSNLinking>2398-6352</ISSNLinking></MedlineJournalInfo><CoiStatement>Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>18</Day><Hour>1</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>18</Day><Hour>1</Hour><Minute>40</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>17</Day><Hour>23</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40676203</ArticleId><ArticleId IdType="pmc">PMC12271539</ArticleId><ArticleId IdType="doi">10.1038/s41746-025-01821-w</ArticleId><ArticleId IdType="pii">10.1038/s41746-025-01821-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sherman, R. E. et al. Real-world evidence&#x2014;what is it and what can it tell us? <i>N. Engl. J. Med.</i><b>375</b>, 2293&#x2013;2297 (2016).
</Citation><ArticleIdList><ArticleId IdType="pubmed">27959688</ArticleId></ArticleIdList></Reference><Reference><Citation>Abernethy, A. P., Gippetti, J., Parulkar, R. &amp; Revol, C. Use of electronic health record data for quality reporting. <i>J. Oncol. Pr.</i><b>13</b>, 530&#x2013;534 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28745935</ArticleId></ArticleIdList></Reference><Reference><Citation>Corrigan-Curay, J., Sacks, L. &amp; Woodcock, J. Real-world evidence and real-world data for evaluating drug safety and effectiveness. <i>JAMA</i><b>320</b>, 867&#x2013;868 (2018).
</Citation><ArticleIdList><ArticleId IdType="pubmed">30105359</ArticleId></ArticleIdList></Reference><Reference><Citation>Makady, A., de Boer, A., Hillege, H., Klungel, O. &amp; Goettsch, W. What is real-world data? A review of definitions based on literature and stakeholder interviews. <i>Value Health</i><b>20</b>, 858&#x2013;865 (2017).
</Citation><ArticleIdList><ArticleId IdType="pubmed">28712614</ArticleId></ArticleIdList></Reference><Reference><Citation>FDA. Real-World Data: Assessing Electronic Health Records and Medical Claims Data To Support Regulatory Decision-Making for Drug and Biological Products: Guidance for Industry. https://www.fda.gov/regulatory&#x2010;information/search&#x2010;fda&#x2010;guidance&#x2010;documents/real&#x2010;world&#x2010;data&#x2010;assessing&#x2010;electronic&#x2010;health&#x2010;records&#x2010;and&#x2010;medical&#x2010;claims&#x2010;data&#x2010;support&#x2010;regulatory (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9320939</ArticleId><ArticleId IdType="pubmed">35471704</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh, A. et al. Incorporating temporal EHR data in predictive models for risk stratification of renal function deterioration. <i>J. Biomed. Inf.</i><b>53</b>, 220&#x2013;228 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4520404</ArticleId><ArticleId IdType="pubmed">25460205</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta, A., Liu, T. &amp; Crick, C. Utilizing time series data embedded in electronic health records to develop continuous mortality risk prediction models using hidden Markov models: a sepsis case study. <i>Stat. Methods Med. Res.</i><b>29</b>, 3409&#x2013;3423 (2020).
</Citation><ArticleIdList><ArticleId IdType="pubmed">32552573</ArticleId></ArticleIdList></Reference><Reference><Citation>Franklin, J. M. &amp; Schneeweiss, S. When and how can real world data analyses substitute for randomized controlled trials? <i>Clin. Pharm. Ther.</i><b>102</b>, 924&#x2013;933 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28836267</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;n, M. A. &amp; Robins, J. M. Using big data to emulate a target trial when a randomized trial is not available. <i>Am. J. Epidemiol.</i><b>183</b>, 758&#x2013;764 (2016).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4832051</ArticleId><ArticleId IdType="pubmed">26994063</ArticleId></ArticleIdList></Reference><Reference><Citation>Dimick, J. B. &amp; Ryan, A. M. Methods for evaluating changes in health care policy: the difference-in-differences approach. <i>JAMA</i><b>312</b>, 2401&#x2013;2402 (2014).
</Citation><ArticleIdList><ArticleId IdType="pubmed">25490331</ArticleId></ArticleIdList></Reference><Reference><Citation>Wing, C., Simon, K. &amp; Bello-Gomez, R. A. Designing difference in difference studies: best practices for public health policy research. <i>Annu. Rev. Public Health</i><b>39</b>, 453&#x2013;469 (2018).
</Citation><ArticleIdList><ArticleId IdType="pubmed">29328877</ArticleId></ArticleIdList></Reference><Reference><Citation>Whittaker, W. et al. Associations between extending access to primary care and emergency department visits: a difference-in-differences analysis. <i>PLoS Med.</i><b>13</b>, e1002113 (2016).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5012704</ArticleId><ArticleId IdType="pubmed">27598248</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris, S. et al. Impact of centralising acute stroke services in English metropolitan areas on mortality and length of hospital stay: difference-in-differences analysis. <i>BMJ</i><b>349</b>, g4757 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4122734</ArticleId><ArticleId IdType="pubmed">25098169</ArticleId></ArticleIdList></Reference><Reference><Citation>Burden, B. C., Canon, D. T., Mayer, K. R. &amp; Moynihan, D. P. Election laws, mobilization, and turnout: the unanticipated consequences of election reform. <i>Am. J. Pol. Sci.</i><b>58</b>, 95&#x2013;109 (2014).</Citation></Reference><Reference><Citation>Hansen, S. W. Polity size and local political trust: a quasi&#x2010;experiment using municipal mergers in Denmark. <i>Scan Polit. Stud.</i><b>36</b>, 43&#x2013;66 (2013).</Citation></Reference><Reference><Citation>Neureiter, M. Evaluating the effects of immigrant integration policies in Western Europe using a difference-in-differences approach. <i>J. Ethn. Migr. Stud.</i><b>45</b>, 2779&#x2013;2800 (2019).</Citation></Reference><Reference><Citation>Malesky, E. J., Nguyen, C. V. &amp; Tran, A. The impact of recentralization on public services: a difference-in-differences analysis of the abolition of elected councils in Vietnam. <i>Am. Political Sci. Rev.</i><b>108</b>, 144&#x2013;168 (2014).</Citation></Reference><Reference><Citation>Callaway, B. &amp; Sant&#x2019;Anna, P. H. C. Difference-in-differences with multiple time periods. <i>J. Econ.</i><b>225</b>, 200&#x2013;230 (2021).</Citation></Reference><Reference><Citation>Abadie, A. Semiparametric difference-in-differences estimators. <i>Rev. Econ. Stud.</i><b>72</b>, 1&#x2013;19 (2005).</Citation></Reference><Reference><Citation>Apathy, N. C., Holmgren, A. J. &amp; Cross, D. A. Physician EHR time and visit volume following adoption of team-based documentation support. <i>JAMA Intern. Med.</i><b>184</b>, 1212&#x2013;1221 (2024).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11348094</ArticleId><ArticleId IdType="pubmed">39186284</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilinski, A. &amp; Ganguli, I. Methodological considerations for difference-in-differences. <i>JAMA Intern. Med.</i><b>184</b>, 1161&#x2013;1162 (2024).
</Citation><ArticleIdList><ArticleId IdType="pubmed">39186291</ArticleId></ArticleIdList></Reference><Reference><Citation>Angier, H. et al. Racial/ethnic disparities in health insurance and differences in visit type for a population of patients with diabetes after Medicaid expansion. <i>J. Health Care Poor Underserved</i><b>30</b>, 116 (2019).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6429963</ArticleId><ArticleId IdType="pubmed">30827973</ArticleId></ArticleIdList></Reference><Reference><Citation>Pazzagli, L. et al. Methods for time&#x2010;varying exposure related problems in pharmacoepidemiology: an overview. <i>Pharmacoepidemiol. Drug Saf.</i><b>27</b>, 148&#x2013;160 (2018).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5814826</ArticleId><ArticleId IdType="pubmed">29285840</ArticleId></ArticleIdList></Reference><Reference><Citation>Streeter, A. J. et al. Adjusting for unmeasured confounding in nonrandomized longitudinal studies: a methodological review. <i>J. Clin. Epidemiol.</i><b>87</b>, 23&#x2013;34 (2017).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5589113</ArticleId><ArticleId IdType="pubmed">28460857</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson, D. B., Ye, T. &amp; Tchetgen, E. J. T. Generalized difference-in-differences. <i>Epidemiology</i><b>34</b>, 167&#x2013;174 (2023).
</Citation><ArticleIdList><ArticleId IdType="pubmed">36722798</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibson, L. &amp; Zimmerman, F. Measuring the sensitivity of difference-in-difference estimates to the parallel trends assumption. <i>Res. Methods Med. Health Sci.</i><b>2</b>, 148&#x2013;156 (2021).</Citation></Reference><Reference><Citation>Ye, T., Ertefaie, A., Flory, J., Hennessy, S. &amp; Small, D. S. Instrumented difference&#x2010;in&#x2010;differences. <i>Biometrics</i><b>79</b>, 569&#x2013;581 (2023).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10484497</ArticleId><ArticleId IdType="pubmed">36305081</ArticleId></ArticleIdList></Reference><Reference><Citation>Stuart, E. A. et al. Using propensity scores in difference-in-differences models to estimate the effects of a policy change. <i>Health Serv. Outcomes Res. Methodol.</i><b>14</b>, 166&#x2013;182 (2014).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4267761</ArticleId><ArticleId IdType="pubmed">25530705</ArticleId></ArticleIdList></Reference><Reference><Citation>Imai, K., Kim, I. S. &amp; Wang, E. H. Matching methods for causal inference with time&#x2010;series cross&#x2010;sectional data. <i>Am. J. Pol. Sci.</i><b>67</b>, 587&#x2013;605 (2023).</Citation></Reference><Reference><Citation>Ham, D. W. &amp; Miratrix, L. Benefits and costs of matching prior to a difference in differences analysis when parallel trends does not hold. <i>Ann. Appl. Stat.</i><b>18</b>, 2096&#x2013;2122 (2024).</Citation></Reference><Reference><Citation>Schuemie, M. J., Hripcsak, G., Ryan, P. B., Madigan, D. &amp; Suchard, M. A. Empirical confidence interval calibration for population-level effect estimation studies in observational healthcare data. <i>Proc. Natl Acad. Sci. USA</i><b>115</b>, 2571&#x2013;2577 (2018).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5856503</ArticleId><ArticleId IdType="pubmed">29531023</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie, M. J., Ryan, P. B., Dumouchel, W., Suchard, M. A. &amp; Madigan, D. Interpreting observational studies: why empirical calibration is needed to correct p-values. <i>Stat. Med</i><b>33</b>, 209&#x2013;218 (2014).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4285234</ArticleId><ArticleId IdType="pubmed">23900808</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo, X., Chen, Y., Ohno-Machado, L. &amp; Xu, H. How do we share data in COVID-19 research? A systematic review of COVID-19 datasets in PubMed Central Articles. <i>Brief. Bioinform.</i><b>22</b>, 800&#x2013;811 (2021).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7799277</ArticleId><ArticleId IdType="pubmed">33757278</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao, S. et al. Clinical features and burden of postacute sequelae of SARS-CoV-2 infection in children and adolescents. <i>JAMA Pediatr.</i><b>176</b>, 1000&#x2013;1009 (2022).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9396470</ArticleId><ArticleId IdType="pubmed">35994282</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu, Q. et al. Real-world effectiveness of BNT162b2 against infection and severe diseases in children and adolescents. <i>Ann. Intern. Med</i><b>177</b>, 165&#x2013;176 (2024).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11956830</ArticleId><ArticleId IdType="pubmed">38190711</ArticleId></ArticleIdList></Reference><Reference><Citation>Forrest, C. B. et al. Severity of acute COVID-19 in children&lt; 18 years old March 2020 to December 2021. <i>Pediatrics</i><b>149</b>, e2021055765 (2022).
</Citation><ArticleIdList><ArticleId IdType="pubmed">35322270</ArticleId></ArticleIdList></Reference><Reference><Citation>Roth, J., Sant&#x2019;Anna, P. H. C., Bilinski, A. &amp; Poe, J. What&#x2019;s trending in difference-in-differences? A synthesis of the recent econometrics literature. <i>J. Econ.</i><b>235</b>, 2218&#x2013;2244 (2023).</Citation></Reference><Reference><Citation>Roth, J. Pretest with caution: event-study estimates after testing for parallel trends. <i>Am. Econ. Rev. Insights</i><b>4</b>, 305&#x2013;322 (2022).</Citation></Reference><Reference><Citation>Greenland, S., Pearl, J. &amp; Robins, J. M. Confounding and collapsibility in causal inference. <i>Stat. Sci.</i><b>14</b>, 29&#x2013;46 (1999).</Citation></Reference><Reference><Citation>Whitcomb, B. W. &amp; Naimi, A. I. Defining, quantifying, and interpreting &#x201c;noncollapsibility&#x201d; in epidemiologic studies of measures of &#x201c;effect&#x201d;. <i>Am. J. Epidemiol.</i><b>190</b>, 697 (2021).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8530151</ArticleId><ArticleId IdType="pubmed">33305812</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40677680</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1532-4435</ISSN><JournalIssue CitedMedium="Print"><Volume>26</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Journal of machine learning research : JMLR</Title><ISOAbbreviation>J Mach Learn Res</ISOAbbreviation></Journal><ArticleTitle>DisC<sup>2</sup>o-HD: Distributed causal inference with covariates shift for analyzing real-world high-dimensional data.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">3</ELocationID><Abstract><AbstractText>High-dimensional healthcare data, such as electronic health records (EHR) data and claims data, present two primary challenges due to the large number of variables and the need to consolidate data from multiple clinical sites. The third key challenge is the potential existence of heterogeneity in terms of covariate shift. In this paper, we propose a distributed learning algorithm accounting for covariate shift to estimate the average treatment effect (ATE) for high-dimensional data, named DisC<sup>2</sup>o-HD. Leveraging the surrogate likelihood method, our method calibrates the estimates of the propensity score and outcome models to approximately attain the desired covariate balancing property, while accounting for the covariate shift across multiple clinical sites. We show that our distributed covariate balancing propensity score estimator can approximate the pooled estimator, which is obtained by pooling the data from multiple sites together. The proposed estimator remains consistent if either the propensity score model or the outcome regression model is correctly specified. The semiparametric efficiency bound is achieved when both the propensity score and the outcome models are correctly specified. We conduct simulation studies to demonstrate the performance of the proposed algorithm; additionally, we apply the algorithm to a real-world data set to present the readiness of implementation and validity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tong</LastName><ForeName>Jiayi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Jie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY 10027, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ning</LastName><ForeName>Yang</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Statistics and Data Sciences, Cornell University, Ithaca, NY 14853, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology and Informatics, University of Pennsylvania, Philadelphia, PA 19104, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R56 AG069880</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG077820</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM013519</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AI167418</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 TR003709</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DK128237</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM014344</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG074604</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG073435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM012607</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 MH136069</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI130460</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 EY034179</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Mach Learn Res</MedlineTA><NlmUniqueID>101262635</NlmUniqueID><ISSNLinking>1532-4435</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Causal Inference</Keyword><Keyword MajorTopicYN="N">Distribution Shift</Keyword><Keyword MajorTopicYN="N">Federated Learning</Keyword><Keyword MajorTopicYN="N">High-dimensional Data</Keyword><Keyword MajorTopicYN="N">Real-World Data</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>18</Day><Hour>6</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>18</Day><Hour>6</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>18</Day><Hour>5</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40677680</ArticleId><ArticleId IdType="mid">NIHMS2087339</ArticleId><ArticleId IdType="pmc">PMC12269483</ArticleId><ArticleId IdType="pii">3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Athey Susan, Imbens Guido W, and Wager Stefan. Approximate residual balancing: debiased inference of average treatment effects in high dimensions. Journal of the Royal Statistical Society Series B: Statistical Methodology, 80(4):597&#x2013;623, 2018.</Citation></Reference><Reference><Citation>Battey Heather, Fan Jianqing, Liu Han, Lu Junwei, and Zhu Ziwei. Distributed testing and estimation under sparse high dimensional models. Annals of statistics, 46(3):1352, 2018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6051757</ArticleId><ArticleId IdType="pubmed">30034040</ArticleId></ArticleIdList></Reference><Reference><Citation>Behlen Fred M and Johnson Stephen B. Multicenter patient records research: security policies and tools. Journal of the American Medical Informatics Association, 6(6):435&#x2013;443, 1999.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC61386</ArticleId><ArticleId IdType="pubmed">10579601</ArticleId></ArticleIdList></Reference><Reference><Citation>Belloni Alexandre, Chernozhukov Victor, and Hansen Christian. Inference on treatment effects after selection among high-dimensional controls. Review of Economic Studies, 81(2):608&#x2013;650, 2014.</Citation></Reference><Reference><Citation>Belloni Alexandre, Chernozhukov Victor, Fernandez-Val Ivan, and Hansen Christian. Program evaluation and causal inference with high-dimensional data. Econometrica, 85(1):233&#x2013;298, 2017.</Citation></Reference><Reference><Citation>Bradic Jelena, Wager Stefan, and Zhu Yinchu. Sparsity double robust inference of average treatment effects. arXiv preprint arXiv:1905.00744, 2019.</Citation></Reference><Reference><Citation>Chernozhukov Victor, Chetverikov Denis, Demirer Mert, Duflo Esther, Hansen Christian, Newey Whitney, and Robins James. Double/debiased machine learning for treatment and structural parameters, 2018.</Citation></Reference><Reference><Citation>Collins Francis S, Hudson Kathy L, Briggs Josephine P, and Lauer Michael S. Pcornet: turning a dream into reality, 2014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4078299</ArticleId><ArticleId IdType="pubmed">24821744</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan Rui, Boland Mary Regina, Moore Jason H, and Chen Yong. Odal: A one-shot distributed algorithm to perform logistic regressions on electronic health records data from multiple clinical sites. In BIOCOMPUTING 2019: Proceedings of the Pacific Symposium, pages 30&#x2013;41. World Scientific, 2018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6417819</ArticleId><ArticleId IdType="pubmed">30864308</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan Rui, Boland Mary Regina, Liu Zixuan, Liu Yue, Chang Howard H, Xu Hua, Chu Haitao, Schmid Christopher H, Forrest Christopher B, Holmes John H, et al. Learning from electronic health records across multiple sites: A communication-efficient and privacy-preserving distributed algorithm. Journal of the American Medical Informatics Association, 27(3):376&#x2013;385, 2020a.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7025371</ArticleId><ArticleId IdType="pubmed">31816040</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan Rui, Luo Chongliang, Schuemie Martijn J, Tong Jiayi, Liang C Jason, Chang Howard H, Boland Mary Regina, Bian Jiang, Xu Hua, Holmes John H, et al. Learning from local to global: An efficient distributed algorithm for modeling time-to-event data. Journal of the American Medical Informatics Association, 27(7):1028&#x2013;1036, 2020b.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7647322</ArticleId><ArticleId IdType="pubmed">32626900</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan Rui, Ning Yang, and Chen Yong. Heterogeneity-aware and communication-efficient distributed statistical inference. Biometrika, 109(1):67&#x2013;83, 2022.</Citation></Reference><Reference><Citation>Farrell Max H. Robust inference on average treatment effects with possibly more covariates than observations. Journal of Econometrics, 189(1):1&#x2013;23, 2015.</Citation></Reference><Reference><Citation>Fleurence Rachael L, Curtis Lesley H, Califf Robert M, Platt Richard, Selby Joe V, and Brown Jeffrey S. Launching pcornet, a national patient-centered clinical research network. Journal of the American Medical Informatics Association, 21(4):578&#x2013;582, 2014.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4078292</ArticleId><ArticleId IdType="pubmed">24821743</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman Charles P, Wong Adam K, and Blumenthal David. Achieving a nationwide learning health system. Science translational medicine, 2(57):57cm29&#x2013;57cm29, 2010.</Citation><ArticleIdList><ArticleId IdType="pubmed">21068440</ArticleId></ArticleIdList></Reference><Reference><Citation>Hahn Jinyong. On the role of the propensity score in efficient semiparametric estimation of average treatment effects. Econometrica, 66(2):315&#x2013;331, 1998. ISSN 00129682, 14680262. URL http://www.jstor.org/stable/2998560.</Citation></Reference><Reference><Citation>Han Larry, Hou Jue, Cho Kelly, Duan Rui, and Cai Tianxi. Federated adaptive causal estimation (face) of target treatment effects. arXiv preprint arXiv:2112.09313, 2021.</Citation></Reference><Reference><Citation>Hern&#xe1;n Miguel A and Robins James M. Causal inference, 2010.</Citation></Reference><Reference><Citation>Hirshberg David A and Wager Stefan. Augmented minimax linear estimation. The Annals of Statistics, 49(6):3206&#x2013;3227, 2021.</Citation></Reference><Reference><Citation>Hripcsak George, Duke Jon D, Shah Nigam H, Reich Christian G, Huser Vojtech, Schuemie Martijn J, Suchard Marc A, Park Rae Woong, Wong Ian Chi Kei, Rijnbeek Peter R, et al. Observational health data sciences and informatics (ohdsi): opportunities for observational researchers. Studies in health technology and informatics, 216:574, 2015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Jordan Michael I, Lee Jason D, and Yang Yun. Communication-efficient distributed statistical inference. Journal of the American Statistical Association, 2018.</Citation></Reference><Reference><Citation>Lee Jason D, Liu Qiang, Sun Yuekai, and Taylor Jonathan E. Communication-efficient sparse regression. The Journal of Machine Learning Research, 18(1):115&#x2013;144, 2017.</Citation></Reference><Reference><Citation>Newey Whitney K and Robins James R. Cross-fitting and fast remainder rates for semiparametric estimation. arXiv preprint arXiv:1801.09138, 2018.</Citation></Reference><Reference><Citation>Ning Yang and Liu Han. A general theory of hypothesis tests and confidence regions for sparse high dimensional models. The Annals of Statistics, 45(1):158&#x2013;195, 2017.</Citation></Reference><Reference><Citation>Ning Yang, Sida Peng, and Imai Kosuke. Robust estimation of causal effects via a high-dimensional covariate balancing propensity score. Biometrika, 107(3):533&#x2013;554, 2020.</Citation></Reference><Reference><Citation>Rosenbaum Paul R and Rubin Donald B. The central role of the propensity score in observational studies for causal effects. Biometrika, 70(1):41&#x2013;55, 1983.</Citation></Reference><Reference><Citation>Simon Tamara D, Haaland Wren, Hawley Katherine, Lambka Karen, and Mangione-Smith Rita. Development and validation of the pediatric medical complexity algorithm (pmca) version 3.0. Academic pediatrics, 18(5):577&#x2013;580, 2018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6035108</ArticleId><ArticleId IdType="pubmed">29496546</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan Zhiqiang. Model-assisted inference for treatment effects using regularized calibrated estimation with high-dimensional data. The Annals of Statistics, 48(2):811&#x2013;837, 2020a.</Citation></Reference><Reference><Citation>Tan Zhiqiang. Regularized calibrated estimation of propensity scores with model misspecification and high-dimensional data. Biometrika, 107(1):137&#x2013;158, 2020b.</Citation></Reference><Reference><Citation>Van de Geer Sara, B&#xfc;hlmann Peter, Ritov Ya&#x2019;acov, and Dezeure Ruben. On asymptotically optimal confidence regions and tests for high-dimensional models. The Annals of Statistics, 42(3):1166&#x2013;1202, 2014.</Citation></Reference><Reference><Citation>van der Laan Mark J, Rose Sherri, Zheng Wenjing, and van der Laan Mark J. Cross-validated targeted minimum-loss-based estimation. Targeted learning: causal inference for observational and experimental data, pages 459&#x2013;474, 2011.</Citation></Reference><Reference><Citation>Wang Jialei, Kolar Mladen, Srebro Nathan, and Zhang Tong. Efficient distributed learning with sparsity. In International conference on machine learning, pages 3636&#x2013;3645. PMLR, 2017.</Citation></Reference><Reference><Citation>Wedderburn Robert WM. Quasi-likelihood functions, generalized linear models, and the gauss&#x2014;newton method. Biometrika, 61(3):439&#x2013;447, 1974.</Citation></Reference><Reference><Citation>Wu Yonghui, Warner Jeremy L, Wang Liwei, Jiang Min, Xu Jun, Chen Qingxia, Nian Hui, Dai Qi, Du Xianglin, Yang Ping, et al. Discovery of noncancer drug effects on survival in electronic health records of patients with cancer: a new paradigm for drug repurposing. JCO clinical cancer informatics, 3:1&#x2013;9, 2019.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6693869</ArticleId><ArticleId IdType="pubmed">31141421</ArticleId></ArticleIdList></Reference><Reference><Citation>Wynberg Elke, Han Alvin X, Boyd Anders, van Willigen Hugo DG, Verveen Anouk, Lebbink Romy, van der Straten Karlijn, Kootstra Neeltje, van Gils Marit J, Russell Colin, et al. The effect of sars-cov-2 vaccination on post-acute sequelae of covid-19 (pasc): A prospective cohort study. Vaccine, 40(32):4424&#x2013;4431, 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9170535</ArticleId><ArticleId IdType="pubmed">35725782</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong Ruoxuan, Koenecke Allison, Powell Michael, Shen Zhu, Vogelstein Joshua T, and Athey Susan. Federated causal inference in heterogeneous observational data. arXiv preprint arXiv:2107.11732, 2021.</Citation><ArticleIdList><ArticleId IdType="pubmed">37553084</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Hua, Aldrich Melinda C, Chen Qingxia, Liu Hongfang, Peterson Neeraja B, Dai Qi, Levy Mia, Shah Anushi, Han Xue, Ruan Xiaoyang, et al. Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality. Journal of the American Medical Informatics Association, 22(1):179&#x2013;191, 2015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4433365</ArticleId><ArticleId IdType="pubmed">25053577</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Yuchen, Duchi John C., and Wainwright Martin J.. Communication-efficient algorithms for statistical optimization. Journal of Machine Learning Research, 14(68):3321&#x2013;3363, 2013. URL http://jmlr.org/papers/v14/zhang13b.html.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40680297</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>18</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1527-974X</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jul</Month><Day>18</Day></PubDate></JournalIssue><Title>Journal of the American Medical Informatics Association : JAMIA</Title><ISOAbbreviation>J Am Med Inform Assoc</ISOAbbreviation></Journal><ArticleTitle>Breaking data silos: incorporating the DICOM imaging standard into the OMOP CDM to enable multimodal research.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">ocaf091</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/jamia/ocaf091</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This work incorporates the Digital Imaging Communications in Medicine (DICOM) Standard into the Observational Medical Outcomes Partnership Common Data Model (OMOP CDM) to standardize and accurately represent imaging studies, such as acquisition parameters, in multimodal research studies.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">DICOM is the internationally adopted standard that defines entities and relationships for biomedical imaging data used for clinical imaging studies. Most of the complexity in the DICOM data structure centers around the metadata. This metadata contains information about the patient and the modality acquisition parameters. We parsed the DICOM vocabularies in Parts 3, 6, and 16 to obtain structured metadata definitions and added these as custom concepts in the OMOP CDM vocabulary. To validate our pipeline, we harvested and transformed DICOM metadata from magnetic resonance images in the Alzheimer's Disease Neuroimaging Initiative (ADNI) study.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We extracted and added 5183 attributes and 3628 coded values from the DICOM standard as custom concepts to the OMOP CDM vocabulary. We ingested 545 ADNI imaging studies containing 4756 series and harvested 691&#xa0;224 metadata values. They were filtered, transformed, and loaded in the OMOP CDM imaging extension using the OMOP concepts for the DICOM attributes and values.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">This work is adaptable to clinical DICOM data. Future work will validate scalability and incorporate outcomes from automated analysis to provide a complete characterization research study within the OMOP framework.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The incorporation of medical imaging into clinical observational studies has been a barrier to multi model research. This work demonstrates detailed phenotypes and paves the way for observational multimodal research.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2025. Published by Oxford University Press on behalf of the American Medical Informatics Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Woo Yeon</ForeName><Initials>WY</Initials><Identifier Source="ORCID">0000-0001-9932-1485</Identifier><AffiliationInfo><Affiliation>Biomedical Informatics and Data Science, Johns Hopkins University, Baltimore, MD 21205, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sippel Schmidt</LastName><ForeName>Teri</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Biomedical Informatics and Data Science, Johns Hopkins University, Baltimore, MD 21205, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salvador</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Biomedical Informatics and Data Science, Johns Hopkins University, Baltimore, MD 21205, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Donnell</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Canon Medical Research United States Inc., Vernon Hills, IL 60061, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Genereaux</LastName><ForeName>Brad</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Biomedical Informatics and Data Science, Johns Hopkins University, Baltimore, MD 21205, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NVIDIA Corporation, Santa Clara, CA 95051, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeon</LastName><ForeName>Kyulee</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Innovation in Digital Healthcare, Yonsei University Health System, Seoul 03722, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>You</LastName><ForeName>Seng Chan</ForeName><Initials>SC</Initials><AffiliationInfo><Affiliation>Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul 03722, Republic of Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Innovation in Digital Healthcare, Yonsei University Health System, Seoul 03722, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dewey</LastName><ForeName>Blake E</ForeName><Initials>BE</Initials><AffiliationInfo><Affiliation>Biomedical Informatics and Data Science, Johns Hopkins University, Baltimore, MD 21205, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, Johns Hopkins University, Baltimore, MD 21287, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nagy</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Biomedical Informatics and Data Science, Johns Hopkins University, Baltimore, MD 21205, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Alzheimer&#x2019;s Disease Neuroimaging Initiative
</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>Global Research Imaging Platform initiative</Agency><Country/></Grant><Grant><Agency>NAVER Digital Bio Innovation Research Fund</Agency><Country/></Grant><Grant><GrantID>3720230020</GrantID><Agency>NAVER Corporation</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Am Med Inform Assoc</MedlineTA><NlmUniqueID>9430800</NlmUniqueID><ISSNLinking>1067-5027</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">DICOM</Keyword><Keyword MajorTopicYN="N">OMOP CDM</Keyword><Keyword MajorTopicYN="N">multimodal data</Keyword><Keyword MajorTopicYN="N">standardization</Keyword></KeywordList><InvestigatorList><Investigator ValidYN="Y"><LastName>Park</LastName><ForeName>Woo Yeon</ForeName><Initials>WY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sippel Schmidt</LastName><ForeName>Teri</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salvador</LastName><ForeName>Gabriel</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Donnell</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Genereaux</LastName><ForeName>Brad</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jeon</LastName><ForeName>Kyulee</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>You</LastName><ForeName>Seng Chan</ForeName><Initials>SC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dewey</LastName><ForeName>Blake E</ForeName><Initials>BE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nagy</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>5</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>18</Day><Hour>18</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>18</Day><Hour>18</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>18</Day><Hour>17</Hour><Minute>33</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40680297</ArticleId><ArticleId IdType="doi">10.1093/jamia/ocaf091</ArticleId><ArticleId IdType="pii">8206314</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40681761</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2398-6352</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>19</Day></PubDate></JournalIssue><Title>NPJ digital medicine</Title><ISOAbbreviation>NPJ Digit Med</ISOAbbreviation></Journal><ArticleTitle>Unlocking efficiency in real-world collaborative studies: a multi-site international study with one-shot lossless GLMM algorithm.</ArticleTitle><Pagination><StartPage>457</StartPage><MedlinePgn>457</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">457</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41746-025-01846-1</ELocationID><Abstract><AbstractText>The widespread adoption of real-world data has given rise to numerous healthcare-distributed research networks, but multi-site analyses still face administrative burdens and data privacy challenges. In response, we developed a Collaborative One-shot Lossless Algorithm for Generalized Linear Mixed Models (COLA-GLMM), the first-ever algorithm that achieves both lossless and one-shot properties. COLA-GLMM ensures accuracy against the gold standard of pooled data while requiring only summary statistics and completes within a single communication round, eliminating the usual back-and-forth overhead. We further introduced an enhanced version that employs homomorphic encryption to reduce the risks of summary statistics misuse at the coordinating center. The simulation studies showed near-exact agreement with the gold standard in parameter estimation, with relative differences of 7.8&#x2009;&#xd7;&#x2009;10<sup>-6</sup>%-3.0% under various cell suppression settings. We also validated COLA&#x2011;GLMM on eight international decentralized databases to identify risk factors for COVID&#x2011;19 mortality. Together, these results show that COLA&#x2011;GLMM enables accurate, low&#x2011;burden, and privacy-preserving multi&#x2011;site research.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tong</LastName><ForeName>Jiayi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. jtong20@jhu.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, PA, USA. jtong20@jhu.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. jtong20@jhu.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reps</LastName><ForeName>Jenna M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Johnson &amp; Johnson, Titusville, NJ, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics (OHDSI), New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Chongliang</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Public Health Sciences, Department of Surgery, Washington University in St. Louis, St. Louis, MO, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Yiwen</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Lu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramirez-Anguita</LastName><ForeName>Juan Manuel</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Hospital del Mar Research Institute (HMRIB), Hospital del Mar, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brand</LastName><ForeName>Milou T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Real World Solutions, IQVIA, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DuVall</LastName><ForeName>Scott L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VA Informatics and Computing Infrastructure, US Department of Veterans Affairs, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falconer</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fuentes</LastName><ForeName>Alex Mayer</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Parc Taul&#xed; Hospital Universitari, Sabadell, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Xing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Health Data Science, Indiana University, Indianapolis, IN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matheny</LastName><ForeName>Michael E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>VA Informatics and Computing Infrastructure, US Department of Veterans Affairs, Nashville, TN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayer</LastName><ForeName>Miguel A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Hospital del Mar Research Institute (HMRIB), Hospital del Mar, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Bhavnisha K</ForeName><Initials>BK</Initials><AffiliationInfo><Affiliation>VA Informatics and Computing Infrastructure, US Department of Veterans Affairs, Nashville, TN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simon</LastName><ForeName>Katherine R</ForeName><Initials>KR</Initials><AffiliationInfo><Affiliation>VA Informatics and Computing Infrastructure, US Department of Veterans Affairs, Nashville, TN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Vanderbilt University Medical Center, Nashville, TN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>VA Informatics and Computing Infrastructure, US Department of Veterans Affairs, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, University of California, Los Angeles, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Guojun</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Electrical and Software Engineering, University of Calgary, Calgary, AB, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Viernes</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>VA Informatics and Computing Infrastructure, US Department of Veterans Affairs, Salt Lake City, UT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Ross D</ForeName><Initials>RD</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Zandt</LastName><ForeName>Mui</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Real World Solutions, IQVIA, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Fei</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bian</LastName><ForeName>Jiang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Biostatistics and Health Data Science, Indiana University, Indianapolis, IN, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Biomedical Informatics, Regenstrief Institute, Indianapolis, IN, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Jiayu</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>School of Information, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asch</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Division of General Internal Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leonard Davis Institute of Health Economics, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. ychen123@upenn.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, PA, USA. ychen123@upenn.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leonard Davis Institute of Health Economics, Philadelphia, PA, USA. ychen123@upenn.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R56 AG069880</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01TR003709, U24MH136069, RF1AG077820, 1R01LM014344, 1R01AG077820, R01LM012607, R01AI130460, R01AG073435, R56AG074604, R01LM013519, R01DK128237, R56AG069880, R21AI167418, R21EY034179</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG077820</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM013519</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>VA ORD 22-D4V</GrantID><Agency>US Department of Veterans Affairs</Agency><Country/></Grant><Grant><GrantID>ME-2019C3-18315; ME-2018C3-14899</GrantID><Acronym>PCORI</Acronym><Agency>Patient-Centered Outcomes Research Institute</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AI167418</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 TR003709</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DK128237</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM014344</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG074604</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG073435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM012607</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 MH136069</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI130460</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 EY034179</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>NPJ Digit Med</MedlineTA><NlmUniqueID>101731738</NlmUniqueID><ISSNLinking>2398-6352</ISSNLinking></MedlineJournalInfo><CoiStatement>Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>10</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>19</Day><Hour>16</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>19</Day><Hour>16</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>18</Day><Hour>23</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40681761</ArticleId><ArticleId IdType="pmc">PMC12274576</ArticleId><ArticleId IdType="doi">10.1038/s41746-025-01846-1</ArticleId><ArticleId IdType="pii">10.1038/s41746-025-01846-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Friedman, C. P., Wong, A. K. &amp; Blumenthal, D. Achieving a nationwide learning health system. <i>Sci. Transl. Med.</i><b>2</b>, 57cm29 (2010).</Citation><ArticleIdList><ArticleId IdType="pubmed">21068440</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins, F. S., Hudson, K. L., Briggs, J. P. &amp; Lauer, M. S. PCORnet: turning a dream into reality. <i>J. Am. Med. Inform. Assoc.</i><b>21</b>, 576&#x2013;577 (2014).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4078299</ArticleId><ArticleId IdType="pubmed">24821744</ArticleId></ArticleIdList></Reference><Reference><Citation>Forrest, C. B. et al. PCORnet&#xae; 2020: current state, accomplishments, and future directions. <i>J. Clin. Epidemiol.</i><b>129</b>, 60&#x2013;67 (2021).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7521354</ArticleId><ArticleId IdType="pubmed">33002635</ArticleId></ArticleIdList></Reference><Reference><Citation>Forrest, C. B. et al. PEDSnet: a national pediatric learning health system. <i>J. Am. Med. Inform. Assoc.</i><b>21</b>, 602&#x2013;606 (2014).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4078288</ArticleId><ArticleId IdType="pubmed">24821737</ArticleId></ArticleIdList></Reference><Reference><Citation>Shenkman, E. et al. OneFlorida Clinical Research Consortium: Linking a clinical and translational science institute with a community-based distributive medical education model. <i>Acad. Med.</i><b>93</b>, 451&#x2013;455 (2018).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5839715</ArticleId><ArticleId IdType="pubmed">29045273</ArticleId></ArticleIdList></Reference><Reference><Citation>INSIGHT Clinical Research Network. https://insightcrn.org/.</Citation></Reference><Reference><Citation>Healthcare. IBM. https://www.ibm.com/industries/healthcare.</Citation></Reference><Reference><Citation>All of Us Research Program Investigators. The &#x201c;All of Us&#x201d; research program. N. Engl. J. Med. <b>381</b>, 668&#x2013;876 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8291101</ArticleId><ArticleId IdType="pubmed">31412182</ArticleId></ArticleIdList></Reference><Reference><Citation>Flatiron Health. Reimagining the infrastructure of cancer care. https://flatiron.com/.</Citation></Reference><Reference><Citation>Claims Data. Optum. https://www.optum.com/en/business/life-sciences/real-world-data/claims-data.html.</Citation></Reference><Reference><Citation>Electronic Health Records (EHR) Data. Optum. https://www.optum.com/en/business/life-sciences/real-world-data/ehr-data.html.</Citation></Reference><Reference><Citation>UK Biobank&#x2014;UK Biobank. https://www.ukbiobank.ac.uk/.</Citation></Reference><Reference><Citation>Electronic Medical Records and Genomics (eMERGE) Network. https://www.genome.gov/Funded-Programs-Projects/Electronic-Medical-Records-and-Genomics-Network-eMERGE.</Citation></Reference><Reference><Citation>Haendel, M. A. et al. The National COVID Cohort Collaborative (N3C): rationale, design, infrastructure, and deployment. <i>J. Am. Med. Inform. Assoc.</i><b>28</b>, 427&#x2013;443 (2021).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7454687</ArticleId><ArticleId IdType="pubmed">32805036</ArticleId></ArticleIdList></Reference><Reference><Citation>National COVID Cohort Collaborative. National Center for Advancing Translational Sciences. https://ncats.nih.gov/research/research-activities/n3c.</Citation></Reference><Reference><Citation>About the Initiative. RECOVER COVID. https://recovercovid.org/.</Citation></Reference><Reference><Citation>PaTH Network. https://pathnetwork.org/.</Citation></Reference><Reference><Citation>STAR Clinical Research Network. https://starcrn.org/.</Citation></Reference><Reference><Citation>GPC&#x2014;Greater Plains Collaborative. https://gpcnetwork.org/.</Citation></Reference><Reference><Citation>4CE. https://covidclinical.net/.</Citation></Reference><Reference><Citation>Brat, G. A. et al. International electronic health record-derived COVID-19 clinical course profiles: the 4CE consortium. <i>npj Digit. Med.</i><b>3</b>, 1&#x2013;9 (2020).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7438496</ArticleId><ArticleId IdType="pubmed">32864472</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak, G. et al. Characterizing treatment pathways at scale using the OHDSI network. <i>Proc. Natl Acad. Sci. USA</i><b>113</b>, 7329&#x2013;7336 (2016).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4941483</ArticleId><ArticleId IdType="pubmed">27274072</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss, E. A. et al. European Health Data &amp; Evidence Network&#x2014;learnings from building out a standardized international health data network. <i>J. Am. Med. Inform. Assoc.</i><b>31</b>, 209&#x2013;219 (2023).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10746315</ArticleId><ArticleId IdType="pubmed">37952118</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen, Yixin et al. Regression cubes with lossless compression and aggregation. <i>IEEE Trans. Knowl. Data Eng.</i><b>18</b>, 1585&#x2013;1599 (2006).</Citation></Reference><Reference><Citation>Luo, C. et al. DLMM as a lossless one-shot algorithm for collaborative multi-site distributed linear mixed models. <i>Nat. Commun.</i><b>13</b>, 1&#x2013;10 (2022).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8967932</ArticleId><ArticleId IdType="pubmed">35354802</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan Z, Zachrison KS, Schwamm LH, Estrada JJ, Duan R. A privacy-preserving and computation-efficient federated algorithm for generalized linear mixed models to analyze correlated electronic health records data. <i>PloS one</i>. <b>18</b>, e0280192 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9844867</ArticleId><ArticleId IdType="pubmed">36649349</ArticleId></ArticleIdList></Reference><Reference><Citation>Li, W. et al. Federated learning algorithms for generalized mixed-effects model (GLMM) on horizontally partitioned data from distributed sources. <i>BMC Med. Inform. Decis. Mak.</i><b>22</b>, 1&#x2013;12 (2022).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9569919</ArticleId><ArticleId IdType="pubmed">36244993</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo, C. et al. dPQL: a lossless distributed algorithm for generalized linear mixed model with application to privacy-preserving hospital profiling. <i>J. Am. Med. Inform. Assoc.</i><b>29</b>, 1366&#x2013;1371 (2022).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9277633</ArticleId><ArticleId IdType="pubmed">35579348</ArticleId></ArticleIdList></Reference><Reference><Citation>Jordan MI, Lee JD, Yang Y. Communication-efficient distributed statistical inference. <i>J. Am. Stat. Assoc.</i> (2019).</Citation></Reference><Reference><Citation>Hazay, C. &amp; Lindell, Y. Semi-honest adversaries. <i>Inf. Secur. Cryptogr.</i><b>15</b>, 53&#x2013;80 (2010).</Citation></Reference><Reference><Citation>PDA-OTA. https://pda-ota.pdamethods.org/login.</Citation></Reference><Reference><Citation>PDA website. https://pdamethods.org/.</Citation></Reference><Reference><Citation>CRAN&#x2014;Package pda. https://cran.r-project.org/web/packages/pda/index.html.</Citation></Reference><Reference><Citation>Hripcsak, G. et al. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. <i>Stud. Health Technol. Inf.</i><b>216</b>, 574&#x2013;578 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleurence, R. L. et al. Launching PCORnet, a national patient-centered clinical research network. <i>J. Am. Med. Inf. Assoc.</i><b>21</b>, 578&#x2013;582 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4078292</ArticleId><ArticleId IdType="pubmed">24821743</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia, W. et al. Managing re-identification risks while providing access to the All of Us research program. <i>J. Am. Med. Inf. Assoc.</i><b>30</b>, 907&#x2013;914 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10114067</ArticleId><ArticleId IdType="pubmed">36809550</ArticleId></ArticleIdList></Reference><Reference><Citation>Reiter, R. On closed world data bases. in <i>Readings in Artificial Intelligence</i> 119&#x2013;140. 10.1016/B978-0-934613-03-3.50014-3 (1981).</Citation></Reference><Reference><Citation>Reich, C. et al. OHDSI Standardized Vocabularies&#x2014;a large-scale centralized reference ontology for international data harmonization. <i>J. Am. Med. Inform. Assoc.</i><b>31</b>, 583&#x2013;590 (2024).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10873827</ArticleId><ArticleId IdType="pubmed">38175665</ArticleId></ArticleIdList></Reference><Reference><Citation>CMS Cell Size Suppression Policy. ResDAC. https://resdac.org/articles/cms-cell-size-suppression-policy.</Citation></Reference><Reference><Citation>Wasserman C, Ossiander E. Department of Health Agency Standards for Reporting Data with Small Numbers. Accessed July 08, 2025. https://www.doh.wa.gov/Portals/1/Documents/1500/SmallNumbers.pdf.</Citation></Reference><Reference><Citation>Utah Department of Health Data Suppression/Data Aggregation Guidelines Summary. Accessed July 08, 2025. https://uofuhealth.utah.edu/documents/data-suppression-summary.</Citation></Reference><Reference><Citation>Shokri, R. &amp; Shmatikov, V. Privacy-preserving deep learning. In <i>Proc. 2015 53rd Annual Allerton Conference on Communication, Control, and Computing (Allerton)</i> 909&#x2013;910. 10.1109/ALLERTON.2015.7447103 (IEEE, 2015)</Citation></Reference><Reference><Citation>Phong, L. T., Aono, Y., Hayashi, T., Wang, L. &amp; Moriai, S. Privacy-preserving deep learning via additively homomorphic encryption. <i>IEEE Trans. Inf. Forensics Secur.</i><b>13</b>, 1333&#x2013;1345 (2018).</Citation></Reference><Reference><Citation>Zhang, C. et al. BatchCrypt: efficient homomorphic encryption for cross-silo federated learning. In <i>Proc. 2020 USENIX Conference on Usenix Annual Technical Conference</i> (USENIX Association, 2020).</Citation></Reference><Reference><Citation>Cheon, J. H., Kim, A., Kim, M. &amp; Song, Y. Homomorphic encryption for arithmetic of approximate numbers. In <i>Proc.</i><i>Advances in Cryptology&#x2013;ASIACRYPT 2017: 23rd International Conference on the Theory and Applications of Cryptology and Information Security, Hong Kong, China, December 3-7, 2017, Part I</i> 409&#x2013;437 (Springer, 2017).</Citation></Reference><Reference><Citation>CMS Cell Size Suppression Policy. https://resdac.org/articles/cms-cell-size-suppression-policy.</Citation></Reference><Reference><Citation>Noor, F. M. &amp; Islam, M. M. Prevalence and associated risk factors of mortality among COVID-19 patients: a meta-analysis. <i>J. Community Health</i><b>45</b>, 1270&#x2013;1282 (2020).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7486583</ArticleId><ArticleId IdType="pubmed">32918645</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawad Hashim, M., Alsuwaidi, A. R. &amp; Khan, G. Population risk factors for COVID-19 mortality in 93 countries. <i>J. Epidemiol. Glob. Health</i><b>10</b>, 204&#x2013;208 (2020).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7509102</ArticleId><ArticleId IdType="pubmed">32954710</ArticleId></ArticleIdList></Reference><Reference><Citation>Albitar, O., Ballouze, R., Ooi, J. P. &amp; Ghadzi, S. M. S. Risk factors for mortality among COVID-19 patients. <i>Diab. Res. Clin. Pract.</i><b>166</b>, 108293 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7332436</ArticleId><ArticleId IdType="pubmed">32623035</ArticleId></ArticleIdList></Reference><Reference><Citation>Comoglu, S. &amp; Kant, A. Does the Charlson Comorbidity Index help predict the risk of death in COVID-19 patients? <i>North Clin. Istanb.</i><b>9</b>, 117 (2022).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9039643</ArticleId><ArticleId IdType="pubmed">35582508</ArticleId></ArticleIdList></Reference><Reference><Citation>Breslow, N. E. &amp; Clayton, D. G. Approximate inference in generalized linear mixed models. <i>J. Am. Stat. Assoc.</i><b>88</b>, 9&#x2013;25 (1993).</Citation></Reference><Reference><Citation>Wilmut, I., Schnieke, A. E., McWhir, J., Kind, A. J. &amp; Campbell, K. H. S. Viable offspring derived from fetal and adult mammalian cells. <i>Nature</i><b>385</b>, 810&#x2013;813 (1997). <i>1997 385:6619</i>.
</Citation><ArticleIdList><ArticleId IdType="pubmed">9039911</ArticleId></ArticleIdList></Reference><Reference><Citation>Sampson, R. J., Raudenbush, S. W. &amp; Earls, F. Neighborhoods and violent crime: a multilevel study of collective efficacy. <i>Science</i><b>277</b>, 918&#x2013;924 (1997).
</Citation><ArticleIdList><ArticleId IdType="pubmed">9252316</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, W. et al. Efficiently controlling for case-control imbalance and sample relatedness in large-scale genetic association studies. <i>Nat. Genet.</i><b>50</b>, 1335&#x2013;1341 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6119127</ArticleId><ArticleId IdType="pubmed">30104761</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40694804</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>13</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1527-974X</ISSN><JournalIssue CitedMedium="Internet"><Volume>32</Volume><Issue>9</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Journal of the American Medical Informatics Association : JAMIA</Title><ISOAbbreviation>J Am Med Inform Assoc</ISOAbbreviation></Journal><ArticleTitle>Evaluation of the impact of defining observable time in real-world data on outcome incidence.</ArticleTitle><Pagination><StartPage>1434</StartPage><EndPage>1444</EndPage><MedlinePgn>1434-1444</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1093/jamia/ocaf119</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">In real-world data (RWD), defining the observation period-the time during which a patient is considered observable-is critical for estimating incidence rates (IRs) and other outcomes. Yet, in the absence of explicit enrollment information, this period must often be inferred, introducing potential bias.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">This study evaluates methods for defining observation periods and their impact on IR estimates across multiple database types. We applied 3 methods for defining observation periods: (1) a persistence + surveillance window approach, (2) an age- and gender-adjusted method based on time between healthcare events, and (3) the min/max method. These were tested across 11 RWD databases, including both enrollment-based and encounter-based sources. Enrollment time was used as the reference standard in eligible databases. To assess the impact on epidemiologic results, we replicated a prior study of adverse event incidence, comparing IRs and calculating mean squared error between methods.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Incidence rates decreased as observation periods lengthened, driven by increases in the person-time denominator. The persistence + surveillance method produced estimates closest to enrollment-based rates when appropriately balanced. The min/max approach yielded inconsistent results, particularly in encounter-based databases, with greater error observed in databases with longer time spans.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">These findings suggest that assumptions about data completeness and population observability significantly affect incidence estimates. Observation period definitions substantially influence outcome measurement in RWD studies.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Standardized, transparent approaches are necessary to ensure valid, reproducible results-especially in databases lacking defined enrollment.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2025. Published by Oxford University Press on behalf of the American Medical Informatics Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Blacketer</LastName><ForeName>Clair</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-2570-2124</Identifier><AffiliationInfo><Affiliation>Coordinating Center, Observational Health Data Sciences and Informatics (OHDSI), New York, NY, 10032, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, NL, 3015 GD, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Johnson &amp; Johnson, Raritan, NJ, 08869, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>DeFalco</LastName><ForeName>Frank J</ForeName><Initials>FJ</Initials><AffiliationInfo><Affiliation>Coordinating Center, Observational Health Data Sciences and Informatics (OHDSI), New York, NY, 10032, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Johnson &amp; Johnson, Raritan, NJ, 08869, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conover</LastName><ForeName>Mitchell M</ForeName><Initials>MM</Initials><Identifier Source="ORCID">0000-0001-5682-3688</Identifier><AffiliationInfo><Affiliation>Coordinating Center, Observational Health Data Sciences and Informatics (OHDSI), New York, NY, 10032, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Johnson &amp; Johnson, Raritan, NJ, 08869, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Coordinating Center, Observational Health Data Sciences and Informatics (OHDSI), New York, NY, 10032, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Johnson &amp; Johnson, Raritan, NJ, 08869, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, 10032, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Coordinating Center, Observational Health Data Sciences and Informatics (OHDSI), New York, NY, 10032, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, University of California, Los Angeles, Los Angeles, CA, 90095, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rijnbeek</LastName><ForeName>Peter R</ForeName><Initials>PR</Initials><Identifier Source="ORCID">0000-0003-0621-1979</Identifier><AffiliationInfo><Affiliation>Coordinating Center, Observational Health Data Sciences and Informatics (OHDSI), New York, NY, 10032, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, NL, 3015 GD, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>European Medicines Agency</Agency><Country/></Grant><Grant><Agency>Innovative Medicines Initiative</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Am Med Inform Assoc</MedlineTA><NlmUniqueID>9430800</NlmUniqueID><ISSNLinking>1067-5027</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="Y">Outcome Assessment, Health Care</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">data quality</Keyword><Keyword MajorTopicYN="N">data standardization</Keyword><Keyword MajorTopicYN="N">incidence rates</Keyword><Keyword MajorTopicYN="N">observation period</Keyword><Keyword MajorTopicYN="N">real-world data</Keyword></KeywordList><CoiStatement>C.B., M.J.S., F.J.D., M.M.C., P.B.R., are employees of Johnson &amp; Johnson and hold stock and stock options. P.R.R. works for a department that receives/received unconditional research grants from Amgen, Chiesi, Johnson and Johnson, UCB Biopharma, the European Medicines Agency and the Innovative Medicines Initiative.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>14</Day><Hour>0</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>23</Day><Hour>11</Hour><Minute>27</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>22</Day><Hour>16</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40694804</ArticleId><ArticleId IdType="pmc">PMC12361855</ArticleId><ArticleId IdType="doi">10.1093/jamia/ocaf119</ArticleId><ArticleId IdType="pii">8210594</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Mahmood SS, Levy D, Vasan RS, et&#xa0;al The Framingham heart study and the epidemiology of cardiovascular diseases: a historical perspective. Lancet. 2014;383:999-1008. 10.1016/S0140-6736(13)61752-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(13)61752-3</ArticleId><ArticleId IdType="pmc">PMC4159698</ArticleId><ArticleId IdType="pubmed">24084292</ArticleId></ArticleIdList></Reference><Reference><Citation>Young JC, Conover MM, Jonsson Funk M. &#xa0;Measurement error and misclassification in electronic medical records: methods to mitigate bias. Curr Epidemiol Rep. 2018;5:343-356. 10.1007/s40471-018-0164-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40471-018-0164-x</ArticleId><ArticleId IdType="pmc">PMC9141310</ArticleId><ArticleId IdType="pubmed">35633879</ArticleId></ArticleIdList></Reference><Reference><Citation>
Optum Claims Data. Accessed January 23, 2024. https://www.optum.com/business/life-sciences/real-world-data/medical-pharmacy-claims-asset.html</Citation></Reference><Reference><Citation>
Merative Marketscan Research Databases. Accessed January 23, 2024. https://www.merative.com/documents/brief/marketscan-explainer-general</Citation></Reference><Reference><Citation>Wolf A, Dedman D, Campbell J, et&#xa0;al Data resource profile: clinical practice research datalink (CPRD) Aurum. Int J Epidemiol. 2019;48:1740-1740g. 10.1093/ije/dyz034</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyz034</ArticleId><ArticleId IdType="pmc">PMC6929522</ArticleId><ArticleId IdType="pubmed">30859197</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrett E, Gallagher AM, Bhaskaran K, et&#xa0;al Data resource profile: clinical practice research datalink (CPRD). Int J Epidemiol. 2015;44:827-836. 10.1093/ije/dyv098</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyv098</ArticleId><ArticleId IdType="pmc">PMC4521131</ArticleId><ArticleId IdType="pubmed">26050254</ArticleId></ArticleIdList></Reference><Reference><Citation>Carey IM, Banchoff E, Nirmalananthan N, et&#xa0;al Prevalence and incidence of neuromuscular conditions in the UK between 2000 and 2019: a retrospective study using primary care data. PLoS One. 2021;16:e0261983. 10.1371/journal.pone.0261983</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0261983</ArticleId><ArticleId IdType="pmc">PMC8719665</ArticleId><ArticleId IdType="pubmed">34972157</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiskopf NG, Bakken S, Hripcsak G, et&#xa0;al A data quality assessment guideline for electronic health record data reuse. EGEMS (Wash DC). 2017;5:14. 10.5334/egems.218</Citation><ArticleIdList><ArticleId IdType="doi">10.5334/egems.218</ArticleId><ArticleId IdType="pmc">PMC5983018</ArticleId><ArticleId IdType="pubmed">29881734</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiskopf NG, Hripcsak G, Swaminathan S, et&#xa0;al Defining and measuring completeness of electronic health records for secondary use. J Biomed Informatics. 2013;46:830-836. 10.1016/j.jbi.2013.06.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2013.06.010</ArticleId><ArticleId IdType="pmc">PMC3810243</ArticleId><ArticleId IdType="pubmed">23820016</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin KJ, Glynn RJ, Singer DE, et&#xa0;al Out-of-system care and recording of patient characteristics critical for comparative effectiveness research. Epidemiology. 2018;29:356-363. 10.1097/EDE.0000000000000794</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0000000000000794</ArticleId><ArticleId IdType="pmc">PMC5882528</ArticleId><ArticleId IdType="pubmed">29283893</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin KJ, Singer DE, Glynn RJ, et&#xa0;al Identifying patients with high data completeness to improve validity of comparative effectiveness research in electronic health records data. Clin Pharmacol Ther. 2018;103:899-905. 10.1002/cpt.861</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.861</ArticleId><ArticleId IdType="pmc">PMC6026022</ArticleId><ArticleId IdType="pubmed">28865143</ArticleId></ArticleIdList></Reference><Reference><Citation>Weber GM, Adams WG, Bernstam EV, et&#xa0;al Biases introduced by filtering electronic health records for patients with &#x201c;complete data. J Am Med Informatics Assoc. 2017;24:1134-1141. 10.1093/jamia/ocx071</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocx071</ArticleId><ArticleId IdType="pmc">PMC6080680</ArticleId><ArticleId IdType="pubmed">29016972</ArticleId></ArticleIdList></Reference><Reference><Citation>
The National Patient-Centered Clinical Research Network. <i>Common Data Model (CDM) Specification</i>, Version 6.1. 2023.</Citation></Reference><Reference><Citation>
Observation Period Considerations for EHR Data. Accessed June 6, 2023. http://ohdsi.github.io/CommonDataModel/ehrObsPeriods.html</Citation></Reference><Reference><Citation>Eberly LA, Garg L, Yang L, et&#xa0;al Racial/ethnic and socioeconomic disparities in management of incident paroxysmal atrial fibrillation. JAMA Netw Open. 2021;4:e210247. 10.1001/jamanetworkopen.2021.0247</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.0247</ArticleId><ArticleId IdType="pmc">PMC7910819</ArticleId><ArticleId IdType="pubmed">33635328</ArticleId></ArticleIdList></Reference><Reference><Citation>Spronk I, Korevaar JC, Poos R, et&#xa0;al Calculating incidence rates and prevalence proportions: not as simple as it seems. BMC Public Health. 2019;19:512. 10.1186/s12889-019-6820-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12889-019-6820-3</ArticleId><ArticleId IdType="pmc">PMC6501456</ArticleId><ArticleId IdType="pubmed">31060532</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng C-Y. &#xa0;Risk of osteoporosis among individuals with varicose veins: a multi-institution cohort study. Arch Osteoporos. 2023;18:141. 10.1007/s11657-023-01351-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11657-023-01351-6</ArticleId><ArticleId IdType="pubmed">38008860</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai M-S, Lin M-H, Lee C-P, et&#xa0;al Chang Gung research database: a multi-institutional database consisting of original medical records. Biomed J. 2017;40:263-269. 10.1016/j.bj.2017.08.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bj.2017.08.002</ArticleId><ArticleId IdType="pmc">PMC6138604</ArticleId><ArticleId IdType="pubmed">29179881</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, et&#xa0;al Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216:574-578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>
Observational Health Data Sciences and Informatics. OMOP Common Data Model (CDM). Accessed June 6, 2023. https://ohdsi.github.io/CommonDataModel/.</Citation></Reference><Reference><Citation>Li X, Ostropolets A, Makadia R, et&#xa0;al Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study. BMJ. 2021;373:n1435. 10.1136/bmj.n1435</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1435</ArticleId><ArticleId IdType="pmc">PMC8193077</ArticleId><ArticleId IdType="pubmed">35727911</ArticleId></ArticleIdList></Reference><Reference><Citation>Makadia R, Shoaibi A, Rao GA, et&#xa0;al Evaluating the impact of alternative phenotype definitions on incidence rates across a global data network. JAMIA Open. 2023;6:ooad096. 10.1093/jamiaopen/ooad096</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamiaopen/ooad096</ArticleId><ArticleId IdType="pmc">PMC10662662</ArticleId><ArticleId IdType="pubmed">38028730</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian Y, Schuemie MJ, Suchard MA. &#xa0;Evaluating large-scale propensity score performance through real-world and synthetic data experiments. Int J Epidemiol. 2018;47:2005-2014. 10.1093/ije/dyy120</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyy120</ArticleId><ArticleId IdType="pmc">PMC6280944</ArticleId><ArticleId IdType="pubmed">29939268</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneeweiss S, Rassen JA, Glynn RJ, et&#xa0;al High-dimensional propensity score adjustment in studies of treatment effects using health care claims data. Epidemiology. 2009;20:512-522. 10.1097/EDE.0b013e3181a663cc</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0b013e3181a663cc</ArticleId><ArticleId IdType="pmc">PMC3077219</ArticleId><ArticleId IdType="pubmed">19487948</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40698026</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2574-2531</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>4</Issue><PubDate><Year>2025</Year><Month>Aug</Month></PubDate></JournalIssue><Title>JAMIA open</Title><ISOAbbreviation>JAMIA Open</ISOAbbreviation></Journal><ArticleTitle>Using the Observational Medical Outcomes Partnership Common Data Model for a multi-registry intensive care unit benchmarking federated analysis: lessons learned.</ArticleTitle><Pagination><StartPage>ooaf052</StartPage><MedlinePgn>ooaf052</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">ooaf052</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/jamiaopen/ooaf052</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">Federated analysis is a method that allows data analysis to be performed on similar datasets without exchanging any data, thus facilitating international research collaboration while adhering to strict privacy laws. This study aimed to evaluate the feasibility of using federated analysis to benchmark mortality in 2 critical care quality registry databases converted to the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM), describing challenges to and recommendations for performing federated analysis on data transformed to OMOP CDM.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="UNASSIGNED">To identify as many challenges as possible and to be able to complete the benchmarking phase, a 2-step approach was taken during implementation. The first step was a naive implementation to allow challenges to surface naturally; the second step was developing solutions for the encountered challenges. Expected patient mortality risk was calculated by applying the Acute Physiology and Chronic Health Evaluation II (APACHE II) model to data from OMOP CDM databases containing adult ICU encounters between July 1, 2019 and December 31, 2022. An analysis script was developed to calculate comparable, registry level standardized mortality ratios. Challenges were recorded and categorized into predefined categories: "data preparation," "data analysis plan," and "data interpretation." Challenges specific to the OMOP CDM were further categorized using published steps from an existing generic harmonization process.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 7 challenges were identified, 4 of which were related to data preparation, 1 to data analysis, and 1 to data interpretation. Out of all 7 challenges, 4 stemmed from decisions made during the implementation of OMOP CDM. Several recommended solutions were distilled from the naive approach.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="UNASSIGNED">Federated analysis facilitated by a CDM is a feasible option for critical care quality registries. However, future analysis is influenced by decisions made during the CDM implementation process. Thus, prior publication of data dictionaries and the use of metadata to communicate data handling and data source classification during CDM implementation will improve the efficiency and accuracy of subsequent analysis.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2025. Published by Oxford University Press on behalf of the American Medical Informatics Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rashan</LastName><ForeName>Aasiyah</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-7456-4322</Identifier><AffiliationInfo><Affiliation>Institute of Health Informatics, University College London, London WC1E 6BT, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xfc;ttmann</LastName><ForeName>Daniel P</ForeName><Initials>DP</Initials><Identifier Source="ORCID">0000-0002-9362-1951</Identifier><AffiliationInfo><Affiliation>Department of Medical Informatics, Amsterdam Public Health Institute, Amsterdam UMC, University of Amsterdam, Amsterdam 1105 AZ, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Intensive Care Evaluation (NICE) Foundation, Amsterdam 1105 AZ, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Quality of Care, Amsterdam Public Health Institute, Amsterdam 1105 AZ, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Keizer</LastName><ForeName>Nicolette F</ForeName><Initials>NF</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Amsterdam Public Health Institute, Amsterdam UMC, University of Amsterdam, Amsterdam 1105 AZ, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Intensive Care Evaluation (NICE) Foundation, Amsterdam 1105 AZ, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Quality of Care, Amsterdam Public Health Institute, Amsterdam 1105 AZ, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dongelmans</LastName><ForeName>Dave A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>National Intensive Care Evaluation (NICE) Foundation, Amsterdam 1105 AZ, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Intensive Care, Amsterdam University Medical Centers Location Academic Medical Center, Amsterdam 1105 AZ, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cornet</LastName><ForeName>Ronald</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Amsterdam Public Health Institute, Amsterdam UMC, University of Amsterdam, Amsterdam 1105 AZ, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Digital Health, Amsterdam Public Health Institute, Amsterdam 1105 AZ, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ranzani</LastName><ForeName>Otavio</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Barcelona Institute for Global Health, ISGlobal, 08036 Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DataHealth Lab, Institut de Recerca Sant Pau (IR SANT PAU), 08041 Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Waweru-Siika</LastName><ForeName>Wangari</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Anaesthesia, Aga Khan University, Nairobi 30270-00100, Kenya.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Smith</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medical Statistics, London School of Hygiene and Tropical Medicine, London WC1E 7HT, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harris</LastName><ForeName>Steve</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-4982-1374</Identifier><AffiliationInfo><Affiliation>Institute of Health Informatics, University College London, London WC1E 6BT, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beane</LastName><ForeName>Abi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pandemic Science Hub, Institute of Regeneration and Repair, University of Edinburgh, Edinburgh EH16 4UU, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bakhshi-Raiez</LastName><ForeName>Ferishta</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Amsterdam Public Health Institute, Amsterdam UMC, University of Amsterdam, Amsterdam 1105 AZ, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Intensive Care Evaluation (NICE) Foundation, Amsterdam 1105 AZ, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Quality of Care, Amsterdam Public Health Institute, Amsterdam 1105 AZ, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Collaboration for Research, Implementation and Training in Critical Care&#x2014;Asia and Africa Investigators, and the Dutch National Intensive Care Registry </CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>figshare</DataBankName><AccessionNumberList><AccessionNumber>10.6084/m9.figshare.26268322.v1</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMIA Open</MedlineTA><NlmUniqueID>101730643</NlmUniqueID><ISSNLinking>2574-2531</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">APACHE II</Keyword><Keyword MajorTopicYN="N">OMOP CDM</Keyword><Keyword MajorTopicYN="N">critical care</Keyword><Keyword MajorTopicYN="N">data standardization</Keyword><Keyword MajorTopicYN="N">federated analysis</Keyword><Keyword MajorTopicYN="N">global health</Keyword><Keyword MajorTopicYN="N">registries</Keyword></KeywordList><CoiStatement>The authors have no competing interests to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>23</Day><Hour>11</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>23</Day><Hour>11</Hour><Minute>25</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>23</Day><Hour>5</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40698026</ArticleId><ArticleId IdType="pmc">PMC12282983</ArticleId><ArticleId IdType="doi">10.1093/jamiaopen/ooaf052</ArticleId><ArticleId IdType="pii">ooaf052</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>National Intensive Care Evaluation. Dutch National Intensive Care Evaluation (NICE) registry [Internet]. Accessed August 15, 2024. https://www.stichting-nice.nl</Citation></Reference><Reference><Citation>Pisani L, Rashan T, Shamal M, Collaboration for Research, Implementation and Training in Critical Care&#x2014;Asia Investigators, et al. &#xa0;Performance evaluation of a multinational data platform for critical care in Asia. Wellcome Open Res. 2021;6:251.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8812332</ArticleId><ArticleId IdType="pubmed">35141427</ArticleId></ArticleIdList></Reference><Reference><Citation>Dongelmans DA, Pilcher D, Beane A, et al. &#xa0;Linking of global intensive care (LOGIC): an international benchmarking in critical care initiative. J Crit Care. 2020;60:305-310.</Citation><ArticleIdList><ArticleId IdType="pubmed">32979689</ArticleId></ArticleIdList></Reference><Reference><Citation>Salluh JIF, Quintairos A, Dongelmans DA, Linking of Global Intensive Care (LOGIC) and Japanese Intensive care PAtient Database (JIPAD) Working Group, et al. &#xa0;National ICU Registries as enablers of clinical research and quality improvement. Crit Care Med. 2024;52:125-135.</Citation><ArticleIdList><ArticleId IdType="pubmed">37698452</ArticleId></ArticleIdList></Reference><Reference><Citation>Wortel SA, Bakhshi-Raiez F, Sjoe WGTS, van der Zwan EPA, de Keizer NF, Dongelmans DA. &#xa0;The role of the Dutch National Intensive Care Evaluation registry during the COVID-19 pandemic. Neth J Crit Care. 2022;30:152-155.</Citation></Reference><Reference><Citation>Garcia-Gallo E, Merson L, Kennon K, ISARIC Clinical Characterization Group, et al. &#xa0;ISARIC-COVID-19 dataset: a prospective, standardized, global dataset of patients hospitalized with COVID-19. Sci Data. 2022;9:454.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9339000</ArticleId><ArticleId IdType="pubmed">35908040</ArticleId></ArticleIdList></Reference><Reference><Citation>Kroes JA, Bansal AT, Berret E, et al. &#xa0;Blueprint for harmonising unstandardised disease registries to allow federated data analysis: prepare for the future. ERJ Open Res. 2022;8:00168. 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9530887</ArticleId><ArticleId IdType="pubmed">36199590</ArticleId></ArticleIdList></Reference><Reference><Citation>Tacconelli E, Gorska A, Carrara E, et al. &#xa0;Challenges of data sharing in European Covid-19 projects: a learning opportunity for advancing pandemic preparedness and response. Lancet Reg. 2022;21:100467.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9351292</ArticleId><ArticleId IdType="pubmed">35942201</ArticleId></ArticleIdList></Reference><Reference><Citation>Freeman EE, McMahon DE, Hruza GJ, et al. &#xa0;International collaboration and rapid harmonization across dermatologic COVID-19 registries. J Am Acad Dermatol. 2020;83:e261-e266.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7833847</ArticleId><ArticleId IdType="pubmed">32562840</ArticleId></ArticleIdList></Reference><Reference><Citation>Quintairos A, Pilcher D, Salluh JIF. &#xa0;ICU scoring systems. Intensive Care Med. 2023;49:223-225. 10.1007/s00134-022-06914-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-022-06914-8</ArticleId><ArticleId IdType="pmc">PMC9619008</ArticleId><ArticleId IdType="pubmed">36315260</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenert L, McSwain BY. &#xa0;Balancing health privacy, health information exchange, and research in the context of the COVID-19 pandemic. J Am Med Inform Assoc. 2020;27:963-966.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7184334</ArticleId><ArticleId IdType="pubmed">32232432</ArticleId></ArticleIdList></Reference><Reference><Citation>Zwitter A, Gstrein OJ. &#xa0;Big Data, Privacy and COVID-19-Learning from Humanitarian Expertise in Data Protection. Springer; 2020:1-7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7232912</ArticleId><ArticleId IdType="pubmed">38624331</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradford L, Aboy M, Liddell K. &#xa0;COVID-19 contact tracing apps: a stress test for privacy, the GDPR, and data protection regimes. J Law Biosci. 2020;7:lsaa034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7313893</ArticleId><ArticleId IdType="pubmed">32728470</ArticleId></ArticleIdList></Reference><Reference><Citation>Casaletto J, Bernier A, McDougall R, Cline MS. &#xa0;Federated analysis for privacy-preserving data sharing: a technical and legal primer. Annu Rev Genomics Hum Genet. 2023;24:347-368.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10846631</ArticleId><ArticleId IdType="pubmed">37253596</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuchinke W, Aerts J, Semler SC, Ohmann C. &#xa0;CDISC standard-based electronic archiving of clinical trials. Methods Inf Med. 2009;48:408-413.</Citation><ArticleIdList><ArticleId IdType="pubmed">19621114</ArticleId></ArticleIdList></Reference><Reference><Citation>
THIN. The Health Improvement Network [Internet]. Accessed August 15, 2024. https://www.the-health-improvement-network.com/</Citation></Reference><Reference><Citation>Overhage JM, Ryan PB, Reich CG, Hartzema AG, Stang PE. &#xa0;Validation of a common data model for active safety surveillance research. J Am Med Inform Assoc. 2012;19:54-60.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3240764</ArticleId><ArticleId IdType="pubmed">22037893</ArticleId></ArticleIdList></Reference><Reference><Citation>Sentinel Initiative. Sentinel common data model [Internet]. Accessed August 15, 2024. https://www.sentinelinitiative.org/methods-data-tools/sentinel-common-data-model</Citation></Reference><Reference><Citation>Roblin DW, Rubenstein KB, Tavel HM, et al. &#xa0;Development of a common data model for a multisite and multiyear study of virtual visit implementation: a case study. Med Care &#xa0;2023;61:S54-S61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9994571</ArticleId><ArticleId IdType="pubmed">36893419</ArticleId></ArticleIdList></Reference><Reference><Citation>
Weber GM, Klann J, Mendis M, Murphy S, Potenzone R, Rice P. i2b2 Common data model documentation v1.0. [Internet]. 2021. Accessed August 15, 2024. https://community.i2b2.org/wiki/display/BUN/i2b2&#xb1;Common&#xb1;Data&#xb1;Model&#xb1;Documentation</Citation></Reference><Reference><Citation>
Health Level 7. HL7 FHIR [Internet]. Accessed August 15, 2024. https://www.hl7.org/fhir/</Citation></Reference><Reference><Citation>Puttmann D, De Keizer N, Cornet R, Van Der Zwan E, Bakhshi-Raiez F. &#xa0;FAIRifying a Quality Registry using OMOP CDM: challenges and solutions. Stud Health Technol Inform. 2022;294:367-371.</Citation><ArticleIdList><ArticleId IdType="pubmed">35612098</ArticleId></ArticleIdList></Reference><Reference><Citation>Biedermann P, Ong R, Davydov A, et al. &#xa0;Standardizing registry data to the OMOP Common Data Model: experience from three pulmonary hypertension databases. BMC Med Res Methodol. 2021;21:238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8565035</ArticleId><ArticleId IdType="pubmed">34727871</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Y, Zong N, Wen A, et al. &#xa0;Developing an ETL tool for converting the PCORnet CDM into the OMOP CDM to facilitate the COVID-19 data integration. J Biomed Inform. 2022;127:104002.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8791245</ArticleId><ArticleId IdType="pubmed">35077901</ArticleId></ArticleIdList></Reference><Reference><Citation>
Blacketer C, Voss E. The Book of OHDSI: Observational Health Data Sciences and Informatics. Extract transform load [Internet]. 2019. Accessed August 15, 2024. https://ohdsi.github.io/TheBookOfOhdsi/ExtractTransformLoad.html</Citation></Reference><Reference><Citation>
OHDSI. Common Data Model GitHub Repository [Internet]. Accessed August 15, 2024. https://github.com/OHDSI/CommonDataModel</Citation></Reference><Reference><Citation>National Intensive Care Evaluation. NICE data dictionary [Internet]. Accessed August 15, 2024. https://www.stichting-nice.nl/dd</Citation></Reference><Reference><Citation>
DeFalco F, Ryan P, Schuemie M, et al.  &#xa0;<i>Achilles: Achilles Data Source Characterization</i>. R package version 1.7.2., 2023.</Citation></Reference><Reference><Citation>Blacketer C, Defalco FJ, Ryan PB, Rijnbeek PR. &#xa0;Increasing trust in real-world evidence through evaluation of observational data quality. J Am Med Inform Assoc. 2021;28:2251-2257. 10.1093/jamia/ocab132.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocab132</ArticleId><ArticleId IdType="pmc">PMC8449628</ArticleId><ArticleId IdType="pubmed">34313749</ArticleId></ArticleIdList></Reference><Reference><Citation>Charlson ME, Pompei P, Ales KL, MacKenzie CR. &#xa0;A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.</Citation><ArticleIdList><ArticleId IdType="pubmed">3558716</ArticleId></ArticleIdList></Reference><Reference><Citation>SNOMED International. SNOMED CT National Library of Medicine [Internet]. Accessed August 15, 2024. https://www.nlm.nih.gov/healthit/snomedct/index.html</Citation></Reference><Reference><Citation>Knaus WA, Draper EA, Wagner DP, Zimmerman JE. &#xa0;APACHE II. Crit Care Med. 1985;13:818-829.</Citation><ArticleIdList><ArticleId IdType="pubmed">3928249</ArticleId></ArticleIdList></Reference><Reference><Citation>Haniffa R, Pubudu De Silva A, Weerathunga P, et al. &#xa0;Applicability of the APACHE II model to a lower middle income country. J Crit Care. 2017;42:178-183.</Citation><ArticleIdList><ArticleId IdType="pubmed">28755619</ArticleId></ArticleIdList></Reference><Reference><Citation>Czajka S, Zi&#x119;bi&#x144;ska K, Marczenko K, Posmyk B, Szczepa&#x144;ska AJ, Krzych &#x141;J. &#xa0;Validation of APACHE II, APACHE III and SAPS II scores in in-hospital and one year mortality prediction in a mixed intensive care unit in Poland: a cohort study. BMC Anesthesiol. 2020;20:296-298.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7709291</ArticleId><ArticleId IdType="pubmed">33267777</ArticleId></ArticleIdList></Reference><Reference><Citation>Sungono V, Hariyanto H, Soesilo TEB, et al. &#xa0;Cohort study of the APACHE II score and mortality for different types of intensive care unit patients. Postgrad Med J. 2022;98:914-918.</Citation><ArticleIdList><ArticleId IdType="pubmed">37063012</ArticleId></ArticleIdList></Reference><Reference><Citation>Verburg IW, Holman R, Peek N, Abu-Hanna A, de Keizer NF. &#xa0;Guidelines on constructing funnel plots for quality indicators: a case study on mortality in intensive care unit patients. Stat Methods Med Res. 2018;27:3350-3366.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6193208</ArticleId><ArticleId IdType="pubmed">28330409</ArticleId></ArticleIdList></Reference><Reference><Citation>
Schuemie M, Suchard M. SqlRender: rendering parameterized SQL and translation to dialects. [Internet]. Accessed August 15, 2024. https://github.com/OHDSI/SqlRender</Citation></Reference><Reference><Citation>R Foundation for Statistical Computing: CRAN Team. R: a language and environment for statistical computing. R version 4.1.2 (2021-11-01) ed [Internet]. Accessed August 15, 2024. Index of/bin/windows/base/old/4.1.2 (r-project.org)</Citation></Reference><Reference><Citation>Henke E, Zoch M, Peng Y, Reinecke I, Sedlmayr M, Bathelt F. &#xa0;Conceptual design of a generic data harmonization process for OMOP common data model. BMC Med Inform Decis Mak. 2024;24:58.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10895818</ArticleId><ArticleId IdType="pubmed">38408983</ArticleId></ArticleIdList></Reference><Reference><Citation>The PostgreSQL Global Development Group. PostgreSQL: the world&#x2019;s most advanced open source relational database [Internet]. Accessed August 15, 2024. https://www.postgresql.org/</Citation></Reference><Reference><Citation>Microsoft. Transact-SQL reference (Database Engine) [Internet]. Accessed August 15, 2024. https://learn.microsoft.com/en-us/sql/t-sql</Citation></Reference><Reference><Citation>Gamage D, Beane A, Venkataraman R, et al. Validation of a simplified risk prediction model using a cloud based critical care registry in a lower-middle income country. Network for Improving Critical Care Systems and Training Aasiyah Rashan Network for Improving Critical care Systems and Training; 2020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7775074</ArticleId><ArticleId IdType="pubmed">33382834</ArticleId></ArticleIdList></Reference><Reference><Citation>
Buuren S. Flexible imputation of missing data. Multiple imputation in a nutshell [Internet]. Bookdown. 2018. Accessed August 15, 2024. https://stefvanbuuren.name/fimd/sec-nutshell.html.</Citation></Reference><Reference><Citation>
Allison P. Imputation by predictive mean matching: promise &amp; peril [Internet]. 2015. Accessed August 15, 2024. https://statisticalhorizons.com/predictive-mean-matching/</Citation></Reference><Reference><Citation>
Buuren S. Flexible imputation of missing data. Predictive mean matching [Internet]. Bookdown. 2018. Accessed August 15, 2024. https://stefvanbuuren.name/fimd/sec-pmm.html</Citation></Reference><Reference><Citation>Devaraju A, Huber R, Mokrane M, et al. &#xa0;FAIRsFAIR data object assesment metrics. Zenodo; 2022. 10.5281/zenodo.6461229</Citation><ArticleIdList><ArticleId IdType="doi">10.5281/zenodo.6461229</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson MD, Dumontier M, Aalbersberg IJ, et al. &#xa0;The FAIR guiding principles for scientific data management and stewardship. Sci Data. 2016;3:160018.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4792175</ArticleId><ArticleId IdType="pubmed">26978244</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI. ATLAS GitHub repository [Internet]. Accessed August 15, 2024. https://github.com/OHDSI/Atlas</Citation></Reference><Reference><Citation>
Madigan D. The Book of OHDSI: Observational Health Data Sciences and Informatics. Data analytics use cases [Internet]. 2019. Accessed August 15, 2024. https://ohdsi.github.io/TheBookOfOhdsi/DataAnalyticsUseCases.html</Citation></Reference><Reference><Citation>
Falconer T, Chen R, Hripcsak G. Running an OHDSI Network Study [Internet]. 2016. Accessed August 15, 2024. https://www.ohdsi.org/web/wiki/lib/exe/fetch.php?media=research:nci-ohdsi_instruction_manual2.pdf</Citation></Reference><Reference><Citation>Kiwuwa-Muyingo S, Todd J, Bhattacharjee T, Taylor A, Greenfield J. &#xa0;Enabling data sharing and utilization for African population health data using OHDSI tools with an OMOP-common data model. Front Public Health. 2023;11:1116682.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10287979</ArticleId><ArticleId IdType="pubmed">37361151</ArticleId></ArticleIdList></Reference><Reference><Citation>
Abedtash H. Using OHDSI Data Network for capturing real-world evidence: our experience with a multi-country study on an obese and overweight cohort. In: <i>Observational Health Data Sciences and Informatics Symposium</i>. Washington, DC: Observational Health Data Sciences and Informatics; 2019.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40706107</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>26</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2860</ISSN><JournalIssue CitedMedium="Internet"><Volume>168</Volume><PubDate><Year>2025</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Artificial intelligence in medicine</Title><ISOAbbreviation>Artif Intell Med</ISOAbbreviation></Journal><ArticleTitle>LLM-based approaches for automated vocabulary mapping between SIGTAP and OMOP CDM concepts.</ArticleTitle><Pagination><StartPage>103204</StartPage><MedlinePgn>103204</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.artmed.2025.103204</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0933-3657(25)00139-3</ELocationID><Abstract><AbstractText>In the context of global healthcare systems, integrating diverse medical terminologies and classification systems has become a priority due to the adoption of Electronic Health Record (EHR) systems and the imperative for information exchange between healthcare systems. This study addresses the necessity for mapping between the SIGTAP vocabulary used in Brazilian healthcare systems and the broader medical terms of the OMOP CDM terminologies. Two distinct pipelines are evaluated for the vocabulary mapping process, focusing on two subsets of the SIGTAP vocabulary: medicines and medical procedures. The first pipeline utilizes textual embeddings for semantic similarity evaluation, followed by Large Language Models (LLMs) for correspondences selection through a retrieval-augmented generation (RAG) approach. In the second pipeline, LLM agents employ predefined protocols for vocabulary mapping and query refinement. Our results show comparable performance between pipelines in both the Procedures subset (F<sub>1</sub> of 0.684 versus 0.678), and the Medicines subset (F<sub>1</sub> of 0.846 versus 0.839), indicating the viability of the multi-stage filtering approach. The second pipeline demonstrates an advantage over the first in terms of recall, highlighting the efficacy of dynamic query refinement by the agent. These findings provide evidence that LLM-based methods significantly reduce manual effort required by experts, enabling domain specialists to focus on more challenging cases.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>de Barros Vanzin</LastName><ForeName>Vin&#xed;cius Jo&#xe3;o</ForeName><Initials>VJ</Initials><AffiliationInfo><Affiliation>Institute of Mathematics and Computer Sciences (ICMC) - University of Sao Paulo (USP), Av. Trab. S&#xe3;o Carlense, 400, S&#xe3;o Carlos, 13566-590, SP, Brazil. Electronic address: vinicius.vanzin@usp.br.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Abreu Moreira</LastName><ForeName>Dilvan</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute of Mathematics and Computer Sciences (ICMC) - University of Sao Paulo (USP), Av. Trab. S&#xe3;o Carlense, 400, S&#xe3;o Carlos, 13566-590, SP, Brazil. Electronic address: dilvan@icmc.usp.br.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marcondes Marcacini</LastName><ForeName>Ricardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Mathematics and Computer Sciences (ICMC) - University of Sao Paulo (USP), Av. Trab. S&#xe3;o Carlense, 400, S&#xe3;o Carlos, 13566-590, SP, Brazil. Electronic address: ricardo.marcacini@usp.br.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Artif Intell Med</MedlineTA><NlmUniqueID>8915031</NlmUniqueID><ISSNLinking>0933-3657</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012660" MajorTopicYN="N">Semantics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018875" MajorTopicYN="Y">Vocabulary, Controlled</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009323" MajorTopicYN="Y">Natural Language Processing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001938" MajorTopicYN="N" Type="Geographic">Brazil</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">LLM agent</Keyword><Keyword MajorTopicYN="N">Ontology mapping</Keyword><Keyword MajorTopicYN="N">Retrieval-augmented generation</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>1</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>8</Day><Hour>8</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>24</Day><Hour>18</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>24</Day><Hour>17</Hour><Minute>59</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40706107</ArticleId><ArticleId IdType="doi">10.1016/j.artmed.2025.103204</ArticleId><ArticleId IdType="pii">S0933-3657(25)00139-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40707478</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>24</Day></DateCompleted><DateRevised><Year>2025</Year><Month>07</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1723</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Jul</Month><Day>24</Day></PubDate></JournalIssue><Title>Nature communications</Title><ISOAbbreviation>Nat Commun</ISOAbbreviation></Journal><ArticleTitle>Risk of neuropsychiatric and related conditions associated with SARS-CoV-2 infection: a difference-in-differences analysis.</ArticleTitle><Pagination><StartPage>6829</StartPage><MedlinePgn>6829</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">6829</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41467-025-61961-1</ELocationID><Abstract><AbstractText>The COVID-19 pandemic has been associated with increased neuropsychiatric conditions in children and youths, with evidence suggesting that SARS-CoV-2 infection may contribute additional risks beyond pandemic stressors. This study aims to assess the full spectrum of neuropsychiatric conditions in COVID-19 positive children (ages 5-12) and youths (ages 12-20) compared to a matched COVID-19 negative cohort, accounting for factors influencing infection risk. Using EHR data from 25 institutions in the RECOVER program, we conduct a retrospective analysis of 326,074 COVID-19 positive and 887,314 negative participants matched for risk factors and stratified by age. Neuropsychiatric outcomes are examined 28 to 179 days post-infection or negative test between March 2020 and December 2022. SARS-CoV-2 positivity is confirmed via PCR, serology, or antigen tests, while negativity requires negative test results and no related diagnoses. Risk differences reveal higher frequencies of neuropsychiatric conditions in the COVID-19 positive cohort. Children face increased risks for anxiety, OCD, ADHD, autism, and other conditions, while youths exhibit elevated risks for anxiety, suicidality, depression, and related symptoms. These findings highlight SARS-CoV-2 infection as a potential contributor to neuropsychiatric risks, emphasizing the importance of research into tailored treatments and preventive strategies for affected individuals.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Lu</LastName><ForeName>Yiwen</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-8610-2416</Identifier><AffiliationInfo><Affiliation>Center for Health AI and Synthesis of Evidence (CHASE), Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Graduate Group in Applied Mathematics and Computational Science, School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Tong</LastName><ForeName>Jiayi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Health AI and Synthesis of Evidence (CHASE), Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Zhang</LastName><ForeName>Dazheng</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-1431-0785</Identifier><AffiliationInfo><Affiliation>Center for Health AI and Synthesis of Evidence (CHASE), Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jiajie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Center for Health AI and Synthesis of Evidence (CHASE), Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Lu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Center for Health AI and Synthesis of Evidence (CHASE), Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Graduate Group in Applied Mathematics and Computational Science, School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lei</LastName><ForeName>Yuqing</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Center for Health AI and Synthesis of Evidence (CHASE), Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Ting</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center for Health AI and Synthesis of Evidence (CHASE), Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aragon</LastName><ForeName>Leyna V</ForeName><Initials>LV</Initials><AffiliationInfo><Affiliation>RECOVER Patient, Caregiver, or Community Advocate Representative, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University of New Mexico, Health Sciences Center, Albuquerque, NM, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Becich</LastName><ForeName>Michael J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0001-5998-8074</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blecker</LastName><ForeName>Saul</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Population Health, NYU Grossman School of Medicine, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blum</LastName><ForeName>Nathan J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Division of Developmental and Behavioral Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Christakis</LastName><ForeName>Dimitri A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Center for Child Health, Behavior and Development, Seattle Children's Research Institute, Seattle, WA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hornig</LastName><ForeName>Mady</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7572-3092</Identifier><AffiliationInfo><Affiliation>RECOVER Patient, Caregiver, or Community Advocate Representative, New York, NY, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Feinstein Institutes for Medical Research, Northwell Health, Manhasset, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hornig-Rohan</LastName><ForeName>Maxwell M</ForeName><Initials>MM</Initials><Identifier Source="ORCID">0009-0005-0985-0225</Identifier><AffiliationInfo><Affiliation>RECOVER Patient, Caregiver, or Community Advocate Representative, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jhaveri</LastName><ForeName>Ravi</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Ann &amp; Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>W Schuyler</ForeName><Initials>WS</Initials><AffiliationInfo><Affiliation>Duke Clinical Research Institute, Duke University Health System, Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Keebler</LastName><ForeName>Amber Brown</ForeName><Initials>AB</Initials><Identifier Source="ORCID">0000-0002-7246-2859</Identifier><AffiliationInfo><Affiliation>Division of General Internal Medicine, Department of Internal Medicine, University of Nebraska Medical Center, Omaha, NE, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kelleher</LastName><ForeName>Kelly</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>The Research Institute, Nationwide Children's Hospital, Department of Pediatrics, The Ohio State University College of Medicine, Columbus, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>University of California, San Francisco, Division of Rheumatology, Benioff Children's Hospital, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mosa</LastName><ForeName>Abu Saleh Mohammad</ForeName><Initials>ASM</Initials><Identifier Source="ORCID">0000-0002-8956-1466</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Biostatistics, and Medical Epidemiology, University of Missouri School of Medicine, Columbia, MO, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics and Data Science, University of Alabama at Birmingham, Birmingham, AL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pajer</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>University of Ottawa Department of Psychiatry, Children's Hospital of Eastern Ontario, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Platt</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, The University of Iowa College of Public Health, Iowa City, IA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwenk</LastName><ForeName>Hayden T</ForeName><Initials>HT</Initials><AffiliationInfo><Affiliation>Stanford School of Medicine, Division of Pediatric Infectious Diseases, Stanford, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>Bradley W</ForeName><Initials>BW</Initials><Identifier Source="ORCID">0000-0002-6414-4172</Identifier><AffiliationInfo><Affiliation>Clinical and Translational Science Institute, The Medical College of Wisconsin, Milwaukee, WI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Utidjian</LastName><ForeName>Levon H</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Applied Clinical Research Center, Children's Hospital of Philadelphia, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>David A</ForeName><Initials>DA</Initials><Identifier Source="ORCID">0000-0002-5052-4895</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology, University of Michigan, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prasad</LastName><ForeName>Raghuram</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Child and Adolescent Psychiatry, Children's Hospital of Philadelphia, Perelman School of Medicine, the University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elia</LastName><ForeName>Josephine</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-5037-1622</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, Nemours Children's Health Delaware, Sydney Kimmel School of Medicine, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forrest</LastName><ForeName>Christopher B</ForeName><Initials>CB</Initials><Identifier Source="ORCID">0000-0003-1252-068X</Identifier><AffiliationInfo><Affiliation>Applied Clinical Research Center, Children's Hospital of Philadelphia, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-0835-0788</Identifier><AffiliationInfo><Affiliation>Center for Health AI and Synthesis of Evidence (CHASE), Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. ychen123@upenn.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Graduate Group in Applied Mathematics and Computational Science, School of Arts and Sciences, University of Pennsylvania, Philadelphia, PA, USA. ychen123@upenn.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. ychen123@upenn.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Leonard Davis Institute of Health Economics, Philadelphia, PA, USA. ychen123@upenn.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Penn Medicine Center for Evidence-based Practice (CEP), Philadelphia, PA, USA. ychen123@upenn.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Penn Institute for Biomedical Informatics (IBI), Philadelphia, PA, USA. ychen123@upenn.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>OT2 HL161847</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1 AG077820</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM013519</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 MH136069</GrantID><Acronym>MH</Acronym><Agency>NIMH NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 EY034179</GrantID><Acronym>EY</Acronym><Agency>NEI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 AI167418</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 TR003709</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 DK128237</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM014344</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AG074604</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AG073435</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Nat Commun</MedlineTA><NlmUniqueID>101528555</NlmUniqueID><ISSNLinking>2041-1723</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>Res Sq. 2025 Jan 08:rs.3.rs-5621095. doi: 10.21203/rs.3.rs-5621095/v1.</RefSource><PMID Version="1">39866876</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001523" MajorTopicYN="Y">Mental Disorders</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001321" MajorTopicYN="N">Autistic Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001289" MajorTopicYN="N">Attention Deficit Disorder with Hyperactivity</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009771" MajorTopicYN="N">Obsessive-Compulsive Disorder</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Competing interests: R.J. is a consultant for AstraZeneca, Seqirus, Dynavax, receives an editorial stipend from Elsevier and Pediatric Infectious Diseases Society and royalties from Up To Date/Wolters Kluwer. The remaining authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>12</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>0</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>25</Day><Hour>0</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>24</Day><Hour>23</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40707478</ArticleId><ArticleId IdType="pmc">PMC12290120</ArticleId><ArticleId IdType="doi">10.1038/s41467-025-61961-1</ArticleId><ArticleId IdType="pii">10.1038/s41467-025-61961-1</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Meade, J. Mental health effects of the COVID-19 pandemic on children and adolescents: A review of the current research. <i>Pediatr. Clin. North Am.</i><b>68</b>, 945&#x2013;959 (2021).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8445752</ArticleId><ArticleId IdType="pubmed">34538305</ArticleId></ArticleIdList></Reference><Reference><Citation>de Figueiredo, C. S. et al. COVID-19 pandemic impact on children and adolescents&#x2019; mental health: Biological, environmental, and social factors. <i>Prog. Neuropsychopharmacol. Biol. Psychiatry</i><b>106</b>, 110171 (2021).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7657035</ArticleId><ArticleId IdType="pubmed">33186638</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenthal, E. et al. Impact of COVID-19 on Youth With ADHD: Predictors and moderators of response to pandemic restrictions on daily life. <i>J. Atten. Disord.</i><b>26</b>, 1223&#x2013;1234 (2022).
</Citation><ArticleIdList><ArticleId IdType="pubmed">34920689</ArticleId></ArticleIdList></Reference><Reference><Citation>Loades, M. E. et al. Rapid systematic review: The impact of social isolation and loneliness on the mental health of children and adolescents in the context of COVID-19. <i>J. Am. Acad. Child Adolesc. Psychiatry</i><b>59</b>, 1218 (2020).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7267797</ArticleId><ArticleId IdType="pubmed">32504808</ArticleId></ArticleIdList></Reference><Reference><Citation>Meherali, S. et al. Mental health of children and adolescents amidst covid-19 and past pandemics: A rapid systematic review. <i>Int J. Environ. Res Public Health</i><b>18</b>, 3432 (2021).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8038056</ArticleId><ArticleId IdType="pubmed">33810225</ArticleId></ArticleIdList></Reference><Reference><Citation>Vahia, I. V., Jeste, D. V. &amp; Reynolds, C. F. Older adults and the mental health effects of COVID-19. <i>JAMA</i><b>324</b>, 2253&#x2013;2254 (2020).
</Citation><ArticleIdList><ArticleId IdType="pubmed">33216114</ArticleId></ArticleIdList></Reference><Reference><Citation>Horwitz, L. I. et al. Researching COVID to enhance recovery (RECOVER) adult study protocol: Rationale, objectives, and design. <i>PLoS One</i><b>18</b>, e0286297 (2023).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10289397</ArticleId><ArticleId IdType="pubmed">37352211</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirschtick, J. L. et al. Population-based estimates of post-acute sequelae of SARS-CoV-2 infection (PASC) prevalence and characteristics. <i>Clin. Infect. Dis.</i><b>73</b>, ciab408 (2021).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8240848</ArticleId><ArticleId IdType="pubmed">34007978</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephenson, T. et al. Physical and mental health 3 months after SARS-CoV-2 infection (long COVID) among adolescents in England (CLoCk): a national matched cohort study. <i>Lancet Child Adolesc. Health</i><b>6</b>, 230&#x2013;239 (2022).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8820961</ArticleId><ArticleId IdType="pubmed">35143770</ArticleId></ArticleIdList></Reference><Reference><Citation>Gross, R. S. et al. Characterizing long COVID in children and adolescents. <i>JAMA</i><b>332</b>, 1174&#x2013;1188 (2024).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11339705</ArticleId><ArticleId IdType="pubmed">39196964</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao, S. et al. Clinical features and burden of postacute sequelae of SARS-CoV-2 infection in children and adolescents. <i>JAMA Pediatr.</i><b>176</b>, 1000&#x2013;1009 (2022).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9396470</ArticleId><ArticleId IdType="pubmed">35994282</ArticleId></ArticleIdList></Reference><Reference><Citation>Younger, D. S. Post-acute sequelae of SARS-CoV-2 infection (PASC): peripheral, autonomic, and central nervous system features in a child. <i>Neurol. Sci.</i><b>42</b>, 3959&#x2013;3963 (2021).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8272686</ArticleId><ArticleId IdType="pubmed">34247285</ArticleId></ArticleIdList></Reference><Reference><Citation>Roessler, M. et al. Post-COVID-19-associated morbidity in children, adolescents, and adults: A matched cohort study including more than 157,000 individuals with COVID-19 in Germany. <i>PLoS Med.</i><b>19</b>, 11 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9648706</ArticleId><ArticleId IdType="pubmed">36355754</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet, M. et al. Neurological and psychiatric risk trajectories after SARS-CoV-2 infection: an analysis of 2-year retrospective cohort studies including 1 284 437 patients. <i>Lancet Psychiatry</i><b>9</b>, 815&#x2013;827 (2022).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9385200</ArticleId><ArticleId IdType="pubmed">35987197</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang-James, Y., Clay, J. W. S., Aber, R. B., Gamble, H. M. &amp; Faraone, S. V. Post-COVID-19 mental health distress in 13 million youth: A retrospective cohort study of electronic health records. <i>J. Am. Acad. Child Adolesc. Psychiatry</i>10.1016/J.JAAC.2024.03.023. (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38815620</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu, Q. et al. Real-World Effectiveness of BNT162b2 Against Infection and Severe Diseases in Children and Adolescents. <i>Ann Intern Med.</i><b>177</b>, 165&#x2013;176 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11956830</ArticleId><ArticleId IdType="pubmed">38190711</ArticleId></ArticleIdList></Reference><Reference><Citation>Elia, J. et al. Electronic health records identify timely trends in childhood mental health conditions. <i>Child Adolesc. Psychiatry Ment. Health</i><b>17</b>, 1&#x2013;17 (2023).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10503059</ArticleId><ArticleId IdType="pubmed">37710303</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xf6;hler-Forsberg, O. et al. A nationwide study in denmark of the association between treated infections and the subsequent risk of treated mental disorders in children and adolescents. <i>JAMA Psychiatry</i><b>76</b>, 271&#x2013;279 (2019).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6439826</ArticleId><ArticleId IdType="pubmed">30516814</ArticleId></ArticleIdList></Reference><Reference><Citation>Penninx, B. W. J. H., Benros, M. E., Klein, R. S. &amp; Vinkers, C. H. How COVID-19 shaped mental health: From infection to pandemic effects. <i>Nat. Med</i>. <b>28</b>, 2027&#x2013;2037 (2022).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9711928</ArticleId><ArticleId IdType="pubmed">36192553</ArticleId></ArticleIdList></Reference><Reference><Citation>Shorter, J. R. et al. Infection polygenic factors account for a small proportion of the relationship between infections and mental disorders. <i>Biol. Psychiatry</i><b>92</b>, 283&#x2013;290 (2022).
</Citation><ArticleIdList><ArticleId IdType="pubmed">35305821</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo, X., Chen, Y., Ohno-Machado, L., Xu, H. How do we share data in COVID-19 research? A systematic review of COVID-19 datasets in PubMed Central Articles. <i>Brief Bioinform.</i> 22, 800&#x2013;811 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7799277</ArticleId><ArticleId IdType="pubmed">33757278</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll, R., Bice, A. A., Roberto, A. &amp; Prentice, C. R. Examining mental health disorders in overweight and obese pediatric patients. <i>J. Pediatr. Health Care</i><b>36</b>, 507&#x2013;519 (2022).
</Citation><ArticleIdList><ArticleId IdType="pubmed">35760667</ArticleId></ArticleIdList></Reference><Reference><Citation>Elkin, P. L. et al. Evaluation of the content coverage of SNOMED CT: Ability of SNOMED clinical terms to represent clinical problem lists. <i>Mayo Clin. Proc.</i><b>81</b>, 741&#x2013;748 (2006).
</Citation><ArticleIdList><ArticleId IdType="pubmed">16770974</ArticleId></ArticleIdList></Reference><Reference><Citation>Home | SNOMED International. https://www.snomed.org/.</Citation></Reference><Reference><Citation>Taquet, M. et al. Cognitive and psychiatric symptom trajectories 2&#x2013;3 years after hospital admission for COVID-19: a longitudinal, prospective cohort study in the UK. <i>Lancet Psychiatry</i><b>11</b>, 696&#x2013;708 (2024).
</Citation><ArticleIdList><ArticleId IdType="pubmed">39096931</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang, Q. Q., Xu, R. &amp; Volkow, N. D. Increased risk of COVID-19 infection and mortality in people with mental disorders: analysis from electronic health records in the United States. <i>World Psychiatry</i><b>20</b>, 124&#x2013;130 (2021).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7675495</ArticleId><ArticleId IdType="pubmed">33026219</ArticleId></ArticleIdList></Reference><Reference><Citation>Taquet, M., Luciano, S., Geddes, J. R. &amp; Harrison, P. J. Bidirectional associations between COVID-19 and psychiatric disorder: Retrospective cohort studies of 62 354 COVID-19 cases in the USA. <i>Lancet Psychiatry</i><b>8</b>, 130&#x2013;140 (2021).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7820108</ArticleId><ArticleId IdType="pubmed">33181098</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu, Q. et al. Real-world effectiveness and causal mediation study of BNT162b2 on long COVID risks in children and adolescents. <i>EClinicalMedicine</i><b>79</b>, 102962 (2025).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11667630</ArticleId><ArticleId IdType="pubmed">39720603</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou, T. et al. Body mass index and postacute sequelae of SARS-CoV-2 infection in children and young adults. <i>JAMA Netw. Open</i><b>7</b>, e2441970&#x2013;e2441970 (2024).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11581483</ArticleId><ArticleId IdType="pubmed">39466241</ArticleId></ArticleIdList></Reference><Reference><Citation>Razzaghi, H. et al. Vaccine effectiveness against long COVID in children. <i>Pediatrics</i><b>153</b>, e2023064446 (2024).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10979300</ArticleId><ArticleId IdType="pubmed">38225804</ArticleId></ArticleIdList></Reference><Reference><Citation>Shen, Y. et al. Assessment of nirmatrelvir-ritonavir effects on acute and post-acute COVID-19 illness in US adolescents: Target trial emulation. <i>medRxiv</i> 2025.04.02.25324861 10.1101/2025.04.02.25324861. (2025)</Citation></Reference><Reference><Citation>Chen, J. et al. Vaccine effectiveness among 5- to 17-year-old individuals with prior SARS-CoV-2 Infection: An EHR-based target trial emulation study from the recover project. <i>medRxiv</i> 2025.02.07.25321814 10.1101/2025.02.07.25321814. (2025)</Citation></Reference><Reference><Citation>Zhang, B. et al. Reinfection with SARS-CoV-2 in the omicron era is associated with increased risk of post-acute sequelae of SARS-CoV-2 infection: A RECOVER-EHR Cohort Study. <i>medRxiv</i> 2025.03.28.25324858 10.1101/2025.03.28.25324858. (2025)</Citation></Reference><Reference><Citation>Li, L. et al. Kidney function following COVID-19 in children and adolescents. <i>JAMA Netw. Open</i><b>8</b>, e254129&#x2013;e254129 (2025).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11992607</ArticleId><ArticleId IdType="pubmed">40214993</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, D. et al. Pediatric gastrointestinal tract outcomes during the postacute phase of COVID-19. <i>JAMA Netw. Open</i><b>8</b>, e2458366&#x2013;e2458366 (2025).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11806396</ArticleId><ArticleId IdType="pubmed">39918822</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, B. et al. Cardiovascular post-acute sequelae of SARS-CoV-2 in children and adolescents: cohort study using electronic health records. <i>Nat. Commun.</i><b>16</b>, 1&#x2013;12 (2025). <i>2025 16:1</i>.
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11992182</ArticleId><ArticleId IdType="pubmed">40216777</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang, D. et al. Racial/ethnic differences in post-acute sequelae of SARS-CoV-2 in children and adolescents in the United States. <i>Nat. Commun.</i><b>16</b>, 1&#x2013;11 (2025). <i>2025 16:1</i>.
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11751291</ArticleId><ArticleId IdType="pubmed">39837828</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung, S. J. et al. Impact of COVID-19 on mental health according to prior depression status: A mental health survey of community prospective cohort data. <i>J. Psychosom. Res</i><b>148</b>, 110552 (2021).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8590509</ArticleId><ArticleId IdType="pubmed">34171768</ArticleId></ArticleIdList></Reference><Reference><Citation>Prati, G. Mental health and its psychosocial predictors during national quarantine in Italy against the coronavirus disease 2019 (COVID-19). <i>Anxiety Stress Coping</i><b>34</b>, 145&#x2013;156 (2021).
</Citation><ArticleIdList><ArticleId IdType="pubmed">33350343</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon, T. D., Haaland, W., Hawley, K., Lambka, K. &amp; Mangione-Smith, R. Development and validation of the pediatric medical complexity algorithm (PMCA) version 3.0. <i>Acad. Pediatr.</i><b>18</b>, 577&#x2013;580 (2018).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6035108</ArticleId><ArticleId IdType="pubmed">29496546</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon, T. D. et al. Development and validation of the pediatric medical complexity algorithm (PMCA) version 2.0. <i>Hosp. Pediatr.</i><b>7</b>, 373&#x2013;377 (2017).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5485351</ArticleId><ArticleId IdType="pubmed">28634166</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto, K. Repurposing of CNS drugs to treat COVID-19 infection: targeting the sigma-1 receptor. <i>Eur. Arch. Psychiatry Clin. Neurosci.</i><b>271</b>, 249&#x2013;258 (2021).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7785036</ArticleId><ArticleId IdType="pubmed">33403480</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishima, T., Fujita, Y. &amp; Hashimoto, K. Interaction of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cells. <i>Eur. J. Pharm.</i><b>727</b>, 167&#x2013;173 (2014).</Citation><ArticleIdList><ArticleId IdType="pubmed">24508523</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie, Y., Xu, E. &amp; Al-Aly, Z. Risks of mental health outcomes in people with covid-19: cohort study. <i>BMJ</i><b>376</b>, e068993 (2022).
</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8847881</ArticleId><ArticleId IdType="pubmed">35172971</ArticleId></ArticleIdList></Reference><Reference><Citation>Cornet, R. &amp; Keizer, N. D. Forty years of SNOMED: A literature review. <i>BMC Med Inf. Decis. Mak.</i><b>8</b>, 1&#x2013;6 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2582789</ArticleId><ArticleId IdType="pubmed">19007439</ArticleId></ArticleIdList></Reference><Reference><Citation>American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. <i>Diagnostic and Statistical Manual of Mental Disorders</i>10.1176/APPI.BOOKS.9780890425596. (2013)</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40727112</PMID><DateRevised><Year>2025</Year><Month>07</Month><Day>31</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2574-2531</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>4</Issue><PubDate><Year>2025</Year><Month>Aug</Month></PubDate></JournalIssue><Title>JAMIA open</Title><ISOAbbreviation>JAMIA Open</ISOAbbreviation></Journal><ArticleTitle>Comparison of 2 electronic health record data extraction methods for laboratory tests used in the Veterans Aging Cohort Study Index.</ArticleTitle><Pagination><StartPage>ooaf074</StartPage><MedlinePgn>ooaf074</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">ooaf074</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/jamiaopen/ooaf074</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To compare Observational Medical Outcomes Partnership (OMOP) Logical Observation Identifiers Names and Codes (LOINC) and Veterans Aging Cohort Study (VACS) methods for extracting laboratory chemistry data from Veterans Health Administration (VA) electronic health records (EHR).</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="UNASSIGNED">Laboratory chemistry test results for 16 laboratory tests commonly assess in Veterans in VACS HIV (<i>N</i>&#x2009;=&#x2009;143&#x2009;830) followed in the VA 2015-2019 were extracted from the EHR and compared using 2 different data extraction approaches.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">The LOINC approach captured laboratory results from all 130 VA stations for all 16 labs. The VACS approach captured laboratory results from 128 to130 stations. Both approaches yielded laboratory results for a patient on a given date for 97% or more of the observations for 10 of the tests, 94%-97% for 5 of the tests, and 89% for 1 test. The percentage of exact matches on the value of the test result exceeded 99% for 10 of the laboratory tests and 92% for all other laboratory tests.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="UNASSIGNED">Both approaches resulted in extraction of similar amounts of data in terms of individual patients, VA stations and total observations for all 16 tests. Both approaches yielded high agreement on test results in terms of identical values and correlation of test results for all tests.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">The high level of agreement between VACS and LOINC approaches in this study demonstrate the favorable use of the LOINC approach for extracting laboratory results for most tests due to the ease and efficiency of this approach without compromising validity.</AbstractText><CopyrightInformation>Published by Oxford University Press on behalf of the American Medical Informatics Association 2025.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ramsey-Hardy</LastName><ForeName>Christine</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Nutritional Sciences, University of Texas at Austin, Austin, TX 78712, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VA Connecticut Healthcare System, West Haven, CT 06516, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06510, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Skanderson</LastName><ForeName>Melissa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>VA Connecticut Healthcare System, West Haven, CT 06516, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tate</LastName><ForeName>Janet P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>VA Connecticut Healthcare System, West Haven, CT 06516, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06510, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Justice</LastName><ForeName>Amy C</ForeName><Initials>AC</Initials><Identifier Source="ORCID">0000-0003-0139-5502</Identifier><AffiliationInfo><Affiliation>VA Connecticut Healthcare System, West Haven, CT 06516, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, Yale School of Medicine, New Haven, CT 06510, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marconi</LastName><ForeName>Vincent C</ForeName><Initials>VC</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, Emory University School of Medicine, Atlanta, GA 30322, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Global Health, Rollins School of Public Health, Atlanta, GA 30322, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Atlanta Veterans Affairs Medical Center, Atlanta, GA 30033, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alcorn</LastName><ForeName>Charles</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hauser</LastName><ForeName>Ronald G</ForeName><Initials>RG</Initials><Identifier Source="ORCID">0000-0002-7361-7162</Identifier><AffiliationInfo><Affiliation>VA Connecticut Healthcare System, West Haven, CT 06516, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vanderbilt Center for Population Science and Randomized Clinical Trials, Vanderbilt University Medical Center, Nashville, TN 37322, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anderson-Mellies</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Cardiovascular Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Vanderbilt Center for Population Science and Randomized Clinical Trials, Vanderbilt University Medical Center, Nashville, TN 37322, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VA Tennessee Valley Healthcare System, Nashville, TN 37212, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGinnis</LastName><ForeName>Kathleen A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>VA Connecticut Healthcare System, West Haven, CT 06516, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMIA Open</MedlineTA><NlmUniqueID>101730643</NlmUniqueID><ISSNLinking>2574-2531</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Veterans Aging Cohort OMOP</Keyword><Keyword MajorTopicYN="N">Veterans Aging Cohort Study</Keyword><Keyword MajorTopicYN="N">laboratory test results</Keyword><Keyword MajorTopicYN="N">study</Keyword></KeywordList><CoiStatement>V.C.M has received investigator-initiated research grants (to the institution) and support from Eli Lilly, Bayer, Gilead Sciences, Merck, and ViiV.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>7</Month><Day>29</Day><Hour>6</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>29</Day><Hour>5</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>28</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40727112</ArticleId><ArticleId IdType="pmc">PMC12303373</ArticleId><ArticleId IdType="doi">10.1093/jamiaopen/ooaf074</ArticleId><ArticleId IdType="pii">ooaf074</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bhargava A, Kim T, Quine DB, Hauser RG. &#xa0;A 20-year evaluation of LOINC in the United States&#x2019; largest integrated health system. Arch Pathol Lab Med. 2020;144:478-484. 10.5858/arpa.2019-0055-OA</Citation><ArticleIdList><ArticleId IdType="doi">10.5858/arpa.2019-0055-OA</ArticleId><ArticleId IdType="pubmed">31469586</ArticleId></ArticleIdList></Reference><Reference><Citation>Justice AC, Dombrowski E, Conigliaro J, et al. &#xa0;Veterans aging cohort study (VACS): overview and description. Med Care. 2006;44:S13-S24. 10.1097/01.mlr.0000223741.02074.66</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.mlr.0000223741.02074.66</ArticleId><ArticleId IdType="pmc">PMC3049942</ArticleId><ArticleId IdType="pubmed">16849964</ArticleId></ArticleIdList></Reference><Reference><Citation>Justice AC, Landefeld CS, Asch SM, Gifford AL, Whalen CC, Covinsky KE. &#xa0;Justification for a new cohort study of people aging with and without HIV infection. J Clin Epidemiol. &#xa0;2001;54(Suppl 1):S3-S8. 10.1016/s0895-4356(01)00440-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0895-4356(01)00440-1</ArticleId><ArticleId IdType="pmc">PMC6563331</ArticleId><ArticleId IdType="pubmed">11750202</ArticleId></ArticleIdList></Reference><Reference><Citation>McGinnis KA, Skanderson M, Levin FL, Brandt C, Erdos J, Justice AC. &#xa0;Comparison of two VA laboratory data repositories indicates that missing data vary despite originating from the same source. Med Care. 2009;47:121-124. 10.1097/MLR.0b013e31817d69c2</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MLR.0b013e31817d69c2</ArticleId><ArticleId IdType="pmc">PMC3032537</ArticleId><ArticleId IdType="pubmed">19106740</ArticleId></ArticleIdList></Reference><Reference><Citation>McGinnis KA, Justice AC, Moore RD, et al. &#xa0;Discrimination and calibration of the veterans aging cohort study index 2.0 for predicting mortality among people with human immunodeficiency virus in North America. Clin Infect Dis. 2022;75:297-304. 10.1093/cid/ciab883</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab883</ArticleId><ArticleId IdType="pmc">PMC9410720</ArticleId><ArticleId IdType="pubmed">34609485</ArticleId></ArticleIdList></Reference><Reference><Citation>Tate JP, Sterne JAC, Justice AC, Veterans Aging Cohort Study (VACS) and the Antiretroviral Therapy Cohort Collaboration (ART-CC). Albumin, white blood cell count, and body mass index improve discrimination of mortality in HIV-positive individuals. AIDS. 2019;33:903-912. 10.1097/QAD.0000000000002140</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAD.0000000000002140</ArticleId><ArticleId IdType="pmc">PMC6749990</ArticleId><ArticleId IdType="pubmed">30649058</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo Re V, Lim JK, Goetz MB, et al. &#xa0;Validity of diagnostic codes and liver-related laboratory abnormalities to identify hepatic decompensation events in the veterans aging cohort study. Pharmacoepidemiol Drug Saf. 2011;20:689-699. 10.1002/pds.2148</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.2148</ArticleId><ArticleId IdType="pmc">PMC3131229</ArticleId><ArticleId IdType="pubmed">21626605</ArticleId></ArticleIdList></Reference><Reference><Citation>
Data Standardization&#x2014;OHDSI. Accessed June 17, 2024. https://www.ohdsi.org/data-standardization/</Citation></Reference><Reference><Citation>Hern&#xe1;ndez-Favela CG, Hern&#xe1;ndez-Ruiz VA, Bello-Chavolla OY, et al. &#xa0;Higher veterans aging cohort study 2.0 index score predicts functional decline among older adults living with HIV. AIDS Res Hum Retroviruses. 2021;37:878-883. 10.1089/AID.2020.0295</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/AID.2020.0295</ArticleId><ArticleId IdType="pubmed">34465139</ArticleId></ArticleIdList></Reference><Reference><Citation>McGinnis KA, Skanderson M, Edelman EJ, et al. &#xa0;Impact of behavioral and medication treatment for alcohol use disorder on changes in HIV-related outcomes among patients with HIV: a longitudinal analysis. Drug Alcohol Depend. 2020;217:108272. 10.1016/j.drugalcdep.2020.108272</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drugalcdep.2020.108272</ArticleId><ArticleId IdType="pmc">PMC7757793</ArticleId><ArticleId IdType="pubmed">32971391</ArticleId></ArticleIdList></Reference><Reference><Citation>Justice AC, Tate JP. &#xa0;Strengths and limitations of the veterans aging cohort study index as a measure of physiologic frailty. AIDS Res Hum Retroviruses. 2019;35:1023-1033. 10.1089/AID.2019.0136</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/AID.2019.0136</ArticleId><ArticleId IdType="pmc">PMC7133454</ArticleId><ArticleId IdType="pubmed">31565954</ArticleId></ArticleIdList></Reference><Reference><Citation>Justice AC, Modur SP, Tate JP, NA-ACCORD and VACS Project Teams, et al. &#xa0;Predictive accuracy of the veterans aging cohort study index for mortality with HIV infection: a North American cross cohort analysis. J Acquir Immune Defic Syndr 1999. 2013;62:149-163. 10.1097/QAI.0b013e31827df36c</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAI.0b013e31827df36c</ArticleId><ArticleId IdType="pmc">PMC3619393</ArticleId><ArticleId IdType="pubmed">23187941</ArticleId></ArticleIdList></Reference><Reference><Citation>Bebu I, Tate J, Rimland D, et al. &#xa0;The VACS index predicts mortality in a young, healthy HIV population starting highly active antiretroviral therapy. J Acquir Immune Defic Syndr 1999. 2014;65:226-230. 10.1097/QAI.0000000000000045</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAI.0000000000000045</ArticleId><ArticleId IdType="pmc">PMC4091811</ArticleId><ArticleId IdType="pubmed">24226058</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;ndez-Ruiz VA, Erlandson KM, Amieva H, Avila-Funes JA. &#xa0;Veterans aging cohort study index and frailty: one part of the whole. AIDS Res Hum Retroviruses. 2022;38:792-797. 10.1089/AID.2022.0075</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/AID.2022.0075</ArticleId><ArticleId IdType="pubmed">35972736</ArticleId></ArticleIdList></Reference><Reference><Citation>Womack JA, Murphy TE, Leo-Summers L, et al. &#xa0;Predictive risk model for serious falls among older persons living with HIV. J Acquir Immune Defic Syndr 1999. 2022;91:168-174. 10.1097/QAI.0000000000003030</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAI.0000000000003030</ArticleId><ArticleId IdType="pmc">PMC9470988</ArticleId><ArticleId IdType="pubmed">36094483</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40744316</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-0480</ISSN><JournalIssue CitedMedium="Internet"><Volume>169</Volume><PubDate><Year>2025</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Journal of biomedical informatics</Title><ISOAbbreviation>J Biomed Inform</ISOAbbreviation></Journal><ArticleTitle>CLEAR: A vision to support clinical evidence lifecycle with continuous learning.</ArticleTitle><Pagination><StartPage>104884</StartPage><MedlinePgn>104884</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jbi.2025.104884</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1532-0464(25)00113-3</ELocationID><Abstract><AbstractText>Human knowledge of diseases, treatments, and prevention techniques is constantly evolving. The generation of clinical evidence using randomized controlled trials on human subjects occurs notably slowly and inefficiently. The Learning Health System (LHS) has been proposed to facilitate the continuous improvement of individual and population health through a cycle of knowledge, practice, and data. However, the gap between the demand for high-quality evidence to support clinical decisions and the available evidence continues to enlarge. While the current LHS vision articulates the integration of Real-World Data (RWD), the rapid generation of RWD often outpaces the rate of effective evidence synthesis and implementation. Considering this, we propose a new framework that more effectively leverages RWD to support the entire clinical evidence lifecycle through a continuous learning mechanism. This framework, powered by modern data science and informatics, offers enhanced scalability and efficiency. In this vision, specifically, RWD is integrated into the clinical evidence lifecycle via four closed feedback loops: 1) guiding research prioritization and study design, 2) facilitating clinical guideline development, 3) assisting guideline evaluation, and 4) supporting shared decision-making. Our framework enables rapid responsiveness to emerging health data and evolving healthcare needs, timely development of clinical guidelines to optimize clinical recommendations, and sustained improvements in clinical practice and patient outcomes. This vision calls for informatics support for an efficient, scalable, and stakeholder-aware clinical evidence lifecycle.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Author(s). Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Yilu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Gongbo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Fangyi</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York 10032, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Yifan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Weill Cornell Medicine, Department of Population Health Sciences, New York 10022, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York 10032, USA; Observational Health Data Analytics, Janssen Research and Development, Titusville, NJ 08560, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weng</LastName><ForeName>Chunhua</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York 10032, USA. Electronic address: cw2384@cumc.columbia.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 LM014344</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM014573</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Biomed Inform</MedlineTA><NlmUniqueID>100970413</NlmUniqueID><ISSNLinking>1532-0464</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000080891" MajorTopicYN="Y">Learning Health System</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019317" MajorTopicYN="Y">Evidence-Based Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008490" MajorTopicYN="Y">Medical Informatics</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Continuous learning</Keyword><Keyword MajorTopicYN="N">Evidence-based medicine</Keyword><Keyword MajorTopicYN="N">Evidence-based research</Keyword><Keyword MajorTopicYN="N">Real-world data</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2026</Year><Month>7</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>8</Day><Hour>2</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>1</Day><Hour>0</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>7</Month><Day>31</Day><Hour>19</Hour><Minute>39</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40744316</ArticleId><ArticleId IdType="mid">NIHMS2102299</ArticleId><ArticleId IdType="pmc">PMC12339056</ArticleId><ArticleId IdType="doi">10.1016/j.jbi.2025.104884</ArticleId><ArticleId IdType="pii">S1532-0464(25)00113-3</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Sackett DL, Rosenberg WM, Gray JA, Haynes RB &amp; Richardson WS Evidence based medicine: what it is and what it isn&#x2019;t. BMJ 312, 71&#x2013;2 (1996).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2349778</ArticleId><ArticleId IdType="pubmed">8555924</ArticleId></ArticleIdList></Reference><Reference><Citation>Devereaux PJ &amp; Yusuf S The evolution of the randomized controlled trial and its role in evidence-based decision making. J. Intern. Med 254, 105&#x2013;113 (2003).</Citation><ArticleIdList><ArticleId IdType="pubmed">12859691</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddiqui S et al. Unmet Needs in Severe Asthma Subtyping and Precision Medicine Trials. Bridging Clinical and Patient Perspectives. Am J Respir Crit Care Med 199, 823&#x2013;829 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6835084</ArticleId><ArticleId IdType="pubmed">30726120</ArticleId></ArticleIdList></Reference><Reference><Citation>Wechsler ME et al. Unmet needs and evidence gaps in hypereosinophilic syndrome and eosinophilic granulomatosis with polyangiitis. J Allergy Clin Immunol 151, 1415&#x2013;1428 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37086239</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalmers I &amp; Glasziou P Avoidable waste in the production and reporting of research evidence. Lancet 374, 86&#x2013;9 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19525005</ArticleId></ArticleIdList></Reference><Reference><Citation>Friedman CP What is unique about learning health systems? Learn. Health Syst 6, e10328 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9284922</ArticleId><ArticleId IdType="pubmed">35860320</ArticleId></ArticleIdList></Reference><Reference><Citation>Institute of Medicine (US) Roundtable on Evidence-Based Medicine. The Learning Healthcare System: Workshop Summary. (National Academies Press (US), Washington (DC), 2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">21452449</ArticleId></ArticleIdList></Reference><Reference><Citation>Committee on the Learning Health Care System in America &amp; Institute of Medicine. Best Care at Lower Cost: The Path to Continuously Learning Health Care in America. (National Academies Press (US), Washington (DC), 2013).</Citation><ArticleIdList><ArticleId IdType="pubmed">24901184</ArticleId></ArticleIdList></Reference><Reference><Citation>The U.S. Food and Drug Administration. Framework for FDA&#x2019;s Real-World Evidence Program. (2018).</Citation></Reference><Reference><Citation>Rethinking evidence in medicine. Nat. Med 29, 1&#x2013;1 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36694061</ArticleId></ArticleIdList></Reference><Reference><Citation>Guyatt GH et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336, 924&#x2013;926 (2008).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2335261</ArticleId><ArticleId IdType="pubmed">18436948</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson KA et al. Evidence-Based Research Series-Paper 1: What Evidence-Based Research is and why is it important? J Clin Epidemiol 129, 151&#x2013;157 (2021).</Citation><ArticleIdList><ArticleId IdType="pubmed">32979491</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalmers I &amp; Glasziou P Avoidable waste in the production and reporting of research evidence. The lancet 374, 86&#x2013;89 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19525005</ArticleId></ArticleIdList></Reference><Reference><Citation>Crowe S, Fenton M, Hall M, Cowan K &amp; Chalmers I Patients&#x2019;, clinicians&#x2019; and the research communities&#x2019; priorities for treatment research: there is an important mismatch. Res. Involv. Engagem 1, 1&#x2013;10 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5598091</ArticleId><ArticleId IdType="pubmed">29062491</ArticleId></ArticleIdList></Reference><Reference><Citation>Concato J, Stein P, Dal Pan GJ, Ball R &amp; Corrigan-Curay J Randomized, observational, interventional, and real-world&#x2014;What&#x2019;s in a name? Pharmacoepidemiol. Drug Saf 29, 1514&#x2013;1517 (2020).</Citation><ArticleIdList><ArticleId IdType="pubmed">32940401</ArticleId></ArticleIdList></Reference><Reference><Citation>Bucher HC et al. Users&#x2019; guides to the medical literature: XIX. Applying clinical trial results A. How to use an article measuring the effect of an intervention on surrogate end points. Jama 282, 771&#x2013;778 (1999).</Citation><ArticleIdList><ArticleId IdType="pubmed">10463714</ArticleId></ArticleIdList></Reference><Reference><Citation>Gluud C, Brok J, Gong Y &amp; Koretz RL Hepatology may have problems with putative surrogate outcome measures. J. Hepatol 46, 734&#x2013;742 (2007).</Citation><ArticleIdList><ArticleId IdType="pubmed">17316871</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogel DB Factors associated with clinical trials that fail and opportunities for improving the likelihood of success: a review. Contemp. Clin. Trials Commun 11, 156&#x2013;164 (2018).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6092479</ArticleId><ArticleId IdType="pubmed">30112460</ArticleId></ArticleIdList></Reference><Reference><Citation>Unger JM, Cook E, Tai E &amp; Bleyer A Role of clinical trial participation in cancer research: barriers, evidence, and strategies. in vol. 35 185 (NIH Public Access, 2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5495113</ArticleId><ArticleId IdType="pubmed">27249699</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim JH et al. Towards clinical data-driven eligibility criteria optimization for interventional COVID-19 clinical trials. J. Am. Med. Inform. Assoc 28, 14&#x2013;22 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7798960</ArticleId><ArticleId IdType="pubmed">33260201</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu R et al. Evaluating eligibility criteria of oncology trials using real-world data and AI. Nature 592, 629&#x2013;633 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9007176</ArticleId><ArticleId IdType="pubmed">33828294</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagenais S, Russo L, Madsen A, Webster J &amp; Becnel L Use of real-world evidence to drive drug development strategy and inform clinical trial design. Clin. Pharmacol. Ther 111, 77&#x2013;89 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9299990</ArticleId><ArticleId IdType="pubmed">34839524</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang Y et al. A data-driven approach to optimizing clinical study eligibility criteria. J. Biomed. Inform 142, 104375 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10262300</ArticleId><ArticleId IdType="pubmed">37141977</ArticleId></ArticleIdList></Reference><Reference><Citation>Galbreath AD, Smith B, Wood P, Forkner E &amp; Peters JI Cumulative recruitment experience in two large single-center randomized, controlled clinical trials. Contemp. Clin. Trials 29, 335&#x2013;342 (2008).</Citation><ArticleIdList><ArticleId IdType="pubmed">18032118</ArticleId></ArticleIdList></Reference><Reference><Citation>Idnay B et al. Uncovering key clinical trial features influencing recruitment. J. Clin. Transl. Sci 7, e199 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10565197</ArticleId><ArticleId IdType="pubmed">37830010</ArticleId></ArticleIdList></Reference><Reference><Citation>Borkar DS, Parke DW &amp; Lee AY Leveraging Real-World Evidence to Enhance Clinical Trials. Ophthalmology 131, 756&#x2013;758 (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38906640</ArticleId></ArticleIdList></Reference><Reference><Citation>Hulstaert L, Twick I, Sarsour K &amp; Verstraete H Enhancing site selection strategies in clinical trial recruitment using real-world data modeling. Plos One 19, e0300109 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10927105</ArticleId><ArticleId IdType="pubmed">38466688</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J et al. Advancing the utilization of real-world data and real-world evidence in clinical pharmacology and translational research&#x2014;Proceedings from the ASCPT 2023 preconference workshop. Clin. Transl. Sci 17, e13785 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10993776</ArticleId><ArticleId IdType="pubmed">38572980</ArticleId></ArticleIdList></Reference><Reference><Citation>Frieden TR Evidence for Health Decision Making - Beyond Randomized, Controlled Trials. N. Engl. J. Med 377, 465&#x2013;475 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28767357</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew SY et al. Making Clinical Practice Guidelines Pragmatic: How Big Data and Real World Evidence Can Close the Gap. Ann Acad Med Singap 47, 523&#x2013;527 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">30636269</ArticleId></ArticleIdList></Reference><Reference><Citation>Herland K, Akselsen JP, Skjonsberg OH &amp; Bjermer L How representative are clinical study patients with asthma or COPD for a larger &#x2018;real life&#x2019; population of patients with obstructive lung disease? Respir. Med 99, 11&#x2013;19 (2005).</Citation><ArticleIdList><ArticleId IdType="pubmed">15672843</ArticleId></ArticleIdList></Reference><Reference><Citation>Sen A et al. GIST 2.0: A scalable multi-trait metric for quantifying population representativeness of individual clinical studies. J Biomed Inf. 63, 325&#x2013;336 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5077682</ArticleId><ArticleId IdType="pubmed">27600407</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott PE et al. Participation of Women in Clinical Trials Supporting FDA Approval of Cardiovascular Drugs. J Am Coll Cardiol 71, 1960&#x2013;1969 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29724348</ArticleId></ArticleIdList></Reference><Reference><Citation>Tobb K, Kocher M &amp; Bullock-Palmer RP Underrepresentation of women in cardiovascular trials- it is time to shatter this glass ceiling. Am Heart J Plus 13, 100109 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10978176</ArticleId><ArticleId IdType="pubmed">38560055</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen R et al. Comparative First-Line Effectiveness and Safety of ACE (Angiotensin-Converting Enzyme) Inhibitors and Angiotensin Receptor Blockers: A Multinational Cohort Study. Hypertension 78, 591&#x2013;603 (2021).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8363588</ArticleId><ArticleId IdType="pubmed">34304580</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruan E et al. HowOften: Large Scale Incidence Rate Calculation of Every Side Effect for Every Drug.</Citation></Reference><Reference><Citation>Dreyer NA Strengthening evidence-based medicine with real-world evidence. Lancet Healthy Longev. 3, e641&#x2013;e642 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36150401</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens KR ACE star model of EBP: Knowledge transformation. Acad. Cent. Evid.-Based Pract. Univ. Tex. Health Sci. Cent. San Antonio Retrieved July 30, 2009 (2004).</Citation></Reference><Reference><Citation>Rycroft-Malone J &amp; Bucknall T Models and Frameworks for Implementing Evidence-Based Practice: Linking Evidence to Action. (John Wiley &amp; Sons, 2010).</Citation></Reference><Reference><Citation>Rycroft-Malone J Promoting action on research implementation in health services (PARIHS). Models Framew. Implement. Evid.-Based Pract. Link. Evid. Action 109, 135 (2010).</Citation></Reference><Reference><Citation>Rycroft-Malone J The PARIHS framework&#x2014;a framework for guiding the implementation of evidence-based practice. J. Nurs. Care Qual 19, 297&#x2013;304 (2004).</Citation><ArticleIdList><ArticleId IdType="pubmed">15535533</ArticleId></ArticleIdList></Reference><Reference><Citation>Harvey G &amp; Kitson A PARIHS revisited: from heuristic to integrated framework for the successful implementation of knowledge into practice. Implement. Sci 11, 1&#x2013;13 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4807546</ArticleId><ArticleId IdType="pubmed">27013464</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham ID et al. Lost in knowledge translation: time for a map? J Contin Educ Health Prof 26, 13&#x2013;24 (2006).</Citation><ArticleIdList><ArticleId IdType="pubmed">16557505</ArticleId></ArticleIdList></Reference><Reference><Citation>Titler MG et al. The Iowa Model of Evidence-Based Practice to Promote Quality Care. Crit Care Nurs Clin North Am 13, 497&#x2013;509 (2001).</Citation><ArticleIdList><ArticleId IdType="pubmed">11778337</ArticleId></ArticleIdList></Reference><Reference><Citation>Newhouse RP, Dearholt SL, Poe SS, Pugh LC &amp; White KM Johns Hopkins Nursing Evidence-Based Practice Model and Guidelines. (Sigma Theta Tau International Honor Society of Nursing; Indianapolis, IN, 2007).</Citation></Reference><Reference><Citation>Rajit D, Johnson A, Callander E, Teede H &amp; Enticott J Learning health systems and evidence ecosystems: a perspective on the future of evidence-based medicine and evidence-based guideline development. Health Res. Policy Syst 22, 4 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10768258</ArticleId><ArticleId IdType="pubmed">38178086</ArticleId></ArticleIdList></Reference><Reference><Citation>Marra C, Chen JL, Coravos A &amp; Stern AD Quantifying the use of connected digital products in clinical research. NPJ Digit. Med 3, 50 (2020).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7125096</ArticleId><ArticleId IdType="pubmed">32285011</ArticleId></ArticleIdList></Reference><Reference><Citation>Moses H et al. The anatomy of medical research: US and international comparisons. Jama 313, 174&#x2013;189 (2015).</Citation><ArticleIdList><ArticleId IdType="pubmed">25585329</ArticleId></ArticleIdList></Reference><Reference><Citation>Glickman SW et al. Ethical and scientific implications of the globalization of clinical research. N Engl J Med 360, 816&#x2013;823 (2009).</Citation><ArticleIdList><ArticleId IdType="pubmed">19228627</ArticleId></ArticleIdList></Reference><Reference><Citation>Leiter A, Diefenbach MA, Doucette J, Oh WK &amp; Galsky MD Clinical trial awareness: Changes over time and sociodemographic disparities. Clin. Trials 12, 215&#x2013;223 (2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4667750</ArticleId><ArticleId IdType="pubmed">25673636</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen QD et al. Evolution of age and female representation in the most-cited randomized controlled trials of cardiology of the last 20 years. Circ. Cardiovasc. Qual. Outcomes 11, e004713 (2018).</Citation><ArticleIdList><ArticleId IdType="pubmed">29853466</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramamoorthy A et al. Promoting clinical trial diversity: a highlight of select US FDA initiatives. Clin. Pharmacol. Ther 113, 528&#x2013;535 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">36514867</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherman RE et al. Real-world evidence&#x2014;what is it and what can it tell us. N Engl J Med 375, 2293&#x2013;2297 (2016).</Citation><ArticleIdList><ArticleId IdType="pubmed">27959688</ArticleId></ArticleIdList></Reference><Reference><Citation>Casey JA, Schwartz BS, Stewart WF &amp; Adler NE Using electronic health records for population health research: a review of methods and applications. Annu. Rev. Public Health 37, 61&#x2013;81 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6724703</ArticleId><ArticleId IdType="pubmed">26667605</ArticleId></ArticleIdList></Reference><Reference><Citation>Fleurence RL et al. Launching PCORnet, a national patient-centered clinical research network. J. Am. Med. Inform. Assoc 21, 578&#x2013;582 (2014).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4078292</ArticleId><ArticleId IdType="pubmed">24821743</ArticleId></ArticleIdList></Reference><Reference><Citation>All of Us Research Program Investigators. The &#x201c;All of Us&#x201d; research program. N. Engl. J. Med 381, 668&#x2013;676 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8291101</ArticleId><ArticleId IdType="pubmed">31412182</ArticleId></ArticleIdList></Reference><Reference><Citation>US Food &amp; Drug Administration. Use of real-world evidence to support regulatory decision-making for medical devices: guidance for industry and Food and Drug Administration staff. Food Drug Adm. (2017).</Citation></Reference><Reference><Citation>Djulbegovic B &amp; Guyatt GH Progress in evidence-based medicine: a quarter century on. The lancet 390, 415&#x2013;423 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28215660</ArticleId></ArticleIdList></Reference><Reference><Citation>Gopalakrishnan S &amp; Ganeshkumar P Systematic reviews and meta-analysis: understanding the best evidence in primary healthcare. J. Fam. Med. Prim. Care 2, 9&#x2013;14 (2013).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3894019</ArticleId><ArticleId IdType="pubmed">24479036</ArticleId></ArticleIdList></Reference><Reference><Citation>Borah R, Brown AW, Capers PL &amp; Kaiser KA Analysis of the time and workers needed to conduct systematic reviews of medical interventions using data from the PROSPERO registry. BMJ Open 7, e012545 (2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5337708</ArticleId><ArticleId IdType="pubmed">28242767</ArticleId></ArticleIdList></Reference><Reference><Citation>Sogi GM Research Waste. Contemp Clin Dent 14, 179 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10699190</ArticleId><ArticleId IdType="pubmed">38075541</ArticleId></ArticleIdList></Reference><Reference><Citation>T&#xf3;th B, Berek L, Gul&#xe1;csi L, P&#xe9;ntek M &amp; Zrubka Z Automation of systematic reviews of biomedical literature: a scoping review of studies indexed in PubMed. Syst. Rev 13, 174 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11229257</ArticleId><ArticleId IdType="pubmed">38978132</ArticleId></ArticleIdList></Reference><Reference><Citation>Ofori-Boateng R, Aceves-Martins M, Wiratunga N &amp; Moreno-Garcia CF Towards the automation of systematic reviews using natural language processing, machine learning, and deep learning: a comprehensive review. Artif. Intell. Rev 57, 1&#x2013;60 (2024).</Citation></Reference><Reference><Citation>Marshall IJ, Kuiper J, Banner E &amp; Wallace BC Automating biomedical evidence synthesis: RobotReviewer. in vol. 2017 7 (NIH Public Access, 2017).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5662138</ArticleId><ArticleId IdType="pubmed">29093610</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahuli SA, Rai A, Mahuli AV &amp; Kumar A Application ChatGPT in conducting systematic reviews and meta-analyses. Br Dent J 235, 90&#x2013;92 (2023).</Citation><ArticleIdList><ArticleId IdType="pubmed">37500847</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z et al. Accelerating Clinical Evidence Synthesis with Large Language Models. ArXiv Prepr. ArXiv240617755 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC12331930</ArticleId><ArticleId IdType="pubmed">40775042</ArticleId></ArticleIdList></Reference><Reference><Citation>Elliott JH et al. Living systematic review: 1. Introduction&#x2014;the why, what, when, and how. J. Clin. Epidemiol 91, 23&#x2013;30 (2017).</Citation><ArticleIdList><ArticleId IdType="pubmed">28912002</ArticleId></ArticleIdList></Reference><Reference><Citation>Gartlehner G et al. Data extraction for evidence synthesis using a large language model: A proof-of-concept study. Res. Synth. Methods (2024).</Citation><ArticleIdList><ArticleId IdType="pubmed">38432227</ArticleId></ArticleIdList></Reference><Reference><Citation>Konet A et al. Performance of two large language models for data extraction in evidence synthesis. Res. Synth. Methods</Citation><ArticleIdList><ArticleId IdType="pubmed">38895747</ArticleId></ArticleIdList></Reference><Reference><Citation>Riaz IB, Naqvi SAA, Hasan B &amp; Murad MH Future of Evidence Synthesis: Automated, Living, and Interactive Systematic Reviews and Meta-Analyses. Mayo Clin. Proc. Digit. Health (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11975841</ArticleId><ArticleId IdType="pubmed">40206128</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng YF, Rousseau JF, Shortliffe EH &amp; Weng CH AI-generated text may have a role in evidence-based medicine. Nat. Med 29, 1593&#x2013;1594 (2023).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11193148</ArticleId><ArticleId IdType="pubmed">37221382</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang G et al. Leveraging generative AI for clinical evidence synthesis needs to ensure trustworthiness. J Biomed Inf. 153, 104640 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11217921</ArticleId><ArticleId IdType="pubmed">38608915</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang G et al. A span-based model for extracting overlapping PICO entities from randomized controlled trial publications. J Am Med Inf. Assoc 31, 1163&#x2013;1171 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11031223</ArticleId><ArticleId IdType="pubmed">38471120</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Q et al. Demystifying Large Language Models for Medicine: A Primer. ArXiv (2024).</Citation></Reference><Reference><Citation>Chen F, Zhang G, Fang Y, Peng Y &amp; Weng C Semi-supervised learning from small annotated data and large unlabeled data for fine-grained Participants, Intervention, Comparison, and Outcomes entity recognition. J Am Med Inf. Assoc 32, 555&#x2013;565 (2025).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11833487</ArticleId><ArticleId IdType="pubmed">39823371</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang GB et al. Closing the gap between open source and commercial large language models for medical evidence summarization. NPJ Digit. Med 7, (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11383939</ArticleId><ArticleId IdType="pubmed">39251804</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang G et al. Leveraging long context in retrieval augmented language models for medical question answering. NPJ Digit. Med 8, 239 (2025).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC12048518</ArticleId><ArticleId IdType="pubmed">40316710</ArticleId></ArticleIdList></Reference><Reference><Citation>Overview - FHIR v5.0.0.</Citation></Reference><Reference><Citation>Hripcsak G et al. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. in MEDINFO 2015: eHealth-enabled Health 574&#x2013;578 (IOS Press, 2015).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G et al. Facilitating phenotype transfer using a common data model. J. Biomed. Inform 96, 103253 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6697565</ArticleId><ArticleId IdType="pubmed">31325501</ArticleId></ArticleIdList></Reference><Reference><Citation>Acosta JN, Falcone GJ, Rajpurkar P &amp; Topol EJ Multimodal biomedical AI. Nat. Med 28, 1773&#x2013;1784 (2022).</Citation><ArticleIdList><ArticleId IdType="pubmed">36109635</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuan C et al. Criteria2Query: a natural language interface to clinical databases for cohort definition. J. Am. Med. Inform. Assoc 26, 294&#x2013;305 (2019).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6402359</ArticleId><ArticleId IdType="pubmed">30753493</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang Y et al. Combining human and machine intelligence for clinical trial eligibility querying. J. Am. Med. Inform. Assoc 29, 1161&#x2013;1171 (2022).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9196697</ArticleId><ArticleId IdType="pubmed">35426943</ArticleId></ArticleIdList></Reference><Reference><Citation>Park J et al. Criteria2Query 3.0: Leveraging generative large language models for clinical trial eligibility query generation. J. Biomed. Inform 154, 104649 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11129920</ArticleId><ArticleId IdType="pubmed">38697494</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin Q et al. Matching patients to clinical trials with large language models. Nat. Commun 15, 9074 (2024).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11574183</ArticleId><ArticleId IdType="pubmed">39557832</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">40749680</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>26</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2666-3791</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>8</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>19</Day></PubDate></JournalIssue><Title>Cell reports. Medicine</Title><ISOAbbreviation>Cell Rep Med</ISOAbbreviation></Journal><ArticleTitle>Comorbidity analysis and clustering of endometriosis patients using electronic health records.</ArticleTitle><Pagination><StartPage>102245</StartPage><MedlinePgn>102245</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">102245</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.xcrm.2025.102245</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2666-3791(25)00318-0</ELocationID><Abstract><AbstractText>Endometriosis is a prevalent, complex, inflammatory condition associated with a diverse range of symptoms and comorbidities. Despite its substantial burden on patients, population-level studies that explore its comorbid patterns and heterogeneity are limited. In this retrospective case-control study, we analyze comorbidities from over forty thousand endometriosis patients across six University of California medical centers using de-identified electronic health record (EHR) data. We find hundreds of conditions significantly associated with endometriosis, including genitourinary disorders, neoplasms, and autoimmune diseases, with strong replication across datasets. Clustering analyses identify patient subpopulations with distinct comorbidity patterns, including psychiatric and autoimmune conditions. This study provides a comprehensive analysis of endometriosis comorbidities and highlights the heterogeneity within the patient population. Our findings demonstrate the utility of EHR data in uncovering clinically meaningful patterns and suggest pathways for personalized disease management and future research on biological mechanisms underlying endometriosis.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Khan</LastName><ForeName>Umair</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Bakar Computational Health Sciences Institute, University of California, San Francisco, San Francisco, CA, USA; Biological and Medical Informatics Graduate Program, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oskotsky</LastName><ForeName>Tomiko T</ForeName><Initials>TT</Initials><AffiliationInfo><Affiliation>Bakar Computational Health Sciences Institute, University of California, San Francisco, San Francisco, CA, USA; Division of Clinical Informatics and Digital Transformation, Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yilmaz</LastName><ForeName>Bahar D</ForeName><Initials>BD</Initials><AffiliationInfo><Affiliation>Department of Obstetrics, Gynecology, and Reproductive Sciences, Center for Reproductive Sciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roger</LastName><ForeName>Jacquelyn</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Biological and Medical Informatics Graduate Program, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gjoni</LastName><ForeName>Ketrin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Pharmaceutical Sciences and Pharmacogenomics Graduate Program, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Irwin</LastName><ForeName>Juan C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Obstetrics, Gynecology, and Reproductive Sciences, Center for Reproductive Sciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Opoku-Anane</LastName><ForeName>Jessica</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Robert Wood Johnson Medical School, Rutgers University, New Brunswick, NJ, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elhadad</LastName><ForeName>No&#xe9;mie</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giudice</LastName><ForeName>Linda C</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Department of Obstetrics, Gynecology, and Reproductive Sciences, Center for Reproductive Sciences, University of California, San Francisco, San Francisco, CA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sirota</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Bakar Computational Health Sciences Institute, University of California, San Francisco, San Francisco, CA, USA. Electronic address: marina.sirota@ucsf.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 HD106414</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM067547</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 GM142516</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001872</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cell Rep Med</MedlineTA><NlmUniqueID>101766894</NlmUniqueID><ISSNLinking>2666-3791</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>medRxiv. 2025 Feb 19:2025.02.13.25322244. doi: 10.1101/2025.02.13.25322244.</RefSource><PMID Version="1">39990556</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="N">Electronic Health Records</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004715" MajorTopicYN="Y">Endometriosis</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002140" MajorTopicYN="N" Type="Geographic">California</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000046" MajorTopicYN="N">Academic Medical Centers</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016000" MajorTopicYN="N">Cluster Analysis</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">case-control</Keyword><Keyword MajorTopicYN="N">comorbidities</Keyword><Keyword MajorTopicYN="N">electronic health records</Keyword><Keyword MajorTopicYN="N">endometriosis</Keyword><Keyword MajorTopicYN="N">propensity score matching</Keyword><Keyword MajorTopicYN="N">unsupervised clustering</Keyword></KeywordList><CoiStatement>Declaration of interests L.C.G. is a consultant to Myovant Sciences, Gesynta Pharma, Celmatix, NextGen Jane, and Chugai Pharmaceutical Co.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>5</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>6</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>31</Day><Hour>20</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>2</Day><Hour>10</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>1</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>7</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40749680</ArticleId><ArticleId IdType="pmc">PMC12432376</ArticleId><ArticleId IdType="doi">10.1016/j.xcrm.2025.102245</ArticleId><ArticleId IdType="pii">S2666-3791(25)00318-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Zondervan K.T., Becker C.M., Missmer S.A. Endometriosis. N. Engl. J. Med. 2020;382:1244&#x2013;1256. doi: 10.1056/NEJMra1810764.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1810764</ArticleId><ArticleId IdType="pubmed">32212520</ArticleId></ArticleIdList></Reference><Reference><Citation>Zondervan K.T., Becker C.M., Koga K., Missmer S.A., Taylor R.N., Vigan&#xf2; P. Endometriosis. Nat. Rev. Dis. Primers. 2018;4:9&#x2013;25. doi: 10.1038/s41572-018-0008-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41572-018-0008-5</ArticleId><ArticleId IdType="pubmed">30026507</ArticleId></ArticleIdList></Reference><Reference><Citation>Nnoaham K.E., Hummelshoj L., Webster P., d'Hooghe T., de Cicco Nardone F., de Cicco Nardone C., Jenkinson C., Kennedy S.H., Zondervan K.T., World Endometriosis Research Foundation Global Study of Women's Health consortium Impact of endometriosis on quality of life and work productivity: a multicenter study across ten countries. Fertil. Steril. 2011;96:366&#x2013;373.e8. doi: 10.1016/j.fertnstert.2011.05.090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fertnstert.2011.05.090</ArticleId><ArticleId IdType="pmc">PMC3679489</ArticleId><ArticleId IdType="pubmed">21718982</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballard K.D., Seaman H.E., de Vries C.S., Wright J.T. Can symptomatology help in the diagnosis of endometriosis? Findings from a national case&#x2013;control study&#x2014;Part 1. BJOG Int. J. Obstet. Gynaecol. 2008;115:1382&#x2013;1391. doi: 10.1111/j.1471-0528.2008.01878.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-0528.2008.01878.x</ArticleId><ArticleId IdType="pubmed">18715240</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker C.M., Gattrell W.T., Gude K., Singh S.S. Reevaluating response and failure of medical treatment of endometriosis: a systematic review. Fertil. Steril. 2017;108:125&#x2013;136. doi: 10.1016/j.fertnstert.2017.05.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fertnstert.2017.05.004</ArticleId><ArticleId IdType="pmc">PMC5494290</ArticleId><ArticleId IdType="pubmed">28668150</ArticleId></ArticleIdList></Reference><Reference><Citation>Simoens S., Dunselman G., Dirksen C., Hummelshoj L., Bokor A., Brandes I., Brodszky V., Canis M., Colombo G.L., DeLeire T., et al. The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres. Hum. Reprod. 2012;27:1292&#x2013;1299. doi: 10.1093/humrep/des073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/humrep/des073</ArticleId><ArticleId IdType="pubmed">22422778</ArticleId></ArticleIdList></Reference><Reference><Citation>Kvaskoff M., Mu F., Terry K.L., Harris H.R., Poole E.M., Farland L., Missmer S.A. Endometriosis: a high-risk population for major chronic diseases? Hum. Reprod. Update. 2015;21:500&#x2013;516. doi: 10.1093/humupd/dmv013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/humupd/dmv013</ArticleId><ArticleId IdType="pmc">PMC4463000</ArticleId><ArticleId IdType="pubmed">25765863</ArticleId></ArticleIdList></Reference><Reference><Citation>Pearce C.L., Templeman C., Rossing M.A., Lee A., Near A.M., Webb P.M., Nagle C.M., Doherty J.A., Cushing-Haugen K.L., Wicklund K.G., et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case&#x2013;control studies. Lancet Oncol. 2012;13:385&#x2013;394. doi: 10.1016/S1470-2045(11)70404-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1470-2045(11)70404-1</ArticleId><ArticleId IdType="pmc">PMC3664011</ArticleId><ArticleId IdType="pubmed">22361336</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen N.M., J&#xf8;rgensen K.T., Pedersen B.V., Rostgaard K., Frisch M. The co-occurrence of endometriosis with multiple sclerosis, systemic lupus erythematosus and Sj&#xf6;gren syndrome. Hum. Reprod. 2011;26:1555&#x2013;1559. doi: 10.1093/humrep/der105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/humrep/der105</ArticleId><ArticleId IdType="pubmed">21471158</ArticleId></ArticleIdList></Reference><Reference><Citation>Caserta D., Mallozzi M., Pulcinelli F.M., Mossa B., Moscarini M. Endometriosis allergic or autoimmune disease: pathogenetic aspects - a case control study. Clin. Exp. Obstet. Gynecol. 2016;43:354&#x2013;357. doi: 10.12891/ceog2122.2016.</Citation><ArticleIdList><ArticleId IdType="doi">10.12891/ceog2122.2016</ArticleId><ArticleId IdType="pubmed">27328490</ArticleId></ArticleIdList></Reference><Reference><Citation>Casey J.A., Schwartz B.S., Stewart W.F., Adler N.E. Using Electronic Health Records for Population Health Research: A Review of Methods and Applications. Annu. Rev. Public Health. 2016;37:61&#x2013;81. doi: 10.1146/annurev-publhealth-032315-021353.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-publhealth-032315-021353</ArticleId><ArticleId IdType="pmc">PMC6724703</ArticleId><ArticleId IdType="pubmed">26667605</ArticleId></ArticleIdList></Reference><Reference><Citation>Penrod N., Okeh C., Velez Edwards D.R., Barnhart K., Senapati S., Verma S.S. Leveraging electronic health record data for endometriosis research. Front. Digit. Health. 2023;5 doi: 10.3389/fdgth.2023.1150687.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fdgth.2023.1150687</ArticleId><ArticleId IdType="pmc">PMC10278662</ArticleId><ArticleId IdType="pubmed">37342866</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi E.J., Cho S.B., Lee S.R., Lim Y.M., Jeong K., Moon H.S., Chung H. Comorbidity of gynecological and non-gynecological diseases with adenomyosis and endometriosis. Obstet. Gynecol. Sci. 2017;60:579&#x2013;586. doi: 10.5468/ogs.2017.60.6.579.</Citation><ArticleIdList><ArticleId IdType="doi">10.5468/ogs.2017.60.6.579</ArticleId><ArticleId IdType="pmc">PMC5694733</ArticleId><ArticleId IdType="pubmed">29184867</ArticleId></ArticleIdList></Reference><Reference><Citation>Estes S.J., Huisingh C.E., Chiuve S.E., Petruski-Ivleva N., Missmer S.A. Depression, Anxiety, and Self-Directed Violence in Women With Endometriosis: A Retrospective Matched-Cohort Study. Am. J. Epidemiol. 2021;190:843&#x2013;852. doi: 10.1093/aje/kwaa249.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwaa249</ArticleId><ArticleId IdType="pmc">PMC8247611</ArticleId><ArticleId IdType="pubmed">33184648</ArticleId></ArticleIdList></Reference><Reference><Citation>Melgaard A., Vestergaard C.H., Kesmodel U.S., Ris&#xf8;r B.W., Forman A., Zondervan K.T., Nath M., Ayansina D., Saunders P.T.K., Horne A.W., et al. Exploring pre-diagnosis hospital contacts in women with endometriosis using ICD-10: a Danish case&#x2013;control study. Hum. Reprod. 2025;40:280&#x2013;288. doi: 10.1093/humrep/deae273.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/humrep/deae273</ArticleId><ArticleId IdType="pmc">PMC11788223</ArticleId><ArticleId IdType="pubmed">39704775</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarria-Santamera A., Yemenkhan Y., Terzic M., Ortega M.A., Asunsolo del Barco A. A Novel Classification of Endometriosis Based on Clusters of Comorbidities. Biomedicines. 2023;11:2448. doi: 10.3390/biomedicines11092448.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines11092448</ArticleId><ArticleId IdType="pmc">PMC10525703</ArticleId><ArticleId IdType="pubmed">37760889</ArticleId></ArticleIdList></Reference><Reference><Citation>Urteaga I., McKillop M., Elhadad N. Learning endometriosis phenotypes from patient-generated data. npj Digit. Med. 2020;3:88. doi: 10.1038/s41746-020-0292-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41746-020-0292-9</ArticleId><ArticleId IdType="pmc">PMC7314826</ArticleId><ArticleId IdType="pubmed">32596513</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulletti C., Coccia M.E., Battistoni S., Borini A. Endometriosis and infertility. J. Assist. Reprod. Genet. 2010;27:441&#x2013;447. doi: 10.1007/s10815-010-9436-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10815-010-9436-1</ArticleId><ArticleId IdType="pmc">PMC2941592</ArticleId><ArticleId IdType="pubmed">20574791</ArticleId></ArticleIdList></Reference><Reference><Citation>Shigesi N., Kvaskoff M., Kirtley S., Feng Q., Fang H., Knight J.C., Missmer S.A., Rahmioglu N., Zondervan K.T., Becker C.M. The association between endometriosis and autoimmune diseases: a systematic review and meta-analysis. Hum. Reprod. Update. 2019;25:486&#x2013;503. doi: 10.1093/humupd/dmz014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/humupd/dmz014</ArticleId><ArticleId IdType="pmc">PMC6601386</ArticleId><ArticleId IdType="pubmed">31260048</ArticleId></ArticleIdList></Reference><Reference><Citation>Tietjen G.E., Conway A., Utley C., Gunning W.T., Herial N.A. Migraine is associated with menorrhagia and endometriosis. Headache. 2006;46:422&#x2013;428. doi: 10.1111/j.1526-4610.2006.00290.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1526-4610.2006.00290.x</ArticleId><ArticleId IdType="pubmed">16618258</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller J.A., Missmer S.A., Vitonis A.F., Sarda V., Laufer M.R., DiVasta A.D. Prevalence of migraines in adolescents with endometriosis. Fertil. Steril. 2018;109:685&#x2013;690. doi: 10.1016/j.fertnstert.2017.12.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fertnstert.2017.12.016</ArticleId><ArticleId IdType="pubmed">29605402</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu Y., Wang H., Chen S., Lin Y., Xie X., Zhong G., Zhang Q. Migraine Is More Prevalent in Advanced-Stage Endometriosis, Especially When Co-Occuring with Adenomoysis. Front. Endocrinol. 2021;12 doi: 10.3389/fendo.2021.814474.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fendo.2021.814474</ArticleId><ArticleId IdType="pmc">PMC8818695</ArticleId><ArticleId IdType="pubmed">35140688</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Z., Li Z., Wang K., Yang F. The causal role of gastroesophageal reflux disease in endometriosis: a bidirectional Mendelian randomization study. Front. Med. 2024;11 doi: 10.3389/fmed.2024.1440157.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2024.1440157</ArticleId><ArticleId IdType="pmc">PMC11558527</ArticleId><ArticleId IdType="pubmed">39540050</ArticleId></ArticleIdList></Reference><Reference><Citation>Adewuyi E.O., Mehta D., International Endogene Consortium IEC. 23andMe Research Team. Nyholt D.R. Genetic overlap analysis of endometriosis and asthma identifies shared loci implicating sex hormones and thyroid signalling pathways. Hum. Reprod. 2022;37:366&#x2013;383. doi: 10.1093/humrep/deab254.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/humrep/deab254</ArticleId><ArticleId IdType="pmc">PMC8804329</ArticleId><ArticleId IdType="pubmed">35472084</ArticleId></ArticleIdList></Reference><Reference><Citation>Kahlon B.K., Simon-Collins M., Nylander E., Segars J., Singh B. A systematic review of vitamin D and endometriosis: role in pathophysiology, diagnosis, treatment, and prevention. FS Rev. 2023;4:1&#x2013;14. doi: 10.1016/j.xfnr.2022.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xfnr.2022.11.005</ArticleId></ArticleIdList></Reference><Reference><Citation>Muyldermans M., Cornillie F.J., Koninckx P.R. CA125 and endometriosis. Hum. Reprod. Update. 1995;1:173&#x2013;187. doi: 10.1093/humupd/1.2.173.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/humupd/1.2.173</ArticleId><ArticleId IdType="pubmed">15726771</ArticleId></ArticleIdList></Reference><Reference><Citation>Bloski T., Pierson R. Endometriosis and Chronic Pelvic Pain. Nurs. Womens Health. 2008;12:382&#x2013;395. doi: 10.1111/j.1751-486X.2008.00362.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1751-486X.2008.00362.x</ArticleId><ArticleId IdType="pmc">PMC3096669</ArticleId><ArticleId IdType="pubmed">18837717</ArticleId></ArticleIdList></Reference><Reference><Citation>Ek M., Roth B., Ekstr&#xf6;m P., Valentin L., Bengtsson M., Ohlsson B. Gastrointestinal symptoms among endometriosis patients&#x2014;A case-cohort study. BMC Womens Health. 2015;15:59. doi: 10.1186/s12905-015-0213-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12905-015-0213-2</ArticleId><ArticleId IdType="pmc">PMC4535676</ArticleId><ArticleId IdType="pubmed">26272803</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahmioglu N., Mortlock S., Ghiasi M., M&#xf8;ller P.L., Stefansdottir L., Galarneau G., Turman C., Danning R., Law M.H., Sapkota Y., et al. The genetic basis of endometriosis and comorbidity with other pain and inflammatory conditions. Nat. Genet. 2023;55:423&#x2013;436. doi: 10.1038/s41588-023-01323-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41588-023-01323-z</ArticleId><ArticleId IdType="pmc">PMC10042257</ArticleId><ArticleId IdType="pubmed">36914876</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang F., Wu Y., Hockey R., International Endometriosis Genetics Consortium. Doust J., Mishra G.D., Montgomery G.W., Mortlock S. Evidence of shared genetic factors in the etiology of gastrointestinal disorders and endometriosis and clinical implications for disease management. Cell Rep. Med. 2023;4 doi: 10.1016/j.xcrm.2023.101250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.xcrm.2023.101250</ArticleId><ArticleId IdType="pmc">PMC10694629</ArticleId><ArticleId IdType="pubmed">37909040</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulun S.E., Yildiz S., Adli M., Chakravarti D., Parker J.B., Milad M., Yang L., Chaudhari A., Tsai S., Wei J.J., Yin P. Endometriosis and adenomyosis: shared pathophysiology. Fertil. Steril. 2023;119:746&#x2013;750. doi: 10.1016/j.fertnstert.2023.03.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fertnstert.2023.03.006</ArticleId><ArticleId IdType="pubmed">36925057</ArticleId></ArticleIdList></Reference><Reference><Citation>Esfandiari N., Khazaei M., Ai J., Bielecki R., Gotlieb L., Ryan E., Casper R.F. Effect of a statin on an in vitro model of endometriosis. Fertil. Steril. 2007;87:257&#x2013;262. doi: 10.1016/j.fertnstert.2006.06.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.fertnstert.2006.06.040</ArticleId><ArticleId IdType="pubmed">17097652</ArticleId></ArticleIdList></Reference><Reference><Citation>Gibran L., Maranh&#xe3;o R.C., Abr&#xe3;o M.S., Baracat E.C., Podgaec S. Could statins constitute a novel treatment for endometriosis? Systematic review of the literature. Eur. J. Obstet. Gynecol. Reprod. Biol. 2014;179:153&#x2013;158. doi: 10.1016/j.ejogrb.2014.05.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejogrb.2014.05.028</ArticleId><ArticleId IdType="pubmed">24965997</ArticleId></ArticleIdList></Reference><Reference><Citation>Vitagliano A., Noventa M., Quaranta M., Gizzo S. Statins as Targeted &#x201c;Magical Pills&#x201d; for the Conservative Treatment of Endometriosis: May Potential Adverse Effects on Female Fertility Represent the &#x201c;Dark Side of the Same Coin&#x201d;? A Systematic Review of Literature. Reprod. Sci. 2016;23:415&#x2013;428. doi: 10.1177/1933719115584446.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1933719115584446</ArticleId><ArticleId IdType="pubmed">25929256</ArticleId></ArticleIdList></Reference><Reference><Citation>Dillon G.A., Stanhewicz A.E., Serviente C., Flores V.A., Stachenfeld N., Alexander L.M. Seven days of statin treatment improves nitric-oxide mediated endothelial-dependent cutaneous microvascular function in women with endometriosis. Microvasc. Res. 2022;144 doi: 10.1016/j.mvr.2022.104421.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mvr.2022.104421</ArticleId><ArticleId IdType="pmc">PMC9527706</ArticleId><ArticleId IdType="pubmed">35970408</ArticleId></ArticleIdList></Reference><Reference><Citation>Fattori V., Zaninelli T.H., Rasquel-Oliveira F.S., Heintz O.K., Jain A., Sun L., Seshan M.L., Peterse D., Lindholm A.E., Anchan R.M., et al. Nociceptor-to-macrophage communication through CGRP/RAMP1 signaling drives endometriosis-associated pain and lesion growth in mice. Sci. Transl. Med. 2024;16 doi: 10.1126/scitranslmed.adk8230.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.adk8230</ArticleId><ArticleId IdType="pubmed">39504351</ArticleId></ArticleIdList></Reference><Reference><Citation>OHDSI &#x2013; Observational Health Data Sciences and Informatics. Accessed December 19, 2024. https://ohdsi.org/.</Citation></Reference><Reference><Citation>OMOP Common Data Model. Accessed December 19, 2024. https://ohdsi.github.io/CommonDataModel/index.html.</Citation></Reference><Reference><Citation>Ho D.E., Imai K., King G., Stuart E.A. MatchIt: Nonparametric Preprocessing for Parametric Causal Inference. J. Stat. Softw. 2011;42:1&#x2013;28. doi: 10.18637/jss.v042.i08.</Citation><ArticleIdList><ArticleId IdType="doi">10.18637/jss.v042.i08</ArticleId></ArticleIdList></Reference><Reference><Citation>Vovk V., Wang R. Combining p-values via averaging. arXiv. 2020 doi: 10.48550/arXiv.1212.4966. Preprint at.</Citation><ArticleIdList><ArticleId IdType="doi">10.48550/arXiv.1212.4966</ArticleId></ArticleIdList></Reference><Reference><Citation>Traag V.A., Waltman L., van Eck N.J. From Louvain to Leiden: guaranteeing well-connected communities. Sci. Rep. 2019;9:5233. doi: 10.1038/s41598-019-41695-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-41695-z</ArticleId><ArticleId IdType="pmc">PMC6435756</ArticleId><ArticleId IdType="pubmed">30914743</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf F.A., Angerer P., Theis F.J. SCANPY: large-scale single-cell gene expression data analysis. Genome Biol. 2018;19:15. doi: 10.1186/s13059-017-1382-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13059-017-1382-0</ArticleId><ArticleId IdType="pmc">PMC5802054</ArticleId><ArticleId IdType="pubmed">29409532</ArticleId></ArticleIdList></Reference><Reference><Citation>McInnes L., Healy J., Melville J. UMAP: Uniform Manifold Approximation and Projection for Dimension Reduction. arXiv. 2018 doi: 10.48550/arXiv.1802.03426. Preprint at.</Citation><ArticleIdList><ArticleId IdType="doi">10.48550/arXiv.1802.03426</ArticleId></ArticleIdList></Reference><Reference><Citation>Shannon P., Markiel A., Ozier O., Baliga N.S., Wang J.T., Ramage D., Amin N., Schwikowski B., Ideker T. Cytoscape: A Software Environment for Integrated Models of Biomolecular Interaction Networks. Genome Res. 2003;13:2498&#x2013;2504. doi: 10.1101/gr.1239303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gr.1239303</ArticleId><ArticleId IdType="pmc">PMC403769</ArticleId><ArticleId IdType="pubmed">14597658</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunter J.D. Matplotlib: A 2D Graphics Environment. Comput. Sci. Eng. 2007;9:90&#x2013;95. doi: 10.1109/MCSE.2007.55.</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/MCSE.2007.55</ArticleId></ArticleIdList></Reference><Reference><Citation>SNOMED CT to ICD-10-CM Map. Accessed December 19, 2024. https://www.nlm.nih.gov/research/umls/mapping_projects/snomedct_to_icd10cm.html.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40772805</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1097-0258</ISSN><JournalIssue CitedMedium="Internet"><Volume>44</Volume><Issue>18-19</Issue><PubDate><Year>2025</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Statistics in medicine</Title><ISOAbbreviation>Stat Med</ISOAbbreviation></Journal><ArticleTitle>Assessing Covariate Balance With Small Sample Sizes.</ArticleTitle><Pagination><StartPage>e70212</StartPage><MedlinePgn>e70212</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/sim.70212</ELocationID><Abstract><AbstractText>Propensity score adjustment addresses confounding by balancing covariates in subject treatment groups through matching, stratification, or weighting. Diagnostics test the success of adjustment. For example, if the standardized mean difference (SMD) for a relevant covariate exceeds a threshold like 0.1, the covariate is considered imbalanced and the study may be biased. Unfortunately, for studies with small or moderate numbers of subjects, the probability of identifying a study as biased because of chance imbalance can be grossly larger than a given nominal level like 0.05, yet that chance imbalance may not cause significant bias. In this paper, we illustrate that chance imbalance is operative in real-world settings even for moderate sample sizes of 2000. We identify a previously unrecognized challenge that as meta-analyses increase the precision of an effect estimate, the diagnostics must also undergo meta-analysis for a corresponding increase in precision. We propose an alternative diagnostic that checks whether the SMD statistically significantly exceeds the threshold. Through simulation and real-world data, we find that this diagnostic achieves a better trade-off of type 1 error rate and power than standard nominal threshold tests and not testing for sample sizes from 250 to 4000 and for 20 to 100&#x2009;000 covariates. We confirm that in network studies, meta-analysis of effect estimates must be accompanied by meta-analysis of the diagnostics or else systematic confounding may overwhelm the estimated effect. Our procedure supports the review of large numbers of covariates, enabling more rigorous diagnostics.</AbstractText><CopyrightInformation>&#xa9; 2025 John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0003-2664-7614</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University Irving Medical Center, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Observational Health Data Science and Informatics, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VA Informatics and Computing Infrastructure, US Department of Veterans Affairs, Salt Lake City, Utah, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Linying</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Observational Health Data Science and Informatics, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Informatics, Data Science and Biostatistics, Washington University in St. Louis, St. Louis, Missouri, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0003-0835-0788</Identifier><AffiliationInfo><Affiliation>Observational Health Data Science and Informatics, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Applied Mathematics and Computational Science, School of Arts and Sciences, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Kelly</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Observational Health Data Science and Informatics, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, University of California, Los Angeles, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Suchard</LastName><ForeName>Marc A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0001-9818-479X</Identifier><AffiliationInfo><Affiliation>Observational Health Data Science and Informatics, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>VA Informatics and Computing Infrastructure, US Department of Veterans Affairs, Salt Lake City, Utah, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, University of California, Los Angeles, Los Angeles, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Observational Health Data Science and Informatics, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Global Epidemiology Organization, Johnson &amp; Johnson, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0002-0817-5361</Identifier><AffiliationInfo><Affiliation>Observational Health Data Science and Informatics, New York, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Global Epidemiology Organization, Johnson &amp; Johnson, Titusville, New Jersey, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T15 LM007079</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 LM006910</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL169954</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Stat Med</MedlineTA><NlmUniqueID>8215016</NlmUniqueID><ISSNLinking>0277-6715</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>medRxiv. 2025 Feb 21:2024.04.23.24306230. doi: 10.1101/2024.04.23.24306230.</RefSource><PMID Version="1">38712282</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018401" MajorTopicYN="N">Sample Size</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057216" MajorTopicYN="Y">Propensity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003198" MajorTopicYN="N">Computer Simulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015982" MajorTopicYN="N">Bias</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015201" MajorTopicYN="N">Meta-Analysis as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003627" MajorTopicYN="N">Data Interpretation, Statistical</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015233" MajorTopicYN="N">Models, Statistical</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">confounding</Keyword><Keyword MajorTopicYN="N">covariate balance</Keyword><Keyword MajorTopicYN="N">meta&#x2010;analysis</Keyword><Keyword MajorTopicYN="N">observational research</Keyword><Keyword MajorTopicYN="N">propensity score</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>7</Day><Hour>12</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>7</Day><Hour>12</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>7</Day><Hour>9</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40772805</ArticleId><ArticleId IdType="doi">10.1002/sim.70212</ArticleId></ArticleIdList><ReferenceList><Title>References</Title><Reference><Citation>R. Collins, L. Bowman, M. Landray, and R. Peto, &#x201c;The Magic of Randomization Versus the Myth of Real&#x2010;World Evidence,&#x201d; New England Journal of Medicine 382, no. 7 (2020): 674&#x2013;678.</Citation></Reference><Reference><Citation>S. Hoffmann, F. Sch&#xf6;nbrodt, R. Elsas, R. Wilson, U. Strasser, and A.&#x2010;L. Boulesteix, &#x201c;The Multiplicity of Analysis Strategies Jeopardizes Replicability: Lessons Learned Across Disciplines,&#x201d; Royal Society Open Science 8 (2021): 201925.</Citation></Reference><Reference><Citation>M. J. Schuemie, P. B. Ryan, N. Pratt, et al., &#x201c;Principles of Large&#x2010;Scale Evidence Generation and Evaluation Across a Network of Databases (LEGEND),&#x201d; Journal of the American Medical Informatics Association 27 (2020): 1331&#x2013;1337.</Citation></Reference><Reference><Citation>M. J. Schuemie, P. B. Ryan, G. Hripcsak, D. Madigan, and M. A. Suchard, &#x201c;Improving Reproducibility by Using High&#x2010;Throughput Observational Studies With Empirical Calibration,&#x201d; Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences 376 (2018): 20170356.</Citation></Reference><Reference><Citation>M. A. Suchard, M. J. Schuemie, H. M. Krumholz, et al., &#x201c;Comprehensive Comparative Effectiveness and Safety of First&#x2010;Line Antihypertensive Drug Classes,&#x201d; Lancet 394, no. 10211 (2019): 1816&#x2013;1826.</Citation></Reference><Reference><Citation>G. Hripcsak, M. A. Suchard, S. Shea, et al., &#x201c;Comparison of Cardiovascular and Safety Outcomes of Chlorthalidone vs Hydrochlorothiazide to Treat Hypertension,&#x201d; JAMA Internal Medicine 180, no. 4 (2020): 542&#x2013;551.</Citation></Reference><Reference><Citation>R. Khera, A. Aminorroaya, L. S. Dhingra, et al., &#x201c;Comparative Effectiveness of Second&#x2010;Line Antihyperglycemic Agents for Cardiovascular Outcomes: A Multinational, Federated Analysis of LEGEND&#x2010;T2DM,&#x201d; Journal of the American College of Cardiology 84, no. 10 (2024): 904&#x2013;917.</Citation></Reference><Reference><Citation>M. M. Conover, P. B. Ryan, Y. Chen, M. A. Suchard, G. Hripcsak, and M. J. Schuemie, &#x201c;Objective Study Validity Diagnostics: A Framework Requiring Pre&#x2010;Specified, Empirical Verification to Increase Trust in the Reliability of Real&#x2010;World Evidence,&#x201d; Journal of the American Medical Informatics Association 32, no. 3 (2025): 518&#x2013;525.</Citation></Reference><Reference><Citation>P. R. Rosenbaum and D. B. Rubin, &#x201c;The Central Role of the Propensity Score in Observational Studies for Causal Effects,&#x201d; Biometrika 70 (1983): 41&#x2013;55.</Citation></Reference><Reference><Citation>E. Granger, T. Watkins, J. C. Sergeant, and M. Lunt, &#x201c;A Review of the Use of Propensity Score Diagnostics in Papers Published in High&#x2010;Ranking Medical Journals,&#x201d; BMC Medical Research Methodology 20, no. 1 (2020): 132.</Citation></Reference><Reference><Citation>P. C. Austin, &#x201c;Balance Diagnostics for Comparing the Distribution of Baseline Covariates Between Treatment Groups in Propensity&#x2010;Score Matched Samples,&#x201d; Statistics in Medicine 28 (2009): 3083&#x2013;3107.</Citation></Reference><Reference><Citation>S. L. T. Normand, M. B. Landrum, E. Guadagnoli, et al., &#x201c;Validating Recommendations for Coronary Angiography Following an Acute Myocardial Infarction in the Elderly: A Matched Analysis Using Propensity Scores,&#x201d; Journal of Clinical Epidemiology 54 (2001): 387&#x2013;398.</Citation></Reference><Reference><Citation>M. Mamdani, K. Sykora, P. Li, et al., &#x201c;Reader's Guide to Critical Appraisal of Cohort Studies: 2. Assessing Potential for Confounding,&#x201d; British Medical Journal 330, no. 7497 (2005): 960&#x2013;962.</Citation></Reference><Reference><Citation>A. Markoulidakis, K. Taiyari, P. Holmans, et al., &#x201c;A Tutorial Comparing Different Covariate Balancing Methods With an Application Evaluating the Causal Effects of Substance Use Treatment Programs for Adolescents,&#x201d; Health Services &amp; Outcomes Research Methodology 23, no. 2 (2023): 115&#x2013;148.</Citation></Reference><Reference><Citation>P. C. Austin, &#x201c;A Critical Appraisal of Propensity&#x2010;Score Matching in the Medical Literature Between 1996 and 2003,&#x201d; Statistics in Medicine 27, no. 12 (2008): 2037&#x2013;2049.</Citation></Reference><Reference><Citation>P. C. Austin, P. Grootendorst, and G. M. Anderson, &#x201c;A Comparison of the Ability of Different Propensity Score Models to Balance Measured Variables Between Treated and Untreated Subjects: A Monte Carlo Study,&#x201d; Statistics in Medicine 26, no. 4 (2007): 734&#x2013;753.</Citation></Reference><Reference><Citation>B. A. Griffin, D. F. McCaffrey, D. Almirall, L. F. Burgette, and C. M. Setodji, &#x201c;Chasing Balance and Other Recommendations for Improving Nonparametric Propensity Score Models,&#x201d; Journal of Causal Inference 5, no. 2 (2017): 20150026.</Citation></Reference><Reference><Citation>B. A. Griffin, R. Ramchand, D. Almirall, M. E. Slaughter, L. F. Burgette, and D. F. McCaffery, &#x201c;Estimating the Causal Effects of Cumulative Treatment Episodes for Adolescents Using Marginal Structural Models and Inverse Probability of Treatment Weighting,&#x201d; Drug and Alcohol Dependence 136 (2014): 69&#x2013;78.</Citation></Reference><Reference><Citation>D. E. Ho, K. Imai, G. King, and E. A. Stuart, &#x201c;Matching as Nonparametric Preprocessing for Reducing Model Dependence in Parametric Causal Inference,&#x201d; Political Analysis 15, no. 3 (2007): 199&#x2013;236.</Citation></Reference><Reference><Citation>E. A. Stuart, B. K. Lee, and F. P. Leacy, &#x201c;Prognostic Score&#x2010;Based Balance Measures Can be a Useful Diagnostic for Propensity Score Methods in Comparative Effectiveness Research,&#x201d; Journal of Clinical Epidemiology 66, no. 8 (2013): S84&#x2013;S90.</Citation></Reference><Reference><Citation>Z. Zhang, H. J. Kim, G. Lonjon, Y. Zhu, and AME Big&#x2010;Data Clinical Trial Collaborative Group, &#x201c;Balance Diagnostics After Propensity Score Matching,&#x201d; Annals of Translational Medicine 7, no. 1 (2019): 16.</Citation></Reference><Reference><Citation>D. Medaglio, A. J. Stephens&#x2010;Shields, and C. E. Leonard, &#x201c;Research and Scholarly Methods: Propensity Scores,&#x201d; Journal of the American College of Clinical Pharmacy 5, no. 4 (2022): 467&#x2013;475.</Citation></Reference><Reference><Citation>T. H. Chang, T. Q. Nguyen, Y. Lee, J. W. Jackson, and E. A. Stuart, &#x201c;Flexible Propensity Score Estimation Strategies for Clustered Data in Observational Studies,&#x201d; Statistics in Medicine 41, no. 25 (2022): 5016&#x2013;5032.</Citation></Reference><Reference><Citation>S. Schneeweiss, J. A. Rassen, R. J. Glynn, J. Avorn, H. Mogun, and M. A. Brookhart, &#x201c;High&#x2010;Dimensional Propensity Score Adjustment in Studies of Treatment Effects Using Health Care Claims Data,&#x201d; Epidemiology 20, no. 4 (2009): 512&#x2013;522.</Citation></Reference><Reference><Citation>Y. Tian, M. J. Schuemie, and M. A. Suchard, &#x201c;Evaluating Large&#x2010;Scale Propensity Score Performance Through Real&#x2010;World and Synthetic Data Experiments,&#x201d; International Journal of Epidemiology 47 (2018): 2005&#x2013;2014.</Citation></Reference><Reference><Citation>L. Zhang, Y. Wang, M. Schuemie, D. Blei, and G. Hripcsak, &#x201c;Adjusting for Indirectly Measured Confounding Using Large&#x2010;Scale Propensity Score,&#x201d; Journal of Biomedical Informatics 134 (2022): 104204.</Citation></Reference><Reference><Citation>G. Hripcsak, M. J. Schuemie, D. Madigan, P. B. Ryan, and M. A. Suchard, &#x201c;Drawing Reproducible Conclusions From Observational Clinical Data With OHDSI,&#x201d; Yearbook of Medical Informatics 30, no. 1 (2021): 283&#x2013;289.</Citation></Reference><Reference><Citation>F. S. Collins, K. L. Hudson, J. P. Briggs, and M. S. Lauer, &#x201c;PCORnet: Turning a Dream Into Reality,&#x201d; Journal of the American Medical Informatics Association 21 (2014): 576&#x2013;577, https://doi.org/10.1136/amiajnl&#x2010;2014&#x2010;002864.</Citation></Reference><Reference><Citation>FDA's Sentinel Initiative | FDA accessed January 21, 2025, https://www.fda.gov/safety/fdas&#x2010;sentinel&#x2010;initiative.</Citation></Reference><Reference><Citation>G. A. Brat, G. M. Weber, and N. Gehlenborg, &#x201c;International Electronic Health Record&#x2010;Derived COVID&#x2010;19 Clinical Course Profiles: The 4CE Consortium,&#x201d; npj Digital Medicine 3 (2020): 1&#x2013;9.</Citation></Reference><Reference><Citation>S. C. Chien, S. M. Ou, C. J. Shih, et al., &#x201c;Comparative Effectiveness of Angiotensin&#x2010;Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Terms of Major Cardiovascular Disease Outcomes in Elderly Patients,&#x201d; Medicine 94, no. 43 (2015): e1751.</Citation></Reference><Reference><Citation>B. M. Hicks, K. B. Filion, H. Yin, L. Sakr, J. A. Udell, and L. Azoulay, &#x201c;Angiotensin Converting Enzyme Inhibitors and Risk of Lung Cancer: Population Based Cohort Study,&#x201d; BMJ (Clinical Research Ed.) 363 (2018): k4209.</Citation></Reference><Reference><Citation>E. Ku, C. E. McCulloch, E. Vittinghoff, F. Lin, and K. L. Johansen, &#x201c;Use of Antihypertensive Agents and Association With Risk of Adverse Outcomes in Chronic Kidney Disease: Focus on Angiotensin&#x2010;Converting Enzyme Inhibitors and Angiotensin Receptor Blockers,&#x201d; Journal of the American Heart Association 7, no. 19 (2018): e009992.</Citation></Reference><Reference><Citation>D. J. Magid, S. M. Shetterly, K. L. Margolis, et al., &#x201c;Comparative Effectiveness of Angiotensin&#x2010;Converting Enzyme Inhibitors Versus Beta&#x2010;Blockers as Second&#x2010;Line Therapy for Hypertension,&#x201d; Circulation. Cardiovascular Quality and Outcomes 3, no. 5 (2010): 453&#x2013;458.</Citation></Reference><Reference><Citation>L. P. Hasvold, J. Bodeg&#xe5;rd, M. Thuresson, et al., &#x201c;Diabetes and CVD Risk During Angiotensin&#x2010;Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker Treatment in Hypertension: A Study of 15,990 Patients,&#x201d; Journal of Human Hypertension 28, no. 11 (2014): 663&#x2013;669.</Citation></Reference><Reference><Citation>R. B. Weinstein, P. Ryan, J. A. Berlin, et al., &#x201c;Channeling in the Use of Nonprescription Paracetamol and Ibuprofen in an Electronic Medical Records Database: Evidence and Implications,&#x201d; Drug Safety 40 (2017): 1279&#x2013;1292.</Citation></Reference><Reference><Citation>R. B. Weinstein, P. B. Ryan, J. A. Berlin, M. J. Schuemie, J. Swerdel, and D. Fife, &#x201c;Channeling Bias in the Analysis of Risk of Myocardial Infarction, Stroke, Gastrointestinal Bleeding, and Acute Renal Failure With the Use of Paracetamol Compared With Ibuprofen,&#x201d; Drug Safety 43 (2020): 927&#x2013;942.</Citation></Reference><Reference><Citation>R. Zejnullahi and L. V. Hedges, &#x201c;Robust Variance Estimation in Small Meta&#x2010;Analysis With the Standardized Mean Difference,&#x201d; Research Synthesis Methods 15, no. 1 (2024): 44&#x2013;60.</Citation></Reference><Reference><Citation>B. Han and M. A. Sidell, &#x201c;Pseudo P&#x2010;Values for Assessing Covariate Balance in a Finite Study Population With Application to the California Sugar Sweetened Beverage Tax Study,&#x201d; preprint, arXiv, Apr 15, 2024, arXiv:2404.09960.</Citation></Reference><Reference><Citation>S. Dudoit and M. J. van der Laan, Multiple Testing Procedures With Applications in Genomics (Springer, 2008).</Citation></Reference><Reference><Citation>G. Hripcsak, J. D. Duke, N. H. Shah, et al., &#x201c;Observational Health Data Sciences and Informatics (OHDSI): Opportunities for Observational Researchers,&#x201d; in MEDINFO'15 (2015, August 19&#x2013;23, S&#xe3;o Paulo, Brazil).</Citation></Reference><Reference><Citation>J. M. Overhage, P. B. Ryan, C. G. Reich, A. G. Hartzema, and P. E. Stang, &#x201c;Validation of a Common Data Model for Active Safety Surveillance Research,&#x201d; Journal of the American Medical Informatics Association 19, no. 1 (2012): 54&#x2013;60.</Citation></Reference><Reference><Citation>C. Reich, A. Ostropolets, P. Ryan, et al., &#x201c;OHDSI Standardized Vocabularies&#x2014;A Large&#x2010;Scale Centralized Reference Ontology for International Data Harmonization,&#x201d; Journal of the American Medical Informatics Association 31 (2024): ocad247.</Citation></Reference><Reference><Citation>O. Bodenreider, R. Cornet, and D. J. Vreeman, &#x201c;Recent Developments in Clinical Terminologies&#xa0;&#x2013;&#xa0;SNOMED CT, LOINC, and RxNorm,&#x201d; Yearbook of Medical Informatics 27, no. 1 (2018): 129&#x2013;139.</Citation></Reference><Reference><Citation>E. A. Voss, R. D. Boyce, P. B. Ryan, J. van der Lei, P. R. Rijnbeek, and M. J. Schuemie, &#x201c;Accuracy of an Automated Knowledge Base for Identifying Drug Adverse Reactions,&#x201d; Journal of Biomedical Informatics 66 (2017): 72&#x2013;81.</Citation></Reference><Reference><Citation>M. A. Suchard, S. E. Simpson, I. Zorych, P. B. Ryan, and D. Madigan, &#x201c;Massive Parallelization of Serial Inference Algorithms for a Complex Generalized Linear Model,&#x201d; ACM Transactions on Modeling and Computer Simulation 23, no. 1 (2013): 1&#x2013;17.</Citation></Reference><Reference><Citation>M. J. Schuemie, P. B. Ryan, N. Pratt, et al., &#x201c;Principles of Largescale Evidence Generation and Evaluation Across a Network of Databases (LEGEND),&#x201d; Journal of the American Medical Informatics Association 27, no. 8 (2020): 1331&#x2013;1337.</Citation></Reference><Reference><Citation>R. Khera, M. J. Schuemie, Y. Lu, et al., &#x201c;Large&#x2010;Scale Evidence Generation and Evaluation Across a Network of Databases for Type 2 Diabetes Mellitus (LEGEND&#x2010;T2DM): Protocol for a Series of Multinational, Real&#x2010;World Comparative Cardiovascular Effectiveness and Safety Studies,&#x201d; BMJ Open 12, no. 6 (2022): e057977.</Citation></Reference><Reference><Citation>K. Imai, G. King, and E. Stuart, &#x201c;Misunderstandings Between Experimentalists and Observationalists About Causal Inference,&#x201d; Journal of the Royal Statistical Society, Series A 171 (2008): 481&#x2013;502.</Citation></Reference><Reference><Citation>M. M. Garrido, A. S. Kelley, J. Paris, et al., &#x201c;Methods for Constructing and Assessing Propensity Scores,&#x201d; Health Services Research 49, no. 5 (2014): 1701&#x2013;1720.</Citation></Reference><Reference><Citation>M. Schuemie, M. A. Suchard, A. Nishimura, L. Zhang, and G. Hripcsak, &#x201c;Evaluating Confounding Adjustment When Sample Size is Small,&#x201d; in Observational Health Data Sciences and Informatics (OHDSI) Symposium (2023, October 20).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40774333</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>07</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1438-8871</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><PubDate><Year>2025</Year><Month>Aug</Month><Day>07</Day></PubDate></JournalIssue><Title>Journal of medical Internet research</Title><ISOAbbreviation>J Med Internet Res</ISOAbbreviation></Journal><ArticleTitle>Advancing Real-World Evidence Through a Federated Health Data Network (EHDEN): Descriptive Study.</ArticleTitle><Pagination><StartPage>e74119</StartPage><MedlinePgn>e74119</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e74119</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.2196/74119</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Real-world data (RWD) are increasingly used in health research and regulatory decision-making to assess the effectiveness, safety, and value of interventions in routine care. However, the heterogeneity of European health care systems, data capture methods, coding standards, and governance structures poses challenges for generating robust and reproducible real-world evidence. The European Health Data &amp; Evidence Network (EHDEN) was established to address these challenges by building a large-scale federated data infrastructure that harmonizes RWD across Europe.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">This study aims to describe the composition and characteristics of the databases harmonized within EHDEN as of September 2024. We seek to provide transparency regarding the types of RWD available and their potential to support collaborative research and regulatory use.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">EHDEN recruited data partners through structured open calls. Selected data partners received funding and technical support to harmonize their data to the Observational Medical Outcomes Partnership Common Data Model (OMOP CDM), with assistance from certified small-to-medium enterprises trained through the EHDEN Academy. Each data source underwent an extract-transform-load process and data quality assessment using the data quality dashboard. Metadata-including country, care setting, capture method, and population criteria-were compiled in the publicly accessible EHDEN Portal.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">As of September 1, 2024, the EHDEN Portal includes 210 harmonized data sources from 30 countries. The highest representation comes from Italy (13%), Great Britain (12.5%), and Spain (11.5%). The mean number of persons per data source is 2,147,161, with a median of 457,664 individuals. Regarding care setting, 46.7% (n=98) of data sources reflect data exclusively from secondary care, 42.4% (n=89) from mixed care settings (both primary and secondary), and 11% (n=23) from primary care only. In terms of population inclusion criteria, 55.7% (n=117) of data sources include individuals based on health care encounters, 32.9% (n=69) through disease-specific data collection, and 11.4% (n=24) via population-based sources. Data capture methods also vary, with electronic health records (EHRs) being the most common. A total of 74.7% (n=157) of data sources use EHRs, and more than half of those (n=85) rely on EHRs as their sole method of data collection. Laboratory data are used in 29.5% (n=62) of data sources, although only one relies exclusively on laboratory data. Most laboratory-based data sources combine this method with other forms of data capture.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">EHDEN is the largest federated health data network in Europe, enabling standardized, General Data Protection Regulation-compliant analysis of RWD across diverse care settings and populations. This descriptive summary of the network's data sources enhances transparency and supports broader efforts to scale federated research. These findings demonstrate EHDEN's potential to enable collaborative studies and generate trusted evidence for public health and regulatory purposes.</AbstractText><CopyrightInformation>&#xa9; Clair Blacketer, Martijn J Schuemie, Maxim Moinat, Erica A Voss, Montse Camprubi, Peter R Rijnbeek, Patrick B Ryan. Originally published in the Journal of Medical Internet Research (https://www.jmir.org).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Blacketer</LastName><ForeName>Clair</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-2570-2124</Identifier><AffiliationInfo><Affiliation>OHDSI Collaborators, New York, NY, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus MC, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Johnson &amp; Johnson (United States), 920 US Route 202, Raritan, NJ, 08869, United States, 1 7573345788.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schuemie</LastName><ForeName>Martijn J</ForeName><Initials>MJ</Initials><Identifier Source="ORCID">0000-0002-0817-5361</Identifier><AffiliationInfo><Affiliation>OHDSI Collaborators, New York, NY, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Johnson &amp; Johnson (United States), 920 US Route 202, Raritan, NJ, 08869, United States, 1 7573345788.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, University of California, Los Angeles, Los Angeles, CA, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moinat</LastName><ForeName>Maxim</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-8473-2433</Identifier><AffiliationInfo><Affiliation>OHDSI Collaborators, New York, NY, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus MC, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Voss</LastName><ForeName>Erica A</ForeName><Initials>EA</Initials><Identifier Source="ORCID">0000-0002-0651-0613</Identifier><AffiliationInfo><Affiliation>OHDSI Collaborators, New York, NY, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Johnson &amp; Johnson (United States), 920 US Route 202, Raritan, NJ, 08869, United States, 1 7573345788.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Camprubi</LastName><ForeName>Montse</ForeName><Initials>M</Initials><Identifier Source="ORCID">0009-0008-3512-0666</Identifier><AffiliationInfo><Affiliation>OHDSI Collaborators, New York, NY, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Synapse (Spain), Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Rijnbeek</LastName><ForeName>Peter R</ForeName><Initials>PR</Initials><Identifier Source="ORCID">0000-0003-0621-1979</Identifier><AffiliationInfo><Affiliation>OHDSI Collaborators, New York, NY, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus MC, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Ryan</LastName><ForeName>Patrick B</ForeName><Initials>PB</Initials><Identifier Source="ORCID">0000-0002-9727-2138</Identifier><AffiliationInfo><Affiliation>OHDSI Collaborators, New York, NY, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Johnson &amp; Johnson (United States), 920 US Route 202, Raritan, NJ, 08869, United States, 1 7573345788.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, NY, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Canada</Country><MedlineTA>J Med Internet Res</MedlineTA><NlmUniqueID>100959882</NlmUniqueID><ISSNLinking>1438-8871</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005060" MajorTopicYN="N" Type="Geographic">Europe</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="Y">Databases, Factual</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">data governance</Keyword><Keyword MajorTopicYN="N">data quality</Keyword><Keyword MajorTopicYN="N">electronic health records</Keyword><Keyword MajorTopicYN="N">epidemiology</Keyword><Keyword MajorTopicYN="N">health informatics</Keyword><Keyword MajorTopicYN="N">real-world data</Keyword><Keyword MajorTopicYN="N">registries</Keyword></KeywordList><CoiStatement><b>Conflicts of Interest:</b> CB, MJS, EAV, and PBR are employees of Johnson &amp; Johnson and hold stock and stock options. PRR works for a department that receives/received unconditional research grants from Amgen, Chiesi, Johnson &amp; Johnson, UCB Biopharma, the European Medicines Agency, and the Innovative Medicines Initiative.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>5</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>5</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>8</Day><Hour>0</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>8</Day><Hour>0</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>7</Day><Hour>19</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40774333</ArticleId><ArticleId IdType="pmc">PMC12331365</ArticleId><ArticleId IdType="doi">10.2196/74119</ArticleId><ArticleId IdType="pii">v27i1e74119</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Framework for FDA&#x2019;s real-world evidence program. US Food and Drug Administration. 2018.  [25-07-2025]. https://www.fda.gov/media/120060/download URL. Accessed.</Citation></Reference><Reference><Citation>HMA-EMA joint big data taskforce summary report. European Medicines Agency. 2019.  [31-07-2025]. https://www.ema.europa.eu/en/documents/minutes/hma-ema-joint-task-force-big-data-summary-report_en.pdf URL. Accessed.</Citation></Reference><Reference><Citation>Methodological guide. The European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) Guide on Methodological Standards in Pharmacoepidemiology.  [06-09-2024]. https://encepp.europa.eu/encepp-toolkit/methodological-guide_en URL. Accessed.</Citation></Reference><Reference><Citation>Jonker CJ, Bakker E, Kurz X, Plueschke K. Contribution of patient registries to regulatory decision making on rare diseases medicinal products in Europe. Front Pharmacol. 2022;13:924648. doi: 10.3389/fphar.2022.924648. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.924648</ArticleId><ArticleId IdType="pmc">PMC9386590</ArticleId><ArticleId IdType="pubmed">35991868</ArticleId></ArticleIdList></Reference><Reference><Citation>Eskola SM, Leufkens HGM, Bate A, De Bruin ML, Gardarsdottir H. The role of real-world data and evidence in oncology medicines approved in EU in 2018-2019. J Cancer Policy. 2023 Jun;36:100424. doi: 10.1016/j.jcpo.2023.100424. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcpo.2023.100424</ArticleId><ArticleId IdType="pubmed">37116794</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolislis WR, Fay M, K&#xfc;hler TC. Use of real-world data for new drug applications and line extensions. Clin Ther. 2020 May;42(5):926&#x2013;938. doi: 10.1016/j.clinthera.2020.03.006. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2020.03.006</ArticleId><ArticleId IdType="pubmed">32340916</ArticleId></ArticleIdList></Reference><Reference><Citation>Guidance on good pharmacovigilance practices (GVP) module VIII post-authorisation safety studies. European Medicines Agency.  [06-08-2024]. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-good-pharmacovigilance-practices-gvp-module-viii-post-authorisation-safety-studies-rev-3_en.pdf URL. Accessed.</Citation></Reference><Reference><Citation>Santoro A, Genov G, Spooner A, Raine J, Arlett P. Promoting and protecting public health: how the European Union pharmacovigilance system works. Drug Saf. 2017 Oct;40(10):855&#x2013;869. doi: 10.1007/s40264-017-0572-8. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-017-0572-8</ArticleId><ArticleId IdType="pmc">PMC5606958</ArticleId><ArticleId IdType="pubmed">28735357</ArticleId></ArticleIdList></Reference><Reference><Citation>Goedecke T, Morales DR, Pacurariu A, Kurz X. Measuring the impact of medicines regulatory interventions - systematic review and methodological considerations. Br J Clin Pharmacol. 2018 Mar;84(3):419&#x2013;433. doi: 10.1111/bcp.13469. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.13469</ArticleId><ArticleId IdType="pmc">PMC5809349</ArticleId><ArticleId IdType="pubmed">29105853</ArticleId></ArticleIdList></Reference><Reference><Citation>Health at a glance: Europe 2022: state of health in the EU cycle. Organisation for Economic Co-operation and Development. 2022.  [22-08-2024]. https://www.oecd-ilibrary.org/social-issues-migration-health/health-at-a-glance-europe-2022_507433b0-en URL. Accessed.</Citation></Reference><Reference><Citation>Cave A, Kurz X, Arlett P. Real-world data for regulatory decision making: challenges and possible solutions for Europe. Clin Pharmacol Ther. 2019 Jul;106(1):36&#x2013;39. doi: 10.1002/cpt.1426. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.1426</ArticleId><ArticleId IdType="pmc">PMC6617710</ArticleId><ArticleId IdType="pubmed">30970161</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakker E, Plueschke K, Jonker CJ, Kurz X, Starokozhko V, Mol PGM. Contribution of real-world evidence in European Medicines Agency&#x2019;s regulatory decision making. Clin Pharmacol Ther. 2023 Jan;113(1):135&#x2013;151. doi: 10.1002/cpt.2766. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.2766</ArticleId><ArticleId IdType="pmc">PMC10099093</ArticleId><ArticleId IdType="pubmed">36254408</ArticleId></ArticleIdList></Reference><Reference><Citation>Flynn R, Plueschke K, Quinten C, et al. Marketing authorization applications made to the European Medicines Agency in 2018-2019: what was the contribution of real-world evidence? Clin Pharmacol Ther. 2022 Jan;111(1):90&#x2013;97. doi: 10.1002/cpt.2461. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpt.2461</ArticleId><ArticleId IdType="pmc">PMC9299056</ArticleId><ArticleId IdType="pubmed">34689339</ArticleId></ArticleIdList></Reference><Reference><Citation>Gini R, Schuemie M, Brown J, et al. Data extraction and management in networks of observational health care databases for scientific research: a comparison of EU-ADR, OMOP, Mini-Sentinel and MATRICE strategies. EGEMS (Wash DC) 2016;4(1):1189. doi: 10.13063/2327-9214.1189. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.13063/2327-9214.1189</ArticleId><ArticleId IdType="pmc">PMC4780748</ArticleId><ArticleId IdType="pubmed">27014709</ArticleId></ArticleIdList></Reference><Reference><Citation>Coloma PM, Schuemie MJ, Trifir&#xf2; G, et al. Combining electronic healthcare databases in Europe to allow for large-scale drug safety monitoring: the EU-ADR Project. Pharmacoepidemiol Drug Saf. 2011 Jan;20(1):1&#x2013;11. doi: 10.1002/pds.2053. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.2053</ArticleId><ArticleId IdType="pubmed">21182150</ArticleId></ArticleIdList></Reference><Reference><Citation>Trifir&#xf2; G, Coloma PM, Rijnbeek PR, et al. Combining multiple healthcare databases for postmarketing drug and vaccine safety surveillance: why and how? J Intern Med. 2014 Jun;275(6):551&#x2013;561. doi: 10.1111/joim.12159. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.12159</ArticleId><ArticleId IdType="pubmed">24635221</ArticleId></ArticleIdList></Reference><Reference><Citation>Stang PE, Ryan PB, Racoosin JA, et al. Advancing the science for active surveillance: rationale and design for the Observational Medical Outcomes Partnership. Ann Intern Med. 2010 Nov 2;153(9):600&#x2013;606. doi: 10.7326/0003-4819-153-9-201011020-00010. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-153-9-201011020-00010</ArticleId><ArticleId IdType="pubmed">21041580</ArticleId></ArticleIdList></Reference><Reference><Citation>Reynolds RF, Kurz X, de Groot MCH, et al. The IMI PROTECT project: purpose, organizational structure, and procedures. Pharmacoepidemiol Drug Saf. 2016 Mar;25 Suppl 1(5&#x2013;10):5&#x2013;10. doi: 10.1002/pds.3933. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.3933</ArticleId><ArticleId IdType="pubmed">27038353</ArticleId></ArticleIdList></Reference><Reference><Citation>EFPIA recommendations on a connected data system in Europe. European Federation of Pharmaceutical Industries and Associations.  [06-09-2024]. https://www.efpia.eu/news-events/the-efpia-view/efpia-news/efpia-recommendations-on-a-connected-data-system-in-europe/ URL. Accessed.</Citation></Reference><Reference><Citation>European Health Data &amp; Evidence Network.  [12-03-2024]. https://www.ehden.eu/ URL. Accessed.</Citation></Reference><Reference><Citation>Innovative Health Initiative. 2024.  [12-09-2024]. http://www.ihi.europa.eu/ URL. Accessed.</Citation></Reference><Reference><Citation>Voss EA, Makadia R, Matcho A, et al. Feasibility and utility of applications of the common data model to multiple, disparate observational health databases. J Am Med Inform Assoc. 2015 May;22(3):553&#x2013;564. doi: 10.1093/jamia/ocu023. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocu023</ArticleId><ArticleId IdType="pmc">PMC4457111</ArticleId><ArticleId IdType="pubmed">25670757</ArticleId></ArticleIdList></Reference><Reference><Citation>OMOP Common Data Model.  [25-07-2025]. https://ohdsi.github.io/CommonDataModel/ URL. Accessed.</Citation></Reference><Reference><Citation>Voss EA, Blacketer C, van Sandijk S, et al. European Health Data &amp; Evidence Network &#x2013; learnings from building out a standardized international health data network. J Am Med Inform Assoc. 2023 Dec 22;31(1):209&#x2013;219. doi: 10.1093/jamia/ocad214. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocad214</ArticleId><ArticleId IdType="pmc">PMC10746315</ArticleId><ArticleId IdType="pubmed">37952118</ArticleId></ArticleIdList></Reference><Reference><Citation>Hripcsak G, Duke JD, Shah NH, et al. Observational Health Data Sciences and Informatics (OHDSI): opportunities for observational researchers. Stud Health Technol Inform. 2015;216(574&#x2013;578):574&#x2013;578. Medline.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4815923</ArticleId><ArticleId IdType="pubmed">26262116</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie M, Reps J, Black A, et al. Health-Analytics Data to Evidence Suite (HADES): open-source software for observational research. Stud Health Technol Inform. 2024 Jan 25;310:966&#x2013;970. doi: 10.3233/SHTI231108. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/SHTI231108</ArticleId><ArticleId IdType="pmc">PMC10868467</ArticleId><ArticleId IdType="pubmed">38269952</ArticleId></ArticleIdList></Reference><Reference><Citation>The Book of OHDSI.  [25-07-2025]. Chapter 4: the common data model.https://ohdsi.github.io/TheBookOfOhdsi/ URL. Accessed.</Citation></Reference><Reference><Citation>Reich C, Ostropolets A, Ryan P, et al. OHDSI standardized vocabularies &#x2013; a large-scale centralized reference ontology for international data harmonization. J Am Med Inform Assoc. 2024 Feb 16;31(3):583&#x2013;590. doi: 10.1093/jamia/ocad247. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocad247</ArticleId><ArticleId IdType="pmc">PMC10873827</ArticleId><ArticleId IdType="pubmed">38175665</ArticleId></ArticleIdList></Reference><Reference><Citation>Papez V, Moinat M, Voss EA, et al. Transforming and evaluating the UK Biobank to the OMOP Common Data Model for COVID-19 research and beyond. J Am Med Inform Assoc. 2022 Dec 13;30(1):103&#x2013;111. doi: 10.1093/jamia/ocac203. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocac203</ArticleId><ArticleId IdType="pmc">PMC9619789</ArticleId><ArticleId IdType="pubmed">36227072</ArticleId></ArticleIdList></Reference><Reference><Citation>THEMIS convention repository for the OMOP CDM. THEMIS.  [13-09-2024]. https://ohdsi.github.io/Themis/ URL. Accessed.</Citation></Reference><Reference><Citation>OHDSI/databaseconnector. GitHub. 2025.  [07-05-2024]. https://github.com/OHDSI/DatabaseConnector URL. Accessed.</Citation></Reference><Reference><Citation>Blacketer C, Defalco FJ, Ryan PB, Rijnbeek PR. Increasing trust in real-world evidence through evaluation of observational data quality. J Am Med Inform Assoc. 2021 Sep 18;28(10):2251&#x2013;2257. doi: 10.1093/jamia/ocab132. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocab132</ArticleId><ArticleId IdType="pmc">PMC8449628</ArticleId><ArticleId IdType="pubmed">34313749</ArticleId></ArticleIdList></Reference><Reference><Citation>Blacketer C, Voss EA, DeFalco F, et al. Using the data quality dashboard to improve the EHDEN network. Appl Sci (Basel) 2021 Jan;11(24):11920. doi: 10.3390/app112411920. doi.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/app112411920</ArticleId></ArticleIdList></Reference><Reference><Citation>EHDEN/cdminspection: r package to support quality control inspection of an OMOP-CDM instance. GitHub.  [13-09-2024]. https://github.com/EHDEN/CdmInspection URL. Accessed.</Citation></Reference><Reference><Citation>EHDEN Portal.  [13-09-2024]. https://portal.ehden.eu/wordpress/index.php/landing-page-2/ URL. Accessed.</Citation></Reference><Reference><Citation>Klungel OH, Kurz X, de Groot MCH, et al. Multi-centre, multi-database studies with common protocols: lessons learnt from the IMI PROTECT project. Pharmacoepidemiol Drug Saf. 2016 Mar;25 Suppl 1:156&#x2013;165. doi: 10.1002/pds.3968. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.3968</ArticleId><ArticleId IdType="pubmed">27038361</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovestone S, EMIF Consortium The European medical information framework: a novel ecosystem for sharing healthcare data across Europe. Learn Health Syst. 2020 Apr;4(2):e10214. doi: 10.1002/lrh2.10214. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/lrh2.10214</ArticleId><ArticleId IdType="pmc">PMC7156868</ArticleId><ArticleId IdType="pubmed">32313838</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational health data sciences and informatics national nodes. Observational Health Data Sciences and Informatics.  [27-09-2024]. https://www.ohdsi-europe.org/index.php/national-nodes URL. Accessed.</Citation></Reference><Reference><Citation>The Draghi report on EU competitiveness. European Union. 2024.  [25-07-2025]. https://commission.europa.eu/topics/strengthening-european-competitiveness/eu-competitiveness-looking-ahead_en#paragraph_47059 URL. Accessed.</Citation></Reference><Reference><Citation>Yang C, Fridgeirsson EA, Kors JA, Reps JM, Rijnbeek PR. Impact of random oversampling and random undersampling on the performance of prediction models developed using observational health data. J Big Data. 2024 Jan 3;11(1):7. doi: 10.1186/s40537-023-00857-7. doi.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40537-023-00857-7</ArticleId></ArticleIdList></Reference><Reference><Citation>Fridgeirsson EA, Williams R, Rijnbeek P, Suchard MA, Reps JM. Comparing penalization methods for linear models on large observational health data. J Am Med Inform Assoc. 2024 Jun 20;31(7):1514&#x2013;1521. doi: 10.1093/jamia/ocae109. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocae109</ArticleId><ArticleId IdType="pmc">PMC11187433</ArticleId><ArticleId IdType="pubmed">38767857</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams RD, den Otter S, Reps JM, Rijnbeek PR. The DELPHI library: improving model validation, transparency and dissemination through a centralised library of prediction models. Stud Health Technol Inform. 2023 May 18;302:139&#x2013;140. doi: 10.3233/SHTI230085. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/SHTI230085</ArticleId><ArticleId IdType="pubmed">37203630</ArticleId></ArticleIdList></Reference><Reference><Citation>Markus AF, Kors JA, Rijnbeek PR. The role of explainability in creating trustworthy artificial intelligence for health care: a comprehensive survey of the terminology, design choices, and evaluation strategies. J Biomed Inform. 2021 Jan;113:103655. doi: 10.1016/j.jbi.2020.103655. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2020.103655</ArticleId><ArticleId IdType="pubmed">33309898</ArticleId></ArticleIdList></Reference><Reference><Citation>Morales DR, Ostropolets A, Lai L, et al. Characteristics and outcomes of COVID-19 patients with and without asthma from the United States, South Korea, and Europe. J Asthma. 2023 Jan;60(1):76&#x2013;86. doi: 10.1080/02770903.2021.2025392. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/02770903.2021.2025392</ArticleId><ArticleId IdType="pubmed">35012410</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X, Ostropolets A, Makadia R, et al. Characterising the background incidence rates of adverse events of special interest for Covid-19 vaccines in eight countries: multinational network cohort study. BMJ. 2021 Jun 14;373:n1435. doi: 10.1136/bmj.n1435. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.n1435</ArticleId><ArticleId IdType="pmc">PMC8193077</ArticleId><ArticleId IdType="pubmed">35727911</ArticleId></ArticleIdList></Reference><Reference><Citation>Voss EA, Shoaibi A, Yin Hui Lai L, et al. Contextualising adverse events of special interest to characterise the baseline incidence rates in 24 million patients with COVID-19 across 26 databases: a multinational retrospective cohort study. EClinicalMedicine. 2023 Apr;58:101932. doi: 10.1016/j.eclinm.2023.101932. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2023.101932</ArticleId><ArticleId IdType="pmc">PMC10072853</ArticleId><ArticleId IdType="pubmed">37034358</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams RD, Reps JM, OHDSI/EHDEN Knee Arthroplasty Group. Rijnbeek PR, Ryan PB, Prieto-Alhambra D. 90-Day all-cause mortality can be predicted following a total knee replacement: an international, network study to develop and validate a prediction model. Knee Surg Sports Traumatol Arthrosc. 2022 Sep;30(9):3068&#x2013;3075. doi: 10.1007/s00167-021-06799-y. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00167-021-06799-y</ArticleId><ArticleId IdType="pmc">PMC9418076</ArticleId><ArticleId IdType="pubmed">34870731</ArticleId></ArticleIdList></Reference><Reference><Citation>Reps JM, Williams RD, You SC, et al. Feasibility and evaluation of a large-scale external validation approach for patient-level prediction in an international data network: validation of models predicting stroke in female patients newly diagnosed with atrial fibrillation. BMC Med Res Methodol. 2020 May 6;20(1):102. doi: 10.1186/s12874-020-00991-3. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12874-020-00991-3</ArticleId><ArticleId IdType="pmc">PMC7201646</ArticleId><ArticleId IdType="pubmed">32375693</ArticleId></ArticleIdList></Reference><Reference><Citation>Lane JCE, Weaver J, Kostka K, et al. Risk of depression, suicide and psychosis with hydroxychloroquine treatment for rheumatoid arthritis: a multinational network cohort study. Rheumatology (Oxford) 2021 Jul 1;60(7):3222&#x2013;3234. doi: 10.1093/rheumatology/keaa771. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa771</ArticleId><ArticleId IdType="pmc">PMC7798671</ArticleId><ArticleId IdType="pubmed">33367863</ArticleId></ArticleIdList></Reference><Reference><Citation>Burn E, Weaver J, Morales D, et al. Opioid use, postoperative complications, and implant survival after unicompartmental versus total knee replacement: a population-based network study. Lancet Rheumatol. 2019 Dec;1(4):e229&#x2013;e236. doi: 10.1016/S2665-9913(19)30075-X. doi. Medline.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(19)30075-X</ArticleId><ArticleId IdType="pubmed">38229379</ArticleId></ArticleIdList></Reference><Reference><Citation>Pineda-Moncus&#xed; M, Rekkas A, P&#xe9;rez &#xc1;M, et al. Trends of drug use with suggested shortages and their alternatives across 41 real world data sources and 18 countries in Europe and North America. medRxiv. 2024 doi: 10.1101/2024.08.28.24312695. Preprint posted online on. doi.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2024.08.28.24312695</ArticleId></ArticleIdList></Reference><Reference><Citation>PIONEER - European Network of Excellence for Big Data in Prostate Cancer.  [07-11-2024]. https://prostate-pioneer.eu/ URL. Accessed.</Citation></Reference><Reference><Citation>BigData@Heart &gt; Home.  [07-11-2024]. https://www.bigdata-heart.eu/ URL. Accessed.</Citation></Reference><Reference><Citation>HARMONY is part of the IMI &#x201c;Big data for better outcomes. HARMONY Alliance.  [07-11-2024]. https://www.harmony-alliance.eu/en/harmony-is-part-of-the-imi-big-data-for-better-outcomes-program URL. Accessed.</Citation></Reference><Reference><Citation>Innovative patient centric clinical trial platforms. EU-PEARL.  [07-11-2024]. https://eu-pearl.eu/ URL. Accessed.</Citation></Reference><Reference><Citation>Darwin EU. European Medicines Agency.  [26-09-2024]. https://www.darwin-eu.org/ URL. Accessed.</Citation></Reference><Reference><Citation>European Health Data &amp; Evidence Network. EHDEN platform.  [15-07-2025]. https://portal.ehden.eu/summary URL. Accessed.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40775952</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>08</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>329</Volume><PubDate><Year>2025</Year><Month>Aug</Month><Day>07</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>PheCatcher: Leveraging LLM-Generated Synthetic Data for Automated Phenotype Definition Extraction from Biomedical Literature.</ArticleTitle><Pagination><StartPage>718</StartPage><EndPage>722</EndPage><MedlinePgn>718-722</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI250934</ELocationID><Abstract><AbstractText>Phenotype definitions are crucial for the progression of precision and personalized medicine. Although phenotype knowledge bases such as PheKB and the OHDSI library are available, they rely heavily on manual input. This study introduces PheCatcher, an automated pipeline that integrates BiomedBERT-based Named Entity Recognition (NER) and Relation Extraction (RE) to extract phenotypes and standardized codes from biomedical literature. To complement human annotation, GPT-4 was utilized to generate synthetic data, which improved model performance. The NER model's F1 score for "phenotype" entities increased from 0.616 to 0.800, and the RE model achieved an F1 score of 0.901. The application of the pipeline to the PubMed Central (PMC) articles resulted in the extraction of 173,283 phenotype definitions, which are now publicly accessible. Our study underscores the potential of synthetic data for information extraction (IE) and offers the first evidence of the feasibility of leveraging synthetic data to build a complete IE system.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Yan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>McWilliams School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Na</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics and Data Science, Yale School of Medicine, Yale University, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yiming</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>McWilliams School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Xueqing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics and Data Science, Yale School of Medicine, Yale University, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Hua</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Biomedical Informatics and Data Science, Yale School of Medicine, Yale University, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="Y">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009323" MajorTopicYN="Y">Natural Language Processing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057225" MajorTopicYN="Y">Data Mining</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Information Extraction</Keyword><Keyword MajorTopicYN="N">Phenotype Definition</Keyword><Keyword MajorTopicYN="N">Synthetic Data</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>8</Day><Hour>1</Hour><Minute>5</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40775952</ArticleId><ArticleId IdType="doi">10.3233/SHTI250934</ArticleId><ArticleId IdType="pii">SHTI250934</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40776123</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>08</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>329</Volume><PubDate><Year>2025</Year><Month>Aug</Month><Day>07</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Transforming the Medicare Claims Data to the OMOP Common Data Model.</ArticleTitle><Pagination><StartPage>1570</StartPage><EndPage>1571</EndPage><MedlinePgn>1570-1571</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI251106</ELocationID><Abstract><AbstractText>Integrating heterogeneous healthcare datasets, such as claims and electronic health records, is important for making real-world data analytical-ready but poses challenges due to variations in data structures and clinical terminologies. We developed a systematic Extract, Transform, Load (ETL) pipeline to transform Medicare claims data into the Observational Medical Outcomes Partnership Common Data Model, enabling interoperability and standardized analytics. The ETL process was developed using the ETL-CMS framework and enhanced with updated procedures utilizing open-source ETL tools-WhiteRabbit. Rigorous testing ensured data accuracy and consistency, achieving a 99.2% passing rate in quality check assessment using the Data Quality Dashboard. Comparative analysis demonstrated an accurate representation of demographics and clinical comorbidities, with slight variations attributed to syntactic errors in the source data. This scalable framework fosters interoperability, supports global standards, and enables collaborative clinical research, advancing the integration of diverse healthcare datasets for improved analytics.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Yao An</ForeName><Initials>YA</Initials><AffiliationInfo><Affiliation>Pharmaceutical Outcomes &amp; Policy, College of Pharmacy, University of Florida, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Pharmaceutical Outcomes &amp; Policy, College of Pharmacy, University of Florida, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bian</LastName><ForeName>Jiang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Biostatistics and Health Data Science, School of Medicine, Indiana University, Indiana, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Biomedical Informatics, Regenstrief Institute, Indiana, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Jingchuan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Pharmaceutical Outcomes &amp; Policy, College of Pharmacy, University of Florida, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Xing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Biostatistics and Health Data Science, School of Medicine, Indiana University, Indiana, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Biomedical Informatics, Regenstrief Institute, Indiana, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006278" MajorTopicYN="Y">Medicare</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName><QualifierName UI="Q000458" MajorTopicYN="N">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="N">organization &amp; administration</QualifierName><QualifierName UI="Q000592" MajorTopicYN="N">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007345" MajorTopicYN="Y">Insurance Claim Review</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="N">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D065709" MajorTopicYN="Y">Common Data Elements</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Common Data Model</Keyword><Keyword MajorTopicYN="N">Medicare claim data</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>8</Day><Hour>1</Hour><Minute>6</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40776123</ArticleId><ArticleId IdType="doi">10.3233/SHTI251106</ArticleId><ArticleId IdType="pii">SHTI251106</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40776309</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>08</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>329</Volume><PubDate><Year>2025</Year><Month>Aug</Month><Day>07</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Feasibility of Converting EMR Data to OMOP CDM and Utilizing OHDSI Analysis Tools in Japan.</ArticleTitle><Pagination><StartPage>1946</StartPage><EndPage>1947</EndPage><MedlinePgn>1946-1947</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI251292</ELocationID><Abstract><AbstractText>The study investigates the feasibility of converting electronic medical record (EMR) data to the Observational Medical Outcomes Partnership Common Data Model (OMOP CDM) and utilizing Observational Health Data Sciences and Informatics (OHDSI) analysis tools in Japan. Data from 8,387 breast cancer patients at the National Cancer Centre Hospital East were extracted and transformed into OMOP CDM. OHDSI software and standard vocabulary were installed, and the transformed data were displayed on ATLAS for analysis. The quality of the converted datasets was assessed using the Data Quality Dashboard developed by the OHDSI community. Mapping to OHDSI standard vocabulary was performed for 7,259 terms, with SNOMED-CT, RxNorm, and LOINC frequently used. The conversion program was applied to all cases, but there were challenges, such as race data and anticancer drug specification selection. ATLAS displayed reports on the observation period and drug use. The study demonstrated the feasibility of converting EMR data to OMOP CDM and utilizing ATLAS in Japan. However, there were challenges in software installation, vocabulary mapping, and data quality evaluation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Aoyagi</LastName><ForeName>Yoshihiro</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Medical Information, National Cancer Center Hospital East.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Research Management Division, Clinical Research Support Office, National Cancer Center Hospital East.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baba</LastName><ForeName>Masahiro</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Clinical Research Management Division, Clinical Research Support Office, National Cancer Center Hospital East.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Terao</LastName><ForeName>Suzue</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Clinical Research Management Division, Clinical Research Support Office, National Cancer Center Hospital East.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ikeda</LastName><ForeName>Yuya</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Clinical Research Management Division, Clinical Research Support Office, National Cancer Center Hospital East.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nomura</LastName><ForeName>Keiichi</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medical Information, National Cancer Center Hospital East.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sato</LastName><ForeName>Akihiro</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Clinical Research Management Division, Clinical Research Support Office, National Cancer Center Hospital East.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="N">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007564" MajorTopicYN="N" Type="Geographic">Japan</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005240" MajorTopicYN="N">Feasibility Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001943" MajorTopicYN="Y">Breast Neoplasms</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018875" MajorTopicYN="N">Vocabulary, Controlled</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D039061" MajorTopicYN="N">Systematized Nomenclature of Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="Y">Outcome Assessment, Health Care</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">EMR</Keyword><Keyword MajorTopicYN="N">LOINC</Keyword><Keyword MajorTopicYN="N">OHDSI</Keyword><Keyword MajorTopicYN="N">OMOP CDM</Keyword><Keyword MajorTopicYN="N">RxNorm</Keyword><Keyword MajorTopicYN="N">SNOMED-CT</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>8</Day><Hour>1</Hour><Minute>7</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40776309</ArticleId><ArticleId IdType="doi">10.3233/SHTI251292</ArticleId><ArticleId IdType="pii">SHTI251292</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40787090</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1932-1864</ISSN><JournalIssue CitedMedium="Print"><Volume>17</Volume><Issue>6</Issue><PubDate><Year>2024</Year><Month>Dec</Month></PubDate></JournalIssue><Title>Statistical analysis and data mining</Title><ISOAbbreviation>Stat Anal Data Min</ISOAbbreviation></Journal><ArticleTitle>Bayesian Posterior Interval Calibration to Improve the Interpretability of Observational Studies.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e11715</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1002/sam.11715</ELocationID><Abstract><AbstractText>Observational healthcare data offer the potential to estimate causal effects of medical products on a large scale. However, the confidence intervals and p-values produced by observational studies only account for random error and fail to account for systematic error. As a consequence, operating characteristics such as confidence interval coverage and Type I error rates often deviate sharply from their nominal values and render interpretation impossible. While there is a longstanding awareness of systematic error in observational studies, analytic approaches to empirically account for systematic error are relatively new. Several authors have proposed approaches using negative controls (also known as "falsification hypotheses") and positive controls. The basic idea is to adjust confidence intervals and p-values in light of the bias (if any) detected in the analyses of the negative and positive control. In this work, we propose a Bayesian statistical procedure for posterior interval calibration that uses negative and positive controls. We show that the posterior interval calibration procedure restores nominal characteristics, such as 95% coverage of the true effect size by the 95% posterior interval.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mulgrave</LastName><ForeName>Jami J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics (OHDSI), New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Madigan</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics (OHDSI), New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Khoury College of Computer Sciences, Northeastern University, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hripcsak</LastName><ForeName>George</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics (OHDSI), New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Columbia University, New York, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Medical Informatics Services, New York-Presbyterian Hospital, New York, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 LM006910</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T15 LM007079</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>12</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Stat Anal Data Min</MedlineTA><NlmUniqueID>101492808</NlmUniqueID><ISSNLinking>1932-1864</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">hierarchical model</Keyword><Keyword MajorTopicYN="N">observational study</Keyword><Keyword MajorTopicYN="N">patient data</Keyword></KeywordList><CoiStatement>Conflict of interest The authors declare no potential conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>12</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>11</Day><Hour>12</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>11</Day><Hour>12</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>25</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40787090</ArticleId><ArticleId IdType="mid">NIHMS2036067</ArticleId><ArticleId IdType="pmc">PMC12332498</ArticleId><ArticleId IdType="doi">10.1002/sam.11715</ArticleId><ArticleId IdType="pii">e11715</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Arnold BF, Ercumen A, Benjamin-Chung J, and Colford JM, 2016: Brief Report: Negative Controls to Detect Selection Bias and Measurement Bias in Epidemiologic Studies. Epidemiology, 27, no. 5, 637&#x2013;641, doi: 10.1097/EDE.0000000000000504. URL http://Insights.ovid.com/crossref?an=00001648-201609000-00006
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0000000000000504</ArticleId><ArticleId IdType="pmc">PMC4969055</ArticleId><ArticleId IdType="pubmed">27182642</ArticleId></ArticleIdList></Reference><Reference><Citation>Desai JR, Hyde CL, Kabadi S, St Louis M, Bonato V, Katrina Loomis A, Galaznik A, and Berger ML, 2017: Utilization of Positive and Negative Controls to Examine Comorbid Associations in Observational Database Studies:. Medical Care, 55, no. 3, 244&#x2013;251, doi: 10.1097/MLR.0000000000000640. URL http://Insights.ovid.com/crossref?an=00005650-201703000-00007
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MLR.0000000000000640</ArticleId><ArticleId IdType="pmc">PMC5318155</ArticleId><ArticleId IdType="pubmed">27787351</ArticleId></ArticleIdList></Reference><Reference><Citation>Dias S, Welton NJ, Marinho VCC, Salanti G, Higgins JPT, and Ades AE, 2010: Estimation and adjustment of bias in randomized evidence by using mixed treatment comparison meta-analysis: Estimation and Adjustment of Bias. Journal of the Royal Statistical Society: Series A (Statistics in Society), 173, no. 3, 613&#x2013;629, doi: 10.1111/j.1467-985X.2010.00639.x. URL https://onlinelibrary.wiley.com/doi/10.1111/j.1467-985X.2010.00639.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1467-985X.2010.00639.x</ArticleId><ArticleId IdType="doi">10.1111/j.1467-985X.2010.00639.x</ArticleId></ArticleIdList></Reference><Reference><Citation>Dusetzina SB, Brookhart MA, and Maciejewski ML, 2015: Control Outcomes and Exposures for Improving Internal Validity of Nonrandomized Studies. Health Services Research, 50, no. 5, 1432&#x2013;1451, doi: 10.1111/1475-6773.12279. URL http://doi.wiley.com/10.1111/1475-6773.12279
</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1475-6773.12279</ArticleId><ArticleId IdType="doi">10.1111/1475-6773.12279</ArticleId><ArticleId IdType="pmc">PMC4600355</ArticleId><ArticleId IdType="pubmed">25598384</ArticleId></ArticleIdList></Reference><Reference><Citation>Flanders WD, Strickland MJ, and Klein M, 2017: A New Method for Partial Correction of Residual Confounding in Time-Series and Other Observational Studies. American Journal of Epidemiology, 185, no. 10, 941&#x2013;949, doi: 10.1093/aje/kwx013. URL https://academic.oup.com/aje/article/185/10/941/3738872
</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwx013</ArticleId><ArticleId IdType="pubmed">28430842</ArticleId></ArticleIdList></Reference><Reference><Citation>Lipsitch M, Tchetgen Tchetgen E, and Cohen T, 2010: Negative Controls: A Tool for Detecting Confounding and Bias in Observational Studies. Epidemiology, 21, no. 3, 383&#x2013;388, doi: 10.1097/EDE.0b013e3181d61eeb. URL. https://insights.ovid.com/crossref?an=00001648-201005000-00017
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0b013e3181d61eeb</ArticleId><ArticleId IdType="pmc">PMC3053408</ArticleId><ArticleId IdType="pubmed">20335814</ArticleId></ArticleIdList></Reference><Reference><Citation>Raices Cruz I, Troffaes MCM, Lindstr&#xf6;m J, and Sahlin U, 2022: A robust Bayesian bias-adjusted random effects model for consideration of uncertainty about bias terms in evidence synthesis. Statistics in Medicine, 41, no. 17, 3365&#x2013;3379, doi: 10.1002/sim.9422. URL https://onlinelibrary.wiley.com/doi/10.1002/sim.9422
</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.9422</ArticleId><ArticleId IdType="doi">10.1002/sim.9422</ArticleId><ArticleId IdType="pmc">PMC9544319</ArticleId><ArticleId IdType="pubmed">35487762</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Hripcsak G, Ryan PB, Madigan D, and Suchard MA, 2018: Empirical confidence interval calibration for population-level effect estimation studies in observational healthcare data. Proceedings of the National Academy of Sciences, 115, no. 11, 2571&#x2013;2577, doi: 10.1073/pnas.1708282114. URL http://www.pnas.org/lookup/doi/10.1073/pnas.1708282114</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1708282114</ArticleId><ArticleId IdType="doi">10.1073/pnas.1708282114</ArticleId><ArticleId IdType="pmc">PMC5856503</ArticleId><ArticleId IdType="pubmed">29531023</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Ryan PB, DuMouchel W, Suchard MA, and Madigan D, 2014: Interpreting observational studies: why empirical calibration is needed to correct <i>p</i> -values. Statistics in Medicine, 33, no. 2, 209&#x2013;218, doi: 10.1002/sim.5925. URL http://doi.wiley.com/10.1002/sim.5925
</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/sim.5925</ArticleId><ArticleId IdType="doi">10.1002/sim.5925</ArticleId><ArticleId IdType="pmc">PMC4285234</ArticleId><ArticleId IdType="pubmed">23900808</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Ryan PB, Hripcsak G, Madigan D, and Suchard MA, 2018: Improving reproducibility by using high-throughput observational studies with empirical calibration. Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences, 376, no. 2128, 20170356, doi: 10.1098/rsta.2017.0356. URL http://rsta.royalsocietypublishing.org/lookup/doi/10.1098/rsta.2017.0356</Citation><ArticleIdList><ArticleId IdType="doi">10.1098/rsta.2017.0356</ArticleId><ArticleId IdType="doi">10.1098/rsta.2017.0356</ArticleId><ArticleId IdType="pmc">PMC6107542</ArticleId><ArticleId IdType="pubmed">30082302</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, Schuemie MJ, Krumholz HM, You SC, Chen R, Pratt N, Reich CG, Duke J, Madigan D, Hripcsak G, and Ryan PB, 2019: Comprehensive comparative effectiveness and safety of first-line anti-hypertensive drug classes: a systematic, multinational, large-scale analysis. The Lancet, 394, no. 10211, 1816&#x2013;1826, doi: 10.1016/S0140-6736(19)32317-7. URL https://linkinghub.elsevier.com/retrieve/pii/S0140673619323177</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)32317-7</ArticleId><ArticleId IdType="pmc">PMC6924620</ArticleId><ArticleId IdType="pubmed">31668726</ArticleId></ArticleIdList></Reference><Reference><Citation>Tchetgen Tchetgen E, 2014: The Control Outcome Calibration Approach for Causal Inference With Unobserved Confounding. American Journal of Epidemiology, 179, no. 5, 633&#x2013;640, doi: 10.1093/aje/kwt303. URL https://academic.oup.com/aje/article-lookup/doi/10.1093/aje/kwt303
</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/aje/kwt303</ArticleId><ArticleId IdType="doi">10.1093/aje/kwt303</ArticleId><ArticleId IdType="pmc">PMC3927977</ArticleId><ArticleId IdType="pubmed">24363326</ArticleId></ArticleIdList></Reference><Reference><Citation>Verde PE, 2021: A bias-corrected meta-analysis model for combining, studies of different types and quality. Biometrical Journal, 63, no. 2, 406&#x2013;422, doi: 10.1002/bimj.201900376. URL https://onlinelibrary.wiley.com/doi/10.1002/bimj.201900376
</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/bimj.201900376</ArticleId><ArticleId IdType="doi">10.1002/bimj.201900376</ArticleId><ArticleId IdType="pubmed">32996196</ArticleId></ArticleIdList></Reference><Reference><Citation>Welton NJ, Ades AE, Carlin JB, Altman DG, and Sterne JAC, 2009: Models for potentially biased evidence in meta-analysis using empirically based priors. Journal of the Royal Statistical Society: Series A (Statistics in Society), 172, no. 1, 119&#x2013;136, doi: 10.1111/j.1467-985X.2008.00548.x. URL https://onlinelibrary.wiley.com/doi/10.1111/j.1467-985X.2008.00548.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1467-985X.2008.00548.x</ArticleId><ArticleId IdType="doi">10.1111/j.1467-985X.2008.00548.x</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40790972</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2151-4658</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>12</Day></PubDate></JournalIssue><Title>Arthritis care &amp; research</Title><ISOAbbreviation>Arthritis Care Res (Hoboken)</ISOAbbreviation></Journal><ArticleTitle>Identification of Adult Dermatomyositis Patients Using Real-World Data Sources.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1002/acr.25625</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Studying rare diseases like dermatomyositis (DM) in single-center cohorts is challenging due to small sample sizes and limited generalizability. This study develops and evaluates case identification algorithms for DM to enable coordinated analysis across multiple data sources.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Case identification algorithms were developed to identify adult DM patients within eleven independent electronic health record or claims databases, totaling over 800 million patients, using the Observational Medical Outcomes Partnership (OMOP) Common Data Model. Algorithm performance was assessed through manual chart review and using OHDSI open-source tools (CohortDiagnostics, PheValuator), which quantify incidence rates and performance metrics such as sensitivity and positive predictive value (PPV).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Eight DM case identification algorithms were evaluated across eleven databases, revealing significant variability in performance, with sensitivity and PPV differing by more than 30% between some databases. Overall, we identified one incidence algorithm and one prevalence algorithm with good performance, demonstrated by sensitivity rates of 42% and 49% and PPV values of 83% and 84%, respectively. PheValuator quantified algorithm performance within each database, allowing for direct comparison of different criteria. Additionally, CohortDiagnostics generated incidence rates stratified by age decile and sex, aligning with previous epidemiological data.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">We developed and validated multiple DM case identification algorithms across diverse databases, demonstrating their accuracy through multiple evaluation methods. This approach enables more generalizable, reproducible research using real-world data and can be applied to other rheumatic diseases.</AbstractText><CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Martin</LastName><ForeName>Benjamin</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-6510-6824</Identifier><AffiliationInfo><Affiliation>Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Kelly</LastName><ForeName>Will</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morgan-Cooper</LastName><ForeName>Hannah</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Stanford University School of Medicine and Stanford Health Care, Redwood City, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Falconer</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Columbia University Irving Medical Center/New York Presbyterian Hospital, New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Elizabeth</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-5277-349X</Identifier><AffiliationInfo><Affiliation>Stanford University School of Medicine and Stanford Health Care, Redwood City, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Desai</LastName><ForeName>Priya</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Stanford University School of Medicine and Stanford Health Care, Redwood City, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fiorentino</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0001-7951-3674</Identifier><AffiliationInfo><Affiliation>Stanford University School of Medicine and Stanford Health Care, Redwood City, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Lorinda</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Stanford University School of Medicine and Stanford Health Care, Redwood City, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yen</LastName><ForeName>Sean</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zachary</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saygin</LastName><ForeName>Didem</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Rush University Medical Center, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>George</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-0398-2308</Identifier><AffiliationInfo><Affiliation>University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Gowtham A</ForeName><Initials>GA</Initials><Identifier Source="ORCID">0000-0002-4949-7236</Identifier><AffiliationInfo><Affiliation>OHDSI Collaborators, Observational Health Data Sciences and Informatics (OHDSI), New York, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Swerdel</LastName><ForeName>Joel</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>OHDSI Collaborators, Observational Health Data Sciences and Informatics (OHDSI), New York, NY.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Global Epidemiology, Office of the Chief Medical Officer, Johnson and Johnson, NJ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shoaibi</LastName><ForeName>Azza</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>OHDSI Collaborators, Observational Health Data Sciences and Informatics (OHDSI), New York, NY.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Global Epidemiology, Office of the Chief Medical Officer, Johnson and Johnson, NJ.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mecoli</LastName><ForeName>Christopher A</ForeName><Initials>CA</Initials><Identifier Source="ORCID">0000-0002-1429-8392</Identifier><AffiliationInfo><Affiliation>Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T15 LM013979</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 HD113136</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Arthritis Care Res (Hoboken)</MedlineTA><NlmUniqueID>101518086</NlmUniqueID><ISSNLinking>2151-464X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>12</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>12</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>12</Day><Hour>3</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>16</Day></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40790972</ArticleId><ArticleId IdType="mid">NIHMS2101046</ArticleId><ArticleId IdType="pmc">PMC12440357</ArticleId><ArticleId IdType="doi">10.1002/acr.25625</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lundberg IE, Fujimoto M, Vencovsky J, Aggarwal R, Holmqvist M, Christopher-Stine L, Mammen AL, Miller FW. Idiopathic inflammatory myopathies. Nat Rev Dis Primers. 2021. Dec 2;7(1):86. doi: 10.1038/s41572-021-00321-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41572-021-00321-x</ArticleId><ArticleId IdType="pubmed">34857798</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoo T, Lilleker JB, Thong BYH, Leclair V, Lamb JA, Chinoy H. Epidemiology of the idiopathic inflammatory myopathies. Nat Rev Rheumatol 2023;19(11):695&#x2013;712. doi: 10.1038/s41584-023-01033-0</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-023-01033-0</ArticleId><ArticleId IdType="pubmed">37803078</ArticleId></ArticleIdList></Reference><Reference><Citation>Kronzer VL, Kimbrough BA, Crowson CS, Davis JM, Holmqvist M, Ernste FC. Incidence, prevalence, and mortality of dermatomyositis: a population-based cohort study. Arthritis Care Res 2023;75(2):348&#x2013;355. doi: 10.1002/acr.24786</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.24786</ArticleId><ArticleId IdType="pmc">PMC8934743</ArticleId><ArticleId IdType="pubmed">34549549</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernatsky S, Joseph L, Pineau CA, et al. Estimating the prevalence of polymyositis and dermatomyositis from administrative data: age, sex and regional differences. Ann Rheum Dis 2009;68(7):1192&#x2013;1196. doi: 10.1136/ard.2008.093161</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2008.093161</ArticleId><ArticleId IdType="pubmed">18713785</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernatsky S, Linehan T, Hanly JG. The accuracy of administrative data diagnoses of systemic autoimmune rheumatic diseases. J Rheumatol 2011;38(8):1612&#x2013;1616. doi: 10.3899/jrheum.101149</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.101149</ArticleId><ArticleId IdType="pubmed">21532057</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobloug C, Garen T, Bitter H, et al. Prevalence and clinical characteristics of adult polymyositis and dermatomyositis; data from a large and unselected Norwegian cohort. Ann Rheum Dis 2015;74(8):1551&#x2013;1556. doi: 10.1136/annrheumdis-2013-205127</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2013-205127</ArticleId><ArticleId IdType="pubmed">24695011</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwa MC, Ardalan K, Laumann AE, Nardone B, West DP, Silverberg JI. Validation of International Classification of Diseases Codes for the Epidemiologic Study of Dermatomyositis. Arthritis Care Res 2017;69(5):753&#x2013;757. doi: 10.1002/acr.23010</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/acr.23010</ArticleId><ArticleId IdType="pubmed">27564726</ArticleId></ArticleIdList></Reference><Reference><Citation>Svensson J, Arkema EV, Lundberg IE, Holmqvist M. Incidence and prevalence of idiopathic inflammatory myopathies in Sweden: a nationwide population-based study. Rheumatol Oxf Engl 2017;56(5):802&#x2013;810. doi: 10.1093/rheumatology/kew503</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kew503</ArticleId><ArticleId IdType="pubmed">28160487</ArticleId></ArticleIdList></Reference><Reference><Citation>DeFalco F, Sena AG, Knoll C, et al. 
ATLAS. Published online December
14, 2023. https://github.com/OHDSI/Atlas/wiki</Citation></Reference><Reference><Citation>Lundberg IE, Tj&#xe4;rnlund A, Bottai M, et al. 2017 European League Against Rheumatism/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis 2017;76(12):1955&#x2013;1964. doi: 10.1136/annrheumdis-2017-211468</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2017-211468</ArticleId><ArticleId IdType="pmc">PMC5736307</ArticleId><ArticleId IdType="pubmed">29079590</ArticleId></ArticleIdList></Reference><Reference><Citation>Rao GA, Shoaibi A, Makadia R, et al. CohortDiagnostics: Phenotype evaluation across a network of observational data sources using population-level characterization. PLOS ONE. 2025;20(1):e0310634. doi: 10.1371/journal.pone.0310634</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0310634</ArticleId><ArticleId IdType="pmc">PMC11737733</ArticleId><ArticleId IdType="pubmed">39820599</ArticleId></ArticleIdList></Reference><Reference><Citation>Swerdel JN, Schuemie M, Murray G, Ryan PB. PheValuator 2.0: Methodological improvements for the PheValuator approach to semi-automated phenotype algorithm evaluation. J Biomed Inform 2022;135:104177. doi: 10.1016/j.jbi.2022.104177</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2022.104177</ArticleId><ArticleId IdType="pubmed">35995107</ArticleId></ArticleIdList></Reference><Reference><Citation>Swerdel JN, Hripcsak G, Ryan PB. PheValuator: Development and Evaluation of a Phenotype Algorithm Evaluator. J Biomed Inform 2019;97:103258. doi: 10.1016/j.jbi.2019.103258</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2019.103258</ArticleId><ArticleId IdType="pmc">PMC7736922</ArticleId><ArticleId IdType="pubmed">31369862</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40791563</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>14</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>14</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2692-8205</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Jul</Month><Day>18</Day></PubDate></JournalIssue><Title>bioRxiv : the preprint server for biology</Title><ISOAbbreviation>bioRxiv</ISOAbbreviation></Journal><ArticleTitle>Mapping and Harmonization of CVX vaccine terms to the Vaccine Ontology.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2025.07.15.664501</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1101/2025.07.15.664501</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">With many vaccines developed and used, it is critical to standardize vaccine information. The OHDSI OMOP Common Data Model (CDM), widely used to support EHR data integration and analysis, leverages CVX, RxNorm, and RxNorm Extension codes to standardize vaccine-related records. However, these terminologies lack robust semantic relations, making the vaccine classification ineffective in OMOP CDM. To address this issue, our OHDSI Vaccine Vocabulary Working Group proposes to use the Vaccine Ontology (VO) to map these standards and build up its own semantic relations. As a first study of the work, we performed the mapping and alignment of the Vaccine Administered (CVX) codes with the VO using a combination of semi-automatic and manual mapping methods.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 273 CVX terms were first collected and classified. A high-level VO design pattern and an exact one-to-one mapping strategy were developed to guide the CVX-to-VO term mapping. To facilitate the manual mapping and harmonization process, we also developed and evaluated three semi-automated mapping approaches utilizing lexical and semantic information of vaccine concepts to map CVX to VO. These approaches suggested candidate VO mappings for CVX terms and also indicated CVX terms that were unmappable to VO and required new term additions to VO. The application of the best approach to the 2022-10-05 release of VO achieved an accuracy of 85.55% for its suggestions. The suggestions made by the semi-automated approaches were taken into account to further enhance the mappings, which led to our eventual mapping of all CVX terms to the latest version of VO. We innovatively proposed the inclusion of the 'passive vaccine' branch in VO, which includes 24 immunoglobulins and antitoxins from CVX as passive vaccines. A specific CVX-VO OWL file was developed and added to the VO GitHub. Use case queries were developed to demonstrate its support for computer-assisted queries of vaccine groups based on CVX-VO hierarchies.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">All CVX terms were mapped to the VO using our combined semi-automatic and manual mapping methods. The mapped results enhanced semantic vaccine classification, providing a basis for further OMOP vaccine classification and EHR data analysis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Yuanyi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>University of Michigan Medical School, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manuel</LastName><ForeName>Warren</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>McWilliams School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Abeysinghe</LastName><ForeName>Rashmie</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, The University of Texas Health Science Center at Houston, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zheng</LastName><ForeName>Jie</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-2999-0103</Identifier><AffiliationInfo><Affiliation>University of Michigan Medical School, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davydov</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Observational Health Data Sciences and Informatics, New York City, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Qi</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>IQVIA, Inc., Durham, NC, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lin</LastName><ForeName>Asiyah Yu</ForeName><Initials>AY</Initials><AffiliationInfo><Affiliation>Axle Research and Technology, Rockville, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Licong</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>McWilliams School of Biomedical Informatics, The University of Texas Health Science Center at Houston, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Yongqun Oliver</ForeName><Initials>YO</Initials><Identifier Source="ORCID">0000-0001-9189-9661</Identifier><AffiliationInfo><Affiliation>University of Michigan Medical School, Ann Arbor, MI, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 NS116287</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24 AI171008</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000076942">Preprint</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>07</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>bioRxiv</MedlineTA><NlmUniqueID>101680187</NlmUniqueID><ISSNLinking>2692-8205</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">CVX code</Keyword><Keyword MajorTopicYN="N">Embedding-based similarity</Keyword><Keyword MajorTopicYN="N">Large Language Model-aided mapping</Keyword><Keyword MajorTopicYN="N">OMOP CDM</Keyword><Keyword MajorTopicYN="N">Ontology design pattern</Keyword><Keyword MajorTopicYN="N">Ontology mapping</Keyword><Keyword MajorTopicYN="N">Vaccine Ontology</Keyword><Keyword MajorTopicYN="N">Word-level similarity</Keyword></KeywordList><CoiStatement>Competing interests The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>12</Day><Hour>11</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>12</Day><Hour>11</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>12</Day><Hour>5</Hour><Minute>13</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40791563</ArticleId><ArticleId IdType="pmc">PMC12338626</ArticleId><ArticleId IdType="doi">10.1101/2025.07.15.664501</ArticleId><ArticleId IdType="pii">2025.07.15.664501</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Makadia R, Ryan PB. Transforming the Premier Perspective Hospital Database into the Observational Medical Outcomes Partnership (OMOP) Common Data Model. EGEMS (Wash DC). 2014;2(1):1110.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4371500</ArticleId><ArticleId IdType="pubmed">25848597</ArticleId></ArticleIdList></Reference><Reference><Citation>Abeysinghe R, Black A, Kaduk D, Li Y, Reich C, Davydov A, et al. Towards quality improvement of vaccine concept mappings in the OMOP vocabulary with a semi-automated method. J Biomed Inform. 2022;134:104162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9940475</ArticleId><ArticleId IdType="pubmed">36029954</ArticleId></ArticleIdList></Reference><Reference><Citation>Yupeng Li AB, Baltus Gretchen A., Cho Carolyn, Chandrasekaran Vasu, Dasbach Erik, Yao Lixia. Quality assessment of vaccine concepts in OMOP common data model. 2020 OHDSI global symposium2020.</Citation></Reference><Reference><Citation>He Y, Cowell L, Diehl A, Mobley H, Peters B, Ruttenberg A, et al. VO: Vaccine Ontology. Nature Precedings. 2009.</Citation></Reference><Reference><Citation>Jackson R, Matentzoglu N, Overton JA, Vita R, Balhoff JP, Buttigieg PL, et al. OBO Foundry in 2021: operationalizing open data principles to evaluate ontologies. Database (Oxford). 2021;2021.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8546234</ArticleId><ArticleId IdType="pubmed">34697637</ArticleId></ArticleIdList></Reference><Reference><Citation>IIS: Current HL7 Standard Code Set CVX -- Vaccines Administered. https://www2a.cdc.gov/vaccines/iis/iisstandards/vaccines.asp?rpt=cvx. Accessed 24 May, 2024.</Citation></Reference><Reference><Citation>CVX Source Information. https://www.nlm.nih.gov/research/umls/rxnorm/sourcereleasedocs/cvx.html. Accessed 30 May, 2024.</Citation></Reference><Reference><Citation>Violetta Komar DD, Talapova Polina, Bezeha Yevhenii, Reich Christian, Davydov Aleksander, editor Incorporation of CVX Vaccines into OMOP Drug Hierarchy. 2020 OHDSI global symposium; 2020.</Citation></Reference><Reference><Citation>Otero-Cerdeira L, Rodr&#xed;guez-Mart&#xed;nez FJ, G&#xf3;mez-Rodr&#xed;guez A. Ontology matching: A literature review. Expert Systems with Applications. 2015;42(2):949&#x2013;71.</Citation></Reference><Reference><Citation>Vaccine Code Set Considerations. https://repository.immregistries.org/files/resources/5ec6ba69859a6/vaccine_code_set_considerations_final-0.pdf. Accessed 30 May, 2024.</Citation></Reference><Reference><Citation>Vaccine Ontology. https://github.com/vaccineontology. Accessed 1 Jun, 2024.</Citation></Reference><Reference><Citation>Ong E, Xiang Z, Zhao B, Liu Y, Lin Y, Zheng J, et al. Ontobee: A linked ontology data server to support ontology term dereferencing, linkage, query and integration. Nucleic Acids Res. 2017;45(D1):D347&#x2013;d52.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5210626</ArticleId><ArticleId IdType="pubmed">27733503</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y, He Y. Ontology representation and analysis of vaccine formulation and administration and their effects on vaccine immune responses. J Biomed Semantics. 2012;3(1): 17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3639077</ArticleId><ArticleId IdType="pubmed">23256535</ArticleId></ArticleIdList></Reference><Reference><Citation>Musen MA. The Prot&#xe9;g&#xe9; Project: A Look Back and a Look Forward. AI Matters. 2015;1(4):4&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4883684</ArticleId><ArticleId IdType="pubmed">27239556</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiang Z, Zheng J, Lin Y, He Y. Ontorat: automatic generation of new ontology terms, annotations, and axioms based on ontology design patterns. J Biomed Semantics. 2015;6:4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4362828</ArticleId><ArticleId IdType="pubmed">25785185</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Vaccine Names. https://www.cdc.gov/vaccines/terms/usvaccines.html. Accessed 24 May 2024.</Citation></Reference><Reference><Citation>Vaccine Abbreviations. https://www.cdc.gov/vaccines/terms/vacc-abbrev.html. Accessed 20 May, 2024.</Citation></Reference><Reference><Citation>tavakolih. all-MiniLM-L6-v2-pubmed-full &#x2022; Hugging Face. (n.d.). https://huggingface.co/tavakolih/all-MiniLM-L6-v2-pubmed-full. Accessed 8 Dec, 2023.</Citation></Reference><Reference><Citation>Jaccard P. Nouvelles recherches sur la distribution florale. Bull Soc Vaud Sci Nat. 1908;44:223&#x2013;70.</Citation></Reference><Reference><Citation>Hello GPT-4o. https://openai.com/index/hello-gpt-4o/. Accessed 30 May, 2024.</Citation></Reference><Reference><Citation>Staphage Lysate (SPL). https://www.drugs.com/vet/staphage-lysate-spl.html. Accessed 1 May, 2024.</Citation></Reference><Reference><Citation>Capparelli R, Parlato M, Borriello G, Salvatore P, Iannelli D. Experimental phage therapy against Staphylococcus aureus in mice. Antimicrob Agents Chemother. 2007;51(8):2765&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1932491</ArticleId><ArticleId IdType="pubmed">17517843</ArticleId></ArticleIdList></Reference><Reference><Citation>Siman-Tov DD, Navon-Perry L, Haigwood NL, Gershoni JM. Differentiation of a passive vaccine and the humoral immune response toward infection: analysis of phage displayed peptides. Vaccine. 2006;24(5):607&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">16171907</ArticleId></ArticleIdList></Reference><Reference><Citation>Class: passive vaccine. https://ontobee.org/ontology/VO?iri=http://purl.obolibrary.org/obo/VO_0005439. Accessed 25 May, 2024.</Citation></Reference><Reference><Citation>Marcotte H, Hammarstr&#xf6;m L. Passive Immunization: Toward Magic Bullets: Mucosal Immunology. 2015:1403&#x2013;34. doi: 10.1016/B978-0-12-415847-4.00071-9. Epub 2015 Mar 13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-0-12-415847-4.00071-9</ArticleId></ArticleIdList></Reference><Reference><Citation>Aizenshtein E, Pinchasov Y, Morag E, Leitner G, Shpanir Y, Reimond D, et al. Immunological complex for enhancement of innate immune response in passive vaccination. Vaccine. 2013;31(4):626&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pubmed">23212028</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xfc;lseweh B, R&#xfc;lker T, Pelat T, Langermann C, Frenzel A, Schirrmann T, et al. Human-like antibodies neutralizing Western equine encephalitis virus. MAbs. 2014;6(3):718&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4011916</ArticleId><ArticleId IdType="pubmed">24518197</ArticleId></ArticleIdList></Reference><Reference><Citation>Camboni M, Wang CM, Miranda C, Yoon JH, Xu R, Zygmunt D, et al. Active and passive immunization strategies based on the SDPM1 peptide demonstrate pre-clinical efficacy in the APPswePSEN1dE9 mouse model for Alzheimer&#x2019;s disease. Neurobiol Dis. 2014;62:31&#x2013;43.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3881373</ArticleId><ArticleId IdType="pubmed">24021662</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudolf MP, Zuercher AW, Nechansky A, Ruf C, Vogel M, Miescher SM, et al. Molecular basis for nonanaphylactogenicity of a monoclonal anti-IgE antibody. J Immunol. 2000;165(2):813&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10878355</ArticleId></ArticleIdList></Reference><Reference><Citation>ImmPort. https://www.immport.org/shared/home. Accessed 4 Jun, 2024.</Citation></Reference><Reference><Citation>Human Immunology Project Consortium (HIPC). https://immunespace.org/. Accessed 4 Jun, 2024.</Citation></Reference><Reference><Citation>Vaccine Adjuvant Compendium(VAC). https://vac.niaid.nih.gov/. Accessed 4 Jun, 2024.</Citation></Reference><Reference><Citation>Reich C, Ostropolets A, Ryan P, Rijnbeek P, Schuemie M, Davydov A, et al. OHDSI Standardized Vocabularies-a large-scale centralized reference ontology for international data harmonization. J Am Med Inform Assoc. 2024;31(3):583&#x2013;90</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10873827</ArticleId><ArticleId IdType="pubmed">38175665</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40833208</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>20</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1468-2834</ISSN><JournalIssue CitedMedium="Internet"><Volume>54</Volume><Issue>8</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>01</Day></PubDate></JournalIssue><Title>Age and ageing</Title><ISOAbbreviation>Age Ageing</ISOAbbreviation></Journal><ArticleTitle>Longitudinal trajectories of polypharmacy in older people, and their association with the risk of mortality: a joint latent class model analysis of real-world data from the UK and the Netherlands.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">afaf233</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/ageing/afaf233</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Polypharmacy is the use of multiple drugs. Many definitions have been established for polypharmacy, often cross-sectionally, despite it naturally changing over time. In this study, we aimed to identify clusters of older people with distinct polypharmacy trajectories over time and associated mortality risks. We then characterised the identified clusters and assessed their generalisability in two external databases.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Data were extracted from three primary care databases: the UK Clinical Practice Research Datalink (CPRD) GOLD, CPRD Aurum and the Dutch Integrated Primary Care Information (IPCI). People aged &#x2265;65 on 1 January 2015 were included. Polypharmacy, defined as the cumulative number of prescribed ingredients, was calculated at baseline and at the end of each subsequent follow-up year (2015-19). We applied joint latent class modelling, which divides the population into clusters with different trajectories and associated mortality risks. The model was trained in GOLD and validated in Aurum and IPCI.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Four clusters were identified and characterised based on polypharmacy baseline and rate of progression: low-steady, intermediate-slow/increasing, intermediate-fast/increasing and high-decreasing. The high-decreasing cluster had the highest average baseline polypharmacy (intercept&#x2009;=&#x2009;23.4) and prevalence of non-cancer chronic comorbidities, whilst the intermediate-fast/increasing had the steepest polypharmacy rate of progression per year (slope&#x2009;=&#x2009;6.4), highest baseline and cumulative incidence of cancer, and worst survival outcome. Good validation was found in Aurum and IPCI.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">High baseline levels and increasing levels of polypharmacy were associated with an increased mortality risk in older people. The clusters identified in this study were externally validated in two European databases, confirming their robustness and generalisability.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2025. Published by Oxford University Press on behalf of the British Geriatrics Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Elhussein</LastName><ForeName>Leena</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Ross D</ForeName><Initials>RD</Initials><Identifier Source="ORCID">0000-0001-7723-417X</Identifier><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus University Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Man</LastName><ForeName>Wai Yi</ForeName><Initials>WY</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burn</LastName><ForeName>Edward</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-9286-1128</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delmestri</LastName><ForeName>Antonella</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strauss</LastName><ForeName>Victoria Y</ForeName><Initials>VY</Initials><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-3950-6346</Identifier><AffiliationInfo><Affiliation>Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><Agency>European Health Data and Evidence Network (EHDEN)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Age Ageing</MedlineTA><NlmUniqueID>0375655</NlmUniqueID><ISSNLinking>0002-0729</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019338" MajorTopicYN="Y">Polypharmacy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006113" MajorTopicYN="N" Type="Geographic">United Kingdom</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009426" MajorTopicYN="N" Type="Geographic">Netherlands</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077272" MajorTopicYN="N">Latent Class Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016208" MajorTopicYN="N">Databases, Factual</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009026" MajorTopicYN="Y">Mortality</DescriptorName><QualifierName UI="Q000639" MajorTopicYN="N">trends</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">joint latent class models</Keyword><Keyword MajorTopicYN="N">longitudinal</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">older people</Keyword><Keyword MajorTopicYN="N">polypharmacy</Keyword></KeywordList><CoiStatement>DPA&#x2019;s department has received grant/s from Amgen, Chiesi-Taylor, Lilly, Janssen, Novartis and UCB Biopharma. His research group has received consultancy fees from Astra Zeneca and UCB Biopharma. Amgen, Astellas, Janssen, Synapse Management Partners and UCB Biopharma have funded or supported training programmes organised by DPA&#x2019;s department. VYS. is a full-time employee at Boehringer Ingelheim Pharma GmbH &amp; Co. KG.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>6</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>12</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>12</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>20</Day><Hour>9</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40833208</ArticleId><ArticleId IdType="pmc">PMC12365978</ArticleId><ArticleId IdType="doi">10.1093/ageing/afaf233</ArticleId><ArticleId IdType="pii">8238519</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pazan &#xa0;F, Wehling &#xa0;M. Polypharmacy in older adults: a narrative review of definitions, epidemiology and consequences. Eur Geriatr Med &#xa0;2021;12:443&#x2013;52. 10.1007/s41999-021-00479-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s41999-021-00479-3</ArticleId><ArticleId IdType="pmc">PMC8149355</ArticleId><ArticleId IdType="pubmed">33694123</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen &#xa0;EY, Bell &#xa0;JS, Ilomaki &#xa0;J &#xa0;et al. &#xa0;Medication regimen complexity in 8 Australian residential aged care facilities: impact of age, length of stay, comorbidity, frailty, and dependence in activities of daily living. Clin Interv Aging &#xa0;2019;14:1783&#x2013;95. 10.2147/CIA.S216705.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/CIA.S216705</ArticleId><ArticleId IdType="pmc">PMC6815218</ArticleId><ArticleId IdType="pubmed">31695348</ArticleId></ArticleIdList></Reference><Reference><Citation>Turk &#xa0;A, Wong &#xa0;G, Mahtani &#xa0;KR &#xa0;et al. &#xa0;Optimising a person-centred approach to stopping medicines in older people with multimorbidity and polypharmacy using the DExTruS framework: a realist review. BMC Med &#xa0;2022;20:297. 10.1186/s12916-022-02475-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-022-02475-1</ArticleId><ArticleId IdType="pmc">PMC9429627</ArticleId><ArticleId IdType="pubmed">36042454</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksen &#xa0;CU, Kyriakidis &#xa0;S, Christensen &#xa0;LD &#xa0;et al. &#xa0;Medication-related experiences of patients with polypharmacy: a systematic review of qualitative studies. BMJ Open &#xa0;2020;10: e036158. 10.1136/bmjopen-2019-036158.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2019-036158</ArticleId><ArticleId IdType="pmc">PMC7477975</ArticleId><ArticleId IdType="pubmed">32895268</ArticleId></ArticleIdList></Reference><Reference><Citation>Leelakanok &#xa0;N, Holcombe &#xa0;AL, Lund &#xa0;BC &#xa0;et al. &#xa0;Association between polypharmacy and death: a systematic review and meta-analysis. J Am Pharm Assoc &#xa0;2017;57:729&#x2013;738.e10. 10.1016/j.japh.2017.06.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.japh.2017.06.002</ArticleId><ArticleId IdType="pubmed">28784299</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgess &#xa0;CL, Holman &#xa0;CD, Satti &#xa0;AG. Adverse drug reactions in older Australians, 1981-2002. Med J Aust &#xa0;2005;182:267&#x2013;70. 10.5694/j.1326-5377.2005.tb06698.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.5694/j.1326-5377.2005.tb06698.x</ArticleId><ArticleId IdType="pubmed">15777140</ArticleId></ArticleIdList></Reference><Reference><Citation>Milton &#xa0;JC, Hill-Smith &#xa0;I, Jackson &#xa0;SHD. Prescribing for older people. BMJ &#xa0;2008;336:606&#x2013;9. 10.1136/bmj.39503.424653.80.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.39503.424653.80</ArticleId><ArticleId IdType="pmc">PMC2267940</ArticleId><ArticleId IdType="pubmed">18340075</ArticleId></ArticleIdList></Reference><Reference><Citation>Palmer &#xa0;K, Villani &#xa0;ER, Vetrano &#xa0;DL &#xa0;et al. &#xa0;Association of polypharmacy and hyperpolypharmacy with frailty states: a systematic review and meta-analysis. Eur Geriatr Med &#xa0;2019;10:9&#x2013;36. 10.1007/s41999-018-0124-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s41999-018-0124-5</ArticleId><ArticleId IdType="pubmed">32720270</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson &#xa0;K, Ananou &#xa0;A, Lafortune &#xa0;L &#xa0;et al. &#xa0;Variation over time in the association between polypharmacy and mortality in the older population. Drugs Aging &#xa0;2011;28:547&#x2013;60. 10.2165/11592000-000000000-00000.</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/11592000-000000000-00000</ArticleId><ArticleId IdType="pubmed">21721599</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhalwani &#xa0;NN, Fahami &#xa0;R, Sathanapally &#xa0;H &#xa0;et al. &#xa0;Association between polypharmacy and falls in older adults: a longitudinal study from England. BMJ Open &#xa0;2017;7:e016358&#x2013;8. 10.1136/bmjopen-2017-016358.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2017-016358</ArticleId><ArticleId IdType="pmc">PMC5652576</ArticleId><ArticleId IdType="pubmed">29042378</ArticleId></ArticleIdList></Reference><Reference><Citation>Vill&#xe9;n &#xa0;N, Guisado-Clavero &#xa0;M, Fern&#xe1;ndez-Bertol&#xed;n &#xa0;S &#xa0;et al. &#xa0;Multimorbidity patterns, polypharmacy and their association with liver and kidney abnormalities in people over 65&#x2009;years of age: a longitudinal study. BMC Geriatr &#xa0;2020;20:206. 10.1186/s12877-020-01580-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12877-020-01580-1</ArticleId><ArticleId IdType="pmc">PMC7291454</ArticleId><ArticleId IdType="pubmed">32532213</ArticleId></ArticleIdList></Reference><Reference><Citation>Veehof &#xa0;LJG, Stewart &#xa0;RE, Haaijer-Ruskamp &#xa0;FM &#xa0;et al. &#xa0;The development of polypharmacy. A longitudinal study. Fam Pract &#xa0;2000;17:261&#x2013;7. 10.1093/fampra/17.3.261.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/fampra/17.3.261</ArticleId><ArticleId IdType="pubmed">10846147</ArticleId></ArticleIdList></Reference><Reference><Citation>Morin &#xa0;L, Vetrano &#xa0;DL, Rizzuto &#xa0;D &#xa0;et al. &#xa0;Choosing wisely? Measuring the burden of medications in older adults near the end of life: nationwide, longitudinal cohort study. Am J Med &#xa0;2017;130:927&#x2013;936.e9. 10.1016/j.amjmed.2017.02.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjmed.2017.02.028</ArticleId><ArticleId IdType="pubmed">28454668</ArticleId></ArticleIdList></Reference><Reference><Citation>Falster &#xa0;MO, Charrier &#xa0;R, Pearson &#xa0;SA &#xa0;et al. &#xa0;Long-term trajectories of medicine use among older adults experiencing polypharmacy in Australia. Br J Clin Pharmacol &#xa0;2021; 87:1264&#x2013;74. 10.1111/bcp.14504.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.14504</ArticleId><ArticleId IdType="pubmed">32737910</ArticleId></ArticleIdList></Reference><Reference><Citation>Thapaliya &#xa0;K, Harris &#xa0;ML, Byles &#xa0;JE. Polypharmacy trajectories among older women with and without dementia: a longitudinal cohort study. Explor Res Clin Soc Pharm &#xa0;2021;3:100053. 10.1016/j.rcsop.2021.100053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rcsop.2021.100053</ArticleId><ArticleId IdType="pmc">PMC9031090</ArticleId><ArticleId IdType="pubmed">35480610</ArticleId></ArticleIdList></Reference><Reference><Citation>Wastesson &#xa0;JW, Oksuzyan &#xa0;A, von &#xa0;Bornemann Hjelmborg &#xa0;J &#xa0;et al. &#xa0;Changes in drug use and polypharmacy after the age of 90: a longitudinal study of the Danish 1905 cohort. J Am Geriatr Soc &#xa0;2017;65:160&#x2013;4. 10.1111/jgs.14416.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgs.14416</ArticleId><ArticleId IdType="pmc">PMC5258828</ArticleId><ArticleId IdType="pubmed">27891576</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrett &#xa0;E, Gallagher &#xa0;AM, Bhaskaran &#xa0;K &#xa0;et al. &#xa0;Data resource profile: clinical practice research datalink (CPRD). Int J Epidemiol &#xa0;2015;44:827&#x2013;36. 10.1093/ije/dyv098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyv098</ArticleId><ArticleId IdType="pmc">PMC4521131</ArticleId><ArticleId IdType="pubmed">26050254</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf &#xa0;A, Dedman &#xa0;D, Campbell &#xa0;J &#xa0;et al. &#xa0;Data resource profile: clinical practice research datalink (CPRD) aurum. Int J Epidemiol &#xa0;2019;48:1740&#x2013;1740g. 10.1093/ije/dyz034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyz034</ArticleId><ArticleId IdType="pmc">PMC6929522</ArticleId><ArticleId IdType="pubmed">30859197</ArticleId></ArticleIdList></Reference><Reference><Citation>de &#xa0;Ridder &#xa0;MAJ, de &#xa0;Wilde &#xa0;M, de &#xa0;Ben &#xa0;C &#xa0;et al. &#xa0;Data resource profile: the integrated primary care information (IPCI) database, the Netherlands. Int J Epidemiol &#xa0;2022;51:e314&#x2013;23. 10.1093/ije/dyac0268</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyac026</ArticleId><ArticleId IdType="pmc">PMC9749682</ArticleId><ArticleId IdType="pubmed">35182144</ArticleId></ArticleIdList></Reference><Reference><Citation>Observational Health Data Sciences and Informatics. The Book of OHDSI; 2021. Available from: https://ohdsi.github.io/TheBookOfOhdsi/</Citation></Reference><Reference><Citation>Delmestri &#xa0;A, Prieto-Alhambra &#xa0;D. CPRD GOLD and linked ONS mortality records: reconciling guidelines. Int J Med Inform &#xa0;2020;136:104038. 10.1016/j.ijmedinf.2019.104038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijmedinf.2019.104038</ArticleId><ArticleId IdType="pubmed">32078979</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiapella &#xa0;LC, Montemarani Menna &#xa0;J, Mamprin &#xa0;ME. Assessment of polypharmacy in elderly patients by using data from dispensed medications in community pharmacies: analysis of results by using different methods of estimation. Int J Clin Pharmacol &#xa0;2018;40:987&#x2013;90. 10.1007/s11096-018-0663-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11096-018-0663-3</ArticleId><ArticleId IdType="pubmed">29881908</ArticleId></ArticleIdList></Reference><Reference><Citation>Fincke &#xa0;BG, Snyder &#xa0;K, Cantillon &#xa0;C &#xa0;et al. &#xa0;Three complementary definitions of polypharmacy: methods, application and comparison of findings in a large prescription database. Pharmacoepidemiol Drug Saf &#xa0;2005;14:121&#x2013;8. 10.1002/pds.966.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.966</ArticleId><ArticleId IdType="pubmed">15386712</ArticleId></ArticleIdList></Reference><Reference><Citation>Gagnon &#xa0;M-E, M&#xe9;sidor &#xa0;M, Simard &#xa0;M &#xa0;et al. &#xa0;A comparative analysis of medication counting methods to assess polypharmacy in medico-administrative databases. Res Soc Adm Pharm &#xa0;2024;20:905&#x2013;10. 10.1016/j.sapharm.2024.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.sapharm.2024.05.006</ArticleId><ArticleId IdType="pubmed">38797631</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallagher &#xa0;AM, Dedman &#xa0;D, Padmanabhan &#xa0;S &#xa0;et al. &#xa0;The accuracy of date of death recording in the clinical practice research datalink GOLD database in England compared with the Office for National Statistics death registrations. Pharmacoepidemiol Drug Saf &#xa0;2019;28:563&#x2013;9. 10.1002/pds.4747.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.4747</ArticleId><ArticleId IdType="pmc">PMC6593793</ArticleId><ArticleId IdType="pubmed">30908785</ArticleId></ArticleIdList></Reference><Reference><Citation>Proust-Lima &#xa0;C, S&#xe9;ne &#xa0;M, Taylor &#xa0;JM &#xa0;et al. &#xa0;Joint latent class models for longitudinal and time-to-event data: a review. Stat Methods Med Res &#xa0;2014;23:74&#x2013;90. 10.1177/0962280212445839.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0962280212445839</ArticleId><ArticleId IdType="pmc">PMC5863083</ArticleId><ArticleId IdType="pubmed">22517270</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyheng &#xa0;M, Babykina &#xa0;G, Ternynck &#xa0;C &#xa0;et al. &#xa0;Joint latent class model: simulation study of model properties and application to amyotrophic lateral sclerosis disease. BMC Med Res Methodol &#xa0;2021;21:198. 10.1186/s12874-021-01377-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12874-021-01377-9</ArticleId><ArticleId IdType="pmc">PMC8482570</ArticleId><ArticleId IdType="pubmed">34592944</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagin &#xa0;D, Odgers &#xa0;C. Group-based trajectory modeling in clinical research. Annu Rev Clin Psychol &#xa0;2010;6:109&#x2013;38. 10.1146/annurev.clinpsy.121208.131413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.clinpsy.121208.131413</ArticleId><ArticleId IdType="pubmed">20192788</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang &#xa0;YT, Steptoe &#xa0;A, Wei &#xa0;L &#xa0;et al. &#xa0;The impact of high-risk medications on mortality risk among older adults with polypharmacy: evidence from the English longitudinal study of ageing. BMC Med &#xa0;2021;19:321. 10.1186/s12916-021-02192-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-021-02192-1</ArticleId><ArticleId IdType="pmc">PMC8675465</ArticleId><ArticleId IdType="pubmed">34911547</ArticleId></ArticleIdList></Reference><Reference><Citation>Holvast &#xa0;F, van &#xa0;Hattem &#xa0;BA, Sinnige &#xa0;J &#xa0;et al. &#xa0;Late-life depression and the association with multimorbidity and polypharmacy: a cross-sectional study. Fam Pract &#xa0;2017;34:539&#x2013;45. 10.1093/fampra/cmx018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/fampra/cmx018</ArticleId><ArticleId IdType="pubmed">28369380</ArticleId></ArticleIdList></Reference><Reference><Citation>Magnuson &#xa0;A, Sattar &#xa0;S, Nightingale &#xa0;G &#xa0;et al. &#xa0;A practical guide to geriatric syndromes in older adults with cancer: a focus on falls, cognition, polypharmacy, and depression. Am Soc Clin Oncol Educ Book &#xa0;2019;39:e96&#x2013;109. 10.1200/EDBK_237641.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/EDBK_237641</ArticleId><ArticleId IdType="pubmed">31099668</ArticleId></ArticleIdList></Reference><Reference><Citation>Nightingale &#xa0;G, Hajjar &#xa0;E, Swartz &#xa0;K &#xa0;et al. &#xa0;Evaluation of a pharmacist-led medication assessment used to identify prevalence of and associations with polypharmacy and potentially inappropriate medication use among ambulatory senior adults with cancer. J Clin Oncol Off J Am Soc Clin Oncol &#xa0;2015;33:1453&#x2013;9. 10.1200/JCO.2014.58.7550.</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.2014.58.7550</ArticleId><ArticleId IdType="pubmed">25800766</ArticleId></ArticleIdList></Reference><Reference><Citation>Bandidwattanawong &#xa0;C, Rattanaserikulchai &#xa0;P, Jetsadavanit &#xa0;N. Polypharmacy and potentially-inappropriate medications are prevalent in the elderly cancer patients receiving systemic cancer therapy and they co-relate with adverse outcomes. BMC Geriatr &#xa0;2023;23:775. 10.1186/s12877-023-04471-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12877-023-04471-3</ArticleId><ArticleId IdType="pmc">PMC10680314</ArticleId><ArticleId IdType="pubmed">38012569</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmittdiel &#xa0;JA, Raebel &#xa0;MA, Dyer &#xa0;W &#xa0;et al. &#xa0;Prescription medication burden in patients with newly diagnosed diabetes: a SUrveillance, PREvention, and ManagEment of diabetes mellitus (SUPREME-DM) study. J Am Pharm Assoc &#xa0;2014;54:374&#x2013;82. 10.1331/JAPhA.2014.13195.</Citation><ArticleIdList><ArticleId IdType="doi">10.1331/JAPhA.2014.13195</ArticleId><ArticleId IdType="pmc">PMC4161641</ArticleId><ArticleId IdType="pubmed">24860866</ArticleId></ArticleIdList></Reference><Reference><Citation>NICE guideline [NG136]. Hypertension in adults: diagnosis and management. https://www.nice.org.uk/guidance/ng136/chapter/Recommendations#choosing-antihypertensive-drug-treatment-for-people-with-or-without-type-2-diabetes. Date accessed 15 July 2024.</Citation></Reference><Reference><Citation>NICE guideline [NG28]. Type 2 diabetes in adults: management. https://www.nice.org.uk/guidance/ng28. Date accessed 7 June 2024.</Citation></Reference><Reference><Citation>Reeve &#xa0;J, Maden &#xa0;M, Hill &#xa0;R &#xa0;et al. &#xa0;Deprescribing medicines in older people living with multimorbidity and polypharmacy: the TAILOR evidence synthesis. Health Technol Assess &#xa0;2022;26:1&#x2013;148. 10.3310/AAFO2475.</Citation><ArticleIdList><ArticleId IdType="doi">10.3310/AAFO2475</ArticleId><ArticleId IdType="pmc">PMC9376985</ArticleId><ArticleId IdType="pubmed">35894932</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang &#xa0;X, Yang &#xa0;C, Jiang &#xa0;J &#xa0;et al. &#xa0;Polypharmacy, chronic kidney disease, and mortality among older adults: a prospective study of National Health and nutrition examination survey, 1999-2018. Front Public Health &#xa0;2023;11:1116583. 10.3389/fpubh.2023.1116583.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpubh.2023.1116583</ArticleId><ArticleId IdType="pmc">PMC10077868</ArticleId><ArticleId IdType="pubmed">37033012</ArticleId></ArticleIdList></Reference><Reference><Citation>Bibliography. https://cprd.com/bibliography. Date accessed 9 November 2024.</Citation></Reference><Reference><Citation>Mangoni &#xa0;AA, Jackson &#xa0;SH. Age-related changes in pharmacokinetics and pharmacodynamics: basic principles and practical applications. Br J Clin Pharmacol &#xa0;2004;57:6&#x2013;14. 10.1046/j.1365-2125.2003.02007.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2125.2003.02007.x</ArticleId><ArticleId IdType="pmc">PMC1884408</ArticleId><ArticleId IdType="pubmed">14678335</ArticleId></ArticleIdList></Reference><Reference><Citation>Nightingale &#xa0;G, Schwartz &#xa0;R, Kachur &#xa0;E &#xa0;et al. &#xa0;Clinical pharmacology of oncology agents in older adults: a comprehensive review of how chronologic and functional age can influence treatment-related effects. J Geriatr Oncol &#xa0;2019;10:4&#x2013;30. 10.1016/j.jgo.2018.06.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jgo.2018.06.008</ArticleId><ArticleId IdType="pubmed">30017734</ArticleId></ArticleIdList></Reference><Reference><Citation>Vos &#xa0;R, Boesten &#xa0;J, van den &#xa0;Akker &#xa0;M. Fifteen-year trajectories of multimorbidity and polypharmacy in Dutch primary care&#x2014;a longitudinal analysis of age and sex patterns. PloS One &#xa0;2022;17:e0264343. 10.1371/journal.pone.0264343.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0264343</ArticleId><ArticleId IdType="pmc">PMC8880753</ArticleId><ArticleId IdType="pubmed">35213615</ArticleId></ArticleIdList></Reference><Reference><Citation>Herr &#xa0;M, Robine &#xa0;J-M, Pinot &#xa0;J &#xa0;et al. &#xa0;Polypharmacy and frailty: prevalence, relationship, and impact on mortality in a French sample of 2350 old people. Pharmacoepidemiol Drug Saf &#xa0;2015;24:637&#x2013;46. 10.1002/pds.3772.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.3772</ArticleId><ArticleId IdType="pubmed">25858336</ArticleId></ArticleIdList></Reference><Reference><Citation>Saum &#xa0;KU, Schottker &#xa0;B, Meid &#xa0;AD &#xa0;et al. &#xa0;Is polypharmacy associated with frailty in older people? Results from the ESTHER cohort study. J Am Geriatr Soc &#xa0;2017;65:e27&#x2013;32. 10.1111/jgs.14718.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jgs.14718</ArticleId><ArticleId IdType="pubmed">28024089</ArticleId></ArticleIdList></Reference><Reference><Citation>Woolford &#xa0;SJ, Aggarwal &#xa0;P, Sheikh &#xa0;CJ &#xa0;et al. &#xa0;Frailty, multimorbidity and polypharmacy. Medicine &#xa0;2021;49:166&#x2013;72. 10.1016/j.mpmed.2020.12.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.mpmed.2020.12.010</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutierrez-Valencia &#xa0;M, Izquierdo &#xa0;M, Cesari &#xa0;M &#xa0;et al. &#xa0;The relationship between frailty and polypharmacy in older people: a systematic review. Br J Clin Pharmacol &#xa0;2018;84:1432&#x2013;44. 10.1111/bcp.13590.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.13590</ArticleId><ArticleId IdType="pmc">PMC6005607</ArticleId><ArticleId IdType="pubmed">29575094</ArticleId></ArticleIdList></Reference><Reference><Citation>Clegg &#xa0;A, Bates &#xa0;C, Young &#xa0;J &#xa0;et al. &#xa0;Development and validation of an electronic frailty index using routine primary care electronic health record data. Age Ageing &#xa0;2016;45:353&#x2013;60. 10.1093/ageing/afw039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ageing/afw039</ArticleId><ArticleId IdType="pmc">PMC4846793</ArticleId><ArticleId IdType="pubmed">26944937</ArticleId></ArticleIdList></Reference><Reference><Citation>Barlow &#xa0;A, Prusak &#xa0;ES, Barlow &#xa0;B &#xa0;et al. &#xa0;Interventions to reduce polypharmacy and optimize medication use in older adults with cancer. J Geriatr Oncol &#xa0;2021;12:863&#x2013;71. 10.1016/j.jgo.2020.12.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jgo.2020.12.007</ArticleId><ArticleId IdType="pubmed">33353854</ArticleId></ArticleIdList></Reference><Reference><Citation>Olesen &#xa0;AE, Vaever &#xa0;TJ, Simonsen &#xa0;M &#xa0;et al. &#xa0;Deprescribing in primary care without deterioration of health-related outcomes: a real-life, quality improvement project. Basic Clin Pharmacol Toxicol &#xa0;2024;134:72&#x2013;82. 10.1111/bcpt.13925.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcpt.13925</ArticleId><ArticleId IdType="pubmed">37400998</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40841963</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2041-1480</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>21</Day></PubDate></JournalIssue><Title>Journal of biomedical semantics</Title><ISOAbbreviation>J Biomed Semantics</ISOAbbreviation></Journal><ArticleTitle>Mapping between clinical and preclinical terminologies: eTRANSAFE's Rosetta stone approach.</ArticleTitle><Pagination><StartPage>15</StartPage><MedlinePgn>15</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">15</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13326-025-00337-2</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The eTRANSAFE project developed tools that support translational research. One of the challenges in this project was to combine preclinical and clinical data, which are coded with different terminologies and granularities, and are expressed as single pre-coordinated, clinical concepts and as combinations of preclinical concepts from different terminologies. This study develops and evaluates the Rosetta Stone approach, which maps combinations of preclinical concepts to clinical, pre-coordinated concepts, allowing for different levels of exactness of mappings.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Concepts from preclinical and clinical terminologies used in eTRANSAFE have been mapped to the Systematized Nomenclature of Medicine Clinical Terms (SNOMED CT). SNOMED CT acts as an intermediary terminology that provides the semantics to bridge between pre-coordinated clinical concepts and combinations of preclinical concepts with different levels of granularity. The mappings from clinical terminologies to SNOMED CT were taken from existing resources, while mappings from the preclinical terminologies to SNOMED CT were manually created. A coordination template defines the relation types that can be explored for a mapping and assigns a penalty score that reflects the inexactness of the mapping. A subset of 60 pre-coordinated concepts was mapped both with the Rosetta Stone semantic approach and with a lexical term matching approach. Both results were manually evaluated.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 34,308 concepts from preclinical terminologies (Histopathology terminology, Standard for Exchange of Nonclinical Data (SEND) code lists, Mouse Adult Gross Anatomy Ontology) and a clinical terminology (MedDRA) were mapped to SNOMED CT as the intermediary bridging terminology. A terminology service has been developed that returns dynamically the exact and inexact mappings between preclinical and clinical concepts. On the evaluation set, the precision of the mappings from the terminology service was high (95%), much higher than for lexical term matching (22%).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The Rosetta Stone approach uses a semantically rich intermediate terminology to map between pre-coordinated clinical concepts and a combination of preclinical concepts with different levels of exactness. The possibility to generate not only exact but also inexact mappings allows to relate larger amounts of preclinical and clinical data, which can be helpful in translational use cases.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van Mulligen</LastName><ForeName>Erik M</ForeName><Initials>EM</Initials><AffiliationInfo><Affiliation>Dept of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands. e.vanmulligen@erasmusmc.nl.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parry</LastName><ForeName>Rowan</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Dept of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Lei</LastName><ForeName>Johan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Dept of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kors</LastName><ForeName>Jan A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Dept of Medical Informatics, Erasmus University Medical Center, Rotterdam, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>777365</GrantID><Agency>European Union's Horizon 2020 research and innovation program and EFPIA</Agency><Country/></Grant><Grant><GrantID>777365</GrantID><Agency>European Union's Horizon 2020 research and innovation program and EFPIA</Agency><Country/></Grant><Grant><GrantID>777365</GrantID><Agency>European Union's Horizon 2020 research and innovation program and EFPIA</Agency><Country/></Grant><Grant><GrantID>777365</GrantID><Agency>European Union's Horizon 2020 research and innovation program and EFPIA</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Biomed Semantics</MedlineTA><NlmUniqueID>101531992</NlmUniqueID></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D039061" MajorTopicYN="Y">Systematized Nomenclature of Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009626" MajorTopicYN="Y">Terminology as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012660" MajorTopicYN="N">Semantics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064229" MajorTopicYN="N">Biological Ontologies</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coordination</Keyword><Keyword MajorTopicYN="N">SNOMED CT</Keyword><Keyword MajorTopicYN="N">Terminology mapping</Keyword><Keyword MajorTopicYN="N">eTRANSAFE</Keyword></KeywordList><CoiStatement>Declarations. Ethics approval: Not applicable. Competing interests: The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>9</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>26</Day><Hour>4</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>26</Day><Hour>4</Hour><Minute>47</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>22</Day><Hour>0</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40841963</ArticleId><ArticleId IdType="pmc">PMC12372267</ArticleId><ArticleId IdType="doi">10.1186/s13326-025-00337-2</ArticleId><ArticleId IdType="pii">10.1186/s13326-025-00337-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pognan F, Steger-Hartmann T, D&#xed;az C, et al. The etransafe project on translational safety assessment through integrative knowledge management: achievements and perspectives. Pharmaceuticals. 2021;14(3):1&#x2013;18. 10.3390/ph14030237</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7999019</ArticleId><ArticleId IdType="pubmed">33800393</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanz F, Pognan F, Steger-Hartmann T, et al. eTRANSAFE: data science to empower translational safety assessment. Nat Rev Drug Discov. 2023;22(8):605&#x2013;6. 10.1038/d41573-023-00099-5</Citation><ArticleIdList><ArticleId IdType="pubmed">37316648</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodenreider O, The Unified Medical Language System (UMLS). Integrating biomedical terminology. Nucleic Acids Res. 2004;32:267&#x2013;70. 10.1093/nar/gkh061. DATABASE ISS.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC308795</ArticleId><ArticleId IdType="pubmed">14681409</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodenreider O, Nelson S&#x2019;J, Hole WT, Chang HF. Beyond Synonymy: Exploiting the UMLS Semantics in Mapping Vocabularies. 1998.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2232139</ArticleId><ArticleId IdType="pubmed">9929332</ArticleId></ArticleIdList></Reference><Reference><Citation>Fung KW, Bodenreider O. Utilizing the UMLS for Semantic Mapping between Terminologies. In: AMIA Annu Symp Proc. 2005;266&#x2013;270.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1560893</ArticleId><ArticleId IdType="pubmed">16779043</ArticleId></ArticleIdList></Reference><Reference><Citation>Fung KW, Xu J, Ameye F, Romero Guti&#xe9;rrez A. Leveraging Lexical Matching and Ontological Alignment to Map SNOMED CT Surgical Procedures to ICD-10-PCS. In: AMIA Annu Symp Proc. 2017;570&#x2013;579.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5333287</ArticleId><ArticleId IdType="pubmed">28269853</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison J, December. IMI WEB-RADR 2 Project and Overview of the SNOMED CT &#x2013; MedDRA Mapping. 2019. Accessed August 2, 2024. https://admin.meddra.org/sites/default/files/page/documents_insert/3_web-radr_2_and_snomed_-_meddra_mapping_3_dec_2019_final.pdf</Citation></Reference><Reference><Citation>Tregunno P. WEB-RADR 2. June 2020. Accessed August 2, 2024. https://www.imi.europa.eu/projects-results/project-factsheets/web-radr-2</Citation></Reference><Reference><Citation>Salvadores M, Alexander PR, Musen MA, Noy NF. BioPortal as a dataset of linked biomedical ontologies and terminologies in RDF. Semant Web. 2013;4(3):277&#x2013;84.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4159173</ArticleId><ArticleId IdType="pubmed">25214827</ArticleId></ArticleIdList></Reference><Reference><Citation>Jupp S, Liener T, Sarntivijai S, Vrousgou O, Burdett T, Parkinson H. OxO-a gravy of ontology mapping extracts. October 2016. 10.5281/zenodo.163459</Citation></Reference><Reference><Citation>Dhombres F, Winnenburg R, Case JT, Bodenreider O. Extending the coverage of phenotypes in SNOMED CT through post-coordination. Studies in health technology and informatics. IOS 2015;216:795&#x2013;9. 10.3233/978-1-61499-564-7-795</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5875691</ArticleId><ArticleId IdType="pubmed">26262161</ArticleId></ArticleIdList></Reference><Reference><Citation>Thi&#xe9;blin E, Haemmerl&#xe9; O, Hernandez N, Trojahn C. Survey on complex ontology matching. Semant Web. 2020;11(4):689&#x2013;727. 10.3233/SW-190366</Citation></Reference><Reference><Citation>Ochieng P, Kyanda S. Large-scale ontology matching: State-of-the-art analysis. ACM Comput Surv. 2018;51(4):1&#x2013;35. 10.1145/3211871</Citation></Reference><Reference><Citation>Cases M, Briggs K, Steger-Hartmann T, et al. The eTOX data-sharing project to advance in Silico drug-induced toxicity prediction. Int J Mol Sci. 2014;15(11):21136&#x2013;54. 10.3390/ijms151121136</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4264217</ArticleId><ArticleId IdType="pubmed">25405742</ArticleId></ArticleIdList></Reference><Reference><Citation>McCray AT. Better access to information about clinical trials. Ann Intern Med. 2000;133(8):609&#x2013;14. 10.7326/0003-4819-133-8-200010170-00013/ASSET/IMAGES/13TT2.JPG</Citation><ArticleIdList><ArticleId IdType="pubmed">11033590</ArticleId></ArticleIdList></Reference><Reference><Citation>U.S. Food and Drug Administration. FDA Adverse Event Reporting System. Accessed August 8, 2024. https://open.fda.gov/data/faers/</Citation></Reference><Reference><Citation>DailyMed. Accessed August 2, 2024. https://dailymed.nlm.nih.gov/dailymed/</Citation></Reference><Reference><Citation>MEDLINE overview. Accessed August 2, 2024. https://www.nlm.nih.gov/medline/medline_overview.html</Citation></Reference><Reference><Citation>Novartis HPATH, Accessed. August 2, 2024. https://github.com/Novartis/hpath</Citation></Reference><Reference><Citation>Hayamizu TF, Mangan M, Corradi JP, Kadin JA, Ringwald M. Open access the adult mouse anatomical dictionary: a tool for annotating and integrating data. Genome Biol. 2005;6(3):R291&#x2013;8. http://genomebiology.com/2005/6/3/R29</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1088948</ArticleId><ArticleId IdType="pubmed">15774030</ArticleId></ArticleIdList></Reference><Reference><Citation>CDISC. CDISC terminology. Accessed August 2, 2024. https://datascience.cancer.gov/resources/cancer-vocabulary/cdisc-terminology</Citation></Reference><Reference><Citation>MedDRA. Introductory Guide. Accessed August 2, 2024. https://alt.meddra.org/files_acrobat/intguide_24_1_English.pdf</Citation></Reference><Reference><Citation>Reich C, Ostropolets A, Ryan P, et al. OHDSI standardized Vocabularies-a large-scale centralized reference ontology for international data harmonization. J Am Med Assoc. 2024;31(3):583&#x2013;90. 10.1093/jamia/ocad247</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10873827</ArticleId><ArticleId IdType="pubmed">38175665</ArticleId></ArticleIdList></Reference><Reference><Citation>Parry R, van Mulligen E, Semantic, Service. September 8, 2022. Accessed August 2, 2024. https://github.com/mi-erasmusmc/semantic-service</Citation></Reference><Reference><Citation>OHDSI. OHDSI Vocabulary 5.0. November 7, 2022. Accessed August 2, 2024. https://github.com/OHDSI/Vocabulary-v5.0/wiki/General-Structure-and-Use</Citation></Reference><Reference><Citation>UMLS API Technical Documentation. Accessed April 14. 2025. https://documentation.uts.nlm.nih.gov/rest/home.html</Citation></Reference><Reference><Citation>Enhancing. TRANslational SAFEty Assessment through Integrative Knowledge Management. February 28, 2023. Accessed April 14, 2025. https://cordis.europa.eu/project/id/777365/results</Citation></Reference><Reference><Citation>Usagi. https://github.com/OHDSI/Usagi. Accessed August 2, 2024. https://github.com/OHDSI/Usagi</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40870856</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>14</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>14</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2075-4418</ISSN><JournalIssue CitedMedium="Print"><Volume>15</Volume><Issue>16</Issue><PubDate><Year>2025</Year><Month>Aug</Month><Day>11</Day></PubDate></JournalIssue><Title>Diagnostics (Basel, Switzerland)</Title><ISOAbbreviation>Diagnostics (Basel)</ISOAbbreviation></Journal><ArticleTitle>Carbapenem Resistance and ESBL-Producing Enterobacteriaceae in Patients with Urological Infections from 2012 to 2021 in Three Korean Hospitals.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2004</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/diagnostics15162004</ELocationID><Abstract><AbstractText><b>Background:</b> Urinary tract infections (UTIs) remain a leading cause of community- and hospital-onset bacterial infections worldwide. Although many countries have implemented antimicrobial resistance (AMR) surveillance systems, longitudinal multicenter data on key uropathogens in Korea remain limited. <b>Methods:</b> We retrospectively evaluated <i>Escherichia coli</i> and <i>Klebsiella pneumoniae</i> isolates from patients with clinically diagnosed UTIs at three tertiary-care Korean hospitals (2012-2021). Using a harmonized Observational Medical Outcomes Partnership Common Data Model (OMOP CDM), we analyzed antibiotic susceptibility based on Clinical and Laboratory Standards Institute breakpoints. Trends in resistance to key antibiotics (including fluoroquinolones, cephalosporins, and carbapenems) were assessed using the Cochran-Armitage test. <b>Results:</b> From 2012 to 2021, ESBL-producing <i>E. coli</i> and <i>K. pneumoniae</i> increased from 24.1% to 38.2% and 39.2% to 46.4%, respectively. The rates for <i>K. pneumoniae</i> remained stable over the last 6 years, and for <i>E. coli</i>, they remained stable over the last 3 years. Resistance rates for <i>E. coli</i> increased from 44.5% to 60.0% (ciprofloxacin) and from 26.3% to 40.2% (cefotaxime), while carbapenem resistance (ertapenem) remained low, at 0.3% to 1.2%. In contrast, <i>K. pneumoniae</i> exhibited high resistance levels to fluoroquinolones, cephalosporins, and other broad-spectrum antibiotics, with notable increases in resistance to ertapenem, from 3.0% to 18.1%, and imipenem, from 0.4% to 16.8%. This escalation mainly stemmed from the rise in ertapenem (6.6% to 17.0%) and imipenem (0.8% to 14.6%) resistance rates among <i>Klebsiella</i>-ESBL producers. <b>Conclusions:</b> We conclude that in Korea, the proportion of ESBL-producing <i>E. coli</i> and <i>K. pneumoniae</i> increased significantly from 2012 to 2018 and has since remained stable for the last 3 years (<i>E. coli</i>) and 6 years (<i>K. pneumoniae</i>). Although carbapenem resistance in <i>E. coli</i> remains low, <i>K. pneumoniae</i> has experienced a significant rise, primarily attributable to its ESBL-producing strains. These findings underscore the importance of vigilant antimicrobial stewardship and continuous surveillance to guide empirical UTI therapies in Korean clinical practice.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jo</LastName><ForeName>Seon Beom</ForeName><Initials>SB</Initials><Identifier Source="ORCID">0009-0002-7393-2936</Identifier><AffiliationInfo><Affiliation>Department of Urology, Korea University Guro Hospital, Seoul 08308, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahn</LastName><ForeName>Sun Tae</ForeName><Initials>ST</Initials><Identifier Source="ORCID">0000-0003-1233-5951</Identifier><AffiliationInfo><Affiliation>Department of Urology, Korea University Guro Hospital, Seoul 08308, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Joo</LastName><ForeName>Hyung Joon</ForeName><Initials>HJ</Initials><Identifier Source="ORCID">0000-0003-1846-8464</Identifier><AffiliationInfo><Affiliation>Department of Cardiology, Korea University Anam Hospital, Seoul 02841, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jong Wook</ForeName><Initials>JW</Initials><Identifier Source="ORCID">0000-0003-2228-0640</Identifier><AffiliationInfo><Affiliation>Department of Urology, Korea University Guro Hospital, Seoul 08308, Republic of Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oh</LastName><ForeName>Mi Mi</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Department of Urology, Korea University Guro Hospital, Seoul 08308, Republic of Korea.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K2210751</GrantID><Agency>Korea University</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Diagnostics (Basel)</MedlineTA><NlmUniqueID>101658402</NlmUniqueID><ISSNLinking>2075-4418</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antibiotic resistance</Keyword><Keyword MajorTopicYN="N">antibiotic stewardship</Keyword><Keyword MajorTopicYN="N">antimicrobial therapy</Keyword><Keyword MajorTopicYN="N">infection control</Keyword><Keyword MajorTopicYN="N">multidrug-resistant organisms (MDRO)</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>7</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>8</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>30</Day><Hour>4</Hour><Minute>50</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>30</Day><Hour>4</Hour><Minute>49</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>28</Day><Hour>1</Hour><Minute>17</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40870856</ArticleId><ArticleId IdType="pmc">PMC12385634</ArticleId><ArticleId IdType="doi">10.3390/diagnostics15162004</ArticleId><ArticleId IdType="pii">diagnostics15162004</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Medina M., Castillo-Pino E. An Introduction to the Epidemiology and Burden of Urinary Tract Infections. Ther. Adv. Urol. 2019;11:1756287219832172. doi: 10.1177/1756287219832172.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1756287219832172</ArticleId><ArticleId IdType="pmc">PMC6502976</ArticleId><ArticleId IdType="pubmed">31105774</ArticleId></ArticleIdList></Reference><Reference><Citation>Foxman B. Epidemiology of Urinary Tract Infections: Incidence, Morbidity, and Economic Costs. Disease-a-Month. 2003;49:53&#x2013;70. doi: 10.1067/mda.2003.7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1067/mda.2003.7</ArticleId><ArticleId IdType="pubmed">12601337</ArticleId></ArticleIdList></Reference><Reference><Citation>Flores-Mireles A.L., Walker J.N., Caparon M., Hultgren S.J. Urinary Tract Infections: Epidemiology, Mechanisms of Infection and Treatment Options. Nat. Rev. Microbiol. 2015;13:269&#x2013;284. doi: 10.1038/nrmicro3432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrmicro3432</ArticleId><ArticleId IdType="pmc">PMC4457377</ArticleId><ArticleId IdType="pubmed">25853778</ArticleId></ArticleIdList></Reference><Reference><Citation>Pau B.-N., Vicen&#xe7; F., Bel&#xe9;n V., Antonia A., Oscar L., Benito A., Carles P. A Cohort Study of Risk Factors That Influence Empirical Treatment of Patients with Acute Pyelonephritis. Antimicrob. Agents Chemother. 2017;61:e01317-17. doi: 10.1128/aac.01317-17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/aac.01317-17</ArticleId><ArticleId IdType="pmc">PMC5700303</ArticleId><ArticleId IdType="pubmed">28971876</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi J.H. The Meaning and Impact of Appropriate Use of Antibiotics. Infect. Chemother. 2012;44:331&#x2013;337. doi: 10.3947/ic.2012.44.5.331.</Citation><ArticleIdList><ArticleId IdType="doi">10.3947/ic.2012.44.5.331</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta K., Hooton T.M., Naber K.G., Wullt B., Colgan R., Miller L.G., Moran G.J., Nicolle L.E., Raz R., Schaeffer A.J., et al. International Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin. Infect. Dis. 2011;52:e103&#x2013;e120. doi: 10.1093/cid/ciq257.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciq257</ArticleId><ArticleId IdType="pubmed">21292654</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO . Library Cataloguing-in-Publication Data Global Action Plan on Antimicrobial Resistance. WHO; Geneva, Switzerland: 2015.</Citation></Reference><Reference><Citation>Bonkat G., Pickard R., Bartoletti R., Bruy&#xe8;re F., Geerlings S., Wagenlehner F., Wullt B., Pradere B., Veeratterapillay R. Urological Infections.  [(accessed on 8 August 2025)];Arnh. Eur. Assoc. Urol. 2018  Available online:  https://uroweb.org/guidelines/urological-infections.</Citation></Reference><Reference><Citation>Murray C.J., Ikuta K.S., Sharara F., Swetschinski L., Robles Aguilar G., Gray A., Han C., Bisignano C., Rao P., Wool E., et al. Global Burden of Bacterial Antimicrobial Resistance in 2019: A Systematic Analysis. Lancet. 2022;399:629&#x2013;655. doi: 10.1016/S0140-6736(21)02724-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02724-0</ArticleId><ArticleId IdType="pmc">PMC8841637</ArticleId><ArticleId IdType="pubmed">35065702</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghafourian S., Sadeghifard N., Soheili S., Sekawi Z. Extended Spectrum Beta-Lactamases: Definition, Classification and Epidemiology. Curr. Issues Mol. Biol. 2015;17:11&#x2013;22. doi: 10.21775/cimb.017.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.21775/cimb.017.011</ArticleId><ArticleId IdType="pubmed">24821872</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradford P.A. Extended-Spectrum &#x3b2;-Lactamases in the 21st Century: Characterization, Epidemiology, and Detection of This Important Resistance Threat. Clin. Microbiol. Rev. 2001;14:933&#x2013;951. doi: 10.1128/CMR.14.4.933-951.2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.14.4.933-951.2001</ArticleId><ArticleId IdType="pmc">PMC89009</ArticleId><ArticleId IdType="pubmed">11585791</ArticleId></ArticleIdList></Reference><Reference><Citation>Paterson D.L., Bonomo R.A. Extended-Spectrum &#x3b2;-Lactamases: A Clinical Update. Clin. Microbiol. Rev. 2005;18:657&#x2013;686. doi: 10.1128/CMR.18.4.657-686.2005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.18.4.657-686.2005</ArticleId><ArticleId IdType="pmc">PMC1265908</ArticleId><ArticleId IdType="pubmed">16223952</ArticleId></ArticleIdList></Reference><Reference><Citation>Gniadkowski M. Evolution and Epidemiology of Extended-Spectrum b-Lactamases (ESBLs) and ESBL-Producing Microorganisms. Clin. Microbiol. Infect. 2001;7:597&#x2013;608. doi: 10.1046/j.1198-743x.2001.00330.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1198-743x.2001.00330.x</ArticleId><ArticleId IdType="pubmed">11737084</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim J.H., Sun H.Y., Kim T.H., Shim S.R., Doo S.W., Yang W.J., Lee E.J., Song Y.S. Prevalence of Antibiotic Susceptibility and Resistance of Escherichia Coli in Acute Uncomplicated Cystitis in Korea Systematic Review and Meta-Analysis. Medicine. 2016;95:e4663. doi: 10.1097/MD.0000000000004663.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MD.0000000000004663</ArticleId><ArticleId IdType="pmc">PMC5023881</ArticleId><ArticleId IdType="pubmed">27603359</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang S., Lee S.Y., Seo S.H., Lee J., Moon D.C., Yoo J.S., Choi Y.H. Antimicrobial Resistance of Major Clinical Pathogens Isolated from General Hospitals in Korea: Results from the 2nd Phase (2020&#x2013;2022) Kor-GLASS. Public Health Wkly. Rep. 2024;17:1034&#x2013;1054. doi: 10.56786/PHWR.2024.17.24.2.</Citation><ArticleIdList><ArticleId IdType="doi">10.56786/PHWR.2024.17.24.2</ArticleId></ArticleIdList></Reference><Reference><Citation>Li X., Chen S., Lu Y., Shen W., Wang W., Gao J., Gao J., Shao P., Zhou Z. Molecular Epidemiology and Genetic Dynamics of Carbapenem-Resistant Hypervirulent Klebsiella Pneumoniae in China. Front. Cell Infect. Microbiol. 2025;15:1529929. doi: 10.3389/fcimb.2025.1529929.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcimb.2025.1529929</ArticleId><ArticleId IdType="pmc">PMC11868059</ArticleId><ArticleId IdType="pubmed">40028179</ArticleId></ArticleIdList></Reference><Reference><Citation>Bae M.H., Kim M.S., Kim T.S., Kim S., Yong D., Ha G.Y., Ryoo N.H., Uh Y., Shin J.H., Lee H.S., et al. Changing Epidemiology of Pathogenic Bacteria Over the Past 20 Years in Korea. J. Korean Med. Sci. 2023;38:e73. doi: 10.3346/jkms.2023.38.e73.</Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2023.38.e73</ArticleId><ArticleId IdType="pmc">PMC10010907</ArticleId><ArticleId IdType="pubmed">36918027</ArticleId></ArticleIdList></Reference><Reference><Citation>van Duin D., Doi Y. The Global Epidemiology of Carbapenemase-Producing Enterobacteriaceae. Virulence. 2017;8:460&#x2013;469. doi: 10.1080/21505594.2016.1222343.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21505594.2016.1222343</ArticleId><ArticleId IdType="pmc">PMC5477705</ArticleId><ArticleId IdType="pubmed">27593176</ArticleId></ArticleIdList></Reference><Reference><Citation>European Centre for Disease Prevention and Control (ECDC)   Antimicrobial Resistance Surveillance in Europe, 2022&#x2013;2020 Data. ECDC; Solna, Sweden: 2023.  [(accessed on 8 August 2025)].  Available online:  https://www.ecdc.europa.eu/en/publications-data/antimicrobial-resistance-surveillance-europe-2022-2020-data.</Citation></Reference><Reference><Citation>Antimicrobial Resistance Surveillance in Europe 2023: 2021 Data. Publications Office of the European Union; Luxembourg: 2023.</Citation></Reference><Reference><Citation>Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report 2022. World Health Organization; Geneva, Switzerland: 2022.</Citation></Reference><Reference><Citation>Tamma P.D., Heil E.L., Justo J.A., Mathers A.J., Satlin M.J., Bonomo R.A. Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. Clin. Infect. Dis. 2024:ciae403. doi: 10.1093/cid/ciae403.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciae403</ArticleId><ArticleId IdType="pubmed">39108079</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathers A.J., Peirano G., Pitout J.D.D. The Role of Epidemic Resistance Plasmids and International High- Risk Clones in the Spread of Multidrug-Resistant Enterobacteriaceae. Clin. Microbiol. Rev. 2015;28:565&#x2013;591. doi: 10.1128/CMR.00116-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.00116-14</ArticleId><ArticleId IdType="pmc">PMC4405625</ArticleId><ArticleId IdType="pubmed">25926236</ArticleId></ArticleIdList></Reference><Reference><Citation>Codjoe F.S., Donkor E.S. Carbapenem Resistance: A Review. Med. Sci. 2017;6:1. doi: 10.3390/medsci6010001.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/medsci6010001</ArticleId><ArticleId IdType="pmc">PMC5872158</ArticleId><ArticleId IdType="pubmed">29267233</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung Wook K., Song Mee B., Sung Young L., Jung Sik Y., Soo Young C. Trends of Antimicrobial Resistance Rates of Major Clinical Pathogens Isolated from General Hospitals in Korea in 2016&#x2013;2019: Results from Kor-GLASS. Public Health Wkly. Rep. 2021;14:2007&#x2013;2024.</Citation></Reference><Reference><Citation>European Association of Urology (EAU) EAU Guidelines on Urological Infections. EAU; Arnhem, The Netherlands: 2023.</Citation></Reference><Reference><Citation>Yu S.H., Jung S.I., Lee S.J., Oh M.M., Choi J.B., Choi C., II, Kim Y.J., Park D.J., Bae S., Min S.K. Nationwide Surveillance of Antimicrobial Resistance for Uncomplicated Cystitis in 2023: Conducted by the Korean Association of Urogenital Tract Infection and Inflammation. Investig. Clin. Urol. 2025;66:161&#x2013;171. doi: 10.4111/icu.20240302.</Citation><ArticleIdList><ArticleId IdType="doi">10.4111/icu.20240302</ArticleId><ArticleId IdType="pmc">PMC11885923</ArticleId><ArticleId IdType="pubmed">40047130</ArticleId></ArticleIdList></Reference><Reference><Citation>Korea Disease Control and Prevention Agency. Korean Society for Antimicrobial Therapy . Guidelines for the Antibiotic Use for Carbapenem-Resistant Enterobacterales (CRE) Infections. Korea Disease Control and Prevention Agency; Cheongju, Republic of Korea: 2024.</Citation></Reference><Reference><Citation>Ahn S.T., Han D.E., Lee D.H., Kim J.W., Park H.S., Moon D.G., Oh M.M. Single-Dose Amikacin plus 7 Days of Amoxicillin/ Clavulanate to Treat Acute Cystitis Caused by Extended-Spectrum Beta-Lactamase-Producing Escherichia Coli: A Retrospective Cohort Study. Investig. Clin. Urol. 2021;62:310&#x2013;316. doi: 10.4111/icu.20200240.</Citation><ArticleIdList><ArticleId IdType="doi">10.4111/icu.20200240</ArticleId><ArticleId IdType="pmc">PMC8100019</ArticleId><ArticleId IdType="pubmed">33943052</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H.Y., Ryu S., Jeong G.Y., Kang K.M., Yoo H. Introduction to the Antimicrobial Stewardship Program: Its Current Status and Policy Direction in the Republic of Korea. Public Health Wkly. Rep. 2022;15:2971&#x2013;3003. doi: 10.56786/phwr.2022.15.50.2971.</Citation><ArticleIdList><ArticleId IdType="doi">10.56786/phwr.2022.15.50.2971</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim Y.A., Park Y.S., Youk T., Lee H., Lee K. Changes in Antimicrobial Usage Patterns in Korea: 12-Year Analysis Based on Database of the National Health Insurance Service-National Sample Cohort. Sci. Rep. 2018;8:12210. doi: 10.1038/s41598-018-30673-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-30673-6</ArticleId><ArticleId IdType="pmc">PMC6093866</ArticleId><ArticleId IdType="pubmed">30111796</ArticleId></ArticleIdList></Reference><Reference><Citation>Shin D.H., Kang M., Song K.H., Jung J., Kim E.S., Kim H. Bin A Call for Antimicrobial Stewardship in Patients with COVID-19: A Nationwide Cohort Study in Korea. Clin. Microbiol. Infect. 2021;27:653&#x2013;655. doi: 10.1016/j.cmi.2020.10.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.10.024</ArticleId><ArticleId IdType="pmc">PMC7604125</ArticleId><ArticleId IdType="pubmed">33137513</ArticleId></ArticleIdList></Reference><Reference><Citation>Bari&#x161;i&#x107; V., Kova&#x10d;evi&#x107; T., Travar M., Goli&#x107; Jeli&#x107; A., Kova&#x10d;evi&#x107; P., Milakovi&#x107; D., &#x160;krbi&#x107; R. A Retrospective Study of the Impact of the COVID-19 Pandemic on the Utilization and Quality of Antibiotic Use in a Tertiary Care Teaching Hospital in Low-Resource Settings. Antibiotics. 2025;14:535. doi: 10.3390/antibiotics14060535.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antibiotics14060535</ArticleId><ArticleId IdType="pmc">PMC12189705</ArticleId><ArticleId IdType="pubmed">40558125</ArticleId></ArticleIdList></Reference><Reference><Citation>Farzana R., Harbarth S.J., Yu L.M., Carretto E., Moore C.E., Feasey N.A., Gales A.C., Galal U., Ergonul O., Yong D., et al. The Impact of the COVID-19 Pandemic on Antimicrobial Usage: An International Patient-Level Cohort Study. JAC Antimicrob. Resist. 2025;7:dlaf037. doi: 10.1093/jacamr/dlaf037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jacamr/dlaf037</ArticleId><ArticleId IdType="pmc">PMC11945301</ArticleId><ArticleId IdType="pubmed">40151230</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40873141</PMID><DateCompleted><Year>2025</Year><Month>08</Month><Day>28</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1976-2437</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>9</Issue><PubDate><Year>2025</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Yonsei medical journal</Title><ISOAbbreviation>Yonsei Med J</ISOAbbreviation></Journal><ArticleTitle>Real-World Effectiveness of Omalizumab Treatment in Adult Asthma Patients.</ArticleTitle><Pagination><StartPage>545</StartPage><EndPage>555</EndPage><MedlinePgn>545-555</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3349/ymj.2024.0320</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Omalizumab improves clinical outcomes for patients with severe asthma (SA), but its long-term effectiveness and potential biomarkers for predicting patient response require further investigation. This study aimed to evaluate the real-world effectiveness of omalizumab in treating SA and to identify potential biomarkers for predicting a favorable treatment response.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Clinical outcomes were compared between asthma patients receiving omalizumab (omalizumab group) and those on inhaled corticosteroid with long-acting beta-agonist (ICS-LABA) alone (ICS-LABA group). Propensity score matching and Cox proportional hazards model were used to calculate hazard ratios (HRs). Study outcomes included severe asthma exacerbation (SAE), incompletely controlled asthma, intravenous (IV) corticosteroid use, and asthma-related hospitalization. Incompletely controlled asthma was defined by blood eosinophil counts &#x2265;150 cells/&#xb5;L, fractional exhaled nitric oxide (FeNO) &#x2265;25 ppb, forced expiratory volume in one second (FEV1%) &lt;80%, or SAE occurrence.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The omalizumab group had significantly lower risks of SAE (HR 0.17, <i>p</i>=0.03), incompletely controlled asthma (HR 0.56, <i>p</i>=0.04), IV corticosteroid treatment (HR 0.38, <i>p</i>=0.02), and asthma-related hospitalization (HR 0.27, <i>p</i>=0.05). Blood eosinophil count stayed lower in the omalizumab group. FEV1% was higher with the omalizumab group, while blood neutrophil count, FeNO, and serum total IgE showed no differences. Furthermore, subgroup analysis showed patients with treatment-favorable response (&gt;50% reduction in systemic corticosteroid dose) exhibited decreased blood neutrophil counts but increased FEV1% and serum total IgE levels compared with the treatment-unfavorable group.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Omalizumab treatment effectively reduces SAE and improves lung function and asthma control. Blood neutrophil counts and serum total IgE may be potential biomarkers for predicting favorable responses to omalizumab treatment.</AbstractText><CopyrightInformation>&#xa9; Copyright: Yonsei University College of Medicine 2025.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Jang</LastName><ForeName>Jae-Hyuk</ForeName><Initials>JH</Initials><Identifier Source="ORCID">0000-0002-4225-7117</Identifier><AffiliationInfo><Affiliation>Department of Allergy &amp; Clinical Immunology, Ajou University School of Medicine, Suwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Park</LastName><ForeName>ChulHyoung</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-0531-9144</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Chungsoo</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0003-1802-1777</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Section of Cardiovascular Medicine, Yale University School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Outcomes Research and Evaluation, Yale-New Haven Hospital, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Youngsoo</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0001-8918-9353</Identifier><AffiliationInfo><Affiliation>Department of Allergy &amp; Clinical Immunology, Ajou University School of Medicine, Suwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Eunyoung</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-9440-9119</Identifier><AffiliationInfo><Affiliation>Department of Neurology, McGovern Medical School, University of Texas Health Science Center at Houston, Houston, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Rae Woong</ForeName><Initials>RW</Initials><Identifier Source="ORCID">0000-0003-4989-3287</Identifier><AffiliationInfo><Affiliation>Department of Biomedical Informatics, Ajou University School of Medicine, Suwon, Korea.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Sciences, Ajou University Graduate School of Medicine, Suwon, Korea. veritas@ajou.ac.kr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Hae-Sim</ForeName><Initials>HS</Initials><Identifier Source="ORCID">0000-0003-2614-0303</Identifier><AffiliationInfo><Affiliation>Department of Allergy &amp; Clinical Immunology, Ajou University School of Medicine, Suwon, Korea. hspark@ajou.ac.kr.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>HR16C0001</GrantID><Agency>Korea Health Industry Development Institute</Agency><Country>Republic of Korea</Country></Grant><Grant><GrantID>HG22C0024</GrantID><Acronym>MOHW</Acronym><Agency>Ministry of Health &amp; Welfare</Agency><Country>Korea</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>Yonsei Med J</MedlineTA><NlmUniqueID>0414003</NlmUniqueID><ISSNLinking>0513-5796</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>2P471X1Z11</RegistryNumber><NameOfSubstance UI="D000069444">Omalizumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018927">Anti-Asthmatic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000305">Adrenal Cortex Hormones</NameOfSubstance></Chemical><Chemical><RegistryNumber>37341-29-0</RegistryNumber><NameOfSubstance UI="D007073">Immunoglobulin E</NameOfSubstance></Chemical><Chemical><RegistryNumber>31C4KY9ESH</RegistryNumber><NameOfSubstance UI="D009569">Nitric Oxide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069444" MajorTopicYN="Y">Omalizumab</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001249" MajorTopicYN="Y">Asthma</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018927" MajorTopicYN="Y">Anti-Asthmatic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000305" MajorTopicYN="N">Adrenal Cortex Hormones</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005541" MajorTopicYN="N">Forced Expiratory Volume</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004804" MajorTopicYN="N">Eosinophils</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007073" MajorTopicYN="N">Immunoglobulin E</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009569" MajorTopicYN="N">Nitric Oxide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Asthma</Keyword><Keyword MajorTopicYN="N">IgE</Keyword><Keyword MajorTopicYN="N">neutrophils</Keyword><Keyword MajorTopicYN="N">omalizumab</Keyword></KeywordList><CoiStatement>The authors have no potential conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>3</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>3</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>1</Day><Hour>4</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>1</Day><Hour>4</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>28</Day><Hour>2</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40873141</ArticleId><ArticleId IdType="pmc">PMC12394757</ArticleId><ArticleId IdType="doi">10.3349/ymj.2024.0320</ArticleId><ArticleId IdType="pii">66.545</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wang Z, Li Y, Gao Y, Fu Y, Lin J, Lei X, et al. Global, regional, and national burden of asthma and its attributable risk factors from 1990 to 2019: a systematic analysis for the global burden of disease study 2019. Respir Res. 2023;24:169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10288698</ArticleId><ArticleId IdType="pubmed">37353829</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen S, von B&#xfc;low A, Sandin P, Ernstsson O, Janson C, Lehtim&#xe4;ki L, et al. Prevalence and management of severe asthma in the Nordic countries: findings from the NORDSTAR cohort. ERJ Open Res. 2023;9:00687&#x2013;02022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10068510</ArticleId><ArticleId IdType="pubmed">37020835</ArticleId></ArticleIdList></Reference><Reference><Citation>Chervinsky P, Casale T, Townley R, Tripathy I, Hedgecock S, Fowler-Taylor A, et al. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol. 2003;91:160&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pubmed">12952110</ArticleId></ArticleIdList></Reference><Reference><Citation>Braunstahl GJ, Chlumsk&#xfd; J, Peachey G, Chen CW. Reduction in oral corticosteroid use in patients receiving omalizumab for allergic asthma in the real-world setting. Allergy Asthma Clin Immunol. 2013;9:47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3879326</ArticleId><ArticleId IdType="pubmed">24305549</ArticleId></ArticleIdList></Reference><Reference><Citation>Casale TB, Luskin AT, Busse W, Zeiger RS, Trzaskoma B, Yang M, et al. Omalizumab effectiveness by biomarker status in patients with asthma: evidence from PROSPERO, a prospective real-world study. J Allergy Clin Immunol Pract. 2019;7:156&#x2013;164.e1.</Citation><ArticleIdList><ArticleId IdType="pubmed">29800752</ArticleId></ArticleIdList></Reference><Reference><Citation>Canonica GW, Rottoli P, Bucca C, Zappa MC, Michetti G, Macciocchi B, et al. Improvement of patient-reported outcomes in severe allergic asthma by omalizumab treatment: the real life observational PROXIMA study. World Allergy Organ J. 2018;11:33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6214174</ArticleId><ArticleId IdType="pubmed">30410639</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee JH, Lee HY, Jung CG, Ban GY, Shin YS, Ye YM, et al. Therapeutic effect of omalizumab in severe asthma: a real-world study in Korea. Allergy Asthma Immunol Res. 2018;10:121&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5809760</ArticleId><ArticleId IdType="pubmed">29411552</ArticleId></ArticleIdList></Reference><Reference><Citation>Bousquet J, Humbert M, Gibson PG, Kostikas K, Jaumont X, Pfister P, et al. Real-world effectiveness of omalizumab in severe allergic asthma: a meta-analysis of observational studies. J Allergy Clin Immunol Pract. 2021;9:2702&#x2013;2714.</Citation><ArticleIdList><ArticleId IdType="pubmed">33486142</ArticleId></ArticleIdList></Reference><Reference><Citation>MacDonald KM, Kavati A, Ortiz B, Alhossan A, Lee CS, Abraham I. Short- and long-term real-world effectiveness of omalizumab in severe allergic asthma: systematic review of 42 studies published 2008-2018. Expert Rev Clin Immunol. 2019;15:553&#x2013;569.</Citation><ArticleIdList><ArticleId IdType="pubmed">30763137</ArticleId></ArticleIdList></Reference><Reference><Citation>Austin PC. Optimal caliper widths for propensity-score matching when estimating differences in means and differences in proportions in observational studies. Pharm Stat. 2011;10:150&#x2013;161.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3120982</ArticleId><ArticleId IdType="pubmed">20925139</ArticleId></ArticleIdList></Reference><Reference><Citation>Suchard MA, Simpson SE, Zorych I, Ryan P, Madigan D. Massive parallelization of serial inference algorithms for a complex generalized linear model. ACM Trans Model Comput Simul. 2013;23:10.1145/2414416.2414791</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4201181</ArticleId><ArticleId IdType="pubmed">25328363</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuemie MJ, Cepeda MS, Suchard MA, Yang J, Tian Y, Schuler A, et al. How confident are we about observational findings in healthcare: a benchmark study. Harv Data Sci Rev. 2020;2:10.1162/99608f92.147cc28e</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7755157</ArticleId><ArticleId IdType="pubmed">33367288</ArticleId></ArticleIdList></Reference><Reference><Citation>Kavati A, Zhdanava M, Ortiz B, Lecocq J, Schiffman B, Pilon D, et al. Retrospective study on the association of biomarkers with realworld outcomes of omalizumab-treated patients with allergic asthma. Clin Ther. 2019;41:1956&#x2013;1971.</Citation><ArticleIdList><ArticleId IdType="pubmed">31563391</ArticleId></ArticleIdList></Reference><Reference><Citation>Busse WW. Anti-immunoglobulin E (omalizumab) therapy in allergic asthma. Am J Respir Crit Care Med. 2001;164(8 Pt 2):S12&#x2013;S17.</Citation><ArticleIdList><ArticleId IdType="pubmed">11704612</ArticleId></ArticleIdList></Reference><Reference><Citation>Humbert M, Bourdin A, Taill&#xe9; C, Kamar D, Thonnelier C, Lajoinie A, et al. Real-life omalizumab exposure and discontinuation in a large nationwide population-based study of paediatric and adult asthma patients. Eur Respir J. 2022;60:2103130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9647070</ArticleId><ArticleId IdType="pubmed">35618272</ArticleId></ArticleIdList></Reference><Reference><Citation>Ledford D, Busse W, Trzaskoma B, Omachi TA, Ros&#xe9;n K, Chipps BE, et al. A randomized multicenter study evaluating Xolair persistence of response after long-term therapy. J Allergy Clin Immunol. 2017;140:162&#x2013;169.e2.</Citation><ArticleIdList><ArticleId IdType="pubmed">27826098</ArticleId></ArticleIdList></Reference><Reference><Citation>Sullivan PW, Li Q, Bilir SP, Dang J, Kavati A, Yang M, et al. Cost-effectiveness of omalizumab for the treatment of moderate-to-severe uncontrolled allergic asthma in the United States. Curr Med Res Opin. 2020;36:23&#x2013;32.</Citation><ArticleIdList><ArticleId IdType="pubmed">31491337</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas D, McDonald VM, Pavord ID, Gibson PG. Asthma remission: what is it and how can it be achieved? Eur Respir J. 2022;60:2102583.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9630609</ArticleId><ArticleId IdType="pubmed">35361633</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavord I, Gardiner F, Heaney LG, Domingo C, Price RG, Pullan A, et al. Remission outcomes in severe eosinophilic asthma with mepolizumab therapy: analysis of the REDES study. Front Immunol. 2023;14:1150162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10131245</ArticleId><ArticleId IdType="pubmed">37122713</ArticleId></ArticleIdList></Reference><Reference><Citation>Oishi K, Hamada K, Murata Y, Matsuda K, Ohata S, Yamaji Y, et al. A real-world study of achievement rate and predictive factors of clinical and deep remission to biologics in patients with severe asthma. J Clin Med. 2023;12:2900.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10142972</ArticleId><ArticleId IdType="pubmed">37109237</ArticleId></ArticleIdList></Reference><Reference><Citation>Almqvist L, R&#xf6;nmark E, Stridsman C, Backman H, Lindberg A, Lundb&#xe4;ck B, et al. Remission of adult-onset asthma is rare: a 15-year follow-up study. ERJ Open Res. 2020;6:00620&#x2013;02020.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7680910</ArticleId><ArticleId IdType="pubmed">33263024</ArticleId></ArticleIdList></Reference><Reference><Citation>Menzies-Gow A, Hoyte FL, Price DB, Cohen D, Barker P, Kreindler J, et al. Clinical remission in severe asthma: a pooled post hoc analysis of the patient journey with benralizumab. Adv Ther. 2022;39:2065&#x2013;2084.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9056458</ArticleId><ArticleId IdType="pubmed">35287231</ArticleId></ArticleIdList></Reference><Reference><Citation>Maglio A, Vitale C, Pelaia C, D&#x2019;Amato M, Ciampo L, Sferra E, et al. Severe asthma remissions induced by biologics targeting IL5/IL5r: results from a multicenter real-life study. Int J Mol Sci. 2023;24:2455.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9916787</ArticleId><ArticleId IdType="pubmed">36768778</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas D, McDonald VM, Stevens S, Harvey ES, Baraket M, Bardin P, et al. Biologics (mepolizumab and omalizumab) induced remission in severe asthma patients. Allergy. 2024;79:384&#x2013;392.</Citation><ArticleIdList><ArticleId IdType="pubmed">37632144</ArticleId></ArticleIdList></Reference><Reference><Citation>Mormile M, Mormile I, Fuschillo S, Rossi FW, Lamagna L, Ambrosino P, et al. Eosinophilic airway diseases: from pathophysiological mechanisms to clinical practice. Int J Mol Sci. 2023;24:7254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10138384</ArticleId><ArticleId IdType="pubmed">37108417</ArticleId></ArticleIdList></Reference><Reference><Citation>Pham DD, Lee JH, Kim JY, An J, Song WJ, Kwon HS, et al. Different impacts of blood and sputum eosinophil counts on lung function and clinical outcomes in asthma: findings from the COREA cohort. Lung. 2022;200:697&#x2013;706.</Citation><ArticleIdList><ArticleId IdType="pubmed">36264333</ArticleId></ArticleIdList></Reference><Reference><Citation>Yancey SW, Keene ON, Albers FC, Ortega H, Bates S, Bleecker ER, et al. Biomarkers for severe eosinophilic asthma. J Allergy Clin Immunol. 2017;140:1509&#x2013;1518.</Citation><ArticleIdList><ArticleId IdType="pubmed">29221581</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojo-Tolosa S, Gonz&#xe1;lez-Guti&#xe9;rrez MV, S&#xe1;nchez-Mart&#xed;nez JA, Jim&#xe9;nez-G&#xe1;lvez G, Pineda-Lancheros LE, G&#xe1;lvez-Navas JM, et al. Impact of omalizumab in patients with severe uncontrolled asthma and possible predictive biomarkers of response: a real-life study. Pharmaceutics. 2023;15:523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9962091</ArticleId><ArticleId IdType="pubmed">36839845</ArticleId></ArticleIdList></Reference><Reference><Citation>Soremekun S, Heaney LG, Skinner D, Bulathsinhala L, Carter V, Chaudhry I, et al. Asthma exacerbations are associated with a decline in lung function: a longitudinal population-based study. Thorax. 2023;78:643&#x2013;652.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10313996</ArticleId><ArticleId IdType="pubmed">35922128</ArticleId></ArticleIdList></Reference><Reference><Citation>Fahy JV, Kim KW, Liu J, Boushey HA. Prominent neutrophilic inflammation in sputum from subjects with asthma exacerbation. J Allergy Clin Immunol. 1995;95:843&#x2013;852.</Citation><ArticleIdList><ArticleId IdType="pubmed">7722165</ArticleId></ArticleIdList></Reference><Reference><Citation>Varricchi G, Modestino L, Poto R, Cristinziano L, Gentile L, Postiglione L, et al. Neutrophil extracellular traps and neutrophil-derived mediators as possible biomarkers in bronchial asthma. Clin Exp Med. 2022;22:285&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9110438</ArticleId><ArticleId IdType="pubmed">34342773</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee Y, Park Y, Kim C, Lee E, Lee HY, Woo SD, et al. Longitudinal outcomes of severe asthma: real-world evidence of multidimensional analyses. J Allergy Clin Immunol Pract. 2021;9:1285&#x2013;1294.e6.</Citation><ArticleIdList><ArticleId IdType="pubmed">33049391</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim SH, Jung HW, Kim M, Moon JY, Ban GY, Kim SJ, et al. Ceramide/sphingosine-1-phosphate imbalance is associated with distinct inflammatory phenotypes of uncontrolled asthma. Allergy. 2020;75:1991&#x2013;2004.</Citation><ArticleIdList><ArticleId IdType="pubmed">32072647</ArticleId></ArticleIdList></Reference><Reference><Citation>Lowe PJ, Georgiou P, Canvin J. Revision of omalizumab dosing table for dosing every 4 instead of 2 weeks for specific ranges of bodyweight and baseline IgE. Regul Toxicol Pharmacol. 2015;71:68&#x2013;77.</Citation><ArticleIdList><ArticleId IdType="pubmed">25497995</ArticleId></ArticleIdList></Reference><Reference><Citation>Menzella F, Just J, Sauerbeck IS, Mailaender C, Saccheri F, Thonnelier C, et al. Omalizumab for the treatment of patients with severe allergic asthma with immunoglobulin E levels above &gt;1500 IU/mL. World Allergy Organ J. 2023;16:100787.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10276275</ArticleId><ArticleId IdType="pubmed">37332525</ArticleId></ArticleIdList></Reference><Reference><Citation>Mora J, Riggs EK, Fu J, MacGlashan DW, Jr, Fox SA, Yu B, et al. Expression of the high affinity IgE receptor by neutrophils of individuals with allergic asthma is both minimal and insensitive to regulation by serum IgE. Clin Immunol. 2009;132:132&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2739590</ArticleId><ArticleId IdType="pubmed">19359220</ArticleId></ArticleIdList></Reference><Reference><Citation>Walsh LJ, Sullivan A, Ward C, Fanning LJ, O&#x2019;Byrne PM, MacSharry JA, et al. Impact of airway virus in severe asthmatic patients: a pilot study. Allergy Asthma Immunol Res. 2023;15:406&#x2013;411.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10186128</ArticleId><ArticleId IdType="pubmed">37075793</ArticleId></ArticleIdList></Reference><Reference><Citation>Esquivel A, Busse WW, Calatroni A, Togias AG, Grindle KG, Bochkov YA, et al. Effects of omalizumab on rhinovirus infections, illnesses, and exacerbations of asthma. Am J Respir Crit Care Med. 2017;196:985&#x2013;992.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5649984</ArticleId><ArticleId IdType="pubmed">28608756</ArticleId></ArticleIdList></Reference><Reference><Citation>Korn S, Haasler I, Fliedner F, Becher G, Strohner P, Staatz A, et al. Monitoring free serum IgE in severe asthma patients treated with omalizumab. Respir Med. 2012;106:1494&#x2013;1500.</Citation><ArticleIdList><ArticleId IdType="pubmed">22884459</ArticleId></ArticleIdList></Reference><Reference><Citation>Li B, Huang M, Huang S, Zeng X, Yuan Y, Peng X, et al. Prediction of clinical response to omalizumab in moderate-to-severe asthma patients using the change in total serum IgE level. J Thorac Dis. 2020;12:7097&#x2013;7105.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7797858</ArticleId><ArticleId IdType="pubmed">33447398</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40874398</PMID><DateRevised><Year>2025</Year><Month>08</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1463-1326</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Aug</Month><Day>28</Day></PubDate></JournalIssue><Title>Diabetes, obesity &amp; metabolism</Title><ISOAbbreviation>Diabetes Obes Metab</ISOAbbreviation></Journal><ArticleTitle>Cardiovascular and kidney outcomes of GLP-1 receptor agonists in adults with obesity: A target trial emulation study.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1111/dom.70054</ELocationID><Abstract><AbstractText Label="AIMS" NlmCategory="OBJECTIVE">Glucagon-like peptide-1 receptor agonists (GLP-1RAs) provide cardiovascular and renal benefits in type 2 diabetes, but their real-world effects in individuals with obesity without diabetes are unclear. This study aimed to evaluate the cardiovascular and kidney outcomes of GLP-1RAs versus other anti-obesity medications (AOMs) in adults with obesity.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">This target trial emulation used TriNetX electronic health records (July 2021-May 2025) to identify adults with obesity and no diabetes history who initiated GLP-1RAs (liraglutide, semaglutide, or tirzepatide) or other AOMs. Outcomes included major adverse cardiovascular events (MACE), major adverse kidney events (MAKE), all-cause mortality, mental health conditions, and safety outcomes. Propensity score matching (1:1) balanced baseline characteristics; Cox models estimated hazard ratios (HRs) with 95% confidence intervals (CIs).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The study included 140&#x2009;169 matched pairs of GLP-1RA and AOM initiators. Mean follow-up was 392&#x2009;days for GLP-1RA users and 564&#x2009;days for AOM users. Compared to AOMs, GLP-1RA use was associated with lower risks of MACE (HR, 0.76; 95% CI, 0.72-0.81), MAKE (HR, 0.64; 95% CI, 0.55-0.74), and all-cause mortality (HR, 0.49; 95% CI, 0.42-0.57). Mental health outcomes also improved, with reduced risks of depression (HR, 0.63), suicidal ideation/attempt (HR, 0.42), and substance use disorder (HR, 0.58). GLP-1RAs were not associated with increased risks of acute pancreatitis (HR, 1.17), hypoglycemia (HR, 1.08), or gastrointestinal symptoms (HR, 0.99).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Among adults with obesity but without diabetes, GLP-1RA use was associated with reduced cardiovascular, kidney, mortality, and mental health risks compared to other AOMs.</AbstractText><CopyrightInformation>&#xa9; 2025 The Author(s). Diabetes, Obesity and Metabolism published by John Wiley &amp; Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Huilin</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-5814-6657</Identifier><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Yiwen</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Graduate Group in Applied Mathematics and Computational Science, School of Arts and Sciences, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Bingyu</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Graduate Group in Applied Mathematics and Computational Science, School of Arts and Sciences, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Ting</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Dazheng</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Jiajie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Pfizer Inc., New York City, New York, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asch</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Wharton School, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of General Internal Medicine, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Graduate Group in Applied Mathematics and Computational Science, School of Arts and Sciences, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Penn Medicine Center for Evidence-Based Practice (CEP), University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Penn Institute for Biomedical Informatics (IBI), University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01AG073435</GrantID><Acronym>CL</Acronym><Agency>CLC NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01DK128237</GrantID><Acronym>CL</Acronym><Agency>CLC NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01LM013519</GrantID><Acronym>CL</Acronym><Agency>CLC NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21AI167418</GrantID><Acronym>CL</Acronym><Agency>CLC NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21EY034179</GrantID><Acronym>CL</Acronym><Agency>CLC NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56AG074604</GrantID><Acronym>CL</Acronym><Agency>CLC NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>RF1AG077820</GrantID><Acronym>CL</Acronym><Agency>CLC NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01TR003709</GrantID><Acronym>CL</Acronym><Agency>CLC NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U24MH136069</GrantID><Acronym>CL</Acronym><Agency>CLC NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Diabetes Obes Metab</MedlineTA><NlmUniqueID>100883645</NlmUniqueID><ISSNLinking>1462-8902</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">GLP&#x2010;1 receptor agonists</Keyword><Keyword MajorTopicYN="N">anti&#x2010;obesity medication</Keyword><Keyword MajorTopicYN="N">major adverse cardiovascular events</Keyword><Keyword MajorTopicYN="N">major adverse kidney events</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>8</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>6</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>8</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>8</Month><Day>28</Day><Hour>8</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>8</Month><Day>28</Day><Hour>6</Hour><Minute>7</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40874398</ArticleId><ArticleId IdType="doi">10.1111/dom.70054</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>World Health Organization. Obesity and overweight. 2025 Accessed February 21, 2025. https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight</Citation></Reference><Reference><Citation>Powell&#x2010;Wiley TM, Poirier P, Burke LE, et al. Obesity and cardiovascular disease: a scientific Statement from the American Heart Association. Circulation. 2021;143(21):e984&#x2010;e1010. doi:10.1161/CIR.0000000000000973</Citation></Reference><Reference><Citation>Field AE, Coakley EH, Must A, et al. Impact of overweight on the risk of developing common chronic diseases during a 10&#x2010;year period. Arch Intern Med. 2001;161(13):1581&#x2010;1586. doi:10.1001/archinte.161.13.1581</Citation></Reference><Reference><Citation>Kivim&#xe4;ki M, Strandberg T, Pentti J, et al. Body&#x2010;mass index and risk of obesity&#x2010;related complex multimorbidity: an observational multicohort study. Lancet Diabetes Endocrinol. 2022;10(4):253&#x2010;263. doi:10.1016/S2213&#x2010;8587(22)00033&#x2010;X</Citation></Reference><Reference><Citation>Wilding JPH, Batterham RL, Calanna S, et al. Once&#x2010;weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989&#x2010;1002. doi:10.1056/NEJMoa2032183</Citation></Reference><Reference><Citation>Jastreboff AM, le Roux CW, Stefanski A, et al. Tirzepatide for obesity treatment and diabetes prevention. N Engl J Med. 2025;392(10):958&#x2010;971. doi:10.1056/NEJMoa2410819</Citation></Reference><Reference><Citation>Garvey WT, Frias JP, Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT&#x2010;2): a double&#x2010;blind, randomised, multicentre, placebo&#x2010;controlled, phase 3 trial. Lancet. 2023;402(10402):613&#x2010;626. doi:10.1016/S0140&#x2010;6736(23)01200&#x2010;X</Citation></Reference><Reference><Citation>Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834&#x2010;1844. doi:10.1056/NEJMoa1607141</Citation></Reference><Reference><Citation>Badve SV, Bilal A, Lee MMY, et al. Effects of GLP&#x2010;1 receptor agonists on kidney and cardiovascular disease outcomes: a meta&#x2010;analysis of randomised controlled trials. Lancet Diabetes Endocrinol. 2025;13(1):15&#x2010;28. doi:10.1016/S2213&#x2010;8587(24)00271&#x2010;7</Citation></Reference><Reference><Citation>Hern&#xe1;n MA, Dahabreh IJ, Dickerman BA, Swanson SA. The target trial framework for causal inference from observational data: why and when is it helpful? Ann Intern Med. 2025;178(3):402&#x2010;407. doi:10.7326/ANNALS&#x2010;24&#x2010;01871</Citation></Reference><Reference><Citation>Palchuk MB, London JW, Perez&#x2010;Rey D, et al. A global federated real&#x2010;world data and analytics platform for research. JAMIA Open. 2023;6(2):ooad035. doi:10.1093/jamiaopen/ooad035</Citation></Reference><Reference><Citation>Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity&#x2010;score matched samples. Stat Med. 2009;28(25):3083&#x2010;3107. doi:10.1002/sim.3697</Citation></Reference><Reference><Citation>Hess KR. Graphical methods for assessing violations of the proportional hazards assumption in cox regression. Stat Med. 1995;14(15):1707&#x2010;1723. doi:10.1002/sim.4780141510</Citation></Reference><Reference><Citation>Lipsitch M, Tchetgen Tchetgen E, Cohen T. Negative controls: a tool for detecting confounding and bias in observational studies. Epidemiology. 2010;21(3):383&#x2010;388. doi:10.1097/EDE.0b013e3181d61eeb</Citation></Reference><Reference><Citation>Fonseca VA, Capehorn MS, Garg SK, et al. Reductions in insulin resistance are mediated primarily via weight loss in subjects with type 2 diabetes on semaglutide. J Clin Endocrinol Metab. 2019;104(9):4078&#x2010;4086. doi:10.1210/jc.2018&#x2010;02685</Citation></Reference><Reference><Citation>Mather KJ, Mari A, Weerakkody G, et al. Greater improvement in insulin sensitivity per unit weight loss associated with tirzepatide versus semaglutide: an exploratory analysis. Diabetes Obes Metab. 2025;27(3):1507&#x2010;1514. doi:10.1111/dom.16159</Citation></Reference><Reference><Citation>Verma S, Bhatta M, Davies M, et al. Effects of once&#x2010;weekly semaglutide 2.4 mg on C&#x2010;reactive protein in adults with overweight or obesity (STEP 1, 2, and 3): exploratory analyses of three randomised, double&#x2010;blind, placebo&#x2010;controlled, phase 3 trials. eClinicalMedicine. 2023;55:101737. doi:10.1016/j.eclinm.2022.101737</Citation></Reference><Reference><Citation>Lobo L, Masson W, Nogueira JP, et al. Anti&#x2010;inflammatory effect of semaglutide: updated systematic review and meta&#x2010;analysis. Eur Heart J. 2024;45(Supplement_1):ehae666.2917. doi:10.1093/eurheartj/ehae666.2917</Citation></Reference><Reference><Citation>Nystr&#xf6;m T, Gutniak MK, Zhang Q, et al. Effects of glucagon&#x2010;like peptide&#x2010;1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol&#x2010;Endocrinol Metab. 2004;287(6):E1209&#x2010;E1215. doi:10.1152/ajpendo.00237.2004</Citation></Reference><Reference><Citation>Pan X, Yang L, Wang S, Liu Y, Yue L, Chen S. Semaglutide alleviates inflammation&#x2010;induced endothelial progenitor cells injury by inhibiting MiR&#x2010;155 expression in macrophage exosomes. Int Immunopharmacol. 2023;119:110196. doi:10.1016/j.intimp.2023.110196</Citation></Reference><Reference><Citation>Granata A, Maccarrone R, Anzaldi M, et al. GLP&#x2010;1 receptor agonists and renal outcomes in patients with diabetes mellitus type 2 and diabetic kidney disease: state of the art. Clin Kidney J. 2022;15(9):1657&#x2010;1665. doi:10.1093/ckj/sfac069</Citation></Reference><Reference><Citation>Trevella P, Ekinci EI, MacIsaac RJ. Potential kidney protective effects of glucagon&#x2010;like peptide&#x2010;1 receptor agonists. Nephrology. 2024;29(8):457&#x2010;469. doi:10.1111/nep.14336</Citation></Reference><Reference><Citation>Sattar N, Presslie C, Rutter MK, McGuire DK. Cardiovascular and kidney risks in individuals with type 2 diabetes: contemporary understanding with greater emphasis on excess adiposity. Diabetes Care. 2024;47(4):531&#x2010;543. doi:10.2337/dci23&#x2010;0041</Citation></Reference><Reference><Citation>Chen X, Zhao P, Wang W, Guo L, Pan Q. The antidepressant effects of GLP&#x2010;1 receptor agonists: a systematic review and meta&#x2010;analysis. Am J Geriatr Psychiatry. 2024;32(1):117&#x2010;127. doi:10.1016/j.jagp.2023.08.010</Citation></Reference><Reference><Citation>Eren&#x2010;Yazicioglu CY, Yigit A, Dogruoz RE, Yapici&#x2010;Eser H. Can GLP&#x2010;1 Be a target for reward system related disorders? A qualitative synthesis and systematic review analysis of studies on palatable food, drugs of abuse, and alcohol. Front Behav Neurosci. 2021;14:614884. doi:10.3389/fnbeh.2020.614884</Citation></Reference><Reference><Citation>Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Association of semaglutide with risk of suicidal ideation in a real&#x2010;world cohort. Nat Med. 2024;30(1):168&#x2010;176. doi:10.1038/s41591&#x2010;023&#x2010;02672&#x2010;2</Citation></Reference><Reference><Citation>Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Associations of semaglutide with incidence and recurrence of alcohol use disorder in real&#x2010;world population. Nat Commun. 2024;15(1):4548. doi:10.1038/s41467&#x2010;024&#x2010;48780&#x2010;6</Citation></Reference><Reference><Citation>Wang W, Volkow ND, Wang Q, et al. Semaglutide and opioid overdose risk in patients with type 2 diabetes and opioid use disorder. JAMA Netw Open. 2024;7(9):e2435247. doi:10.1001/jamanetworkopen.2024.35247</Citation></Reference><Reference><Citation>Badulescu S, Tabassum A, Le GH, et al. Glucagon&#x2010;like peptide 1 agonist and effects on reward behaviour: a systematic review. Physiol Behav. 2024;283:114622. doi:10.1016/j.physbeh.2024.114622</Citation></Reference><Reference><Citation>Hayes MR, Schmidt HD. GLP&#x2010;1 influences food and drug reward. Curr Opin Behav Sci. 2016;9:66&#x2010;70. doi:10.1016/j.cobeha.2016.02.005</Citation></Reference><Reference><Citation>Alhadeff AL, Rupprecht LE, Hayes MR. GLP&#x2010;1 neurons in the nucleus of the solitary tract project directly to the ventral tegmental area and nucleus Accumbens to control for food intake. Endocrinology. 2012;153(2):647&#x2010;658. doi:10.1210/en.2011&#x2010;1443</Citation></Reference><Reference><Citation>Billes SK, Sinnayah P, Cowley MA. Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. Pharmacol Res. 2014;84:1&#x2010;11. doi:10.1016/j.phrs.2014.04.004</Citation></Reference><Reference><Citation>Coulter AA, Rebello CJ, Greenway FL. Centrally acting drugs for obesity: past, present, and future. Drugs. 2018;78(11):1113&#x2010;1132. doi:10.1007/s40265&#x2010;018&#x2010;0946&#x2010;y</Citation></Reference><Reference><Citation>Okobi OE, Okorie JC, Ewuzie ZDD, et al. Bidirectional relationship between obesity, psychiatric disorders, and renal disease: a systematic review. Med Res Arch. 2024;12(7):1&#x2010;15. doi:10.18103/mra.v12i7.5497</Citation></Reference><Reference><Citation>Storgaard H, Cold F, Gluud LL, Vilsb&#xf8;ll T, Knop FK. Glucagon&#x2010;like peptide&#x2010;1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes. Diabetes Obes Metab. 2017;19(6):906&#x2010;908. doi:10.1111/dom.12885</Citation></Reference><Reference><Citation>Ayoub M, Chela H, Amin N, et al. Pancreatitis risk associated with GLP&#x2010;1 receptor agonists, considered as a single class, in a comorbidity&#x2010;free subgroup of type 2 diabetes patients in the United States: a propensity score&#x2010;matched analysis. J Clin Med. 2025;14(3):944. doi:10.3390/jcm14030944</Citation></Reference><Reference><Citation>Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Risk of gastrointestinal adverse events associated with glucagon&#x2010;like Peptide&#x2010;1 receptor agonists for weight loss. JAMA. 2023;330(18):1795&#x2010;1797. doi:10.1001/jama.2023.19574</Citation></Reference><Reference><Citation>Moll H, Frey E, Gerber P, et al. GLP&#x2010;1 receptor agonists for weight reduction in people living with obesity but without diabetes: a living benefit&#x2013;harm modelling study. eClinicalMedicine. 2024;73:102661. doi:10.1016/j.eclinm.2024.102661</Citation></Reference><Reference><Citation>Perets O, Stagno E, Yehuda EB, et al. Inherent bias in electronic health records: a scoping review of sources of bias. MedRxiv: The Preprint Server for Health Sciences. 2024.04.09.24305594. doi:10.1101/2024.04.09.24305594</Citation></Reference><Reference><Citation>Wu Q, Tong J, Zhang B, et al. Real&#x2010;world effectiveness of BNT162b2 against infection and severe diseases in children and adolescents. Ann Intern Med. 2024;177(2):165&#x2010;176. doi:10.7326/M23&#x2010;1754</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40898779</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2230</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Sep</Month><Day>03</Day></PubDate></JournalIssue><Title>Clinical and experimental dermatology</Title><ISOAbbreviation>Clin Exp Dermatol</ISOAbbreviation></Journal><ArticleTitle>The prevalence of endometriosis in adult female patients with hidradenitis suppurativa: a cross-sectional study using the All of Us Research Program.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">llaf395</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/ced/llaf395</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hodelin</LastName><ForeName>Christine</ForeName><Initials>C</Initials><Identifier Source="ORCID">0009-0009-9958-2410</Identifier><AffiliationInfo><Affiliation>Yale School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohen</LastName><ForeName>Jeffrey M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0002-7709-0548</Identifier><AffiliationInfo><Affiliation>Department of Dermatology, Yale School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biomedical Informatics and Data Science, Yale School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eisenstein</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Yale School of Medicine, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Clin Exp Dermatol</MedlineTA><NlmUniqueID>7606847</NlmUniqueID><ISSNLinking>0307-6938</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>3</Day><Hour>2</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40898779</ArticleId><ArticleId IdType="doi">10.1093/ced/llaf395</ArticleId><ArticleId IdType="pii">8246379</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">40899561</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>03</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-8365</ISSN><JournalIssue CitedMedium="Internet"><Volume>331</Volume><PubDate><Year>2025</Year><Month>Sep</Month><Day>03</Day></PubDate></JournalIssue><Title>Studies in health technology and informatics</Title><ISOAbbreviation>Stud Health Technol Inform</ISOAbbreviation></Journal><ArticleTitle>Development and Implementation of an Open, Modular, and Participatory Toolchain for Distributed IT Development in Healthcare Research - Lessons Learned.</ArticleTitle><Pagination><StartPage>378</StartPage><EndPage>385</EndPage><MedlinePgn>378-385</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3233/SHTI251418</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Distributed healthcare research infrastructures face significant challenges when translating routine clinical data into harmonized, research-ready formats using HL7 FHIR standards.</AbstractText><AbstractText Label="STATE OF THE ART" NlmCategory="BACKGROUND">Existing FHIR-based pipelines such as the SMART/HL7 FHIR Bulk Data Access API, FHIR-to-OMOP mappings, and analytical services like Pathling demonstrate technical feasibility. However, most assume semantically valid FHIR data, operate within single-institution settings, and lack practical guidance for deployment across heterogeneous, regulated environments. Technical Framework and Deployment: Within the German Medical Informatics Initiative (MII) and the INTERPOLAR project, we developed an open, modular, and participatory toolchain for decentralized FHIR-based data transformation and export across multiple Data Integration Centers (DICs). The toolchain supports FHIR extraction, profile-based transformation, REDCap integration, and OMOP-compatible export. Deployment required adapting to local infrastructures, regulatory boundaries (e.g., de-identified FHIR stores, restricted network access), and clinical domain needs. Configurable modules, proxy support, and site-specific adaptations were essential for integration into operational hospital workflows.</AbstractText><AbstractText Label="LESSONS LEARNED" NlmCategory="CONCLUSIONS">Key lessons include the necessity of early access to real data, the limitations of synthetic test data, the value of joint workshops for profile interpretation, and the need for adaptable validation tooling. Organizational knowledge gaps, inconsistent FHIR implementations, and performance issues in resource flattening were addressed through co-design and iterative rollout strategies. Validator modules are essential across technical, content, and cross-site consistency levels.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Centralized development paired with decentralized, participatory deployment enables scalable, GDPR-compliant infrastructures for embedded clinical research. This approach offers a replicable framework for future multi-site initiatives aiming to leverage real-world data across diverse environments.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Neumann</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics, Statistics and Epidemiology (IMISE), University Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gebler</LastName><ForeName>Richard</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics and Biometry, Carl Gustav Carus Faculty of Medicine, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kiederle</LastName><ForeName>Jana</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Institute of Medical Informatics, University Hospital Heidelberg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beck</LastName><ForeName>J&#xf6;rdis</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>University Hospital Giessen and Marburg, Giessen, German.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aubele</LastName><ForeName>Fabio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Medical Data Integration Center, LMU University Hospital, Ludwig-Maximilians-Universit&#xe4;t M&#xfc;nchen, Munich, German.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Struebing</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics, Statistics and Epidemiology (IMISE), University Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schmidt</LastName><ForeName>Florian</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics, Statistics and Epidemiology (IMISE), University Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reusche</LastName><ForeName>Matthias</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics, Statistics and Epidemiology (IMISE), University Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koester</LastName><ForeName>Helene</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Medical Centre for Information and Communication Technology, Universit&#xe4;tsklinikum Erlangen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loeffler</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics, Statistics and Epidemiology (IMISE), University Leipzig, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Staeubert</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute for Medical Informatics, Statistics and Epidemiology (IMISE), University Leipzig, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Stud Health Technol Inform</MedlineTA><NlmUniqueID>9214582</NlmUniqueID><ISSNLinking>0926-9630</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006302" MajorTopicYN="Y">Health Services Research</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="N">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008490" MajorTopicYN="Y">Medical Informatics</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="N">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057286" MajorTopicYN="Y">Electronic Health Records</DescriptorName><QualifierName UI="Q000458" MajorTopicYN="N">organization &amp; administration</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057208" MajorTopicYN="N">Health Level Seven</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018511" MajorTopicYN="N">Systems Integration</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clinical Informatics</Keyword><Keyword MajorTopicYN="N">Data Integration</Keyword><Keyword MajorTopicYN="N">Health Information Exchange</Keyword><Keyword MajorTopicYN="N">Implementation Science</Keyword><Keyword MajorTopicYN="N">Interoperability</Keyword><Keyword MajorTopicYN="N">Medical Informatics Applications</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>3</Day><Hour>18</Hour><Minute>35</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>3</Day><Hour>11</Hour><Minute>15</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>3</Day><Hour>7</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40899561</ArticleId><ArticleId IdType="doi">10.3233/SHTI251418</ArticleId><ArticleId IdType="pii">SHTI251418</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40900825</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>15</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1663-9812</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>Frontiers in pharmacology</Title><ISOAbbreviation>Front Pharmacol</ISOAbbreviation></Journal><ArticleTitle>Trends in prescription opioid use in Europe: A DARWIN EU<sup>&#xae;</sup> multinational cohort study including seven European countries.</ArticleTitle><Pagination><StartPage>1608051</StartPage><MedlinePgn>1608051</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">1608051</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3389/fphar.2025.1608051</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">The opioid crisis has been a serious public health challenge in North America for decades, despite numerous efforts to mitigate its devastating consequences. As concerns grow about a similar situation developing in Europe, we evaluated the trends in opioid use and characterized prescribing indications across seven European countries.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We conducted a multinational cohort study using electronic health records from various healthcare settings: primary care [Clinical Practice Research Datalink (CPRD) GOLD (United Kingdom), Sistema d'Informaci&#xf3; per al Desenvolupament de la Investigaci&#xf3; en Atenci&#xf3; Prim&#xe0;ria (SIDIAP, Spain), and Integrated Primary Care Information Project (IPCI, the Netherlands)]; primary and outpatient specialist care [IQVIA Disease Analyzer (DA) Germany and IQVIA Longitudinal Patient Database (LPD) Belgium]; hospital care [Clinical Data Warehouse of Bordeaux University Hospital (CHUBX, France)]; and the Estonian Biobank (EBB). All data were mapped to the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM). All people registered in a contributing database for &#x2265;365&#xa0;days between 2012 and 2022 were included. Annual period prevalence and incidence rates of opioid prescriptions were estimated, and long-term trends were quantified as the percent change from 2012 to 2019. New opioid users were characterized, including potential prescribing indications.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Between 2012 and 2019, the incidence of opioid prescriptions in primary care decreased by -50&#xb7;7% (CPRD GOLD) and -2&#xb7;0% (SIDIAP), while it increased in EBB (+52&#xb7;8%) and CHUBX (+25&#xb7;3%) data. The incidence of codeine and tramadol use decreased in most databases. However, the prevalence of oxycodone, morphine, and fentanyl increased. Opioid use was highest among older age groups, and the majority of prescriptions were for oral formulations. Respiratory and pain-related conditions were the most common indications for new opioid users in outpatient settings.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Despite a decrease in new opioid prescriptions in many European countries, the prevalence of opioid use remained largely stable over the last decade. More data are needed to monitor evolving opioid prescription patterns in Europe, particularly in the post-pandemic era.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 Xie, Du, Guo, Barboza, Brash, Delmestri, Duarte-Salles, Gratton, Griffier, Kolde, Man, Mercad&#xe9;-Besora, Oja, Seager, Verhamme, Vojinovic, Burn, Prieto-Alhambra, Catal&#xe0; and J&#xf6;dicke.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Xie</LastName><ForeName>Junqing</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Pharmaco- and Device Epidemiology Group, Centre of Statistics in Medicine, NDORMS, University of Oxford, England, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Du</LastName><ForeName>Mike</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pharmaco- and Device Epidemiology Group, Centre of Statistics in Medicine, NDORMS, University of Oxford, England, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guo</LastName><ForeName>Yuchen</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Pharmaco- and Device Epidemiology Group, Centre of Statistics in Medicine, NDORMS, University of Oxford, England, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barboza</LastName><ForeName>Cesar</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brash</LastName><ForeName>James T</ForeName><Initials>JT</Initials><AffiliationInfo><Affiliation>IQVIA, Real World Solution, Brighton, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Delmestri</LastName><ForeName>Antonella</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pharmaco- and Device Epidemiology Group, Centre of Statistics in Medicine, NDORMS, University of Oxford, England, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duarte-Salles</LastName><ForeName>Talita</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gratton</LastName><ForeName>Jasmine</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>IQVIA, Real World Solution, Brighton, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Griffier</LastName><ForeName>Romain</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Public Health Department, Medical Information Service, Bordeaux University Hospital, Bordeaux, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kolde</LastName><ForeName>Raivo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Institute of Computer Science, University of Tartu, Tartu, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Man</LastName><ForeName>Wai Yi</ForeName><Initials>WY</Initials><AffiliationInfo><Affiliation>Pharmaco- and Device Epidemiology Group, Centre of Statistics in Medicine, NDORMS, University of Oxford, England, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mercad&#xe9;-Besora</LastName><ForeName>N&#xfa;ria</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Fundaci&#xf3; Institut Universitari per a la recerca a l'Atenci&#xf3; Prim&#xe0;ria de Salut Jordi Gol i Gurina (IDIAPJGol), Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oja</LastName><ForeName>Marek</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Institute of Computer Science, University of Tartu, Tartu, Estonia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seager</LastName><ForeName>Sarah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>IQVIA, Real World Solution, Brighton, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Verhamme</LastName><ForeName>Katia</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vojinovic</LastName><ForeName>Dina</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>IQVIA, Real World Solutions, Amsterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burn</LastName><ForeName>Edward</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Pharmaco- and Device Epidemiology Group, Centre of Statistics in Medicine, NDORMS, University of Oxford, England, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prieto-Alhambra</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Pharmaco- and Device Epidemiology Group, Centre of Statistics in Medicine, NDORMS, University of Oxford, England, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medical Informatics, Erasmus Medical Center, Rotterdam, Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Catal&#xe0;</LastName><ForeName>Mart&#xed;</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pharmaco- and Device Epidemiology Group, Centre of Statistics in Medicine, NDORMS, University of Oxford, England, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>J&#xf6;dicke</LastName><ForeName>Annika M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Pharmaco- and Device Epidemiology Group, Centre of Statistics in Medicine, NDORMS, University of Oxford, England, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>08</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Front Pharmacol</MedlineTA><NlmUniqueID>101548923</NlmUniqueID><ISSNLinking>1663-9812</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">common data model</Keyword><Keyword MajorTopicYN="N">electronic health records</Keyword><Keyword MajorTopicYN="N">opioids</Keyword><Keyword MajorTopicYN="N">real-world data</Keyword><Keyword MajorTopicYN="N">trends multinational</Keyword></KeywordList><CoiStatement>For this project, a data partner&#x2019;s role was only to execute code at their data source, and they did not have an investigator role. The manuscript received support from the European Medicines Agency through the DARWIN Coordination Center. RK and MO received support from the Estonian Science Agency through Grant PRG1844. All other authors declare no conflicts of interest related to this study. The authors report the following conflicts of interest not related to this study: KV works for a research group who, in the past 3&#xa0;years, received unconditional research grants from UCB, Chiesi, Amgen, and J&amp;J. JB worked on a project for a pharmaceutical client that explored the use of painkillers in the context of COVID. This project was completed by the start of 2022, and opioids were not examined in this study. DPA&#x2019;s department has received grant/s from Amgen, Chiesi-Taylor, Lilly, Janssen, Novartis, and UCB Biopharma. His research group has received consultancy fees from Astra Zeneca and UCB Biopharma. Amgen, Astellas, Janssen, Synapse Management Partners, and UCB Biopharma have funded or supported training programs organized by DPA&#x2019;s department. Author(s) JB and JG were employed by IQVIA, Real World Solutions. Author DV was employed by IQVIA, Real World Solutions.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>3</Day><Hour>18</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>3</Day><Hour>18</Hour><Minute>36</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>3</Day><Hour>12</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>8</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40900825</ArticleId><ArticleId IdType="pmc">PMC12399544</ArticleId><ArticleId IdType="doi">10.3389/fphar.2025.1608051</ArticleId><ArticleId IdType="pii">1608051</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Alenezi A., Yahyouche A., Paudyal V. (2021). Current status of opioid epidemic in the United Kingdom and strategies for treatment optimisation in chronic pain. Int. J. Clin. Pharm. 43 (2), 318&#x2013;322. 10.1007/s11096-020-01205-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11096-020-01205-y</ArticleId><ArticleId IdType="pmc">PMC8079300</ArticleId><ArticleId IdType="pubmed">33252724</ArticleId></ArticleIdList></Reference><Reference><Citation>Anekar A. A., Hendrix J. M., Cascella M. (2023). WHO analgesic ladder. Treasure Island, FL: StatPearls.</Citation><ArticleIdList><ArticleId IdType="pubmed">32119322</ArticleId></ArticleIdList></Reference><Reference><Citation>
Australian Government: Department of Health and Aged Care (2019). Addressing prescription opioid use and misuse in Australia: regulatory impact self-assessment report. Available online at: https://www.tga.gov.au/resources/publication/publications/addressing-prescription-opioid-use-and-misuse-australia.
</Citation></Reference><Reference><Citation>Ballreich J., Mansour O., Hu E., Chingcuanco F., Pollack H. A., Dowdy D. W., et al. (2020). Modeling mitigation strategies to reduce opioid-related morbidity and mortality in the US. JAMA Netw. Open 3 (11), e2023677. 10.1001/jamanetworkopen.2020.23677</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.23677</ArticleId><ArticleId IdType="pmc">PMC7643029</ArticleId><ArticleId IdType="pubmed">33146732</ArticleId></ArticleIdList></Reference><Reference><Citation>Catala M., Du M., Guo Y., Lopez-Guell K., Burn E., Li X. (2025). DrugUtilisation: summarise patient-level drug utilisation in data mapped to the OMOP common data. Model. 10.32614/CRAN.package.DrugUtilisation</Citation><ArticleIdList><ArticleId IdType="doi">10.32614/CRAN.package.DrugUtilisation</ArticleId></ArticleIdList></Reference><Reference><Citation>
Centers for Disease Control and Prevention (2025). CDC&#x2019;s clinical practice guideline for prescribing opioids for pain. Available online at: https://www.cdc.gov/opioids/healthcare-professionals/prescribing/guideline/index.html.
</Citation></Reference><Reference><Citation>Cheung A., Marchand J., Mark P. (2023). Loss of life and labor productivity: the Canadian opioid crisis. Ann. Am. Acad. Political Soc. Sci. 703 (1), 303&#x2013;323. 10.1177/00027162231155040</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/00027162231155040</ArticleId></ArticleIdList></Reference><Reference><Citation>Curtis H. J., Croker R., Walker A. J., Richards G. C., Quinlan J., Goldacre B. (2019). Opioid prescribing trends and geographical variation in England, 1998-2018: a retrospective database study. Lancet Psychiatry 6 (2), 140&#x2013;150. 10.1016/S2215-0366(18)30471-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(18)30471-1</ArticleId><ArticleId IdType="pubmed">30580987</ArticleId></ArticleIdList></Reference><Reference><Citation>Degenhardt L., Grebely J., Stone J., Hickman M., Vickerman P., Marshall B. D. L., et al. (2019). Global patterns of opioid use and dependence: harms to populations, interventions, and future action. Lancet. 394 (10208), 1560&#x2013;1579. 10.1016/S0140-6736(19)32229-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)32229-9</ArticleId><ArticleId IdType="pmc">PMC7068135</ArticleId><ArticleId IdType="pubmed">31657732</ArticleId></ArticleIdList></Reference><Reference><Citation>de Ridder M., de Wilde M., de Ben C., Leyba A., Mosseveld B., Verhamme K., et al. (2022). Data resource profile: the integrated primary care information project (IPCI) database, the Netherlands. Int. J. Epidemiol. 51 (6), e314&#x2013;e323. 10.1093/ije/dyac026</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyac026</ArticleId><ArticleId IdType="pmc">PMC9749682</ArticleId><ArticleId IdType="pubmed">35182144</ArticleId></ArticleIdList></Reference><Reference><Citation>Dowell D., Haegerich T. M., Chou R. (2016). CDC guideline for prescribing opioids for chronic Pain--United States, 2016. JAMA 315 (15), 1624&#x2013;1645. 10.1001/jama.2016.1464</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2016.1464</ArticleId><ArticleId IdType="pmc">PMC6390846</ArticleId><ArticleId IdType="pubmed">26977696</ArticleId></ArticleIdList></Reference><Reference><Citation>Fornari C., Antonazzo I., Paoletti O., Cei E., Bartolini C., Conti S., et al. (2021). Use of antidepressants during COVID19 outbreak: a real-world drug-utilization study. Eur. J. Public Health 31 (3). 10.1093/eurpub/ckab165.075</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurpub/ckab165.075</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomes T., Khuu W., Martins D., Tadrous M., Mamdani M. M., Paterson J. M., et al. (2018). Contributions of prescribed and non-prescribed opioids to opioid related deaths: population based cohort study in Ontario, Canada. BMJ 362, k3207. 10.1136/bmj.k3207</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.k3207</ArticleId><ArticleId IdType="pmc">PMC6113771</ArticleId><ArticleId IdType="pubmed">30158106</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomes T., Kim K. C., Suda K. J., Garg R., Tadrous M. (2022). International trends in prescription opioid sales among developed and developing economies, and the impact of the COVID-19 pandemic: a cross-sectional analysis of 66 countries. Pharmacoepidemiol Drug Saf. 31 (7), 779&#x2013;787. 10.1002/pds.5443</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.5443</ArticleId><ArticleId IdType="pmc">PMC9088547</ArticleId><ArticleId IdType="pubmed">35460142</ArticleId></ArticleIdList></Reference><Reference><Citation>Gomes T., Ledlie S., Tadrous M., Mamdani M., Paterson J., Juurlink D. (2023). Trends in opioid Toxicity&#x2013; related deaths in the US before and after the start of the COVID-19 pandemic, 2011-2021. JAMA Netw. Open 6 (7), e2322303. 10.1001/jamanetworkopen.2023.22303</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2023.22303</ArticleId><ArticleId IdType="pmc">PMC10329206</ArticleId><ArticleId IdType="pubmed">37418260</ArticleId></ArticleIdList></Reference><Reference><Citation>Hauser W., Buchser E., Finn D. P., Dom G., Fors E., Heiskanen T., et al. (2021). Is Europe also facing an opioid crisis? A survey of european pain Federation chapters. Eur. J. Pain 25 (8), 1760&#x2013;1769. 10.1002/ejp.1786</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejp.1786</ArticleId><ArticleId IdType="pubmed">33960569</ArticleId></ArticleIdList></Reference><Reference><Citation>Herrett E., Gallagher A. M., Bhaskaran K., Forbes H., Mathur R., van Staa T., et al. (2015). Data resource profile: Clinical practice research datalink (CPRD). Int. J. Epidemiol. 44 (3), 827&#x2013;836. 10.1093/ije/dyv098</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyv098</ArticleId><ArticleId IdType="pmc">PMC4521131</ArticleId><ArticleId IdType="pubmed">26050254</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurtado I., Garcia-Sempere A., Peiro S., Sanfelix-Gimeno G. (2020). Increasing trends in opioid use from 2010 to 2018 in the region of Valencia, Spain: a real-world, population-based study. Front. Pharmacol. 11, 612556. 10.3389/fphar.2020.612556</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.612556</ArticleId><ArticleId IdType="pmc">PMC7759684</ArticleId><ArticleId IdType="pubmed">33362564</ArticleId></ArticleIdList></Reference><Reference><Citation>Iaboni A., Campitelli M. A., Bronskill S. E., Diong C., Kumar M., Maclagan L. C., et al. (2019). Time trends in opioid prescribing among Ontario long-term care residents: a repeated cross-sectional study. CMAJ Open 7 (3), E582&#x2013;E589. 10.9778/cmajo.20190052</Citation><ArticleIdList><ArticleId IdType="doi">10.9778/cmajo.20190052</ArticleId><ArticleId IdType="pmc">PMC6759016</ArticleId><ArticleId IdType="pubmed">31551235</ArticleId></ArticleIdList></Reference><Reference><Citation>Jayawardana S., Forman R., Johnston-Webber C., Campbell A., Berterame S., de Joncheere C., et al. (2021). Global consumption of prescription opioid analgesics between 2009-2019: a country-level observational study. EClinicalMedicine 42, 101198. 10.1016/j.eclinm.2021.101198</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101198</ArticleId><ArticleId IdType="pmc">PMC8599097</ArticleId><ArticleId IdType="pubmed">34820610</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeffery M. M., Hooten W. M., Henk H. J., Bellolio M. F., Hess E. P., Meara E., et al. (2018). Trends in opioid use in commercially insured and medicare advantage populations in 2007-16: retrospective cohort study. BMJ 362, k2833. 10.1136/bmj.k2833</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.k2833</ArticleId><ArticleId IdType="pmc">PMC6066997</ArticleId><ArticleId IdType="pubmed">30068513</ArticleId></ArticleIdList></Reference><Reference><Citation>Ju C., Wei L., Man K. K. C., Wang Z., Ma T. T., Chan A. Y. L., et al. (2022). Global, regional, and national trends in opioid analgesic consumption from 2015 to 2019: a longitudinal study. Lancet Public Health 7 (4), e335&#x2013;e346. 10.1016/S2468-2667(22)00013-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2468-2667(22)00013-5</ArticleId><ArticleId IdType="pubmed">35366408</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalkman G. A., van den Brink W., Pierce M., Atsma F., Vissers K. C. P., Schers H. J., et al. (2022). Monitoring opioids in Europe: the need for shared definitions and measuring drivers of opioid use and related harms. Eur. Addict. Res. 28 (3), 231&#x2013;240. 10.1159/000521996</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000521996</ArticleId><ArticleId IdType="pubmed">35196659</ArticleId></ArticleIdList></Reference><Reference><Citation>Karmali R. N., Bush C., Raman S. R., Campbell C. I., Skinner A. C., Roberts A. W. (2020). Long-term opioid therapy definitions and predictors: a systematic review. Pharmacoepidemiol Drug Saf. 29 (3), 252&#x2013;269. 10.1002/pds.4929</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.4929</ArticleId><ArticleId IdType="pmc">PMC7058495</ArticleId><ArticleId IdType="pubmed">31851773</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimber J., Hickman M., Strang J., Thomas K., Hutchinson S. (2019). Rising opioid-related deaths in England and Scotland must be recognised as a public health crisis. Lancet Psychiatry 6 (8), 639&#x2013;640. 10.1016/S2215-0366(19)30209-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2215-0366(19)30209-3</ArticleId><ArticleId IdType="pubmed">31201043</ArticleId></ArticleIdList></Reference><Reference><Citation>Lalic S., Ilomaki J., Bell J. S., Korhonen M. J., Gisev N. (2019). Prevalence and incidence of prescription opioid analgesic use in Australia. Br. J. Clin. Pharmacol. 85 (1), 202&#x2013;215. 10.1111/bcp.13792</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.13792</ArticleId><ArticleId IdType="pmc">PMC6303244</ArticleId><ArticleId IdType="pubmed">30338545</ArticleId></ArticleIdList></Reference><Reference><Citation>Leitsalu L., Haller T., Esko T., Tammesoo M. L., Alavere H., Snieder H., et al. (2015). Cohort profile: estonian biobank of the Estonian genome center, university of Tartu. Int. J. Epidemiol. 44 (4), 1137&#x2013;1147. 10.1093/ije/dyt268</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyt268</ArticleId><ArticleId IdType="pubmed">24518929</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchetti Calonego M. A., Sikandar S., Ferris F. D., Moreira de Barros G. A. (2020). Spread the word: there are two opioid crises. Drugs 80 (12), 1147&#x2013;1154. 10.1007/s40265-020-01342-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40265-020-01342-8</ArticleId><ArticleId IdType="pubmed">32533500</ArticleId></ArticleIdList></Reference><Reference><Citation>Marengoni A., Cangini A., Pierantozzi A., Onder G., Da Cas R., Ippoliti I., et al. (2023). Impact of COVID-19 pandemic on medication use in the older Italian population. Aging Clin. Exp. Res. 35 (2), 443&#x2013;453. 10.1007/s40520-022-02303-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40520-022-02303-9</ArticleId><ArticleId IdType="pmc">PMC9734516</ArticleId><ArticleId IdType="pubmed">36469252</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosher H. J., Krebs E. E., Carrel M., Kaboli P. J., Weg M. W., Lund B. C. (2015). Trends in prevalent and incident opioid receipt: an observational study in veterans health administration 2004-2012. J. Gen. Intern Med. 30 (5), 597&#x2013;604. 10.1007/s11606-014-3143-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11606-014-3143-z</ArticleId><ArticleId IdType="pmc">PMC4395612</ArticleId><ArticleId IdType="pubmed">25519224</ArticleId></ArticleIdList></Reference><Reference><Citation>
National Institute for Health and Care Excellence (2016). Palliative care for adults: strong opioids for pain relief. Available online at: https://www.nice.org.uk/guidance/cg140.
</Citation><ArticleIdList><ArticleId IdType="pubmed">32208569</ArticleId></ArticleIdList></Reference><Reference><Citation>Paice J. A., Bohlke K., Barton D., Craig D. S., El-Jawahri A., Hershman D. L., et al. (2023). Use of opioids for adults with pain from cancer or cancer treatment: ASCO guideline. J. Clin. Oncol. 41 (4), 914&#x2013;930. 10.1200/JCO.22.02198</Citation><ArticleIdList><ArticleId IdType="doi">10.1200/JCO.22.02198</ArticleId><ArticleId IdType="pubmed">36469839</ArticleId></ArticleIdList></Reference><Reference><Citation>Pierce M., Van Amsterdam J., Kalkman G., Schellekens A., Van den Brink W. (2021). Is Europe facing an opioid crisis like the United States? An analysis of opioid use and related adverse effects in 19 European countries between 2010 and 2018. Eur. Psychiatry 64 (1), E47. 10.1192/j.eurpsy.2021.2219</Citation><ArticleIdList><ArticleId IdType="doi">10.1192/j.eurpsy.2021.2219</ArticleId><ArticleId IdType="pmc">PMC8316471</ArticleId><ArticleId IdType="pubmed">34165059</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravent&#xf3;s B., Catal&#xe0; M., Du M., Guo Y., Black A., Inberg G., et al. (2023). IncidencePrevalence: an R package to calculate population-level incidence rates and prevalence using the OMOP common data model. Pharmacoepidemiol Drug Saf. 25, e5717. 10.1002/pds.5717</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pds.5717</ArticleId><ArticleId IdType="pubmed">37876360</ArticleId></ArticleIdList></Reference><Reference><Citation>Recalde M., Rodriguez C., Burn E., Far M., Garcia D., Carrere-Molina J., et al. (2022). Data resource profile: the information system for research in primary care (SIDIAP). Int. J. Epidemiol. 51 (6), e324&#x2013;e336. 10.1093/ije/dyac068</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ije/dyac068</ArticleId><ArticleId IdType="pmc">PMC9749711</ArticleId><ArticleId IdType="pubmed">35415748</ArticleId></ArticleIdList></Reference><Reference><Citation>Robert M., Jouanjus E., Khouri C., Fouilhe Sam-Lai N., Revol B. (2023). The opioid epidemic: a worldwide exploratory study using the WHO pharmacovigilance database. Addiction 118 (4), 771&#x2013;775. 10.1111/add.16081</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/add.16081</ArticleId><ArticleId IdType="pubmed">36331523</ArticleId></ArticleIdList></Reference><Reference><Citation>Roxburgh A., Hall W., Dobbins T., Gisev N., Burns L., Pearson S., et al. (2017). Trends in heroin and pharmaceutical opioid overdose deaths in Australia. Drug Alcohol Depend. 179, 291&#x2013;298. 10.1016/j.drugalcdep.2017.07.018</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.drugalcdep.2017.07.018</ArticleId><ArticleId IdType="pubmed">28826104</ArticleId></ArticleIdList></Reference><Reference><Citation>Seyler T., Giraudon I., Noor A., Mounteney J., Griffiths P. (2021). Is Europe facing an opioid epidemic: what does European monitoring data tell us? Eur. J. Pain 25 (5), 1072&#x2013;1080. 10.1002/ejp.1728</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ejp.1728</ArticleId><ArticleId IdType="pubmed">33428812</ArticleId></ArticleIdList></Reference><Reference><Citation>Svendsen K., Borchgrevink P., Fredheim O., Hamunen K., Mellbye A., Dale O. (2011). Choosing the unit of measurement counts: the use of oral morphine equivalents in studies of opioid consumption is a useful addition to defined daily doses. Palliat. Med. 25 (7), 725&#x2013;732. 10.1177/0269216311398300</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0269216311398300</ArticleId><ArticleId IdType="pubmed">21378066</ArticleId></ArticleIdList></Reference><Reference><Citation>van Amsterdam J., van den Brink W. (2015). The misuse of prescription opioids: a threat for Europe? Curr. Drug Abuse Rev. 8 (1), 3&#x2013;14. 10.2174/187447370801150611184218</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/187447370801150611184218</ArticleId><ArticleId IdType="pubmed">26084418</ArticleId></ArticleIdList></Reference><Reference><Citation>Vojtila L., Pang M., Goldman B., Kurdyak P., Fischer B. (2019). Non-medical opioid use, harms, and interventions in Canada &#x2013; a 10-year update on an unprecedented substance use-related public health crisis. Drugs Educ. Prev. Policy 27 (2), 118&#x2013;122. 10.1080/09687637.2019.1645094</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09687637.2019.1645094</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie J., Strauss V. Y., Collins G. S., Khalid S., Delmestri A., Turkiewicz A., et al. (2022). Trends of dispensed opioids in Catalonia, Spain, 2007-19: a population-based cohort study of over 5 million individuals. Front. Pharmacol. 13, 912361. 10.3389/fphar.2022.912361</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.912361</ArticleId><ArticleId IdType="pmc">PMC9213744</ArticleId><ArticleId IdType="pubmed">35754470</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie J., Strauss V. Y., Martinez-Laguna D., Carbonell-Abella C., Diez-Perez A., Nogues X., et al. (2021). Association of tramadol vs codeine prescription dispensation with mortality and other adverse clinical outcomes. JAMA 326 (15), 1504&#x2013;1515. 10.1001/jama.2021.15255</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.15255</ArticleId><ArticleId IdType="pmc">PMC8527363</ArticleId><ArticleId IdType="pubmed">34665205</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeng C., Dubreuil M., LaRochelle M. R., Lu N., Wei J., Choi H. K., et al. (2019). Association of tramadol with all-cause mortality among patients with osteoarthritis. JAMA 321 (10), 969&#x2013;982. 10.1001/jama.2019.1347</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2019.1347</ArticleId><ArticleId IdType="pmc">PMC6439672</ArticleId><ArticleId IdType="pubmed">30860559</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40913926</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2772-963X</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>10 Pt 2</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>05</Day></PubDate></JournalIssue><Title>JACC. Advances</Title><ISOAbbreviation>JACC Adv</ISOAbbreviation></Journal><ArticleTitle>Adults With Congenital Heart Disease Have an Increased Prevalence of Autoimmunity.</ArticleTitle><Pagination><StartPage>102116</StartPage><MedlinePgn>102116</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jacadv.2025.102116</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S2772-963X(25)00541-1</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Adult congenital heart disease (ACHD) individuals have increased risk of noncardiac comorbidities including cancer and infections. Whether they are at increased risk of autoimmunity is unknown.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The purpose of this study was to understand the association of ACHD and risk for autoimmunity.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A case-control study was performed using All of Us, a nationwide biomedical database. In 2024, we queried autoimmune conditions and ACHD individuals &#x2265;18 year of age with congenital heart disease (CHD) diagnoses determined using SNOMED, International Classification of Diseases (ICD)-9-CM, and ICD-100-CM classifications. ACHD individuals were matched 1:20 to controls for age, race, sex, smoking, and obesity. We examined subcategories of mild/moderate/severe CHD.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 287,012 participants, 2941 ACHD (1.02%) individuals (mean age 62 years, 55.3% female) were identified. ACHD individuals had increased odds of autoimmunity (OR: 1.95; P &lt; 0.05), both systemic (OR: 1.94; P &lt; 0.05) and organ specific (OR: 1.54; P &lt; 0.05) conditions. Sixty-nine percent had sufficient detail to be classified into mild/moderate/severe CHD; severe group was smaller and younger (n = 162, mean age = 47.6 years) compared to mild (n = 1169, mean age = 63.8) and moderate (n = 703, mean age = 61.8 years) groups. Mild and moderate CHD were associated with autoimmunity (OR: 1.93; P &lt; 0.05 and OR: 1.56; P &lt; 0.05, respectively). The entire severe CHD group did not show an increase in odds of autoimmunity (OR: 1.45; P = 0.168). When the groups were subdivided by age, severe ACHD individuals &#x2265;60 years did show increased odds of autoimmunity (OR: 2.71; P &lt; 0.05).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">ACHD individuals showed a nearly 2-fold increased odds of developing autoimmune conditions, both for systemic and organ-specific autoimmunity, which persisted among those with simple/moderate CHD. In an age-related analysis, the severe CHD group &#x2265;60 years has a similar risk.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025 The Authors. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Yale University, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Insoo</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Section of Rheumatology, Allergy &amp; Immunology, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choate</LastName><ForeName>Keith A</ForeName><Initials>KA</Initials><AffiliationInfo><Affiliation>Departments of Dermatology, Genetics, and Pathology, Yale School of Medicine, New Haven, Connecticut, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Elder</LastName><ForeName>Robert W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Departments of Pediatrics and Internal Medicine, Yale School of Medicine, New Haven, Connecticut, USA. Electronic address: robert.elder@yale.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JACC Adv</MedlineTA><NlmUniqueID>9918419284106676</NlmUniqueID><ISSNLinking>2772-963X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">adult congenital heart disease</Keyword><Keyword MajorTopicYN="N">autoimmunity</Keyword><Keyword MajorTopicYN="N">genetics</Keyword><Keyword MajorTopicYN="N">noncardiac comorbidities</Keyword></KeywordList><CoiStatement>Funding support and author disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>4</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>7</Day><Hour>0</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>7</Day><Hour>0</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>6</Day><Hour>18</Hour><Minute>5</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40913926</ArticleId><ArticleId IdType="doi">10.1016/j.jacadv.2025.102116</ArticleId><ArticleId IdType="pii">S2772-963X(25)00541-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="In-Process" Owner="NLM"><PMID Version="1">40918941</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>10</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2574-2531</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><Issue>5</Issue><PubDate><Year>2025</Year><Month>Oct</Month></PubDate></JournalIssue><Title>JAMIA open</Title><ISOAbbreviation>JAMIA Open</ISOAbbreviation></Journal><ArticleTitle>A natural language processing pipeline for identifying pediatric long COVID symptoms and functional impacts in freeform clinical notes: a RECOVER study.</ArticleTitle><Pagination><StartPage>ooaf089</StartPage><MedlinePgn>ooaf089</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">ooaf089</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/jamiaopen/ooaf089</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">To develop a natural language processing (NLP) pipeline for unstructured electronic health record (EHR) data to identify symptoms and functional impacts associated with Long COVID in children.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="UNASSIGNED">We analyzed 48&#xa0;287 outpatient progress notes from 10&#xa0;618 pediatric patients from 12 institutions. We evaluated notes obtained 28 to 179 days after a COVID-19 diagnosis or positive test. Two samples were examined: patients with evidence of Long COVID and patients with acute COVID but no evidence of Long COVID based on diagnostic codes. The pipeline identified clinical concepts associated with 21 symptoms and 4 functional impact categories. Subject matter experts (SMEs) screened a sample of 4586 terms from the NLP output to assess pipeline accuracy. Prevalence and concordance of each of the 25 concepts was compared between the 2 patient samples.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A binary assertion measure comparing SME and NLP assertions showed moderate accuracy (N&#x2009;=&#x2009;4133; F1 = .80) and improved substantially when only high-confidence SME assertions were considered (N&#x2009;=&#x2009;2043; F1 = .90). Overall, the 25 Long COVID concept categories were markedly more prevalent in the presumptive Long COVID cohort, and differences were noted between concepts identified in notes versus structured data.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="UNASSIGNED">This preliminary analysis illustrates the additional insight into a syndrome such as Long COVID gained from incorporating notes data, characterizing symptoms and functional impacts.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">These data support the importance of incorporating NLP methodology when possible into designing computable phenotypes and to accurately characterize patients with Long COVID.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2025. Published by Oxford University Press on behalf of the American Medical Informatics Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bunnell</LastName><ForeName>H Timothy</ForeName><Initials>HT</Initials><AffiliationInfo><Affiliation>Biomedical Research Informatics Center, Nemours Children's Health, Wilmington, DE 19803, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Reedy</LastName><ForeName>Cara</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Biomedical Research Informatics Center, Nemours Children's Health, Wilmington, DE 19803, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lorman</LastName><ForeName>Vitaly</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Applied Clinical Research Center, Children's Hospital of Philadelphia, Philadelphia, PA 19104, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jhaveri</LastName><ForeName>Ravi</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-9921-0419</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Ann &amp; Robert H. Lurie Children's Hospital of Chicago, Chicago, IL 60611, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rivera-Sepulveda</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Emergency Medicine and Urgent Care, Nemours Children's Health, Orlando, FL 32867, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salamon</LastName><ForeName>Katherine S</ForeName><Initials>KS</Initials><Identifier Source="ORCID">0000-0003-0372-7670</Identifier><AffiliationInfo><Affiliation>Department of Anesthesiology, Perioperative, and Pain Medicine, Stanford University School of Medicine, Menlo Park, CA 94025, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Payal B</ForeName><Initials>PB</Initials><AffiliationInfo><Affiliation>Department of Neurology, Seattle Children's Hospital, Seattle, WA 98105, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morse</LastName><ForeName>Keith E</ForeName><Initials>KE</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Stanford University, Palo Alto, CA 94305, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davenport</LastName><ForeName>Mattina A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Center for Child Health Equity and Outcomes Research, Abigail Wexner Research Institute at Nationwide Children's Hospital, Columbus, OH 43205, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cowell</LastName><ForeName>Lindsay G</ForeName><Initials>LG</Initials><AffiliationInfo><Affiliation>Department of Health Data Science and Biostatistics, O'Donnell School of Public Health, UT Southwestern Medical Center, Dallas, TX 75390, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Utidjian</LastName><ForeName>Levon</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-2189-108X</Identifier><AffiliationInfo><Affiliation>Applied Clinical Research Center, Children's Hospital of Philadelphia, Philadelphia, PA 19104, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Christakis</LastName><ForeName>Dimitri A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Center for Child Health, Behavior and Development, Seattle Children's Research Institute, Seattle, WA 98105, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rao</LastName><ForeName>Suchitra</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-0334-6301</Identifier><AffiliationInfo><Affiliation>Department of Pediatrics, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, CO 80045, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sills</LastName><ForeName>Marion R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department of Research, OCHIN Inc, Portland, OR 97228, United States.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pediatrics and Emergency Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO 80045, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Case</LastName><ForeName>Abigail</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pediatrics and Rehabilitation Medicine, University of Pennsylvania and Children's Hospital of Philadelphia, Philadelphia, PA 19104, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mendonca</LastName><ForeName>Eneida A</ForeName><Initials>EA</Initials><Identifier Source="ORCID">0000-0003-4297-9221</Identifier><AffiliationInfo><Affiliation>Division of Biomedical Informatics, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>Bradley W</ForeName><Initials>BW</Initials><AffiliationInfo><Affiliation>Clinical and Translational Science Institute, The Medical College of Wisconsin, Milwaukee, WI 53226, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rutter</LastName><ForeName>Jacqueline</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>RECOVER Patient, Caregiver, or Community Advocate Representative, New York, NY 10012, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martinez</LastName><ForeName>Aaron Thomas</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>RECOVER Patient, Caregiver, or Community Advocate Representative, New York, NY 10012, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Letts</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>RECOVER Patient, Caregiver, or Community Advocate Representative, New York, NY 10012, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bailey</LastName><ForeName>L Charles</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>Applied Clinical Research Center, Children's Hospital of Philadelphia, Philadelphia, PA 19104, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Forrest</LastName><ForeName>Christopher B</ForeName><Initials>CB</Initials><Identifier Source="ORCID">0000-0003-1252-068X</Identifier><AffiliationInfo><Affiliation>Applied Clinical Research Center, Children's Hospital of Philadelphia, Philadelphia, PA 19104, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>RECOVER Consortium </CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMIA Open</MedlineTA><NlmUniqueID>101730643</NlmUniqueID><ISSNLinking>2574-2531</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">NLP</Keyword><Keyword MajorTopicYN="N">PEDSnet</Keyword><Keyword MajorTopicYN="N">RECOVER</Keyword><Keyword MajorTopicYN="N">pediatrics</Keyword></KeywordList><CoiStatement>R.J. is a consultant for AstraZeneca, Seqirus, Dynavax, receives an editorial stipend from Elsevier and Pediatric Infectious Diseases Society and royalties from Up To Date/Wolters Kluwer. P.P. reports funding from the National Institute of Health and Bayer Pharmaceuticals. M.A.D. is funded by the National Heart, Lung, Blood Institute (NHLBI) award number: 1K01HL169493-01. S.R. reports prior grant support from GSK and Biofire and is a consultant for Sequiris. L.C.B. has received grants from Patient-Centered Outcomes Research Institute. All other authors have no conflicts of interest to report.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Diaz</LastName><ForeName>Iv&#xe1;n</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kenny</LastName><ForeName>Rachel</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Divers</LastName><ForeName>Jasmin</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thorpe</LastName><ForeName>Lorna</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mandel</LastName><ForeName>Hannah</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Truong</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wuller</LastName><ForeName>Shannon Wilneff</ForeName><Initials>SW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jhaveri</LastName><ForeName>Ravi</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rosenman</LastName><ForeName>Marc</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rao</LastName><ForeName>Suchitra</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Davies</LastName><ForeName>Sara J Deakyne</ForeName><Initials>SJD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bailey</LastName><ForeName>L Charles</ForeName><Initials>LC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Forrest</LastName><ForeName>Christopher B</ForeName><Initials>CB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pajor</LastName><ForeName>Nathan M</ForeName><Initials>NM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nandagopal</LastName><ForeName>Jyothi Priya Alekapatti</ForeName><Initials>JPA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Taylor</LastName><ForeName>Bradley W</ForeName><Initials>BW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stoddard</LastName><ForeName>Alexander</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kelleher</LastName><ForeName>Kelly J</ForeName><Initials>KJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huang</LastName><ForeName>Yungui</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bunnell</LastName><ForeName>H Timothy</ForeName><Initials>HT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sills</LastName><ForeName>Marion R</ForeName><Initials>MR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Le</LastName><ForeName>Thuy</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Christakis</LastName><ForeName>Dimitri A</ForeName><Initials>DA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ranade</LastName><ForeName>Daksha</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schroeder</LastName><ForeName>Alan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Morse</LastName><ForeName>Keith E</ForeName><Initials>KE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cummins</LastName><ForeName>Mollie R</ForeName><Initials>MR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gouripeddi</LastName><ForeName>Ramkiran</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cowell</LastName><ForeName>Lindsay G</ForeName><Initials>LG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Reeder</LastName><ForeName>Phillip</ForeName><Initials>P</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>2</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>7</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>7</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>8</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>8</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>8</Day><Hour>7</Hour><Minute>16</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40918941</ArticleId><ArticleId IdType="pmc">PMC12409404</ArticleId><ArticleId IdType="doi">10.1093/jamiaopen/ooaf089</ArticleId><ArticleId IdType="pii">ooaf089</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rytter MJH. &#xa0;Difficult questions about long COVID in children. Lancet Child Adolesc Health. 2022;6:595-597. 10.1016/S2352-4642(22)00167-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-4642(22)00167-5</ArticleId><ArticleId IdType="pmc">PMC9221929</ArticleId><ArticleId IdType="pubmed">35752193</ArticleId></ArticleIdList></Reference><Reference><Citation>Courtney D, Watson P, Battaglia M, et al. &#xa0;COVID-19 impacts on child and youth anxiety and depression: challenges and opportunities. Can J Psychiatry. 2020;65:688-691. 10.1177/0706743720935646</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0706743720935646</ArticleId><ArticleId IdType="pmc">PMC7502880</ArticleId><ArticleId IdType="pubmed">32567353</ArticleId></ArticleIdList></Reference><Reference><Citation>Committee on Examining the Working Definition for Long COVID, Board on Health Sciences Policy, Board on Global Health, et al. &#xa0;A Long COVID Definition: A Chronic, Systemic Disease State with Profound Consequences. National Academies Press; 2024.</Citation><ArticleIdList><ArticleId IdType="pubmed">39110819</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfaff ER, Madlock-Brown C, Baratta JM, et al. ; RECOVER Consortium. Coding long COVID: characterizing a new disease through an ICD-10 lens. BMC Med. 2023;21:58. 10.1186/s12916-023-02737-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-023-02737-6</ArticleId><ArticleId IdType="pmc">PMC9931566</ArticleId><ArticleId IdType="pubmed">36793086</ArticleId></ArticleIdList></Reference><Reference><Citation>Malden DE, Tartof SY, Ackerson BK, et al. &#xa0;Natural language processing for improved characterization of COVID-19 symptoms: observational study of 350,000 patients in a large integrated health care system. JMIR Public Health Surveill. 2022;8:e41529. 10.2196/41529</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/41529</ArticleId><ArticleId IdType="pmc">PMC9822566</ArticleId><ArticleId IdType="pubmed">36446133</ArticleId></ArticleIdList></Reference><Reference><Citation>Silverman GM, Sahoo HS, Ingraham NE, et al. &#xa0;NLP methods for extraction of symptoms from unstructured data for use in prognostic COVID-19 analytic models. JAIR. 2021;72:429-474. 10.1613/jair.1.12631</Citation><ArticleIdList><ArticleId IdType="doi">10.1613/jair.1.12631</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang L, Foer D, MacPhaul E, et al. &#xa0;PASCLex: a comprehensive post-acute sequelae of COVID-19 (PASC) symptom lexicon derived from electronic health record clinical notes. J Biomed Inform. 2022;125:103951. 10.1016/j.jbi.2021.103951</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2021.103951</ArticleId><ArticleId IdType="pmc">PMC8590503</ArticleId><ArticleId IdType="pubmed">34785382</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S, Wen A, Wang L, et al. &#xa0;An open natural language processing (NLP) framework for EHR-based clinical research: a case demonstration using the national COVID cohort collaborative (N3C). J Am Med Inform Assoc. 2023;30:2036-2040. 10.1093/jamia/ocad134</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamia/ocad134</ArticleId><ArticleId IdType="pmc">PMC10654844</ArticleId><ArticleId IdType="pubmed">37555837</ArticleId></ArticleIdList></Reference><Reference><Citation>Bailey LC, Razzaghi H, Burrows EK, et al. &#xa0;Assessment of 135&#x202f;794 pediatric patients tested for severe acute respiratory syndrome coronavirus 2 across the United States. JAMA Pediatr. 2021;175:176-184. 10.1001/jamapediatrics.2020.5052</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapediatrics.2020.5052</ArticleId><ArticleId IdType="pmc">PMC7684518</ArticleId><ArticleId IdType="pubmed">33226415</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorman V, Razzaghi H, Song X, et al. &#xa0;A machine learning-based phenotype for long COVID in children: an EHR-based study from the RECOVER program. PLoS One. 2023;18:e0289774. 10.1371/journal.pone.0289774</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0289774</ArticleId><ArticleId IdType="pmc">PMC10414557</ArticleId><ArticleId IdType="pubmed">37561683</ArticleId></ArticleIdList></Reference><Reference><Citation>
RECOVER COVID Initiative. Accessed November 4, 2024. https://recovercovid.org/</Citation></Reference><Reference><Citation>
Datta S, Posada J, Olson G, et al.  A new paradigm for accelerating clinical data science at Stanford Medicine. <i>arXiv preprint arXiv:2003.10534</i>. 2020.</Citation></Reference><Reference><Citation>
John Snow Labs. John Snow Labs. Accessed November 4, 2024. https://www.johnsnowlabs.com</Citation></Reference><Reference><Citation>
Mikolov T, Chen K, Corrado G, et al.  Efficient estimation of word representations in vector space. <i>arXiv preprint arXiv:1301.3781</i>. 2013.</Citation></Reference><Reference><Citation>Rao S, Jing N, Liu X, et al. &#xa0;Spectrum of severity of multisystem inflammatory syndrome in children: an EHR-based cohort study from the RECOVER program. Sci Rep. 2023;13:21005. 10.1038/s41598-023-47655-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-47655-y</ArticleId><ArticleId IdType="pmc">PMC10684592</ArticleId><ArticleId IdType="pubmed">38017007</ArticleId></ArticleIdList></Reference><Reference><Citation>
Gamer M, Lemon J, Singh IFP. irr: various coefficients of interrater reliability and agreement. R package version 0.84.1.2019. https://CRAN.R-project.org/package=irr</Citation></Reference><Reference><Citation>Huang J, Yang DM, Rong R, et al. &#xa0;A critical assessment of using ChatGPT for extracting structured data from clinical notes. npj Digit Med. 2024;7:106. 10.1038/s41746-024-01079-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41746-024-01079-8</ArticleId><ArticleId IdType="pmc">PMC11063058</ArticleId><ArticleId IdType="pubmed">38693429</ArticleId></ArticleIdList></Reference><Reference><Citation>Reategui-Rivera CM, Finkelstein J. &#xa0;Evaluation of the performance of a large language model to extract signs and symptoms from clinical notes. Stud Health Technol Inform. 2025;323:71-75. 10.3233/SHTI250051</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/SHTI250051</ArticleId><ArticleId IdType="pubmed">40200448</ArticleId></ArticleIdList></Reference><Reference><Citation>
Mialon G, Dess&#xec; R, Lomeli M, et al.  Augmented language models: a survey. <i>arXiv preparint arXiv:2302.07842.</i> &#xa0;2023.</Citation></Reference><Reference><Citation>Rao S, Lee GM, Razzaghi H, et al. &#xa0;Clinical features and burden of postacute sequelae of SARS-CoV-2 infection in children and adolescents. JAMA Pediatr. 2022;176:1000-1009. 10.1001/jamapediatrics.2022.2800</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapediatrics.2022.2800</ArticleId><ArticleId IdType="pmc">PMC9396470</ArticleId><ArticleId IdType="pubmed">35994282</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorman V, Rao S, Jhaveri R, et al. &#xa0;Understanding pediatric long COVID using a tree-based scan statistic approach: an EHR-based cohort study from the RECOVER program. JAMIA Open. 2023;6:ooad016. 10.1093/jamiaopen/ooad016</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamiaopen/ooad016</ArticleId><ArticleId IdType="pmc">PMC10013630</ArticleId><ArticleId IdType="pubmed">36926600</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40921381</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1916-7075</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Sep</Month><Day>06</Day></PubDate></JournalIssue><Title>The Canadian journal of cardiology</Title><ISOAbbreviation>Can J Cardiol</ISOAbbreviation></Journal><ArticleTitle>GLP-1 receptor agonists versus SGLT2 inhibitors in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">S0828-282X(25)01056-6</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cjca.2025.08.359</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Huilin</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, Pennsylvania, USA; Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Ting</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, Pennsylvania, USA; Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Bingyu</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, Pennsylvania, USA; The Graduate Group in Applied Mathematics and Computational Science, School of Arts and Sciences, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Yiwen</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, Pennsylvania, USA; The Graduate Group in Applied Mathematics and Computational Science, School of Arts and Sciences, University of Pennsylvania, Philadelphia, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kimmel</LastName><ForeName>Stephen E</ForeName><Initials>SE</Initials><AffiliationInfo><Affiliation>Department of Epidemiology, College of Public Health and Health Professions and College of Medicine, University of Florida, Gainesville, Florida, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lu</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Section of Cardiovascular Medicine, Department of Medicine, Yale School of Medicine, New Haven, CT, USA; Center for Outcomes Research and Evaluation, Yale New Haven Health, New Haven, CT, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Asch</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, PA, USA; Wharton School, University of Pennsylvania, Philadelphia, PA, USA; Division of General Internal Medicine, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yong</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>The Center for Health AI and Synthesis of Evidence (CHASE), University of Pennsylvania, Philadelphia, Pennsylvania, USA; Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA; The Graduate Group in Applied Mathematics and Computational Science, School of Arts and Sciences, University of Pennsylvania, Philadelphia, Pennsylvania, USA; Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, PA, USA; Penn Medicine Center for Evidence-based Practice (CEP), Philadelphia, Pennsylvania, USA; Penn Institute for Biomedical Informatics (IBI), Philadelphia, Pennsylvania, USA. Electronic address: ychen123@upenn.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Can J Cardiol</MedlineTA><NlmUniqueID>8510280</NlmUniqueID><ISSNLinking>0828-282X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>7</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>9</Day><Hour>0</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>9</Day><Hour>0</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>8</Day><Hour>19</Hour><Minute>13</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40921381</ArticleId><ArticleId IdType="doi">10.1016/j.cjca.2025.08.359</ArticleId><ArticleId IdType="pii">S0828-282X(25)01056-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40922038</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2230</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2025</Year><Month>Sep</Month><Day>09</Day></PubDate></JournalIssue><Title>Clinical and experimental dermatology</Title><ISOAbbreviation>Clin Exp Dermatol</ISOAbbreviation></Journal><ArticleTitle>Association of Autoimmune Disease with Melanoma and Non-Melanoma Skin Cancers.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">llaf409</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/ced/llaf409</ELocationID><Abstract><AbstractText>This study examines the association between autoimmune diseases and melanoma and non-melanoma skin cancer using data from the All of Us Research Program. We conducted a cross-sectional analysis including 419,789 participants using multivariable logistic regression models adjusting for sociodemographic variables, comorbidities, and immunosuppressant use. We found significant associations between melanoma and Sj&#xf6;gren's syndrome, inflammatory bowel disease (IBD), vitiligo, and autoimmune thyroiditis. Non-melanoma skin cancer risk was elevated in Sj&#xf6;gren's, IBD, and Type 1 diabetes mellitus. Notably, our finding of increased melanoma and basal cell carcinoma risk in vitiligo contrasts with prior studies. These differences may reflect increased genetic diversity in our cohort or confounding by immune checkpoint inhibitor use. Our findings demonstrate increased risk of both melanoma and non-melanoma skin cancer in patients with select autoimmune diseases, highlighting the importance of heightened surveillance in high-risk autoimmune populations and the need for future research into immune-related mechanisms driving skin cancer susceptibility.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2025. Published by Oxford University Press on behalf of British Association of Dermatologists. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site&#x2014;for further information please contact journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Joel</LastName><ForeName>Marina Z</ForeName><Initials>MZ</Initials><Identifier Source="ORCID">0000-0001-8208-011X</Identifier><AffiliationInfo><Affiliation>Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Saloni</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Jun</ForeName><Initials>J</Initials><Identifier Source="ORCID">0009-0001-7883-0798</Identifier><AffiliationInfo><Affiliation>Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sunshine</LastName><ForeName>Joel C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Dermatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Clin Exp Dermatol</MedlineTA><NlmUniqueID>7606847</NlmUniqueID><ISSNLinking>0307-6938</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>8</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>9</Day><Hour>0</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>9</Day><Hour>0</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>8</Day><Hour>23</Hour><Minute>32</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40922038</ArticleId><ArticleId IdType="doi">10.1093/ced/llaf409</ArticleId><ArticleId IdType="pii">8249447</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">40937424</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>15</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2753-4294</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>2</Issue><PubDate><Year>2025</Year></PubDate></JournalIssue><Title>BMJ public health</Title><ISOAbbreviation>BMJ Public Health</ISOAbbreviation></Journal><ArticleTitle>Changes in mental health care utilisation before and during the COVID-19 pandemic among people living with HIV in the USA: a retrospective cohort study using the All of Us dataset.</ArticleTitle><Pagination><StartPage>e002173</StartPage><MedlinePgn>e002173</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e002173</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjph-2024-002173</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">Despite the profound impact of the COVID-19 pandemic on people living with HIV (PLWH) mental health, large-scale, real-world data on mental healthcare utilisation and associated factors among PLWH remain limited. This study explores mental healthcare utilisation and associated factors among PLWH during the COVID-19 pandemic.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Using a retrospective cohort design, we identified and included 4575 PLWH through computational phenotyping based on relevant Observational Medical Outcomes Partnership Common Data Model concept sets from the All of Us programme between March 2018 and March 2022. Mental healthcare utilisation was measured using the yearly count of mental healthcare visits and compared between pre-pandemic (2018-2020) and during the pandemic (2020-2022). Incidence rate ratios (IRRs) from the Poisson generalised linear mixed models were used to examine associations between mental healthcare utilisation, history of COVID-19 infection, demographic factors, pre-existing chronic conditions and socioeconomic status.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">Annual number of mental healthcare visits among PLWH decreased significantly during the pandemic compared with pre-pandemic (IRR=0.89, p&lt;0.001). COVID-19 infection (IRR=1.35, p&lt;0.001), pre-existing comorbidities (one comorbidity: IRR=5.49; two or more: IRR=10.4, p&lt;0.001) and Medicaid health insurance (IRR=1.29, p=0.007) were associated with a higher number of visits. Middle-aged group participants (aged 30-39: IRR=2.35, p=0.002; 40-49: IRR=3.49, p&lt;0.001 and 50-64: IRR=2.07, p=0.004) had higher visit numbers compared with the youngest group (18-29 years). Compared with white participants, black or African American (IRR=0.71, p=0.002) and those with employer-sponsored or union-sponsored insurance (IRR=0.54, p&lt;0.001) had fewer visits.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">This study reveals a decrease in mental healthcare utilisation and diverse experiences of mental healthcare among PLWH during the COVID-19 pandemic. Addressing these disparities is crucial, particularly during public health emergencies.</AbstractText><CopyrightInformation>Copyright &#xa9; Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. Published by BMJ Group.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pasha</LastName><ForeName>Atena</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0001-5603-4961</Identifier><AffiliationInfo><Affiliation>Department of Health Promotion, Education, and Behavior, Arnold School of Public Health, University of South Carolina, Columbia, South Carolina, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>South Carolina SmartState Center for Healthcare Quality, Arnold School of Public Health, University of South Carolina, Columbia, South Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiao</LastName><ForeName>Shan</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-1834-1834</Identifier><AffiliationInfo><Affiliation>Department of Health Promotion, Education, and Behavior, Arnold School of Public Health, University of South Carolina, Columbia, South Carolina, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>South Carolina SmartState Center for Healthcare Quality, Arnold School of Public Health, University of South Carolina, Columbia, South Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jiajia</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>South Carolina SmartState Center for Healthcare Quality, Arnold School of Public Health, University of South Carolina, Columbia, South Carolina, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, Arnold School of Public Health, University of South Carolina, Columbia, South Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cai</LastName><ForeName>Ruilie</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>South Carolina SmartState Center for Healthcare Quality, Arnold School of Public Health, University of South Carolina, Columbia, South Carolina, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, Arnold School of Public Health, University of South Carolina, Columbia, South Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Buwei</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>South Carolina SmartState Center for Healthcare Quality, Arnold School of Public Health, University of South Carolina, Columbia, South Carolina, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, Arnold School of Public Health, University of South Carolina, Columbia, South Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Xueying</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Health Promotion, Education, and Behavior, Arnold School of Public Health, University of South Carolina, Columbia, South Carolina, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>South Carolina SmartState Center for Healthcare Quality, Arnold School of Public Health, University of South Carolina, Columbia, South Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Chen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>South Carolina SmartState Center for Healthcare Quality, Arnold School of Public Health, University of South Carolina, Columbia, South Carolina, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Health Services Policy and Management, Arnold School of Public Health, University of South Carolina, Columbia, South Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weissman</LastName><ForeName>Sharon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>South Carolina SmartState Center for Healthcare Quality, Arnold School of Public Health, University of South Carolina, Columbia, South Carolina, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Internal Medicine, School of Medicine Columbia, University of South Carolina, Columbia, South Carolina, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiaoming</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Health Promotion, Education, and Behavior, Arnold School of Public Health, University of South Carolina, Columbia, South Carolina, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>South Carolina SmartState Center for Healthcare Quality, Arnold School of Public Health, University of South Carolina, Columbia, South Carolina, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Public Health</MedlineTA><NlmUniqueID>9918697578906676</NlmUniqueID><ISSNLinking>2753-4294</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">HIV</Keyword><Keyword MajorTopicYN="N">Health Services Accessibility</Keyword><Keyword MajorTopicYN="N">Mental Health</Keyword></KeywordList><CoiStatement>None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>10</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>12</Day><Hour>4</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40937424</ArticleId><ArticleId IdType="pmc">PMC12421162</ArticleId><ArticleId IdType="doi">10.1136/bmjph-2024-002173</ArticleId><ArticleId IdType="pii">bmjph-2024-002173</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Joseph OL, Hall A, Devlin SA, et al. &#x201c;When you have an immune disease like HIV and there is a pandemic, you still have to pay your bills&#x201d;: COVID-19-related challenges among people living with HIV and lessons for care delivery. AIDS Care. 2022;34:1405&#x2013;12. doi: 10.1080/09540121.2022.2067314.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09540121.2022.2067314</ArticleId><ArticleId IdType="pmc">PMC9596614</ArticleId><ArticleId IdType="pubmed">35473487</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicola M, Alsafi Z, Sohrabi C, et al. The socio-economic implications of the coronavirus pandemic (COVID-19): A review. Int J Surg. 2020;78:185&#x2013;93. doi: 10.1016/j.ijsu.2020.04.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijsu.2020.04.018</ArticleId><ArticleId IdType="pmc">PMC7162753</ArticleId><ArticleId IdType="pubmed">32305533</ArticleId></ArticleIdList></Reference><Reference><Citation>Olff M, Primasari I, Qing Y, et al. Mental health responses to COVID-19 around the world. Eur J Psychotraumatol. 2021;12:1929754. doi: 10.1080/20008198.2021.1929754.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/20008198.2021.1929754</ArticleId><ArticleId IdType="pmc">PMC8253206</ArticleId><ArticleId IdType="pubmed">34262666</ArticleId></ArticleIdList></Reference><Reference><Citation>Nedelcovych MT, Manning AA, Semenova S, et al. The psychiatric impact of HIV. ACS Publications; 2017. pp. 1432&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5769465</ArticleId><ArticleId IdType="pubmed">28537385</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe9;mar V, Hessamfar M, Neau D, et al. A comprehensive analysis of excess depressive disorder in women and men living with HIV in France compared to the general population. Sci Rep. 2022;12:6364. doi: 10.1038/s41598-022-10263-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-10263-3</ArticleId><ArticleId IdType="pmc">PMC9013369</ArticleId><ArticleId IdType="pubmed">35430622</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO COVID-19 pandemic triggers 25% increase in prevalence of anxiety and depression worldwide. 2022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9998057</ArticleId><ArticleId IdType="pubmed">35414629</ArticleId></ArticleIdList></Reference><Reference><Citation>Robertson K, Parsons TD, Van Der Horst C, et al. Thoughts of death and suicidal ideation in nonpsychiatric human immunodeficiency virus seropositive individuals. Death Stud. 2006;30:455&#x2013;69. doi: 10.1080/07481180600614435.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07481180600614435</ArticleId><ArticleId IdType="pubmed">16610158</ArticleId></ArticleIdList></Reference><Reference><Citation>Keiser O, Spoerri A, Brinkhof MWG, et al. Suicide in HIV-infected individuals and the general population in Switzerland, 1988-2008. Am J Psychiatry. 2010;167:143&#x2013;50. doi: 10.1176/appi.ajp.2009.09050651.</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.2009.09050651</ArticleId><ArticleId IdType="pubmed">20008942</ArticleId></ArticleIdList></Reference><Reference><Citation>Ji J, Zhang Y, Ma Y, et al. People who living with HIV/AIDS also have a high prevalence of anxiety disorders: a systematic review and meta-analysis. Front Psychiatry. 2024;15:1259290. doi: 10.3389/fpsyt.2024.1259290.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fpsyt.2024.1259290</ArticleId><ArticleId IdType="pmc">PMC10877523</ArticleId><ArticleId IdType="pubmed">38380124</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee KW, Ang CS, Lim SH, et al. Prevalence of mental health conditions among people living with HIV during the COVID-19 pandemic: A rapid systematic review and meta-analysis. HIV Med. 2022;23:990&#x2013;1001. doi: 10.1111/hiv.13299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/hiv.13299</ArticleId><ArticleId IdType="pmc">PMC9111307</ArticleId><ArticleId IdType="pubmed">35304829</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong C, Queiroz A, Hoskin J. The impact of the COVID&#x2010;19 pandemic on mental health, associated factors and coping strategies in people living with HIV: a scoping review. J Int AIDS Soc . 2023;26:e26060. doi: 10.1002/jia2.26060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jia2.26060</ArticleId><ArticleId IdType="pmc">PMC10009802</ArticleId><ArticleId IdType="pubmed">36912238</ArticleId></ArticleIdList></Reference><Reference><Citation>Remien RH, Stirratt MJ, Nguyen N, et al. Mental health and HIV/AIDS: the need for an integrated response. AIDS. 2019;33:1411&#x2013;20. doi: 10.1097/QAD.0000000000002227.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAD.0000000000002227</ArticleId><ArticleId IdType="pmc">PMC6635049</ArticleId><ArticleId IdType="pubmed">30950883</ArticleId></ArticleIdList></Reference><Reference><Citation>Shiau S, Krause KD, Valera P, et al. The Burden of COVID-19 in People Living with HIV: A Syndemic Perspective. AIDS Behav. 2020;24:2244&#x2013;9. doi: 10.1007/s10461-020-02871-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10461-020-02871-9</ArticleId><ArticleId IdType="pmc">PMC7165075</ArticleId><ArticleId IdType="pubmed">32303925</ArticleId></ArticleIdList></Reference><Reference><Citation>Marhefka S, Lockhart E, Turner D. Achieve Research Continuity During Social Distancing by Rapidly Implementing Individual and Group Videoconferencing with Participants: Key Considerations, Best Practices, and Protocols. AIDS Behav. 2020;24:1983&#x2013;9. doi: 10.1007/s10461-020-02837-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10461-020-02837-x</ArticleId><ArticleId IdType="pmc">PMC7114952</ArticleId><ArticleId IdType="pubmed">32240428</ArticleId></ArticleIdList></Reference><Reference><Citation>Gogia SB, Maeder A, Mars M, et al. Unintended Consequences of Tele Health and their Possible Solutions. Yearb Med Inform. 2016;25:41&#x2013;6. doi: 10.15265/IY-2016-012.</Citation><ArticleIdList><ArticleId IdType="doi">10.15265/IY-2016-012</ArticleId><ArticleId IdType="pmc">PMC5171569</ArticleId><ArticleId IdType="pubmed">27830229</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson M, Perrin A. Technology use among seniors. Washington, DC: Pew Research Center for Internet &amp; Technology; 2017.</Citation></Reference><Reference><Citation>Qiao S, Zhang J, Liang C, et al. Using All of Us data to examine the mental health change during COVID-19 pandemic among people living with HIV: A longitudinal study protocol. BMJ Open. 2023;13:e071285. doi: 10.1136/bmjopen-2022-071285.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2022-071285</ArticleId><ArticleId IdType="pmc">PMC10551941</ArticleId><ArticleId IdType="pubmed">37788923</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun S, Hou J, Chen Y, et al. Challenges to HIV Care and Psychological Health During the COVID-19 Pandemic Among People Living with HIV in China. AIDS Behav. 2020;24:2764&#x2013;5. doi: 10.1007/s10461-020-02903-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10461-020-02903-4</ArticleId><ArticleId IdType="pmc">PMC7203543</ArticleId><ArticleId IdType="pubmed">32382824</ArticleId></ArticleIdList></Reference><Reference><Citation>Uribe PRS, Zetina ASS, Montgomerie EK, et al. 482. impact of COVID-19 pandemic on psychosocial and clinical factors among people with and without HIV living in Miami. Oxford University Press US; 2020. S308</Citation></Reference><Reference><Citation>Ciesla JA, Roberts JE. Meta-analysis of the relationship between HIV infection and risk for depressive disorders. Am J Psychiatry. 2001;158:725&#x2013;30. doi: 10.1176/appi.ajp.158.5.725.</Citation><ArticleIdList><ArticleId IdType="doi">10.1176/appi.ajp.158.5.725</ArticleId><ArticleId IdType="pubmed">11329393</ArticleId></ArticleIdList></Reference><Reference><Citation>Winwood JJ, Fitzgerald L, Gardiner B, et al. Exploring the Social Impacts of the COVID-19 Pandemic on People Living with HIV (PLHIV): A Scoping Review. AIDS Behav. 2021;25:4125&#x2013;40. doi: 10.1007/s10461-021-03300-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10461-021-03300-1</ArticleId><ArticleId IdType="pmc">PMC8137806</ArticleId><ArticleId IdType="pubmed">34019203</ArticleId></ArticleIdList></Reference><Reference><Citation>Ssentongo P, Heilbrunn ES, Ssentongo AE, et al. Epidemiology and outcomes of COVID-19 in HIV-infected individuals: a systematic review and meta-analysis. Sci Rep. 2021;11:6283. doi: 10.1038/s41598-021-85359-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-85359-3</ArticleId><ArticleId IdType="pmc">PMC7973415</ArticleId><ArticleId IdType="pubmed">33737527</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Penney AT, Iudicello JE, Riggs PK, et al. Co-morbidities in persons infected with HIV: increased burden with older age and negative effects on health-related quality of life. AIDS Patient Care STDS. 2013;27:5&#x2013;16. doi: 10.1089/apc.2012.0329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/apc.2012.0329</ArticleId><ArticleId IdType="pmc">PMC3545369</ArticleId><ArticleId IdType="pubmed">23305257</ArticleId></ArticleIdList></Reference><Reference><Citation>Surveillances V. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19)&#x2014;China, 2020. China CDC Weekly. 2020;2:113&#x2013;22. doi: 10.46234/ccdcw2020.032.</Citation><ArticleIdList><ArticleId IdType="doi">10.46234/ccdcw2020.032</ArticleId><ArticleId IdType="pmc">PMC8392929</ArticleId><ArticleId IdType="pubmed">34594836</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020;395:1054&#x2013;62. doi: 10.1016/S0140-6736(20)30566-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30566-3</ArticleId><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao J, Tu W-J, Cheng W, et al. Clinical Features and Short-term Outcomes of 102 Patients with Coronavirus Disease 2019 in Wuhan, China. Clin Infect Dis. 2020;71:748&#x2013;55. doi: 10.1093/cid/ciaa243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa243</ArticleId><ArticleId IdType="pmc">PMC7184479</ArticleId><ArticleId IdType="pubmed">32239127</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos G-M, Ackerman B, Rao A, et al. Economic, Mental Health, HIV Prevention and HIV Treatment Impacts of COVID-19 and the COVID-19 Response on a Global Sample of Cisgender Gay Men and Other Men Who Have Sex with Men. AIDS Behav. 2021;25:311&#x2013;21. doi: 10.1007/s10461-020-02969-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10461-020-02969-0</ArticleId><ArticleId IdType="pmc">PMC7352092</ArticleId><ArticleId IdType="pubmed">32654021</ArticleId></ArticleIdList></Reference><Reference><Citation>Javanbakht M, Rosen A, Ragsdale A, et al. Interruptions in Mental Health Care, Cannabis Use, Depression, and Anxiety during the COVID-19 Pandemic: Findings from a Cohort of HIV-Positive and HIV-Negative MSM in Los Angeles, California. J Urban Health. 2022;99:305&#x2013;15. doi: 10.1007/s11524-022-00607-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11524-022-00607-9</ArticleId><ArticleId IdType="pmc">PMC8890012</ArticleId><ArticleId IdType="pubmed">35235134</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X, Zhang J, Cai R, et al. Computational phenotyping with the All of Us Research Program: identifying underrepresented people with HIV or at risk of HIV. JAMIA Open. 2023;6:ooad071. doi: 10.1093/jamiaopen/ooad071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jamiaopen/ooad071</ArticleId><ArticleId IdType="pmc">PMC10444028</ArticleId><ArticleId IdType="pubmed">37614566</ArticleId></ArticleIdList></Reference><Reference><Citation>Barr PB, Bigdeli TB, Meyers JL. Prevalence, Comorbidity, and Sociodemographic Correlates of Psychiatric Disorders Reported in the All of Us Research Program. JAMA Psychiatry. 2022;79:622&#x2013;8. doi: 10.1001/jamapsychiatry.2022.0685.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapsychiatry.2022.0685</ArticleId><ArticleId IdType="pmc">PMC9021986</ArticleId><ArticleId IdType="pubmed">35442391</ArticleId></ArticleIdList></Reference><Reference><Citation>Sundararajan V, Henderson T, Perry C, et al. New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality. J Clin Epidemiol. 2004;57:1288&#x2013;94. doi: 10.1016/j.jclinepi.2004.03.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jclinepi.2004.03.012</ArticleId><ArticleId IdType="pubmed">15617955</ArticleId></ArticleIdList></Reference><Reference><Citation>May D, Fullilove R. Depression, HIV, and COVID-19: A Deadly Trifecta. Public Health Rep . 2022;137:420&#x2013;4. doi: 10.1177/00333549221074389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/00333549221074389</ArticleId><ArticleId IdType="pmc">PMC9109531</ArticleId><ArticleId IdType="pubmed">35137644</ArticleId></ArticleIdList></Reference><Reference><Citation>Pantelic M, Martin K, Fitzpatrick C, et al. &#x201c;I have the strength to get through this using my past experiences with HIV&#x201d;: findings from a mixed-method survey of health outcomes, service accessibility, and psychosocial wellbeing among people living with HIV during the Covid-19 pandemic. AIDS Care. 2022;34:821&#x2013;7. doi: 10.1080/09540121.2021.1975628.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09540121.2021.1975628</ArticleId><ArticleId IdType="pubmed">34530649</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaafari Z, Eybpoosh S, Sharifi H, et al. Exploration of the Impact of Coronavirus Disease 2019 on People Living With HIV in Kerman, Iran: A Qualitative Study. J Assoc Nurses AIDS Care. 2022;33:386&#x2013;94. doi: 10.1097/JNC.0000000000000303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/JNC.0000000000000303</ArticleId><ArticleId IdType="pubmed">35772075</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO The impact of COVID-19 on mental, neurological and substance use services: results of a rapid assessment. 2020</Citation></Reference><Reference><Citation>Delle Donne V, Ciccarelli N, Massaroni V, et al. Psychological distress during the initial stage of the COVID-19 pandemic in an Italian population living with HIV: an online survey. Infez Med. 2021;29:54&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">33664173</ArticleId></ArticleIdList></Reference><Reference><Citation>Pizzirusso M, Carrion-Park C, Clark US, et al. Physical and Mental Health Screening in a New York City HIV Cohort During the COVID-19 Pandemic: A Preliminary Report. J Acquir Immune Defic Syndr . 2021;86:e54&#x2013;60. doi: 10.1097/QAI.0000000000002564.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAI.0000000000002564</ArticleId><ArticleId IdType="pmc">PMC7878300</ArticleId><ArticleId IdType="pubmed">33148994</ArticleId></ArticleIdList></Reference><Reference><Citation>Kalichman SC, El-Krab R. Social and Behavioral Impacts of COVID-19 on People Living with HIV: Review of the First Year of Research. Curr HIV/AIDS Rep. 2022;19:54&#x2013;75. doi: 10.1007/s11904-021-00593-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11904-021-00593-8</ArticleId><ArticleId IdType="pmc">PMC8617547</ArticleId><ArticleId IdType="pubmed">34826067</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigel K, Swartz T, Golden E, et al. Coronavirus 2019 and People Living With Human Immunodeficiency Virus: Outcomes for Hospitalized Patients in New York City. Clin Infect Dis. 2020;71:2933&#x2013;8. doi: 10.1093/cid/ciaa880.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa880</ArticleId><ArticleId IdType="pmc">PMC7337691</ArticleId><ArticleId IdType="pubmed">32594164</ArticleId></ArticleIdList></Reference><Reference><Citation>Rockwell KL, Gilroy AS. Incorporating telemedicine as part of COVID-19 outbreak response systems. Am J Manag Care. 2020;26:147&#x2013;8. doi: 10.37765/ajmc.2020.42784.</Citation><ArticleIdList><ArticleId IdType="doi">10.37765/ajmc.2020.42784</ArticleId><ArticleId IdType="pubmed">32270980</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson M, Perrin A.  Science &amp; Tech; 2017. Technology use among seniors. Pew research center.https://www pewresearch org/internet/2017/05/17/technology-use-among-seniors Available.</Citation></Reference><Reference><Citation>Jones DL, Morgan KE, Martinez PC, et al. COVID-19 Burden and Risk Among People With HIV. J Acquir Immune Defic Syndr. 2021;87:869&#x2013;74. doi: 10.1097/QAI.0000000000002656.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAI.0000000000002656</ArticleId><ArticleId IdType="pmc">PMC8136457</ArticleId><ArticleId IdType="pubmed">33999015</ArticleId></ArticleIdList></Reference><Reference><Citation>Too EK, Abubakar A, Nasambu C, et al. Prevalence and factors associated with common mental disorders in young people living with HIV in sub-Saharan Africa: a systematic review. J Int AIDS Soc. 2021;24 Suppl 2:e25705. doi: 10.1002/jia2.25705.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jia2.25705</ArticleId><ArticleId IdType="pmc">PMC8222842</ArticleId><ArticleId IdType="pubmed">34164931</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiong J, Lipsitz O, Nasri F, et al. Impact of COVID-19 pandemic on mental health in the general population: A systematic review. J Affect Disord. 2020;277:55&#x2013;64. doi: 10.1016/j.jad.2020.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jad.2020.08.001</ArticleId><ArticleId IdType="pmc">PMC7413844</ArticleId><ArticleId IdType="pubmed">32799105</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasha A, Bahrainian SA, Farahani H. The relationship between type D personality and the stress level of life events, personality traits and anxiety sensitivity in people with breast cancer. Annales M&#xe9;dico-Psychologiques, Revue Psychiatrique. 2022;180:527&#x2013;32. doi: 10.1016/j.amp.2021.02.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amp.2021.02.012</ArticleId></ArticleIdList></Reference><Reference><Citation>Tesoriero JM, Swain C-A, Pierce JL, et al. COVID-19 Outcomes Among Persons Living With or Without Diagnosed HIV Infection in New York State. JAMA Netw Open. 2021;4:e2037069. doi: 10.1001/jamanetworkopen.2020.37069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.37069</ArticleId><ArticleId IdType="pmc">PMC7859843</ArticleId><ArticleId IdType="pubmed">33533933</ArticleId></ArticleIdList></Reference><Reference><Citation>Balaji AB, Bowles KE, Hess KL, et al. Association Between Enacted Stigma and HIV-Related Risk Behavior Among MSM, National HIV Behavioral Surveillance System, 2011. AIDS Behav. 2017;21:227&#x2013;37. doi: 10.1007/s10461-016-1599-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10461-016-1599-z</ArticleId><ArticleId IdType="pubmed">27830344</ArticleId></ArticleIdList></Reference><Reference><Citation>Karram S, Sanger C, Convery C, et al. Social Determinants of Health Among Persons Living with HIV Impact Important Health Outcomes in Michigan. AIDS Behav. 2024;28:547&#x2013;63. doi: 10.1007/s10461-023-04243-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10461-023-04243-5</ArticleId><ArticleId IdType="pubmed">38180620</ArticleId></ArticleIdList></Reference><Reference><Citation>Iloanusi S, Yunusa I, Mgbere O, et al. Development and internal validation of a risk prediction model for HIV disease severity among people living with HIV and mental illness or substance use disorder. Ann Epidemiol. 2023;87:79&#x2013;92. doi: 10.1016/j.annepidem.2023.09.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annepidem.2023.09.007</ArticleId><ArticleId IdType="pubmed">37742879</ArticleId></ArticleIdList></Reference><Reference><Citation>Monroe AK, Myint L, M. Rutstein R, et al. Factors Associated With Gaps in Medicaid Enrollment Among People With HIV and the Effect of Gaps on Viral Suppression. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2018;78:413&#x2013;20. doi: 10.1097/QAI.0000000000001702.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAI.0000000000001702</ArticleId><ArticleId IdType="pmc">PMC8461635</ArticleId><ArticleId IdType="pubmed">29697594</ArticleId></ArticleIdList></Reference><Reference><Citation>Zefi V. Psycho-social challenges faced by people living with HIV during COVID-19 in Kosovo: a qualitative study. HIV &amp; AIDS Review. 2024;23:84&#x2013;9. doi: 10.5114/hivar.2024.135830.</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/hivar.2024.135830</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">40939242</PMID><DateRevised><Year>2025</Year><Month>09</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1532-8171</ISSN><JournalIssue CitedMedium="Internet"><Volume>98</Volume><PubDate><Year>2025</Year><Month>Sep</Month><Day>02</Day></PubDate></JournalIssue><Title>The American journal of emergency medicine</Title><ISOAbbreviation>Am J Emerg Med</ISOAbbreviation></Journal><ArticleTitle>Factors associated with acute unscheduled care visits for asthma in the all of US dataset.</ArticleTitle><Pagination><StartPage>276</StartPage><EndPage>282</EndPage><MedlinePgn>276-282</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ajem.2025.09.002</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0735-6757(25)00605-9</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Asthma exacerbations can cause patients to visit the emergency department (ED) without prior appointments. This study analyzed factors associated with unscheduled ED visits among asthma patients by examining the All of Us Research Program dataset.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a retrospective cohort study using the All of Us database (2018-2024). Electronic health records (EHR) were utilized to identify asthma patients based on physician-reported asthma diagnoses. Patients were divided into three groups based on ED visit frequency during the study period: General Asthma Patients (no ED visits), Single ED Visit Asthma Patients (one visit), and Frequent ED Visit Asthma Patients (more than one visit). Python and R were utilized to perform a multinomial logistic regression analysis in order to examine demographic factors, social determinants, healthcare accessibility, neighborhood conditions and comorbidities.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The research included 47, 227 asthma patients from a total participant pool of 409,420 individuals. The study included 33,046 (70.0&#xa0;%) General Asthma Patients with no ED visit record, 4779 (10.1&#xa0;%) Single ED Visit Asthma Patients with a single reported visit and 9402 (19.9&#xa0;%) Frequent ED Visit Asthma Patients with two or more ED visits. Factors significantly associated with frequent ED visits included income less than $10,000/year (OR&#xa0;=&#xa0;1.42; 95&#xa0;% CI [1.25-1.61]), Black/African American race (OR&#xa0;=&#xa0;2.08; 95&#xa0;% CI [1.61-2.68]), chest pain (OR&#xa0;=&#xa0;2.31; 95&#xa0;% CI [2.16-2.48]), hypertension (OR&#xa0;=&#xa0;1.19; 95&#xa0;% CI [1.11-1.28]), respiratory tract infections (OR&#xa0;=&#xa0;1.60; 95&#xa0;% CI [1.50-1.71]), anxiety (OR&#xa0;=&#xa0;1.17; 95&#xa0;% CI [1.08-1.28]), living near abandoned buildings (OR&#xa0;=&#xa0;1.20; 95&#xa0;% CI [1.14-1.26]), and perceived daytime neighborhood unsafety (OR&#xa0;=&#xa0;1.07; 95&#xa0;% CI [1.02-1.13]). Protective factors included higher income (&gt;$200,000/year, OR&#xa0;=&#xa0;0.55; 95&#xa0;% CI [0.42-0.70]), insurance coverage (OR&#xa0;=&#xa0;0.65; 95&#xa0;% CI [0.58-0.71]), older age (OR per year&#xa0;=&#xa0;0.99; 95&#xa0;% CI [0.99-0.99]), and male sex (OR&#xa0;=&#xa0;0.86; 95&#xa0;% CI [0.81-0.92]). Female patients and younger age were associated with increased likelihood of ED visits.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The frequency of unscheduled ED visits for asthma patients was significantly influenced by social determinants which include race, socioeconomic status, neighborhood factors, and specific comorbidities. Understanding these disparities can aid in the improvement of asthma management and the development of targeted interventions to address these critical factors.</AbstractText><CopyrightInformation>Published by Elsevier Inc.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rodriguez</LastName><ForeName>Deyaneira Gonzalez</ForeName><Initials>DG</Initials><AffiliationInfo><Affiliation>Department of Medicine, San Juan Bautista School of Medicine, Caguas, PR, Puerto Rico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yuan</LastName><ForeName>Qinxin</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Department of Biostatistics, Yale School of Public Health, New Haven, CT, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bakare</LastName><ForeName>Tolulope</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Section for Biomedical Informatics and Data Science, Yale University School of Medicine, New Haven, CT, United States of America; Department of Health Informatics, Yale School of Public Health, New Haven, CT, United States of America.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Sangil</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, University of Iowa Carver College of Medicine, IA, United States of America. Electronic address: sangil-lee@uiowa.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taylor</LastName><ForeName>R Andrew</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Emergency Medicine, University of Virginia, Charlottesville, VA, United States of America.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Am J Emerg Med</MedlineTA><NlmUniqueID>8309942</NlmUniqueID><ISSNLinking>0735-6757</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute care utilization</Keyword><Keyword MajorTopicYN="N">All of us research program</Keyword><Keyword MajorTopicYN="N">Asthma</Keyword><Keyword MajorTopicYN="N">Chronic respiratory disease</Keyword><Keyword MajorTopicYN="N">Comorbidities</Keyword><Keyword MajorTopicYN="N">Emergency department visits</Keyword><Keyword MajorTopicYN="N">Epidemiology</Keyword><Keyword MajorTopicYN="N">Health data analytics</Keyword><Keyword MajorTopicYN="N">Healthcare access</Keyword><Keyword MajorTopicYN="N">Healthcare disparities</Keyword><Keyword MajorTopicYN="N">Healthcare utilization patterns</Keyword><Keyword MajorTopicYN="N">Logistic regression</Keyword><Keyword MajorTopicYN="N">Patient outcomes</Keyword><Keyword MajorTopicYN="N">Population health</Keyword><Keyword MajorTopicYN="N">Predictive modeling</Keyword><Keyword MajorTopicYN="N">Risk factors</Keyword><Keyword MajorTopicYN="N">Social determinants of health</Keyword><Keyword MajorTopicYN="N">Socioeconomic status</Keyword><Keyword MajorTopicYN="N">Unscheduled healthcare visits</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>5</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2025</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>9</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>12</Day><Hour>18</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>12</Day><Hour>18</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>12</Day><Hour>18</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40939242</ArticleId><ArticleId IdType="doi">10.1016/j.ajem.2025.09.002</ArticleId><ArticleId IdType="pii">S0735-6757(25)00605-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40940077</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>15</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2397-3269</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>12</Day></PubDate></JournalIssue><Title>BMJ open ophthalmology</Title><ISOAbbreviation>BMJ Open Ophthalmol</ISOAbbreviation></Journal><ArticleTitle>Association of metformin use with primary open-angle glaucoma using data from the National Institutes of Health <i>All of Us</i> Program.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e002027</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjophth-2024-002027</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Few studies have assessed the impact of metformin use on glaucoma risk. The purpose of this study was to examine the association between metformin use and the incidence of primary open-angle glaucoma (POAG) in a diverse and large nationwide cohort.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We included a retrospective cohort study of 18&#x2009;440 participants in the National Institutes of Health <i>All of Us</i> Research Program aged 40 years or older, with a diagnosis of diabetes mellitus and without a diagnosis of POAG prior to diabetes diagnosis or metformin use. Bivariate logistic regression, multivariable logistic regression and survival analysis were used to analyse the association between ever use of metformin and incidence of POAG.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Within the cohort, 240 participants acquired a diagnosis of POAG during all available follow-up time, while 18&#x2009;200 did not. In regression-based bivariate analysis, metformin use was significantly associated with a lower odds of developing POAG (OR 0.35, 95% CI 0.26 to 0.47, p&lt;0.001). In multivariable regression analysis, metformin remained protective against POAG (OR 0.33, 95%&#x2009;CI 0.21 to 0.50, p&lt;0.001), while the use of other diabetic medications was associated with an increased odds of developing POAG (OR 2.39, 95%&#x2009;CI 1.48 to 3.90, p&lt;0.001). In survival analysis, the probability of developing POAG was significantly lower for the participants using metformin than for the participants not using metformin (log-rank p&lt;0.001, Cox proportional HR 0.38, 95%&#x2009;CI 0.29 to 0.51).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">This study provides additional large-scale observational health data supporting the protective role of metformin in the development of POAG. However, limitations include the study's observational design and lack of data on metformin dosage and duration, glaucoma severity and ocular exam findings. Despite these limitations, our findings contribute to the growing body of evidence suggesting a potential protective effect of metformin against POAG.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2025. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ Group.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sidhu</LastName><ForeName>Sophia</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-5371-3483</Identifier><AffiliationInfo><Affiliation>Division of Ophthalmology Informatics and Data Science, Viterbi Family Department of Ophthalmology and Shiley Eye Institute, University of California San Diego, La Jolla, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Radha Saseendrakumar</LastName><ForeName>Bharanidharan</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Ophthalmology Informatics and Data Science, Viterbi Family Department of Ophthalmology and Shiley Eye Institute, University of California San Diego, La Jolla, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Biomedical Informatics, Department of Medicine, University of California San Diego, La Jolla, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Varkhedi</LastName><ForeName>Varsha</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Division of Ophthalmology Informatics and Data Science, Viterbi Family Department of Ophthalmology and Shiley Eye Institute, University of California San Diego, La Jolla, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Biomedical Informatics, Department of Medicine, University of California San Diego, La Jolla, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Jo-Hsuan</ForeName><Initials>JH</Initials><Identifier Source="ORCID">0000-0002-9435-746X</Identifier><AffiliationInfo><Affiliation>Division of Ophthalmology Informatics and Data Science, Viterbi Family Department of Ophthalmology and Shiley Eye Institute, University of California San Diego, La Jolla, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parikh</LastName><ForeName>Aman</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Ophthalmology Informatics and Data Science, Viterbi Family Department of Ophthalmology and Shiley Eye Institute, University of California San Diego, La Jolla, California, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Biomedical Informatics, Department of Medicine, University of California San Diego, La Jolla, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nudleman</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Division of Ophthalmology Informatics and Data Science, Viterbi Family Department of Ophthalmology and Shiley Eye Institute, University of California San Diego, La Jolla, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Do</LastName><ForeName>Jiun L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Division of Ophthalmology Informatics and Data Science, Viterbi Family Department of Ophthalmology and Shiley Eye Institute, University of California San Diego, La Jolla, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moghimi</LastName><ForeName>Sasan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Ophthalmology Informatics and Data Science, Viterbi Family Department of Ophthalmology and Shiley Eye Institute, University of California San Diego, La Jolla, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weinreb</LastName><ForeName>Robert N</ForeName><Initials>RN</Initials><AffiliationInfo><Affiliation>Division of Ophthalmology Informatics and Data Science, Viterbi Family Department of Ophthalmology and Shiley Eye Institute, University of California San Diego, La Jolla, California, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baxter</LastName><ForeName>Sally L</ForeName><Initials>SL</Initials><Identifier Source="ORCID">0000-0002-5271-7690</Identifier><AffiliationInfo><Affiliation>Division of Ophthalmology Informatics and Data Science, Viterbi Family Department of Ophthalmology and Shiley Eye Institute, University of California San Diego, La Jolla, California, USA s1baxter@health.ucsd.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Biomedical Informatics, Department of Medicine, University of California San Diego, La Jolla, California, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open Ophthalmol</MedlineTA><NlmUniqueID>101714806</NlmUniqueID><ISSNLinking>2397-3269</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>9100L32L2N</RegistryNumber><NameOfSubstance UI="D008687">Metformin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007004">Hypoglycemic Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008687" MajorTopicYN="Y">Metformin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005902" MajorTopicYN="Y">Glaucoma, Open-Angle</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007004" MajorTopicYN="Y">Hypoglycemic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009316" MajorTopicYN="Y">National Institutes of Health (U.S.)</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Drugs</Keyword><Keyword MajorTopicYN="N">Epidemiology</Keyword><Keyword MajorTopicYN="N">Glaucoma</Keyword></KeywordList><CoiStatement>Competing interests: Sasan Moghimi reports grants from the National Eye Institute. Sally L Baxter reports equipment support from Optomed and Topcon and consulting/speaker fees from Topcon, outside the submitted work. Jiun L Do reports grants from the National Eye Institute, American Glaucoma Society, and Glaucoma Research Foundation; personal fees from VoxelCloud. Eric Nudleman reports grants from the National Institutes of Health and Roche. Eric Nudleman is a consultant for EyeBio, Genentech/Roche, Alcon, Allergan and EyePoint. Robert N Weinreb reports financial support in the form of grants from the National Eye Institute, National Institute of Minority Health and Health Disparities and Research to Prevent Blindness. He reports other non-financial support (research instruments) from Heidelberg Engineering, Carl Zeiss Meditec, Centervue and Topcon. He reports consulting fees from AbbVie, Alcon, Allergan, Amydis, Balance, Eyenovia, iSTAR Medical, Nicox and Topcon and patents from UCSD licensed to Toromedes and Carl Zeiss Meditec. He also reports support for attending meetings by Alcon, participation on a Data Safety Monitoring Board or Advisory Board for Amydis, Eyenovia, Iantrek and Implandata and stock or stock options with Amydis, Eyenovia and Iantrek. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>10</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>16</Day><Hour>0</Hour><Minute>32</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>13</Day><Hour>0</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>12</Day><Hour>20</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40940077</ArticleId><ArticleId IdType="doi">10.1136/bmjophth-2024-002027</ArticleId><ArticleId IdType="pii">bmjophth-2024-002027</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>